[
    {
        "id": "284ee034-5981-46c9-bbb0-b790b475c843",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "SMART GUIDELINES COLLECTION Digital adaptation kit self-monitoring blood pressure pregnancy Operational requirement implementing recommendation digital systemsDigital adaptation kit self-monitoring blood pressure pregnancy Operational requirement implementing recommendation digital system SMART GUIDELINES COLLECTIONDigital adaptation kit self-monitoring blood pressure pregnancy: operational requirement implementing recommendation digital system (SMART Guidelines collection) ISBN 978-92-4-011035-9 (electronic version) ISBN 978-92-4-011036-6 (print version) © World Health Organization 2025 right reserved. work available Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC-BY-NC-SA-3.0-IGO https://creativecommons.org/ licenses/by-nc-sa/3.0/igo/ ). term licence, may copy, redistribute adapt work non-commercial p",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "01710c8c-86e1-4d35-b9dd-a70c876863ae",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "term licence, may copy, redistribute adapt work non-commercial purposes, provided work appropriately cited, indicated below. use work, suggestion endorses specific organization, product services. use logo permitted. adapt work, must license work equivalent Creative Commons licence. Suggested citation. Digital adaptation kit self-monitoring blood pressure pregnancy: operational requirement implementing recommendation digital systems. Geneva: World Health Organization; 2025 (SMART Guidelines collection). https://iris.who.int/handle/10665/381616 . Licence: CC BY-NC-SA 3.0 IGO . create translation adaptation work, add following disclaimer along suggested citation: “This translation/adaptation created World Health Organization (WHO).",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a17f03bd-728f-4acd-aa43-87c04843ae33",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ation: “This translation/adaptation created World Health Organization (WHO). responsible content accuracy translation/adaptation. original English edition shall binding authentic edition” . would like develop Digital Adaptation Kit create implementation guide based DAK, access SMART Guidelines template here: https://smart. who.int/ig-starter-kit/ . mediation relating dispute arising licence shall conducted accordance mediation rule World Intellectual Property Organization https://www.wipo. int/amc/en/mediation/rules submit request commercial use query right licensing, see https://www.who.int/copyright Third-party materials. wish reuse material work attributed third party, tables, figure images, responsibility determine whether permission needed",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9212b95f-1fab-4935-891a-d25496e4d745",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "figure images, responsibility determine whether permission needed reuse obtain permission copyright holder. risk claim resulting infringement third-party-owned component work rest solely user. General disclaimers. designation employed presentation material publication imply expression opinion whatsoever part concerning legal status country, territory, city area authorities, concerning delimitation frontier boundaries. Dotted dashed line map represent approximate border line may yet full agreement. mention specific company certain manufacturers’ product imply endorsed recommended preference others similar nature mentioned. Errors omission excepted, name proprietary product di",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c386612b-45e4-4d8e-b6c4-f8774a328589",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ure mentioned. Errors omission excepted, name proprietary product distinguished initial capital letters. reasonable precaution taken verify information contained publication. However, published material distributed without warranty kind, either expressed implied. responsibility interpretation use material lie reader. event shall liable damage arising use. Design layout RRD Design LLC.iii Contents Acknowledgements iv Abbreviations",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a2dc1ad3-6956-46b8-b68d-2bf0c5f3e4ac",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "v Glossary vi Part 1. Overview digital adaptation kit Background 2 Digital adaptation kit within strategic vision SMART guideline",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "658a111c-8c22-4f17-90d2-47f9810031b7",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "5 Digital self-care intervention 6 Objectives digital adaptation kit 7 Components digital adaptation kit 8 digital adaptation kit developed",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c35f0279-f1ea-4cfb-88bf-dab5e7839d1a",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "8 digital adaptation kit developed 11 use digital adaptation kit 11 Part 2. Digital adaptation kit content self-monitoring blood pressure pregnancy Component 1. Health intervention recommendation 16 Component 2. Generic persona 19 Component 3. User scenario 22 Component 4. Business process workflow 24 Component 5. Core data element 37 Component 6. Decision-support logic 41 Component 7. High-level functional non-functional requirement 44 References",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b62d02ef-304b-49d4-8b5f-6b991ae0d932",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "level functional non-functional requirement 44 References 49 Implementation tool Core data dictionary https://smart.who.int/dak-smbp/dictionary.html Decision-support logic https://smart.who.int/dak-smbp/decision-support.html Functional non-functional requirement",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "27e3b1f8-f8fc-48bd-9603-409447c954ee",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "https://smart.who.int/dak-smbp/system-requirements.htmliv Digital adaptation kit self-monitoring blood pressure pregnancyAcknowledgements World Health Organization (WHO) gratefully acknowledges contribution many individual organization development document. digital adaptation kit (DAK) coordinated (in alphabetical order): Maria Barreix, Manjulaa Narasimhan, Tigest Tamrat Özge Tunçalp Department Sexual Reproductive Health Research (WHO SRH); Garrett Mehl Natschja Ratanaprayul Department Digital Health Innovations (DHI). Susan Duvall (Consultant, SRH) Samira Haddad (Consultant, SRH) drafted content DAK. grateful following individual feedback throughout process (in alphabetical order): Kaosar Afsana (BRAC University, Bangladesh),",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ea78bbb9-d53e-4899-8717-8d8a84c357d5",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "edback throughout process (in alphabetical order): Kaosar Afsana (BRAC University, Bangladesh), Michalina Drejza (International Youth Alliance Family Planning, Poland), Faysal El-Kak (American University Beirut, Lebanon), Austen El-Osta (Imperial College, United Kingdom Great Britain Northern Ireland), Tabassum Firoz (Yale School Medicine, United States America), Hussain Jafri (World Patients Alliance, Pakistan), Alvin Marcelo (University Philippines, Philippines), Kevin Moody (independent consultant, Kingdom Netherlands), Jayalakshmi Shreedhar (Resource Group Education Awareness Community Health [REACH], India), Steven Wanyee (IntelliSOFT Consulting, Kenya). following staff provided valuable input various stage development documents: Constantin Corman (WHO DHI), Siobhan Fitzpatrick (WHO Health Workforce Department [HWF]), Karima Gholbzouri (WHO Regional Office Eastern Mediterranean), Rodolfo G",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1b19701d-83bc-4613-ac0f-1fe2e903530d",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "Department [HWF]), Karima Gholbzouri (WHO Regional Office Eastern Mediterranean), Rodolfo Gomez (WHO Regional Offices Americas), Oleg Kuzmenko (WHO Regional Office Europe; Copenhagen, Denmark), Carl Massonneau (WHO SRH), Candide Tran Ngoc (WHO Country Office, Rwanda); Léopold Ouedraogo (WHO Regional Office Africa), Akshita Palliwal (WHO DHI), Anayda Portela (WHO Department Maternal, Child, Adolescent Health), Lale Say (WHO SRH), Aminata Seydi (WHO Regional Office Africa), Meera Thapa Upadhyay (WHO Regional Office South-East Asia), Tana Wuliji (WHO HWF); Hongyi Xu (WHO Department Noncommunicable Diseases) consultants: Sarah Borg (WHO SRH), Briana Lucido (WHO SRH), Israa Siddig (WHO HWF), Kabir Singh (WHO SRH). Funding provided Children’s Investment Fund Foundation, Bill & Melinda Gates Foundation, UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme Research, Development Research Training Human Reproduc",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "471132bd-aa9b-45c6-ae56-0c5bc32abd93",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "F-WHO-World Bank Special Programme Research, Development Research Training Human Reproduction (HRP).v Abbreviations ANC antenatal care ANM auxiliary nurse midwife BP blood pressure BPMN business process model notation CHW community health worker DAK digital adaptation kit DHI digital health intervention DT decision-support table eHealth electronic health HB/PHR home-based personal health record ICD International Classification Diseases ICF International Classification Functioning, Disability HealthICHI International Classification Health Interventions ICT information communication technology ID identification ISCO International Standard Classification Occupations LOINC Logical Observation Identifiers Names Codes PCPOSS person-centred point-of-service system SMART standards-based, machine-readable, adaptive, requirements-based testable SMBP self-monitoring blood pressure SNOMED Systematized Nomenclature Medicine UHC univer",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b214edd8-024c-4043-a44e-3a24f6877fd0",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ble SMBP self-monitoring blood pressure SNOMED Systematized Nomenclature Medicine UHC universal health coverage World Health Organizationvi Digital adaptation kit self-monitoring blood pressure pregnancyGlossary Note : Terms definition also defined glossary shown italic . Business process set related activity task performed together achieve objective health programme area, registration, counselling, referral (1,2) . Data dictionary centralized repository information data element contains definition, relationships, origin, usage type data. digital adaptation kit, data dictionary provided spreadsheet. Data element unit data specific precise meaning. Decision-support logic set decision rule standard exceptional case separate business process . help reduce complexity business process",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1d068205-da6d-48ad-9c8f-f39c02ab68be",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "separate business process . help reduce complexity business process depiction without losing detail necessary coding rule required system functionality. Decision support (for health workers)Digitized job aid combine individual’s health information health worker’s knowledge clinical protocol assist health worker making diagnosis treatment decision (3,4) . Decision-support table Semi-structured way depict discrete decision need embedded system. Depending complexity clinical guidelines, likely multiple decision-support tables. Digital health systematic application information communication technologies, computer science data support informed decision-making individuals, health workforce health systems, strengthen resilience disease improve health wellness (1,5). Functional requirement capa",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "71bc190b-cc43-40e2-ac55-4bc9f3eea3e7",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "rengthen resilience disease improve health wellness (1,5). Functional requirement capability system must order meet end users’ need achieve task within business process . Health information systemA system integrates data collection, processing, reporting use information necessary improving health service effectiveness efficiency better management level health service (6). Health management information system (HMIS)An information system specifically designed assist management planning health programmes, opposed delivery care (6).Interoperability ability different application access, exchange, integrate use data coordinated manner use shared application interface standards, within across organizational, regional national boundaries, provide timely seamless portability information optimize health outc",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "961ae209-d46d-433c-9559-ffef390594ea",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "nal boundaries, provide timely seamless portability information optimize health outcomes. Non-functional requirementGeneral attribute feature digital system ensure usability overcome technical physical constraints. Examples non-functional requirement include ability work offline, multiple language setting password protection. Persona generic aggregate description person involved benefitting health programme. Self-care ability individuals, family community promote health, prevent disease, maintain health cope illness disability without support health worker (7). Self-management Management oneself; taking responsibility one’s behaviour, health well-being (7). Standard software, standard speciﬁcation used digital application development established, approved published authoritative organization",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "865acc00-b4dc-4c81-87b8-e7e7c94dbfa3",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "tion development established, approved published authoritative organization. rule allow information shared processed uniform, consistent manner independent particular application. Task specific action business process . Terminologies clinical care, terminology structured vocabulary covering health-related concept – diseases, diagnoses, laboratory test treatment – enable storage, analysis exchange data consistent standard way (8). Workflow visual representation progression activity ( task , events, decision points) logical flow illustrating interaction within business process (2).vii REFERENCES 1. Digital implementation investment guide (DIIG): integrating digital intervention health programmes. Geneva: World Health Organization; 2020 ( https://iris.who.int/handle/10665/334306 ). Licence: CC BY-NC-SA 3.0 IGO. 2. Collaborative Requirem",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "07d78ffb-3430-40df-bd63-9b7707489870",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "https://iris.who.int/handle/10665/334306 ). Licence: CC BY-NC-SA 3.0 IGO. 2. Collaborative Requirements Development Methodology (CRDM): collaborative approach public health systems. In: Public Health Informatics Institute [website]. Task Force Global Health; 2024 ( https://www.phii.org/crdm/ , accessed 11 September 2023). 3. guideline: recommendation digital intervention health system strengthening: evidence recommendations. Geneva: World Health Organization; 2019 ( https://iris.who.int/ handle/10665/311980 ). Licence: CC BY-NC-SA 3.0 IGO. 4. Classification digital interventions, service application health: shared language describe us digital technology health, second ed. Geneva: World Health Organization; 2023 ( https://iris.who.int/handle/10665/373581 ). Licence: CC BY-NC-SA 3.0 IGO. 5. Global strategy digital health 2020–2025. Geneva: World Health Organization; 2021 ( https://iris.who.int/handle/10665/344249 ). Licen",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "212d9a17-fa87-4ad3-b367-894aa97c07a5",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "20–2025. Geneva: World Health Organization; 2021 ( https://iris.who.int/handle/10665/344249 ). Licence: CC BY-NC-SA 3.0 IGO. 6. Developing health management information systems: practical guide developing countries. Manila: Regional Office Western Pacific; 2004 ( https://apps.who.int/iris/ handle/10665/207050 ). 7. guideline self-care intervention health well-being, 2022 revision. Geneva: World Health Organization; 2022 ( https://www.who.int/publications/i/item/9789240052192 ). Licence: CC BY-NC-SA 3.0 IGO. 8. International Statistical Classification Diseases Related Health Problems (ICD). In: World Health Organization [website]. Geneva: World Health Organization; 2024 ( https://www.who.int/ standards/classifications/classification-of-diseases , accessed 19 January 2024).OVERVIEWviii Digital adaptation kit self-monitoring blood pressure pregnancyOVERVIEW1 OverviewPart 1. Overview digital adaptation kits1OVERVIEW2 Digital ad",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "26020654-5bb3-4dbb-811e-1a853b946f05",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "pregnancyOVERVIEW1 OverviewPart 1. Overview digital adaptation kits1OVERVIEW2 Digital adaptation kit self-monitoring blood pressure pregnancyBackground digital technology increasingly leveraged enable support health-service delivery accountability, health ministry partner recognized value digital health articulated within World Health Assembly resolution (1) Global strategy digital health 2020–2025 (2). Similarly, funding agency advocated rational use digital tool part effort expand coverage quality services, well promote data use monitoring effort (3–5) . However, guideline often available narrative format requires resource-intensive process elaborated specification needed operationalizing digital systems. translation guideline digital system often result subjective int",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9225d2fe-8eaf-4f79-a5ac-8e63f7572924",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "digital systems. translation guideline digital system often result subjective interpretation implementers software vendors, lead inconsistency inability verify content within systems, potentially leading adverse health outcome unintended effect (6–9) . Despite abundance digital tool developed deployed health care, often limited transparency data model, logic model, evidence-based clinical public health recommendation contained digital tools, system documentation may unavailable proprietary, requiring government start scratch expend additional resource time intend update deploy system. lack documentation undermines credibility systems, leading dependency one vendor haphazard deployment unscalable, impeding opportunity interoperability would otherwise enable c",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e81d6b67-80ed-429e-8361-5d6763faa811",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "t unscalable, impeding opportunity interoperability would otherwise enable continuity care (9–11) . standards-based, machine-readable, adaptive, requirements-based testable (SMART) guideline provide essential ingredient facilitate digital health transformation health programme way consistent recommended clinical, public health data practice interoperability standards. ensure country effectively benefit digital health investments, digital adaptation kit (DAKs), second, operational guideline layer SMART guideline approach, designed facilitate accurate reflection clinical, public health data use guideline within digital system country adopting. DAKs operational, software-neutral, standardized documentation distil clinical, public health data use guidance format transparently incorporated digital system (1",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3748ca2f-0ab4-4e9b-9345-ac5efcee3db5",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "data use guidance format transparently incorporated digital system (11) . Although digital implementation comprise multiple factor – including (i) health domain data content, (ii) digital intervention functionality (iii) digital application communication channel delivering digital intervention – DAKs focus primarily ensuring validity health content ( Fig. 1 ) (12, 13) . Accordingly, DAKs provide generic content requirement housed within digital systems, independent specific software application intention country customize local needs. DAK, requirement based system provide functionality personal health tracking (see Box 1 ) include component personas, workflows, core data element decision-support algorithms. Operational outputs, spreadsheet data dictionary detailed decision-su",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "befead93-e4c8-4ad0-996f-400d0160f9d9",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "thms. Operational outputs, spreadsheet data dictionary detailed decision-support algorithms, included part DAK practical resource implementers use starting point developing digital systems. Furthermore, data component within DAK mapped standards-based classification terminologies, International Classification Diseases (ICD), Logical Observation Identifiers Names Codes (LOINC), International Classification Health Interventions (ICHI), International Classification Functioning, Disability Health (ICF) Systematized Nomenclature Medicine (SNOMED) facilitate interoperability.OVERVIEW3 OverviewDescription personal health trackingBox 1 Personal health tracking use mobile applications, phone-based sensors, health records, wearable individual monitor health status. include example wearable sensors, web-tools apps allow ind",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "293100f2-c2c5-4ae8-acb3-7daafba08de4",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "health status. include example wearable sensors, web-tools apps allow individual review track clinical general health status. 1.4.1 Access individual medical summary health records- Self-access health record individual; patient’s access health record. - Ability person track health history clinical record.Electronic personal health record : “makes possible patient augment medical record health status data gathered own”. 1.4.2 Self-monitoring health diagnostic data individual- Personal health monitoring, self-tracking self-care, self- monitoring. - Sensors wearable personal health monitoring. - Person’s health data collected based device person us own.Wearables fitness tracker : Applications track every part day—including activity, exercise, food, weight",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b81b34f9-ab9e-4fce-bee4-ff12e8ffe21f",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "er : Applications track every part day—including activity, exercise, food, weight sleep. 1.4.3 Active data capture/ documentation individual- Personal health monitoring, self-tracking self-care, self- monitoring, journaling (capture patient-originated data), documentation health status activity individual(s).Period-tracking application : individual “enters date last period service informs fertile day cycle. receives alert ‘unsafe days’ throughout month.” 1.4.4 Access individual verifiable documentation health event health status- Confirmation/verification individual’s status various public private transaction including insurance status, vaccination record, disability record, social protection. - Access documentation health status via verifiable certificate.Applications provide individual access",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "70f4c5f0-3162-43f1-93d3-b90afe53e546",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "health status via verifiable certificate.Applications provide individual access verifiable credential confirm health status including occurrence health event. Source : (14).OVERVIEW4 Digital adaptation kit self-monitoring blood pressure pregnancyThe DAKs follow modular approach detailing data content requirement specific health programme area – antenatal care, family planning, HIV/AIDs, tuberculosis – among different health area DAKs developed. Figure 1 outline DAKs implementation digital health care. DAK focus providing content requirement self-monitoring blood pressure (SMBP) pregnancy use tracking digital personal health records. Personal health record defined “record individual’s health information structured digital format set defined use case person agen",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2f082818-d933-4020-af48-5e38fd989c05",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "mation structured digital format set defined use case person agency. ” Foundational Layer: ICT enabling environment LEADERSHIP & GOVERNANCE STRATEGY INVESTMENTSERVICES APPLICATIONSLEGISLATION, POLICY COMPLIANCEWORKFORCE STANDARDS INTEROPERABILITY INFRASTRUCTUREHEAL TH CONTENT Information aligned recommended health practice validated health content DIGITAL HEAL TH INTERVENTIONS discrete function digital technology achieve health-sector objectivesDIGITAL APPLICATIONS ICT system communication channel facilitate delivery digital intervention health content+ +Digital adaptation kit role within digital health implementationsFig. 1 SMART GUIDELINES Digital Adaptation Kit Self-care Interventions Operational requirement implementing recommendation digital system ICT: information communication technology.OVERVIEW5 OverviewPaper sys",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dbaa7f26-2eec-4735-8205-e7868329ae1d",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "tions digital system ICT: information communication technology.OVERVIEW5 OverviewPaper system Smart digital system Country implementation Paper system L1 Adaptation National policies, guidelines, data, operational procedure L3 Adaptation Localised machine-readable code standard L4 Adaptation Localised static digital service application within digital health enterprise L5 Adaptation Dynamic digital application service trained optimised prioritised local outcome L2 Adaptation Localised requirementsLocalisationDigital adaptation kit within strategic vision SMART guideline operational standardized documentation reflected within DAKs represents one step within broader vision SMART guidelines. SMART guideline aim maximize health impact improved fidelity uptake recommendation within standards-based digital system via systematic process transforming guideline development,",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "edd6098a-5cb2-4606-b1b9-10a1d1e43b26",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "n standards-based digital system via systematic process transforming guideline development, delivery application (8, 15). DAKs serve prerequisite developing computable machine-readable guidelines, well executable reference software advanced analytics precision health. Figure 2 provides overview different layer SMART guideline continuum DAKs fit within strategy (8, 15, 16). Progressive layer across SMART guideline componentsFig. 2 NarrativeEvidence-based guideline recommendation accompanying implementation data guidanceNarrative guideline L1 Operational Digital adaptation kit Machine readableStructured software-neutral specifications, code, terminology interoperability standard Machine- readable recommendation ExecutableSoftware able execute static algorithm interoperable digital component deliver operational functional requirementsReference softwar",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a05b6034-6ba9-4359-85cc-a040871df54f",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "rable digital component deliver operational functional requirementsReference software DynamicExecutable dynamic algorithm trained optimized advanced analytics achieve prioritized outcomesPrecision health model L2 L3 L4 L5 SMART GUIDELINES Digital Adaptation Kit Self-care Interventions Operational requirement implementing recommendation digital system guideline self-care intervention health well-being, 2022 revision Human-readable software-neutral documentation operational functional requirement (e.g. personas, workflows, relevant metadata, transparently documented algorithms, minimum data sets, priority metrics, listing relevant health interventions, functional requirements) Smart digital systemsOVERVIEW6 Digital adaptation kit self-monitoring blood pressure pregnancyDigital self-care intervention 1 Throughout DAK, “clients” refers self-carers careg",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4d3717d5-e189-48f9-850a-5639488a3c4b",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "gital self-care intervention 1 Throughout DAK, “clients” refers self-carers caregiver parent caring child. See definition client Part 2: Component 2: Generic persona DAK detailed definition.Self-care intervention enable individuals, family community promote health, prevent disease, maintain health, cope illness disability without support health worker (17) . Self-care intervention relevant health area categorized various modality self-testing self-management (see Fig. 3 ) (17, 18) . Digital technology platform support clients1 achieving task essential access, use uptake self-care interventions. includes accessing health information, learning use health-care product intervention, managing personal health data, making informed health decision evidence-based drug therapeutic",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e471f932-64ea-4d5e-af0a-aab4d086cda6",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "personal health data, making informed health decision evidence-based drug therapeutics, medical device diagnostics, information product (17) . Digital health intervention (DHIs) within tool make accomplishment task easier effective. DHIs software application service client level, also software used health care worker – key player digital self-care intervention ecosystem. Whether user using client-facing system provider-facing system, digital tool (delivering one DHIs) support user’s capability achieving different task essential successful use self- care intervention (19) .Self-care context intervention linked health systemsFig. 3 HEAL TH SYSTEMS EVERYDAY LIFESELF-CARE SELF-MANAGEMENT Self-medication, self-treatment, self-examination, self-injection, self-administration, self-use SELF-TESTING Sel",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e4cebe83-c33c-4f5a-9e87-931898c3337a",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": ", self-treatment, self-examination, self-injection, self-administration, self-use SELF-TESTING Self-sampling, self-screening, self-diagnosis, self-collection, self-monitoring SELF-AWARENESS Self-help, self-education, self-regulation, self-efficacy, self-determinationOVERVIEW7 OverviewObjectives digital adaptation kit DAK focus SMBP pregnancy aim provide common language across various audience – health programme managers, software developers, implementers digital system – ensure common understanding appropriate health information content requirement within defined health programme area, mechanism catalyse effective use digital systems. DAK also complement health worker-facing Digital adaptation kit antenatal care: operational requirement implementing recommendation digital system (ANC DAK) (20) , self-care intervention SMBP may integrated. key obje",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7daa48bd-e7f4-4969-80c4-6f598754d260",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "em (ANC DAK) (20) , self-care intervention SMBP may integrated. key objective DAK are: » foster common understanding particular content need digital self-care intervention ecosystem among health programme lead digital health team (including software developers); » ensure adherence clinical, public health device use guideline facilitate consistency health content used specific aspect provider-facing client-facing digital system support self-monitoring interventions; » provide starting point specification self-care intervention may executed digital home-based record, describing core data element decision-support logic included type tool expectation additional content added modular fashion. Specifically, DAK detail digital requirement implement f",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7cca8a9b-7c7c-4285-a46b-f0c85019d725",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "modular fashion. Specifically, DAK detail digital requirement implement following recommendations: recommends self-care intervention within safe, supportive enabling environment appropriate link health system (21) . first edition DAK self-care intervention focus self-monitoring blood pressure pregnancy suggests making self-monitoring blood pressure pregnancy available additional option clinic blood pressure monitoring health worker solely antenatal contacts, individual hypertensive disorder pregnancy (17) . DAKs also developed antenatal care (ANC), family planning, tuberculosis, child health humanitarian settings, immunization HIV. approach expanded additional health domains, postnatal care community health. DAKs work towards comprehensive approach standardized software requirement",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0fe23797-d9f2-4abb-9289-979a8bdb13d8",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "health. DAKs work towards comprehensive approach standardized software requirement primary health-care settings.OVERVIEW8 Digital adaptation kit self-monitoring blood pressure pregnancyComponents digital adaptation kit SMART guideline DAK comprises following interlinked components: (1) health intervention associated recommendations; (2) generic personas; (3) user scenarios; (4) generic business process workflows; (5) core data elements; (6) decision-support logic; (7) scheduling logic; (8) indicator reporting requirements; (9) high-level functional non-functional requirements. Table 1 provides overview contributing component DAK, document elaborates. information within digital adaptation kit represents generic starting point, adapted according specific context. Table 1. Components digital adaptation kit Component Desc",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "07139ce7-9e49-4100-a508-ea5328814184",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "according specific context. Table 1. Components digital adaptation kit Component Description Purpose Outputs Adaptation needed 1. Health intervention recommendationsOverview health intervention recommendation included within digital adaptation kit (DAK). DAKs meant repackaging integration guideline guidance document particular health domain. list health intervention drawn universal health coverage menu intervention compiled (22, 23) .Setting stage understand DAK would applied person-centred point-of- service system (PCPOSS) context specific health programme intervention »List related health intervention based WHO’s Universal health coverage essential intervention (22) »List related recommendation based guideline guidance document »Contextualization reflect current planned national pol",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2e09641d-10e9-4188-a1da-b5488451cdd0",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "guideline guidance document »Contextualization reflect current planned national policy 2. Generic personasDepiction end user related stakeholder would interacting digital system involved care pathway. Contextualization understand wants, need constraint end user »Description, competency essential intervention performed targeted persona »Greater specification detail end user based real people (e.g. health workers) given context »High-level information describe provider health service (e.g. general background, role responsibilities, motivations, challenge environmental factors) 3. User scenariosNarratives describe different persona may interact digital system other. user scenario illustrative intended give idea typical workflow.Contextualization understa",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "983d737a-da44-4502-83fe-4cb40254ee8b",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "llustrative intended give idea typical workflow.Contextualization understand system would used would fit existing workflow »Example narrative targeted persona may interact system workflow »Greater specification detail real need end user given context 4. Generic business process workflowsA business process set related activity task performed together achieve objective health programme area, registration, counselling, referral (12, 24). Workflows visual representation progression activity (tasks, decision points, interactions) performed within business process (12, 24). Contextualization system design understand digital system would fit existing workflow best design system purpose »Overview matrix presenting key p",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2ea5644b-c3a2-4a82-a0d8-1887fc3e4c7d",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "rkflows best design system purpose »Overview matrix presenting key process self-monitoring blood pressure (SMBP) pregnancy »Workflows identified business process annotation »Customization workflow include additional forks, alternative pathway entirely new workflowsOVERVIEW9 Overview Component Description Purpose Outputs Adaptation needed 5. Core data elementsData element required throughout different point workflow. data element mapped standards-based classification terminology ensure data dictionary compatible digital systems.System design interoperability know data element need logged map standard terminology (e.g. International Classification Diseases [ICD] Logical Observation Identifiers Names Codes [LOINC]) interoperability standards-based system »List",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4a7dcdab-cd92-4f26-bd37-bc7df4f2613b",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "entifiers Names Codes [LOINC]) interoperability standards-based system »List data element »Link data dictionary detailed data specification spreadsheet format (available : https://smart.who.int/dak- smbp/dictionary.html ) »Translation data label local language additional data element created depending context 6. Decision- support logicDecision-support logic algorithm support appropriate service delivery accordance clinical, public health data use guidelines.System design adherence recommended clinical practice know underlying logic need coded system »List decision need made throughout encounter »Link decision-support table spreadsheet format inputs, output trigger decision-support logic (available : https://smart.who.int/dak- smbp/decision-logic.html ) »Change specific threshold",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "795c6c8c-dcb1-418d-a350-854c9e3d4660",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "le : https://smart.who.int/dak- smbp/decision-logic.html ) »Change specific threshold trigger logic (IF/THEN) statement (e.g. body mass index [BMI] cut-off age trigger youth-friendly services) »Additional decision-support logic formula depending context 7. Scheduling logicScheduling logic support appropriate reminder follow-up visit service accordance clinical, public health data use guidelines.System design adherence recommended clinical practice know service schedule need coded system appropriate reminder generated. »List scheduling logic tables. »Not included DAK »Additional scheduling logic depending context. 8. Indicators performance metricsCore set indicator need aggregated decision-making, performance metrics, subnational national reporting. indicator metric based data fe",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "82d4a817-e553-4c86-af18-787ff1b34c6b",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "subnational national reporting. indicator metric based data feasibly captured routine digital system, rather survey- based tools.System design adherence recommended health monitoring practice know calculation secondary data use needed system, based principle “collect once, use many. ” »Indicators table numerator denominator data element calculation, along appropriate disaggregation »Not included DAK »Changing calculation formula indicators; »Adding indicators; »Changing definition primary data element used calculate indicator based available data. 9. Functional non- functional requirementsList core function capability system must order meet end users’ need achieve task within business process.System design know system able",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "346cf611-6c0d-41a1-896a-6249348d29c2",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "task within business process.System design know system able »Link table functional non-functional requirement intended end user requirement, reason end user need functionality system (available : https://smart. who.int/dak-smbp/system- requirements.html ) »Adding reducing function system capability based budget end user need preferencesOVERVIEW10 Digital adaptation kit self-monitoring blood pressure pregnancyThroughout DAK, identification (ID) number simplify tracking referencing components. Note DAK represents overview across different components, comprehensive complete output component (e.g. data dictionary decision-support tables) linked implementation tools. Box 2 provides overview notation guidance. Box 2 ID notation guidance Compone",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f910e675-986a-45cb-a61e-87d606c41099",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "tion tools. Box 2 provides overview notation guidance. Box 2 ID notation guidance Component 1: Health intervention recommendation notation used. Component 2: Generic persona notation used. Component 3: User scenario notation used. Component 4: Business process workflow » workflow “Process name” corresponding letter. » workflow also “ process ID ” structured: “abbreviated health domain ” “ corresponding letter process ” (e.g. abbreviated health domain SMBP corresponding letter B: SMBP .B). » activity workflow numbered “ activity ID ” structured “ process ID ” “ activity number ” (e.g. activity number 7: [SMBP].B7)Component 5: Core data element (data dictionary) » data element “ data element (DE) ID ” structured “ activity ID ”, “abbreviated health",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0ec95aa0-961d-40b3-9ad5-b0f22aa1811a",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ave “ data element (DE) ID ” structured “ activity ID ”, “abbreviated health domain ” (e.g. DE) “sequential number data element ” (e.g. activity ID B7 sequential number data element 1: [SMBP].B7.DE.1; sequential number 2: [SMBP].B7.DE.2) Component 6: Decision-support logic » decision-support logic table “ decision-support table (DT) ID ” structured “ activity ID ” “DT” (e.g. decision-support table ID B3: [SMBP].B3.DT; ID B5: [SMBP].B5.DT) Component 8: High-level system requirement » functional requirement “ functional requirement (FXNREQ) ID ” structured “ abbreviated health domain ”, “FXNREQ” “ sequential number functional requirement ” (e.g. sequential number functional requirement 1: [SMBP]. FXNREQ.1; sequential number 2: [SMBP].FXNREQ.2) » non-functional requi",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ca70b927-5949-42f9-90e5-b3b3c951b38d",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "1: [SMBP]. FXNREQ.1; sequential number 2: [SMBP].FXNREQ.2) » non-functional requirement “ non-functional requirement (NFNREQ) ID ” structured “ abbreviated health domain ” , “NFXNREQ” “ sequential number non-functional requirement ” (e.g. non-functional requirement number 1: [SMBP].NFXNREQ.1; sequential number 2: [SMBP]. NFXNREQ.2)OVERVIEW11 OverviewHow digital adaptation kit developed Existing guidelines, guidance tool considered relevant development DAK dedicated SMBP pregnancy mapped. Key resource included guideline self-care intervention health well-being, 2022 revision ( 17) additional relevant guidance document focused management blood pressure complication pregnancy (see guidelines, recommendation guidance section chapter). Relevant recommendation guideline extracted inf",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0d10a5f8-5a77-4633-b88f-2f987fc57054",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "idance section chapter). Relevant recommendation guideline extracted inform basis DAK. process also informed development workflows, data dictionary decision-support logic algorithms. component refined external reviewer staff. specialist hypertensive disorder pregnancy reviewed technical content validation. published DAKs, including team responsible development, consulted needed ensure alignment across across SMART guideline programme . individual external contributor involved development review DAK declared potential conflict interest prior providing contributions, including contribution made participation technical consultations. declaration reviewed WHO, found none contributor conflicting interest would influence con",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "240d91f3-7591-4b19-b098-b4f5ec3c9491",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "HO, found none contributor conflicting interest would influence content publication. use digital adaptation kit strategic vision point-of-service system developed, SMART guideline assist determining necessary health content requirement based available guidance. context overarching vision may exist, user first consult WHO–International Telecommunication Union National eHealth strategy toolkit (25) , guideline: recommendation digital intervention health system strengthening (13) , WHO’s Digital implementation investment guide (DIIG) (12) establish better understanding select apply appropriate DHIs. Figure 4 situates DAKs within broader set resource planning implementing digital health systems.OVERVIEW12 Digital adaptation kit self-monitoring blood pressure pregnancyDAKs within broader digital",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9768f385-8b18-42f4-b4f8-5c6e3b6e76d8",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "adaptation kit self-monitoring blood pressure pregnancyDAKs within broader digital health ecosystemFig. 3 HIS:health information system; ICT: information communication technology; ITU: International Telecommunication Union; M&E: monitoring evaluation; MAPS: mHealth Assessment Planning Scale; SDG: Sustainable Development Goal. Source: Adapted (12).Fig. 4 core indicator setsGlobal digital health monitorWHO digital health atlasDigital health investment review toolHIS stage continuous improvement+ Conduct inventory existing previously used software applications, ICT system tool better understand requirement reuse interoperability + Develop national digital health strategy outlining overarching needs, desired activity outcome + Define vision health system strengthened use digital technology + Formulate digital health investment roadmap",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4dcae6fa-9d4b-4566-8690-796b66eb15c5",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "strengthened use digital technology + Formulate digital health investment roadmap support national digital health strategy + Plan identify appropriate digital interventions, alongside health data content, improve health system process address programmatic need + Review current state develop architecture blueprint design digital health implementation + Identify validated open standard ensure data exchange, system integration future-proofing digital health implementation + Monitor implementation ensure digital implementation functioning intended desired effect + Foster data-driven adaptive change management within overall health system+ Identify validated health content appropriate implementation context + Ensure use content aligned identified standard future state + Maintain sustain digital health implementation + Identify risk",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cb08ab50-95ff-4b96-bd08-c35b445ae251",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "andards future state + Maintain sustain digital health implementation + Identify risk appropriate mitigationsASSESSING CURRENT STATE ENABLING ENVIRONMENT PHASE 01 DEFINING FUTURE STATE PHASE 03 M&E DIGITAL HEAL TH IMPLEMENTATIONS FOSTERING DATA USE PHASE 06DETERMINING HEAL TH CONTENT REQUIREMENTS PHASE 05ESTABLISHING SHARED UNDERSTANDING STRATEGIC PLANNING PHASE 02 IMPLEMENTING, MAINTAINING SCALING PHASE 07PLANNING ENTERPRISE ARCHITECTURE PHASE 04WHO–ITU National eHealth strategy toolkitWHO classification digital health interventionsWHO guideline: recommendation digital intervention health system strengthening ITU digital health platform handbookUNICEF human- centred design toolkit World Bank digital identity toolkitWHO digital clearing- house Digital implemen - tation investment guideDIIG Quick deployment guide Asian Development Bank total cost",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e0fb7b61-78cf-41ce-b441-58645e640cbe",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ion investment guideDIIG Quick deployment guide Asian Development Bank total cost ownership toolDigital transformation handbook health supply chain architecture Handbook approach implementing standardized national product catalogWHO MAPS toolkit: mHealth assessment planning scale handbook digitalizing primary health careBe He@lthy, Mobile handbook non- communicable diseasesMachine- readable recommen- dations Digital adaptation kit (this document) PATH Defining building data use culture MEASURE Tools Data Demand Use Health SectorWHO SCORE health data technical packageEthics governance artificial intelligence healthWHO M&E digital health interventionsITU SDG digital investment frameworkOpen Health Information Exchange (Open HIE) PDF print Online environmentThe Open Group Architecture Framework (TOGAF)Global Digital Hea",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b815f67f-1da1-4216-bc8b-0e7c877485b1",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "print Online environmentThe Open Group Architecture Framework (TOGAF)Global Digital Health Certification Network (GDHCN)Terminology Service FIC ICD-11 HL7 FHIR LOINCDigital Square global good guidebookPrinciples donor alignmentPrinciples digital developmentTraining Planning National Systems course SMART guidelinesSTEPSOVERVIEW13 OverviewTarget audience primary target audience DAK software developer health programme manager within health ministries, working digital health information system counterpart determining health content requirement SMBP pregnancy. DAK also equips individual responsible translating health-system process guidance document use within digital system necessary component kick-start process developing personal health tracking system standards-compliant manner. individual also known busines",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4a7e2c85-6441-4e91-b085-e34945236dfe",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "health tracking system standards-compliant manner. individual also known business analyst interface health content expert software development teams. Additionally, using DAK requires collaboration health programme manager responsible maternal health counterpart digital health health information systems. Although DAK focus particular health programme area (in case, SMBP pregnancy), DAKs envisioned used modular format link health programme area within primary health-care setting support integration across services. Scenarios using DAK DAK may used across various scenarios, listed below. Scenario 1 Incorporating guideline content existing personal health tracking systemsImplementers may already developed personal health tracking system may use information DAK cross- check whether underlyi",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "691616d9-361d-4c81-8165-a143109b7881",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "onal health tracking system may use information DAK cross- check whether underlying content data specific health programme area aligned guidelines. Users DAK identify extract specific decision algorithm would need incorporated existing digital systems. reviewing systematic documentation, implementers readily identify difference workflows, data input decision-support logic examine rationale deviation understanding local adaption guideline content. Scenario 2 Transitioning paper digitalSome implementers may currently paper-based approach personal health tracking would like digitize. Users scenario may review DAK starting point streamlining necessary data element decision support optimized client-level digital system. Users may also refer paper-based tool deter",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "74b8dad6-94ec-4cbd-878b-0824f6ccefd4",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "e optimized client-level digital system. Users may also refer paper-based tool determine whether missing field content also included within digital system. Scenario 3 Leveraging data standard promote interoperability integrated systemsThis DAK includes data element mapped ICD 11th Revision (ICD-11) codes, ICD 10th Revision (ICD-10) codes, LOINC, ICHI, ICF SNOMED code support design interoperable systems. data dictionary provides necessary code different data elements, thus reducing time implementers incorporate global standard design digital systems. Box 3 provides guidance developing third layer SMART guideline role designing interoperable systems, linking point-of-service system (e.g. electronic health record) managed health worker.OVERVIEW14 Digital adaptation kit self-monitoring blood pressure durin",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4e68bb26-b8e4-4f02-82fe-09ffba569153",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ged health worker.OVERVIEW14 Digital adaptation kit self-monitoring blood pressure pregnancyScenario 4 Establishing benchmark requirement facilitate governance digital health systemsThe DAK allows country clearly outline software-agnostic baseline expectation requirement digital service application particular use case. templated format allows country establish standard digital service application implemented within country. DAK provides shared language allow alignment across relevant stakeholders, regardless software system used. Box 3 Third knowledge layer (L3) SMART guideline next step digitalization journey normative content involves development and/or implementation computable machine-readable content standards-based, machine-readable, adaptive, requirements-based testable (SMART) guidelines,",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fe0d165e-278a-480e-9bff-3a1240becb3d",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "standards-based, machine-readable, adaptive, requirements-based testable (SMART) guidelines, also known third knowledge layer (L3). layer build L2 represented Fast Healthcare Interoperability Resources (FHIR) implementation guide. focus producing machine- readable recommendation tested conformance interoperability standards. step ensures semi-structured normative content, form digital adaptation kit (DAK), converted machine-readable format promotes interoperability easily adapted meet requirement different contexts. Developing L3 provides benefit multiple stakeholders. Some, all, listed below: » Ministry health : localized implementation guide promote local ecosystem standard many software vendor tap into, thereby avoiding software lock-in; » Technology partner : standards-based machine-readable co",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "89347ca9-2463-4bd3-8e63-3a23056284f8",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "hereby avoiding software lock-in; » Technology partner : standards-based machine-readable code available within implementation guide, partner quicker development cycle easier adoption standards-based code solutions; » Health worker : greater support day-to-day workload access decision-support logic within digital systems.Stakeholders looking understand importance interoperability key components, plan investment integrating component national digital health systems, consult Stepwise toolkit planning & budgeting interoperability digital health solution (12, 26). Key consideration developing L3 developing implementing L3, important to: » Scope need : identify requirement digital tool, translation need test data generation needs; » Budget resource : determine necessary budget required resources; » Te",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0b871550-db61-477a-992a-94b271c6dc4e",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ation needs; » Budget resource : determine necessary budget required resources; » Team competence : assemble team required software development skill experience develop and/or implement FHIR implementation guide; » Review L3 SOP : L3 SOP intended guide developer implementers process creating HL7 FHIR implementation guide following SMART guideline approach. SMART guideline community actively working defining SOP authoring L3 implementation guide latest version available (https://smart. who.int/ig-starter-kit/) . status L3 implementation guide developed implementation partner consulted Smart Guidelines Publications site . DAK: digital adaptation kit; FHIR: Fast Healthcare Interoperability Resources; SMART: standards-based, machine-readable, adaptive, requirements-based testable; SOP: standard operating procedure.OVERV",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0cb28cc5-0663-473e-9af1-a196ec6fd218",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "machine-readable, adaptive, requirements-based testable; SOP: standard operating procedure.OVERVIEW15 OverviewPart 2. Digital adaptation kit content self-monitoring blood pressure pregnancy216 recommendation persona scenario workflow data decision requirementsDigital system deployed context overall health intervention, multiple interventions. World Health Organization (WHO) guideline guidance document support intervention form basis digital adaptation kit (DAK) content, reformatted use software development. 2 intervention requires proper connectivity digital infrastructure, implementation timeline may differ country country, depending upon maturity country’s digital ecosystem.Interventions based WHO’s UHC Compendium DAK module focus self-care intervention antenatal period may benefit pregnant client’s use digi",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e9c5b75f-8f7d-4a4f-b751-d18b1785c932",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "intervention antenatal period may benefit pregnant client’s use digital home-based personal health record (HB/PHR) similar software. Specifically, DAK module detail software requirement following, listed UHC Compendium health intervention universal health coverage (UHC) (22) : » blood pressure (BP) monitoring management antenatal care (ANC) complication » electronic telephonic transfer home blood pressure reading using validated devices2 (where possible) Self-monitoring blood pressure pregnancy monitor help manage hypertensive disorder pregnancy, including early detection pre-eclampsia, suggests pregnant client choose measure BP addition BP measurement clinic setting (17) . Following diagnosis hypertensive disorder deemed eligible health worker, client us BP device approved hom",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "71dfc0a9-d163-4414-bce5-b11fcea8ae97",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "er deemed eligible health worker, client us BP device approved home-based use take BP measurements, sometimes multiple time day, depending treatment plan. time pregnant client take BP reading, enter information BP measurement device. response, personal health tracking application generates various action based system’s comparison self-monitoring blood pressure (SMBP) measurement result standard BP threshold specific hypertensive conditions. One action could collect contextual data client’s current condition, behaviour environment around time SMBP measurement. Another action may instruct client contact health worker go health facility right away consultation, addition continuing regular ANC contacts. SMBP continues birth (or birth needed), health worker change manag",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c765e3ca-690b-4d3d-88dd-46e708c41c9d",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "SMBP continues birth (or birth needed), health worker change management plan.1Health intervention recommendation Component17 Health intervention recommendationsrecommendations persona scenario workflow data decision requirementsDigital health intervention covered DAK Table 2 contains digital health intervention (DHI) incorporated DAK, extracted WHO’s Classification digital intervention (14) : Table 2. Digital health intervention DHI category DHIs 1.1 Targeted communication person 1.1.1 Transmit health event alert specific population group(s) 1.1.2 Transmit targeted health information specific person(s) based health status demographic 1.1.3 Transmit targeted alert reminder person(s) 1.1.4 Transmit diagnostics result, availability result, person(s) 2.1 Identification registration person 2.1.2 Enrol person(s) health services/clinical care plan 1.4",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8277aa89-02c9-49e3-94f3-33d470e48c96",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "tion registration person 2.1.2 Enrol person(s) health services/clinical care plan 1.4 Personal health tracking 1.4.1 Access individual medical summary health record 1.4.2 Self-monitoring health diagnostic data individual 1.4.3 Active data capture/documentation individual 1.4.4 Access individual verifiable documentation health event health status 2.10 Laboratory diagnostics imaging management 2.10.3 Capture diagnostic result digital device guidelines, recommendation guidance DAKs intended reflect health recommendation content already published guideline guidance documents. health content intervention DAK module based following documents. guideline self-care intervention health well- being, 2022 revision (2022) (17) Managing complication pregnancy childbirth: guide midwife doctors,",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8f33b17d-4c56-4053-b230-f947342014c6",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "(2022) (17) Managing complication pregnancy childbirth: guide midwife doctors, second edition (2017) (27) recommendation antenatal care positive pregnancy experience (2016) (28)18 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirement technical specification automated non-invasive blood pressure measuring device cuff (2020) (29) HEARTS: technical package cardiovascular disease management primary health care: evidence-based treatment protocol (2018) (30) recommendation home-based record maternal, newborn child health (2018) (31) Counselling maternal newborn health care: handbook building skill (2013) (32) Classification self-care intervention health: shared language describe us self-care intervention (2021) (18) Pregnancy, childbirth, postpartum newborn c",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "594e26de-4a3c-44ca-af98-687ade2761db",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "e us self-care intervention (2021) (18) Pregnancy, childbirth, postpartum newborn care: guide essential practice, third edition (2015) (33) document represented DAK include: » HEARTS: technical package cardiovascular disease management primary health care: healthy-lifestyle counselling (2018) (34) ; » Implementation tools: package essential noncommunicable (PEN) disease intervention primary health care low-resource setting (2013) (35) ; » recommendation prevention treatment pre-eclampsia eclampsia (2011) (36) ; » Noncommunicable disease education manual primary health care professional patient (2017) (37) ; » Practical guide design, use promotion home-based record immunization programme (2015) (38) .19 recommendation persona scenario workflow data decision requirementsA persona depiction relevant stakeholder, end user digital system. speci",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "88a0f70e-b763-4c54-918a-dc03b350c57c",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "entsA persona depiction relevant stakeholder, end user digital system. specific role demographic profile persona vary depending local setting. available, generic persona various health worker role based description International Standard Classification Occupations (ISCO) (39) , competency qualification denoted health workforce documentation. Generic persona role self-care intervention ecosystem, including clients, based characteristic people use self-care intervention (21) , well published literature. noted persona reflect synthesis profile across multiple contexts. contextualization required local level according needs, motivation challenge persona setting. Targeted generic persona persona generic depiction relevant stake",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b521a033-73d7-48ec-b20d-6a4aa9b6b216",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "onas setting. Targeted generic persona persona generic depiction relevant stakeholder, end user system. key user persona self-care intervention vary depending business process, well self-care intervention used. focus self-care intervention client – key persona business process – health worker also play essential roles. Descriptions key persona given Table 3 . Table 3. Descriptions key generic persona self-care intervention Occupational titleDescription Different name ISCO code (39) Client person acting “promote health, prevent disease, maintain health, cope illness disability without support health worker” (21) using self-care intervention themselves, family member friend voluntarily give care without compensation. Clients diverse population group, representing different demogra",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "90e96ddb-6d88-46b4-bd91-494b83e2e4a5",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "care without compensation. Clients diverse population group, representing different demographics, background social situations, varying motivation choosing self-care interventions. Clients may use self-care intervention one condition choose facility-based intervention another. may also choose self-care intervention vulnerable population, avoiding facility-based care access issue fear stigma, discrimination repercussions. Clients typically extensive health-care knowledge training.Self-carer, individual, family member, pregnant womanNone ISCO: International Standard Classification Occupations.2Generic persona Component20 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirementsRelated persona addition targeted persona detailed above, may value explori",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b2a58c08-879a-45bd-ac97-962d03df9ee5",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "tsRelated persona addition targeted persona detailed above, may value exploring health worker occupational group persona within context SMBP . However, identified central persona data decision-support content detailed DAK. Additional related persona listed Table 4 . Table 4. Descriptions additional related persona Occupational titleDescription Different name ISCO code (39) Midwife person assessed registered state midwifery regulatory authority similar regulatory authority. offer care childbearing woman pregnancy, labour birth, postpartum period. also care newborn assist mother breastfeeding. education last three, four year nursing school, lead university postgraduate university degree, equivalent. registered midwife full range midwifery skill (39) . R",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2a0c721a-3a88-41be-827a-e4b074b40a9c",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ity degree, equivalent. registered midwife full range midwifery skill (39) . Registered midwife, professional midwife, community midwife2222 (Midwifery professionals) Nurse graduate legally authorized (registered) practise examination state board nurse examiner similar regulatory authority. Education includes three, four year nursing school, lead university postgraduate university degree, equivalent. registered nurse full range nursing skill (39) .Registered nurse, nurse practitioner, clinical nurse specialist, advance practice nurse, practice nurse, licensed nurse, diploma nurse, nurse clinician2221 (Nursing professionals) Auxiliary nurse midwife Auxiliary nurse midwife (ANMs) assist midwife physician provision maternal newborn health care, particularly childbirth, also antenatal postpartum periods. ANMs also advise educate",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "28d25f7b-f903-48d1-b8e7-9201799db449",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "childbirth, also antenatal postpartum periods. ANMs also advise educate expectant mother symptom management, behaviour, hygiene diet pregnancy, well baby care postpartum. possess competency needed midwifery fully qualified midwife (39, 40) .Auxiliary midwife (e.g. bidan Indonesia), assistant midwife3231 (Nursing associate professionals) 3222 (Midwifery associate professionals) Community health workerCommunity health worker (CHWs) provide health education referral wide range services, provide support assistance communities, family individual preventive health measure gaining access appropriate curative health social services. create bridge provider health, social community service community may difficulty accessing service (41) . Lay health worker, community health volunteer, village health",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "29f5fedc-4522-445b-b162-adc98cb21bf0",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "accessing service (41) . Lay health worker, community health volunteer, village health worker, treatment supporter, promoter3253 (Community health workers); would vary context ISCO: International Standard Classification Occupations.21 Generic personasrecommendations persona scenario workflow data decision requirementsAdditional consideration contextualizing persona Although section provides overview generic role targeted personas, important contextualize persona setting. persona described Tables 3 4 supplemented reflecting additional considerations. » Background demographic : example, age familiarity digital devices? mobile phone smartphone? » Context : level internet connectivity? persona compensated? far away nearest referral facility? persona health worker",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b23e80a8-7efd-458c-8e87-ff27095c01e1",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "mpensated? far away nearest referral facility? persona health worker interact with? » Challenges : day-to-day challenge end user might face?22 recommendation persona scenario workflow data decision requirementsUser scenario narrative description end user would interact digital system. user scenario provided help reader better understand system used would fit existing workflows. provide context story format. Furthermore, within user scenario, possible derive key component elaborated rest DAK. includes core data elements, decision-support logic core functionality needed digital system. user scenario should: » include persona involved based generic persona component; » narrative description digital system would used; » provide de",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b7f6fc79-ed27-4111-91f4-8b67e3f4e6c1",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "mponent; » narrative description digital system would used; » provide detail kind data collected decision made; » reflect workflow elaborated Component 4: Business process workflow . interpret user scenario User scenario helpful tool improve understanding context digital tool would operate also generate insight key data element would need recorded accounted database. Additionally, context tool would operate, illuminated user scenarios, provides insight functional non-functional requirement system would also need. example, user scenario below, key data element need recorded and/or calculated highlighted yellow. Highlighted blue decision-support logic automated system. Highlighted green",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d935528f-42fc-4cac-876c-a9ae173a44ed",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "blue decision-support logic automated system. Highlighted green key functional non-functional requirement included system. Table 5 provides interpretation example user scenario.33Component User scenarios23 User scenariosrecommendations persona scenario workflow data decision requirementsTable 5. Interpretation scenario identification preparation SMBP Data element collected Decision logic embedded Functional non-functional requirement Unique identifier Gestational age/expected date delivery Systolic blood pressure (BP) Diastolic BP Current health condition Type hypertensive disorder pregnancyDetermine contextual data self-monitoring blood pressure (SMBP) SMBP health action Danger signsAbility generate list health action response SMBP result Provide link training material review use SMBP device User scenario",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1067f6cf-68d4-46cd-9ac5-3bb911c467e3",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "P result Provide link training material review use SMBP device User scenario identification preparation SMBP Key Personas Client: Grace Community health worker: Irene Nurse/midwife: Aisha Grace pregnant life far away nearest health clinic. Irene, community health worker (CHW), visit Grace regularly check provide ANC support, clinic contacts. Grace fifth month pregnancy , Irene find Grace’s BP elevated, 148/94 mmHg . arranges Grace visit clinic right away, Aisha, nurse/midwife, performs clinical examination (including proteinuria test) find Grace immediate danger . However, diagnose Grace gestational hypertension. prevent complications, Aisha want monitor Grace’s BP daily, Irene check frequently. challenging Grace travel clinic, Aish",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "502fd903-1353-4a9f-b67b-dd469a6c52c6",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "eck frequently. challenging Grace travel clinic, Aisha belief Grace good candidate SMBP , Aisha discusses SMBP intervention Grace. Aisha teach Grace use BP measurement device properly, giving pamphlet link training video . also show Grace help option personal health tracking application . asks Grace demonstrate learned taking BP measurement examination room.24 recommendation persona scenario workflow data decision requirementsA business process set related activity task performed together achieve objective health programme area, registration, counselling, referral (12, 24). Workflows visual representation progression activity (tasks, events, interactions) performed within business process (24) . workflow provides story business process diagram",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3e3519c7-0939-4013-94e1-52bb8ad7ff29",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "business process (24) . workflow provides story business process diagrammed used enhance communication collaboration among users, stakeholder engineers. DAK focus key business process conducted persona (described Component 2 ) part SMBP pregnancy. business process described Table 6 . business processes, corresponding business processes, data element decision-support need detailed within following section document. Table 6 provides overview key business process conducted various persona self-care intervention ecosystem. business process, table summarizes objective, task set trigger motivate persona tasks. Taken together, business process provide comprehensive picture self-care client’s health journey using intervention may benefit pe",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "278f31c4-ecd5-4de0-bd98-456a3a4ec5c8",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "icture self-care client’s health journey using intervention may benefit personal health tracking application. However, keep scope manageable within realm WHO’s mission, business process fully operationalized. Therefore, although DAK module describes business process workflows, annotations, functional non-functional requirements, half decision logic data element ready DAK reader adapt deploy digital systems. Future iteration DAK operationalize business process further.4Business process workflowsComponent25 Business process workflowsrecommendations persona scenario workflow data decision requirementsTable 6. Overview business process SMBP pregnancy Process name Process ID Personas Objective Task set Title ID used reference process throughout digital adaptation kit (DAK)Individuals interacti",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "13c277a6-b734-4734-808d-66a330545dca",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "used reference process throughout digital adaptation kit (DAK)Individuals interacting complete processA concrete statement describing process seek achieveThe general set activity performed within process A. Identification preparation SMBPSMBP .A »Nurse »Auxiliary nurse midwife (ANM) »Community Health Worker (CHW) »Physician »Midwife »ClientTo identify client eligible self- monitoring blood pressure (SMBP), counsel client SMBP , guide client taking blood pressure (BP) measurement set personal health tracking intervention. component workflow meant integrated antenatal care (ANC) contact client diagnosed hypertensive disorder pregnancy. Starting point: SMBP option management client’s condition. »Identify need self-monitoring intervention consultation (identification health worker) »Obt",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e2d88f69-d832-4d0b-a5dd-ca77536e54b2",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "need self-monitoring intervention consultation (identification health worker) »Obtain self-monitoring device/health-care product access »Set personal health tracking application »Learn use self-monitoring device run test scenario client perform home B. Conduct SMBP SMBP .B »Client conduct SMBP understand health action response BP measurement/ data outputStarting point: client need take measurement using self- monitoring device. »Prepare measurement »Conduct measurement register system »Check action level support »Seek professional support care services, needed »Confirm schedule next measurement event C. ANC contactaSMBP .C/ ANC.B »Client »ANM nurse midwifeTo counsel provide ANC service pregnant womanStarting point: woman registered ready begin ANC contact. »Record health history »Assess da",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ce1d642b-ea93-4d24-a41d-137912051f17",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "t: woman registered ready begin ANC contact. »Record health history »Assess danger sign »Assess current pregnancy conditions, including symptoms, perform physical exam lab test »Conduct case management make referral »Schedule follow-up contact »Provide counselling health topic necessary (e.g. nutrition, HIV testing, family planning, psychosocial support services) ANC: antenatal care; ANM: auxiliary nurse midwife; BP: blood pressure; CHW: community health worker; DAK: digital adaptation kit; ID: identification; SMBP: self-monitoring blood pressure. See WHO’s Digital adaptation kit antenatal care: operational requirement implementing recommendation digital system (ANC DAK) (20) . 26 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirementsOverview key process section illustrates workflow identified",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3b1061d2-81eb-480f-a2f0-51d482b4d30a",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "sion requirementsOverview key process section illustrates workflow identified process using standardized notation business process mapping, based business process model notation (BPMN) standard (42) . Table 7 provides overview notation, Figure 5 show overview key process SMBP . Table 7. Business process symbol used workflow Symbol Symbol name DescriptionLane 1 Lane 2 Lane 3PoolPool pool assumes process control – words, assigns tasks. pool consists one so-called swim lane depict individual type user involved carrying business process workflow. Diagrams clear, neat easy viewer understand relationship across different swim lanes. example, pool would depict business process conducting outreach activity, involves multiple stakeholder represented different lane po",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "86e4d768-c1a5-4294-b054-820b76cbc029",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "n outreach activity, involves multiple stakeholder represented different lane pool. business process diagram contain two pool connect message flow (messages received outside pool). indicates different process owner collaborating exchanging information. example, case referral, health facility (the referring facility) represents process owner assigns internally task actor represented swim lane pool. Health facility B (the receiving facility) allocated pool considered different process owner, role. two facility exchange information relevant referral (client history, referral details, etc.), represented message flows, facility control internal activities, without directly impacting activity facility.Lane 2 Lane 3Pool Lane 1Swim lane individual type user",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a4c8f01d-2fd3-4408-8835-af68f610eae4",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "tivities facility.Lane 2 Lane 3Pool Lane 1Swim lane individual type user assigned swim lane , designated area noting activity performed expected specific actor. example, health worker may one swim lane; supervisor would another swim lane; client patient would classified another swim lane. Start event trigger eventThe workflow diagram contain start end event , defining beginning completion task, respectively. Start event messageThis type start event. instances, workflow start message . message business process model notation indicate letters, email calls, also includes information exchanged two different systems, data exchange, notifications. action refers specific addressee represents contains information addressee message. End e",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ed921333-d78c-4e58-bbaa-ab964559b72b",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "specific addressee represents contains information addressee message. End event multiple end event depicted across multiple swim lane business process diagram. However, diagram clarity, one end event per swim lane. Activity, process, step taskEach activity start verb, example, “register client” , “calculate risk” . start end workflow, series activity noting successive action performed actor swim lane. also subprocesses activity. +Activity subprocessThis denotes activity much longer subprocess detailed another diagram. diagram start become complex unhelpful, subprocess symbol used reference another process depicted another page. Activity business ruleThis denotes decision-making activity requires business rule , decisi",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8993f614-5e78-4aec-9881-29ebcf841bfe",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "th business ruleThis denotes decision-making activity requires business rule , decision-support logic , detailed decision-support table. mean logic described decision-support table come play activity, outlined business process. usually reserved complex decisions. 27 Business process workflowsrecommendations persona scenario workflow data decision requirementsSymbol Symbol name Description Sequence flow denotes flow direction one process next. end event output arrows. symbol (except start event) may unlimited number input arrows. symbol (except end event gateway) one one output arrow, leading new symbol, looping back previously used symbol end event symbol. Connecting arrow intersect (cross) other. Message flow denotes flow data",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "03ab2301-949d-4317-b8ac-bb1c772b2220",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "g arrow intersect (cross) other. Message flow denotes flow data information one process another. usually used data shared across swim lane stakeholder groups. Exclusive gateway symbol used depict fork , decision point , workflow, may simple binary (e.g. yes/no) filter two corresponding output arrows, different set outputs. two different output originate decision point. find needing two output sequence flow arrows, likely trying depict decision-support logic business rule. depicted activity business rule (above) instead. Parallel gateway parallel gateway used model concurrency process. type gateway allows forking multiple path execution joining multiple incoming path execution. important difference g",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "04f15334-d3eb-4f2b-8fc5-241ebc5896e4",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "execution joining multiple incoming path execution. important difference gateway type parallel gateway evaluate conditions. Throw – link event throw – link event serf start off-page connector. end process room page workflow. end process current page end subprocess part larger process. catch – link need follow throw – link . Catch – link event catch – link serf end off-page connector. start new process different page throw – link start subprocess part larger process. throw – link must aligned catch – link . ~Ad hoc marker ad hoc subprocess contain multiple activity (tasks subprocesses), executed order, executed several time skipped. However, activity need",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dee7c33b-3d88-4beb-9dc2-79bf70a1287b",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "executed order, executed several time skipped. However, activity need finished moving next activity. Loop activity loop activity indicates activity repeat defined condition either applies cease apply. condition loop executes included annotation.28 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirementsFig. 5. Overview key process SMBP antenatal period * See Digital adaptation kit antenatal care: operational requirement implementing recommendation digital system (ANC DAK) information (20) . Health facility home Client Health workerStart 1. ANC contact 2. Preparation SMBP 4. Referral needed3. Conduct SMBP 6. ANC referralYes7. ANC Contact EndNo* Health facility home Client Health workerStart 1. ANC contact 2. Preparation fo",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "527fbb92-5493-4201-9159-af13fa6b3b06",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "Contact EndNo* Health facility home Client Health workerStart 1. ANC contact 2. Preparation SMBP 4. Referral needed3. Conduct SMBP 6. ANC referralYes7. ANC Contact EndNo29 Business process workflowsrecommendations persona scenario workflow data decision requirementsWorkflows Workflows represent progression activity performed within business process. help user stakeholder understand relationship activities, data element decision-support needs. workflow shown depict process generalized may reflect variation nuance across different settings. Also, simplicity workflow may adequately illustrate non-linear step may occur. Business process A: Identification preparation SMBP Objective: identify client eligible SMBP , counsel client SMBP , guide client taking blood pressure measurement set personal health tracking applicat",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3742ac1c-0c79-439d-9d31-61445d6f724d",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "lients taking blood pressure measurement set personal health tracking application ( Fig. 6 ). Fig. 6. Workflow A: Identification preparation SMBP Health facility Client Health worker Start1. Identification hypertensive condition ANC contact2. Determine eligibility SMBP3. Counsel propose SMBP5. Continue traditional facility- based monitoring6. Teach client SMBP End Follow-up ANC Contact4. Accepts SMBP?7. Wishes continue 8. Calibrate BP measurement device10. Demonstrate SMBP procedure B. Conduct SMBP 11. Reinforce provide assistance necessary9. Download setup personal health tracking application NoYes NoYes Health facility home Client Health workerStart 1. ANC contact 2. Preparation SMBP 4. Referral needed3. Conduct SMBP 6. ANC referralYes7. ANC Contact EndNo30 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow dat",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3fe5666a-9fee-4c5a-b686-4254ae7688e7",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "r self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirementsIDENTIFICATION PREPARATION SMBP PROCESS NOTES ANNOTATIONS 1. Identification hypertensive condition ANC contact »The Digital adaptation kit antenatal care: operational requirement implementing recommendation digital system (ANC DAK) (20) describes clinical protocol relevant diagnosing hypertensive disorder pregnancy identifying whether sign symptom common indicate something serious. Therefore, data dictionary element decision logic table DAK module refer activity ANC DAK. 2. Determine client eligibility SMBP »The health worker identifies whether client eligible use SMBP intervention, assessing client’s ability meet criterion defined decision logic health worker-facing module sel",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f2709804-aa5f-4598-933c-5ecb6faba787",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ility meet criterion defined decision logic health worker-facing module self-care interventions. »For SMBP intervention, facility-based health worker determines eligibility. Also, intervention may appropriate pregnant clients, even wish use it. »The health worker request permission client share SMBP data digital personal health record facility-based health record. Alternatively, SMBP data may recorded paper, client counselled requested share BP information. permission granted, skip Step 5 continue routine ANC contacts. Also, client opts initially, may change mind, health worker check step subsequent contacts. 3. Counsel propose SMBP »The health worker provides counselling option SMBP , describing option work,",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e1a1993f-e75d-4b2b-8fc5-b3569ff125d9",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "th worker provides counselling option SMBP , describing option work, pro con each.4. Accepts SMBP? »Based counselling provided health worker (as well information learned earlier client’s research), client decides whether conduct SMBP . »The health worker record client’s choice facility record. 5. Continue facility-based monitoring care »If client chooses conduct SMBP , health worker continue traditional facility-based monitoring care. 6. Teach client SMBP work »The health worker teach client conduct SMBP . health worker demonstrates use BP measurement device personal health tracking intervention. client need use tool own, health worker spend time step, including asking client practise using tool front health worker. »When appropriate,",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "de63fdcc-3534-4c57-a940-668901dfafcb",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "sking client practise using tool front health worker. »When appropriate, health worker provides client training materials. include link training video electronic written/ visual material client access personal health tracking application, printed handout client take home. »For client using SMBP intervention, health worker tell client follow-up appointment scheduled soon one, check client BP measurement device. »The client also counselled obtain BP device SMBP . 7. Client wish continue? »The client determines whether wish continue. wish continue SMBP , may continue traditional facility-based monitoring next scheduled ANC contact.31 Business process workflowsrecommendations persona scenario workflow data decision r",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "30086560-5404-46f1-b00d-552dd31b0853",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "act.31 Business process workflowsrecommendations persona scenario workflow data decision requirements8. Calibrate BP measurement device »Health worker calibrate BP measurement device needed. may also include determining cuff size preferred arm measurements. 9. Download set personal health tracking application/intervention »Together health worker, client selects downloads personal health tracking application use installs device. »Some client may need review instruction obtain assistance health worker, community support worker personal contact. Prompt client find needed give assistance necessary. »The client input basic health data, date birth, height weight. Included set data client’s unique ID number, used client’s facility-based health record enable accurate record look-up well",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8b13eb49-b839-4315-bd0a-5ba6308db222",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "used client’s facility-based health record enable accurate record look-up well authentication data sharing. »The client input past existing health conditions, well current medication allergies, relevant self- monitoring intervention. medication input, prompt client set reminder ensure medication taken regularly re-order prescriptions. »Prompt client undertake set-up task SMBP . also take baseline BP measurement record personal health tracking application. »Prompt client set schedule reminder SMBP . client’s facility-based health worker determine frequently time day BP measurement taken. recommendation vary depending client’s condition. 10. Client demonstrates SMBP procedure »Encourage client demonstrate procedure SMBP ,",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "eea354c0-0e0d-447d-8739-0613aee8b177",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "lient demonstrates SMBP procedure »Encourage client demonstrate procedure SMBP , health worker help doubt difficulty identified. 11. Reinforce provide assistance necessary »Determine whether client need assistance steps. assistance needed, client fill system relevant information. »Counsel reinforce client procedure SMBP , including need rest reading, body position, need empty bladder, arm position, avoidance speaking measurement relevant information. »Help client cuff positioning, needed, device management measuring BP . »Some client may need refresher training tip use personal health tracking application, including navigate specific part record, input data, see result different formats, etc. Ask clien",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3fc95c1f-9da0-446e-9ee3-8dc257e18f37",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "part record, input data, see result different formats, etc. Ask client need help using software. »Prompt client use tool provided help use software effectively. Note software help tool clear, comprehensive, accessible, appropriate easy follow. »For clients, written instruction may sufficient help use personal health tracking application properly. In-person help may preferred, especially learning technology. help could come personal contact organization (including health facility) aim improve users’ digital literacy, even provide specific support self-monitoring intervention personal health tracking application. 12. Attend ANC follow-up contact »For client using SMBP intervention, important health worker schedule one two follow-up appointment check client",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f1bdcf47-f218-4db8-b6ff-c8ccf4438cc9",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "health worker schedule one two follow-up appointment check client BP monitoring device. »These appointment occur relatively soon initial visit. BP monitoring intervention pregnant client risk pre-eclampsia likely require check-in within one two day initial visit, risk involved outpatient management condition. »At follow-up sessions, health worker discus client’s access usage BP measurement device well personal health tracking application. health worker also coach client different part SMBP intervention. 32 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirementsBusiness process B: Conduct SMBP Objective: conduct SMBP understand health action response BP meas",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e5be20c7-eb8a-4ac3-af69-c066ee8e6f6b",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "onduct SMBP Objective: conduct SMBP understand health action response BP measurement/data output ( Fig. 7 ). Fig. 7. Workflow B: Conduct SMBP Health facility home Client Health workerStart2. Update/confirm personal health record EndC. Follow-up ANC contact1. Determine time conduct SMBP3. Take blood pressure measurement 6.Provide assistance needed4. Input result personal health tracking application7.Review health action 9 .Seek health- care assistance5. Assistance needed10. Share SMBP data8. Action needed11. Repeat SMBP EndNo YesYesHealth facility home Client Health workerStart2. Update/confirm personal health record EndC. Follow-up ANC contact1. Determine time conduct SMBP3. Take blood pressure measurement 6.Provide assistance needed4. Input result personal health tracking application7.Review health action 9 .Seek health- care assistance5. Assistance needed10. Share SMBP data8. Action nee",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9ce96399-f158-4a61-955a-2042532e3799",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "th action 9 .Seek health- care assistance5. Assistance needed10. Share SMBP data8. Action needed11. Repeat SMBP EndNo YesYes33 Business process workflowsrecommendations persona scenario workflow data decision requirementsCONDUCT SMBP PROCESS NOTES ANNOTATIONS 1. Determine time conduct SMBP »The client conduct SMBP agreed time. could learn various ways: reminder set within app another app device; note made paper; memory; family member, caregiver, friend person community. »For SMBP , client need wait least 30 minute eating, drinking physically active measure BP . 2. Update/confirm health profile »Prompt client determine whether change need made health profile created setting personal health tracking application. 3. Take BP measurement »The client take BP measurement acco",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5a7d2e27-23de-492d-911c-d1476af4c180",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "rsonal health tracking application. 3. Take BP measurement »The client take BP measurement according device’s usage instructions. Instructions include educational material intervention product instruction provided device manufacturer. Accurate data collection requires correct device use. »For BP monitoring, one measurement comprises average two reading taken 1–2 minute apart. 4. Input result personal health tracking application »The client input self-monitoring data, BP measurements, personal health tracking application. case client using smart connected device, step may automated. »Some client may need review instruction obtain assistance health worker, community support worker personal contact. 5. Assistance needed? »Client assesses need assistance prior steps.6. Obtain assistance needed »The client obtains assistance using",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fda22415-bc5e-4101-af64-82901d6c6b53",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ith prior steps.6. Obtain assistance needed »The client obtains assistance using BP measurement device, personal health tracking application both. Find question concern client self-monitoring. –Is difficult access BP device? –Are problem using BP device? –Do understand device usage instructions? –Do need help setting up? –Do need learn use correctly, refresher lesson? –Do need help determining read results? –Are trouble remembering self-monitor right time? –Is difficult access device personal health tracking application it? –Are problem using personal health tracking application device? –Do need help inputting information? –Do wish discus health action suggested personal health tracking application? »Coach client co",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "19447b27-054b-49c8-b9e2-5c228674ea03",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "cuss health action suggested personal health tracking application? »Coach client conducting SMBP –Provide client support use device app based issue question noted. –To check client comprehension confidence using device app, ask client demonstrate use device. –If train retrain client proper use device app, demonstrate usage afterwards. –Provide educational material SMBP , available. »Some client may need refresher training tip use personal health tracking application, including navigate specific part record, input data, see result different formats.34 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirements7. Review-health action »Application provides health action(s) based SMBP data var",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d7d71a90-883b-40d4-81a5-3d0d1e45abec",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "nts7. Review-health action »Application provides health action(s) based SMBP data various input pertaining client’s individual health condition, health history, personal information, need preferences. 8. Action needed? »This depends whether client need perform health action provided personal health tracking application response self-monitoring measurement results. One health action could simply continue self-monitoring. »If additional intervention needed, client continues conduct SMBP . 9. Seek health-care assistance »The client seek care service needed information health condition self-monitoring. »This step might occur parallel others within workflow since client may seek information different time self- monitoring. »If health-care product needed additional self-care intervention health acti",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d27103fa-fead-4d93-bb90-f666c925e5e8",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "»If health-care product needed additional self-care intervention health action recommends, help client determine needed provide information products. »Discuss health action personal health tracking application. –Find client need information clarification suggested health action provided personal health tracking application response self-monitoring data inputs. –Do understand health action(s) information? –Do concern question health action(s)? –Do face barrier performing health action(s)? –How interested performing action(s)? –Note level information provided vary depending upon health worker cadre training. 10. Share SMBP data »If client opted electronic data transfer, information communication technology infrastructure support it, transf",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a7c62ead-9e19-4f96-a3f3-81a6d7409fc7",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "data transfer, information communication technology infrastructure support it, transfer SMBP data client’s personal health tracking application facility-based health record. not, health worker copy data hand paper register record ANC contact. 11. Repeat SMBP »The client continues SMBP , returning start workflow time next measurement event next scheduled ANC contact/SMBP follow-up appointment. 35 Business process workflowsrecommendations persona scenario workflow data decision requirementsBusiness process C. ANC contact additional consideration SMBP Objective: counsel provide routine ANC service pregnant women. workflow business process seen Figure 8 (see ANC DAK Business process B. ANC contact [20] information). Additional consideration within Activity 10 (Counselling, in-facility mana",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "46cc92a7-6ee7-4f88-92fa-c91d7d0ee985",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "information). Additional consideration within Activity 10 (Counselling, in-facility management treatment) include: » health worker review client’s self-monitoring data, either within facility-based client record (or community health information system) data transferred, directly digital HB/PHR client opted data transfer. » health worker first-lines quality check data. health worker asks client missing day data, recording relevant information. » Based client assessment review self-monitoring data, health worker provides counselling health condition self- monitored client. » counselling appropriate health worker’s cadre level topic discussed vary intervention client’s specific needs. Fig. 8. Workflow C: ANC contact SRH: sexual reproductive health. Health facility Client Heal",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3a21ecba-bcb2-4df0-81f2-54e26fed00eb",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": ". Fig. 8. Workflow C: ANC contact SRH: sexual reproductive health. Health facility Client Health worker ANC Assessment10. Counselling, in-facility management & treatmentStartArrive facility A. Registration1. Rapid Assessment Management (RAM)2. Danger sign needing referral?3. Confirm pregnancy C. ANC referralYesNo Refer SRH servicesNot pregnant 4. First contact?Pregnant 6. Collect woman’s profile & history 7. Check symptom follow-up8. Conduct physical exam9. Conduct laboratory test imaging11. Referral needed? C. ANC referralYes12. Scheduling13. Self-care intervention home community No14. Woman returns? EndNoYes 5. Quick checkFirst contact first contact10.1 Behaviour counselling10.2 Physiological symptom counselling10.3 Diet counselling 10.4 Diagnosis & treatment 10.5 Nutrition supplementation 10.8 Intimate partner violence first line support care10.6 Risk reduction general counselling",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "57d14da8-05f7-4438-8328-7fa8a4511b3c",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "imate partner violence first line support care10.6 Risk reduction general counselling 10.7 Immunizations10.9 Deworming; malaria counselling prophylaxis36 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirementsAdditional consideration adapting workflow reminder, workflow meant generic high level. require level customization adaptation translated digital system specific context. workflow considered around 80% complete, whereby 20% need completed series human-centred design method mechanism complete workflow implementation. Although workflow considered starting point, helpful conduct validation interview targeted persona obtain better sense difference",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1d208bb2-a780-4f2e-8511-d4e8d3b6afc5",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ation interview targeted persona obtain better sense difference would need reflected digital system.37 recommendation persona scenario workflow data decision requirementsThis section outline minimum set data corresponding different point workflow within identified business processes. data set used software system list data element relevant service delivery executing decision-support logic, populating indicator performance metrics. Although section provides high-level overview data elements, complete data dictionary spreadsheet form detailing input options, validation check concept dictionary code available (https://smart.who.int/dak-smbp/dictionary.html ). Inclusion data element table indicate collection data required. Additionally, data element dependent",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "27a0ca5f-4417-4101-8a79-c8865db293c7",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "indicate collection data required. Additionally, data element dependent data elements, feasibility inclusion, contextual factors. Simplified list core data element Tables 8 9 provide simplified list core data element merely snapshot comprehensive data dictionary. workflows, data dictionary considered 80% generic expectation 20% supplemented modified adaptation appropriate context type end user.5Core data elementsComponent38 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirementsTable 8. Core data element preparation SMBP Activity ID nameData element ID Data element name Description definition Business process SMBP .A: Preparation SMBP SMBP .A1 Identification hypertensive condition ANCSee WHO’s Digital",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4b7ea3f7-d273-4e36-9b3c-b9c0d56ed314",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "paration SMBP SMBP .A1 Identification hypertensive condition ANCSee WHO’s Digital adaptation kit antenatal care: operational requirement implementing recommendation digital system (ANC DAK) (20) SMBP .A2 Determine client eligibility SMBPN/A – data recorded activity SMBP .A3 Counsel propose SMBP option managementN/A – data recorded activity SMBP .A4 Accept SMBPN/A – data recorded activity SMBP .A5 Continue traditional facility-based monitoringN/A – data recorded activity SMBP .A6 Teach client perform SMBPN/A – data recorded activity SMBP .A7 Wishes continueN/A – data recorded activity SMBP .A8 Calibrate BP measurement deviceN/A – data recorded activity SMBP .A9 Download set personal health trackingSMBP .A9.DE1 Unique identification Unique identifier generated",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "762b2e4b-eceb-4ebe-a169-5c6faf9a68a5",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "personal health trackingSMBP .A9.DE1 Unique identification Unique identifier generated health system universal ID, used country SMBP .A9.DE2 Date birth Client’s date birth, known, age SMBP .A9.DE3 Height client’s current height centimetre SMBP .A9.DE4 Current weight client’s current weight kilogram SMBP .A9.DE5 Body mass index (BMI) BMI: calculated taking weight kilogram divided squared height metres, i.e. kg/(m2) SMBP .A9.DE6 Expected date delivery Client’s expected date delivery SMBP .A9.DE7–8 Alternative contact’s name phone number Name phone number alternative contact, could next kin (e.g. partner, mother, sibling) friend; contact used emergency situation SMBP .A9.DE9–11 Contact information closest hospital clinic Name, phone number address closest hospital clinic SMBP .A9.DE12–14 Contact information health worker Name, phone number addr",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e570b71f-53d5-4475-af17-0257291f2170",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "hospital clinic SMBP .A9.DE12–14 Contact information health worker Name, phone number address client’s facility-based health worker SMBP .A9.DE15–17 Contact information pharmacist pharmacy Name, phone number address pharmacist pharmacy client us SMBP .A9.DE18–20 Contact information community health worker (CHW)Name, phone number address client’s community-based health worker contact (if applicable) SMBP .A9.DE21–25 Type hypertensive disorder pregnancy hypertensive disorder pregnancy client diagnosed SMBP .A9.DE26–32 Current health condition Current health condition client relevant self-monitoring blood pressure (SMBP) intervention SMBP .A9.DE33–40 Current medication Medications client currently taking help manage BP SMBP .A9.DE41–43 Pre-pregnancy blood pressure (BP) reading available?Whether BP measurement becoming pregnant available use",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b831a18a-8290-4837-b677-d299f8698d90",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "BP) reading available?Whether BP measurement becoming pregnant available used baseline measurement39 Core data elementsrecommendations persona scenario workflow data decision requirementsActivity ID nameData element ID Data element name Description definition SMBP .A9.DE44–45 Pre-pregnancy systolic BP reading client’s last systolic BP measurement result taken becoming pregnant SMBP .A9.DE46–47 Pre-pregnancy diastolic BP reading client’s last diastolic BP measurement result taken becoming pregnant SMBP .A9.DE48–49 Systolic BP reading taken health worker SMBP prescribedThe client’s last systolic BP measurement taken health worker SMBP recommended SMBP .A9.DE50–51 Diastolic BP reading taken health worker SMBP prescribedThe client’s last diastolic BP measurement taken health worker SMBP recommended SMBP .A9.DE52–58 SMBP cuff previously fitted properly? Whether cl",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e5e2631c-f65b-4a67-85e0-d67a17252651",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "en SMBP recommended SMBP .A9.DE52–58 SMBP cuff previously fitted properly? Whether client already determined proper cuff size SMBP cuff, using cuff-based device SMBP .A9.DE59–65 BP cuff fit Fit BP cuff client’s arm determined decision logic SMBP .A9.DE66–69 Arm determined SMBP measurements? Whether arm SMBP measurement determined, either client health facility SMBP .A9.DE70–72 First seated systolic reading left arm First two systolic BP reading taken left arm, 1–2 minute apart, client seated SMBP .A9.DE73–75 First seated diastolic reading left arm First two diastolic BP reading taken left arm, 1–2 minute apart, client seated SMBP .A9.DE76–78 First seated systolic reading right arm First two systolic BP reading taken right arm, 1–2 minute apart, client seated SMBP .A9.DE79–81 First se",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "792cc45e-df35-4e8c-97fc-d49ed9dc630c",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "g taken right arm, 1–2 minute apart, client seated SMBP .A9.DE79–81 First seated diastolic reading right arm First two diastolic BP reading taken right arm, 1–2 minute apart, client seated SMBP .A9.DE82–86 Arm SMBP measurement Arm used SMBP measurements, based arm producing higher average number set-up SMBP .A9.DE87–88 First seated systolic reading arm SMBP measurementsFirst two systolic BP reading taken designated arm determined set-up SMBP .A9.DE89–91 Second seated systolic reading arm SMBP measurementsSecond two systolic BP reading taken designated arm determined set-up SMBP .A9.DE92–93 First seated diastolic reading arm SMBP measurementsFirst two diastolic BP reading taken designated arm determined set-up SMBP .A9.DE94–97 Second seated diastolic reading arm SMBP measurementsSecond two diastolic BP",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fd728144-39b9-4c62-85a3-2f4f46784839",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": ".A9.DE94–97 Second seated diastolic reading arm SMBP measurementsSecond two diastolic BP reading taken designated arm determined set-up40 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirementsTable 9. Core data element conducting SMBP Activity ID name Data element ID Data element name Description Business process SMBP .B: Conduct SMBP SMBP .B1 Prepare conduct SMBP N/A – data recorded activity SMBP .B2 update health profile? See SMBP .A9 Download set personal health tracking SMBP .B3 Take blood pressure measurement N/A – data recorded activity SMBP .B4 Input result personal health tracking applicationSMBP .B4.DE1 Time measurement Date time self-monitoring blood pressure (SMBP) measurement SMBP .B4.DE2 First seated systolic reading arm SMBP measurementsFirst two systoli",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3bd6ef1c-e9d0-4e47-8431-ff5d0e800a2d",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "urement SMBP .B4.DE2 First seated systolic reading arm SMBP measurementsFirst two systolic blood pressure (BP) reading taken designated arm determined set-up SMBP .B4.DE3 Second seated systolic reading arm SMBP measurementsSecond two systolic BP reading taken designated arm determined set-up SMBP .B4.DE4 Average seated systolic reading arm SMBP measurementsAverage two systolic BP reading taken designated arm, 1–2 minute apart, client seated SMBP .B4.DE5 First seated diastolic reading arm SMBP measurementsFirst two diastolic BP reading taken designated arm determined set-up SMBP .B4.DE6 Second seated diastolic reading arm SMBP measurementsSecond two diastolic BP reading taken designated arm determined set-up SMBP .B4.DE7 Average seated diastolic reading arm SMBP measurementsAverage two diastolic BP reading taken designa",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "40c8ef6f-2a19-4dee-a918-638fe04a2a9c",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "lic reading arm SMBP measurementsAverage two diastolic BP reading taken designated arm, 1–2 minute apart, client seated SMBP .B4.DE8–39 Contextual data measurement requiredWhether client need input contextual data SMBP measurement, current symptoms, recent food drink consumed, recent physical activity SMBP .B4.DE40–50 Danger sign Symptom classified danger sign pregnancy; select “No danger signs” none moment SMBP .B5 Assistance needed? N/A – data recorded activity SMBP .B6 Provide assistance needed N/A – data recorded activity SMBP .B7 Review health action based SMBP resultsN/A – data recorded activity SMBP .B8 Action needed? N/A – data recorded activity SMBP .B9 Seek health-care assistance N/A – data recorded activity SMBP .B10 Share SMBP data N/A – data recorded activity",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e3e756a3-87e5-403c-b949-6a46b4a6aa3a",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "orded activity SMBP .B10 Share SMBP data N/A – data recorded activity SMBP .B11 Repeat SMBP N/A – data recorded activity BP: blood pressure; SMBP: self-monitoring blood pressure.41 recommendation persona scenario workflow data decision requirementsThe decision-support logic component DAK provides decision logic algorithms, scheduling services, accordance guidelines. DAK, decision logic algorithm deconstruct recommendation SMBP pregnancy format clearly label input output would operationalized digital decision-support system. Decision-support logic overview Table 10 provides overview decision-support table algorithm SMBP pregnancy business processes. structure decision-support table based adaptation Decision Model Notation (DMN), industry standard modelling",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "599e0108-30f0-4a37-a80f-b0e3ba647c46",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ased adaptation Decision Model Notation (DMN), industry standard modelling executing decision logic (43) . decision- support table detail business rules, data input output support SMBP pregnancy module. Table 10. Overview decision logic table SMBP pregnancy Activity ID name Decision table ID name Decision table description Reference/source SMBP .B4 Input result personal health tracking applicationSMBP .B4.DT .01 Contextual data SMBPDetermine system prompt client enter contextual data behaviours, mental state environment SMBP measurement takenManaging complication pregnancy childbirth: guide midwife doctors, second edition (2017) (27) HEARTS: technical package cardiovascular disease management primary health care: evidence-based treatment protocol (2018) (30) technical specification automated non-invasive blood p",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7d2a9c90-cd48-495c-bb6e-4dd3a1a1eb59",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "sed treatment protocol (2018) (30) technical specification automated non-invasive blood pressure measuring device cuff (2020) (29) SMBP .B7 Review health action based SMBP resultsSMBP .B7.DT .01 SMBP health actionsDetermine health action client take, based SMBP measurement health condition affect BP cut-off valuesManaging complication pregnancy childbirth: guide midwife doctors, second edition (2017) (27) HEARTS: technical package cardiovascular disease management primary health care: evidence-based treatment protocol (2018) (30) SMBP .B7 Review health action based SMBP resultsSMBP .B7.DT .02 Danger sign Determine client’s current symptom danger sign pregnancy not, health action need taken based determinationManaging complication pregnancy childbirth: guide midwife doctors, second edition (2017) (27) Pregn",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "44b81db2-9c48-42ee-afcd-9c2a43df68da",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "pregnancy childbirth: guide midwife doctors, second edition (2017) (27) Pregnancy, childbirth, postpartum newborn care: guide essential practice, third edition (IMPAC) (2015) (33) SMBP: self-monitoring blood pressure.6Decision-support logicComponent42 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirementsDecision-support table decision logic listed overview table elaborated decision-support implementation tool found (https://smart.who.int/dak-smbp/ decision-logic.html ). decision-support table include component described Table 11 . Table 12 example decision-support logic table danger sign example. Note decision-support logic translated directly guideline guidance document reviewed panel expert created guideline",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "21a37fcf-8353-4f9b-9b48-ab39ed950b6f",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "guidance document reviewed panel expert created guidelines. Although level adaptation may needed depending change workflow change data dictionary, change decision-support logic considered carefully embedded decision-support system greatly affect quality care. helpful decision-support logic health worker client, incorrect decision-support logic also detrimental. Thus, new decision-support logic carefully reviewed agreed upon in-country clinical experts. Table 11. Components decision table Decision ID name decision describing algorithm logic represented (e.g. health action SMBP measurement). decision ID correspond number overview table above. Business rule description decision need made based IF/THEN statement approp",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6b1b6ddd-a01f-4d4d-8605-2f6071772524",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "le description decision need made based IF/THEN statement appropriate data element name variables. rule demonstrate relationship input variable expected output action within decision-support logic (e.g. BP higher 160 systolic BP/110 diastolic BP , client go closest health facility right away). Trigger event would indicate decision-support logic appear within workflow , activity would trigger decision made. Input(s) Output Action Annotations variable condition need considered determine consequent action outputs. multiple input entry row, different input considered condition need place time. resulting action decision based combination input entries. state",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fbadefc6-5ae2-454c-849a-cd64678ac302",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "e time. resulting action decision based combination input entries. statement immediately follows THEN. Examples output may include qualitative measure client’s blood pressure (BP) level (e.g. high high), whether contextual data required accompany self-monitoring blood pressure (SMBP) measurement, presence pregnancy danger sign eligibility SMBP intervention. Note output system variable use decision-support tables.Concrete measure taken based output (e.g. contact health worker, try self-care intervention [to manage routine symptom pregnancy]). cases, output action may same. output may yield multiple actions, denoted separate column. Actions first word sentence case versus capital letter (e.g. use versus USE) action client undertake. Actions first",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b661f92c-28e9-4384-b589-815358b62fad",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "letter (e.g. use versus USE) action client undertake. Actions first word capital letter action system take.Additional explanation descriptions, including possible pop-up alert message relevant background information. section also include written content would appear pop-up message notifying client appropriate health action take and, cases, reason recommended actions. include health information accompany action provide context motivation client take health action, referral health worker, facility community organization, health information explain self-monitoring result.Inputs placed different row considered condition considered independently input rows. BP: blood pressure; SMBP: self-monitoring blood pressure.43 Decision-support logicrec",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a7ab3258-ec13-4341-bc7a-c13ed6129f36",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ther rows. BP: blood pressure; SMBP: self-monitoring blood pressure.43 Decision-support logicrecommendations persona scenario workflow data decision requirementsTable 12. Example decision-support logic table danger sign Decision-support table ID SMBP .B7.DT .02 Decision name Danger sign Activity ID SMBP .B7 Review health action based SMBP result Inputs Outputs Action Annotations References \"Danger sign\" = \"Breathing difficulty\" \"Danger sign present?\" = TRUE Contact health worker right away contact health worker go nearest health facility right away.Managing complication pregnancy childbirth: guide midwife doctors, second edition (2017) (27) Pregnancy, childbirth, postpartum newborn care: guide essential practice, third edition (IMPAC) (2015) (33) \"Danger sign\" = \"Bleeding vaginally\" \"Danger sign present?\" = TRUE Contact health worker right away contact health worker go",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "abb96b98-4579-48ad-9972-ecbc4f4ad9be",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "present?\" = TRUE Contact health worker right away contact health worker go nearest health facility right away. \"Danger sign\" = \"Convulsing\" \"Danger sign present?\" = TRUE Contact health worker right away contact health worker go nearest health facility right away. \"Danger sign\" = \"Severe headache\" \"Danger sign present?\" = TRUE Contact health worker right away contact health worker go nearest health facility right away. \"Danger sign\" = \"Visual disturbance\" \"Danger sign present?\" = TRUE Contact health worker right away contact health worker go nearest health facility right away. \"Danger sign\" = \"Severe abdominal pain\" \"Danger sign present?\" = TRUE Contact health worker right away contact health worker go nearest health facility right away. \"Danger sign\" = \"Fever\" \"Danger sign present?\" = TRUE Contact health worker right away contact health wor",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fb408924-7ef1-4ac0-8a6a-06c716d68f4b",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ver\" \"Danger sign present?\" = TRUE Contact health worker right away contact health worker go nearest health facility right away. \"Danger sign\" = \"Severe vomiting\" \"Danger sign present?\" = TRUE Contact health worker right away contact health worker go nearest health facility right away. \"Danger sign\" = \"No danger signs\" \"Danger sign present?\" = FALSEContinue SMBP current symptom danger sign pregnancy. Continue self-monitor regularly danger sign though. SMBP: self-monitoring blood pressure.44 recommendation persona scenario workflow data decision requirementsThis section provides overview illustrative functional non-functional requirement may considered kick-start process designing adapting personal health tracking application. Functional requirement describe capability system must meet end users’ need achieve task within busine",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a9073045-70ff-4a59-87fb-a82abe454c8b",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "capability system must meet end users’ need achieve task within business process. Non-functional requirement provide general attribute feature digital system ensure usability overcome technical physical constraints. Examples non-functional requirement include ability work offline, multiple language setting password protection. Table 13 highlight key functional requirement executing business process listed Component 4 document. Table 14 provides non-functional requirement general characteristic overall system. complete set functional non-functional requirement accessed functional non-functional requirement implementation tool, available (https://smart.who.int/dak-smbp/system-requirements.html ). Please note exhaustive list modified according context user persona needs. Functional requirement",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "32fb806a-62e1-44d3-a6a9-fb8b7ec2dbcc",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "e list modified according context user persona needs. Functional requirement Table 13. Functional requirement Requirement ID Activity ID name a… want… that… Business process A: Identification preparation SMBP pregnancy SMBP .FXNREQ.1 SMBP .A9 Download set personal health tracking applicationPregnant woman conducting self-monitoring blood pressure (SMBP)To view location information health workerI contact health worker needed. SMBP .FXNREQ.2 SMBP .A9 Download set personal health tracking applicationPregnant woman conducting SMBP able enter contact information information sharing health worker. SMBP .FXNREQ.3 SMBP .A9 Download set personal health tracking applicationPregnant woman conducting SMBP view step need follow setting SMBP intervention initiate SMBP right information. SMBP .FXNREQ.4 SMBP .A9 Download",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9db87011-9664-490a-a4c1-96e3de4572fc",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ervention initiate SMBP right information. SMBP .FXNREQ.4 SMBP .A9 Download set personal health tracking applicationPregnant woman conducting SMBP view brief explanation importance set-up taskI initiate SMBP right information.9High-level functional non-functional requirement Component45 High-level functional non-functional requirementsrecommendations persona scenario workflow data decision requirementsRequirement ID Activity ID name a… want… that… SMBP .FXNREQ.5 SMBP .A9 Download set personal health tracking applicationPregnant woman conducting SMBP system provide prompt step set-up taskI ensure necessary information completed. SMBP .FXNREQ.6 SMBP .A9 Download set personal health tracking applicationPregnant woman conducting SMBP view link information training material demonstrate set-up task SMBP interventio",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a53c7ba7-8045-4bda-b0d2-1703f6c522a4",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "k information training material demonstrate set-up task SMBP interventionI initiate SMBP right information. Business process B: Conduct SMBP SMBP .FXNREQ.7 SMBP .B2 Updates/confirms personal health recordPregnant woman conducting SMBP prompt reminding perform SMBP intervention set scheduled health eventI take appropriate health action conduct SMBP safely. SMBP .FXNREQ.8 SMBP .B2 Updates/confirms personal health recordPregnant woman conducting SMBP prompt reminding protocol need follow advance taking measurement SMBP device, applicableI take appropriate health action conduct SMBP safely. SMBP .FXNREQ.9 SMBP .B2 Updates/confirms personal health recordPregnant woman conducting SMBP prompt asking input new health condition diagnosed personal health tracking application set-up last health profile",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "25956472-652b-47d7-9ce3-f24651dab896",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "agnosed personal health tracking application set-up last health profile updateI take appropriate health action conduct SMBP safely. SMBP .FXNREQ.10 SMBP .B4 Input result personal health recordPregnant woman conducting SMBP prompt reminding key symptom need watch conducting symptom monitoringI take appropriate health action conduct SMBP safely. SMBP .FXNREQ.11 SMBP .B4 Input result personal health recordPregnant woman conducting SMBP prompt reminding key step need remember using SMBP measurement device, applicableI take appropriate health action conduct SMBP safely. SMBP .FXNREQ.12 SMBP .B4 Input result personal health recordPregnant woman conducting SMBP view brief explanation importance using SMBP measurement device correctlyI take appropriate health action conduct SMBP safely. SMBP .FXNREQ.13 SMBP .B",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cbaa0de8-9bbc-4c36-9629-186d0818c0eb",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "correctlyI take appropriate health action conduct SMBP safely. SMBP .FXNREQ.13 SMBP .B4 Input result personal health recordPregnant woman conducting SMBP view link training material use learn review use SMBP deviceI conduct SMBP appropriately. SMBP .FXNREQ.14 SMBP .B4 Input result personal health recordPregnant woman conducting SMBP compare measurement data input indicator health condition monitoredI take appropriate health action conduct SMBP safely. SMBP .FXNREQ.15 SMBP .B7 Review health action Pregnant woman conducting SMBP list health action response SMBP data inputI know action take conducting SMBP . SMBP .FXNREQ.16 SMBP .B7 Review health action Pregnant woman conducting SMBP system provide context-sensitive, real- time decision support response entry SMBP data (alerts, advice, resources)I know acti",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a5f2fc6c-3b93-4fb7-88ef-a4ed462c4a2b",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "time decision support response entry SMBP data (alerts, advice, resources)I know action take conducting SMBP . SMBP .FXNREQ.17 SMBP .B7 Review health action Pregnant woman conducting SMBP view context-specific information response entry SMBP dataI know action take conducting SMBP . SMBP .FXNREQ.18 SMBP .B7 Review health action Pregnant woman conducting SMBP prompt suggests need contact health worker based decision supportI know action take conducting SMBP .46 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirementsNon-functional requirement Table 14. Non-functional requirement Requirement ID Category Non-functional requirement SMBP .NFXNREQ.1 System requirement – general Provide unique version number revision SMBP .NFXNREQ.2 System requirement – general Enable earlier vers",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9993dc50-389a-4dca-8aec-7a2147b4fc3c",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "version number revision SMBP .NFXNREQ.2 System requirement – general Enable earlier version record recoverable SMBP .NFXNREQ.3 System requirement – general Enable deployment environment subject power loss SMBP .NFXNREQ.4 System requirement – general Work environment subject loss connectivity SMBP .NFXNREQ.5 System requirement – general Report version number saving data database SMBP .NFXNREQ.6 System requirement – general designed flexible accommodate future change SMBP .NFXNREQ.7 System requirement – general Allow offline online functionality SMBP .NFXNREQ.8 System requirement – general Show number record yet synchronized SMBP .NFXNREQ.9 System requirement – general ability easily back information SMBP .NFXNREQ.10 System requirement – general Warn user valid back-up predefined number day SMBP .NFXNREQ.11 System requirement – general",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0f97b98e-3c1d-4965-a5cd-51d4ba60a583",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "id back-up predefined number day SMBP .NFXNREQ.11 System requirement – general Able store image unstructured data SMBP .NFXNREQ.12 System requirement – general Provide ability user share data systems, including remote one SMBP .NFXNREQ.13 System requirement – configuration Configure business rule line guideline standard operating procedure SMBP .NFXNREQ.14 System requirement – configuration Configure error message SMBP .NFXNREQ.15 System requirement – configuration Configure workflow business rule accommodate difference facility SMBP .NFXNREQ.16 System requirement – hardware connectivity Allow data exchange efficient synchronization across multiple facility point service internet available, even intermittent slow SMBP .NFXNREQ.17 System requirement – interoperability Communicate external system mediator SMBP .NFXNREQ.18 System",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "030e5a98-01d9-4b05-884e-5a2546076f6b",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "t – interoperability Communicate external system mediator SMBP .NFXNREQ.18 System requirement – interoperability Provide access data application programming interface SMBP .NFXNREQ.19 System requirement – interoperability interoperable external system mediator SMBP .NFXNREQ.20 System requirement – interoperability Link financial system process insurance claims, voucher health financing option order verify eligibility submit claim SMBP .NFXNREQ.21 System requirement – interoperability Exchange data approved system SMBP .NFXNREQ.22 System requirement – interoperability Accept data multiple input method including paper, geocoding (geopolitical positioning system [GPS]) SMBP .NFXNREQ.23 System requirement – usability end user-friendly, including people low computer literacy SMBP .NFXNREQ.24 System requirement – usability Provide informative error message tooltips SMBP",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3ba8ba4e-7762-4884-baa2-0668748622fc",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "P .NFXNREQ.24 System requirement – usability Provide informative error message tooltips SMBP .NFXNREQ.25 System requirement – usability Alert end user navigating away form without saving SMBP .NFXNREQ.26 System requirement – usability Support real-time data entry validation feedback prevent data entry error recorded SMBP .NFXNREQ.27 System requirement – usability Simplify data recording predefined drop-down searchable lists, radio buttons, checkboxes SMBP .NFXNREQ.28 System requirement – usability Support multiple language SMBP .NFXNREQ.29 System requirement – usability Use industry standard user-interface practice apply consistent manner throughout system47 High-level functional non-functional requirementsrecommendations persona scenario workflow data decision requirementsRequirement ID Category Non-functional requirement SMBP .NFXNREQ.30 System requirement – usability Easy learn intuitive en",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6f359c5e-0c44-4746-9b1f-f8384540144e",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ional requirement SMBP .NFXNREQ.30 System requirement – usability Easy learn intuitive enable end user navigate page SMBP .NFXNREQ.31 System requirement – usability Provide guidance end user better support clinical guideline best clinical practice SMBP .NFXNREQ.32 System requirement – usability reliable robust (minimize number system crashes) SMBP .NFXNREQ.33 System requirement – usability designed tested local end user ensure appropriate approachable user experience/user interface (UX/UI) SMBP .NFXNREQ.34 System requirement – usability Provide help menu content understandable, including end user limited language digital literacy SMBP .NFXNREQ.35 System requirement – usability Use culturally appropriate icon instead text possible SMBP .NFXNREQ.36 Security – authentication Notify system user change password first time log SMBP .NFXNREQ.37 Security – auth",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1f5fbf18-4f8b-4960-83bc-11e7b276c7bc",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "system user change password first time log SMBP .NFXNREQ.37 Security – authentication Adhere password requirement SMBP .NFXNREQ.38 Security – authentication Provide mechanism securely change system user’s password SMBP .NFXNREQ.39 Security – authentication Notify system user password change account SMBP .NFXNREQ.40 Security – authentication Provide role-based access system SMBP .NFXNREQ.41 Security – confidentiality privacy Provide mean ensure confidentiality privacy personal health information SMBP .NFXNREQ.42 Security – confidentiality privacy Provide password-protected access authorized system user SMBP .NFXNREQ.43 Security – confidentiality privacy Provide ability allowed end user view confidential data SMBP .NFXNREQ.44 Security – confidentiality privacy Anonymize data exported system SMBP .NFXNREQ.45 Security – confidentiality privacy Prevent system remember",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "88ada1d3-4054-42d7-948a-953998a5d71c",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "rted system SMBP .NFXNREQ.45 Security – confidentiality privacy Prevent system remembering username password SMBP .NFXNREQ.46 Security – confidentiality privacy Log system user specified time inactivity SMBP .NFXNREQ.47 Security – confidentiality privacy Provide encrypted communication component SMBP .NFXNREQ.48 Security – user management Allow system user create new username temporary password permission SMBP .NFXNREQ.49 Security – user management Provide role-based access SMBP .NFXNREQ.50 Security – user management Allow system user change password SMBP .NFXNREQ.51 Security – user management Notify system user regularly change password SMBP .NFXNREQ.52 Security – user management Allow system user assigned one role SMBP .NFXNREQ.53 Security – user management Support definition unlimited role assigned level access, viewing, entry, editing auditing SMBP .N",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9d0e7f28-d931-40ad-8549-d1063f2e68f7",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ion unlimited role assigned level access, viewing, entry, editing auditing SMBP .NFXNREQ.54 Security – confidentiality privacy Allow end user choose delivery medium messages, either voice, text email, well means, opting either push pull content SMBP .NFXNREQ.55 Security – confidentiality privacy Use discreet word symbol messages, application names, icon content source SMBP .NFXNREQ.56 Security – confidentiality privacy Allow end user choose whether receive personalized content general content shared SMBP .NFXNREQ.57 Security – confidentiality privacy Provide mechanism end user leave page screen quickly SMBP .NFXNREQ.58 Security – confidentiality privacy Provide prompt advising end user delete message search concerned privacy SMBP .NFXNREQ.59 Security – confidentiality privacy Allow end user choose whether enable automated data track",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "adabdcce-68d5-458e-97a4-72b882669d62",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "urity – confidentiality privacy Allow end user choose whether enable automated data tracking SMBP .NFXNREQ.60 Security – confidentiality privacy Allow end user choose whether share data data share SMBP .NFXNREQ.51 System requirement – configuration Configure workflow business rule accommodate difference facility SMBP .NFXNREQ.62 System requirement – interoperability Communicate external system mediators48 Digital adaptation kit self-monitoring blood pressure pregnancyrecommendations persona scenario workflow data decision requirementsRequirement ID Category Non-functional requirement SMBP .NFXNREQ.63 System requirement – interoperability Provide access data application programming interface (APIs) SMBP .NFXNREQ.64 System requirement – interoperability interoperable external system mediator SMBP .NFXNREQ.65 System requirement – interoperability Link insurance sy",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a01c489b-d28f-4685-9f1f-57f41fdbce9a",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "em mediator SMBP .NFXNREQ.65 System requirement – interoperability Link insurance system verify eligibility submit claim SMBP .NFXNREQ.66 System requirement – interoperability Exchange data approved system SMBP .NFXNREQ.67 System requirement – interoperability Accept data multiple input method including paper, geocoding (GPS) SMBP .NFXNREQ.68 System requirement – hardware connectivity Allow data exchange efficient synchronization across multiple facility point service internet available, even intermittent slow full set functional non-functional requirements, please refer functional non-functional requirement implementation tool (https://smart. who.int/dak-smbp/system-requirements.html).49 References 1. Seventy-first World Health Assembly: Geneva, 26 May 2018: digital health. Geneva: World Health Organization; 2018 (WHA71.7; https://iris.who.int/handle/10665/279505 ).",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4747ca2f-8b6a-4112-a11d-81b5d5644662",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ealth. Geneva: World Health Organization; 2018 (WHA71.7; https://iris.who.int/handle/10665/279505 ). 2. Global strategy digital health 2020–2025. Geneva: World Health Organization; 2021 ( https://iris.who.int/handle/10665/344249 ). Licence: CC BY-NC-SA 3.0 IGO. 3. Common Roadmap Steering Committee. roadmap health measurement accountability (MA4Health): common agenda post-2015 era. Washington (DC): World Bank Group; 2015 (https://www.healthdatacollaborative.org/fileadmin/uploads/hdc/Documents/the-roadmap-for-health-measurement-and-accountability.pdf ). 4. Digital strategy 2020–2024. Washington (DC): United States Agency International Development; n.d. ( https://www.ictworks.org/wp-content/uploads/2020/04/USAID_Digital_Strategy.pdf ). 5. Global Fund strategic framework data use action improvement country level: 2017–2022. Geneva: Global Fund; n.d. ( https://www.theglobalfund.org/media/8362/cr_me- data-use-for-action-improvement_framewo",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6cc34c76-ed92-4381-b193-2ed850009cb2",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "Fund; n.d. ( https://www.theglobalfund.org/media/8362/cr_me- data-use-for-action-improvement_framework_en.pdf ). 6. Michaels M. Adapting clinical guideline digital age: summary holistic multidisciplinary approach. J Med Qual. 2023;38(5S):S3–11 ( https://doi. org/10.1097/JMQ.0000000000000138 ). 7. Tan R, Cobuccio L, Beynon F, Levine G, Vaezipour N, Luwanda LB et al. ePOCT+ medAL-suite: development electronic clinical decision support algorithm digital platform pediatric outpatient low- middle-income countries. PLOS Digit Health. 2023;2(1):e0000170 ( https://doi.org/10.1371/journal.pdig.0000170 ). 8. Boxwala AA, Rocha BH, Maviglia S, Kashyap V, Meltzer S, Kim J et al. multi-layered framework disseminating knowledge computer-based decision support. J Med Inform Assoc. 2011;18 Suppl 1(Suppl 1):i132–i139 ( https://doi.org/10.1136/amiajnl-2011-000334 ). 9. Beynon F, Guérin F, Lampariello R, Schmitz , Tan R, Ratanaprayul N et",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fa14f442-3d46-41a4-be90-d83efcdae276",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "36/amiajnl-2011-000334 ). 9. Beynon F, Guérin F, Lampariello R, Schmitz , Tan R, Ratanaprayul N et al. Digitalizing clinical guidelines: experience development clinical decision support algorithm management childhood illness resource-constrained settings. Glob Health Sci Pract. 2023;11(4):e2200439 ( https://doi.org/10.9745/GHSP-D-22-00439 ). 10. Mehl GL, Seneviratne MG, Berg ML, Bidani S, Distler RL, Gorgens et al. full-STAC remedy global digital health transformation: open standards, technologies, architecture content. Oxf Open Digit Health. 2023;1:oqad018 ( https://doi.org/10.1093/oodh/oqad018 ). 11. Tamrat , Ratanaprayul N, Barreix M, Tunçalp Ö, Lowrance D, Thompson J et al. Transitioning digital systems: role World Health Organization’s digital adaptation kit operationalizing recommendation interoperability standards. Glob Health Sci Pract. 2022;10(1):e2100320 ( https://doi.org/10.9745/GHSP-D-21-00320 ). 12. Digital imple",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2f295fac-e1c9-4036-ae9e-f28794fc0517",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "Health Sci Pract. 2022;10(1):e2100320 ( https://doi.org/10.9745/GHSP-D-21-00320 ). 12. Digital implementation investment guide (DIIG): integrating digital intervention health programmes. Geneva: World Health Organization; 2020 ( https://iris.who.int/handle/10665/334306 ). Licence: CC BY-NC-SA 3.0 IGO. 13. guideline: recommendation digital intervention health system strengthening: evidence recommendations. Geneva: World Health Organization; 2019 ( https://iris.who.int/ handle/10665/311980 ). Licence: CC BY-NC-SA 3.0 IGO. 14. Classification digital interventions, service application health: shared language describe us digital technology health, second edition. Geneva: World Health Organization; 2023 ( https://iris.who.int/handle/10665/373581 ). Licence: CC BY-NC-SA 3.0 IGO. 15. Mehl G, Tunçalp Ö, Ratanaprayul N, Tamrat , Barreix M, Lowrance et al. SMART guidelines: optimising country-level use guideline recommendation",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4444eb4f-f9bc-4294-821b-2b097918f252",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "owrance et al. SMART guidelines: optimising country-level use guideline recommendation digital age. Lancet Digit Health. 2021;3(4):e213–e216 ( https://doi.org/10.1016/s2589-7500(21)00038-8 ). 16. SMART Guidelines [website]. World Health Organization; 2024 ( https://www.who.int/teams/digital-health-and-innovation/smart-guidelines ). 17. guideline self-care intervention health well-being, 2022 revision. Geneva: World Health Organization; 2022 ( https://iris.who.int/handle/10665/357828 ). Licence: CC BY-NC-SA 3.0 IGO. 18. Classification self-care intervention health: shared language describe us self-care interventions. Geneva: World Health Organization; 2021 ( https://iris.who.int/ handle/10665/350480 ). Licence: CC BY-NC-SA 3.0 IGO. 19. Narasimhan M, Duvall S, Tamrat . Expanding people-centred primary health care digital adaptation kit self-care interventions. Lancet Digit Health. 2023;5(10):e643–e645 ( https://doi. org",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "465b8185-4a4d-44b7-ac11-8aa61b52c48c",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "ation kit self-care interventions. Lancet Digit Health. 2023;5(10):e643–e645 ( https://doi. org/10.1016/S2589-7500(23)00178-4 ). 20. Digital adaptation kit antenatal care: operational requirement implementing recommendation digital systems. Geneva: World Health Organization; 2021 ( https://iris.who.int/ handle/10665/339745 ). Licence: CC BY-NC-SA 3.0 IGO. 21. Self-care health well-being [fact sheet]. In: World Health Organization [website]; 26 April 2024 ( https://www.who.int/news-room/fact-sheets/detail/self-care-health-interventions ). 22. UHC compendium: repository intervention universal health coverage [website]. World Health Organization; 2025 ( https://www.who.int/universal-health-coverage/compendium/ interventions-by-programme-area ).50 Digital adaptation kit self-monitoring blood pressure pregnancy23. UHC Service Planning, Delivery & Implementation (SPDI) Platform. In: UHC Planning & Packages [website]. World Health Organi",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c0bcbaac-c9f3-4038-89ce-04afb99c2284",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "elivery & Implementation (SPDI) Platform. In: UHC Planning & Packages [website]. World Health Organization ( https://uhcc.who.int/uhcpackages/ ). 24. Collaborative Requirements Development Methodology (CRDM) [website]. Public Health Informatics Institute; 2024 ( https://www.phii.org/crdm/ ). 25. World Health Organization, International Telecommunication Union. National eHealth strategy toolkit. Geneva: International Telecommunication Union; 2012 ( https://iris.who.int/ handle/10665/75211 ). 26. Stepwise toolkit planning & budgeting interoperability digital health solutions. Digital Health Centre Excellence: n.d. ( https://a78da35e-056b-4420-8e4f-41e3283327e3.usrfiles.com/ ugd/55ae33_5af35824932c48d89287928244b60a8d.pdf ). 27. World Health Organization, United Nations Population Fund, United Nations Children’s Fund. Managing complication pregnancy childbirth: guide midwife doctors, second edition. Geneva: World Health Organization; 2017 ( https://iris.who.i",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0432080b-bb73-4202-ae03-689f57293f6c",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "midwife doctors, second edition. Geneva: World Health Organization; 2017 ( https://iris.who.int/handle/10665/255760 ). Licence: CC BY-NC-SA 3.0 IGO. 28. recommendation antenatal care positive pregnancy experience. Geneva: World Health Organization; 2016 ( https://iris.who.int/handle/10665/250796 ). 29. technical specification automated non-invasive blood pressure measuring device cuff. Geneva: World Health Organization; 2020 ( https://iris.who.int/handle/10665/331749 ). Licence: CC BY-NC-SA 3.0 IGO. 30. HEARTS: technical package cardiovascular disease management primary health care: evidence-based treatment protocols. Geneva: World Health Organization; 2018 ( https://iris.who.int/ handle/10665/260421 ). Licence: CC BY-NC-SA 3.0 IGO. 31. recommendation home-based record maternal, newborn child health. Geneva: World Health Organization; 2018 ( https://iris.who.int/handle/10665/274277 ). Licence: CC BY-NC- SA 3.0 IGO. 32. Counse",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bba12c39-1905-4e77-b933-249004fd13c1",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "zation; 2018 ( https://iris.who.int/handle/10665/274277 ). Licence: CC BY-NC- SA 3.0 IGO. 32. Counselling maternal newborn health care: handbook building skills. Geneva: World Health Organization; 2013 ( https://iris.who.int/handle/10665/44016 ). 33. World Health Organization, United Nations Population Fund, World Bank, United Nations Children’s Fund. Pregnancy, childbirth, postpartum newborn care: guide essential practice, third edition. Geneva: World Health Organization; 2015 ( https://iris.who.int/handle/10665/249580 ). 34. HEARTS: technical package cardiovascular disease management primary health care: healthy-lifestyle counselling. Geneva: World Health Organization; 2018 ( https://iris.who.int/ handle/10665/260422 ). Licence: CC BY-NC-SA 3.0 IGO. 35. Implementation tools: package essential noncommunicable (PEN) disease intervention primary health care low-resource settings. Geneva: World Health Organization; 2013 ( https://iris. who.int/h",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2640b687-0458-4d33-86fc-38ee459d6ca6",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "lth care low-resource settings. Geneva: World Health Organization; 2013 ( https://iris. who.int/handle/10665/133525 ). 36. recommendation prevention treatment pre-eclampsia eclampsia. Geneva: World Health Organization; 2011 ( https://iris.who.int/handle/10665/44703 ). 37. Noncommunicable disease education manual primary health care professional patients. Manila: Regional Office Western Pacific; 2017 ( https://iris.who.int/ handle/10665/254746 ). Licence: CC BY-NC-SA 3.0 IGO. 38. Practical guide design, use promotion home-based record immunization programmes. Geneva: World Health Organization; 2015 ( https://iris.who.int/handle/10665/175905 ). 39. International Standard Classification Occupations (ISCO). In: ILOSTAT [website]. International Labour Organization; 2016 ( https://ilostat.ilo.org/methods/concepts-and-definitions/ classification-occupation/ ). 40. recommendations: optimizing health worker role improve",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dcc1ad19-42e2-4ea3-acb0-a9146f27f42a",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "/ classification-occupation/ ). 40. recommendations: optimizing health worker role improve access key maternal newborn health intervention task shifting. Geneva: World Health Organization; 2012 (https://iris.who.int/handle/10665/77764 ). 41. guideline health policy system support optimize community health worker programmes. Geneva: World Health Organization; 2018 ( https://iris.who.int/handle/10665/275474 ). Licence: CC BY-NC-SA 3.0 IGO. 42. Business Process Model Notation. In: Object Management Group: standard development organization [website]. Object Management Group; 2014 ( https://www.omg.org/bpmn/ ). 43. Decision Model Notation. In: Object Management Group: standard development organization [website]. Object Management Group; 2023 ( https://www.omg.org/dmn/ ).World Health Organization 20 Avenue Appia 1211 Geneva 27 Switzerland who.int Department Sexual Reproductive Health Research Email: srhhrp@who.int",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8fb68764-4050-4837-a56f-bc5acd6d3338",
        "title": "Self-monitoring of blood pressure during pregnancy",
        "body": "nt Department Sexual Reproductive Health Research Email: srhhrp@who.int",
        "source": "WHO Guidelines: Self-monitoring of blood pressure during pregnancy.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "896a5626-15e5-4d2a-9815-517e07f49ece",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxisGuidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxisGuidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis ISBN 978-92-4-011160-8 (electronic version) ISBN 978-92-4-011161-5 (print version) © World Healt h Organization 2025 right reserved. work available Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo ). term licence, may copy, redistribute adapt work non-commercial purposes, provided work appropriately cited, indicated below. use work, suggestion endorses specific organization, product services. u",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "85f7377c-2e06-4c9d-914c-d76550eb2427",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "e suggestion endorses specific organization, product services. use logo permitted. adapt work, must license work equivalent Creative Commons licence. create translation work, add following disclaimer along suggested citation: “This translation created World Health Organization (WHO). responsible content accuracy translation. original English edition shall binding authentic edition” . mediation relating dispute arising licence shall conducted accordance mediation rule World Intellectual Property Organization ( http://www.wipo.int/amc/en/mediation/rules/ ). Suggested citation . Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre- exposure prophylaxis (PrEP). Geneva: World Health Organization; 2025. Lic",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "652d5e4d-7112-4f9d-b87f-7a4cc0e7fde1",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ong-acting injectable pre- exposure prophylaxis (PrEP). Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO . Cataloguing-in-Publication (CIP) data. CIP data available https://iris.who.int/ . Sales, right licensing. purchase publications, see https://www.who.int/publications/book-orders . submit request commercial use query right licensing, see https://www.who.int/copyright . Third-party materials. wish reuse material work attributed third party, tables, figure images, responsibility determine whether permission needed reuse obtain permission copyright holder. risk claim resulting infringement third-party-owned component work rest solely user. General disclaimers. designation employed presentation material publication imply expression opinion whatsoeve",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4a681c73-e420-47a9-b4ad-c2a516aa590d",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "esentation material publication imply expression opinion whatsoever part concerning legal status country, territory, city area authorities, concerning delimitation frontier boundaries. Dotted dashed line map represent approximate border line may yet full agreement. mention specific company certain manufacturers’ product imply endorsed recommended preference others similar nature mentioned. Errors omission excepted, name proprietary product distinguished initial capital letters. reasonable precaution taken verify information contained publication. However, published material distributed without warranty kind, either expressed implied. responsibility interpretation use material lie",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "071a6514-31f7-4344-86d5-65a2b8b5b44b",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ither expressed implied. responsibility interpretation use material lie reader. event shall liable damage arising use. iii Contents Acknowledgements ......................................................................................................... v Abbreviations ................................................................................................................ vii Definitions key term ................................................................................................. viii Executive summary ......................................................................................................... ix Purpose .............................................................................................................................................................. ix Guideline development methodology .................................................................................",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d3228fb0-f5f8-4613-bea3-3e142deaabd5",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "pment methodology .............................................................................................................. x New recommendation ...................................................................................................................................... x Implications implementation ...................................................................................................................... xi 1.Introduction ................................................................................................................ 1 1.1 Background ................................................................................................................................................... 1 1.2 Objectives intended audience .............................................................................................................. 2 1.3 Guiding principle ...................................................................................",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3db48d08-30ab-4a95-83e1-490129520fbc",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ding principle ......................................................................................................................................... 2 2.Methods guideline development ............................................................................... 3 3. Rationale supporting evidence: lenacapavir HIV prevention ........................................... 4 3.1 Summary review finding ........................................................................................................................ 4 3.2 Values preference .............................................................................................................................. 12 3.3 Feasibility .................................................................................................................................................... 13 3.4 Cost–effectiveness .....................................................................................................",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8851445a-de78-42c1-91e7-ce90fa9c2f59",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "..................................................................................................................................... 14 3.5 Equity human right ............................................................................................................................ 14 3.6 Rationale recommendation ................................................................................................................ 15 4. Rationale supporting evidence: testing long-acting injectable PrEP ........................ 16 4.1 Summary review finding ...................................................................................................................... 16 4.2 Values preference .............................................................................................................................. 18 4.3 Resource use ........................................................................................................................",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a2e8ebca-af5d-4d3b-8331-0545464ffacc",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "........................................................................................................................... 18 4.4 Equity human right ............................................................................................................................ 19 4.5 Rationale recommendation ................................................................................................................ 20 5. Implementation consideration research gaps: lenacapavir HIV prevention ....................................................................................... 21 5.1 Implementation consideration ................................................................................................................ 21 5.2 Research gap .............................................................................................................................................. 28 6. Implementation consideration research gaps: testing long-",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "986cc70f-2eab-4720-8801-9471f23fe53a",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "........................ 28 6. Implementation consideration research gaps: testing long-acting injectable PrEP ............................................................................. 31 6.1 Implementation consideration ................................................................................................................ 31 6.2 Research gap ............................................................................................................................................. 34 7. Updating dissemination ........................................................................................ 35 ivReferences .................................................................................................................... 36 Annex. Process developing guideline ................................................................... 44 Web annex A. Declarations interest Guideline Development Group external peer reviewer",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8672c077-a88b-4522-87f8-e2aba69545c4",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "nex A. Declarations interest Guideline Development Group external peer reviewer Web annex B. Safety efficacy long-acting injectable lenacapavir pre-exposure prophylaxis reduce risk HIV acquisition: systematic review Web annex C. Systematic review value preference lenacapavir pre-exposure prophylaxis form long-acting injectable PrE P Web annex D. HIV testing service rapid diagnostic test and/or self-tests used initiation continuation injectable long-acting PrEP ? Web annex E. Mathematical modelling lenacapavir: landscaping review impact cost–effectiveness Web annex F. Lenacapavir-associated drug resistance: implication scaling long-acting PrEP Web annex G. Abstract: outcome lenacapavir administration pregnancy vAcknowledgements World Health Organization (WHO) gratefully acknowledges contribution many individual organization th",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e1b43bbb-d468-4eb9-872f-654d76f9da83",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ization (WHO) gratefully acknowledges contribution many individual organization guideline lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis. Guideline Development Group Co-chairs: Hasina Subedar (National Department Health, South Africa) Danvic Rosadiño (LoveYourself, Philippines). Nadia Badran (Society Inclusion Development Community Care (SIDC), Lebanon), Tetiana Deshko (Alliance Public Health, Ukraine), Julie Fox (King’s College London, United Kingdom Great Britain Northern Ireland), Le Minh Giang (Hanoi Medical University, Viet Nam), Chilufya Kasanda Hampongo (Treatment Advocacy Literacy Campaign, Zambia), Mehdi Karkouri (Association de Lutte Contre le Sida, Morocco), Kelika Konda (Universidad Peruana Cayetano Heredia, Peru), Alma de Leon (International Treatment Preparedness Coalition, Guatemala), Nikolay Lunchenkov (Technical University Mun",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e5e4cfac-1ad3-4060-8979-cfbac321d839",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "onal Treatment Preparedness Coalition, Guatemala), Nikolay Lunchenkov (Technical University Munich, Germany), Estelle Piwowar Manning (independent consultant, United States America), Idah Moyo (Ministry Health Child Care, Zimbabwe), Sikhulile Moyo (Botswana Harvard Institute, Botswana), Misael Muñoz (Inspira Cambio, Mexico), Kenneth Mwehonge (Coalition Health Promotion Social Development (HEPS-Uganda), Uganda), Yashwinder Singh (Humsafar Trust, India), Ni Ni Tun (Medical Action, Myanmar), Rebecca Zash (Botswana Harvard Institute, USA). Methodologist Nandi Siegfried (Independent consultant, South Africa). External review group Max Appenroth (Diversity Factory, Germany), Ngauv Bora (National Center HIV/AIDS, Dermatology STD (NCHADS), Cambodia), Erika Castellanos (Global Action Trans Equality (GATE), Netherlands), Elizabeth Corbett (London School Hygiene & Tropical Medicine (LSHTM), United Kingdom), Brenda Crabtree Ramirez (Instituto Nacional",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "96aa2f5c-caf3-42ef-9eba-63d159bae67a",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "Hygiene & Tropical Medicine (LSHTM), United Kingdom), Brenda Crabtree Ramirez (Instituto Nacional de Ciencias Médicas Nutrición, Mexico), Ines Dourado (University Bahia, Brazil), Kimberly Green (PATH, Switzerland), Karin Hatzold (Population Services International, South Africa), Artur Kalichman (Ministry Health, Brazil), Othoman Mellouk (International Treatment Preparedness Coalition, Morocco), Lloyd Mulenga (Ministry Health, Zambia), Urvi Parikh (University Pittsburgh, USA), Jason Reed (Jhpiego, USA), Jeanne Sibiude (Agence nationale de researche sur la SIDA – Maladies infectieuses émergentes (ANRS MIE), France), Christian Stillson (Clinton Health Access Initiative, USA), Lynda Stranix-Chibanda (University Zimbabwe, Zimbabwe), Nicky Suwandi (APCOM, Thailand), Joseph Tucker (University North Carolina Project China, China), François Venter (Ezintsha, South Africa), Rita Wahab (MENA Rosa, Lebanon). External contributor Virginia Fonner (FHI360, USA), Sara",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9f048abc-6194-4e60-9dc8-ba9dd8055e98",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "frica), Rita Wahab (MENA Rosa, Lebanon). External contributor Virginia Fonner (FHI360, USA), Sara Gibbons (University Liverpool, UK), Saye Khoo (University Liverpool, UK), Lara Lorenzetti (FHI360, USA), Kyria Louis Charles (FHI360, USA), Catia Marzolini (University Hospital Lausanne, Switzerland), Jason Ong (Monash University, Australia). vi Observers Carmen Perez Casas (UNITAID, Switzerland), Siobhan Malone (The Gates Foundation, USA), Orapeleng Motlhaoleng (National Department Health, South Africa), Christopher Obermeyer (The Global Fund Fight AIDS, Tuberculosis Malaria, Switzerland), Elo Otobo (Children’s Investment Fund Foundation, United Kingdom), Fode Simaga (Joint United Nations Programme HIV/AIDS (UNAIDS), Switzerland). staff consultant Overall coordination Mateo Prochazka Michelle Rodolph (Global HIV, Hepatitis Sexually Transmitted Infection Programmes) coordinated overall development process, leadership Meg Dohe",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8ab55a1a-c2b3-4852-8e35-8d25a41a8d64",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "Infection Programmes) coordinated overall development process, leadership Meg Doherty (Director, Department Global HIV, Hepatitis Sexually Transmitted Infections Programmes). headquarters following staff member Department Global HIV, Hepatitis Sexually Transmitted Infections Programmes contributed developing guidelines: Carlota Baptista da Silva, Magdalena Barr-DiChiara, Heather Ingold, Cheryl Johnson, Françoise Renaud Heather-Marie Schmidt (WHO/UNAIDS). following staff member department involved guideline process: Anita Sands (Department Regulation Safety) Petrus Steyn (Department Sexual Reproductive Health Research). Administrative support provided Valerie Amiel Fourtas Chokri Braiki. Adriana De Putter Byambaa Khishigbayar managed budget, Yann Siegenthaler provided website support. following consultant also contributed",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4acba1f2-c05a-4be3-bc8d-4bdbb09753ac",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "Yann Siegenthaler provided website support. following consultant also contributed developing guidelines: Britta Jewell, Michael Jordan, Lynne Mofenson, Robert Shafer Gert Van Zyl provided technical writing support, Jura Editorial Services edited text, Lushomo design layout. country regional office Agnes Chetty (WHO Regional Office Africa), Hortencia Peralta (WHO Regional Office Americas), Muhammad Jamil (WHO Regional Office Eastern Mediterranean), Viatcheslav Grankov (WHO Regional Office Europe), Po-lin Chan (WHO Regional Office South-East Asia), Kiyohiko Izumi (WHO Regional Office Western Pacific), Christine Kisia (WHO Kenya). Funding Gates Foundation UNITAID provided funding development guideline. viiAbbreviations ART antiretroviral therapy ARV antiretroviral CAB-LA long-acting injectable cabotegravir DALY disability-adjusted life-year DVR dapivirine",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "21d62196-3ac9-4d9f-b77d-4e7946ae089a",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ral CAB-LA long-acting injectable cabotegravir DALY disability-adjusted life-year DVR dapivirine vaginal ring GAHT gender-affirming hormone therapy GDG Guideline Development Group GRADE Grading Recommendations, Assessment, Development Evaluation HBV hepatitis B virus HCV hepatitis C virus HIVST HIV self-testing ISR injection site reaction LA-PrEP long-acting pre-exposure prophylaxis LEN lenacapavir NAT nucleic acid test PEP post-exposure prophylaxis PICO population, intervention, comparator, outcome PPPY per-person per-year PrEP pre-exposure prophylaxis RDT rapid diagnostic test STI sexually transmitted infection TAF tenofovir alafenamide TAF/FTC tenofovir alafenamide/emtricitabine TDF tenofovir disoproxil fumarate TDF/FTC tenofovir disoproxil fumarate/emtricitabine UNAIDS Joint United Nations Programme HIV/AIDS World Health Organizationviii Definitions key term Age groupsIn guideline following definition adults, adolesce",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fde89d81-3abf-42ea-95c0-635b1b33e6ec",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "efinitions key term Age groupsIn guideline following definition adults, adolescents, child infant used recommendation specific age groups. country may definition national laws. • adult person older 19 year age. • adolescent person 10–19 year age inclusive. • child person one year age younger 10 year age. • infant child younger one year age. Long-acting lenacapavir (LEN) LEN HIV-1 capsid inhibitor. given people HIV, dose 927 mg (2 x 1.5mL injections), subcutaneously, every 26 week prevention HIV acquisition. People starting LEN also take oral loading dose 600 mg (2 x 300 mg tablets) two consecutive days, beginning day first injection. Key populationsKey population defined group increased risk HIV, viral hepatitis sexually transmitted infection (S",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "71ba3955-46a9-47a5-a129-26cced30f1b1",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ined group increased risk HIV, viral hepatitis sexually transmitted infection (STIs), irrespective epidemic type local context. Also, often experience legal social issue due stigma discrimination increase vulnerability HIV. defines five key population be: 1) men sex men, 2) people use injectable drugs, 3) people prison closed settings, 4) sex worker 5) trans gender-diverse people. Risk HIV acquisitionHIV acquisition risk varies considerably within population geographical locations. Population-level HIV incidence important determinant individual-level risk HIV acquisition, important also consider characteristic behaviour individual partner could lead HIV exposure. Even location low overall HIV incidence, may individual risk could benefit pre-exposure prophyl",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4ce34b48-31cf-4484-a5d5-c167d1b7735e",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "overall HIV incidence, may individual risk could benefit pre-exposure prophylaxis (PrEP) services. Individuals requesting PrEP offered PrEP , since requesting PrEP indicates likely risk acquiring HIV. Rapid diagnostic test (RDTs)RDTs type assay produce test result quickly, generally 30 minutes. broad class HIV RDTs serology-based, use fingerprick/capillary whole blood oral fluid sample either lateral-flow (immunochromatographic) vertical-flow (immunofiltration) assays. HIV self-testing (HIVST)A process person collect specimen (oral fluid blood) using simple rapid HIV test performs test interprets result want. Long-acting injectable cabotegravir (CAB-LA)CAB-LA integrase strand-transfer inhibitor. given people HIV infection, dose 600 mg intramuscularly, four week",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8ee11cbe-0961-46f8-9a8c-429451f9d1a1",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "given people HIV infection, dose 600 mg intramuscularly, four week apart first two injection every eight week thereafter, prevention HIV acquisition. Long-acting injectable PrEPThe use injectable antiretrovirals provide extended protection prevention HIV acquisition among people HIV-negative. ixExecutive summary Purpose Ending HIV epidemic public health threat requires high-impact HIV prevention testing services. Pre-exposure prophylaxis (PrEP) key component combination HIV prevention. people substantial risk HIV, World Health Organization (WHO) 2015 recommended oral PrEP containing tenofovir disoproxil fumarate (TDF), 2021 dapivirine vaginal ring (DVR) cisgender woman substantial risk HIV 2022 long-acting injectable cabotegravir (CAB-LA). Expansion access use oral PrEP accelerated recent years, c",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7266332c-209a-41ec-95aa-8d71f1f949b6",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "(CAB-LA). Expansion access use oral PrEP accelerated recent years, country included CAB-LA DVR national guideline begun programmatic implementation. Potential barrier uptake effective use oral PrEP , well CAB-LA DVR, include wanting take oral pill regularly desire less frequent clinic visits. barrier may overcome new PrEP product offer protection longer period time. guidelines, recommends offering six-monthly injectable lenacapavir (LEN) additional HIV prevention option. Offering additional PrEP choice potential increase uptake effective use PrEP HIV prevention overall, allows people choose method prefer. Testing service critical component PrEP delivery. Effective efficient testing service help streamline service provision support broader publ",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "35dd29c8-f5bb-4973-b6db-62ea431ecbc4",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ive efficient testing service help streamline service provision support broader public health approach. ensure effective equitable access PrEP , HIV testing service feasible, accessible scalable. guideline highlight latest evidence benefit using simple rapid diagnostic test (RDTs) providing long-acting injectable PrEP , rather complex costly nucleic acid testing (NAT) technique laboratory- based testing. Simplified testing approach reduce barriers, minimize delays, improve sustainability reduce per-test cost. continues recommend HIV RDTs HIV self-testing (HIVST) part standard HIV testing services. guidelines, recommends using HIV RDTs individual initiating continuing long-acting injectable PrEP , CAB-LA LEN. HIVST remains recommended option oral PrEP , DVR post-exposure prophylaxis (PEP), may offer additional flexi",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fc95b419-e3c9-4ee8-8d4b-a1578a541f3c",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ption oral PrEP , DVR post-exposure prophylaxis (PEP), may offer additional flexibility across PrEP programmes. implementation research needed fully determine role HIVST delivering long-acting injectable PrEP . Flexible HIV testing approach essential ensuring testing become barrier accessing continuing PrEP , including long-acting injectable options. Aligning testing frequency PrEP refill injection visit schedule often practical. enhance access choice, alternative testing schedule may also needed considered, particularly part effort adopt simplified differentiated PrEP delivery (for example, greater task sharing, multi-month dispensing, pharmacy PrEP , TelePrEP online distribution models). primary audience guideline national subnational programme manager policy-makers responsible national health sector response",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7916d75f-1215-42b8-a958-12d5cc0953ac",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "bnational programme manager policy-makers responsible national health sector response HIV, particularly low- middle-income countries.With guidelines, recommends offering six-monthly injectable lenacapavir (LEN) additional HIV prevention option.x Guideline development methodology response emerging new evidence efficacy LEN prevention HIV acquisition across diverse populations, testing long-acting prevention products, Department Global HIV, Hepatitis Sexually Transmitted Infections Programmes led development new guidance, support Guideline Development Group (GDG) External Review Group, January May 2025. steering group formulated two population, intervention, comparator, outcome (PICO) questions, one LEN PrEP another use RDTs context long-acting prevention. External researchers, supported WHO, conducted sys",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "94b15d3a-da8a-43b3-b781-e8afec9bc8a4",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "context long-acting prevention. External researchers, supported WHO, conducted systematic review evidence answer questions. synthesized evidence incorporated evidence-to-decision framework help inform discussion virtual GDG meeting occurred three day 28 30 January 2025, chaired two member GDG facilitated independent methodologist. GDG member made judgement potential benefit harm intervention, stakeholder value preferences, acceptability, feasibility, resource use consideration human right equity. Taken together using Grading Recommendations Assessment, Development Evaluation (GRADE) methodology, judgement contributed determining strength direction recommendations. recommendation formulated consensus. New recommendation Recommendation [NEW] Long-acting injectable",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0859deff-05a3-44a7-bdc0-31c542be9566",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ere formulated consensus. New recommendation Recommendation [NEW] Long-acting injectable lenacapavir offered additional prevention choice people risk HIV, part combination prevention approaches. (strong recommendation, moderate high certainty evidence) Recommendation [NEW] Rapid diagnostic test may used HIV testing initiation, continuation discontinuation long-acting PrEP . (strong recommendation, low certainty evidence) GDG concluded that, time convening, insufficient evidence recommend HIV self-testing long-acting injectable PrEP (LA-PrEP). Evidence reviewed suggest, however, HIVST could increase flexibility testing frequency well decentralize testing access. implementation research needed understand potential role HIVST within LA-PrEP . HIVST continues recommended oral PrEP , DVR PEP . xiImplications",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ddbee062-61e0-4d94-9478-aa23b8c1a50f",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ithin LA-PrEP . HIVST continues recommended oral PrEP , DVR PEP . xiImplications implementation LEN delivered additional choice alongside HIV PrEP prevention options. country plan introduction LEN, consideration include differentiated service delivery model integration maximize acceptability accessibility; population-specific needs; awareness raising demand generation activities; provider training. time, monitoring surveillance system designed, support safety service quality improvement adverse event monitoring pregnancy breastfeeding, seroconversions drug resistance; relative cost potential LEN achieve impact. Successful introduction LEN enhanced full participation community designing, implementing monitoring programmes. Availability LEN date restricted trial settin",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e89af952-b789-4af5-9c5a-6f94d2af2eb0",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "menting monitoring programmes. Availability LEN date restricted trial settings, follow-up time limited. evidence gap regarding optimal testing strategies, best approach support access, adherence dosing schedule, persistence, alternative dosing administration, product switching, ideal provision population geographies, cost impact LEN. However, GDG stressed that, despite evidence gap identified, research delay programmatic implementation LEN countries. Simple HIV testing strategy rely RDTs aligned guidance needed support injectable LA-PrEP implementation within broader PrEP programmes. Adopting approach provide consistency, quality efficiency programme enable country use standard national testing algorithm. Using HIV RDTs also make possible provide same-day injectab",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "08a6e3b6-aaca-4ccc-a4f2-8dc4656ff4dd",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "dard national testing algorithm. Using HIV RDTs also make possible provide same-day injectable LA-PrEP initiation and, thus, facilitate effective continuous use. 1 1. Introduction 1.1 Background HIV remains major public health issue, estimated 39.9 million people living HIV 1.3 million people newly diagnosed HIV 2023 (1). African region made substantial progress preventing new HIV infections, comparable progress less evident elsewhere, people acquiring HIV member key populations. Political Declaration HIV AIDS adopted United National General Assembly 2021, member state committed reducing annual HIV infection 370 000 2025, reducing AIDS-related death fewer 250 000 globally ensuring 95% people risk HIV access HIV prevention options. end HIV epidemic, focus needed comprehensive approach includes com",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "01a2914a-8484-4f91-84ed-aa1077eccae7",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "options. end HIV epidemic, focus needed comprehensive approach includes combination HIV prevention. includes biomedical option HIV testing, pre- exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), voluntary medical male circumcision condom promotion. Rapid, wider access PrEP effective use could significantly reduce number new HIV infections, especially among key population people area HIV incidence high. total number people using PrEP rose little 200 000 2017 3.5 million 2023 still fall far short global 2025 target 10.6 million person-years PrEP protection (1). African region making meaningful progress towards 2025 PrEP targets; progress achieved primarily funding US President’s Emergency Plan AIDS Relief. Currently, recommends multiple PrEP products, including oral tenofovir disoproxi",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3ee5c4e6-3f6f-41d3-b6d0-9cb406848c6f",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "r AIDS Relief. Currently, recommends multiple PrEP products, including oral tenofovir disoproxil- fumarate (TDF)-based PrEP , long-acting injectable cabotegravir (CAB-LA) dapivirine vaginal ring (DVR) (2). range PrEP product expands, focus choice meet users’ different need preference centre differentiated simplified delivery model HIV prevention. includes offering different dosing multi-month dispensing options, well PrEP delivery online, pharmacies, community primary care facilities. Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 2Service delivery model take public health approach must include testing follow- adapted meet client needs. Simplified affordable testing approaches, including HIV rapid diagnostic test (RDTs) self-tests, important ensuring access upt",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "932c7447-1f24-414c-9e5e-b036a8f96177",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "uding HIV rapid diagnostic test (RDTs) self-tests, important ensuring access uptake PrEP service may benefit. 1.2 Objectives intended audience guideline intended provide evidence-informed recommendation lenacapavir (LEN) PrEP HIV prevention testing long-acting PrEP (LA-PrEP). guideline seek support countries’ achievement national target reducing number new HIV infections. operationalize guidelines, important address critical aspect implementation, including improved simplified HIV testing algorithms, long-acting PrEP , HIV testing service gateway prevention treatment services. primary audience guideline national subnational programme manager policy-makers responsible national health sector response HIV, particularly low- middle-income countries. Programme manager nongovernmental",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5bf5165b-d7cc-4e13-97fa-bf2777e1c55e",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "HIV, particularly low- middle-income countries. Programme manager nongovernmental community-based organization also find guideline useful. audience also includes type PrEP providers, particularly primary health community health services, well personnel laboratory support testing services. Finally, guideline also important people could benefit PrEP , including community affected HIV. guideline also help donors, development agency international organization effectively plan support various HIV prevention testing programmes. 1.3 Guiding principle following principle informed development guideline guide implementation recommendation across settings: • Deliver HIV prevention testing service within evidence-based public health universal health coverage framework centred people, communit",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "895a7bdd-0bdc-4341-9c7d-937cab9b7820",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "nce-based public health universal health coverage framework centred people, community human rights. • Promote protect equity human right people risk HIV, making PrEP HIV testing service available, accessible acceptable without stigma discrimination anyone benefit PrEP . • Ensure PrEP HIV testing remain voluntary, never resorting coercive mandatory approaches, adhering principle autonomy, informed consent choice. • Implement prevention programme responsive local contexts, including HIV epidemiology, availability resources, organization capacity health system anticipated cost–effectiveness. • Implement new recommendation full participation affected community developing implementing PrEP testing services. Choice centre differentiated simplified delivery model HIV prevention.3 2. Methods",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "17edc5d0-75e7-4126-94de-d06928acf138",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "centre differentiated simplified delivery model HIV prevention.3 2. Methods guideline development guideline developed accordance procedure established Guidelines Review Committee (3). recommendation developed using Grading Recommendations Assessment, Development Evaluation (GRADE) approach reviewing evidence formulating recommendation (4). Consistent previous guidelines, guideline based public health approach considers effectiveness, acceptability, feasibility resource need across variety settings. external contributor guidelines, including member Guideline Development Group (GDG) External Review Group, completed declaration interest form accordance policy expert (Web Annex A). systematic reviews, one LEN PrEP (Web Annex B) one HIV testing service injectable LA-PrEP (Web Annex D), f",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "84f7f615-9768-4013-b708-15ae073bc6ff",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "LEN PrEP (Web Annex B) one HIV testing service injectable LA-PrEP (Web Annex D), followed research question population, intervention, comparator, outcome (PICO) format. systematic review finding prepared accordance GRADE process, shared advance presented GDG meetings, independent methodologist facilitated discussions. Details method used develop guideline presented Annex 1 document. addition, Web Annexes available website https://www.who.int/publications/i/item/9789240111608 .Guidelines Lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 4 3. Rationale supporting evidence: lenacapavir HIV prevention 3.1 Summary review finding Evidence safety efficacy LEN HIV prevention collected systematic review peer-reviewed scientific reports, incl",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c50fc966-8059-47bd-b239-395844808790",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "N HIV prevention collected systematic review peer-reviewed scientific reports, including published result papers, conference presentations, study protocols, clinical trial registry supporting documentation. review also included unpublished research research undergoing peer-review. Twelve eligible report included, containing data two studies. two included studies, PURPOSE 1 (5) PURPOSE 2 (6), multi-centred, double-blind, randomized, active- controlled trials. study assessed efficacy LEN compared background HIV incidence cohort well daily oral PrEP (tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)). Notably, PURPOSE 1 also assessed efficacy daily tenofovir alafenamide/ emtricitabine (TAF/FTC). However, since focus review LEN, TAF/FTC arm included. study population PURPOSE 1 included cisgender adolescent girl young woman age 16–25 yea",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5655e090-978c-4e77-8827-4b409f04116f",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "study population PURPOSE 1 included cisgender adolescent girl young woman age 16–25 year South Africa Uganda. study population PURPOSE 2 included cisgender gay, bisexual men sex men; transgender women; transgender men gender non-binary persons, least 16 year age, Argentina, Brazil, Mexico, Peru, South Africa, Thailand United States America. Overall, 8660 individual underwent randomization across two trials, 4333 individual randomized receive active LEN. study identified LEN prevention people inject drugs; however, randomized clinical trial LEN prevention HIV population underway (PURPOSE 4). study sought include sex worker people prison closed settings. 3.1.1 Reduction HIV infection Across PURPOSE 1 PURPOSE 2, LEN resulted large reduction HIV acquisition (high certainty evidence). P",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "37a5b7b8-08ac-4520-a62d-7f97c38d8ba7",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "PURPOSE 2, LEN resulted large reduction HIV acquisition (high certainty evidence). PURPOSE 1 participant randomized LEN acquired HIV, PURPOSE 2, two HIV infection identified LEN group. 5 3. Rationale supporting evidence: lenacapavir HIV preventioncompared background HIV incidence, LEN showed 100% efficacy PURPOSE 1 (RR: 0.00; CI 95%: 0.00-0.04) 96% efficacy PURPOSE 2 (RR: 0.04; CI 95%: 0.01-0.18). compared daily oral PrEP TDF/FTC, LEN showed 100% efficacy PURPOSE 1 (RR: 0.00; CI 95%: 0.00-0.10) 89% efficacy PURPOSE 2 (RR: 0.11; 95% CI: 0.02-0.51) (5, 6) . PURPOSE 1, 16 incident HIV infection occurred TDF/FTC group (1.69 per 100 person- years; 95% CI: 0.96–2.74), whereas infection observed LEN group (0 per 100 person-years; 95% CI: 0.00–0.19). PURPOSE 2, nine incident HIV infection identified TDF/FTC group (0.93 per 100 person-years; 95% CI:",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a519fdfa-2e7a-4ea5-8969-0eeb0339b5c9",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ne incident HIV infection identified TDF/FTC group (0.93 per 100 person-years; 95% CI: 0.43–1.77) compared two LEN group (0.10 per 100 person-years; 95% CI: 0.01–0.37). participant acquired HIV LEN group PURPOSE 2 LEN level consistent expected pharmacokinetic range. infection occurred first injection second, week 13 26. Investigators noted evidence delayed HIV detection either cases. Key message PURPOSE 1 2 trial demonstrated high efficacy lenacapavir , showing statistically significant reduction HIV acquisition compared background incidence daily oral PrEP arms. (HIGH certainty evidence) Data remain limited key population , people inject drugs, underscoring need expanded study across diverse demographic regions. Mathematical model suggest LEN could substantially",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a50eb025-f19e-4a1c-8cd8-2170fe35bbba",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "across diverse demographic regions. Mathematical model suggest LEN could substantially reduce new HIV infection , especially uptake adherence optimized (Box 1). Adherence pattern differed LEN TDF/FTC group trials. LEN adherence measured on-time injections, defined within 28 day scheduled dose, TDF/FTC adherence assessed tenofovir diphosphate level dried blood spot randomly selected subset participants. week 52, 92.8% participant receiving LEN trial received injection time. PURPOSE 1 adherence TDF/FTC low participant declined time, many taking fewer two pill per week. PURPOSE 2, 82% participant high adherence oral TDF/FTC (four pill per week) week 8, declined 62% week 52.In two randomized, controlled trials, LEN greatly reduced HIV acquisition.Guidelines lenacapavi",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ff83205e-10e8-4e84-abca-dafe28eab56c",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "two randomized, controlled trials, LEN greatly reduced HIV acquisition.Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 6Box 1Reducing HIV infection population level: evidence mathematical modelling LEN Mathematical model assessed potential impact LEN HIV prevention. Six HIV transmission modelling studies, reporting final preliminary findings, estimated impact LEN introduction different settings. additional nine study identified ongoing planned (Web Annex E: Mathematical modelling LEN: impact cost–effectiveness). South Africa one model estimated LEN could reduce new infection 27–41% 20 years, greater impact scaling oral PrEP CAB-LA (7). Another study, South Africa, western Kenya Zimbabwe, found focusing key populations, including adolescent girl young women, female sex worker",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b40ea67f-cf17-42c5-863d-a8bf4f9d563b",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "hat focusing key populations, including adolescent girl young women, female sex worker individual multiple sex partners, could reduce infection 12–33% 10 year population coverage 2–8% (8). third study, also South Africa, western Kenya Zimbabwe, found prioritizing LEN highest-risk population could reduce new infection 35 year 41%, compared maximum 24% untargeted scale-up, highlighting greater impact prioritizing higher-risk group (9). Among men sex men Thailand, one model predicted transitioning 95% oral PrEP user LEN, two-year duration use, could reduce new infection 37% 10 year (10) . However, LEN use limited six month – average duration oral PrEP use population – impact projected minimal, averting 1% new infection compared oral PrEP period. used high upt",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cd7e85b8-5036-49d9-8795-39168b4ac98f",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ting 1% new infection compared oral PrEP period. used high uptake, LEN potential reduce new HIV infection substantially, model surpassing oral PrEP CAB-LA due higher effectiveness, increased coverage better persistence use. potential LEN outperform PrEP option largely driven capacity increase overall PrEP coverage uptake, although even optimistic scenarios, many new HIV transmission projected still occur population level. 3.1.2 Safety PURPOSE 1 2 trial found little difference rate adverse event (excluding injection site reaction (ISRs)) receiving LEN receiving TDF/FTC (high certainty evidence). PURPOSE 1, 76.3% participant LEN arm 77.6% participant TDF/FTC arm reported least one adverse event (RR: 0.98, CI 95%: 0.94–1.02) (5). PURPOSE 2, 73.6% participant",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a25855a3-9951-4f1c-9101-eaa43859cbff",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "st one adverse event (RR: 0.98, CI 95%: 0.94–1.02) (5). PURPOSE 2, 73.6% participant LEN arm 73.8% TDF/FTC arm experienced adverse event (RR: 1.00, CI 95%: 0.96–1.04) (6). trial reported proportion participant experiencing grade 3 4 adverse events, finding LEN probably result little difference grade 3 4 adverse event compared TDF/FTC (moderate certainty evidence). PURPOSE 1, 4.1% participant receiving LEN 4.7% participant receiving TDF/FTC experienced grade 3 4 adverse event (RR: 0.88, CI 95%: 0.63–1.24) (5). PURPOSE 2, 4.2% LEN arm 6.0% TDF/FTC arm experienced grade 3 4 adverse event (RR: 0.70, CI 95%: 0.51–1.95) (6). ISRs, including nodules, pain erythema, frequently reported study generally mild. ISRs reported participant receiving LEN injection participant receiving placebo injection oral",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "16241656-0bb8-4c72-a355-26d35e9a52f6",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "participant receiving LEN injection participant receiving placebo injection oral TDF/FTC arms. PURPOSE 1, 68.8% participant randomized LEN experienced ISRs compared 33.9% TDF/FTC arm (RR: 2.03, CI 95%: 1.86–2.21) (5). PURPOSE 2, 83.2% participant LEN arm reported ISRs compared 69.5% TDF/FTC arm (RR: 1.20, CI 95%: 1.15–1.25) (6). frequency ISRs severity decreased time. systematic review concluded LEN result increase ISRs compared placebo injection TDF/FTC arm (high certainty evidence). 7 3. Rationale supporting evidence: lenacapavir HIV prevention Key message Overall rate adverse event similar LEN oral TDF/FTC , event mild moderate severity. Injection site reaction common typically mild , decreasing frequency time without leading high discontinuation rates. 3.1.3 Antiretrovira",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cffacc07-b377-4fcc-8966-2a1a677c6e5a",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ecreasing frequency time without leading high discontinuation rates. 3.1.3 Antiretroviral resistance among diagnosed HIV Resistance LEN analysed among participant acquired HIV PURPOSE 1 PURPOSE 2. PURPOSE 1 HIV acquisition LEN arm, thus case resistance reported (5). PURPOSE 2 two, participant LEN arm diagnosed HIV, mutation associated resistance HIV-1 capsid inhibitor (N74D) (6). evidence suggests LEN use may increase antiretroviral resistance capsid inhibitor (low certainty evidence). Given overall high efficacy LEN rarity breakthrough infections, resistance LEN unlikely significant public health impact present. LEN first-in-class drug; antiretrovirals class routinely used prevention treatment. Moreover, currently available evidence suggests",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "50f3c676-27c2-4e3b-80f0-4babd9fa61fe",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "routinely used prevention treatment. Moreover, currently available evidence suggests regimen include capsid inhibitor may retain activity despite resistance selected LEN. N74D mutation reduces susceptibility LEN approximately 20-fold (11-13) . Although associated estimated 50% reduction replication capacity vitro (11-13) , clinical significance decrease remains uncertain. However, mutation diminished replication capacity often revert undetectable level within month emergence. Evidence CAPELLA trial, evaluated LEN combination optimized background regimen antiretroviral therapy (ART) heavily treatment-experienced individuals, suggested LEN may retain activity despite resistance-associated mutation (14) . LEN introduced PrEP possibly future treatment, data needed confirm LEN-associated drug resistance wo",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e29cfb74-9a8e-42f8-89f0-74268e0c2328",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "future treatment, data needed confirm LEN-associated drug resistance would impact treatment combination included capsid inhibitors. Continued surveillance LEN resistance important LEN-based prevention treatment strategy expand. Wider use LEN, especially setting acute HIV infection may go undetected, could lead increased opportunity LEN-resistant variant emerge circulate. Monitoring frequency clinical significance additional LEN resistance mutation arise essential maintaining effectiveness LEN-based regimen informing future programme policy decision (Web Annex F: Drug resistance).Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 8 Key message Two breakthrough infection PURPOSE 2 showed capsid inhibitor resistance mutation (N74D) , highlighting importance ong",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8e0026f7-419d-4b35-9e19-d0567c24b047",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "PURPOSE 2 showed capsid inhibitor resistance mutation (N74D) , highlighting importance ongoing surveillance understand potential population level impact LEN scale-up continues. LEN first drug class prevention , current public health impact possible resistance considered limited, long-term monitoring remains essential. 3.1.4 Pregnancy birth-related outcome systematic review found LEN probably little effect term adverse pregnancy birth outcome compared oral TDF/FTC (moderate certainty evidence). PURPOSE 1 require contraception participation trial, provided contraception pregnancy desired (5). woman became pregnant, could continue study drug, receiving additional counselling risk benefit giving informed consent. PURPOSE 2, enrolled, among others, transgender individuals, transgender men assigned female bir",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8e767491-eb2c-4cbe-ac28-11ba42a7f5ca",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "SE 2, enrolled, among others, transgender individuals, transgender men assigned female birth ability become pregnant required use contraception due high prevalence use testosterone (a teratogen) among transgender men (6). PURPOSE 1, 193 pregnancy confirmed among 184 woman assigned LEN, 105 pregnancy outcome date (5). Rates grade 3 higher pregnancy-related complication (such hypertension, nausea fetal distress) similar LEN arm (1.1%) TDF/ FTC arm (1.5%) (RR: 0.75, CI 95%: 0.40–1.41). Rates birth outcome (live birth, still birth, miscarriages) differ significantly LEN oral PrEP arm significantly different background rate studied population. One minor congenital anomaly (polydactyly) observed infant born woman LEN group family history condition. pregnancy rep",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "de1ab2b2-9c3f-40f0-9abe-3b8924ca61d0",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "born woman LEN group family history condition. pregnancy reported PURPOSE 2 (6). Available data 184 woman LEN exposure became pregnant outcome date suggest possible rule two-fold increase risk adverse pregnancy outcome background prevalence >10% (miscarriage, prematurity, low birth weight), due sample size date (15) . Analysis pharmacokinetic data suggests dose adjustment LEN needed pregnancy (16) . data pregnancy outcome PURPOSE 1 anticipated, additional pregnancy occurred randomized trial since interim analysis, anticipated pregnancy also occur PURPOSE 1 open-label extension. Additionally, detailed pharmacokinetic study LEN pregnancy lactation available soon. However, research safety surveillance pregnancy needed monitor",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ca31b7f8-b415-4238-b98e-b5c68add4ded",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "lable soon. However, research safety surveillance pregnancy needed monitor less common adverse pregnancy infant outcomes, particularly rare adverse events, surveillance PrEP larger surveillance programme antiretroviral (ARV) pregnancy registries. 9 3. Rationale supporting evidence: lenacapavir HIV prevention Key message LEN showed increase adverse pregnancy birth outcome among 193 pregnancy reported PURPOSE 1 far. dose adjustment likely required pregnancy , pharmacokinetic data indicating standard dosing remains effective. Box 2 present updated data pregnancy-related outcome PrEP products. Box 2Beyond LEN: safety oral PrEP , DVR CAB-LA pregnancy Based available safety data, concludes PrEP available product need discontinued pregnancy breastfeeding HIV-negative woman high likelihoo",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6f8eaa63-c263-4bc7-852a-208d16ffbb24",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "discontinued pregnancy breastfeeding HIV-negative woman high likelihood exposure HIV. choice start, continue discontinue PrEP someone becomes pregnant made individual, following discussion risk benefit health care provider. Existing data safety efficacy use PrEP pregnant breastfeeding women, well individual conceive taking PrEP , highlighted three PrEP option – oral TDF- based PrEP , DVR CAB-LA. Oral TDF-based PrEP Available data reassuring regarding use oral TDF-based PrEP pregnancy breastfeeding. systematic review including 13 study assessing 8712 pregnant woman Africa found oral PrEP , compared PrEP , associated adverse perinatal outcome including fetal loss, prematurity, low birth weight neonatal death (17) . follow-up 455 mother–infant pairs, comparin",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7c05034a-7f34-424e-8836-31337d260de0",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "turity, low birth weight neonatal death (17) . follow-up 455 mother–infant pairs, comparing 228 exposed oral PrEP utero 227 without exposure, evidence association utero oral PrEP exposure infant growth (weight, length, head circumference) first 18 month life (18) . pharmacokinetic safety study tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) PrEP HIV-negative woman breastfeeding found drug level breast milk low (3.2 ng/mL tenofovir diphosphate (TFV-DP) 212.5 ng/mL FTC). Tenofovir detected 94% infant plasma specimens, suggesting PrEP used safely breastfeeding, minimal infant drug exposure (19) . Additionally, use oral PrEP effect bone mineral density bone mineral content 300 breastfeeding woman receiving oral PrEP (20) . Also, utero exposure oral PrEP infant born HIV-negative woman receiving",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "097b3d80-642a-4b2a-b17d-d863348ffe1c",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "l PrEP (20) . Also, utero exposure oral PrEP infant born HIV-negative woman receiving oral PrEP pregnancy associated difference bone mineral content first 18 month life exposed unexposed oral PrEP pregnancy (21) . DVR Safety study DVR use pregnancy shown favourable safety profile among pregnant woman infants; evidence negative impact pregnancy infant outcomes. Among used DVR pregnancy, difference preterm labour, stillbirth pregnancy complication seen randomized control trials, described below. Similarly, study DVR oral PrEP use breastfeeding found favourable safety profile among breastfeeding mother–infant pair low drug level breast milk infant blood sample (19, 22) .Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c94f1527-8185-400b-ba4a-9c1408ac43bb",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": ".Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 10Box 2Beyond LEN: safety oral PrEP , DVR CAB-LA pregnancy (continued) • DVR safety pre-conception early pregnancy. original randomized clinical trial DRV, MTN-020/ASPIRE, enrol pregnant individuals, 86 incident pregnancy occurred among participant using DVR, providing pre-conception early pregnancy exposure safety data (23) . Additionally, 58 pregnancy occurred open-label extension ASPIRE trial (HOPE) (24) . Among participant studies, impact fertility rate association preterm birth, pregnancy loss, congenital anomaly poor infant growth. • DVR safety pregnancy. MTN-043/DELIVER study enrolled pregnant individual three gestational age cohort ( >36 weeks, 30–35 week 12–29 weeks’ gestation) randomized use DVR",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f31a8d76-18f9-4ab4-aeeb-1fff0d6f4463",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "tional age cohort ( >36 weeks, 30–35 week 12–29 weeks’ gestation) randomized use DVR oral PrEP delivery (25) . DVR association preterm birth, stillbirth maternal infant serious adverse events. HIV seroconversions, pregnancy complication uncommon, similar background rate observed study communities. • DVR safety breastfeeding. MTN-043/B-PROTECTED study enrolled approximately 200 exclusively breastfeeding mother–infant pairs. Participants randomized DVR (n=148) oral PrEP (n=49), product used 12 weeks. study designed assess maternal infant safety, adherence acceptability. Key finding showed excellent safety profile mother infants, serious adverse event related DVR little dapivirine present milk, even less passed infants; median dapivirine level limit quantification",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f4b5674e-2161-4c1c-a880-4fd006c6e60a",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "even less passed infants; median dapivirine level limit quantification visit (22) . Similarly, receiving oral PrEP (TDF/FTC), median TFV-DP level low observed infant blood specimen (all level quantification visits). CAB-LA data available use CAB-LA pregnancy breastfeeding, research ongoing concern identified date. original efficacy study cisgender women, HPTN 084, excluded pregnant breastfeeding woman enrolment participant tested positive pregnancy switched CAB-LA oral PrEP . ongoing open-label extension HPTN 084 study allows participant continue using CAB-LA became pregnant. Findings analysed separately exposed CAB-LA pregnancy. number implementation study underway several country allowing use CAB-LA PrEP pregnancy brea",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7fb0e552-53c8-4b63-88c9-5fa6bbe0dfe5",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "study underway several country allowing use CAB-LA PrEP pregnancy breastfeeding. Pregnancy, birth newborn outcome monitored reported. • CAB-LA safety pre-conception early pregnancy. Available data small number woman became pregnant HPTN 084 trial suggest CAB-LA safe pregnancy; CAB-LA well tolerated, complication pregnancy delivery due CAB-LA, congenital anomaly reported (26) . Recent evidence HPTN 084 open-label extension included 300 individual became pregnant using CAB-LA stayed regimen (27) . group CAB-LA well tolerated, consistent maternal pregnancy outcome (infant growth, birth weight, median gestational age) across study participant background rate general population. • CAB-LA concentration tail period pregnancy. Available data pharma",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "74fe50aa-752e-44a4-bedc-67f5f42181f4",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ion. • CAB-LA concentration tail period pregnancy. Available data pharmacokinetics CAB-LA pregnancy suggest drug concentration decrease time pregnancy, lowest level third trimester, level remained minimum level needed protection, dose modification needed (27) . Additional analysis ongoing. • CAB-LA safety breastfeeding. pharmacokinetic safety study CAB-LA breastfeeding planned part HPTN 084 open-label study. Data anticipated mid-2025.11 3. Rationale supporting evidence: lenacapavir HIV prevention3.1.5 Efficacy hormonal contraception gender- affirming hormone systematic review find evidence efficacy hormonal contraception gender-affirming hormone therapy (GAHT) co-administered LEN. PURPOSE 2, included transgender non-binary persons, 11.6% (n=253) study participant",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "690e2a4d-d3cb-4e60-b6c4-4c51efec1961",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "PURPOSE 2, included transgender non-binary persons, 11.6% (n=253) study participant randomized LEN 12.0% (n=131) randomized TDF/FTC reported taking gender-affirming hormone baseline (6). influence LEN effectiveness GAHT assessed study. However, preliminary pharmacokinetic data analysis suggest LEN result clinically meaningful change hormone level individual GAHT (either testosterone-based estradiol-based regimens) long-acting hormonal contraceptives, hormone regimen appear affect LEN concentration (28) (see Table 1, page 24). Key message Preliminary evidence suggests LEN clinically meaningful interaction hormonal contraception gender-affirming hormone therapy. 3.1.6 Behavioural outcomes, including incidence sexually transmitted infection (STIs) systematic review ascertained LEN use probably result little",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7d20af14-9569-4593-8409-07f96c599702",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "infection (STIs) systematic review ascertained LEN use probably result little difference STI incidence compared oral TDF/FTC (moderate certainty evidence). PURPOSE 1 gonorrhoea, chlamydia trichomonas frequently diagnosed study arms, 48.7 event per 100 person-years LEN arm 48.4 event per 100 person- year TDF/FTC arm (RR: 1.01; CI 95%: 0.90–1.13) (5). PURPOSE 2 gonorrhoea chlamydia frequently diagnosed across arms: 77.9 event per 100 person-years LEN arm compared 69.4 event per 100 person-years TDF/FTC arm (RR: 1.12; CI 95%: 1.02 1.23) (6). Syphilis rate also similar – 14.1 event per 100 person-years LEN arm 12.4 event per 100 person-years TDF/FTC arm. Neither study reported behavioural outcomes, condom use number sexual partners. Key message LEN likely result little difference STI incidence compared",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c91af00f-d12b-49c3-9e0c-a753dd5a111f",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "tners. Key message LEN likely result little difference STI incidence compared oral TDF/FTC , high rate noted across groups.Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 123.2 Values preference Evidence value preference LEN among end user derived systematic review peer-reviewed publication conference abstract (Web Annex C). included, study must designed understand value preference injectable PrEP also report actual experience using implementing injectable PrEP report relevant comparison assessment various attribute injectable PrEP products. systematic review identified 26 study meeting inclusion criteria, including six study (across nine reports) related experience injectable PrEP (29-37) , specifically CAB-LA, 20 study comparing different attribute",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7faec187-c635-48c5-8214-6b97f03e1475",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "e injectable PrEP (29-37) , specifically CAB-LA, 20 study comparing different attribute injectable PrEP (38-57) (Web Annex C). Study design included qualitative quantitative study (cross-sectional survey discrete choice experiments. commonly, study took place United States America involved gay men men sex men. GDG noted may uncertainty variability end user value LEN injectable prevention option. review found injectable PrEP generally highly acceptable PrEP modality, variation specific preference PrEP different population geographies. six study involving injectable PrEP experience, high acceptability injectable PrEP across diverse population (high confidence evidence), driven perception low burden/perceived ease use, fit lifestyle (convenient, allows discreet use)",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f50eaf01-7f19-470d-98cf-36330dfa0440",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "f low burden/perceived ease use, fit lifestyle (convenient, allows discreet use) perceived effectiveness. Concerns injectable PrEP varied population context (moderate confidence evidence) mostly related burden including side-effects (for example, pain ISRs) location injection; perception efficacy injections, including inaccurate perception waning efficacy injection structural barrier (for example, inability get clinic injection, cost opportunity costs). GDG identified important uncertainty variability end user valued protection offered LEN HIV infection. Findings study examining injectable PrEP attribute show clear preference among end user longer duration efficacy less frequent dosing, study compared six- two-month injection finding preference six-month injection.",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7928b042-20c2-48b6-972a-3b3297b9f18e",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "compared six- two-month injection finding preference six-month injection. study indicated clear preference type injection (intramuscular subcutaneous), preference injection site body varied setting population. Self-administered injection acceptable, especially among population self-injecting experience (for example, hormone injections). GDG observed LEN likely acceptable stakeholders, including provider HIV programme managers, recognized may variability depending type stakeholder. review found implementation injectable PrEP perceived appropriate, feasible acceptable provider based United States America, although internal external barrier implementation identified (for example, challenge injection scheduling, resource management outreach) (low confidence evidence). Addition",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e6ef5226-cd8f-4028-aa3c-7b883bffbff8",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "injection scheduling, resource management outreach) (low confidence evidence). Additionally, result study PrEP provider across 24 country found high level support injectable product (58) . 13 3. Rationale supporting evidence: lenacapavir HIV prevention Key message Injectable PrEP generally perceived highly acceptable , user citing convenience potential discreet use. Concerns varied setting , including worry injection-related pain, potential side-effects scheduling challenge follow-up doses. Evidence suggests provider also find injectable PrEP acceptable , although concern remain cost logistics. 3.3 Feasibility GDG concluded introduction LEN additional prevention option HIV programme would likely feasible. rationale judgement PURPOSE 1 2 trial conducted across eight country Africa, Latin America, North Ame",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0ff0ad70-bed0-4f49-909c-37bee18d0b34",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "PURPOSE 1 2 trial conducted across eight country Africa, Latin America, North America South-East Asia, demonstrating feasibility across 120 well supported controlled trial site (5, 6) . GDG noted LEN implementation conducted outside trial settings, limiting ability make thorough judgement feasibility real world programmes. Instead, GDG discussion considered indirect evidence implementation study CAB-LA, shown feasibility integrating injectable LA-PrEP option broader programme (59-61) . study focused expanding prevention option allowing user choice, resulting increased uptake product coverage. systematic review value preference conducted guidelines, US-based provider perceived implementation injectable PrEP feasible (see section 3.2). However, LEN-specific perspective feasibility ident",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5f972d5b-3ae8-4880-a27b-46376e34c351",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "P feasible (see section 3.2). However, LEN-specific perspective feasibility identified. GDG member also noted uncertainty feasibility LEN implementation due need enabling environment political commitments. Key message Clinical trial site across many country successfully delivered LEN , suggesting that, adequate planning, integrating injectable PrEP existing service may achievable. Indirect evidence CAB-LA implementation support feasibility implementing long-acting injectable PrEP , though real-world data specific LEN still needed.Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 143.4 Cost–effectiveness Evidence cost–effectiveness LEN HIV prevention presented GDG derived landscaping review mathematical modelling study discussed section 3.1.1 (see also Web Annex E).",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d469c79e-bfcd-4dc6-9eb2-c5651bfaed15",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "aping review mathematical modelling study discussed section 3.1.1 (see also Web Annex E). Two study South Africa found LEN could cost–effective per-person-per-year (PPPY) cost remained certain thresholds, using benchmark less US$ 500 per disability-adjusted life-year (DALY) averted (8, 9) . One analysis concluded LEN could cost–effective US$ 213 PPPY (95% CI 191–232), scaled among key population (8). second study estimated maximum cost US$ 106 PPPY (95% CI 98–114) risk-prioritized coverage 5% overall population (9). third study suggested LEN could cost US$ 225 PPPY cost–effective oral PrEP South Africa (7). lower-prevalence settings, western Kenya Zimbabwe, maximum feasible PPPY cost LEN much lower, ranging US$ 10–33 western Kenya US$ 16–42 Zimbabwe, even focusing key population (8, 9) . comparison oth",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bdfa115d-5aa7-4957-b756-9f8a65432aba",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ya US$ 16–42 Zimbabwe, even focusing key population (8, 9) . comparison strategy implementing PrEP , one study found Zimbabwe long-acting PrEP female sex worker would cost-efficient HIV prevention option, incremental cost–effectiveness ratio US$ 1081 per infection averted (62) . Across four model (7-9, 63) important driver cost–effectiveness LEN implementation included annualized price LEN specific setting, service delivery implementation costs, population coverage adherence, prioritization different population delivery, based risk HIV acquisition. model indicate LEN must relatively inexpensive meet threshold less US$ 500 per DALY averted, especially higher coverage level without specific risk targeting. GDG concluded introduction LEN probably cost–effective long term, due high effica",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "529caf63-0e77-462e-a741-3515d57b0602",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "introduction LEN probably cost–effective long term, due high efficacy. GDG noted, however, large scale implementation LEN likely require moderate resource that, time GDG’s considerations, uncertainty due lack available pricing information LEN. pricing information available later, product receives national regulatory approval generic manufacturer enter global market. Key message Modelling study indicate LEN cost–effective , particularly annual per- person cost remain certain threshold higher prevalence settings. LEN cost-effective per DALY averted coverage adherence high service delivery focus greatest risk HIV acquisition . 3.5 Equity human right GDG concluded introducing LEN alongside existing HIV prevention option would likely increase equity. rationale j",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "337a4f00-43c5-4da8-b9d8-c1bdf353669b",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "EN alongside existing HIV prevention option would likely increase equity. rationale judgement expanding product choice accommodate different users’ need preference would help overcome inequity HIV prevention. six-monthly dosing schedule may help reduce cost time barrier often arise requiring frequent clinic visits; reduced schedule could particularly benefit individual caregiving and/or employment responsibilities. long dosing interval also ease integration LEN PrEP preventive services, contraception, antenatal care postnatal care, LEN injection required every six months.15 3. Rationale supporting evidence: lenacapavir HIV preventionThe GDG also noted uncertainty LEN introduction may affect equity. Although injectable product may offer discretion reduce stigma compared daily oral regimens, provider-administe",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0d36aacb-ee9b-45dc-9f0b-e05ef459bbde",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ct may offer discretion reduce stigma compared daily oral regimens, provider-administered nature LEN could inadvertently re-medicalize prevention made available decentralized site community-based venues. Centralized service delivery may limit access living remote area facing transportation financial constraints. prevent reinforcing inequity scaling LEN, programme consider delivery model prioritize users’ convenience, confidentiality community engagement. Countries address structural stigma discrimination removing punitive laws, policy practice explicitly indirectly exclude key population health services. Key message Six-monthly injection may expand prevention option individual struggle daily pill adherence , potentially improving equity HIV services. Centralized delivery could inadvertently limit access paired community-b",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b86098c2-2850-46d1-97d5-2afa15d94012",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "V services. Centralized delivery could inadvertently limit access paired community-based decentralized services; highlight need inclusive implementation strategies. 3.6 Rationale recommendation GDG noted LEN HIV prevention could offer substantial benefits, based moderate-to-high certainty evidence safety efficacy, well potential acceptability end-users providers, feasibility integration existing health services, possible cost–effectiveness certain scenario capacity address equity concern six-monthly dosing schedule. considering synthesized evidence across domains, including uncertainty related real-world implementation beyond PURPOSE trials, lack evidence key population (for example, people inject drug sex workers), GDG made strong recommendation injectable LEN offered additional preve",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "560588a9-8483-4174-9fe5-1df001611cee",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "rkers), GDG made strong recommendation injectable LEN offered additional prevention choice people risk HIV, part combination prevention approaches. GDG recognized data gap remain, particularly longer-term resource cost implication affordability. GDG emphasized need ensure higher cost LEN inadvertently reverse progress toward differentiated service delivery model restrict access due higher costs. Nevertheless, GDG considered six-monthly dosing, suitability individual value discretion difficulty taking daily pills, potential expand HIV prevention option outweigh concerns, given high level efficacy observed trial potential increased coverage uptake. GDG emphasized research evidence gap identified delay programmatic implementation. Recommendation [NEW] Long-acting injectable",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "094ba0c7-9917-4b21-b518-42026a4cecc3",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "entified delay programmatic implementation. Recommendation [NEW] Long-acting injectable lenacapavir offered additional prevention choice people risk HIV, part combination prevention approaches. (strong recommendation, moderate-to-high certainty evidence)Guidelines Lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 16 4. Rationale supporting evidence: testing long- acting injectable PrEP 4.1 Summary review finding existing recommendation HIV testing strategy algorithm encourages country offer strategic mix approach maximize public health impact. detail see Consolidated guideline differentiated HIV testing service (64) . Evidence gathered systematic review synthesized research finding various testing approach injectable LA-PrEP delivery, focus RDTs, HIV self- tests, laborat",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6707b40d-b495-4037-9040-7849b22f7134",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "testing approach injectable LA-PrEP delivery, focus RDTs, HIV self- tests, laboratory-based testing NAT techniques. systematic review included 22 study (CAB-LA: 20 studies, LEN: 2 studies) involving 15 594 participant spanning Africa, Asia, Europe Americas. Evidence included non-randomized comparator study (n=7) observational study without comparator group (n=15). limited information continued HIV testing among discontinued injectable LA-PrEP . 17 4. Rationale supporting evidence: testing long-acting injectable PrEPBox 3 summarizes key finding review. Web Annex present details. Box 3Evidence summary testing injectable LA-PrEP following finding relate HIV RDT supported injectable LA-PrEP compared NAT and/or laboratory- based HIV testing algorithms: • Faster turnaround time providing diagnosis rapid ART initiation following HIV diagnosis (65-68)",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2d12de95-20aa-4cee-b791-7f1c22fba6f2",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "time providing diagnosis rapid ART initiation following HIV diagnosis (65-68) 1 (very low certainty evidence) ; • Fewer delayed missed injection visit (65, 66) (very low certainty evidence) ; • May lower test sensitivity, missing cases, similar negative predictive value positive predictive value across algorithm (5, 6, 65, 66) (low certainty evidence) ; • May difference absolute number missed delayed HIV infection detected (5, 6, 65, 66, 68) (low certainty evidence) ; • May difference detection breakthrough HIV infection among using injectable LA-PrEP (5, 6, 65, 66) (low certainty evidence) ; • May difference prevention integrase strand transfer inhibitor resistance associated mutation (6, 65, 66) (low certainty evidence) ; • difference frequency HIV testing among taking injectable LA-PrEP (59, 68) 2 (very low certainty evidence)",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0e064673-4a67-4b07-afb1-9d5edd74214b",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "HIV testing among taking injectable LA-PrEP (59, 68) 2 (very low certainty evidence) ; • effect clinical social harm consequence misdiagnosis, anxiety domestic violence (5, 6, 59, 65, 66) (very low certainty evidence). Evidence use HIVST injectable LA-PrEP limited focused testing frequency performance.3 Studies reviewed indicated low certainty evidence HIVST could increase testing frequency among using injectable LA-PrEP . Emerging data among adolescent receiving CAB-LA Brazil suggest HIVST RDTs good accuracy demonstrated high sensitivity specificity; produced test result comparable NAT (96) . research needed fully understand potential role HIVST part injectable LA-PrEP implementation. 1 Personal communications: Das M. Gilead Sciences. PURPOSE 1 PURPOSE 2. 2024; Landovitz R, Geffen School",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "28e248d7-4109-4498-bd90-276fd2852f3a",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "mmunications: Das M. Gilead Sciences. PURPOSE 1 PURPOSE 2. 2024; Landovitz R, Geffen School Medicine, HPTN083 study, 2024; Parikh U, University Pittsburgh School Medicine, CATALYST study, 2024.) 2 Personal communications: Dourado I, Universidade Federal da Bahia, PrEP1519, 2024; Dvora JD, Medicine Epidemiology University California, CAB-PK Pregnancy Postpartum study, 2024; Fox J, King’s College London, MOBILE MEN, 2024; Hoagland B, Instituto Nacional de Infectologia Evandro Chagas, ImPrEP CAB-LA Brasil study, 2024; Houssemini Mina, University North Carolina, Project Malawi, Malawi Path Scale, CAB-LA Implementation study, 2024; Langa N, Ministry Health Zambia, Zimbabwe observational cohort, CAB-LA implementation, 2024; Martin C, Wits RHI, University Witwatersrand, Project PrEP , 2024; Mulenga L, Ministry Health Zambia, Zambia observational cohort, CAB-LA implementation, 2024; Parikh U, University Pittsburgh School Medicine, C",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "741add4a-b8a4-4399-ab07-22e03b498ce1",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ional cohort, CAB-LA implementation, 2024; Parikh U, University Pittsburgh School Medicine, CATALYST study, 2024; Saidi F, University North Carolina, Project Malawi, PrIMO study, 2024; Tembo A, Ezintsha South Africa, Axis study, 2024; Zash R, Botswana Harvard Institute Boston, Tshireletso Study, 2024. 3 Personal communications: Dourado I, Universidade Federal da Bahia, PrEP1519, 2024; Fox J, King’s College London, MOBILE MEN, 2024; Hoagland B, Instituto Nacional de Infectologia Evandro Chagas, ImPrEP CAB-LA Brasil study, 2024.Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 18Additional modelling impact using NAT , RDTs HIVST context CAB-LA also showed that, NAT would detect HIV earlier, would measurable difference drug resistance case acute infection breakthrough infection remain rare (69) . modelling also show using lower sen",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d4083be8-1caf-49f8-a667-5a8a716393aa",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "breakthrough infection remain rare (69) . modelling also show using lower sensitivity test missing delaying testing visit minimal impact drug resistance (69) . 4.2 Values preference systematic review (Web Annex D), GDG assessed value preference concerning testing among PrEP provider users. GDG also considered value preference collected online survey in-depth interview development 2022 guideline CAB-LA (70) . systematic review found user generally supported use HIV RDTs injectable LA-PrEP service delivery. study examining preferred setting receive LA-PrEP among men sex men (n =1076) found 26% preferred receiving LA-PrEP home, 14% preferred obtaining pharmacy (71) . finding suggest user favour option reduce clinic visit facilitate decentralized service delivery option",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cb3ebaf0-309a-49b0-b5f5-13e5ccc9252d",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "favour option reduce clinic visit facilitate decentralized service delivery options. 2022 WHO-led value preference process (58, 70) included survey response 1353 participant in-depth interview 30 health workers. Findings indicated HIV testing requirement concern. However, broad support user provider RDTs standard testing strategy. also interest potential use HIVST . Previous guideline process value preference assessment similar findings, indicate simplified testing RDTs self-tests highly feasible acceptable provider user (64) . Key message Providers generally welcomed simplified testing strategy , emphasizing importance rapid, same-day result avoid delay initiating continuing injectable LA-PrEP). End user favoured test method reduce clinic visit , suggesting potentia",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dd7f6a89-336d-4194-a4c0-124f3ace2a78",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "jectable LA-PrEP). End user favoured test method reduce clinic visit , suggesting potential future role HIVST injectable LA-PrEP delivery. implementation research needed fully determine role HIVST delivering injectable LA-PrEP . 4.3 Resource use Among advantages, HIV RDTs cost less HIV tests. systematic review identified evidence cost resource use five study (72-77) . One modelling study included HIV testing commodity cost ranging US$ 0.17–4.00 HIV RDTs, US$ 3–5 HIVST , US$ 1.20–24.08 laboratory-based antigen/antibody test US$ 8.80–85.10 NAT . Additionally, data one CAB-LA open-label extension study (78) indicated detecting one additional case NAT – missed RDT earlier stage – would require testing least 5305 individual using NAT . Given available cost information, would translate cost ranging US$ 46 684 US$ 451 456 per",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "20cff6a1-0ae4-4209-ac9b-413a8f016450",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ilable cost information, would translate cost ranging US$ 46 684 US$ 451 456 per case detected.19 4. Rationale supporting evidence: testing long-acting injectable PrEPAnother modelling study, CAB-LA (79) , reported using standard HIV RDT cost-effective compared NAT , significant difference reducing AIDS death (HIV RDT: mean 28 460 (9520–64 170) AIDS death per year compared NAT: 21 840 (7630–47 300)) despite increased integrase inhibitor resistance, estimated 5% 2030, CAB-LA used, compared 0.5% CAB-LA used. modelling also reported NAT commodity expensive (average cost US$ 22 per test) HIV RDTs (US$ 4). Overall, HIV RDTs HIVST found cost less NAT/RNA testing laboratory-based testing strategy (Web Annex D). Reviewers GDG considered cost resource use information conservative, include",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "eb644997-0243-4ca9-a681-7858575bed99",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "GDG considered cost resource use information conservative, include fully cost as: expense related scale-up, supply, laboratory equipment, human resources, training confirmatory assays. continues one commercially available NAT currently validated diagnostic claim use older 18 month age, hindering access affordable NAT options. Key message RDTs cost significantly less NAT laboratory-based testing. Costly follow-up testing false positive NAT result add financial burden RNA-based testing programmatic settings. 4.4 Equity human right Equity human right consideration informed facilitated discussion among GDG members. GDG concluded using RDT-based testing algorithm and/or self-tests may increase equity enabling people access effectively use LA-PrEP (80) . Key driver",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5b46207c-2f70-40af-bf3b-8c86b9b6c4f5",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "e equity enabling people access effectively use LA-PrEP (80) . Key driver poor access NAT testing, well laboratory-based testing, cost complexity service delivery. NAT laboratory-based testing high commodity cost require highly skilled staff infrastructure including refrigeration electricity. previously reported nearly HIV testing world done primary care community level clinical laboratory (64) . Given unmet need routine viral load monitoring among people HIV receiving ART , increased NAT capacity directed supporting treatment service (81) . GDG concluded requiring NAT/RNA testing laboratory-based HIV testing initiation injectable LA-PrEP would likely limit availability. GDG also noted that, current gap availability NAT viral load monitoring people HI",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2e363ac8-f5e4-46ec-a0d3-2e2447d9914e",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "hat, current gap availability NAT viral load monitoring people HIV, would appropriate prioritize NAT RDTs PrEP initiation continuation.Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 20Key message Access RDTs HIV self-tests improve equity reducing travel time, lowering financial barrier supporting confidential testing. Routine testing requiring NAT laboratory-based testing would likely infeasible many countries, and, therefore, service might miss population need injectable LA-PrEP . 4.5 Rationale recommendation GDG considered overall benefit RDT-based algorithm outweigh potential harms. decision based observed advantage RDT-based testing, including faster turnaround time compared NAT , minimal variation people value rapid results, moderate-to-sub",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a8cb7a8e-ab1e-41a9-a12b-7aa57385c6b1",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ound time compared NAT , minimal variation people value rapid results, moderate-to-substantial cost savings, high feasibility likely acceptability among stakeholder health system. RDT-based algorithm expected improve health equity increasing access, particularly resource-limited settings. addressing barriers, including cost, infrastructure human resources, RDT-based testing potentially expand LA-PrEP accessibility low- middle-income country NAT capacity often scarce. Importantly, GDG emphasized that, despite current evidence gaps, implementation RDT-based testing LA-PrEP programme delayed. Reductions resource use, feasibility value preference favour RDTs key factor led GDG make strong recommendation use HIV RDTs despite low certainty evidence. GDG noted HIVST may important implementation consideration c",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ccdbf347-01b5-46bf-b422-bb1fc70f6bfe",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "evidence. GDG noted HIVST may important implementation consideration contexts, increasing programme flexibility testing frequency. However, insufficient data make formal recommendation. plan review emerging evidence soon available update guidance accordingly. Recommendation [NEW] Rapid diagnostic test may used HIV testing initiation, continuation discontinuation long-acting PrEP . (strong recommendation, low certainty evidence)21 5. Implementation consideration research gaps: lenacapavir HIV prevention 5.1 Implementation consideration success LEN implementation additional HIV prevention option depend political enabling environment global scale-up. Ensuring equitable access among population priority implementation. important national programme partner community people affected b",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b78947ae-7181-45d8-8967-4bbe4105b630",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "lementation. important national programme partner community people affected HIV design implement LEN integration existing programme meaningful participation. develop implementation guidance country support adoption LEN. (See Chapter 6 implementation consideration research gap related HIV testing context LEN delivery.) 5.1.1 Dosing dosing strategy LEN involves mandatory oral loading dose two 300 mg tablet given day 1 2, beginning day first injection (total oral loading dose 1200 mg). injectable component delivered subcutaneously two 1.5 mL injection (total injectable dose 927 mg). Follow-up injection administered every 26 weeks. Oral reloading needed follow-up injections, provided user return time follow- appointment (26 week +/− two week previous injection). Individuals return af",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2a2259ae-ec5c-4ba2-a2cf-e90af3b0f880",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "w- appointment (26 week +/− two week previous injection). Individuals return 28 week wish continue LEN need receive reloading dose oral tablet two days. window follow-up injection two week two week next scheduled appointment.Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 22Programmes provider support individual return on-time follow-up injection maintain protection. support include educating client importance receiving follow-up injection according visit schedule importance using HIV prevention product approach follow-up injection delayed LEN stopped. Systems remind and/or recall client follow-up injection may benefit. system may include automated reminder via digital intervention mobil",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c616ae56-0ff9-408a-ac30-91f020cecdf9",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "benefit. system may include automated reminder via digital intervention mobile platforms. long-acting product, LEN administered subcutaneously dose 927 mg may remain body least 12 month last injection (known pharmacokinetic tail). However, six month LEN concentration body fall protective threshold, although remain detectable contribute HIV drug resistance HIV acquisition occurs. user discontinue LEN, provider support transition HIV prevention approach protect HIV acquisition pharmacokinetic tail period. Similarly, programme ensure continuity supply access remove structural barrier on-time administration follow-up injection reduce risk delayed prematurely stopped LEN. 5.1.2 Service delivery date, evidence available delivery LEN limited highly controlled tri",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b5d1e82e-d607-4bec-8afa-6a05c36b4979",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "elivery date, evidence available delivery LEN limited highly controlled trial settings. However, experience oral PrEP CAB-LA provide relevant important evidence implementation LEN. experience suggests differentiated service delivery options, including task sharing delivery community settings, crucial achieve scale-up create person-centred, accessible acceptable services. LEN offered part comprehensive person-centred service package tailored local context need preference individuals. Importantly, LEN may suit need every client. Clients offered choice PrEP products. Offering choice increase PrEP uptake, coverage persistence. addition, flexibility offering LEN crucial, time individual may change preference specific product. service package LEN may include provision PrEP",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dd99bde1-1efb-4a6e-a10e-f92913388463",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ferences specific product. service package LEN may include provision PrEP option (TDF-based oral PrEP , DVR and/or CAB-LA) support PrEP choice, condom lubricants, PEP , screening treatment STIs viral hepatitis, sexual reproductive health service (including contraceptive services), mental health support, service prevent protect gender-based violence, gender-affirming care, harm reduction service people use drug (including chemsex). People may benefit PrEP service provider engaged design PrEP service LEN. National programme look opportunity differentiated service delivery support LEN access across diverse population within countries. approach differentiated simplified service delivery include: • task sharing nurses, pharmacists, community health worker peers; • delivery community settings, pha",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1c0d0275-19b2-4a30-8587-7978da23d9ad",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "rses, pharmacists, community health worker peers; • delivery community settings, pharmacies, mobile sites, community-based organization type community centres; • leveraging virtual intervention telehealth, including digital tool delivery channels; • integration services, including antenatal postnatal services.23 5. Implementation consideration research gaps: lenacapavir HIV prevention 5.1.3 Hepatitis STIs Following person-centred approaches, avoid missed opportunity prevent manage infections, testing hepatitis B virus (HBV) and/or hepatitis C virus (HCV) offered people starting LEN repeated annually test negative. Vaccination HBV offered people negative HBV. People reactive result HBV HCV follow national diagnostic algorithm hepatitis referred care diagnosis confirmed. Indivi",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f19e1025-4fbc-4705-a383-11b7e993e628",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "nal diagnostic algorithm hepatitis referred care diagnosis confirmed. Individuals HBV infection could consider TDF-based oral PrEP , given dual effectiveness HIV HBV. LEN contraindicated individual HBV HCV. However, important note LEN extensively studied people co-infected HIV active HBV untreated HCV, studied individual severe hepatic impairment. Therefore, close monitoring advisable prescribing LEN patient HBV HCV. Testing STIs gonorrhoea, chlamydia, syphilis trichomoniasis offered people starting continuing LEN. high incidence STIs among PURPOSE 1 PURPOSE 2 trial population strongly suggests regular STI testing part LEN delivery support broader STI control. produced implementation tool follows step-wise approach support integration",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d9c8cf1d-8942-434f-ae02-cb339f8a03dd",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "HO produced implementation tool follows step-wise approach support integration STI control activity HIV prevention programme (82) . testing hepatitis STIs offered, lack limit delay access LEN. 5.1.4 Toxicity drug-to-drug interaction use LEN associated nephrotoxicity hepatotoxicity. Thus, liver kidney function testing monitoring required LEN initiation follow-up. dose adjustment required individual mild, moderate severe renal impairment (creatinine clearance ≥ 15 mL/min). LEN studied individual end-stage renal disease; thus, used caution individuals. administration, LEN undergoes minimal metabolism. Drugs affecting LEN metabolism include moderate strong inducer drug metabolizing enzyme like CYP3A4. time, LEN moderate inhibitor CYP3A4 and, theref",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "02491763-e334-401c-a052-5c39294ce869",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "tabolizing enzyme like CYP3A4. time, LEN moderate inhibitor CYP3A4 and, therefore, affect drug metabolized CYP3A4, particularly narrow therapeutic range (28) . Upon discontinuation LEN, residual concentration LEN may remain circulation prolonged period could affect CYP3A4 substrate metabolized, particularly initiated within nine month last subcutaneous dose. Table 1 summarizes interaction selected key drugs. information management strategy may updated experience LEN implementation increase new data become available. interaction management strategy may found online https://hiv-druginteractions.org; list medicine exhaustive subject change.Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 24Table 1. Summary table drug–drug inter",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "da384ceb-8729-4c06-8b02-d6a8890705b8",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "gy long-acting injectable pre-exposure prophylaxis 24Table 1. Summary table drug–drug interaction lenacapavir used PrEP Drug class Interaction management Antibiotics treatment tuberculosis (TB) Rifabutin Rifampicin RifapentinePotential interaction, requires dose adjustment Induction CYP3A4 substantially reduce LEN concentration may result loss prevention efficacy. Anticonvulsants Carbamazepine Phenobarbital PhenytoinPotential interaction, requires dose adjustment Induction CYP3A4 substantially reduce LEN concentrations, may result loss prevention efficacy. Illicit/recreational KetaminePotential interaction, may persist discontinuation lenacapavir Ketamine concentration may increase due inhibition CYP3A4 LEN may increase side-effects associated ketamine, respiratory depression hallucinations. Erectile dysfunction Avanafil Sildenafil Tadalafil Vard",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "743cd897-862e-4aa4-928f-32582b84913a",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "respiratory depression hallucinations. Erectile dysfunction Avanafil Sildenafil Tadalafil VardenafilPotential interaction, may persist discontinuation lenacapavir Sildenafil, tadalafil vardenafil concentration may increase due inhibition CYP3A4 LEN. Gender-affirming hormone Estradiol Conjugated estrogen Ethinylestradiol Medroxyprogesterone Micronized progesterone TestosteroneNo dose adjustment required. LEN moderate inhibitor CYP3A4 could potentially increase exposure gender-affirming hormone, although extent require dose adjustment. Hormonal contraceptive Ethinylestradiol Etonogestrel Levonorgestrel Medroxyprogesterone Norethisterone NorgestrelNo dose adjustment required. LEN moderate inhibitor CYP3A4 could potentially increase exposure contraceptive hormone, although extent require dose adjustment.25 5. Implementation consideration research gaps: lenacapavi",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cc5a7621-ec78-44e4-a1e5-84456dd27f11",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "require dose adjustment.25 5. Implementation consideration research gaps: lenacapavir HIV prevention 5.1.5 adverse event LEN generally safe, side-effects reported, primarily ISRs. participant PURPOSE 1 2 trial reported discontinue use due ISRs, became less frequent less severe time. However, participant clinical trial given incentive keep using investigational product. Programmes offering LEN monitor discontinuation due ISRs. adverse events, especially serious adverse event related LEN adverse event lead stopping use LEN, documented, aggregated reported relevant stakeholder implementation. Community-led information sharing support monitoring side-effects. 5.1.6 Surveillance monitoring Existing routine monitoring system PrEP adapted incorporate LEN. However, must able",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9e02e6d4-24c0-47c1-8bfd-9c1c596aa4b4",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "routine monitoring system PrEP adapted incorporate LEN. However, must able capture accurately report delivery use different product formulation client programme management improvement. available PrEP product service delivery mode considered monitoring, information used improve access uptake. reporting period, people may start, continue, stop restart PrEP switch PrEP products. Longitudinal data system capturing individual-level data best suited capture information. PURPOSE 1 PURPOSE 2 trial provided LEN participant median 12 month clinical trial conditions. limited data adverse event outcome might occur longer follow-up data real-world implementation LEN currently exist. Programmes offering LEN include robust routine data system monitor LEN initiation",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9333f2d2-f262-47af-afe0-58660ac50a79",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "exist. Programmes offering LEN include robust routine data system monitor LEN initiation persistence, safety adverse events, including pregnancy breastfeeding; seroconversions; drug resistance. Adverse event monitoring particular importance. Table 2 suggests minimum set individual-level data PrEP collect. Detailed information indicator found WHO’s Consolidated guideline person- centred HIV strategic information (83) . Table 2. Recommended minimum dataset PrEP recording national data system Intervention Minimum dataset Pre-exposure prophylaxis (PrEP) Date PrEP prescribed (includes initial prescription repeats) Date PrEP dispensed (if available dispensing pharmacy community distribution) PrEP product prescribed (for example, oral PrEP containing tenofovir, dapivirine vaginal ring (DPV-VR), CAB-LA LEN) Volume PrEP product prescribed/dispensed (for example, number pills,",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "81fb2df8-ccb4-4202-b178-f2225e163c49",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "DPV-VR), CAB-LA LEN) Volume PrEP product prescribed/dispensed (for example, number pills, number devices) Date individual attends follow-up appointment Source : 2022 (83) .Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 265.1.7 Drug resistance risk resistance capsid inhibitor person undetected HIV infection start LEN person acquires HIV LEN use discontinuation. Programmes implementing LEN build surveillance drug resistance among people history LEN use diagnosed HIV. well-resourced settings, may benefit conducting population-level assessment drug resistance capsid inhibitor person newly diagnosed HIV. 5.1.8 Use pregnancy breastfeeding Due infrequent administration, high efficacy safety profile, LEN could acceptable convenient PrEP option dur",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8bb09b18-c56f-403c-ba28-b1042fe22e3f",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ration, high efficacy safety profile, LEN could acceptable convenient PrEP option pregnancy breastfeeding. important woman reproductive potential face barrier use benefit LEN. data available LEN use pregnancy breastfeeding suggest safe, robust system need place monitor adverse pregnancy infant outcome (for example, stillbirth, birth defects, neonatal mortality), particularly uncommon rare adverse events, large-scale surveillance, PrEP programme and/or ARV pregnancy registries. Antenatal postnatal care service offer opportunity offer PrEP product LEN woman risk HIV, operational experience research needed understand unique need challenge population best address them. toolkit facilitate support inclusion pregnant breastfeeding woman clinical study",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4c65db90-dab4-42e7-81d0-f0c994cca6cc",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "kit facilitate support inclusion pregnant breastfeeding woman clinical study ARVs may help addressing gap (84) . Services delivering LEN ensure contraceptive service available woman desire pregnancy linkage antenatal care available woman become pregnant receiving PrEP . 5.1.9 Training support provider National programme furnish provider appropriate training, technical support operational tools, including job aid decision-support algorithm aimed range providers. Providers critical role supporting choice, facilitating safe effective choice of, switching between, PrEP product prevention approaches. Providers also role supporting individual choose LEN start continue using safely effectively. focus support return follow-up injection time ensure coverage",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e310e3df-8d3b-470c-9ffd-a1686a87dfb5",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "e focus support return follow-up injection time ensure coverage protection. Individuals choose LEN equipped start, use stop LEN safely effectively. Training LEN provider include: • discussing HIV prevention need preference clients, including HIV prevention sexual health goals; • supporting choice among different HIV prevention option LEN, oral PrEP , DVR and/or CAB-LA condoms, considering relative efficacy comparative advantage disadvantages; • correct dosing administration LEN, including oral injectable component proper injection technique; • support safe effective use, including importance returning follow-up injection time; • drug−drug interactions, safety toxicity;27 5. Implementation consideration research gaps: lenacapavir HIV prevention • guidance testing strategy following reactive HIV test re",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "295ded98-a290-44ef-a89c-9fcab4aa6f75",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": ": lenacapavir HIV prevention • guidance testing strategy following reactive HIV test result, including linkage care treatment; • provision sexual reproductive health service based individual needs, linkage mental health service harm reduction programme needed. Providers also trained offer respectful inclusive service free discrimination help reduce stigma. includes recognizing responding range health, social emotional need people may benefit PrEP . implementation, particularly context differentiated service delivery, may need additional specific training, registration, accreditation policy support task sharing address evolving need different cadre providers. 5.1.10 Creating awareness generating demand new HIV prevention option, many community provider may limited kno",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "25d16267-5089-42d9-b521-ff9b5638f2dd",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "new HIV prevention option, many community provider may limited knowledge LEN. Countries anticipating LEN introduction launch campaign increase awareness create demand; campaign tailored community provider product introduction, enabling people make informed HIV prevention decisions. One reason HIV programme engage partner network people could benefit PrEP better understand respond people’s concern new product. Broad awareness acceptance within community important also minimize stigma discrimination increase acceptability, thereby supporting uptake effective use. 5.1.11 Engaging community Meeting need people may benefit PrEP HIV prevention service providing LEN requires full participation community designing, implementing monitoring programmes. follo",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f49cc821-bb26-406b-9100-732bc8f59778",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "full participation community designing, implementing monitoring programmes. following good participatory practice apply service priority key populations: • Recognize leadership resilience priority key population addressing HIV epidemic local global level sustain participation adequate funding support community-led organizations. • Strengthen capacity community-based organization educate train community PrEP HIV prevention options. • Promote expand community-based services, especially service led member priority key populations. • Ensure PrEP option offered choice, free coercion access prevention strategy individual substantial risk may prefer. • Increase political commitment rights, including right priority key populations, decriminalizing consensual",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "057029d9-9b85-4034-bd18-c69832f7537a",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ent rights, including right priority key populations, decriminalizing consensual sexual activity, gender expression, sex work drug use. Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 285.1.12 Adolescents, key population vulnerable population currently programmatic implementation experience LEN adolescent key populations. However, PURPOSE 1 PURPOSE 2 trial included adolescent among participants. Subanalyses PURPOSE 1 data found difference LEN safety efficacy adolescent age 16 17 compared participant 18 year older (85), suggesting need dose adjustments. However, evidence HIV prevention programming emphasizes importance person-centred service available, accessible acceptable community involved designing implementing (see section 5",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "15d2ce12-99ba-4e58-96db-64461dc49737",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ble acceptable community involved designing implementing (see section 5.1.9). Members key population adolescent typically experience greater legal social challenge accessing PrEP services, including stigmatization, discrimination criminalization. Adolescents may face additional age-related legal, policy, regulatory social barrier well, including age consent law limit access HIV prevention and/or testing service additional challenge logistics expense associated attending physical PrEP service. Reducing barrier important success LEN implementation. example, delivery within family planning service may beneficial adolescent girl young women. LEN may also important option partner people living HIV, particularly among newly diagnosed HIV, partner member key populations. LEN provider sensitive",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2c901f4f-b22d-43d3-8a05-61d4a884485c",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "agnosed HIV, partner member key populations. LEN provider sensitive need challenge marginalized population conscious intersecting risk HIV − example, drug use, displacement homelessness, may influence decision LEN suitability health support needs. 5.1.13 Costs impact part planning LEN introduction, national programme want consider relative cost benefit (direct, indirect, financial other) introducing LEN additional HIV prevention option. Countries may engage modelling cost potential impact LEN introduction different scenario evaluate best strategies. limited modelling available date suggests LEN may greatest impact increase overall prevention coverage that, highly targeted provision may cost–effective approach, trade-off focus overall impac",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c9f6b3ce-50be-41e1-9293-a9b20886f603",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "provision may cost–effective approach, trade-off focus overall impact. Evaluating feasibility introduction approach also critical. Generic manufacture LEN, high volumes, likely contribute cost savings. Nonetheless, negotiating lowest possible price short-term crucial low- middle-income countries. 5.2 Research gap Implementation science inform decision implementation scale-up LEN rolled out. However, GDG stressed research delay programmatic implementation countries. PURPOSE 1 PURPOSE 2 provided LEN participant median 12 month clinical trial conditions. gap real-world implementation experience limited evidence on, example, optimal HIV testing strategies, best strategy support access, adherence dosing schedule, persistence use, product switching stopping,",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "74481646-aff7-4308-9f80-772a90026051",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "port access, adherence dosing schedule, persistence use, product switching stopping, well provision part differentiated service delivery model across population geographies. 29 5. Implementation consideration research gaps: lenacapavir HIV prevention 5.2.1 Alternative injection site dosing Additional research support safety, effectiveness, acceptability feasibility alternative injection site needed, especially may support scale-up differentiated service delivery models, including self-care models. Phase study found thigh upper arm injection provided similar higher drug exposure abdominal injections, evaluated trial (86) . also insufficient evidence variation dosing schedules, including strategy managing delayed missed doses. 5.2.2 Service delivery Programmatic rollout implementation science play important role",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "be6ad797-64b8-4fae-b716-09997dfbf905",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "5.2.2 Service delivery Programmatic rollout implementation science play important role collecting evidence support differentiated service delivery model LEN, including delivery task sharing different cadre provider provision variety community settings, virtual model self-care models. Implementation science also aim collect evidence strategy support access, uptake persistent use different population − example, adolescents, member key population pregnant breastfeeding women. Investigation include exploring efficient approach recall client on-time injections. 5.2.3 Product choice switching Studies SEARCH (59) programmatic implementation country South Africa (87) demonstrated importance offering choice increase uptake coverage, given variability individual preference HIV prevention. Evidence",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d3b2949f-3222-4de8-9713-9009ce1b691e",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "coverage, given variability individual preference HIV prevention. Evidence systematic review value preference (Chapter 3) suggests considerable preference LEN across population geographies. Implementation science needed evaluate impact providing LEN additional choice alongside PrEP HIV prevention options. individual’s HIV prevention need preference expected change time, currently real-world evidence long individual may choose stay LEN. Research explore pattern LEN use, including persistence optimal strategy supporting on-time injections. Individuals using LEN may need want stop use change PrEP products. Currently, best practice switching LEN PrEP product (oral PrEP , CAB-LA DVR) known; explored part implementation study offer Pr",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ecf6769e-1c65-476d-a84c-fcb02f8dc376",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "DVR) known; explored part implementation study offer PrEP product choice. switching products, provider ensure continuous HIV prevention coverage transition period. may may result short overlap PrEP products. drug–drug interaction expected LEN PrEP products; fact, antiretrovirals often prescribed combination ART (88) . Co-administration long-acting antiretrovirals taking place part trial study long-acting treatment; data expected soon (89) . LEN new PrEP option, limited evidence value preference LEN. systematic review found limited information providers’ perspective LEN, none available outside USA. Providers reported concern including potential costs, HIV testing requirements, adherence injection schedule, drug resistance, additional burden health c",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "67729c49-eb64-42d4-bec5-50049c26adba",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "g requirements, adherence injection schedule, drug resistance, additional burden health care providers, well product-specific efficacy, side-effects drug- drug interactions. Studies collect additional information acceptability, concern feasibility different cadre health care provider geography support quality implementation, including training. Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 305.2.4 Adolescents, key population vulnerable population Neither PURPOSE 1 PURPOSE 2 explicitly included reported people inject drugs. LEN expected efficacious parenteral, well sexual, exposure. Research underway expected yield specific direct evidence safety efficacy, result expected mid-2027. Evidence collected, part implementation science routine monitoring evaluat",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8e6da16a-7526-48eb-a3ee-e9892e5a7d33",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "Evidence collected, part implementation science routine monitoring evaluation, support PrEP specifically LEN service delivery improvement adolescents, member key population vulnerable populations, including experiencing displacement homelessness, well pregnancy breastfeeding ensure equitable access uptake LEN new prevention option. Importantly, evidence needed service delivery model LEN people use injectable drugs, sex worker people prison closed settings. 5.2.5 Costs impact need additional country-specific modelling, including modelling concentrated epidemic (such Latin America Asia−Pacific region), support decision-making LEN introduction low- middle-income countries. Modelling important provide insight potential impact cost adding LEN country’s HIV pr",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2697d84b-77fc-47df-b973-26abde6d966b",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "tant provide insight potential impact cost adding LEN country’s HIV prevention response. also provide insight country global level overall coverage (or volume) LEN needed drive epidemic elimination phase. model aligned realistic assumption programmatic scale-up, feasibility highly targeted approach eligibility fully loaded cost considerations. Models also needed future look scale-up LEN PrEP associated drug resistance.31 6. Implementation consideration research gaps: testing long-acting injectable PrEP 6.1 Implementation consideration HIV testing support PrEP planned implemented using public health approach. Simplified affordable testing approaches, including HIV RDTs self-tests, important ensure access uptake PrEP service among may benefit.",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7f43e8b1-e78b-45ca-b204-948634e33e97",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "f-tests, important ensure access uptake PrEP service among may benefit. Individuals programme may use range different PrEP options, oral TDF/FTC, DVR long-acting product CAB-LA LEN. recommends RDTs routinely used LA-PrEP initiation continuation. NAT laboratory-based HIV testing required prioritized PrEP delivery, including injectable LA-PrEP . Among RDTs, antibody/antigen RDTs appear preferable antibody-only RDTS, less expensive (Box 4). Testing programme need standardized simple support interchangeability user choice across PrEP options. National programme continue effort adopt implement simple low-cost HIV testing strategy algorithm recommended WHO. Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 32Box 4Summary",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9a7f8f88-3f9c-42b9-a850-6102a8cb9c32",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "evention testing strategy long-acting injectable pre-exposure prophylaxis 32Box 4Summary evidence antibody/antigen HIV RDTs Acute HIV infection earliest stage HIV detected. rapid diagnostic test capable identifying HIV stage could enable earlier diagnosis treatment. context injectable LA-PrEP , could help prevent missed HIV case reduce risk unintended consequence drug resistance. Antibody/antigen RDTs available decade, widely used resource-constrained setting due higher cost complexity compared standard antibody-only RDTs. 2024 conducted systematic review understand ability antibody/antigen HIV rapid diagnostic test detect acute HIV infection, including among PrEP users. review found antibody/antigen HIV rapid diagnostic test pooled sensitivity acute HIV infection 50% (95% CI: 35–64)",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "99cb821a-4c13-412e-a0ec-264f6d1b251e",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "rapid diagnostic test pooled sensitivity acute HIV infection 50% (95% CI: 35–64) specificity 99% (95% CI: 96–100). Additionally, acute HIV infection, among PrEP users, sensitivity specificity found 25% (95% CI: 13–44) 94% (95% CI: 64–99) (90-92 ). indicates antigen/antibody RDTs may substantially increase detection acute HIV case context. continues provide standard guidance use quality-assured HIV rapid test self-tests, prequalified (93) . used testing algorithm achieving least 99% positive predictive value (that is, fewer one false positive per 100 diagnoses). evidence supporting prioritization antigen/antibody RDTs antibody-only RDTs. Countries encouraged use toolkit (94) optimize HIV testing strategy product selection based setting population needs. 6.1.1 HIV testing se",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0d3e31c1-d29b-47d1-b053-25a326955bc4",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "strategy product selection based setting population needs. 6.1.1 HIV testing service initiating LA-PrEP HIV testing required initiating injectable LA-PrEP . Individuals reactive test diagnosed HIV according national testing strategy algorithm immediately referred offered treatment. individual HIV-negative test result started PrEP , including injectable LA-PrEP . individual inconclusive test result (initial test reactive, followed negative test) referred testing 14 day rule rule seroconversion. Screening tool address suspected acute infection effective (95) , considered according country’s national guidelines. retesting 14 day later, individual persistent inconclusive result considered HIV- negative started PrEP , including injectable LA-Pr",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6b29c856-0862-4bc5-896a-d800718b8526",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "nclusive result considered HIV- negative started PrEP , including injectable LA-PrEP . Flexible testing option important. Programmes offering HIVST initiating oral PrEP DVR continue offer HIVST . However, individual negative self-test result also offered rapid testing provider initiating injectable LA-PrEP . programmes, Brazil, advise client self-test coming facility first LA-PrEP injection (60) . study expected report result HIVST part injectable LA-PrEP delivery reviewed urgent priority. 33 6. Implementation consideration research gaps: testing long-acting injectable PrEP6.1.2 HIV testing service continuing LA-PrEP HIV testing important part PrEP continuation, including injectable LA-PrEP . practical individual taking PrEP receive testing refill injection v",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "02da44fc-d931-488d-a817-af7d009bd567",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "rEP . practical individual taking PrEP receive testing refill injection visit. Depending PrEP option used, testing schedule may differ − example, every two month CAB-LA every six month LEN. However, important provide client programme flexibility support effective PrEP use. More, less, frequent testing interval may considered warranted based available resources. Self-tests potential option needed considered beneficial client provider. Individuals negative HIV test result continue PrEP , including injectable LA-PrEP , according preference national guidance. Anyone taking injectable LA-PrEP reactive HIV test result, including self-test result, receive testing, according national testing strategy algorithm, confirm diagnosis. Upon confirmation diagnosis, ART initiated",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "868b0547-3adf-4a78-9a40-620a3d5511c2",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "algorithm, confirm diagnosis. Upon confirmation diagnosis, ART initiated promptly, accordance local clinical protocols, minimize risk drug resistance. available, drug resistance testing done inform public health impact. Individuals inconclusive HIV test status taking injectable LA-PrEP retested 14 days, using national testing algorithm, rule rule seroconversion. NAT used resolve case because, among taking injectable LA- PrEP , HIV may adequately detected could greater likelihood false positive (97) . serology profile remains inconclusive, person receiving injectable LA-PrEP considered HIV-negative, LA-PrEP continued. serology profile evolves individual diagnosed HIV according national algorithm, immediately referred care treatment according n",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cf849868-5a62-4166-b0b0-ec2e1c1eb66e",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "national algorithm, immediately referred care treatment according national guidelines. people confirmed HIV diagnosis linked ART HIV care services, ideally day diagnosis soon possible thereafter. suspected breakthrough infection evaluated individually. individual reactive result inconclusive result need testing follow-up counselled ensure understand test results. encouraged continue PrEP information final diagnosis available, consider taking precaution prevent potential onwards transmission HIV, use condom sex. 6.1.3 HIV testing service following discontinuation LA-PrEP Individuals taking PrEP , including injectable LA-PrEP , advised importance HIV testing decide point discontinue transiti",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c62f1c2b-0050-44b7-85bb-fc5f2aa9a8ad",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "advised importance HIV testing decide point discontinue transition another PrEP option. important provide people using PrEP , including injectable LA-PrEP , education simple message testing PrEP discontinuation. General message encourage client discontinue PrEP , including injectable LA-PrEP , retest risk behaviour take place stop, take long break from, using PrEP . Also, individual taking PrEP , including injectable LA-PrEP , informed HIV detection might delayed PrEP use. Self-testing PrEP discontinuation discussed current PrEP user provided discontinue PrEP . Clients informed benefit disclosing past PrEP use future HIV testing providers, may help provide accurate HIV diagnosis; information may important interpreting result encouraging follo",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dc6e4d05-5ddd-4070-9e46-b3e4c1dfe1b7",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ate HIV diagnosis; information may important interpreting result encouraging follow-up retesting. Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 346.2 Research gap Evidence HIV testing injectable LA-PrEP low certainty. several research gap that, filled, could guide improved programming public health impact. 6.2.1 Optimizing frequency flexibility HIV testing service Understanding best time offer HIV testing service client public health impact critical. flexible testing service improve users’ experiences, remove barrier reduce requirements. Implementation science understand promote testing service across PrEP , including injectable LA-PrEP , also needed. 6.2.2 HIV self-test self-care model potential role self-testing support current future LA-PrEP option merit",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a4ff24e9-de8d-4f7e-827e-3b73dba9b480",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "potential role self-testing support current future LA-PrEP option merit exploration. important understand whether self-testing increase programme efficiency, decentralization, access, affordability flexibility help scale-up impact. Self-testing may particularly important mitigate risk PrEP discontinuation transition agent formulations, including injectable LA-PrEP . 6.2.3 Address mitigate HIV drug resistance concern HIV acquisition context PrEP , including injectable LA-PrEP rare even rarely linked development resistance HIV drugs. programme screening tool might help identify acute infection long acting early viral inhibition, evidence feasibility impact limited. Programmatic tools, well simple affordable point-of-care diagnostics, assist early",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0d1cc8fe-82b6-451b-92c3-f20bf8f917ef",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "s, well simple affordable point-of-care diagnostics, assist early diagnosis, prompt linkage ART reduce risk drug resistance important. However, existing diagnostics tool remain expensive; effort simplify reduce cost priority. 35 7. Updating dissemination guideline evidence presented GDG (Web Annexes G) launched web-based product. guideline also incorporated periodic update consolidated guideline HIV, updated full part regular scoping exercise available evidence experience country implementation trigger guide need new guidance. evidence base users’ need change, consider producing technical update document specific subjects. update implementation guidance PrEP include LEN, including consideration programmatic delivery",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "20e2a0ca-5ac6-4380-9e78-22f65f362677",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "implementation guidance PrEP include LEN, including consideration programmatic delivery specific populations, reflect additional relevant evidence becomes available. evidence emerges use HIVST injectable LA-PrEP , prioritize review. headquarters work closely regional country offices, national ministry health implementing partner plan dissemination, adaptation implementation new recommendations. Key step dissemination include presenting recommendation international conferences; conducting workshop support regional country adaptation; rapidly developing adaptation tool help country set priority resource allocation facilitate full implementation time; conducting briefing joint planning dissemination international national implementing partners. Monitoring implementation rely Gl",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b01509b0-a283-44e1-ab6c-a5b527abc692",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "international national implementing partners. Monitoring implementation rely Global AIDS Monitoring indicator framework National Commitments Policy Instrument, annual reporting system country-level information policy adoption programmatic delivery HIV services. Qualitative monitoring include tracking adoption LEN additional PrEP product national guidelines. Quantitative monitoring include number people using PrEP least year, disaggregated product type. 36References 1. 2024 global AIDS report — urgency now: AIDS crossroads. Geneva: Joint United Nations Programme HIV/AIDS; 2024 ( https://www.unaids.org/en/resources/ documents/2024/global-aids-update-2024 , accessed 1 April 2025). 2. implementation tool pre-exposure prophylaxis HIV infection: provider module oral long-acting PrEP . Geneva: World Health Organization; 2024 ( https://www. who.int/p",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5c3baea3-f07c-4c0c-9bfb-98f49fb3b74f",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "le oral long-acting PrEP . Geneva: World Health Organization; 2024 ( https://www. who.int/publications/i/item/9789240097230 , accessed 1 April 2024). 3. handbook guideline development. 2nd ed. Geneva: World Health Organization; 2014 ( https://iris.who.int/handle/10665/145714 , accessed 1 April 2025). 4. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati et al. Going evidence recommendations. BMJ. 2008;336:1049-51. doi: 10.1136/bmj.39493.646875.AE 5. Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W et al. Twice- yearly lenacapavir Daily F/TAF HIV prevention cisgender women. N Engl J Med. 2024;391:1179-92. doi: 10.1056/NEJMoa2407001 6. Kelley CF, Acevedo-Quinones M, Agwu AL, Avihingsanon A, Benson P , Blumenthal J et al. Twice-yearly lenacapavir HIV prevention men gender-diverse persons. N Engl J Med. 2024. doi: 10.1056/NEJMoa2411858 7. Jamieson L M-RG, Johnson L. Lenacapavir: preliminary impact, cost effect",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "05a77292-5052-44d1-b639-dab966e71b13",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "i: 10.1056/NEJMoa2411858 7. Jamieson L M-RG, Johnson L. Lenacapavir: preliminary impact, cost effectiveness cost threshold South Africa. Unpublished preliminary results. 2024. 8. Wu L, Kaftan D, Wittenauer R, Arrouzet C, Patel N, Saravis AL et al. Health impact, budget impact, price threshold cost-effectiveness lenacapavir HIV pre- exposure prophylaxis eastern southern Africa: modelling analysis. Lancet HIV. 2024;11:e765-e73. doi: 10.1016/S2352-3018(24)00239-X 9. Kaftan SM, Resar D, Milali M, Mudimu E, Wu L, et al. Health impact cost threshold emerging long-acting PrEP product Eastern Southern Africa: mathematical modeling study. 2024. 10. van de Vijver vKJ, Dimtrov D, Janamnuaysook R, Wongsa A, Phanuphak N. Impact lenacapavir HIV epidemic among MSM Thailand: modelling study. Unpublished preliminary results. 2025. 11. Link JO, Rhee MS, Tse WC, Zheng J, Somoza JR, Rowe W et al. Clinical targeting HIV cap",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ba952039-6cb0-49d5-809e-257044f9ce04",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "25. 11. Link JO, Rhee MS, Tse WC, Zheng J, Somoza JR, Rowe W et al. Clinical targeting HIV capsid protein long-acting small molecule. Nature. 2020;584:614-8. doi: 10.1038/ s41586-020-2443-1 12. Margot N, Vanderveen L, Naik V, Ram R, Parvangada PC, Martin R et al. Phenotypic resistance lenacapavir monotherapy efficacy proof-of-concept clinical study. J Antimicrob Chemother. 2022;77:989-95. doi: 10.1093/jac/dkab503 13. Margot NA, Naik V, VanderVeen L, Anoshchenko O, Singh R, Dvory-Sobol H et al. Resistance analysis highly treatment-experienced people human immunodeficiency virus (HIV) treated novel capsid HIV inhibitor lenacapavir. J Infect Dis. 2022;226:1985- 91. doi: 10.1093/infdis/jiac364 14. Margot NA, Jogiraju V, Pennetzdorfer N, Naik V, VanderVeen LA, Ling J et al. Resistance analysis heavily treatment-experienced people HIV treated novel HIV capsid inhibitor lenacapavir 2 years. J Infect Dis. 2025. doi: 10.1093/",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "53090429-5733-4833-a4e3-dcab738a1faf",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ed novel HIV capsid inhibitor lenacapavir 2 years. J Infect Dis. 2025. doi: 10.1093/infdis/jiaf05037 References15. Watts DH. Teratogenicity risk antiretroviral therapy pregnancy. Curr HIV/AIDS Rep. 2007;4:135-40. doi: 10.1007/s11904-007-0020-y 16. Bekker L-G, Moodley D, Harkoo I, Kigozi G, Louw CE, Malahleha et al. Inclusion pregnant lactating people PURPOSE 1 study: efficacy, safety, pharmacokinetics. 13th International AIDS Society Conference HIV Science; 12–17 July; Kigali, Rwanda, 2025. 17. Erlwanger A, Rocroi I, Kirtley S, Hemelaar J. Perinatal outcome associated pre- exposure prophylaxis HIV prevention pregnancy: systematic review meta- analysis. EClinicalMedicine. 2024;70:102532. doi: 10.1016/j.eclinm.2024.102532 18. Naidoo M, Naidoo KL, Lombard C, Desmond AC, Clark R, Rooney JF et al. In-utero exposure tenofovir disoproxil fumarate pre-exposure prophylaxis growth metric HIV unexposed breastfed",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c240803c-e4ab-4f53-bd24-e6b689e45529",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "enofovir disoproxil fumarate pre-exposure prophylaxis growth metric HIV unexposed breastfed infant South Africa: post hoc analysis CAP 016 PrEP pregnancy RCT . Front Pediatr. 2024;12:1447173. doi: 10.3389/fped.2024.1447173 19. Mugwanya KK, Hendrix CW, Mugo NR, Marzinke M, Katabira ET , Ngure K et al. Pre- exposure prophylaxis use breastfeeding HIV-uninfected women: prospective short- term study antiretroviral excretion breast milk infant absorption. PLoS Med. 2016;13:e1002132. doi: 10.1371/journal.pmed.1002132 20. Kistan G, Sebitloane M, Lombard C, Godlwana Z, Desmond AC, Clark R et al. Tenofovir disoproxil fumarate/emtricitabine prophylaxis effect bone mineral density bone mineral content African breastfeeding woman receiving pre-exposure prophylaxis HIV. J Acquir Immune Defic Syndr. 2024. doi: 10.1097/qai.0000000000003563 21. Reddy K, Naidoo KL, Lombard C, Godlwana Z, Desmond AC, Clark R et al. In-utero exposure te",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c3718d71-ab99-455f-b396-ba5846bb7870",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "3 21. Reddy K, Naidoo KL, Lombard C, Godlwana Z, Desmond AC, Clark R et al. In-utero exposure tenofovir-containing pre-exposure prophylaxis bone mineral content HIV-unexposed infant South Africa. J Int AIDS Soc. 2024;27:e26379. doi: 10.1002/ jia2.26379 22. Noguchi LM, Owor M, Mgodi NM, Gati Mirembe B, Dadabhai S, Horne E et al. Safety drug quantification dapivirine vaginal ring oral pre-exposure prophylaxis breastfeeding mother-infant pair (MTN-043): phase 3B, open-label, randomised trial. Lancet HIV. 2025. doi: 10.1016/S2352-3018(24)00306-0 23. Makanani B, Balkus JE, Jiao Y, Noguchi LM, Palanee-Phillips , Mbilizi et al. Pregnancy infant outcome among woman using dapivirine vaginal ring early pregnancy. J Acquir Immune Defic Syndr. 2018;79:566-72. doi: 10.1097/QAI.0000000000001861 24. Baeten JM, Palanee-Phillips , Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G et al. Safety, uptake, use dapivirine vaginal ring HIV-1 prev",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "058721bb-338b-43ef-9374-a98dd7af8a4c",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "AJ, Szydlo DW, Ramjee G et al. Safety, uptake, use dapivirine vaginal ring HIV-1 prevention African woman (HOPE): open-label, extension study. Lancet HIV. 2021;8:e87-e95. doi: 10.1016/S2352- 3018(20)30304-0 25. Bunge K, Balkus JE, Fairlie L, Mayo AJ, Nakabiito C, Mgodi N et al. DELIVER: safety study dapivirine vaginal ring oral PrEP prevention HIV pregnancy. J Acquir Immune Defic Syndr. 2024;95:65-73. doi: 10.1097/QAI.0000000000003312 26. Delany-Moretlwe S, Hanscom B, Guo X, Nkabiito C, Mandima P , Nahirya PN et al. Evaluation long-acting cabotegravir safety pharmacokinetics pregnant woman eastern southern Africa: secondary analysis HPTN 084. J Int AIDS Soc. 2025;28:e26401. doi: 10.1002/jia2.26401 27. Delany-Moretlwe VE, Said F. Initial evaluation injectable cabotegravir (CAB-LA) safety pregnancy HPTN 084 open-label extension. 25th International AIDS Society Conference; Munich, Germany, 2",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "240e274b-0ee4-4785-ac9f-e7866780f29a",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "n HPTN 084 open-label extension. 25th International AIDS Society Conference; Munich, Germany, 22–26 July ( https://www.natap.org/2024/IAS/IAS_50.htm , accessed 2 April 2025).Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 3828. Lenacapavir [package insert]. Foster City, CA: Gilead Sciences; 2024. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/ . 29. Clement M, Wang Z, Fichtenbaum C, Thomas S, Bazan J, Richardson P et al. Pre-exposure prophylaxis product choice participant HPTN 083. 25th International AIDS Society Conference; 22–26 July; Munich, Germany, 2024. 30. Delany-Moretlwe S, Hanscom B, Angira F, Dadabhai S, Gadama D, Mirembe B et al. Initial PrEP product choice: result HPTN 084 open-label extension. 12th International AIDS Society Conference HIV Science; 23–26 July; Brisbane, Australia, 2023. 31. Keddem S, Thatipelli S, Caceres O, Roder N, Momplaisir F, Cronh",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "54bcac13-006a-4387-837a-532ec742be7c",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "July; Brisbane, Australia, 2023. 31. Keddem S, Thatipelli S, Caceres O, Roder N, Momplaisir F, Cronholm P . Barriers facilitator long-acting injectable HIV pre-exposure prophylaxis implementation primary care since approval United States. J Acquir Immune Defic Syndr. 2024;95:370-6. doi: 10.1097/qai.0000000000003370 32. Kerrigan D, Mantsios A, Grant R, Markowitz M, Defechereux P , La Mar et al. Expanding menu HIV prevention options: qualitative study experience long-acting injectable cabotegravir PrEP context phase II trial United States. AIDS Behav. 2018;22:3540-9. doi: 10.1007/s10461-017-2017-x 33. Khan , Liu A, Perlotto S, Nelson KL, Stassek L, Fang J et al. Overcoming challenge integrating injectable PrEP care: key strategy PILLAR study. 5th HIV Research Prevention Conference; 6-10 October; Lima, Peru, 2024. 34. Meyers K, Rodriguez K, Brill AL, Wu Y, La Mar M, Dunbar et al. Lessons",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c531054b-e656-4d04-a8d0-bbfa032b3d40",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "Lima, Peru, 2024. 34. Meyers K, Rodriguez K, Brill AL, Wu Y, La Mar M, Dunbar et al. Lessons patient education around long-acting injectable PrEP: finding mixed-method study phase ii trial participants. AIDS Behav. 2018;22:1209-16. doi: 10.1007/s10461-017-1871-x 35. Psaros C, Landovitz R, Rice W, Kelley C, Oyedele , Coelho L et al. Understanding participant experience preference injectable PrEP trial: qualitative sub-study barriers, facilitator preference PrEP use among MSM TGW. J Int AIDS Soc. 2021;24:30-1. 36. Richmond , Dunn M, Bernard M, Urbaityte R, Sutton K, Sutherland-Phillips D. Engaging black woman cabotegravir la PrEP optimizing novel implementation strategy (EBONI) study: provider perception appropriateness cabotegravir LA PrEP cis-and-trans black women. Open Forum Infect Dis. 2023;10. 37. Tolley EE, Bula A, Chitukuta M, Ndimande-Khoza N, Etima J, Namey E et al. Preferences oral",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "aaa9e044-fc46-4408-942f-5b919b1ffa81",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": ". Tolley EE, Bula A, Chitukuta M, Ndimande-Khoza N, Etima J, Namey E et al. Preferences oral injectable PrEP among qualitative sub-study participant HPTN 084. PLoS One. 2024;19:e0309811. doi: 10.1371/journal.pone.0309811 38. Eger WH, Bazzi AR, Valasek CJ, Vera CF, Harvey-Vera A, Strathdee SA et al. HIV pre- exposure prophylaxis programmatic preference among people inject drugs: finding discrete choice experiment. Addict Sci Clin Pract. 2024;19:81. doi: 10.1186/s13722- 024-00505-2 39. Beckham SW, Sanchez , Fowler R, Zlotorzynska M, Rai M, Sullivan P et al. Variation preference long-acting injectable pre-exposure prophylaxis among US men sex men: latent class analysis. AIDS Patient Care STDS. 2023;37:495-503. doi: 10.1089/apc.2023.0109 40. Footer KHA, Lim S, Rael CT , Greene GJ, Carballa-Diéguez A, Giguere R et al. Exploring new existing PrEP modality among female sex worker woman inject drug U.S. city. AIDS",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "17a10403-fb05-41b7-9233-36c53ddeb611",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "existing PrEP modality among female sex worker woman inject drug U.S. city. AIDS Care. 2019;31:1207-13. doi: 10.1080/09540121.2019.158735239 References41. Gutierrez J, Minnis A, . P-P , Ndlovu N, Zulu S, Reddy K et al. Identifying preferred product attribute long-acting implantable injectable pre-exposure prophylaxis among men enrolled South African male user research acceptability implant injection (SAMURAI) study. 5th HIV Research Prevention Conference; 6–10 October; Lima, Peru, 2024. 42. Hill-Rorie J, Biello KB, Quint M, Johnson B, Elopre L, Johnson K et al. Weighing options: PrEP (pre-exposure prophylaxis) modality attribute influence choice young gay bisexual men United States? AIDS Behav. 2024;28:2970-8. doi: 10.1007/s10461-024-04384-1 43. Hsu JH, Ku SW, Chen TW, Li CW, Huang P , Wu HJ et al. Preferences long-acting pre-exposure prophylaxis among gay, bisexual men sex wit",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1568b699-75eb-4bd4-990d-29c555560fd2",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "erences long-acting pre-exposure prophylaxis among gay, bisexual men sex men Taiwan: finding 2021 HEART Survey. J Int AIDS Soc. 2023;26:e26163. doi: 10.1002/jia2.26163 44. John SA, Zapata JP , Dang M, Pleuhs B, O’Neil A, Hirshfield et al. Exploring preference decision-making long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17-24 year old. Sci Rep. 2023;13:5116. doi: 10.1038/ s41598-023-32014-8 45. Little KM, Hanif H, Anderson SM, Clark MR, Gustafson K, Doncel GF. Preferences long-acting PrEP product among woman girls: quantitative survey discrete choice experiment Eswatini, Kenya, South Africa. AIDS Behav. 2024;28:936-50. doi: 10.1007/s10461-023-04202-0 46. Minnis AM, Atujuna M, Browne EN, Ndwayana S, Hartmann M, Sindelo et al. Preferences long-acting pre-exposure prophylaxis (PrEP) HIV prevention among South African youth: result discrete cho",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0e47e22d-c05c-4a2b-955e-28aed7c23369",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "exposure prophylaxis (PrEP) HIV prevention among South African youth: result discrete choice experiment. J Int AIDS Soc. 2020;23:e25528. doi: 10.1002/jia2.25528 47. Montgomery ET , Atujuna M, Krogstad E, Hartmann M, Ndwayana S, ʼRourke et al. invisible product: preference sustained-release, long-acting pre-exposure prophylaxis HIV among South African youth. J Acquir Immune Defic Syndr. 2019;80:542-50. doi: 10.1097/QAI.0000000000001960 48. Odongpiny EL, Nakate V, Onzia A, Bagaya I, Manabe YC, Melendez JH. Willingness use injectable PrEP among people risk HIV accessing service community pharmacy Kampala, Uganda. 5th HIV Research Prevention Conference; 6–10 October; Lima, Peru, 2024. 49. Parsons JT , Rendina HJ, Whitfield TH, Grov C. Familiarity preference oral long-acting injectable HIV pre-exposure prophylaxis (PrEP) national sample gay bisexual men U.S. AIDS Behav. 2016;20:1390-9. doi: 10.10",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ba303688-8240-448e-adb9-2fedda076d43",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "EP) national sample gay bisexual men U.S. AIDS Behav. 2016;20:1390-9. doi: 10.1007/s10461-016-1370-5 50. Patel RR, Crane JS, López J, Chan PA, Liu AY, Tooba R et al. Pre-exposure prophylaxis HIV prevention preference among young adult African American men sex men. PLoS One. 2018;13:e0209484. doi: 10.1371/journal.pone.0209484 51. Rael CT , Lopez-Ríos J, McKenna SA, Das D, Dolezal C, Abascal E et al. Transgender women’s barriers, facilitators, preference tailored injection delivery strategy administer long-acting injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP). AIDS Behav. 2021;25:4180-92. doi: 10.1007/s10461-021-03357-y 52. Restar A, Wilson-Barthes MG, Dusic E, Operario D, Galárraga O. Using stated preference method design gender-affirming long-acting PrEP program transgender nonbinary adults. Sci Rep. 2024;14:23482. doi: 10.1038/s41598-024-72920-zGuidelines lenacapavir HIV prevention",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8a30e24e-58c3-4b5e-93d6-383148c58c27",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "Sci Rep. 2024;14:23482. doi: 10.1038/s41598-024-72920-zGuidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 4053. Rodriguez A, Horvath KJ, Dowshen N, Voss R, Warus J, Jacobs et al. Awareness utilization pre-exposure prophylaxis HIV prevention service among transgender non-binary adolescent young adults. Front Reprod Health. 2023;5:1150370. doi: 10.3389/frph.2023.1150370 54. Schmidt H, Ong J, Chan C, Cassell M, Phanuphak N, Green K. Awareness willingness use 6 monthly long-acting injectable PrEP among gay men sex men transgender woman Asia. 5th HIV Research Prevention Conference; 6–10 October; Lima, Peru, 2024. 55. Schwartz S, Bula A, J H, Chilongosi R, Hoege D, Nyirenda R. Pre-exposure prophylaxis (PrEP) modality service delivery preference among diverse population Malawi: result discrete choice experiment. 5th HIV Research fo",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "041b8e27-8124-427c-bc62-4f16d5a83ebd",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "mong diverse population Malawi: result discrete choice experiment. 5th HIV Research Prevention Conference; 6–10 October; Lima, Peru, 2025. 56. Tagliaferri Rael C, Giguere R, Bryndza Tfaily E, Sutton S, Horn E, Schieffer RJ et al. global impact diversifying PrEP options: result international discrete choice experiment existing potential PrEP strategy gay bisexual men physicians. AIDS Res Hum Retroviruses. 2024;40:591-605. doi: 10.1089/AID.2023.0120 57. Torres , Torres da Silva M, Coutinho C, Hoagloand B, Jalil E, Cardoso S. Long-acting PrEP preference among Brazilian sexual gender minorities: Key influencing factors. 13th International AIDS Society Conference HIV Science; 13–17 July; Kigali, Rwanda, 2025. 58. Henderson M, Schmidt HA, Chitembo L, Peralta H, Alaama AS, Johnson C et al. future pre-exposure prophylaxis (PrEP) HIV prevention: global qualitative consultation provider perspective new pr",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ff984332-5973-4825-8f68-92671145405f",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "xi (PrEP) HIV prevention: global qualitative consultation provider perspective new product differentiated service delivery. AIDS Behav. 2023;27:3755-66. doi: 10.1007/s10461-023-04093-1 59. Kamya MR, Balzer LB, Ayieko J, Kabami J, Kakande E, Chamie G et al. Dynamic choice HIV prevention cabotegravir long-acting injectable rural Uganda Kenya: randomised trial extension. Lancet HIV. 2024;11:e736-e45. doi: 10.1016/s2352- 3018(24)00235-2 60. Dourado I, Dezanet L, Magno L, Westin M, Soares F, Massa P et al. PrEP15-19 choices: implementation study protocol HIV prevention oral long-acting injectable cabotegravir PrEP real-word setting among sexual gender minority adolescent Brazil. BMJ Open. 2025;15:e083146. doi: 10.1136/bmjopen-2023-083146 61. Grinsztejn B, Torres TS, Hoagland B, Jalil EM, Moreira RI, O’Malley G et al. Long- acting injectable cabotegravir HIV preexposure prophylaxis among sexual gender minorities: pro",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a3b69f9e-44cf-40a0-ae09-e5ae862e774b",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ing injectable cabotegravir HIV preexposure prophylaxis among sexual gender minorities: protocol implementation study. JMIR Public Health Surveill. 2023;9:e44961. doi: 10.2196/44961 62. Yeo Y-R WK, Takarinda K, Sithole N, Gwavavy E, Khabo BB, et al. Cost-effectiveness different risk-group targeting across 3 type PrEP Zimbabwe. Conference Retroviruses Opportunistic Infections; 9–12 March; San Francisco, California, 2025. 63. Braithwaite RS CD, Yeo Y-R, Jeetoo M, Su, J. Allocative efficiency research meet EHE 2030 goals: long-acting PrEP preliminary results. Unpublished preliminary results. 2025. 64. Consolidated guideline differentiated HIV testing services. Geneva: World Health Organization; 2024 ( https://www.who.int/publications/i/item/9789240096394 , accessed April 1 2025). 65. Delany-Moretlwe S, Hughes JP , Bock P , Ouma SG, Hunidzarira P , Kalonji et al. Cabotegravir prevention HIV-1 women: result HPTN 084, p",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "036fa278-c8a7-4278-af7c-78df50278d33",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "P , Kalonji et al. Cabotegravir prevention HIV-1 women: result HPTN 084, phase 3, randomised clinical trial. Lancet. 2022;399:1779-89. doi: 10.1016/s0140-6736(22)00538-441 References66. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L et al. Cabotegravir HIV prevention cisgender men transgender women. N Engl J Med. 2021;385:595- 608. doi: 10.1056/NEJMoa2101016 67. Luo R, Fong Y, Boeras D, Jani I, Vojnov L. clinical effect point-of-care HIV diagnosis infants: systematic review meta-analysis. Lancet. 2022;400:887-95. doi: 10.1016/ S0140-6736(22)01492-1 68. Macdonald P . Use HIV rapid detection test initiating long-acting cabotegravir HIV prevention, within implementation science project (FASTPrEP). 5th HIV Research Prevention Conference; 6-10 October; Lima, Peru, 2024. 69. van de Vijver D, van Kampen J, Wongsa A, Janamnuaysook R, Mesplede , Matrajt L et al. Evaluating HIV testing strategie",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "12db80b4-2b1a-43cc-824d-c0cf2a321113",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "Kampen J, Wongsa A, Janamnuaysook R, Mesplede , Matrajt L et al. Evaluating HIV testing strategy reduce drug resistance CAB-LA rollout Thailand. modelling study. 13th International AIDS Society Conference HIV Science; 13–17 July; Kigali, Rwanda, 2025. 70. Henderson M. Web Annex F. Perspectives preference regarding long-acting injectable cabotegravir HIV prevention among pre-exposure prophylaxis (PrEP) providers: global survey in-depth interviews. In: Guidelines long-acting injectable cabotegravir HIV prevention. Geneva: World Health Organization; 2022 ( https://www. who.int/publications/i/item/9789240054097 , accessed 2 April 2025). 71. Glick JL, Nestadt DF, Sanchez , Li K, Hannah M, Rawlings MK et al. Location preference accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men sex men (MSM) currently daily oral PrEP . J Int Assoc Provid AIDS Care. 2024;23:23259582241293336. doi: 10.1177/",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7d596a66-f308-4d11-9f2b-c2c58b4ff839",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "rrently daily oral PrEP . J Int Assoc Provid AIDS Care. 2024;23:23259582241293336. doi: 10.1177/23259582241293336 72. Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Cost-effectiveness cabotegravir long-acting HIV pre-exposure prophylaxis United States. Pharmacoeconomics. 2024;42:447-61. doi: 10.1007/s40273-023-01342-y 73. Paranhos J, Castilho M, Klein HE, Miranda C, Perin FS, Passoni P et al. Costs implementing long-acting injectable cabotegravir HIV prophylaxis Brazil. Physis: Revista de Saúde Coletiva. 2023;33:e33021. 74. Cox SN, Wu L, Wittenauer R, Clark S, Roberts DA, Nwogu IB et al. Impact HIV self-testing oral pre-exposure prophylaxis scale-up drug resistance HIV outcome western Kenya: modelling study. Lancet HIV. 2024;11:e167-e75. doi: 10.1016/S2352- 3018(23)00268-0 75. Walensky RP , Jacobsen MM, Bekker LG, Parker RA, Wood R, Resch SC et al. Potential clinical economic value long-acting preexposur",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c54b407e-1869-4be8-bc54-52c474f2b7f4",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "Parker RA, Wood R, Resch SC et al. Potential clinical economic value long-acting preexposure prophylaxis South African woman high-risk HIV infection. 2016;213 (10): 1523-31. 76. Smith J, Bansi-Matharu L, Cambiano V, Dimitrov D, Bershteyn A, van de Vijver et al. Predicted effect introduction long-acting injectable cabotegravir pre-exposure prophylaxis sub-Saharan Africa: modelling study. Lancet HIV. 2023;10:e254-e65. doi: 10.1016/S2352-3018(22)00365-4 77. Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour MC, Russell C et al. Relative cost-effectiveness long-acting injectable cabotegravir versus oral pre-exposure prophylaxis South Africa based HPTN 083 HPTN 084 trials: modelled economic evaluation threshold analysis. Lancet HIV. 2022;9:e857-e67. doi: 10.1016/ S2352-3018(22)00251-XGuidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 427",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3dfe769b-79da-4455-b7fa-6cfa8b69c442",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 4278. Tieosapjaroen W, Williams, E, Johnson, CC, Baptista Da Silva, C, Barr-DiChiara, M, Siegfried, et al. Balancing accuracy, accessibility, cost: HIV testing strategy long- acting injectable PrEP: systematic review rapid, laboratory-based immunoassay nucleic acid testing strategies. [Poster presentation]. Asia Pacific AIDS & Co-Infections Conference; 12–14 June 2025; Tokyo, Japan. 79. Smith J, Bansi-Matharu L, Cambiano V, Dimitrov D, Bershteyn A, van de Vijver et al. Predicted effect introduction long-acting injectable cabotegravir pre-exposure prophylaxis sub-Saharan Africa: modelling study. Lancet HIV. 2023;10:e254-e65. doi: 10.1016/s2352-3018(22)00365-4 80. Kennedy CE, Yeh PT , Johnson C, Baggaley R. trained lay provider perform HIV testing? systematic review inform World Health Organization guidelines. AIDS Care. 2017;29:1473-",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2cb0b455-55eb-4a5a-84a2-247902821ea8",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "sting? systematic review inform World Health Organization guidelines. AIDS Care. 2017;29:1473-9. doi: 10.1080/09540121.2017.1317710 81. 2024 HIV Market Report, Issue 15, December 2024. Boston: Clinton Health Access Initiative; 2024 ( https://www.clintonhealthaccess.org/report/2024-hiv-market-report/ , accessed 15 June 2025). 82. implementation tool pre-exposure prophylaxis (PrEP) HIV infection. Module 13. Integrating STI services. Geneva: World Health Organization; 2023 ( https://iris.who. int/bitstream/handle/10665/362227/9789240057425-eng.pdf?sequence=1 , accessed 2 April 2025). 83. Consolidated guideline person-centred HIV strategic information: strengthening routine data impact. Geneva: World Health Organization; 2022 ( https://iris.who.int/ handle/10665/360948 , accessed 10 June 2025). 84. Antiretrovirals pregnancy research toolkit [webpage]. Geneva: World Health Organization; 2025 ( https://www.who.int/tools/antiretrovirals-in-pregnancy-research-",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5d59b44a-0eea-4867-8642-74670ff7a403",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "World Health Organization; 2025 ( https://www.who.int/tools/antiretrovirals-in-pregnancy-research- toolkit , accessed 1 April 2025). 85. Gill K, Ndlovu N, Brumskine W, Jaggernath M, Zwane Z, Zhao et al. Lenacapavir pharmacokinetics, safety, efficacy adolescent adult PURPOSE 1. Conference Retroviruses Opportunistic Infections; 9–12 March; San Francisco, California, 2025. 86. Lat AK KA, Zhang H, Lin S, Mortensen E, Palaparthy R, Singh R. Impact subcutaneous administration site clinical pharmacokinetics lenacapavir, long-acting HIV capsid inhibitor: body site matter? Open Forum Infect Dis. doi: 10.1093/ofid/ ofad500.1377 87. Subedar H. Implementing PrEP choice: experience South Africa - update PrEP (including long-acting products) South Africa. 5th HIV Research Prevention Conference; 6–10 October; Lima, Peru, 2024. 88. Interactions lenacapavir. Liverpool: University Liverpool; 2024 ( https://liverpool- hiv-hep.s",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cb51790d-8ca7-41e0-800c-ecfeac039558",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "teractions lenacapavir. Liverpool: University Liverpool; 2024 ( https://liverpool- hiv-hep.s3.amazonaws.com/prescribing_resources/pdfs/000/000/276/original/ Lenacapavir_2024_Oct.pdf?1730389168 accessed 10 June 2025). 89. Gandhi M, Hill L, Grochowski J, Nelson A, Koss CA, Mayorga-Munoz F et al. Case series people HIV long-acting combination lenacapavir cabotegravir: call trial. Open Forum Infect Dis. 2024;11:ofae125. doi: 10.1093/ofid/ofae125 90. Delaugerre C, Antoni G, Mahjoub N, Pialoux G, Cua E, Pasquet et al. Assessment HIV screening test use preexposure prophylaxis programs. J Infect Dis. 2017;216:382-6. doi: 10.1093/infdis/jix29743 References91. Fransen K, de Baetselier I, Rammutla E, Ahmed K, Owino F, Agingu W et al. Performance serological molecular test within acute HIV infection. J Clin Virol. 2017;93:81-4. doi: https://doi.org/10.1016/j.jcv.2017.03.010 92. Livant E, Heaps A, Kelly C, Maharaj R, Samsunder N, Nhlan",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "34a93b2b-2d69-4616-9139-d30f99acf9c4",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "ps://doi.org/10.1016/j.jcv.2017.03.010 92. Livant E, Heaps A, Kelly C, Maharaj R, Samsunder N, Nhlangulela L et al. fourth generation AlereTM HIV Combo rapid test improves detection acute infection MTN-003 (VOICE) samples. J Clin Virol. 2017;94:15–21. doi: https://doi.org/10.1016/j. jcv.2017.06.006 93. Prequalified vitro diagnostics [webpage]. Geneva: World Health Organization; 2023 (https://extranet.who.int/prequal/vitro-diagnostics/prequalified-vitro-diagnostics , accessed 1 April 2025). 94. Toolkit optimize HIV testing algorithm [webpage]. Geneva: World Health Organization; 2025 ( https://www.who.int/tools/optimizing-hiv-testing-algorithms-toolkit , accessed 14 April 2025). 95. Ong JJ, Coulthard K, Quinn C, Tang MJ, Huynh , Jamil MS et al. Risk-based screening tool optimise HIV testing services: systematic review. Curr HIV/AIDS Rep. 2022;19:154-65. doi: 10.1007/s11904-022-00601-5 96. Oliveira Leite B, Magno L, Soares F, Zeballos D, Dezanet L, Ferreir",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bbb1f53d-e9ab-4a14-91e0-035a57944add",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": ": 10.1007/s11904-022-00601-5 96. Oliveira Leite B, Magno L, Soares F, Zeballos D, Dezanet L, Ferreira et al. Equivalent performance HIV oral fluid self-testing rapid testing compared nucleic acid amplification test screening adolescent long-acting injectable cabotegravir Brazil. 13th International AIDS Society Conference HIV Science; 13–17 July; Kigali, Rwanda, 2025. 97. Landovitz RJ, Delany-Moretlwe S, Fogel JM, Marzinke MA, Piwowar-Manning E, Richardson P et al. Features HIV infection context long-acting cabotegravir preexposure prophylaxis. N Engl J Med. 2024;391:1253-6. doi: 10.1056/NEJMc2402088 98. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA et al. GRADE guidelines: 15. Going evidence recommendation-determinants recommendation’s direction strength. J Clin Epidemiol. 2013;66:726-35. doi: 10.1016/j.jclinepi.2013.02.003 44Annex. Process developing guideline A1.1 Overview guidel",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b204fd62-1054-4042-ae6a-6bafd1f3c657",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "16/j.jclinepi.2013.02.003 44Annex. Process developing guideline A1.1 Overview guideline developed accordance procedure established Guidelines Review Committee. recommendation guideline based GRADE approach reviewing evidence formulating recommendations. Consistent previous guidelines, guideline employ public health approach considers effectiveness, acceptability, feasibility resource need across variety settings. external contributor guidelines, including member Guideline Development Group (GDG) External Review Group (ERG), completed declaration interest form accordance policy expert (Web Annex A). systematic review lenacapavir HIV prevention HIV testing strategy injectable long-acting PrEP followed research question population, intervention, comparator, outcome (PICO) format. system",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5c54c65a-780b-4e8e-a26d-d257cae90739",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "owed research question population, intervention, comparator, outcome (PICO) format. systematic review finding evidence-to-decision-making table prepared accordance GRADE process, shared advance presented GDG meetings, independent methodologist facilitated discussions. following section detail aspect guideline development process. A1.2 Establishing group develop guideline guideline development process involved formation five main group guide implement process. group played specific role, described below. member group contributor listed Acknowledgements section. 1. Guideline Steering Group (GSG). GSG, responsible overall coordination guideline development process, led Testing, Prevention Population Unit within Department Global HIV, Hepatitis",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f45a412e-268e-4988-a35b-30232e92f0b5",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "Testing, Prevention Population Unit within Department Global HIV, Hepatitis STI Programmes. Participants included staff member unit department well Department Regulation Prequalification Department Sexual Reproductive Health Research. group also included technical staff regions. 2. Guideline Development Group (GDG). group formulated new recommendations, including implementation service delivery considerations. group also reviewed approved final content guideline document. consisted 19 members, balanced representation geographic regions, gender backgrounds, including academia research, programme implementation policy, community organization networks. selected group member coordination GSG country regional offices. GSG reviewed curriculum vitae, declarat",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0b1f7dfb-3d16-47ac-8253-b24429fca1d9",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "th GSG country regional offices. GSG reviewed curriculum vitae, declaration interest confidentiality agreements. technical staff posted proposed membership list public review comment finalized it. 45 Annex. Process developing guidelines3. External Review Group (ERG). ERG member responsible peer review guidelines. technical staff selected group consultation GSG assure geographic gender balance. comprised 20 peer reviewer academia, policy research, programme implementation community organizations, including network key vulnerable populations. 4. External guideline contributors, led independent methodologist . oversight guideline methodologist input member GSG GDG, independent team expert conducted systematic review mathematical modelling. Additionally, review team compile",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "385da707-cfe7-479f-bfcd-358d472e111b",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "rts conducted systematic review mathematical modelling. Additionally, review team compiled summarized evidence value preferences, feasibility cost–effectiveness. 5. External partner observer . Representatives Children’s Investment Fund Foundation, Gates Foundation; Global Fund Fight HIV, Tuberculosis Malaria; Joint United Nations Programme HIV/AIDS (UNAIDS); National Department Health South Africa Unitaid attended GDG meeting observers. organization potential donor implementers proposed guideline long history collaboration Department Global HIV, Hepatitis STI Programmes. Acknowledgements section list name observer attended GDG meeting. member GDG, non-WHO staff participating meeting guideline development external peer reviewer submitted declaration interest confidentiality statem",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6d669c61-6e0a-4613-beed-3cfa944bf995",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "velopment external peer reviewer submitted declaration interest confidentiality statement secretariat. secretariat GSG reviewed declaration found conflict interest sufficient preclude GDG member participating fully development guidelines. Web Annex provides full compilation summary declaration interests. A1.3 Scope guideline assess need guidelines, convened expert consultation scoping meeting August September 2024. Based outcome meetings, GSG developed scope guideline lenacapavir HIV testing long-acting PrEP October November 2024. GSG also provided support peer review documents. A1.4 Development guideline support development guidelines, commissioned systematic review available evidence on: • lenacapavir HIV prevention • HIV",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "47a1f233-7648-404a-b229-a9219849badc",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "commissioned systematic review available evidence on: • lenacapavir HIV prevention • HIV testing long-acting PrEP . also commissioned mathematical modelling assess effect HIVST-supported PrEP delivery. GSG, along technical staff, developed PICO questions. GDG finalized question defined outcome stratification interest. GDG member prioritized outcome using electronic survey rank importance outcome GRADE rating scale 1–9 (0–3: important; 4–6: important; 7–9: critical). PICO question priority outcome agreed, external researchers, supported team, conducted systematic reviews. Guidelines lenacapavir HIV prevention testing strategy long-acting injectable pre-exposure prophylaxis 46Each systematic review team developed protocol review relevant scientific evidence. independent methodologist assessed",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6e043b76-434b-4815-a7ee-feec4aac6409",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "protocol review relevant scientific evidence. independent methodologist assessed reviewed protocol, GDG, GSG secretariat. conjunction technical team, review team developed search strategies. methodologist advised review team analytical decisions, risk bias quality appraisal, well synthesis grading evidence. review team also summarized value preference resource use, using information identified additional component systematic review. web annex present detail systematic review. subsequently convened virtual technical consultation (January 2025) GDG. independent methodologist facilitated GDG discussion formulation recommendations. Based evidence reviewed presented consultation, GDG made new recommendation regarding lenacapavir HIV prevention HIV testing long-act",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "89ece88c-7e36-4ee3-9457-f6f5504cc6a2",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "GDG made new recommendation regarding lenacapavir HIV prevention HIV testing long-acting injectable PrEP . External peer review completed March 2025. A1.5 Additional evidence recommendation developed according WHO-endorsed GRADE evidence-to- decision-making process, address following questions: • problem priority? • substantial benefits? • substantial harms? • overall certainty evidence? • balance benefit harms? • important variability uncertainty patient preference regarding key outcomes? • large resource requirement (costs)? • intervention cost–effective? • would impact health equity? • intervention acceptable stakeholders? • implementation intervention feasible? guideline development process, GDG formulates recommendation guided certaint",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "45ab2377-9ac7-4028-b44e-cc4a8a2c8ffa",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "guideline development process, GDG formulates recommendation guided certainty available evidence. GRADE approach specifies four level certainty evidence, described Table A1. factor – value preferences, cost feasibility, acceptability, equity human right – taken consideration determining direction strength recommendation (98) . factor weighted, and, formulating recommendations, GDG asked consider factor together. strength recommendation likely strong certainty high factor supportive. certainty low, wide variability uncertainty value preference acceptability, example, conditional recommendation appropriate. 47 Annex. Process developing guidelinesTable A1. Interpretation four GRADE level evidence Certainty evidence Rationale High",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3ed4d667-e613-4816-b80f-0344bb9faea9",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "sTable A1. Interpretation four GRADE level evidence Certainty evidence Rationale High confident true effect lie close estimate effect. Moderate moderately confident estimate effect. true effect likely close estimate effect could substantially different. Low confidence estimate effect limited. true effect may substantially different estimate effect. low little confidence estimate effect. estimate effect uncertain. A1.6 Developing recommendation GDG meeting included presentation final systematic review finding supportive evidence. independent methodologist facilitated meeting. beginning meeting, GDG agreed goal decision-making would reach consensus, defined agreement group, that, consensus could reached, vote would",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "67f3b7e6-d079-4a7d-a3b0-0564d9282819",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "s, defined agreement group, that, consensus could reached, vote would taken. Consensus reached decisions, voting required. meeting GDG discussed finding systematic review supplemental evidence, mathematical modelling. Following discussion, GDG reached consensus direction, strength wording recommendation. drafted full guideline circulated electronically GDG, GSG ERG comment feedback. response considered addressed appropriate final draft. targeted update guideline available website ( https://www.who. int/publications/i/item/9789240111608 ) disseminated member states. final guideline also published disseminated July 2025. Department Global HIV, Hepatitis Sexually Transmitted Infections Programmes World Health Organization Av",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3a177e60-0930-4e74-98ad-1276251be8ad",
        "title": "Lenacapavir for HIV prevention and testing strategies",
        "body": "lobal HIV, Hepatitis Sexually Transmitted Infections Programmes World Health Organization Avenue Appia 20 1211 Geneva Switzerland www.who.int",
        "source": "WHO Guidelines: Lenacapavir for HIV prevention and testing strategies.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "30837e5c-47fa-4106-a3aa-7d4385b7d9e5",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "recommendation management sickle-cell disease pregnancy, childbirth interpregnancy periodWHO recommendation management sickle-cell disease pregnancy, childbirth interpregnancy periodWHO recommendation management sickle cell disease pregnancy, childbirth interpregnancy period ISBN 978-92-4-010912-4 (electronic version) ISBN 978-92-4-010913-1 (print version) © World Health Organization 2025 right reserved. work available Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo ). term licence, may copy, redistribute adapt work non-commercial purposes, provided work appropriately cited, indicated below. use work, suggestion endorses specific organization, product services. use W",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "53765707-57ea-4a61-9da5-11a81d6a34ac",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "e suggestion endorses specific organization, product services. use logo permitted. adapt work, must license work equivalent Creative Commons licence. create translation work, add following disclaimer along suggested citation: “This translation created World Health Organization (WHO). responsible content accuracy translation. original English edition shall binding authentic edition”. mediation relating dispute arising licence shall conducted accordance mediation rule World Intellectual Property Organization ( http://www.wipo.int/amc/en/mediation/ rules/ ). Suggested citation. recommendation management sickle cell disease pregnancy, childbirth interpregnancy period. Geneva: World Health Organization; 2025. Licence: CC BY-NC-S",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b04d11d9-0508-40ab-ba57-a4cbc44f0f1f",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "dbirth interpregnancy period. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO . Cataloguing-in-Publication (CIP) data. CIP data available https://iris.who.int/ . Sales, right licensing. purchase publications, see https://www.who.int/publications/ book-orders . submit request commercial use query right licensing, see https:/ /www. who.int/copyright . Third-party materials. wish reuse material work attributed third party, tables, figure images, responsibility determine whether permission needed reuse obtain permission copyright holder. risk claim resulting infringement third-party-owned component work rest solely user. General disclaimers. designation employed presentation material publication imply expression opinion whatsoever part",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9a0e8ed3-4ad7-4056-80b2-324ca0dc4d96",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "e material publication imply expression opinion whatsoever part concerning legal status country, territory, city area authorities, concerning delimitation frontier boundaries. Dotted dashed line map represent approximate border line may yet full agreement. mention specific company certain manufacturers’ product imply endorsed recommended preference others similar nature mentioned. Errors omission excepted, name proprietary product distinguished initial capital letters. reasonable precaution taken verify information contained publication. However, published material distributed without warranty kind, either expressed implied. responsibility interpretation use material lie reader.",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "512e9d5a-8660-46b4-bf64-1a9e6bb56b4f",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "implied. responsibility interpretation use material lie reader. event shall liable damage arising use. Cover photo: Sickle-cell disease red blood cell motion. Freepik AI Image Generator.Contents Acknowledgements iv Acronyms abbreviation vi Executive Summary viii Introduction viii Target audience ix Guideline development method ix Considerations underpinning recommendation x Recommendations xii 1 Introduction 1 1.1 Background 1 1.2 Rationale objective 2 1.3 Target audience 2 1.4 Scope recommendation 3 1.5 Persons affected recommendation 3 2 Methods 4 2.1 Contributors guideline 4 2.2 Evidence identification retrieval 6 2.3 Quality assessment grading evidence 7 2.4 Formulation recommendation 8 2.5 Management declaration interest 9 2.6 Decision making GDG meeting 10 2.7 Document preparation peer review 10 3 Recommendat",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "921e5d08-ea9a-476f-ba48-d8948cd53863",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "cision making GDG meeting 10 2.7 Document preparation peer review 10 3 Recommendations supporting evidence 11 3.1 Recommendations 11 4 Dissemination implementation guideline 35 4.1 Dissemination evaluation 35 4.2 Implementation consideration 36 4.3 Anticipated impact organization care resource 37 4.4 Monitoring evaluating guideline implementation 38 5 Research implication 39 6 Updating recommendation 40 Annex 1. External expert staff involved preparation recommendation 41 Annex 2. Priority outcome used decision making 45 Annex 3. Summary management declared interest GDG member 47 Web Annex, https://doi.org/10.2471/B09416 51 White paper, https://who.canto.global/b/LIVKQ 51 References 52ivAcknowledgements Department Sexual Reproductive Health Research Department Maternal, Newborn, Child Adolescent Health, World Health Organization (WHO) gr",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2d6f2e2f-9d17-47aa-835c-13c2e6bcf0ed",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Department Maternal, Newborn, Child Adolescent Health, World Health Organization (WHO) gratefully acknowledge contribution many individual organization guideline. Work guideline initiated Department Sexual Reproductive Health Research. Consultants WHO, guideline methodologists Jen Ramson Myfanwy Williams, co-ordinated evidence synthesis technical preparatory activities. Doris Chou Department Sexual Reproductive Health Research managed guideline development process. extends sincere thanks Bosede Afolabi (Chair, University Lagos, Lagos, Nigeria), Tamima Aldughaishi (Sultan Qaboos University Hospital, Muscat, Oman), Eugenia Vicky Asare (Ghana Institute Clinical Genetics/Korle-Bu Teaching Hospital, Accra, Ghana), Monika Asnani (The University West Indies, Mona Campus, Jamaica), Ochuwa Babah (University Lagos, Lagos, Nigeria), Lea Kilenga Bey (Africa Si",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0ceb8eb1-101b-439b-be3b-3f03cc327eff",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ona Campus, Jamaica), Ochuwa Babah (University Lagos, Lagos, Nigeria), Lea Kilenga Bey (Africa Sickle Cell Organization, Nairobi, Kenya), Harriet Birungi (Population Council, Nairobi, Kenya), Rodolfo Cançado (Faculdade de Ciencias Medicas da Santa Casa de São Paulo, São Paulo, Brazil), John Ehiri (University Arizona, Arizona, United States America), Laure Joseph (Département de Biothérapie Hôpital Necker- Enfants Malades, Paris, France), Isaac Odame (The Hospital Sick Children, Toronto, Canada), Eugene Oteng-Ntim (King’s College, London, United Kingdom Great Britain Northern Ireland), Wendy Pollock (Monash University, Melbourne, Australia) served member Guideline Development Group (GDG), Kinga Malinowski (Mount Sinai Hospital, Toronto, Canada), Bertha Maseko (Malawi Liverpool Wellcome Programme, Blantyre, Malawi), Babasola Okusanya (University Lagos, Lagos, Nigeria) Lydia Pecker (John Hopkins School Medicine, Baltimore, U",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fd9fba10-612c-48ef-b0ce-8e4bb81cfcfa",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "niversity Lagos, Lagos, Nigeria) Lydia Pecker (John Hopkins School Medicine, Baltimore, United States America) member External Review Group. acknowledges important contribution member Steering Group, included representative Department Maternal, Newborn, Child Adolescent Health Ageing (Ayesha De Costa, Meera Upadhyay); Department Noncommunicable Diseases (Prebo Barango, Roberta Ortiz Sequeira); Department Nutrition Food Safety (María Nieves Garcia Casal, Lisa Rogers); Department Sexual Reproductive Health Research (Maria Barreix Etchegoimberry, Doris Chou, Olufemi Oladapo). recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Special thanks author systematic review used update assistance collaboration updating them. Kelli Barbour, Sarah Boudova, La’Ron Browne, Soo",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c2117b64-f604-46c1-8896-53875eda5e6b",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "assistance collaboration updating them. Kelli Barbour, Sarah Boudova, La’Ron Browne, Soo Downe, Kenneth Finlayson, Yaneve Fonge, Nampet Jampathong, Apiwat Jongjakapun, Jenny Jung, Pisake Lumbiganon, Chetta Ngamjarus, Porjai Pattanittum, Beth Pineles, Jen Sothornwit, Termtem Waidee member Evidence Synthesis Group, performed synthesis quality appraisal scientific evidence. Jen Ramson Myfanwy Williams drafted Evidence-to-Decision framework final guideline document substantial input Doris Chou document reviewed member Steering Group GDG. External Review Group reviewed final guideline prior publication clearance WHO. grateful contribution A. Kinga Malinowski (Mount Sinai Hospital, Toronto, Canada), Bertha Maseko (Malawi Liverpool Wellcome Programme, Blantyre, Malawi), Babasola Okusanya (University Lagos, Lagos, Nigeria), Lydia Peck",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a4ec6f88-13f7-49bb-bd9c-85e1d0ed42e5",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ogramme, Blantyre, Malawi), Babasola Okusanya (University Lagos, Lagos, Nigeria), Lydia Pecker (John Hopkins School Medicine, Baltimore, United States America). acknowledge following observer technical consultations, represented various organizations: Diana Ramašauskaitė Akaninyene Eseme Bernard Ubom (International Federation Gynecology Obstetrics [FIGO]), Nita Radhakrishnan (International Pediatric Association [IPA]), Mychelle Farmer (NCD Alliance), Meridith Mikulich (United States Agency International Development [USAID]) Raoul Bermejo (United Nations Children’s Fund [UNICEF]). also appreciate support staff regional offices, including Bremen De Mucio, Pablo Durán, Karima Gholbzouri, C. Anoma Jayathilaka, Shogo Kubota, Oleg Kuzmenko, Priya Mannava Léopold Ouedraogo. contribution Peter Olumese, (Medical Officer) Andrea Bosman (Unit Head, Diagnosis, medicine resistance) Glob",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "91f929a4-56ed-446a-8317-dc7d3f4ea2d5",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "(Medical Officer) Andrea Bosman (Unit Head, Diagnosis, medicine resistance) Global Malaria Programme discussion folic acid supplementation gratefully acknowledged. acknowledges financial support work received United Nations Development Programme (UNDP)/ United Nations Population Fund (UNFPA)/UNICEF/WHO/World Bank Special Programme Research, Development Research Training Human Reproduction Programme (HRP); Global Noncommunicable Diseases Platform, USAID (support received prior January 2025). view funding body influenced content guideline. Acknowledgements v recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period viAcronyms abbreviation AMR antimicrobial resistance CERQual Confidence Evidence Reviews Qualitative research CI confidence interval DOI declaration interest ESG Evidence Synthesis Gr",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5b5bcacb-e323-4693-9264-32c31e7ee623",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "f Qualitative research CI confidence interval DOI declaration interest ESG Evidence Synthesis Group EtD evidence-to-decision FIGO International Federation Gynecology Obstetrics GDG Guideline Development Group GFR glomerular filtration rate GRADE Grading Recommendations, Assessment, Development, Evaluation HICs high-income country HIT heparin-induced thrombocytopaenia HRP UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme Research, Development Research Training Human Reproduction IpTp-SP intermittent prophylaxis sulfadoxine-pyrimethamine IV intravenous LICs low-income country LMICs low- middle-income country LMWH low molecular weight heparin LOAEL lowest observed adverse effect level MVM maternal vascular malperfusion NCD noncommunicable disease NSAID nonsteroidal anti-inflammatory drug recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period NWS neonatal withdrawal syndrome odds",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a57e0ce8-592e-45e6-bddd-be05b05ccfe2",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "pregnancy, childbirth interpregnancy period NWS neonatal withdrawal syndrome odds ratio PICO population (P), intervention (I), comparison (C), outcome (O) PPH postpartum haemorrhage QES qualitative evidence synthesis RCT randomized controlled trial RR relative risk SCD sickle-cell disease TOLAC trial labour caesarean UFH unfractionated heparin UNDP United Nations Development Programme UNFPA United Nations Population Fund UNICEF United Nations Children’s Fund USAID United States Agency International Development VTE venous thromboembolism World Health Organization Acronyms abbreviation vii recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period viiiExecutive Summary Introduction Sickle-cell disease (SCD) group autosomal recessive haemoglobin disorder result gene mutation β-subunit haemoglobin ( 1). common inherited condition worldwide, affecting 7.7",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "310c7000-6fb5-40db-9501-dc213b554c7e",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "β-subunit haemoglobin ( 1). common inherited condition worldwide, affecting 7.74 million people ( 2). SCD highly prevalent sub-Saharan Africa, cause significant disease burden historically malaria-endemic region Africa, Middle East, Caribbean South Asia. SCD also affect people many country ( 2). 2000 2021, number people living SCD globally increased 41.4% ( 2). SCD associated severe anaemia, vaso-occlusive crises, cerebrovascular disease, opportunistic infections, premature mortality, see Figure 1 ( 3). addition, quality life significantly reduced depression common patient SCD ( 4). Many infectious diseases, pneumococcal disease, dangerous people SCD without SCD ( 5). infant child mortality SCD decrease due advance disease management, number people reaching reproductive age th",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6b08cd12-ef5b-4850-a980-518fba5328ff",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "eas due advance disease management, number people reaching reproductive age disorder increases. Pregnancies women1 SCD associated increased rate adverse outcome (see Figure 1). Maternal mortality 4- 11-fold higher woman SCD without SCD ( 3, 6, 7). Maternal mortality even higher low-income country (LICs) ( 7). complication pregnancy increased woman SCD include pre-eclampsia, stillbirth, preterm birth small-for-gestational-age baby ( 8). World Health Organization (WHO) guideline exists management SCD pregnancy. review existing guidelines2, five guideline discussed SCD pregnancy found, high-income country (HICs) four based consensus rather systematic review evidence. Given disease burden SCD global, majority case low- middle-income country (LMI",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d5f8cbcf-9cc2-4bbf-8f43-3f67c4b11639",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "disease burden SCD global, majority case low- middle-income country (LMICs), guideline applicable environment needed. 1 term “women” used throughout document refer identify woman regardless sex assigned birth recognises gender diverse individual identify woman reproductive capacity. intention exclude experience reflects current lack data identifying, and/or reflecting specific experience of, gender diverse individuals. 2 Ramson J, Williams MJ. Prioritizing topic area development World Health Organization recommendation care woman noncommunicable disease perinatal period, unpublished. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Target audience primary audience guideline health-care provider r",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fbcc1dee-7a24-4959-bd7e-b3b92513e8e3",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "regnancy period Target audience primary audience guideline health-care provider responsible developing national local health-care protocol policies, well manager maternal child health programmes, policy-makers settings. guideline also useful directly providing care woman pregnancy giving birth, obstetricians, midwives, nurse general practitioners. Finally, information guideline useful developing clinical tool pre- in-service training health worker health-system strengthening effort enhance delivery clinical care. Guideline development method development guideline guided process described handbook guideline development (9). guideline developed using following steps: (i) identification priority question outcomes; (ii) retrieval evidence; (iii) assessment",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3bbefb29-362f-4c24-be39-dc7e04d14803",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "identification priority question outcomes; (ii) retrieval evidence; (iii) assessment synthesis evidence; (iv) formulation recommendations; (v) planning dissemination, implementation, impact evaluation future updating recommendations. De novo systematic review used prepare evidence profile prioritized questions. quality identified scientific evidence underpinning recommendation appraised using Grading Recommendations Assessment, Development Evaluation (GRADE) GRADE Confidence Evidence Reviews Qualitative research (GRADE-CERQual) approaches, quantitative qualitative evidence, respectively. GRADE evidence-to-decision (EtD) framework – evidence-to-decision tool includes intervention effects, values, resource use, equity human rights, acceptability feasibility criterion – used guide formulation recommendation Guideline",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "10926214-b4a5-4ece-9166-ae38b506aa34",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ty feasibility criterion – used guide formulation recommendation Guideline Development Group (GDG). GDG comprised international group expert assembled consideration recommendation 30–31 May 2023, 12–13 December 2023, 8–9 October 2024 26–27 November 2024. Executive Summary ix recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period xConsiderations underpinning recommendation December 2023 GDG meeting, agreed set consideration underlying recommendation developed background information included inform care across maternity journey woman SCD. following point formulated agreed GDG November 2024 meeting. • 2020, 95% maternal mortality occurred LMICs ( 10).3 2015 report inequality reproductive, maternal, newborn child health state “the poo",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "37d59ec2-ab10-4fbc-9eb0-e64e1c334232",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "5 report inequality reproductive, maternal, newborn child health state “the poorest, least educated residing rural area lower health intervention coverage worse health outcome advantaged” ( 11). report also found preventing reducing morbidity mortality childbirth play key role reducing overall health inequities. • SCD highly prevalent sub-Saharan Africa, cause significant disease burden historically malaria-endemic region Africa, Middle East, Caribbean South Asia. SCD also affect people many country ( 2). Globally, number people living SCD increased 41.4% 2000 2021 ( 2). Pregnancies woman SCD associated multiple morbidity affect outcome woman babies. Maternal mortality 4- 11-fold higher woman SCD without SCD ( 6, 7), even higher LICs ( 7).",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7c7f3716-4d27-47fd-9826-a63f1419cd7d",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "-fold higher woman SCD without SCD ( 6, 7), even higher LICs ( 7). complication pregnancy increased woman SCD include pre-eclampsia, stillbirth, preterm birth small-for-gestational-age baby ( 8). • SCD neglected condition, inequality access adequately resourced care SCD reflect geographical distribution ( 12). guideline aim address serious problem pregnant woman SCD propose intervention greatest potential improve outcome woman babies. guideline intended use country especially lower-resource settings. woman right highest attainable standard physical mental health, irrespective SCD pregnancy status ( 13). settings, however, current level care may adequately meet need pregnant woman SCD. • envisions world every pregnant woman",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f189259e-99c5-47fe-99c0-17a4fc4a4c82",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "meet need pregnant woman SCD. • envisions world every pregnant woman newborn baby receives quality care throughout pregnancy, childbirth postnatal period ( 14). recommendation positive pregnancy experience highlight importance providing effective communication physiological, biomedical, behavioural sociocultural issues, well effective support, including social, cultural, emotional psychological support, pregnant woman respectful way ( 14). • recognition research indicating woman value positive childbirth experience, also emphasizes women’s experience pregnancy care critical complementary provision routine clinical practice ( 15). Although woman SCD may face higher risk pregnancy, remains important centre individual woman’s value preference facilitate positive childbirth experience possible w",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c788a5eb-12a4-4d13-afa8-f250f9a896f1",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "’s value preference facilitate positive childbirth experience possible managing risk effectively. 3 Since GDG discussions, maternal mortality estimate updated. 2023, approximately 92% maternal death occurred LMICs. see, https://iris.who.int/bitstream/handle/10665/381012/9789240108462-eng.pdf?sequence=1 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period • potential improve outcome woman baby taking life-course approach integrates care prevention noncommunicable diseases, SCD, sexual, reproductive, maternal, newborn child health care ( 16). • People SCD may experience health-related stigma due condition, contributing factor including race, disease status, socioeconomic status, delayed growth puberty, and/or chronic acute pain need managed opioids",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a93f4c67-eab7-445c-aebb-ea973e8bdfd8",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "yed growth puberty, and/or chronic acute pain need managed opioids ( 17). Women SCD become pregnant may experience additional stigma ( 18). Stigma impact social relationship (with friends, family, co-workers, peer wider community), psychological well-being, physiological well-being, well patient– provider relationship care-seeking behaviour (17). guideline aim challenge prejudice discrimination, raise profile condition, rally change people living SCD. • instances, health-care provider lack knowledge understanding SCD underlying genetics ( 18, 19, 20, 21). highlighting lack knowledge, guideline emphasizes need education, training, accurate accessible information SCD among health-care providers. • community SCD highly prevalent, concept genetically inherited disease align native",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "768d30ec-17e7-4565-a081-74f849ad009e",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "SCD highly prevalent, concept genetically inherited disease align native traditional understanding disease causation ( 22, 23). Local policy-makers care provider sensitive difference understanding actively engage stakeholder develop accurate understanding SCD accessible member affected communities. • Given multifaceted nature SCD, care variety specialist needed, addressing different aspect disease. multidisciplinary team caring woman pregnancy may include obstetrician, haematologist (preferably primary haematologist managed woman pre-pregnancy period) health-care provider expertise SCD, neonatologist, midwife, public health nurse, pulmonologist, intensivist/anaesthesiologist clinical psychologist. • Women SCD experience array psychological emotional challenge",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b38db71a-e9ce-4cf5-8386-753d483491a3",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "psychologist. • Women SCD experience array psychological emotional challenge pregnancy postnatal period (including miscarriage termination) ( 18). People lived experience SCD may require psychological support counselling help cope symptom SCD psychosocial consequence living condition ( 4, 18, 23). Ideally, support would timely, accessible, aim enhance quality life people SCD ( 23) provided skilled practitioner appropriate training genetics mental health. • Information lacking safety many medication pregnancy breastfeeding ( 24, 25, 26). tended lead precautionary approach, whereby woman advised, decline, take medication rely pregnant, receive conflicting advice ( 24). addition safety concerns, decision dis/continuation medication p",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cba7f8a6-0eeb-4ff3-bc0e-7c8ff43577f2",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "advice ( 24). addition safety concerns, decision dis/continuation medication pregnancy reflect commitment equitable access effective medication pregnant breastfeeding woman SCD, responsive woman’s individual risk–benefit preferences. Greater effort made include pregnant woman SCD clinical trials. • People SCD vulnerable infections, susceptibility even greater pregnancy (27). Infection prevention treatment key aspect effective care ( 23). Pregnant woman SCD need access local non-pharmacological infection prevention measure clean water, sanitation, hygiene local immunization programmes. Executive Summary xi recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period xii• normal physiological change pregnancy (such immune-adaptation hypercoagulable state) may exac",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "119a3592-c347-4491-99e9-8a69f134f790",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "l physiological change pregnancy (such immune-adaptation hypercoagulable state) may exacerbate pathophysiological change characteristic SCD, compounding risk woman’s health due SCD ( 8, 27). woman SCD, journey motherhood involve series emotional, physical practical challenge beyond experienced woman less vulnerable circumstance ( 18). placing spotlight complex interaction SCD pregnancy, guideline aim provide actionable guidance improve outcome woman SCD babies. Recommendations GDG issued 21 recommendation — eight medication management, four pain management, two fluid management woman hospitalized SCD, one thromboprophylaxis pregnant woman hospitalized SCD, two fetal monitoring, one timing mode birth, two interpregnancy management. paucity direct empirical",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d934ac42-0c19-430d-9ef3-d79ccfd4862a",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "mode birth, two interpregnancy management. paucity direct empirical evidence effectiveness intervention part maternity care woman SCD, comment strength recommendation possible. Rather, underpinned assessment GDG balance health benefit harm based physiological understanding SCD pregnancy; human right sociocultural acceptability; health equity, equality, non-discrimination; societal implications; financial economic considerations; feasibility health- system considerations; women’s view preferences. ensure recommendation correctly understood applied practice, GDG provided additional remarks. Users recommendation refer remarks, presented directly beneath recommendation Section 3.1. recommendation given below. Topic Recommendation Medication management",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a08d70b3-4af6-4c64-be3f-144d092fbebe",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Section 3.1. recommendation given below. Topic Recommendation Medication management woman SCD presenting antenatal care Folic acid supplementation1a. Advise pregnant woman SCD living outside malaria endemic area continue daily supplementation 5 mg folic acid initiate supplementation dose soon possible. 1b. Advise pregnant woman SCD taking intermittent preventive treatment sulfadoxine-pyrimethamine 400 µg folic acid supplementation daily appropriate, higher dos may counteract efficacy antimalarial. Iron supplementation 1c. Advise pregnant woman SCD iron supplementation needed unless evidence iron deficiency. 1d. pregnant woman SCD iron deficient, advise iron supplementation general pregnant population. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Topic",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b011eaea-b63c-4689-b338-ffceba3092e6",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Management sickle-cell disease pregnancy, childbirth interpregnancy period Topic Recommendation Prophylactic blood transfusion1e. pregnant woman SCD history severe intractable crisis (i.e. recurrent painful crisis and/or event unresponsive treatment modalities) lived experience previous benefit prophylactic transfusion outside pregnancy, consider prophylactic blood transfusion. Hydroxycarbamide (hydroxyurea)1f. pregnant woman SCD previously controlled hydroxycarbamide (hydroxyurea), consider continuation recommencement (after first trimester) medication context shared decision making involving woman multidisciplinary team includes expert SCD pregnancy. Base risk–benefit analysis woman’s symptom severity, stage pregnancy view preferences. Thromboprophylaxis 1g. pregnant woman SCD (not hospitalized), consider additional",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "595e9181-94a5-4762-abc1-f29e00717867",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "erences. Thromboprophylaxis 1g. pregnant woman SCD (not hospitalized), consider additional risk factor thromboembolism (e.g. prior venous thromboembolism [VTE] following vaso-occlusive events) follow local recommendation initiation thromboprophylaxis pregnant woman elevated risk thrombotic event (e.g. prior VTE, obesity, inherited thrombophilia). Infection prophylaxis 1h. pregnant woman SCD, advise routine infection prophylaxis implement frequent screening infection (such urinary tract infection), using low diagnostic threshold bacterial urinary tract infection. Pain management pregnant woman SCD Pain medication 2a. pregnant woman SCD experiencing acute sickle-related pain, offer timely optimal pain relief. 2b. advising use analgesia, option include oral paracetamol, nonsteroidal anti- inflammatory drug (NSAIDs), opioids lowest effective dose short",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "70764d1a-7dcd-4f5d-9640-fecdbfcb6279",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "onsteroidal anti- inflammatory drug (NSAIDs), opioids lowest effective dose shortest period time required manage pain. 2c. advising use analgesia, consider stage pregnancy contraindication specific medications, woman’s views, preference previous experience medication, risk dependence, availability. Pain management plans2d. Collaborate pregnant woman SCD develop individualized pain- management plan early pregnancy possible, basing plan severity frequency pain crises, woman’s view preferences, including multidisciplinary team approach care. Executive Summary xiii recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period xivTopic Recommendation Management woman SCD hospitalized pregnancy Fluid management pregnant woman hospitalized SCD3a. pregnant woman SCD ho",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "35299e5e-7e5b-4072-b866-b018e00ddbc8",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "egnancy Fluid management pregnant woman hospitalized SCD3a. pregnant woman SCD hospitalized vaso-occlusive crisis requiring intravenous fluid hydration, implement frequent clinical monitoring (such lung auscultation, oxygenation/pulse oximetry, respiratory rate) early identification fluid overload pulmonary oedema. 3b. pregnant woman SCD requiring intravenous fluid hydration context obstetric complication pre-eclampsia, implement intensive monitoring sign fluid overload. Thromboprophylaxis pregnant woman hospitalized SCD4. Offer thromboprophylaxis pregnant woman hospitalized SCD unless contraindication present. Fetal monitoring Additional fetal monitoring pregnancy5a. pregnant woman SCD without complication (due SCD obstetric causes), offer growth/biometric scan identify fetal growth restriction every four week 24 32 weeks’",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2f098bc6-c5a6-4ca2-83ac-dd99facebd2e",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "rowth/biometric scan identify fetal growth restriction every four week 24 32 weeks’ gestation, every three week birth. 5b. pregnant woman SCD complication (due SCD obstetric causes), offer individualized intensive fetal monitoring guide management, taking consideration woman’s view preferences, availability equipment staff skilled use. Care around birth Timing birth 6. making decision timing birth (awaiting spontaneous labour planned birth) woman SCD, take individualized approach based anticipated balance benefit continuing pregnancy allow fetal maturation risk maternal neonatal morbidity associated continuation pregnancy, woman’s view preferences. Mode birth 7. Base decision mode birth woman SCD presence absence medical obstetric indication",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d59dfad3-c460-4083-a356-657c6c93e1a6",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ode birth woman SCD presence absence medical obstetric indication caesarean birth, availability local resource (including required woman make informed decisions), well woman’s view preferences. absence medical obstetric indication caesarean birth, vaginal birth preferable. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Topic Recommendation Interpregnancy management Interpregnancy care 8a. Offer woman SCD immediate postnatal period six week childbirth care addition outlined recommendation maternal newborn care positive postnatal experience ( 28): • manage treat SCD complications, using evidence-based intervention including disease-modifying agent hydroxycarbamide (hydroxyurea) pain-management strategies; • prevent morbidity thr",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "717e0dfc-af03-4a8c-bd3b-f36d6d7afa41",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "hydroxycarbamide (hydroxyurea) pain-management strategies; • prevent morbidity thrombotic event considering need initiating thromboprophylaxis, per local recommendations; • guide choice contraceptive methods; • screen newborn SCD; • guide counselling safety breastfeeding baby. Health service program 8b. woman SCD, integrate care across life course, including sexual reproductive health care, specialized disease care, may include: supporting optimal health; providing pre-pregnancy counselling guidance pregnancy planning; optimizing treatment across reproductive continuum. Executive Summary xv recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period xviFigure 1: Pathophysiological interaction pregnancy sickle cell disease Abbreviations: ↓: decrease, ↑: increase, FRC: Functional Residual Capaci",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4949db65-e903-4cf3-9807-00d012a7bde8",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ncy sickle cell disease Abbreviations: ↓: decrease, ↑: increase, FRC: Functional Residual Capacity, Hb: haemoglobin, IUGR: intrauterine growth restriction, PS: phosphatidylserine, RBC: red blood cell, RR: relative risk, SS: homozygous sickle haemoglobin, TF: tissue factor, WG: week gestation Diagram adapted Joseph L, et., al (3).Increase organ damage mother Placental impact • Pre-eclampsia/eclampsia • IUGR • Pregnancy lossPregnancy Sickle cell disease Haemolytic anemia Change Hb level, depending genotype phenotype Chronic inflammation - Endothelial dysfunction - Leukocytosis - Platelet activation Higher thrombosis risk risk depends genotype blood viscosity Multiple factors: ↓ protein protein C, ↓ TF, PS RBC surface Vaso-occlusive event Triggers: hypoxia, infection, dehydration, stress, etc. Functional asplenia Usually age 5 years, SS genotype Haemodilution",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ebdefbb2-82e4-4a0f-a5ba-7634cb4b2c9c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": ", etc. Functional asplenia Usually age 5 years, SS genotype Haemodilution ↑ maternal blood volume (by 40% third trimester) ↓ hemoglobin 1 g/dl Leukocytosis Endocrine effect Higher thrombosis risk RR 4 time greater general population Hypercoagulability, ↓ venous flow 25WG 6 week postpartum Reduced lung volume third trimester, cardiac output increase 30-50%. Increased cardiac output 20 30% ↓ FRC resting lung volume ↑ mother basal organ requirement Susceptibility infection ↑ genitourinary tract infection Hormone change ↑ estrogen, progesterone corticosteroid levelsa b c eb de b c recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 1.1 Background Sickle-cell disease (SCD) group autosomal recessive haemoglobin disorder result gene mutation β-subu",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fb82e165-0630-4b35-9817-c889625d26b8",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "group autosomal recessive haemoglobin disorder result gene mutation β-subunit haemoglobin ( 1). common inherited condition worldwide, affecting 7.74 million people ( 2). SCD highly prevalent sub-Saharan Africa, cause significant disease burden historically malaria- endemic region Africa, Middle East, Caribbean South Asia. SCD also affect people many country ( 2). 2000 2021, number people living SCD globally increased 41.4% ( 2). SCD associated severe anaemia (See Figure 1), vaso-occlusive crises, cerebrovascular disease, opportunistic infections, premature mortality ( 3). addition, quality life significantly reduced depression common people SCD ( 4). Many infectious diseases, pneumococcal disease, dangerous people SCD without SCD ( 5). infant child mortality SCD decrease due advan",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d00b3cfc-76b4-4ced-ba12-197eebd64cb0",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "SCD without SCD ( 5). infant child mortality SCD decrease due advance disease management, number people reaching reproductive age disorder increases. Pregnancies woman SCD associated increased rate adverse outcome (See Figure 1). Maternal mortality 4- 11-fold higher woman SCD without SCD ( 6, 7). Maternal mortality even higher LICs ( 7). complication pregnancy include pre-eclampsia, stillbirth, preterm birth small-for-gestational-age baby ( 8). Steps towards improving management SCD pregnancy childbirth would significantly contribute reducing maternal mortality morbidity. Likewise, improvement overall quality maternal health care prevent treat complication SCD pregnancy critical attaining Sustainable Development Goals health target ( 29) target indicator WHO’s Thirteenth Gen",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9cf29058-3639-40ba-b1ac-c4e701311735",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "nable Development Goals health target ( 29) target indicator WHO’s Thirteenth General Programme Work (30), particularly achieving universal health coverage. fundamental human right, woman adolescent girl entitled sexual reproductive health rights, including accessing evidence-based care pregnancy childbirth ( 31). Similarly, vision “every pregnant woman newborn receives quality care throughout pregnancy, childbirth postnatal period” ( 32). Thus, evidence support effectiveness feasible intervention reduce maternal perinatal mortality morbidity, essential mother baby opportunity receive care. 1 Introduction 1 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 2To provide high-quality care, health workers, especially LMICs grea",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dfd00569-0024-4683-ab4b-66e4ff2c5392",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "gnancy period 2To provide high-quality care, health workers, especially LMICs greatest burden maternal mortality morbidities, need date latest scientific evidence best practices, access trained use life-saving appropriate interventions. Importantly, health managers, policy-makers stakeholder make decision maternal perinatal health service delivery require updated guidance inform policy programmes. effort collectively help optimize quality care woman baby pregnancy, childbirth postnatal period. Ensuring accessibility acceptability intervention improve maternal newborn health outcome consistent international human right laws, include fundamental commitment state enable woman adolescent girl survive pregnancy childbirth, assure sexual reproductive health rights,",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc12f956-c3ae-4809-838a-685c819baebf",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "girl survive pregnancy childbirth, assure sexual reproductive health rights, live life dignity. High-quality health care could reduce profound inequity maternal newborn health globally essential improving pregnancy birth outcomes. 1.2 Rationale objective July 2021, Steering Group convened scoping meeting – comprising independent panel 15 external expert relevant stakeholder six region – explore scope new guideline thematic area covering screening management noncommunicable disease (NCDs) pregnancy, childbirth, postnatal periods. inform discussions, Steering Group developed two evidence syntheses. described existing definition concept related NCDs pregnancy ( 33) mapped (then) current guideline recommendation related maternal health NCDs ( 34). “universe” thematic areas/ condi",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "10d00dc9-c00f-42af-96d7-207cf02785f0",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "recommendation related maternal health NCDs ( 34). “universe” thematic areas/ condition considered inclusion guideline development based upon review indirect maternal conditions. considering breadth depth potential thematic areas, scoping group requested assess general prevalence conditions, interaction condition pregnancy, potential intervention maternal health contacts. following topic area considered highest priorities: • cardiovascular condition • diabetes • respiratory conditions• haemoglobinopathy • mental health disorder substance use. management SCD first topic addressed. 1.3 Target audience maternal perinatal health guideline relevant providing care support pregnancy, labour, childbirth postpartum periods, health-care setting. primary audience gu",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cdf88751-8533-453c-897a-afa0781845f0",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ur, childbirth postpartum periods, health-care setting. primary audience guideline includes health-care provider responsible developing national local health policy related care pregnancy, childbirth postnatal period, recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period directly providing care woman around time birth, including midwives, nurses, general medical practitioners, obstetricians, manager maternal child health programmes, settings. 4 Personal communication, Lisa Rogers, Technical Officer, Department Nutrition Food Safety.The guideline also interest professional society involved care pregnant women, nongovernmental organization concerned promotion woman-centered maternal care, implementers maternal child health programmes. 1.4 Scope recommendat",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1d999fe3-0d1b-45a7-9fc3-fbcacf88c8a8",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ternal care, implementers maternal child health programmes. 1.4 Scope recommendation recommendation focus management SCD pregnancy, childbirth postnatal period. priority question guided evidence synthesis decision making recommendation presented using Population (P), Intervention (I), Comparison (C), Outcome (O) (PICO) format. priority outcome used decision making listed Annex 2 . Priority question 1. pregnant woman SCD, medication management affect outcome compared usual care? 2. pregnant woman SCD, pain-management plan affect outcome compared usual care? 3. pregnant woman hospitalized SCD, fluid-management plan affect outcome compared usual care? 4. hospitalized pregnant woman SCD, thromboprophylaxis affect outcome compared usual care? 5. pregnant woman SCD, additional fetal monitoring affect outcom",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d48193bf-00c8-42a6-bfba-75022db89a02",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ompared usual care? 5. pregnant woman SCD, additional fetal monitoring affect outcome compared usual care? 6. pregnant woman SCD, indicated delivery early term (37–38 weeks) affect outcome compared indicated delivery early term? 7. pregnant woman SCD, benefit harm caesarean section compared vaginal birth (including vaginal birth caesarean section)? 8. woman SCD postnatal period, interpregnancy management intervention affect outcome compared usual care? comprehensive framework action accelerating anaemia reduction identified improved screening management inherited red blood cell disorder key outcome addressed ( 35). part action, set comprehensive recommendation diagnosis, prevention management anaemia pregnant postnatal woman development. include question related screening",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "56973756-0cfe-4b91-8402-98dffcafdaf2",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "nant postnatal woman development. include question related screening diagnosis haemoglobinopathies.4 1.5 Persons affected recommendation population affected recommendation woman SCD receive pregnancy care give birth low-, middle- high-resource settings. Executive Summary 3 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 4The guideline developed using process described handbook guideline development (9). summary, process included: (i) identification priority question outcomes; (ii) retrieval evidence; (iii) assessment synthesis evidence; (iv) formulation recommendations; (v) planning dissemination, implementation, impact evaluation updating recommendations. Six main group participated process — specific role described below. 2.1 C",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4e6f7b78-e583-42b9-8d4f-64e3941a8d2b",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ons. Six main group participated process — specific role described below. 2.1 Contributors guideline 2.1.1 Steering Group Steering Group, comprising staff member Department Sexual Reproductive Health Research Department Maternal, Newborn, Child Adolescent Health managed process. Steering Group drafted key research question PICO format, identified systematic review team guideline methodologists, well member Guideline Development Group External Review Group. addition, Steering Group supervised retrieval synthesis evidence, organized GDG meetings, finalized guideline document, managed dissemination, implementation impact assessment. member Steering Group listed Annex 1 . 2.1.2 Guideline Development Group development guideline, 15 external expert relevant stakeholder",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "49cbd358-702e-4c3e-9db4-868158d197dc",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ent Group development guideline, 15 external expert relevant stakeholder invited participate member GDG. individual drawn pool approximately 50 expert relevant stakeholder constitute Maternal Perinatal Health GDG selected diverse group expertise research, guideline development methods, clinical policy programme relating improving quality care outcome woman SCD, well representative affected population. GDG member selected way that, far possible, represented geographic gender balance also ensured important conflict interest. member area high SCD prevalence sought, Steering Group unable engage member geographic area (notably South-East Asian region). GDG comprised 60% woman 40% men. 2 MethodsBased document prep",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2a78c05d-e277-4958-ba4e-328bfae8b4f6",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "h-East Asian region). GDG comprised 60% woman 40% men. 2 MethodsBased document prepared Steering Group, GDG appraised interpreted evidence, formulated final recommendation meeting convened 30–31 May 2023, 12 – 13 December 2023, 8 – 9 October 2024 26–27 November 2024. group also reviewed approved final guideline document. member group listed Annex 1 . 2.1.3 Evidence Synthesis Group convened Evidence Synthesis Group (ESG) composed guideline methodologists systematic review team conduct updating systematic reviews, appraisal evidence, development EtD frameworks. Two technical consultants, Jen Ramson Myfanwy WIlliams served guideline methodologists. oversaw appraisal evidence using GRADE methodology ( 36). inform guideline, systematic review qualitative evidence SCD maternity care conducted ( 18).",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f52a1c27-7d7d-4c04-ba8a-2634b694ffe6",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ne, systematic review qualitative evidence SCD maternity care conducted ( 18). led expert University Central Lancashire extensive experience qualitative evidence reviews. addition, ESG initiated new systematic review economic evaluation screening management SCD pregnancy ( 37). guideline methodologists worked closely ESG review evidence prepare GRADE EtD frameworks. Members ESG attended GDG meeting provide overview synthesised evidence, respond technical query GDG. member ESG listed Annex 1 . 2.1.4 External partner observer Representatives International Federation Gynecology Obstetrics (FIGO), International Pediatric Association (IPA), NCD Alliance, United Nations Children’s Fund (UNICEF) United States Agency International Development (USAID)5 participated GDG",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "753e0620-aa59-479a-96a2-fdfa9bf12cd0",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "CEF) United States Agency International Development (USAID)5 participated GDG meeting observers. organization collaborate Departments guideline dissemination implementation, identified significant implementers guideline. list observer participated GDG meeting included Annex 1. 2.1.5 External Review Group external review group comprised four technical expert interest expertise provision evidence-based care improve quality care outcome woman SCD. member important conflict interest. Group comprised 75% woman 25% men. expert reviewed final document identify factual error commented clarity language, contextual issue implication implementation. ensured decision-making process considered incorporated contextual value preference person affected th",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c537d0bb-c725-46cd-9ac1-14586cf12104",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "s considered incorporated contextual value preference person affected recommendations, health-care provider policy-makers. within remit group change recommendation formulated GDG. Members External Review Group listed Annex 1 . 5 USAID participated observer discussion prior January 2025. Methods 562.2 Evidence identification retrieval Evidence support development guideline recommendation derived several source systematic review team working collaboration Steering Group. 2.2.1 Evidence effectiveness inform development recommendations, commissioned set eight de novo systematic review management SCD pregnancy, childbirth interpregnancy period. External group systematic reviewer asked prepare review protocol clear PICO question criterion",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "86aa936a-0ef6-438e-9adf-3ffd71d59160",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ystematic reviewer asked prepare review protocol clear PICO question criterion identification studies, including search strategy different bibliographic databases, method assessing risk bias data analysis plan ( 38, 39, 40, 41, 42, 43, 44, 45). Steering Group guideline methodologists reviewed endorsed protocol systematic review conducted. search strategy employed identify study specific criterion inclusion exclusion study described individual systematic reviews. Studies low-, middle- high-income country considered language restrictions. entire systematic review development process iterative, systematic reviewer guideline methodologists constantly communicating Steering Group discus challenge agree solutions. paucity evidence across systematic rev",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "20093f25-9567-4086-94ea-871bc99137c6",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "discus challenge agree solutions. paucity evidence across systematic reviews, one eight review finding randomized controlled trial (RCT) non-randomized evidence, two review finding one non- randomized study intervention each. remaining five review found study eligible inclusion. 2.2.2 Evidence values, resource use cost–effectiveness, equity human rights, acceptability feasibility Values, equity human rights, acceptability feasibility qualitative evidence synthesis (QES) explored view experience woman SCD antenatal, intrapartum postnatal phase maternity care health-care provider caring woman ( 18). review primary source evidence values, equity human rights, acceptability, feasibility. Resource use cost–effectiveness evidence synthesis team initiated new systematic review economic evalu",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "43f7eb38-fe96-4092-9a3b-ba05d6846260",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "cost–effectiveness evidence synthesis team initiated new systematic review economic evaluation screening, management treatment woman SCD ( 37). review aimed to: • synthesize available evidence economic evaluation intervention screen/diagnose, treat and/or manage SCD pregnancy • assess methodological quality economic evaluation study • identify gap evidence economic evaluation intervention manage SCD pregnancy. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 2.3 Quality assessment grading evidence 2.3.1 Quality assessment primary study included review systematic review effectiveness evidence, eligible RCTs identified, two reviewer independently assessed risk bias using revised Cochrane risk-of-bias tool (RoB 2.0). non- randomized studies, Risk Bias",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2e734dd0-5f09-4ed9-8b2e-aa37fb3f97f5",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ing revised Cochrane risk-of-bias tool (RoB 2.0). non- randomized studies, Risk Bias Non-randomized Studies Interventions (ROBINS-I) tool used. disagreement resolved discussion involving third assessor. included RCT outcome, domain bias explored were: randomization process; identification recruitment individual participant within clusters; deviation intended interventions; missing outcome data; measurement outcome; selection reported result; overall bias. non-randomized studies, domain bias explored were: confounding; selection participant study; classification interventions; deviation intended interventions; missing data; measurement outcomes; selection reported result; overall bias. quality study included QES appraised using GRADE-CERQual tool ( 46) outlined below. cost–effectiveness systematic review used th",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d7ece831-4880-4731-95cb-9d8603eff31d",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ng GRADE-CERQual tool ( 46) outlined below. cost–effectiveness systematic review used extended Consensus Health Economics Criteria list ( 47) assessing quality studies. 2.3.2 Assessment certainty effectiveness evidence effectiveness evidence, certainty evidence given outcome rated using standard GRADE approach based consideration study design limitation (risk bias), inconsistency (heterogeneity variability results), indirectness (differences study populations), imprecision (small study population events) publication bias ( 9). possible, summary finding table prepared using GRADEpro software ( 48). included effect estimate (expressed relative absolute risk), explanation certainty assessments, overall certainty rating outcome. GRADE certainty evidence certainty evidence outcome rated ‘high’, ‘mo",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "38a7761a-c164-43d2-8441-d666871bcdb9",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "GRADE certainty evidence certainty evidence outcome rated ‘high’, ‘moderate’, ‘low’ ‘very low’ defined GRADE methodology: • High certainty: confident true effect lie close estimate effect; • Moderate certainty : moderately confident effect estimate. true effect likely close estimate effect, possibility substantially different; • Low certainty: confidence effect estimate limited. true effect may substantially different estimate effect; • low certainty: little confidence effect estimate. true effect likely substantially different estimate effect. Methods 7 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 8Note assessment certainty evidence possib",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7bfc4a3f-4586-4421-920c-2d7a60ce0087",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "interpregnancy period 8Note assessment certainty evidence possible two comparison RCT evidence identified one non-randomized evidence analysed. 2.3.3 Assessment certainty (confidence in) qualitative evidence finding qualitative study included QES appraised using GRADE-CERQual tool (46). GRADE-CERQual tool, us similar conceptual approach GRADE tools, provides transparent method assessing assigning level confidence placed evidence review qualitative research. systematic review team used GRADE-CERQual tool assign level confidence review finding according four components: methodological limitation individual studies; adequacy data; coherence; relevance review question individual study contributing review finding. confidence evidence rev",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "73f04c31-0dad-461c-bd30-0fd08bd95f56",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "f individual study contributing review finding. confidence evidence review finding rated ‘high’, ‘moderate’, ‘low’ ‘very low’ (46): • High confidence: highly likely review finding reasonable representation phenomenon interest; • Moderate confidence : likely review finding reasonable representation phenomenon interest; • Low confidence : possible review finding reasonable representation phenomenon interest; • low confidence : clear whether review finding reasonable representation phenomenon interest. 2.4 Formulation recommendation Steering Group supervised preparation finalization summary finding table narrative evidence summary collaboration guideline methodologists using GRADE EtD framework ( 49). EtD framework includes explicit systematic consideration",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5ad732be-0a75-4188-b039-a90be69002c5",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "GRADE EtD framework ( 49). EtD framework includes explicit systematic consideration evidence intervention term specified domains: effectiveness, values, resources, equity human rights, acceptability feasibility. Using EtD framework template, Steering Group guideline methodologists created summary document priority question covering evidence domain. priority question, judgement made impact intervention domain, order inform guide decision-making process. Steering Group provided EtD framework discussion, including evidence summary summary finding tables, GDG member one week GDG meetings. GDG member asked review electronically provide comment document GDG meeting. online meeting GDG (30–31 May 2023, 12–13 December 2023, 8–9 October 2024 26–27 November 2024), und",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f15662ec-00a7-4637-88d1-377ab839e843",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ng GDG (30–31 May 2023, 12–13 December 2023, 8–9 October 2024 26–27 November 2024), leadership GDG chairperson, GDG member collectively reviewed discussed frameworks. purpose meeting formulate reach consensus recommendations, based explicit consideration range evidence presented EtD framework judgement GDG members. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period formulating recommendations, GDG used GRADE EtD framework considered separately synthesized evidence effectiveness intervention, value stakeholders, resource use cost–effectiveness intervention, acceptability feasibility intervention, impact intervention equity human rights. domains, certainty evidence evaluated using method approp",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "be5f2dc0-0150-408e-8ec6-073083f2c037",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": ". domains, certainty evidence evaluated using method appropriate available supporting evidence synthesis (such GRADE GRADE CerQual) GDG made judgement effect intervention across domains. Across eight EtD framework reviewed GDG, lack direct evidence effectiveness three intervention (prophylactic transfusion, iron supplementation, caesarean section). available direct evidence assessed low low certainty. frameworks, GDG considered probably important uncertainty variability much woman SCD (and families) value main outcome associated interventions, impact intervention equity varies. direct evidence cost–effectiveness, acceptability feasibility reviewed intervention across frameworks. absence direct ev",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b352d118-a68c-42b9-af96-0958b2aa7d02",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ity feasibility reviewed intervention across frameworks. absence direct evidence interventions, GDG drew available evidence physiological change pregnancy, management SCD general SCD population, safety effectiveness intervention general pregnant population, relevant existing guidance formulate recommendations. GDG comment strength recommendation based indirect evidence deliberation GDG. 2.5 Management declaration interest robust process protect integrity normative work, well protect integrity individual expert collaborates. requires expert serving advisory role disclose circumstance could give rise actual ostensible conflict interest. disclosure appropriate management relevant financial non-financial",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2b82e87f-10d8-414c-85b1-5d45cbaaaeb3",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "interest. disclosure appropriate management relevant financial non-financial conflict interest GDG member external expert contributor critical part guideline development WHO. According regulations, expert must declare interest prior participation guideline development process meeting according guideline declaration interest expert ( 9). GDG member therefore required complete standard declaration interest form engaging guideline development process participating guideline-related processes. short biography GDG member also published WHO’s sexual reproductive health website two week public review comment prior GDG meetings. Steering Group reviewed declaration finalizing experts’ invitation participate. conflict interest declared,",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3c46da96-a8d1-4d3d-ba1d-711ae1bdbe50",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "finalizing experts’ invitation participate. conflict interest declared, Steering Group determined whether conflict serious enough affect expert’s objective judgement guideline recommendation development process. ensure consistency, Steering Group applied criterion assessing severity conflict interest outlined handbook guideline development (9) participating experts. finding declaration interest managed accordance procedure ensure work contribution expert is, actually ostensibly, objective Methods 9 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 10independent. conflict interest considered significant enough pose risk guideline development process reduce credibility, expert",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "465a2b22-22c7-4064-a190-d5eafe022db9",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ough pose risk guideline development process reduce credibility, expert required openly declare conflict interest beginning GDG meeting action taken. Annex 3 show summary declaration interest statement conflict interest declared invited expert managed Steering Group. 2.6 Decision making GDG meeting GDG meeting designed allow participant discus supporting evidence reach consensus final wording recommendation. Consensus defined agreement three quarter GDG, provided disagreed feel strongly position. GDG member expressed opposition recommendations. 2.7 Document preparation peer review Steering Group made draft version EtD framework available participant one week meeting comm",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "53acde59-6510-49b7-8fff-643424ad4184",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "rsion EtD framework available participant one week meeting comments. meeting, framework modified line participants’ deliberation remarks. Following meeting, Steering Group worked guideline methodologists prepare full guideline document accurately reflect deliberation decision participants. draft document sent electronically GDG member final review approval. final document also sent peer review four external independent expert involved development guideline. Steering Group evaluated advice peer reviewer inclusion document. meeting external peer reviews, modification made Steering Group document consisted correction factual error edits address lack clarity. recommendations: Management sick",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dcab7c06-3716-4def-9389-07df17a69d07",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "factual error edits address lack clarity. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period GDG issued 21 recommendation – eight medication management, four pain management, two fluid management woman hospitalized SCD, one thromboprophylaxis pregnant woman hospitalized SCD, two fetal monitoring, one timing mode birth, two interpregnancy management. section outline recommendation corresponding priority questions. comment made strength recommendation as, absence direct empirical evidence, recommendation based indirect evidence deliberation GDG. ensure recommendation correctly understood appropriately implemented practice, additional ‘remarks’ reflecting summary discussion GDG included. recommendation",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0b9b39f1-81f6-4cbb-bec2-df44c257262a",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "s’ reflecting summary discussion GDG included. recommendation applied conjunction implementation considerations. EtD framework – presenting available effectiveness evidence, balance desirable undesirable effects, value stakeholders, resource requirements, cost–effectiveness, acceptability, feasibility equity, human right considered formulating recommendation – presented separately Web Annex document. 3.1 Recommendations 3.1.1 Medication management woman SCD presenting antenatal care Various medication used management SCD non-pregnant population. Optimal management improve health well-being people affected SCD includes preventive care measures, symptom control, management disease complications. strategy may need altered pregnancy physiological change pregnancy affe",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2060854e-dd78-409c-8dca-9eb0d3f89a80",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ns. strategy may need altered pregnancy physiological change pregnancy affect symptomology natural history end-organ complications. effect treatment fetus also primary consideration. following advice GDG care beyond routine care pregnancy. 3 Recommendations supporting evidence 11 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 12Vitamins mineral Folic Acid Recommendations — folic acid supplementation 1a. Advise pregnant woman SCD living outside malaria endemic area continue daily supplementation 5 mg folic acid initiate supplementation dose soon possible. 1b. Advise pregnant woman SCD taking intermittent preventive treatment sulfadoxine-pyrimethamine 400 µg folic acid supplementation daily appropriate, higher dos may counteract efficacy antima",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cf38d2f5-8d0b-46e9-94db-c217731aa41d",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "cid supplementation daily appropriate, higher dos may counteract efficacy antimalarial. Rationale • absence direct empirical evidence folic acid supplementation pregnant woman SCD, GDG developed recommendation based available physiological evidence folic acid supplementation general population SCD general pregnant population, existing guidance folic acid supplementation pregnant woman SCD taking intermittent preventive treatment sulfadoxine-pyrimethamine. Remarks Folic acid supplementation general population SCD • Chronic haemolytic anaemia increased red blood cell production turnover SCD thought increase requirement folate, water-soluble family compound essential red blood cell production ( 50, 51). is, however, limited evidence folic acid supplementation improves haematological clinical outcome indi",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "20913156-6f87-47a5-85cb-f340a0582ccb",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "mited evidence folic acid supplementation improves haematological clinical outcome individual SCD ( 50). • Outside pregnancy, individual SCD commonly take 1 mg folic acid daily ( 50). Guidance African region supplementation folic acid 5 mg day 10 20 day month used general SCD population prevent worsening anaemia ( 23). are, however, concern regarding high folate concentration population SCD country national programme refined-grain folic acid fortification (see section Folic acid fortification below) ( 52). Folic acid pregnancy • Low folic acid level pregnancy associated anaemia fetal neural tube defect ( 53). • general pregnant population, recommends daily folic acid supplementation 400 µg weekly supplement 2.8 mg ( 14). Higher-dose folic acid supplementation • Folic acid generally considered safe,",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f6c293af-e54b-4159-a4c0-e0288628d24f",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "mg ( 14). Higher-dose folic acid supplementation • Folic acid generally considered safe, internationally recognized tolerable upper intake level 1 mg/day lowest observed adverse effect level (LOAEL) 5 mg/day ( 54, 55). LOAEL set United States Institute Medicine 5 mg/day based case study small observational study demonstrating folate dos >5 mg/day supplemental fortified food shown exacerbate precipitate neuropathy vitamin B12-deficient individual ( 54). Although long- term follow-up study offspring exposed higher dos folate, evidence direct toxicity even folate dos 15–100 mg/day ( 56, 57, 58). recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period • 2015 systematic review found high-quality evidence periconception folic acid supplementation prevents neural tube defect comp",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "da2f9978-c9a7-4662-af08-b442b1782780",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "h-quality evidence periconception folic acid supplementation prevents neural tube defect compared supplementation (relative risk [RR] 0.31, 95% confidence interval [CI] 0.17 0.58) additional protection provided higher dos folate general pregnant population ( 59). However, Medical Research Council Vitamin Study, large randomized controlled trial conducted seven mostly high-income country (n=1195), demonstrated high-dose folic acid (4 mg/day) resulted 72% relative risk reduction (95% CI 88% 29%) neural tube defect woman previously affected pregnancy ( 60). 4 mg dose selected already available tablet based prior dose-finding studies. author suggested 4 mg dose folate responsible driving reduction neural tube defect ( 60, 61). • Although study suggested link periconceptual high-dose folic acid suppleme",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "33251916-b917-4ada-acbb-346babeb9d73",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "• Although study suggested link periconceptual high-dose folic acid supplementation longer-term outcomes, including asthma offspring ( 62, 63) maternal malignancy, causality established consensus high-dose folic acid (e.g. 5 mg daily) generally safe ( 64). • GDG acknowledged guideline recommended folic acid supplementation higher dos (5 mg daily) prior to, during, early pregnancy woman likely low folate levels, woman diabetes ( 65), woman taking medication epilepsy ( 66), woman obesity ( 67). Availability folic acid supplement • Folic acid supplement dos 5 mg readily available, separate supplement within prenatal vitamin formulations. Folic acid fortification • substantial heterogeneity folic acid fortification policy globally ( 68). Among 193 country examined 31 July 2023, 69 implemented",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "58f362a1-0ef6-49bf-9c68-656466bc8c19",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "tification policy globally ( 68). Among 193 country examined 31 July 2023, 69 implemented mandatory folic acid fortification, 47 voluntary fortification, 77 fortification (accounting 32%, 53% 15% global population, respectively) ( 68). area high burden SCD, fortification mandatory western, eastern southern sub-Saharan Africa Middle-East; voluntary India, Saudi Arabia Sudan; fortification northern central sub-Saharan Africa ( 68). Australian study suggests introduction folic acid food fortification increased maternal folate 63% reduced effect supplementary folic acid (69). Folic acid supplementation malaria • Women SCD living malaria-endemic region remain risk malaria infection. Guidelines malaria recommend antimalarial medicine predetermined interval reduce disease burden pregnancy, adverse",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "953252dc-479b-470e-a4fc-558171e94f5d",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ntimalarial medicine predetermined interval reduce disease burden pregnancy, adverse pregnancy birth outcome ( 70). currently available regimen intermittent prophylaxis sulfadoxine-pyrimethamine (IpTp-SP). • GDG acknowledged evidence underlying recommendation IpTp-SP specify subpopulation pregnant woman SCD living endemic area ( 71). However, GDG also acknowledged availability direct moderate-certainty evidence suggesting reduction malaria infection delivery (and risk malaria-induced anaemia) potential reduction low birthweight infant high-burden area ( low certainty ). Therefore, absence direct evidence regarding use folic acid supplementation pregnant woman SCD, GDG considered Recommendations supporting evidence 13 recommendations: Management sickle-cell disease pregnancy, childbirth inte",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c6722d6f-930f-4aed-ad9a-a8fee4159ca8",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "13 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 14evidence dos folic acid 5 mg daily counteract efficacy IpTp-SP antimalarial (72) thus reaffirms existing recommendation low-dose formulation folic acid (i.e. 400 µg daily) co-administered sulfadoxine-pyrimethamine ( 70). research • GDG noted lack evidence folic acid supplementation dose among woman SCD living malaria-endemic areas. Iron Recommendation — iron supplementation 1c. Advise pregnant woman SCD iron supplementation needed unless evidence iron deficiency. 1d. pregnant woman SCD iron deficient, advise iron supplementation general pregnant population. Rationale • light limited direct empirical evidence available iron supplementation pregnant woman SCD, GDG developed reco",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "96510420-7bfb-4ea4-b0cb-a03711e63d06",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "evidence available iron supplementation pregnant woman SCD, GDG developed recommendation based available physiological evidence iron homeostasis, iron requirement general population SCD, iron requirement pregnancy. Remarks Iron homeostasis • Iron level body balanced absorption dietary iron, iron recycling, utilization loss. human unable excrete iron, iron homeostasis must maintained regulating amount iron absorbed diet absorptive intestinal cell (enterocytes) amount iron may utilized stored extraintestinal tissue ( 73). Iron requirement general population SCD • People SCD often receive blood transfusions, either treatment prophylaxis. Repeated blood transfusion associated risk iron overload, transfusion much efficient form iron uptake dietary absorption. addi",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5f2d17d7-4d0e-4cc7-a3cc-2c202f6a4a8c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "oad, transfusion much efficient form iron uptake dietary absorption. addition, chronic haemolysis SCD increase serum iron, also contributes iron overload ( 74). Iron overload serious consequence including organ damage, particularly liver heart ( 75). Therefore, iron supplementation consideration management SCD, unless iron-deficiency anaemia identified. Increased iron requirement pregnancy • pregnancy increased need iron due need fetus placenta, expansion maternal red blood cell mass ( 76). duodenum increase iron absorption pregnancy increased dietary intake typically also needed ( 76). Pregnant woman frequently suffer iron- deficiency anaemia result ( 76). recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period • Iron-deficiency anaemia pregnancy associ",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0973453b-ce3c-46b0-92ea-530747bb4132",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "pregnancy, childbirth interpregnancy period • Iron-deficiency anaemia pregnancy associated increased rate adverse maternal outcome (e.g. pre-eclampsia, placenta previa, caesarean delivery, longer hospitalization, increased antenatal admission, increased requirement red blood cell transfusion) adverse neonatal outcome (e.g. preterm birth, small gestational age, low 5-min Apgar score, neonatal perinatal death) ( 77, 78). • woman general pregnant population, recommends daily supplementation 30 60 mg elemental iron or, context daily iron acceptable woman due side-effects area prevalence anaemia low (e.g. <20%), weekly supplement 120 mg elemental iron ( 14, 35). Iron supplementation pregnancy woman SCD • systematic review conducted inform guideline found effect iron supplementation compared placebo risk sick",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fcd0bd6d-d248-4f95-b019-b022b54bf1f7",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "guideline found effect iron supplementation compared placebo risk sickle-cell crisis, maternal postnatal haemoglobin birthweight uncertain (one trial; 14 women; low certainty ) (45). priority maternal newborn outcome reported. • GDG noted that, due potential iron overload woman SCD receiving blood transfusions, confirmation iron deficiency (rather cause anaemia) needed anaemia treated iron supplementation. Prenatal vitamin often contain iron may also contribute iron overload woman confirmed iron deficiency. • recommends use ferritin concentration assess iron store healthy individuals. ferritin acute phase protein rise due inflammatory process, use higher threshold (i.e. 70 µg/L) recommended condition infection inflammation diagnose iron deficiency ( 79). Additional",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ec60d0e8-6950-44b6-acc8-94f38bce9465",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "mended condition infection inflammation diagnose iron deficiency ( 79). Additionally, condition ferritin concentration exceeding 500 µg/L may indicate risk iron overload clinical laboratory evaluation recommended. Although recommends ferritin cutoff <15 µg/L diagnosing iron deficiency healthy woman first trimester pregnancy ( 79), guidance threshold defining iron deficiency overload specifically pregnant woman infection inflammation. several change occurring pregnancy may affect plasma serum ferritin concentration assessing iron status, including physiological rise acute phase protein pregnancy expansion plasma volume second trimester ( 80). Vitamin • recommends vitamin supplementation general pregnant population ( 81). evidence extra demand",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5de08c54-3112-47cc-8c7b-a34a62a35366",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "n general pregnant population ( 81). evidence extra demand vitamin among people SCD, GDG considered recommendation topic necessary. Prophylactic blood transfusion Recommendation — prophylactic blood transfusion 1e. pregnant woman SCD history severe intractable crisis (i.e. recurrent painful crisis and/or event unresponsive treatment modalities) lived experience previous benefit prophylactic transfusion outside pregnancy, consider prophylactic blood transfusion. Recommendations supporting evidence 15 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 16Rationale • light limited direct empirical evidence prophylactic blood transfusion pregnant woman SCD, GDG developed recommendation based available evidence role red blood cell transfusion managem",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0b2e69a9-7a2b-4a8a-bc51-12f63076c661",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "mmendation based available evidence role red blood cell transfusion management SCD general SCD population pregnant woman SCD. Remarks Role red blood cell transfusion management SCD • Red blood cell transfusion people SCD may form simple transfusion exchange transfusions, either manual automated ( 82). Simple transfusion consist transfusion red blood cell only. Manual exchange involves manual phlebotomy followed transfusion. Automated exchange involves removal replacement red blood cell using apheresis system ( 83). Red blood cell transfusion person SCD aim increase tissue oxygenation; decrease viscosity diluting relative amount sickle haemoglobin-containing red blood cells; suppress endogenous erythropoiesis ( 82). • Red blood cell transfusion used chronic prophylaxis vaso-occlusive event select patients. Chronic tr",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "843defed-5a07-4102-97a0-5b603a700ff2",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "sion used chronic prophylaxis vaso-occlusive event select patients. Chronic transfusion therapy also shown beneficial prevention stroke (84), recurrent acute chest syndrome ( 85), sickle-cell crisis responsive hydroxycarbamide ( 86), pulmonary hypertension ( 87). Role red blood cell transfusion management SCD pregnancy • pregnancy, when, historically, hydroxycarbamide contraindicated, prophylactic blood transfusion used correct anaemia reduce frequency SCD complication triggered haemoglobin level, relative proportion adult sickle haemoglobin. Guidance African region preventive transfusion programme instituted addition specific obstetrical measure ( 23). Available evidence prophylactic red blood cell transfusion pregnant woman SCD • systematic review conducted inform guideline found that, co",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5c1c9616-b3f2-46e1-a118-0d104e4cae4a",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "pregnant woman SCD • systematic review conducted inform guideline found that, compared usual care (indicated therapeutic transfusion), prophylactic transfusion may reduce risk sickle-cell crisis (RR 0.28, 95% CI 0.12 0.67; one trial, 72 women; low certainty ) (45, 88, 89). effect prophylactic transfusion risk splenic sequestration, acute chest syndrome caesarean section uncertain (one trial; 72 women; low certainty ). priority maternal outcome reported. • systematic review found effect prophylactic transfusion compared usual care (indicated therapeutic transfusion) risk perinatal death, stillbirth/fetal death, neonatal death, preterm birth (<37 weeks), intrauterine growth restriction, Apgar score <7 5 minute uncertain (one trial, 76 fetuses; low certainty ) (45). priority newborn outcome reported. • earlier systematic review nonrando",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "922fa1ff-018e-4626-b4fa-dfcae25a701a",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": ") (45). priority newborn outcome reported. • earlier systematic review nonrandomized study found prophylactic transfusion may positively affect several adverse maternal neonatal outcomes, including maternal mortality, vaso-occlusive pain episodes, pulmonary complications, pulmonary embolism, pyelonephritis, perinatal mortality preterm birth, woman SCD ( 90). noted, however, evidence stem relatively small number study methodological limitation prospective, multicentre, randomized trial needed determine whether potential benefit balance risk prophylactic transfusions. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period • randomized controlled feasibility trial (n=34) serial prophylactic exchange transfusion versus standard care pregnant woman SCD seven hospital United Kingdom Great Britain",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d1450cd0-b4ab-406e-b8aa-5fce306a5ff6",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "standard care pregnant woman SCD seven hospital United Kingdom Great Britain Northern Ireland ( 91) published commissioned systematic review search date. Although several priority outcome reported, conclusive indication effect found. author also call multicentre international trial. Approach transfusion pregnant woman SCD • Decision making red blood cell transfusion need made individual basis, consideration given balance benefit transfusion risk transfusion reactions, hyperhaemolysis, blood-borne infections, iron overload alloimmunization, cost availability. • woman able receive blood transfusion due multiple red cell alloantibody previous severe delayed haemolytic transfusion reactions. • iron-chelation therapy generally used prevent iron overload people chronic simple transfusion, currently use",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "66f7ee34-9d9f-4dff-bf33-d69a5aef3b93",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "generally used prevent iron overload people chronic simple transfusion, currently used chelators recommended pregnancy. Availability safety red blood cell transfusion • many part world, chronic transfusion therapy either available, feasible, available without possibility iron-chelation therapy prevent inevitable potentially fatal consequence iron overload ( 82). settings, advice non-pregnant adult consider replacing transfusion therapy with, transitioning initial transfusion therapy to, hydroxycarbamide maximal tolerable dos ( 82). • consistent supply blood relies regular donation effective health-care infrastructure ( 92). Donation rate differ around world HICs see seven time donation LICs, lack timely, safe transfusion lead otherwise avoidable death ( 92). 2010, passed resolut",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3dafa49c-bbc6-4bf1-a776-ce0fa8c1b486",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "timely, safe transfusion lead otherwise avoidable death ( 92). 2010, passed resolution blood product urge Member States take necessary step establish, implement support nationally coordinated, efficiently managed sustainable blood plasma programme according availability resources, aim achieving self-sufficiency, unless special circumstance preclude ( 93). • Blood product used pregnancy need screened cytomegalovirus addition routine blood-borne pathogens, recommended safe blood transfusion guideline ( 94). research • Questions remain effectiveness prophylactic transfusion pregnant woman SCD, well best timing, frequency thresholds, also regarding comparison simple, manual exchange automatic exchange transfusions. Recommendations supporting evidence 17 recommendations: Management sickle-cell dis",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "58d1c41b-2eb2-4980-8bb8-1710959b5bef",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ons. Recommendations supporting evidence 17 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 18Disease-modifying agent Recommendation — hydroxycarbamide (hydroxyurea) 1f. pregnant woman SCD previously controlled hydroxycarbamide (hydroxyurea), consider continuation recommencement (after first trimester) medication context shared decision making involving woman multidisciplinary team includes expert SCD pregnancy. Base risk–benefit analysis woman’s symptom severity, stage pregnancy view preferences. Rationale • absence direct empirical evidence effectiveness safety hydroxycarbamide pregnant woman SCD, GDG based recommendation available evidence non- randomized studies, available evidence effectiveness hydroxycarbamide general population SCD, saf",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cd11c20d-b8fb-44a7-bf55-c549b070b44f",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "lable evidence effectiveness hydroxycarbamide general population SCD, safety pregnancy, best interest woman baby. Remarks Hydroxycarbamide general population SCD • Hydroxycarbamide most-studied disease-modifying medication SCD. shown increase synthesis fetal haemoglobin, inhibits sickling interfering formation rigid, rod-like polymer deoxygenated haemoglobin molecule ( 95). evidence reduces frequency pain vaso-occlusive crisis ( 96). Safety hydroxycarbamide pregnancy • first-line treatment general SCD population, hydroxycarbamide historically contraindicated pregnancy due teratogenic effect animal (rat rhesus monkey) study ( 97, 98). noted, however, dos used study 10- 100-fold higher therapeutic dos ( 99). • Recent non-random",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c8e40054-5364-48b8-90fd-27a30fd587f0",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "used study 10- 100-fold higher therapeutic dos ( 99). • Recent non-randomized study identified systematic review commissioned inform guideline suggest odds teratogenicity may increased ( 100, 101). author one study, however, reported link miscarriage, stillbirth low birthweight controlling potential confounders ( 100). GDG noted study high risk bias, many pregnancy outcome self-reported without medical-record confirmation. retrospective study safety hydroxycarbamide second trimester pregnancy currently ongoing ( 102). • Guidance African region hydroxycarbamide treatment suspended pregnancy, however timing treatment suspension specified ( 23). noted above, study suggesting teratogenicity animal study ( 97, 98), used higher dos considered therapeutic huma",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0803c028-84ba-47aa-80a3-542a8548a8dd",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "genicity animal study ( 97, 98), used higher dos considered therapeutic human ( 99), teratogenic effect rat rhesus monkey proof teratogenicity human ( 103). Approaches use hydroxycarbamide pregnancy • Fetal organ formed end first trimester, thus theoretical teratogenic potential highest period. However, potential risk miscarriage stillbirth well low birth weight remain throughout pregnancy. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period • Given hydroxycarbamide best studied often feasible disease-modifying agent SCD, GDG considered unethical make blanket recommendation withholding medication duration pregnancy. context limited data, benefit hydroxycarbamide symptom control need weighed potential fetal risk",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2d0880b7-1bbe-4a30-bf34-03cce03e2207",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "nefits hydroxycarbamide symptom control need weighed potential fetal risks. • context shared decision making, pregnant woman SCD controlled condition hydroxycarbamide outside pregnancy candidate transfusion may benefit counselling current state knowledge regarding use pregnancy, including known unknown, assist making informed decision use. research • above-mentioned retrospective study outcome pregnancy exposed hydroxycarbamide expected published soon, research needed effect hydroxycarbamide disease-modifying agent pregnancy maternal fetal/neonatal outcomes. • Qualitative study relating women’s informed consent experience hydroxycarbamide also needed. Thromboprophylaxis pregnant woman SCD (not hospitalized) Recommendation — thro",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6d23eca3-8ef1-47ad-91d6-588b8c5d32c9",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "also needed. Thromboprophylaxis pregnant woman SCD (not hospitalized) Recommendation — thromboprophylaxis 1g. pregnant woman SCD (not hospitalized), consider additional risk factor thromboembolism (e.g. prior VTE following vaso-occlusive events) follow local recommendation initiation thromboprophylaxis pregnant woman elevated risk thrombotic event (e.g. prior VTE, obesity, inherited thrombophilia). Rationale • absence direct empirical evidence thromboprophylaxis pregnant woman SCD, GDG based recommendation available physiological evidence risk thromboembolism general population SCD pregnant women. Remarks Risk thromboembolism general population SCD • SCD hypercoagulable state involving alteration platelet function, activation coagulation cascade, impaired fibrinolysis, venous stasis vaso-occlusion. Consequently, thrombotic event",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "06ba9245-a4f8-42a2-945b-8a877ca0a14e",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ascade, impaired fibrinolysis, venous stasis vaso-occlusion. Consequently, thrombotic event common complication general population SCD. Compared people without SCD, people SCD ~3.5-fold increased risk all-cause thromboembolism ( 104) 50- 100-fold increased risk pulmonary embolism ( 105). Risk thromboembolism pregnancy • Pregnancy also hypercoagulable state. Overall, pregnancy carry four- five-fold higher rate thromboembolism. Thromboembolism still rare event, however, occurring approximately 1/1000 pregnancy (106, 107). Pregnant woman risk thromboembolism throughout pregnancy, including first second trimesters, substantial increase risk third trimester postnatal period ( 108). Thromboembolism responsible 3.2% maternal mortality globally ( 109). Recommendations supporting evidence 19 recommendations: Management sickle-ce",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f4c04c44-7291-41dc-b1ab-42558b7c1136",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "lly ( 109). Recommendations supporting evidence 19 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 20• Pregnant woman SCD increased risk pulmonary thromboembolism (RR 7.74; 95% CI 4.65 12.89) ( 110), all-cause VTE (RR 32.2; 95% CI 9.70 107.00) ( 111). risk even higher woman complicated SCD. prevalence VTE 3.5-fold greater woman complication vaso-occlusive crisis, acute chest syndrome pneumonia compared woman without complication ( 112). • Significant risk factor VTE include previous VTE thrombophilia ( 113, 114). risk factor include obesity ( 107, 115, 116, 117, 118), age 35 year 114,117, 119), immobility long-distance travel (120), admission hospital ( 121), comorbidities — including inflammatory bowel disease ( 122, 123), urinary tract infection ( 122), systemic lupus erythematosus, heart disea",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bce4f345-edbf-4b6b-9f73-929570717d68",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "owel disease ( 122, 123), urinary tract infection ( 122), systemic lupus erythematosus, heart disease ( 114), pregnancy-induced hypertension/pre-eclampsia ( 113, 124). SCD (alone) identified conferring intermediate risk VTE (odds ratio [OR] 6.70; 95% CI 4.40 10.10) ( 107). • Women multiple risk factor may greatly increased risk VTE pregnancy, especially third trimester postnatally ( 125). Considerations thromboprophylaxis use pregnancy • Thromboprophylaxis direct oral anticoagulants, low molecular weight heparin (LMWH), unfractionated heparin, warfarin reduce risk thromboembolism, however antithrombotic benefit need weighed risk postpartum haemorrhage (PPH) may exacerbated anticoagulation. • use direct oral anticoagulant warfarin) generally avoided pregnancy due association adverse pregnancy outcomes, including fetal loss",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7d99d19d-1113-4edf-97d5-33a5214c943a",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "avoided pregnancy due association adverse pregnancy outcomes, including fetal loss fetal anomaly ( 126, 127)6. • Unfractionated heparin (UFH), LMWH danaparoid (a heparinoid) cross placenta safe fetus ( 128, 129, 130, 131, 132, 133, 134, 135, 136). LMWH considered better safety profile UFH ( 137, 138). • LMWHs eliminated primarily renal excretion may accumulate people significant renal dysfunction. non-pregnant population, suggested therapeutic dose LMWH used patient significant renal impairment (e.g. glomerular filtration rate [GFR] less 30 mL/ min), although recognized accumulation people renal impairment may differ various LMWHs ( 139, 140). • LMWH frequently used drug treatment prevention VTE pregnancy, except people heparin-induced thrombocytopaenia (HIT), history H",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "46ad1ed5-4173-4444-9ff0-c80f4b294f22",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "VTE pregnancy, except people heparin-induced thrombocytopaenia (HIT), history HIT, significant renal dysfunction. UFH generally used people significant renal dysfunction ( 140). • LMWHs expensive, especially LMICs, UFH might alternative. • Thromboprophylaxis late pregnancy may preclude use epidural spinal anaesthesia time delivery, discontinuation preventative treatment consideration, line local practice use anticoagulant pregnancy ( 141). 6 Exceptions occur, i.e. woman mechanical replacement cardiac valve require lifelong anticoagulation pregnancy- specific anticoagulation regimen needed, may include use warfarin second third trimester ( 127). recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Infection prophylaxis Recommendation — infection prophylaxis 1h. preg",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3025c591-d621-47ec-8add-6d97ed5ab4d0",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "interpregnancy period Infection prophylaxis Recommendation — infection prophylaxis 1h. pregnant woman SCD, advise routine infection prophylaxis implement frequent screening infection (such urinary tract infection),using low diagnostic threshold bacterial urinary tract infection. Rationale • absence direct empirical evidence infection prophylaxis pregnant woman SCD, GDG based recommendation available evidence risk infection people SCD pregnant women. Remarks Risks infection people SCD • People SCD general functional asplenia risk infection, particular encapsulated bacteria Neisseria meningitides, Streptococcus pneumonia Haemophilus influenzae . Compared people without SCD, individual SCD 36-fold increased odds invasive Streptococcus pneumonia infection 13-fold greater odds invasive Haemophilus influ",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2915dabb-a010-4a17-b5ea-c58b119a253b",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "invasive Streptococcus pneumonia infection 13-fold greater odds invasive Haemophilus influenza infection (142). People SCD also increased risk urinary tract infection ( 143). adult SCD, 14–18% death attributed infectious cause ( 144). Risks infection pregnant woman • People SCD become pregnant vulnerable infection ( 27). • Urinary tract infection one common infection pregnancy, reported prevalence 20% among pregnant woman higher prevalence LICs HICs ( 145). • Pregnant woman SCD increased risk bacterial infection (OR 2.48) ( 77). Infection prophylaxis people SCD • Infection prevention treatment key aspect effective care people SCD. highlight need access local non-pharmacological infection prevention measure clean water, sanitation, hygiene local immunization programmes. Guidance",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9c4ad8a5-e442-4c05-8c72-abf26325d792",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "sures clean water, sanitation, hygiene local immunization programmes. Guidance African Region specific infection prevention measure people SCD include: extended immunization encapsulated organism hepatitis B; antibiotic prophylaxis penicillin; malaria prevention using physical method chemoprophylaxis according local guidelines; systematic deworming child ( 23). Antimicrobial resistance • Prolonged antibiotic use promote development resistance. United Kingdom Great Britain Northern Ireland cohort child SCD, 71% receiving penicillin prophylaxis, nasopharyngeal carriage penicillin-resistant Streptococcus pneumoniae observed 55% isolates (146). Similarly, Ghanaian cohort individual SCD, third Streptococcus pneumoniae isolates resistant penicillin ( 147). Recommendations supporting evidence 21 recommenda",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d8faad1a-7f7b-4597-8542-2574070e6803",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "te resistant penicillin ( 147). Recommendations supporting evidence 21 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 22• Antimicrobial resistance major global public health threat ( 148). important optimize care people SCD, reducing development antimicrobial resistance. AWaRe (access, watch, reserve) antibiotic book (149) provides guidance use “Access” antibiotics, narrow spectrum activity, lower cost, good safety profile generally low resistance potential. Considerations woman SCD • recommends seven-day antibiotic regimen pregnant woman asymptomatic bacteriuria prevent persistent bacteriuria, preterm birth low birthweight ( 14). Antibiotic prophylaxis recommended prevent recurrent urinary tract infection pregnant woman context rigorous research ( 14). • Regardless",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c75de211-72d4-4baf-87e7-8887cd21aa6c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "urinary tract infection pregnant woman context rigorous research ( 14). • Regardless whether pregnant woman SCD prophylactic antibiotics, important health-care provider high degree suspicion infection, screen conduct clinical examination promptly diagnose treat infections, cognizant potential antibiotic resistance. 3.1.2 Pain management pregnant woman SCD Pain medication Recommendation — pain medication 2a. pregnant woman SCD experiencing acute sickle-related pain, offer timely optimal pain relief. 2b. advising use analgesia, option include oral paracetamol, NSAIDs, opioids lowest effective dose shortest period time required manage pain. 2c. advising use analgesia, consider stage pregnancy contraindication specific medications, woman’s views, preference previous experience",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8323dc84-4741-4fac-a741-5509cc086ff5",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ndications specific medications, woman’s views, preference previous experience medication, risk dependence, availability. Rationale • absence direct empirical evidence inform recommendation pain medication pregnant woman SCD, GDG based recommendation evidence safety specific pain medication general pregnant population, general population SCD. Remarks Sickle-related pain • Vaso-occlusion result crisis characterized acute pain, common cause hospitalization SCD ( 150). People typically present severe joint, back, chest extremity pain. Vaso-occlusive crisis may triggered infection, temperature extremes, dehydration, hypoxia, acidosis, may spontaneous. pregnancy, sickle-cell crisis common maternal complication, occurring 55.8% SCD pregnancy ( 151, 152). • [African Region] SICKLE Package Inte",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7389aded-cb14-445a-a843-80d7321d5ad9",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ccurring 55.8% SCD pregnancy ( 151, 152). • [African Region] SICKLE Package Interventions Sickle Cell Disease Management highlight importance managing sickle-related pain within 30 minute presentation care ( 23). Vaso- occlusive episode often inciting event acute chest syndrome, leading cause mortality SCD ( 23). recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Pain medication general pregnant population • Paracetamol: Paracetamol considered safe use throughout pregnancy ( 153). • NSAIDs: use NSAIDs first trimester associated increased risk congenital anomaly ( 154). 30 week gestation, NSAIDs lead premature closure ductus arteriosus neonatal pulmonary hypertension, reduce fetal renal blood flow urine production, leading reduced amniotic fluid volume ( 153). •",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "acdd2c01-99a4-4f41-9fba-35d66da2c690",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "etal renal blood flow urine production, leading reduced amniotic fluid volume ( 153). • Opioids: woman, long-term opioid use pregnancy lead maternal dependence ( 153). neonate, opioid use pregnancy associated low birth weight, preterm birth, stillbirth maternal death. Neonatal withdrawal syndrome also described neonate prolonged exposure utero. limited data safety opioid analgesic first 30 week pregnancy indicate increased risk fetal toxicity ( 153). Opioid use, especially around time delivery, may lead neonatal respiratory depression and/or neonatal withdrawal symptom ( 153). therefore prudent report maternal opioid use pregnancy neonatal care team. Pain medication people SCD • pain mild sickle-cell crisis generally managed paracetamol , NSAID, codeine phosphate, dihydrocodeine tartrate ( 155). Severe",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1911e67a-de6c-4ccd-a3b6-dabef5b4b5df",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "managed paracetamol , NSAID, codeine phosphate, dihydrocodeine tartrate ( 155). Severe crisis may require use morphine diamorphine hydrochloride; concomitant use NSAID may potentiate analgesia allow lower dos opioid used ( 155). Pethidine hydrochloride generally avoided possible accumulation neurotoxic metabolite precipitate seizures; relatively short half-life pethidine hydrochloride necessitates frequent injection ( 155). Considerations people SCD • Guidance African Region pain management includes symptom management prevention, including use disease-modifying agents; individualized tailored treatment; management pain across different level health system; response acute pain crisis includes rapid assessment recent analgesic use, rapid administration therapy, reassessment readministration pain persists ( 23). • NSAIDs",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b201835e-69c4-4d06-bb45-896d9c37e36b",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "administration therapy, reassessment readministration pain persists ( 23). • NSAIDs: NSAIDs may important adjuvant analgesic agent management SCD pain pregnancy. Concomitant use NSAID may potentiate analgesia allow lower dos opioid used ( 155). NSAIDs may used lowest effective dose time period needed medication insufficient control pain ( 153). GDG noted, however, woman SCD may comorbid kidney disease/renal dysfunction. Use NSAIDs individual chronic renal disorder considered contraindicated due risk nephrotoxicity ( 156). • Opioids: GDG noted [African Region] sickle package intervention sickle cell disease management suggests opioids made available centre physicians. Recommendations supporting evidence 23 recommendations: Management sickle-cell disease pregnancy, childbirth th",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "900edeed-4e2a-4565-be34-e7626f28bcc0",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "idence 23 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 24Pain-management plan Recommendation — pain-management plan 2d. Collaborate pregnant woman SCD develop individualized pain-management plan early pregnancy possible, basing plan severity frequency pain crises, woman’s view preferences, including multidisciplinary team approach care. Rationale • absence direct empirical evidence pain-management plan pregnant woman SCD, GDG based recommendation indirect evidence pain-management plan non- pregnant SCD population. Remarks Pain-management plan non-pregnant SCD population • Outside pregnancy, individualized pain-management plan shown reduce length hospital stay, frequency admissions/readmissions time first opioid dose emergency department ( 157, 158 , 159). Aims",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fff4b8ce-14a0-419e-9f97-8bffc39f2947",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "/readmissions time first opioid dose emergency department ( 157, 158 , 159). Aims pain management plan • pain-management plan comprehensive individualized approach goal avoid painful crises, mitigate pain, enhance quality life, address aspect associated pain experience. Pain-management plan may address different aspect treatment sickle-cell pain, including supportive, symptomatic, preventative abortive management ( 160). Individualization component pain-management plan • pain-management plan support self-care strategy (based awareness precipitating factor dehydration, change altitude, extreme temperature, infection physical psychological stress), well providing guidance health-care provider support timely intervention responsive need individual woman taking consideration woman’s knowledge effective pain medication",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0b315021-470c-4d44-a747-6e47e6d12979",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "individual woman taking consideration woman’s knowledge effective pain medication doses, past experience side-effects. • effective, plan need actionable individual woman given living situation available resources, meeting clinical needs. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 3.1.3 Management woman SCD hospitalized pregnancy Fluid management pregnant woman hospitalized SCD Recommendations — fluid management 3a. pregnant woman SCD hospitalized vaso-occlusive crisis requiring intravenous fluid hydration, implement frequent clinical monitoring (such lung auscultation, oxygenation/pulse oximetry, respiratory rate) early identification fluid overload pulmonary oedema. 3b. pregnant woman SCD requiring intravenous fluid hydration context obstetric compli",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3391610b-10d2-49c3-aec3-403bac4b11e6",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "pregnant woman SCD requiring intravenous fluid hydration context obstetric complication pre-eclampsia, implement intensive monitoring sign fluid overload. Rationale • absence direct empirical evidence fluid management woman SCD hospitalized vaso-occlusive crisis, GDG based recommendation available evidence non-pregnant SCD population complicated pregnancy general pregnant population. Remarks Fluid management non-pregnant people SCD • Although helpful overcome dehydration, intravenous (IV) hydration often lead adverse outcome fluid overload, pulmonary oedema, increased length stay, transfer intensive care unit, new oxygen requirement ( 161). Small-scale retrospective study failed conclusively demonstrate benefit well choice IV fluids, rate IV fluid replacement ( 161). • retrospective chart review volume overload",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7d33dbb9-bd48-4fdb-b2ac-d7d1c9f8b192",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ids, rate IV fluid replacement ( 161). • retrospective chart review volume overload SCD found difference incidence volume overload patient treated 0.9% saline versus 0.65% saline ( 162). association volume IV fluid given could assessed. • Another chart review study comparing use normal saline bolus bolus suggested use normal saline bolus associated poorer pain control child SCD vaso-occlusive pain ( 163). • vitro study suggest normal saline may worsen sickling compared hypotonic solution (164, 165). Fluid management pregnancy • Uteroplacental circulation reliant maternal cardiac output, blood pressure metabolic homeostasis function correctly avoid fetal compromise. addition, pregnant woman undergoes number physiological adaptation affect fluid management, including increase circulating volume reduction systemi",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0dae772e-b499-43cc-aa6a-30495322edd5",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "affect fluid management, including increase circulating volume reduction systemic vascular resistance ( 166). • considerable evidence volume overload persistently positive fluid balance associated poorer outcome non-obstetric intensive care unit admission ( 166). • Due factor outlined above, need carefully calibrate readjust rate IV fluid hydration, guided clinical assessment. rate volume fluid administration need balanced risk associated administration IV fluids. Recommendations supporting evidence 25 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 26Choice fluid • limited evidence guide choice fluid general pregnant population. critically ill pregnant patient, isotonic crystalloids represent safe initial choice wide variety maternal condit",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "71115701-4a22-4fc9-843d-56770cde8b09",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "patient, isotonic crystalloids represent safe initial choice wide variety maternal condition ( 166). synthetic colloid starch may associated significant risk ( 166). • choice fluid influenced primarily prescribing clinician’s experience particular fluid, cost local availability. Fluid choice may include isotonic fluid normal saline solution, 5% dextrose water, lactated Ringer’s solution 5% dextrose water. evidence use hypotonic fluid 0.45% saline, 0.25% saline management vaso-occlusive crisis pregnant woman SCD. Areas research • lack RCTs need large multicentre trial assess best route, quantity type fluid replacement people SCD acute painful crisis ( 167). 3.1.4 Thromboprophylaxis pregnant woman hospitalized SCD Recommendation — thromboprophylaxis pregnant woman hospi",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b068d49a-35d3-46f8-b7f1-2956ccb85f5c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "pregnant woman hospitalized SCD Recommendation — thromboprophylaxis pregnant woman hospitalized SCD 4. Offer thromboprophylaxis pregnant woman hospitalized SCD unless contraindication present. Rationale • absence direct empirical evidence thromboprophylaxis pregnant woman hospitalized SCD, GDG based recommendation available physiological evidence risk thromboembolism general population SCD pregnancy. Remarks Risk thromboembolism general population SCD • SCD hypercoagulable state involving alteration platelet function, activation coagulation cascade, impaired fibrinolysis, venous stasis vaso-occlusion. Consequently, thrombotic event common complication. Compared people without SCD, people SCD ~3.5-fold increased risk all-cause thromboembolism ( 104) 50- 100-fold increased risk pulmonary embolism ( 105). Risk",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "10ad64b2-eac8-481e-b210-656f5377dc1f",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "thromboembolism ( 104) 50- 100-fold increased risk pulmonary embolism ( 105). Risk thromboembolism pregnancy • Pregnancy also hypercoagulable state. Overall, pregnancy carry four- five-fold higher rate thromboembolism. Thromboembolism still rare event, however, occurring approximately 1/1000 pregnancy ( 106, 107). Pregnant woman risk thromboembolism throughout pregnancy, including first second trimesters, substantial increase risk third trimester highest risk postnatal period ( 108). Thromboembolism responsible 3.2% maternal mortality globally ( 109). • Pregnant woman SCD increased risk pulmonary thromboembolism (RR 7.74; 95% CI 4.65 12.89) ( 110), all-cause VTE (RR 32.2; 95% CI 9.70 107.00) ( 111). risk even higher woman complicated SCD. prevalence VTE 3.5-fold greater woman complication vaso-occlusive",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e1145e6c-f84f-4025-9c37-96cb5f43e126",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "SCD. prevalence VTE 3.5-fold greater woman complication vaso-occlusive crisis, acute chest syndrome pneumonia compared woman without complication ( 112). recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period • Significant risk factor VTE include previous VTE thrombophilia ( 113, 114). risk factor include obesity 107, 115–118), age 35 year 114,117,119), immobility long-distance travel ( 120), admission hospital ( 121), comorbidities — including inflammatory bowel disease ( 122, 123), urinary tract infection ( 122), systemic lupus erythematosus, heart disease ( 114), pregnancy-induced hypertension/ pre-eclampsia ( 113,124). SCD (alone) identified conferring intermediate risk VTE (OR 6.70; 95% CI 4.40 10.10) ( 107). • Women multiple risk factor may greatly increased risk VTE pregnancy, especially third",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5e448b08-89a8-4893-ad68-18ba1244dc2a",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ltiple risk factor may greatly increased risk VTE pregnancy, especially third trimester postnatally ( 125). • Immobilization hospitalization also risk factor thromboembolism ( 168). Considerations thromboprophylaxis use pregnancy • Thromboprophylaxis direct oral anticoagulants, LMWH, UFH, warfarin reduce risk thromboembolism, however antithrombotic benefit need weighed risk PPH may exacerbated anticoagulation. • Direct oral anticoagulant generally avoided pregnancy due association adverse pregnancy outcome including fetal loss fetal anomaly ( 126)7. • UFH, LMWH danaparoid (a heparinoid) cross placenta safe fetus ( 128–136). LMWH considered better safety profile UFH ( 137, 138). • LMWHs eliminated primarily renal excretion may accumulate people significant renal dysfunction.",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "326b27a9-5634-4e0a-bcdb-d09ec04157bb",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ted primarily renal excretion may accumulate people significant renal dysfunction. non-pregnant population, suggested therapeutic dose LMWH used patient significant renal impairment (e.g. GFR less 30 mL/min), although recognized accumulation people renal impairment may differ various LMWHs (139, 140). • LMWH frequently used drug treatment prevention VTE pregnancy, except people heparin-induced thrombocytopenia (HIT), history HIT, significant renal dysfunction. UFH generally used people significant renal dysfunction ( 140). • LMWHs expensive, especially low- middle-income countries, UFH might alternative. • Thromboprophylaxis late pregnancy may preclude use epidural spinal anaesthesia time delivery, discontinuation preventative treatment consideration line local practi",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d13e5d56-79cd-4ffa-ada4-23a1e46201ee",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ivery, discontinuation preventative treatment consideration line local practice use anticoagulant pregnancy ( 141). Areas research • Research required determine effective thromboprophylaxis schedule woman hospitalized SCD. 7 Exceptions occur, i.e. woman mechanical replacement cardiac valve require lifelong anticoagulation pregnancy- specific anticoagulation regimen needed, may include use warfarin second third trimester ( 127). Recommendations supporting evidence 27 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 283.1.5 Additional fetal monitoring pregnancy Recommendations — additional fetal monitoring pregnancy 5a. pregnant woman SCD without complication (due SCD obstetric causes), offer growth/biometric scan identify fetal growth restriction every",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5780d12a-9ced-48e8-8c77-91411be43b9e",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "obstetric causes), offer growth/biometric scan identify fetal growth restriction every four week 24 32 weeks’ gestation, every three week birth. 5b. pregnant woman SCD complication (due SCD obstetric causes), offer individualized intensive fetal monitoring guide management, taking consideration woman’s view preferences, availability equipment staff skilled use. Rationale • absence direct empirical evidence fetal monitoring woman SCD, GDG considered approach woman-centred, based ethical principle autonomy including importance informed decision making, physiological evidence SCD might affect placenta. pregnant woman SCD without complications, antenatal fetal monitoring may help inform timing childbirth. Remarks Placentation SCD • recent study placentation SCD ( 169),",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "aaf53584-9e89-4b50-8bd2-958a63ea7c58",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "g childbirth. Remarks Placentation SCD • recent study placentation SCD ( 169), 72 placenta woman SCD pregnancy 20 week histopathology available, 50 (69%) placental pathology 29 (40%) maternal vascular malperfusion (MVM). non-SCD healthy pregnancies, MVM found 7–8% placentas. Outside SCD, MVM linked condition associated placental insufficiency, pre-eclampsia. presence MVM associated adverse pregnancy outcome (attributable placental insufficiency), including small gestational age, iatrogenic preterm birth, stillbirth. outcome seen 79% woman MVM, risk adverse outcome low-risk pregnant population MVM reported ~47% ( 170). study author proposed high rate MVM observed may suggest factor inherent SCD, remain yet unidentified, may potentiate",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f29760ab-cf4e-4949-a70d-9360b4c6f815",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "erved may suggest factor inherent SCD, remain yet unidentified, may potentiate placental disease sometimes present unaffected healthy women. Increased risk small-for-gestational age stillbirth woman SCD • Maternal SCD associated increased odds stillbirth (pooled 4.05; 95% CI 2.69 6.32; p<0.001), intrauterine growth restriction (pooled 2.79, 95% CI 1.85 4.21), perinatal mortality (pooled 3.76, 95% CI 2.34 6.06), low birthweight (pooled 2.00, 95% CI 1.42 2.83) ( 7). outcome consistent across low- high-income setting ( 7). pathophysiology behind adverse outcome multifactorial, likely due part placental insufficiency. • Fetal growth restriction (due cause) associated increased risk stillbirth perinatal death. Outcomes often dependent degree growth restriction, highest risk fetus less third percent",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f32ee686-7e1f-4f0d-a88b-eb1d333f4ab9",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "degree growth restriction, highest risk fetus less third percentile doppler ultrasound abnormalities. Identification growth restriction antenatal fetal surveillance help predict prevent stillbirth informing judgement timing birth. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Type monitoring • Depending setting, type fetal monitoring may include ultrasound, fetal phonocardiogram, one-dimensional Doppler, cardiotocography (including non-stress test, contraction stress test, acoustic stimulation), fetal electrocardiogram fetal magnetocardiography, frequency related monitoring method predictive value stillbirth. Timing monitoring • Modelling estimate effect interval examination fetal growth restriction general pregnant population suggests taking measuremen",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "74bdc18f-1d66-4b55-9322-f6c6a2a2789e",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ion fetal growth restriction general pregnant population suggests taking measurement least three week apart may minimize false positive rate ( 171). False positive rate higher first scan performed 36 week (compared first scan 32 weeks) ( 171). Accuracy ultrasound detecting fetal growth restriction • time, several improvement ultrasound technology including high-resolution ultrasonography, linear transducer, radiant flow, three-/four-dimensional ultrasound, artificial intelligence ( 172). accuracy ultrasound estimated fetal weight improved last decade, though lack consistency remains evident ( 173). Key source inaccuracy identified systematic review included difficulty obtaining accurate fetal measurement late gestation. remaining barrier operator dependent, including lack experience insufficient training audit ( 173). Interventions",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5bca7583-d9a5-41b7-88c9-948ca92dee8c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "r dependent, including lack experience insufficient training audit ( 173). Interventions context fetal growth restriction • proven intervention small gestational age fetal-growth restriction birth baby. However, identification fetal-growth restriction trigger assessment fetal wellbeing, including discussion fetal movement cardiotocography. Maternal assessment also offered, including blood pressure proteinuria assessment. Adverse effect associated increased fetal monitoring • advantage fetal monitoring need balanced potential adverse effects. example, certain finding may considered indication induction. note induction labour increase risk iatrogenic complication (i.e. inadvertent prematurity) use resource (i.e. induction agents, health workers, facility preparedness) ( 174). • Though antenatal ultrasound larg",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "63b9f007-dab9-436e-aefa-1e42edf807a7",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "duction agents, health workers, facility preparedness) ( 174). • Though antenatal ultrasound largely seen positive, long-term adverse psychological reproductive consequence reported woman ( 175). Costs • GDG acknowledged need consider cost fetal monitoring women, may increased out-of-pocket costs. • low-income settings, access ultrasound may limited due lack staff resources, well cost incurred woman distance would travel attend appointment ( 175). Recommendations supporting evidence 29 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 303.1.6 Care around birth Timing birth Recommendation — timing birth 6. making decision timing birth (awaiting spontaneous labour planned birth) woman SCD, take individualized approach based anticipated",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc6adbd9-5713-4380-a172-19f169ebc475",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "bour planned birth) woman SCD, take individualized approach based anticipated balance benefit continuing pregnancy allow fetal maturation risk maternal neonatal morbidity associated continuation pregnancy, woman’s view preferences. Rationale • light limited published data stratifies outcome pregnancy woman SCD gestational age, small sample size existing studies, GDG based recommendation physiological understanding SCD pregnancy ethical principle autonomy. Remarks Placentation SCD • recent study placentation SCD ( 169), 72 placenta woman SCD pregnancy 20 week histopathology available, 50 (69%) placental pathology 29 (40%) MVM. non-SCD healthy pregnancies, MVM found 7–8% placentas. Outside SCD, MVM linked condition associated place",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "55c0fb32-adb7-4339-bea9-f61c45536f6d",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "found 7–8% placentas. Outside SCD, MVM linked condition associated placental insufficiency, pre-eclampsia. presence MVM associated adverse pregnancy outcome (attributable placental insufficiency), including small gestational age, iatrogenic preterm birth, stillbirth. outcome seen 79% woman MVM, risk adverse outcome low-risk pregnant population MVM reported ~47% ( 170). study author proposed high rate MVM observed may suggest factor inherent SCD, remain yet unidentified, may potentiate placental disease sometimes present unaffected healthy women. Early birth general pregnant population • recommends induction labour woman known certainty reached 41 week gestation ( moderate certainty ) (174). Routine induction labour, woman uncomplicated pregnancies, less 41 week",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4043158a-bcb2-45c0-8707-a802236e2b52",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "(174). Routine induction labour, woman uncomplicated pregnancies, less 41 week recommended ( low certainty ) (174). Decision making timing birth woman SCD • Decisions timing birth need reflect aspect woman’s pregnancy including pre-existing condition potential maternal neonatal complication pre-eclampsia growth restriction. • Planned early term birth (between 37 38 completed week gestation) may consideration when: –gestational age accurately assessed –the facility sufficiently resourced provide care mother newborn (including management labour birth, potential maternal newborn complications). recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Factors influencing optimal timing birth • GDG acknowledged different clinical context individual situa",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "61d16756-f3f8-4dd4-8b7c-505650ec43c7",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "optimal timing birth • GDG acknowledged different clinical context individual situation may influence optimal timing birth. include: –recurrent acute vaso-occlusive pain crisis 34 weeks’ gestation –admission moderate severe acute chest syndrome 34 weeks’ gestation –fetal growth restriction –settings limited availability blood transfusion resource may necessary complication arise post induction. Areas research • GDG noted paucity evidence identified question sickle-cell pathology placental pregnancy physiology, may inform optimal timing birth woman SCD, research priority. Mode birth Recommendation — mode birth 7. Base decision mode birth woman SCD presence absence medical obstetric indication caesarean birth, availability local resource (including",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "696a9aab-7d30-4a9c-ae19-87004080dff3",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "f medical obstetric indication caesarean birth, availability local resource (including required woman make informed decisions), well woman’s view preferences. absence medical obstetric indication caesarean birth, vaginal birth preferable. Rationale • absence direct empirical evidence mode birth woman SCD, GDG based recommendation evidence derived general pregnant population physiological understanding SCD pregnancy. Remarks Caesarean birth general pregnant population • concludes caesarean section effective saving maternal infant lives, required medically indicated reason ( 176). Caesarean section cause significant sometimes permanent complications, disability death, particularly setting lack facility and/or capacity properly conduct safe surgery treat surgical complication (",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fb861493-1545-4967-999c-e05e7bd5ffdc",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "facility and/or capacity properly conduct safe surgery treat surgical complication ( 176). Caesarean birth woman SCD • systematic review conducted inform guideline found effect caesarean section compared vaginal birth maternal death, stillbirth neonatal death uncertain (one cross- sectional study; 255 women; low certainty ) (44). • GDG acknowledged insufficient evidence support pre-labour caesarean birth woman SCD. Recommendations supporting evidence 31 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 32Decision making mode birth • GDG acknowledged need balance interaction pathophysiological mechanism SCD management birth (i.e. anaemia risk associated haemorrhage; pain, dehydration risk precipitating sickle-cell crises). • Qualitative evidence based",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9f622fcc-efd7-4bd4-a21d-f91e7e9cb812",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ge; pain, dehydration risk precipitating sickle-cell crises). • Qualitative evidence based view healthy pregnant woman ( 177) (largely HICs [76%] including view woman upper-middle income [13%] LICs [11%]) suggests woman preference caesarean birth, factor underlying preference include: strong fear pain injury mother baby labour birth ( high confidence ); positive view caesarean birth based quality associated better organization control birth process (high confidence) . Trial labour caesarean birth • GDG find evidence trial labour caesarean (TOLAC) woman SCD. Consideration TOLAC population informed obstetric indication availability local resources. • GDG acknowledged need clinical judgement shared decision making, reference local protocols, regard",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7fcb5b84-cc2c-4c08-9a2c-73a10de064ad",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "clinical judgement shared decision making, reference local protocols, regard undertaking TOLAC woman SCD. Areas research • GDG noted paucity evidence identifies question optimal mode birth woman SCD research priority. 3.1.7 Interpregnancy management Recommendation — interpregnancy care 8a. Offer woman SCD immediate postnatal period six week childbirth care addition outlined recommendation maternal newborn care positive postnatal experience (28): – manage treat SCD complications, using evidence-based intervention including disease- modifying agent hydroxycarbamide (hydroxyurea) pain-management strategies; – prevent morbidity thrombotic event considering need for, initiating, thromboprophylaxis, per local recommendations; – guide choice contraceptive methods; – screen",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f6f421cb-bf54-4220-82d4-ac3c4e53cb42",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "oprophylaxis, per local recommendations; – guide choice contraceptive methods; – screen newborn SCD; – guide counselling safety breastfeeding baby. Recommendation health service programme 8b. woman SCD, integrate care across life course, including sexual reproductive health care, specialized disease care, may include: supporting optimal health well-being; providing pre- pregnancy counselling guidance pregnancy planning; optimizing treatment across beyond reproductive continuum. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Rationale • absence direct empirical evidence support recommendation specific intervention woman SCD interpregnancy period, GDG based recommendation physiological understanding SCD postnatal period, periconceptually, woman reproduc",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "97c2eb01-dc2f-4299-94b9-d32b4a7c1957",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "siological understanding SCD postnatal period, periconceptually, woman reproductive age. Remarks Conceptual approach • GDG noted interpregnancy phase cannot defined prospectively. Beginning time birth / termination pregnancy, extends beyond initial six week birth. support health throughout reproductive continuum interest inclusivity, woman reproductive age pregnant may considered ‘interpregnancy’ period, unless undergone menopause taken step permanently avoid pregnancy. • initial postnatal period, woman need transitioned back specialized care SCD. woman cared multidisciplinary team pregnancy, transition likely straightforward fundamental rationale “integrated” care outside pregnancy. GDG acknowledged care system may exist, may inad",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5b9dcf79-648a-4d1f-9726-eb17708ac819",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "n outside pregnancy. GDG acknowledged care system may exist, may inadequately organized, remain aspirational many settings. minimum, referral system mechanism need place communicate woman’s pregnancy postnatal course general care providers, including managing SCD. • Although woman SCD previous contact health-care facility manage condition, postnatal period (immediate beyond) may provide additional opportunity “catch care”, ensuring up-to-date immunization. Risks early postnatal period • immediate postnatal period (i.e. first week postnatally) often complication occur. • Women SCD increased risk severe maternal morbidity compared woman without SCD (178). addition, woman active vaso-occlusive crisis delivery admission approximately nine-fold higher risk severe materna",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5ccb0dff-5367-4e85-8b36-78bf5bfdba7f",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "sive crisis delivery admission approximately nine-fold higher risk severe maternal morbidity 42 days’ post-discharge compared woman SCD crisis delivery admission ( 178). • Women SCD increased risk VTE compared general population (see ‘Thromboprophylaxis pregnant woman uncomplicated SCD’; page 26). immediate postnatal period, risk may magnified especially context decreased mobility, following caesarean birth, woman history VTE. Contraception • medical eligibility criterion wheel contraceptive use (179) suggests woman SCD, progestogen-only pills, progestogen-only injectables, implants, levongestrel-releasing intrauterine device used circumstance; combined hormonal contraceptive copper intrauterine device suggested case-by-case basis. availability method, however",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "32dc0859-3d19-4214-a0d6-5f2660e15538",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "rauterine device suggested case-by-case basis. availability method, however, may vary depending context, local guideline may also provide specific guidance. GDG also noted copper intrauterine device may increase bleeding first three month use. Recommendations supporting evidence 33 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 34• Decisions contraception need tailored individual women, taking account woman’s preference noting may change time. Care newborn • Guidance African Region support systematic newborn screening SCD available ( 23). Integration newborn screening existing primary health-care immunization shown feasible setting limited resource ( 180). Point-of-care screening test shown provide affordable, reliable, easy-to",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "64c8209c-cd5a-40b1-b05f-ae14bc0c538c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "180). Point-of-care screening test shown provide affordable, reliable, easy-to-use method screen SCD, ensuring earliest diagnosis possible, highest level follow-up participants, access treatment locally (including penicillin prophylaxis, pneumococcal vaccinations, hydroxycarbamide) effective prevention procedure regionally (e.g. transcranial doppler risk stroke) ( 180). Medications breastfeeding • Pain medications: Paracetamol NSAIDs considered safe breastfeeding. • Hydroxycarbamide: Breastfeeding typically avoided woman SCD receiving hydroxycarbamide therapy, despite sparse pharmacokinetics data. recent study (n=16) hydroxycarbamide transferred breastmilk relative infant dosage 3.4%, recommended 5–10% safety threshold ( 181). • Counselling woman safety breastfeeding baby need include known trans",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "62a0b251-2daf-4a76-96dd-dd324e21bad5",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "woman safety breastfeeding baby need include known transfer hydroxycarbamide baby strength evidence. counselling aim enable woman part shared decision-making process involving woman health care providers. addition woman herself, member decision-making group may include obstetricians, midwives, paediatrician specialist SCD care providers). recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period dissemination implementation guideline considered stakeholder involved provision care pregnant woman international, national local levels. vital need increase women’s access maternal health care, strengthen capacity health care facility level ensure provide high-quality service woman giving",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fb67c462-6d2a-424a-9dea-16fe2447ba96",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "care facility level ensure provide high-quality service woman giving birth. therefore crucial guideline recommendation translated care package programme country health- care facility levels, appropriate. particular, recommendation need incorporated existing programme policy management SCD pregnancy childbirth. 4.1 Dissemination evaluation executive summary containing recommendations, remarks, implementation consideration research priority prepared public dissemination. Steering Group also develop derivative tool aid understanding adaptation recommendation local contexts. recommendation derivative tool disseminated regional country offices, ministry health, professional organizations, collaborating centres, United Nations agency nongovernmenta",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a46c689a-064d-4ec6-921d-fa8b81bd03f0",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "essional organizations, collaborating centres, United Nations agency nongovernmental organizations, among others. recommendation published Department Sexual Reproductive Health Research website promoted quarterly HRP News disseminated 8000 subscribers, including clinicians, health programme managers, policy-makers, researcher service user around world. Updated recommendation also routinely disseminated meeting scientific conference attended maternal perinatal health staff. executive summary recommendation publication translated six official United Nations language dissemination regional country office meeting organized by, attended by, staff Department Sexual Reproductive Health Research Department Maternal, Newborn, Child Adolescent Health. Techni",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "782ab0e3-e697-45aa-a716-63cedaf994c7",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Health Research Department Maternal, Newborn, Child Adolescent Health. Technical assistance provided regional office willing translate recommendation languages. addition, publication journal article presenting recommendation key implementation consideration considered compliance WHO’s open access copyright 4 Dissemination implementation guideline 35 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 36policies. Relevant clusters, department partnerships, Partnership Maternal, Newborn Child Health (PMNCH), also part dissemination process. order ensure recommendation positive impact maternal perinatal health country level, coordinated action international agencies, national department health key matern",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "aded0463-bbf3-4020-b464-62ec00a6669b",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "l, coordinated action international agencies, national department health key maternal perinatal health stakeholder needed. National subnational working group assess current national guideline protocols, determine whether development new guideline updating existing guideline required line new recommendations. staff headquarters, regional country levels, well international agency partner international professional society (such FIGO ICM), national professional associations, support national stakeholder developing revising existing national guideline protocols, optimizing implementation. context humanitarian emergencies, adaptation current recommendation consider integration alignment response strategies. Additional consideration unique need woman emergency settings, including w",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d4ddcb54-de51-40a0-8faf-9cdee203c9e9",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "trategies. Additional consideration unique need woman emergency settings, including women’s value preferences, made. Context- specific tool toolkits may required addition standard tool support implementation recommendation humanitarian emergencies. 4.2 Implementation consideration part recommendation development process, implementation consideration developed. may assist policy-makers, clinician stakeholder better prepare implementation. • successful introduction evidence-based policy related management chronic medical condition SCD pregnancy care model depend well-planned, participatory consensus-driven process integration implementation. process may include development revision national guideline protocol based recommendations, engagement relevant stakeholder groups, includi",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6c1f1610-b982-44f9-bd23-8dd4bbb4e1eb",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "tocols based recommendations, engagement relevant stakeholder groups, including skilled health-care providers. Modifications recommendations, necessary, made justification documented explicit transparent manner. Department Sexual Reproductive Health Research Department Maternal, Newborn, Child Adolescent Health (WHO) support national subnational group adapt implement recommendation based existing strategies. • Implementation recommendation management SCD pregnancy must considered within broader context ensuring woman access respectful, woman-centred care throughout life course. • National health system must support enabling environment implementation recommendations, including education support behaviour change among skilled health personnel team facilitate use evidence-ba",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4d49996c-7361-4391-9f92-5e56c996dec8",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "support behaviour change among skilled health personnel team facilitate use evidence-based practices. Clear up-to-date clinical protocol available skilled health-care provider regarding care medical condition pregnancy. • Local professional society training institution important role implementation. all- inclusive participatory process encouraged. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period • National health system must ensure supply medicine commodity (including blood transfusion) available health-care facility childbirth service provided. resource must safe, legitimate manufactured according good manufacturing practices. ensure resource high quality, robust sustainable regulatory, procurement logistics process must established, ensuring",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f6af34ed-872c-44d1-9906-05ab9537d282",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "bust sustainable regulatory, procurement logistics process must established, ensuring good-quality product obtained, transported stored correctly. • Skilled health-care provider working setting woman give birth require training supportive supervision integrate care chronic medical condition routine pregnancy care, inform counsel women, appropriate. setting new practice introduced (or recommended practice changed), additional training monitoring may required. context high rate personnel turnover, pre-service training regular opportunity ongoing training competency assessment particularly important. • Consideration given health-care provider prescription administration authority medication treat SCD, whether reflected scope practice. 4.3 Anticipated impact organ",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d0237354-a8e1-40cc-9e7b-b63c7f37542b",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "SCD, whether reflected scope practice. 4.3 Anticipated impact organization care resource Effective implementation recommendation guideline may require reorganization care redistribution health-care resources, particularly low- middle-income countries. GDG noted updating training curriculum providing training recommendation would increase impact facilitate implementation. part effort implement recommendations, health system stakeholder may wish consider following potential barrier application: • feasibility component recommendations, barrier facilitator implementation; • lack human resource necessary knowledge condition, inheritance patterns; • lack human resource requisite expertise skill implement, supervise support recommended practices; • lack infrastru",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4eb19b85-17a5-4c3a-b063-b06bb6db0f9a",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "expertise skill implement, supervise support recommended practices; • lack infrastructure multidisciplinary team support interventions; • lack resource active implementation strategies; • lack essential equipment, supply medicines; • lack health information management system designed document monitor recommended practice (e.g. patient records, registers); • lack consistent staffing high provider turnover impacting sustainability scalability interventions. Dissemination implementation guideline 37 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 384.4 Monitoring evaluating guideline implementation implementation impact recommendation monitored health service, country regional levels, part broader effort monitor improve quality maternal newborn care. document St",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "de81849b-aae5-421c-9466-94fd376ab0b7",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "roader effort monitor improve quality maternal newborn care. document Standards improving quality maternal newborn care health facility (182) provides list prioritized input, output outcome measure used define quality care criterion indicator aligned locally agreed targets. collaboration monitoring evaluation team Department Sexual Reproductive Health Research Department Maternal, Newborn, Child, Adolescent Health Ageing, data country- regional-level implementation recommendation collected evaluated short medium term assess impact national policy individual Member States. Interrupted time series could used obtain relevant data use intervention contained guideline. recommendations: Management sickle-cell disease pregnancy, c",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "040aaaf7-d8b5-462f-b254-cb3a45bc1334",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "tained guideline. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period GDG identified important knowledge gap directly related PICO questions, may direct impact implementation recommendations. following area identified priority question high-quality evidence generation, especially setting high prevalence: • folic acid supplementation among pregnant woman SCD taking intermittent preventive treatment sulfadoxine-pyrimethamine; • risk benefit prophylactic transfusion, well best timing, frequency threshold used comparison simple, manual exchange automatic exchange transfusions; • effect hydroxycarbamide disease-modifying agent pregnancy maternal fetal/ neonatal outcomes; • qualitative study relating women’s informed consent experience hydroxycarbamide; •",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "14a7a2c1-fd8a-49ba-8ebb-e1b43102f61b",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "• qualitative study relating women’s informed consent experience hydroxycarbamide; • optimal method pain management antenatal period — specifically around use medications; • thromboprophylaxis non-hospitalized women; • intravenous fluid pregnant woman SCD hospitalized vaso-occlusive crisis, including type volume fluid; • effective thromboprophylaxis schedule woman hospitalized SCD; • outcome pregnancy woman SCD stratified gestational age birth; • effect sickle-cell pathology placental pregnancy physiology, may inform optimal timing birth woman SCD; • optimal timing postnatal visit (e.g. one week compared six weeks); • safety hydroxycarbamide use lactation infant impact use infant feeding choices; • optimal mode contraception. 5 Research implication 39 recommendations: Management",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "344ab4a2-f126-4b2f-9b14-085b7a35302b",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "; • optimal mode contraception. 5 Research implication 39 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 406 Maternal Perinatal Health Guideline Technical Advisory Group convenes regularly review WHO’s current portfolio maternal perinatal health recommendation help prioritize new existing question recommendation development updating. recommendation included reviews. event new evidence could potentially impact current evidence base identified, recommendation may updated. new report information identified, recommendation may revalidated. welcome suggestion regarding additional question inclusion updated recommendations. Please email suggestion srhmph@who.int.Updating recommendation Annex 1 . External expert staff involved preparation",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5e4002a1-7a5c-455f-a252-b872162c9d1c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "dating recommendation Annex 1 . External expert staff involved preparation recommendation Guideline development group Bosede AFOLABI (Chair) Professor Obstetrics Gynecology College Medicine University Lagos Lagos, Nigeria Tamima ALDUGHAISHI Senior Consultant Maternal Fetal Medicine Sultan Qaboos University Hospital Muscat, Oman Monika ASNANI Professor Family Medicine Epidemiology Sickle Cell Unit- Caribbean Institute Health Research University West Indies Mona Campus, Jamaica Eugenia Vicky ASARE Senior Specialist Haematology Ghana Institute Clinical Genetics Korle-Bu Teaching Hospital Accra, Ghana Ochuwa BABAH Senior Lecturer Obstetrics Gynecology College Medicine University Lagos Lagos, NigeriaLea Kilenga BEY Executive Director Africa Sickle Cell Organization Nairobi, Kenya Harriet BIRUNGI Vice President International Programs Division Population Council",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "febc0063-98ae-403d-b6aa-09fe3b6bb70b",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "bi, Kenya Harriet BIRUNGI Vice President International Programs Division Population Council Nairobi, Kenya Rodolfo CANCADO Hematology Faculdade de Ciencias Medicas da Santa Casa de São Paulo São Paulo, Brazil John EHIRI Professor Health Promotion Sciences Senior Associate Dean Academic Affairs University Arizona Arizona, United States America Laure JOSEPH Hematology Département de Biothérapie Hôpital Necker-Enfants Malades Paris, France 4142Isaac ODAME Professor Departments Medicine Paediatrics, Division Haematology/Oncology Global Sickle Cell Disease Network Centre Global Child Health Hospital Sick Children Toronto, Canada Eugene OTENG-NTIM Professor Department Women Children’s Health, School Life Course Population Sciences, King’s College, London, United Kingdom Great Britain Northern Ireland Wendy POLLOCK Associate Professor School Nursing Midwifery Monash Uni",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0d743a52-4fb8-4032-b0ee-aac77e10084c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Northern Ireland Wendy POLLOCK Associate Professor School Nursing Midwifery Monash University Melbourne, Australia Partner organizations/observers International Federation Gynecology Obstetrics (FIGO) Diana RAMASAUSKAITE Akaninyene Eseme Bernard UBOM International Pediatric Association (IPA) Nita RADHAKRISHNAN NCD Alliance Mychelle FARMER United Nations Childrens Fund (UNICEF) Raoul BERMEJO United States Agency International Development (USAID) Meridith MIKULICHGuideline methodologists Jen RAMSON Consultant Myfanwy WILLIAMS Consultant Evidence synthesis group Kelli BARBOUR Assistant Professor Maternal Fetal Medicine Global Women’s Health Baylor College Medicine Texas Children’s Hospital Texas, United States America Sarah BOUDOVA Fellow, Maternal Fetal Medicine Thomas Jefferson University Pennsylvania, United States America La’Ron BROWNE St Jude Hospital Tennessee, United States America Soo DOWNE",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7b272dd5-8c85-43ae-9904-92fd6229f1e3",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "te America La’Ron BROWNE St Jude Hospital Tennessee, United States America Soo DOWNE Professor THRIVE Centre University Central Lancashire School Community Health Midwifery Lancashire, United Kingdom Great Britain Northern Ireland Kenneth FINLAYSON Research Associate University Central Lancashire School Community Health Midwifery Lancashire, United Kingdom Great Britain Northern Ireland Yaneve FONGE Fellow, Maternal Fetal Medicine UPMC Magee-Women’s Hospital Pennsylvania, United States America recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Apiwat JONGJAKAPUN Department Obstetrics Gynecology Faculty Medicine Khon Kaen University Khon Kaen, Thailand Jenny JUNG Maternal, Child Adolescent Health Program Burnet Institute Melbourne, Australia Nampet JAMPATHONG Cochrane Thailand Khon Kaen University Khon Kaen, Thailand Pi",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a5bdf3f6-a948-4e36-a293-98195ece6236",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ourne, Australia Nampet JAMPATHONG Cochrane Thailand Khon Kaen University Khon Kaen, Thailand Pisake LUMBIGANON Professor Faculty Medicine Convenor, Cochrane Thailand Director, Collaborating Centre Research Synthesis Reproductive Health Faculty Medicine Khon Kaen University Khon Kaen, Thailand Chetta NGAMJARUS Associate Professor Department Epidemiology Biostatistics, Faculty Public Health, Khon Kaen University, Khon Kaen, Thailand Porjai PATTANITTUM Associate Professor Department Epidemiology Biostatistics Faculty Public Health Khon Kaen University Khon Kaen, Thailand Beth PINELES Assistant Professor Obstetrics Gynecology Hospital University Pennsylvania Pennsylvania, United States AmericaJen SOTHORNWIT Assistant Professor Department Obstetrics Gynecology Faculty Medicine Khon Kaen University Khon Kaen, Thailand Termtem WAIDEE Department Obstetrics Gynecology",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "397a21a4-967b-40ea-abe2-3b57b68c1c38",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "hon Kaen University Khon Kaen, Thailand Termtem WAIDEE Department Obstetrics Gynecology Faculty Medicine Khon Kaen University Khon Kaen, Thailand country Regional office Bremen DE MUCIO Maternal Health Regional Advisor (CLAP) Pablo DURÁN Regional Adviser Perinatal Health Karima GHOLBZOURI Regional Adviser Sexual Reproductive Health & Research C. Anoma JAYATHILAKA Acting Director Medical Officer Family Health, Gender Life Course Shogo KUBOTA Coordinator Maternal Child Health Quality Safety Oleg KUZMENKO Technical Officer (Sexual reproductive health focal point) Reproductive Health Division Country Health Policies Systems Priya MANNAVA Technical Officer Maternal Child Health Quality Safety External expert staff involved preparation recommendation 43 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 44Léopo",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "da0247e7-d5c5-41f7-996c-9ecf409893d6",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Management sickle-cell disease pregnancy, childbirth interpregnancy period 44Léopold OUEDRAOGO Regional Adviser Reproductive, Maternal Health Ageing steering group Prebo BARANGO Cross-cutting Specialist NCDs Special Initiatives Department Noncommunicable Diseases Maria BARREIX ETCHEGOIMBERRY Technical Officer Maternal Perinatal Health Department Sexual Reproductive Health Research Doris CHOU Medical Officer Maternal Perinatal Health Department Sexual Reproductive Health Research Ayesha DE COSTA Scientist Department Maternal, Newborn, Child Adolescent Health Ageing Maria Nieves GARCIA CASAL Scientist Department Nutrition Food Safety Olufemi OLADAPO Unit Head Maternal Perinatal Health Department Sexual Reproductive Health Research Roberta ORTIZ SEQUEIRA Medical Officer Department Noncommunicable Diseases Lisa ROGERS Technical Officer Depar",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "23ee671c-901b-4e49-bb3c-4c1be3f8f72b",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Medical Officer Department Noncommunicable Diseases Lisa ROGERS Technical Officer Department Nutrition Food SafetyMeera UPADHYAY Medical Officer Department Maternal, Newborn, Child Adolescent Health Ageing External review group A. Kinga MALINOWSKI Associate Professor Maternal-Fetal Medicine Mount Sinai Hospital Toronto, Canada Bertha MASEKO Maternal Health Group Manager Malawi Liverpool Wellcome Programme Blantyre, Malawi Babasola OKUSANYA Associate Professor Obstetrics Gynecology College Medicine University Lagos Lagos, Nigeria Lydia PECKER Associate Professor John Hopkins School Medicine Baltimore, United States America recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period outcome included PICOs Critical maternal outcome • Maternal death • Maternal functioning well-being • Women’s view experience Important materna",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2ae5c8cb-e44b-4a68-a4a0-55767296b391",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ernal death • Maternal functioning well-being • Women’s view experience Important maternal outcome • Antenatal hospitalization • Admission intensive care • Mode birth Critical newborn outcome • Stillbirth/fetal death • Neonatal death • Perinatal deathImportant newborn outcome • Admission neonatal intensive care • Gestational age birth • Preterm birth (<32 weeks; <37 weeks) • Birthweight • Intrauterine growth restriction • Low birthweight (<2500 g) • Small -for-gestational age (<10th centile gestational age) • Apgar score less seven five minute • Neurodevelopmental outcome (into infancy childhood) Health service outcome • Antenatal admission hospital woman length stay • Emergency department visit woman • Admission intensive care unit woman • Length postnatal hospitalization woman • Length neonatal hospitalization • Costs care woman baby bothAnnex 2 . Priority outc",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "41f36bab-155f-4734-87ab-0f5327d11e94",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "h neonatal hospitalization • Costs care woman baby bothAnnex 2 . Priority outcome used decision making 45 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 46Priority outcome individual PICOs Maternal outcome • Antepartum haemorrhage • Caesarean section • Cerebrovascular accident • Hypertensive disorder pregnancy • Identification cause anaemia • Induction labour • Iron overload • Lower respiratory tract infection (bronchitis, pneumonia) • Malaria infection • Maternal postnatal infection • Postpartum haemorrhage • Pyelonephritis • SCD crisis (pain/vaso-occlusive, acute chest syndrome, aplastic, splenic sequestration) • Sepsis • Thrombotic event • Uptake genetic testingNewborn outcome • Fetal diagnosis • Neonatal SCD • Miscarriage • Congenital anomaly • Fetal growth restriction recommendations: Management sickle-cell disease pregnancy, childbirth",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8479c65b-99ba-41e7-8c00-d904b878da63",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "h restriction recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Name title Expertise contributed guideline developmentDeclared Interest Management declared interest Guideline development group Bosede AFOLABI Content expert end user (obstetrics)Received funding TETFund, Nigeria co-investigator PIPSICKLE trial; received honorarium speak conference (under 2000 USD)The expert recused developing recommendation related intervention PIPSICKLE trial. declared conflict interest considered significant enough pose risk guideline development process reduce credibility Tamima ALDUGHAISHIContent expert end user (obstetrics)None declared applicable Eugenia Vicky ASAREContent expert end user (haematology)None declared applicable Monika ASNANI Content expert end user (public health)Partici",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "61c6d8f0-8703-4e31-8532-508f0609e3c5",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ogy)None declared applicable Monika ASNANI Content expert end user (public health)Participated Working Group measure phenotype exposuresNot applicableAnnex 3 . Summary management declared interest GDG member 47 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 48Name title Expertise contributed guideline developmentDeclared Interest Management declared interest Ochuwa BABAH Content expert end user (obstetrics)Received funding TETFund, Nigeria co-investigator PIPSICKLE trialThe expert recused developing recommendation related intervention PIPSICKLE trial. declared conflict interest considered significant enough pose risk guideline development process reduce credibility Lea Kilenga BEY Community stakeholder perspectiveFounded act CEO Africa Sickle Cell",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "daec7d62-45cb-4e14-82ba-57ba56ed0128",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Kilenga BEY Community stakeholder perspectiveFounded act CEO Africa Sickle Cell OrganizationThis declared conflict interest considered significant enough pose risk guideline development process reduce credibility Harriet BIRUNGI Content expert end user (gender rights)None declared applicable Rodolfo CANÇADO Content expert end user (obstetrics)None declared applicable John EHIRI Content expert end user (public health)None declared applicable Laure JOSEPH Content expert end user (haematology)Received honorarium fee consulting activity travel conference (The honorarium received 2000 USD)This declared conflict interest considered significant enough pose risk guideline development process reduce credibility Isaac ODAME Content expert end user (haematology)Received funding research project point care testi",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "78fbb320-e1d2-4234-8024-9e2498d08ff6",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "expert end user (haematology)Received funding research project point care testing sickle cell diseaseNot applicable recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Name title Expertise contributed guideline developmentDeclared Interest Management declared interest Eugene OTENG- NTIMContent expert end user (obstetrics)Received funding feasibility trial prophylactic exchange blood transfusion versus standard care (in sickle cell)The expert recused developing recommendation related intervention (transfusions). declared conflict interest considered significant enough pose risk guideline development process reduce credibility Wendy POLLOCK Content expert end user (obstetrics)None declared applicable Guideline methodologists Jen RAMSON Evidence synthesis, guideline methodologyNone declared ap",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6e395fb1-81f1-400f-9dd0-e6ced02fbc69",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Guideline methodologists Jen RAMSON Evidence synthesis, guideline methodologyNone declared applicable Myfanwy WILLIAMSEvidence synthesis, guideline methodologyNone declared applicable Evidence synthesis group Kelli BARBOUR Evidence synthesis None declared applicable Sarah BOUDOVA Evidence synthesis None declared applicable La'Ron BROWNE Evidence synthesis None declared applicable Soo DOWNE Evidence synthesis None declared applicable Kenneth FINLAYSONEvidence synthesis None declared applicable Yaneve FONGE Evidence synthesis None declared applicable Nampet JAMPATHONGEvidence synthesis None declared applicable Apiwat JONGJAKAPUNEvidence synthesis None declared applicable Summary management declared interest GDG member 49 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 50Name title Expertise contributed guideline developmentDeclared Interest Management",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "47c71abb-ad1b-4b60-ab3c-b10d7532df41",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "eriod 50Name title Expertise contributed guideline developmentDeclared Interest Management declared interest Jenny JUNG Evidence synthesis None declared applicable Pisake LUMBIGANONEvidence synthesis None declared applicable Chetta NGAMJARUSEvidence synthesis None declared applicable Porjai PATTANITTUMEvidence synthesis None declared applicable Beth PINELES Evidence synthesis None declared applicable Jen SOTHORNWIT Evidence synthesis None declared applicable Termtem WAIDEE Evidence synthesis None declared applicable Observers Raoul BERMEJO United Nations partner Mychelle FARMER Observer - Civil society organization None declared applicable Meridith MIKULICH Observer - implementing agencyNone declared applicable Nita RADHAKRISHNANObserver - professional organizationNone declared applicable Diana RAMASAUSKAITEObserver - professional organizationNone declared applicable Akaninyene Eseme Bernard UBOM Observer - profes",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4a10b5ff-b27e-4980-b530-967fe2079cb4",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "essional organizationNone declared applicable Akaninyene Eseme Bernard UBOM Observer - professional organizationNone declared applicable recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period Name title Expertise contributed guideline developmentDeclared Interest Management declared interest External review group A. Kinga MALINOWSKIContent expert end user (obstetrics)Received research fund study looking risk factor adverse outcome pregnant individual SCDThis considered significant preclude external review guideline. Bertha MASEKO Content expert end user (obstetrics)None applicable Babasola OKUSANYAContent expert end user (obstetrics)None applicable Lydia PECKER Content expert end user (hematology)Received research fund study looking risk factor adverse outcome pregnant individual SCDThis c",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "119ef7af-41d0-4229-a022-0cdf27f5a050",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "study looking risk factor adverse outcome pregnant individual SCDThis considered significant preclude external review guideline. Web Annex Evidence-to-decision frameworks. Available here, https://doi.org/10.2471/B09416 . Web Annex SectionComparison 1.0 Medication management pregnant woman SCD 2.0 Pain management pregnant woman SCD 3.0 Fluid-management plan pregnant woman hospitalized SCD 4.0 Thromboprophylaxis pregnant woman hospitalized SCD 5.0 Additional fetal monitoring pregnant woman SCD 6.0 Timing delivery pregnant woman SCD 7.0 Mode birth pregnant woman SCD 8.0 Interpregnancy management postnatal woman SCD White paper Jung J., et al. Additional care pregnancy woman sickle cell disease (SCD). Available here, https://who.canto.global/b/LIVKQ- Summary management declared interest GDG member 51 recommendations: Management si",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1559b3bf-c958-4069-b0a2-66bbd9c4493d",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "mmary management declared interest GDG member 51 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 52References 1 Pincez T, Ashley-Koch AE, Lettre G, Telen MJ. Genetic modifier sickle cell disease. Hematol Oncol Clin North Am. 2022;36(6):1097–124. doi: 10.1016/j.hoc.2022.06.006 . 2 GBD Sickle Cell Disease Collaborators. Global, regional, national prevalence mortality burden sickle cell disease, 2000- 2021: systematic analysis Global Burden Disease Study 2021. Lancet Haematol. 2023;10(8):e585–e99. doi: 10.1016/ S2352-3026(23)00118-7 . 3 Joseph L Driessen M. comprehensive view pregnancy patient sickle cell disease high-income countries: need robust data decline morbidity mortality. Lancet Haematology. 2024 Jan;11(1):e75-e84. doi:10.1016/ S2352-3026(23)00310-1 . 4 Osunkwo I, Andemariam B, Minniti CP , Inusa BPD, El Rassi F, Franci",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7a6b7d85-207c-471e-81d5-0bc00129bd93",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": ".1016/ S2352-3026(23)00310-1 . 4 Osunkwo I, Andemariam B, Minniti CP , Inusa BPD, El Rassi F, Francis-Gibson B, et al. Impact sickle cell disease patients’ daily lives, symptom reported, disease management strategies: Results international Sickle Cell World Assessment Survey (SWAY). J Hematol. 2021;96(4):404–17. doi: 10.1002/ajh.26063 . 5 Oligbu G, Collins S, Sheppard C, Fry N, Dick M, Streetly A, et al. Risk invasive pneumococcal disease child sickle cell disease England: national observational cohort study, 2010–2015. Arch Dis Child. 2018;103(7):643–7. doi: 10.1136/ archdischild-2017-313611 . 6 McCaw-Binns A, Campbell L, Harris A, James LA, Asnani M. Maternal mortality among woman sickle cell disease Jamaica two decade (1998–2017). EClinicalMedicine. 2022;43:101238. doi: 10.1016/j.eclinm.2021.101238 . 7 Boafor TK, Olayemi E, Galadanci N, Hayfron-Benjamin C, Dei-Adomakoh Y, Segbefia C, et al. Pregnancy outcome woman",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f25f8b0f-5fe1-4d22-9635-26aafedfa000",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "aladanci N, Hayfron-Benjamin C, Dei-Adomakoh Y, Segbefia C, et al. Pregnancy outcome woman sickle-cell disease low high income countries: systematic review meta-analysis. BJOG. 2016;123(5):691–8. doi: 10.1111/1471-0528.13786 . 8 Oteng-Ntim E, Meeks D, Seed PT, Webster L, Howard J, Doyle P , et al. Adverse maternal perinatal outcome pregnant woman sickle cell disease: systematic review meta-analysis. Blood. 2015;125(21):3316–25. doi: 10.1182/ blood-2014-11-607317 . 9 handbook guideline development, second edition. Geneva: World Health Organization; 2014 (https://iris.who.int/ handle/10665/145714 , accessed 11 January 2025) . 10 Trends maternal mortality 2000 2020: estimate WHO, UNICEF, UNFPA, World Bank Group UNDESA/Population Division. Geneva: World Health Organization; 2023 ( https://iris.who.int/handle/10665/366225 , accessed 11 January 2025 ). 11 State inequality. Reproductive, maternal, newborn child health. G",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6777ab95-acf7-41ab-87ea-d70d11ef9c02",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "essed 11 January 2025 ). 11 State inequality. Reproductive, maternal, newborn child health. Geneva: World Health Organization; 2015 ( https://iris.who. int/handle/10665/164590 , accessed 11 January 2025 ). 12 Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, et al. Defining global strategy improve outcome sickle cell disease: Lancet Haematology Commission. Lancet Haematol. 2023;10(8):e633–e86. doi: 10.1016/S2352-3026(23)00096-0 . 13 Human right [website]. World Health Organization: 2023 ( https://www.who.int/news-room/fact-sheets/detail/human-rights-and- health , accessed 11 January 2025 ). 14 recommendation antenatal care positive pregnancy experience. Geneva: World Health Organization; 2016. ( https:// iris.who.int/handle/10665/250796 , accessed 11 January 2025 ). 15 recommendations: Intrapartum care positive childbirth experience. Geneva: World Health Organization; 2018. ( https:// iris.who.int/handle/10665/260178 , accessed 11",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "86bdd835-ba57-4da6-8e57-efd9d81910b1",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Geneva: World Health Organization; 2018. ( https:// iris.who.int/handle/10665/260178 , accessed 11 January 2025 ). 16 Ramson JA, Williams MJ, Afolabi BB, Colagiuri S, Finlayson KW, Hemmingsen B, et al. Pregnancy, childbirth postpartum period: opportunity improve lifetime outcome woman non-communicable diseases. Med J Aust. 2024;221(7):350–3. doi: 10.5694/mja2.52452 . 17 Bulgin D, Tanabe P , Jenerette C. Stigma sickle cell disease: systematic review. Issues Ment Health Nurs. 2018;39(8):675–86. doi: 10.1080/01612840.2018.1443530 . 18 Finlayson K, Moncrieff G, Harris C, Downe S, Chou D. Sickle cell disease maternity care: qualitative synthesis women’s health provider experiences. 2024. doi: review. recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 19 Jonathan A, Tutuba H, Lloyd W, Ndunguru J, Makani J, Ruggajo P , et al. Healthcare workers’ knowledge resource availabili",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "30a9cd9e-7408-483e-b5e2-ee5e057fbc1c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "yd W, Ndunguru J, Makani J, Ruggajo P , et al. Healthcare workers’ knowledge resource availability care sickle cell disease Dar e Salaam, Tanzania. Front Genet. 2021;12:773207. doi: 10.3389/fgene.2021.773207 . 20 Azonobi IC, Anderson BL, Byams VR, Grant AM, Schulkin J. Obstetrician-gynecologists’ knowledge sickle cell disease screening management. BMC Pregnancy Childbirth. 2014;14:356. doi: 10.1186/1471-2393-14-356 . 21 Adegoke SA, Akinlosotu MA, Adediji OB, Oyelami OA, Adeodu OO, Adekile AD. Sickle cell disease southwestern Nigeria: assessment knowledge primary health care worker available facilities. Trans R Soc Trop Med Hyg. 2018;112(2):81–7. doi: 10.1093/trstmh/try025 . 22 Zhong A, Darren B, Loiseau B, LQB, Chang T, Hill J, et al. Ethical, social, cultural issue related clinical genetic testing counseling low- middle-income countries: systematic review. Genet Med. 2021;23(12):2270–80. doi: 10.1038/s41436-018- 0090-9 .",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f05b799a-c6e9-4df8-847e-feddcfc0f737",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "countries: systematic review. Genet Med. 2021;23(12):2270–80. doi: 10.1038/s41436-018- 0090-9 . 23 African Region. SICKLE package intervention sickle cell disease management: Module 3 Comprehensive care. Brazzaville, Congo: African Region; 2024. ( https://www.afro.who.int/sites/default/files/2024-06/WHO%20SICKLE_Module_3. pdf, accessed 21 November 2024 ). 24 Sanders J, Blaylock R, Dean C, Petersen I, Trickey H, Murphy C. Women’s experience over-the-counter prescription medication pregnancy UK: finding survey free-text response narrative interviews. BMJ Open. 2023;13(3):e067987. doi: 10.1136/bmjopen-2022-067987 . 25 Birmingham Health Partners. Healthy mum, healthy baby, healthy future. Birmingham: University Birmingham; 2022. ( https:// www.birminghamhealthpartners.co.uk/healthy-mum-healthy-baby-healthy-future-report/ , accessed 21 November 2024) . 26 Ravindran TS, Teerawattananon Y, Tannenbaum C, Vijayasingham L. Making ph",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc1b4c3d-1852-4b6a-886e-1303e34d83ec",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "sed 21 November 2024) . 26 Ravindran TS, Teerawattananon Y, Tannenbaum C, Vijayasingham L. Making pharmaceutical research regulation work women. BMJ. 2020;371:m3808. doi: 10.1136/bmj.m3808 . 27 Jain D, Atmapoojya P , Colah R, Lodha P. Sickle cell disease pregnancy. Mediterr J Hematol Infect Dis. 2019;11(1):e2019040. doi: 10.4084/mjhid.2019.040 . 28 recommendation maternal newborn care positive postnatal experience. Geneva: World Health Organization; 2022. ( https://iris.who.int/handle/10665/352658 , accessed 28 February 2025). 29 Department Economic Social Affairs UN. Sustainable Development Goals: United Nations; 2022 [30 March 2022]. ( https:// sdgs.un.org/goals , accessed 24 November 2024 ). 30 Thirteenth general programme work, 2019–2023. Geneva: World Health Organization; 2018. ( https://iris.who.int/ handle/10665/279451 , accessed 12 January 2025 ). 31 United Nations. Technical guidance application human rights-based approac",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fb3ed110-9e4b-4421-b7ce-7eba133fcb21",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ary 2025 ). 31 United Nations. Technical guidance application human rights-based approach implementation policy programme reduce preventable maternal morbidity mortality. Report Office United Nations High Commissioner Human Rights. Human Rights Council, twentieth session. 2012 ( https://digitallibrary.un.org/ record/731068?v=pdf , accessed 11 January 2025 ). 32 Tunçalp Ӧ, WM, MacLennan C, Oladapo OT, Gülmezoglu AM, Bahl R, et al. Quality care pregnant woman newborns- vision. BJOG. 2015;122(8):1045–9. doi: 10.1111/1471-0528.13451 . 33 Firoz T, Pineles B, Navrange N, Grimshaw A, Oladapo O, Chou D. Non-communicable disease maternal health: scoping review. BMC Pregnancy Childbirth. 2022;22(1):787. doi: 10.1186/s12884-022-05047-6 . 34 Jung J, Karwal EK, McDonald S, Turner T, Chou D, Vogel JP. Prevention control non-communicable disease antenatal, intrapartum, postnatal care: systematic",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6d85c8c4-fad6-46db-8da9-2bdcbd7fd83a",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "control non-communicable disease antenatal, intrapartum, postnatal care: systematic scoping review clinical practice guideline since 2011. BMC Med. 2022;20(1):305. doi: 10.1186/s12916-022-02508-9 . 35 Accelerating anaemia reduction: comprehensive framework action. Geneva: World Health Organization; 2023 ( https://iris. who.int/handle/10665/367661 , accessed 11 January 2025 ). 36 Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating quality evidence. J Clin Epidemiol. 2011;64(4):401–6. doi: 10.1016/j.jclinepi.2010.07.015 . 37 Jung J, Aziz S, Ginnane J, Eddy K, Vogel J. Systematic review economic evaluation intervention sickle cell disease pregnancy. PROSPERO. 2023;CRD42023484748 . doi: progress. 38 Jung J, Fonge Y, Pattanittum P , Waidee T, Sothornwit J, Ngamjarus C, et al. effectiveness pain management plan pregnant woman sickle cell disease: systematic review. PRO",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d9be4bc2-d0f8-4e0f-8775-9662f6bb0a86",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "eness pain management plan pregnant woman sickle cell disease: systematic review. PROSPERO. 2024;CRD42024507518. doi: progress. Summary management declared interest GDG member 53 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 5439 Jung J, Fonge Y, Pattanittum P , Waidee T, Sothornwit J, Ngamjarus C, et al. effectiveness fluid management plan hospitalized pregnant woman sickle cell disease: systematic review. PROSPERO. 2024;CRD42024507813 . doi: progress. 40 Jung J, Fonge Y, Pattanittum P , Waidee T, Sothornwit J, Ngamjarus C, et al. effectiveness thromboprophylaxis low molecular weigth heparin hospitalized pregnant woman sickle cell disease: systematic review. PROSPERO. 2024;CRD42024507817 . doi: progress. 41 Jung J, Fonge Y, Pattanittum P , Waidee T, Sothornwit J, Ngamjarus C, et al. Evaluating effectiveness additional fetal growth",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9bc6dace-73c7-49a7-b3ac-4a764f971ac8",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Waidee T, Sothornwit J, Ngamjarus C, et al. Evaluating effectiveness additional fetal growth monitoring pregnant woman sickle cell disease: systematic review. PROSPERO. 2024;CRD42024507902 . doi: progress. 42 Ngamjarus C, Pattanittum P , Lumbiganon P , Sothornwit J, Waidee T, Fonge Y, et al. Interpregnancy management woman sickle cell disease postnatal period: systematic review. PROSPERO. 2023;CRD42023460798 doi: progress. 43 Pattanittum P , Lumbiganon P , Fonge Y, Waidee T, Sothornwit J, Ngamjarus C, et al. Timing delivery woman sickle cell disease: systematic review. PROSPERO. 2023;CRD42023461767 . doi: progress. 44 Sothornwit J, Ngamjarus C, Pattanittum P , Lumbiganon P , Jongjakapun A, Waidee T, et al. Route delivery woman sickle cell disease: systematic review. PROSPERO. 2023;CRD42023461757 . doi: progress. 45 Fonge Y, Pineles B, Ngamjarus C, Pattanittum P , Lumbiganon P , Sothornwit J, et al. Antenatal",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "38cc1878-6822-4947-bea6-0289bdda111d",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "s. 45 Fonge Y, Pineles B, Ngamjarus C, Pattanittum P , Lumbiganon P , Sothornwit J, et al. Antenatal medication management woman sickle cell disease: systematic review. PROSPERO. 2023;CRD42023484839 doi: progress. 46 Lewin S, Booth A, Glenton C, Munthe-Kaas H, Rashidian A, Wainwright M, et al. Applying GRADE-CERQual qualitative evidence synthesis findings: introduction series. Implement Sci. 2018;13(Suppl 1):2. doi: 10.1186/s13012-017-0688-3 . 47 Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list assessment methodological quality economic evaluations: Consensus Health Economic Criteria. Int J Technol Assess Health Care. 2005;21(2):240–5. doi: PMID: 15921065 . 48 GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. McMaster University Evidence Prime, 2024. 49 Alonso-Coello P , Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. Marcos GRADE de la evidencia la decisión (EtD): un enfoque siste",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7013daef-1940-4ec5-a70a-6e907d73da20",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "rsen R, Akl EA, Davoli M, et al. Marcos GRADE de la evidencia la decisión (EtD): un enfoque sistemático transparente para tomar decisiones sanitarias bien informadas. 1: Introducción [GRADE Evidence Decision (EtD) frameworks: systematic transparent approach making well informed healthcare choices. 1: Introduction]. Gac Sanit. 2018;32(2):166.e1–.e10. doi: 10.1016/j.gaceta.2017.02.010 (in Spanish) . 50 Hilton Boon M, Thomson H, Shaw B, Akl EA, Lhachimi SK, López-Alcalde J, et al. Challenges applying GRADE approach public health guideline systematic reviews: concept article GRADE Public Health Group. J Clin Epidemiol. 2021;135:42–53. doi: 10.1016/j.jclinepi.2021.01.00 1. 51 Dixit R, Nettem S, Madan SS, Soe HHK, Abas AB, Vance LD, et al. Folate supplementation people sickle cell disease. Cochrane Database Syst Rev. 2018;3(3):CD011130. doi: 10.1002/14651858.CD011130.pub3 . 52 Williams BA, Mayer C, McCartney H, Devlin AM, Lamers Y, Ver",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a5ba1611-8083-418d-ac73-9522f2eef20d",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "doi: 10.1002/14651858.CD011130.pub3 . 52 Williams BA, Mayer C, McCartney H, Devlin AM, Lamers Y, Vercauteren SM, et al. Detectable unmetabolized folic acid elevated folate concentration folic acid-supplemented Canadian child sickle cell disease. Front Nutr. 2021;8:642306. doi: 10.3389/fnut.2021.642306 . 53 Viswanathan M, Urrutia RP , Hudson KN, Middleton JC, Kahwati LC. Folic acid supplementation prevent neural tube defects: updated evidence report systematic review US Preventive Services Task Force. JAMA. 2023;330(5):460–6. doi: 10.1001/ jama.2023.9864 . 54 Field MS, Stover PJ. Safety folic acid. Ann N Acad Sci. 2018;1414(1):59–71. doi: 10.1111/nyas.13499 . 55 Institute Medicine. Dietary reference intake thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, choline. Washington DC USA: National Academies Press; 1998 ( https://www.ncbi.nlm.nih.gov/books/NBK114310 , accessed 11 January 2025) . 56 Hunte",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bd69c02d-8cd9-43b0-8049-b24aad9f9c70",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Press; 1998 ( https://www.ncbi.nlm.nih.gov/books/NBK114310 , accessed 11 January 2025) . 56 Hunter R, Barnes J, Oakeley HF, Matthews DM. Toxicity folic acid given pharmacological dos healthy volunteers. Lancet. 1970;1(7637):61–3. doi: 10.1016/s0140-6736(70)91845-3 . 57 Hellstrom L. Lack toxicity folic acid given pharmacological dos healthy volunteers. Lancet. 1971;1(7689):59–61. doi: 10.1016/s0140-6736(71)90780-x . 58 Richens A. Toxicity folic acid. Lancet. 1971;1(7705):912. doi: 10.1016/s0140-6736(71)92473-1 . recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 59 De-Regil LM, Peña-Rosas JP , Fernández-Gaxiola AC, Rayco-Solon P. Effects safety periconceptional oral folate supplementation preventing birth defects. Cochrane Database Syst Rev. 2015;2015(12):CD007950. doi: 10.1002/14651858. CD007950.pub3 . 60 MRC Vitamin Study Research Group. Prevention neural tube defects: Result",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "048aea17-9294-46b6-8b22-6ec938f7c0b6",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "1858. CD007950.pub3 . 60 MRC Vitamin Study Research Group. Prevention neural tube defects: Results Medical Research Council Vitamin Study. Lancet. 1991;338(8760):131–7. doi.org/10.1016/0140-6736(91)90133-A . 61 Dwyer ER, Filion KB, MacFarlane AJ, Platt RW, Mehrabadi A. consume high-dose folic acid supplement early pregnancy prevention neural tube defects? BMJ. 2022;377:e067728. doi: 10.1136/bmj-2021-067728 . 62 Zetstra-van der Woude PA, De Walle HE, Hoek A, Bos HJ, Boezen HM, Koppelman GH, et al. Maternal high-dose folic acid pregnancy asthma medication offspring. Pharmacoepidemiol Drug Saf. 2014;23(10):1059–65. doi: 10.1002/pds.3652 . 63 Wang T, Zhang HP , Zhang X, Liang ZA, Ji YL, Wang G. folate status risk factor asthma allergic diseases? Allergy Asthma Immunol Res. 2015;7(6):538–46. doi: 10.4168/aair.2015.7.6.538 . 64 Moussa HN, Hosseini Nasab S, Haidar ZA, Blackwell SC, Sibai BM. Folic acid",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4b9be5b1-7199-4243-8f8d-ddd2725e3e79",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "8/aair.2015.7.6.538 . 64 Moussa HN, Hosseini Nasab S, Haidar ZA, Blackwell SC, Sibai BM. Folic acid supplementation: new? Fetal, obstetric, long- term benefit risks. Future Sci OA. 2016;2(2):FSO116. doi: 10.4155/fsoa-2015-0015 . 65 Diabetes pregnancy: management preconception postnatal period. London: National Institute Health Clinical Excellence; 2015 (updated 2020). ( https://www.ncbi.nlm.nih.gov/books/NBK555331/ , accessed 21 November 2024 ). 66 Epilepsy pregnancy. Green top Guideline No. 68. London: Royal College Obstetricians Gynaecologists; 2016. ( https:// www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/epilepsy-in-pregnancy-green-top-guideline-no-68/ , accessed 28 February 2025 ). 67 Care woman obesity pregnancy. Green top Guideline No. 72. London: Royal College Obstetricians Gynaecologists; 2018. ( https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/care-of-women-with-obe",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f3294220-399f-420a-aeee-f5cbfe0933cb",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": ". ( https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/care-of-women-with-obesity-in-pregnancy- green-top-guideline-no-72/ , accessed 28 February 2025 ). 68 Quinn M, Halsey J, Sherliker P , Pan H, Chen Z, Bennett DA, et al. Global heterogeneity folic acid fortification policy implication prevention neural tube defect stroke: systematic review. EClinicalMedicine. 2024;67:102366. doi: 10.1016/j.eclinm.2023.102366 . 69 Jankovic-Karasoulos T, Smith MD, Leemaqz S, Williamson J, McCullough D, Arthurs AL, et al. Elevated maternal folate status change maternal prolactin, placental lactogen placental growth hormone following folic acid food fortification: evidence two prospective pregnancy cohorts. Nutrients. 2023;15(7). doi: 10.3390/nu15071553 . 70 guideline malaria. Geneva: World Health Organization; 2023. ( https://iris.who.int/handle/10665/366432 , accessed 11 January 2025 ). 71 Gutman J, van Eijk AM, Rodriguez E,",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2f47a7ec-acff-44e9-bea1-6ddc83d0214b",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "is.who.int/handle/10665/366432 , accessed 11 January 2025 ). 71 Gutman J, van Eijk AM, Rodriguez E, Ahn J, ter Kuile FO. Sulfadoxine-pyrimethamine resistance intermittent preventive treatment pregnancy (IPTp) prevention malaria pregnancy: systematic review meta-analysis. Zenodo. 2022. doi: 10.5281/zenodo.6559908 . 72 Peters PJ, Thigpen MC, Parise ME, Newman RD. Safety toxicity sulfadoxine/pyrimethamine: implication malaria prevention pregnancy using intermittent preventive treatment. Drug Saf. 2007;30(6):481–501. doi: 10.2165/00002018- 200730060-00003 . 73 Coad J, Stewart R, Pedley K. Iron: Physiology iron. In: Caballero B, Finglas PM, Toldrá F, editors. Encyclopedia Food Health. Oxford: Academic Press; 2016. p. 461–7. 74 Allali S, de Montalembert M, Brousse V, Chalumeau M, Karim Z. Management iron overload hemoglobinopathies. Transfus Clin Biol. 2017;24(3):223–6. doi: 10.1016/j.tracli.2017.06.008 . 75 Raghupathy R, Manwan",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fc119b47-afa1-4d53-a03c-1815a11fa6f9",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": ". Transfus Clin Biol. 2017;24(3):223–6. doi: 10.1016/j.tracli.2017.06.008 . 75 Raghupathy R, Manwani D, Little JA. Iron overload sickle cell disease. Adv Hematol. 2010;2010:272940. doi: 10.1155/2010/272940 . 76 Sangkhae V, Fisher AL, Ganz T, Nemeth E. Iron homeostasis pregnancy: maternal, placental, fetal regulatory mechanisms. Annu Rev Nutr. 2023;43:279–300. doi: 10.1146/annurev-nutr-061021-030404 . 77 Smith C, Teng F, Branch E, Chu S, Joseph KS. Maternal perinatal morbidity mortality associated anemia pregnancy. Obstet Gynecol. 2019;134(6):1234–44. doi: 10.1097 /AOG.0000000000003557 . 78 Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, et al. Maternal anemia risk adverse birth health outcome low- middle-income countries: systematic review meta-analysis. J Clin Nutr. 2016;103(2):495–504. doi: 10.3945/ajcn.115.107896 . Summary management declared interest GDG member 55 recommendations: Management",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0b03f236-2f6e-4cd9-bf8b-a0f69d8979d3",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "6 . Summary management declared interest GDG member 55 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 5679 guideline use ferritin concentration assess iron status individual populations. Geneva: World Health Organization; 2020. ( https://iris.who.int/bitstream/handle/10665/331505/9789240000124-eng.pdf?sequence=1 , accessed 21 November 2024 ). 80 Larsson A, Palm M, Hansson LO, Basu S, Axelsson O. Reference value alpha1-acid glycoprotein, alpha1-antitrypsin, albumin, haptoglobin, C-reactive protein, IgA, IgG IgM pregnancy. Acta Obstet Gynecol Scand. 2008;87(10):1084–8. doi: 10.1080/00016340802428146 . 81 antenatal care recommendation positive pregnancy experience: Nutritional intervention update: Vitamin supplement pregnancy. Geneva; 2020 ( https://iris.who.int/handle/10665/333562 , accessed 11 January 2025 ). 82 Educational module clinical",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "93c56e00-8c24-4d8e-92a1-22915b2d92dd",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "://iris.who.int/handle/10665/333562 , accessed 11 January 2025 ). 82 Educational module clinical use blood. Geneva: World Health Organization; 2021 ( https://iris.who.int/ handle/10665/350246 , accessed 11 January 2025 ). 83 Tsitsikas DA, Badle S, Hall R, Meenan J, Bello-Sanyaolu O, Orebayo F, et al. Automated red cell exchange management sickle cell disease. J Clin Med. 2021;10(4). doi: 10.3390/jcm10040767 . 84 Wang WC, Dwan K. Blood transfusion preventing primary secondary stroke people sickle cell disease. Cochrane Database Syst Rev. 2013(11):CD003146. doi: 10.1002/14651858.CD003146.pub2 . 85 Hankins J, Jeng M, Harris S, Li CS, Liu T, Wang W. Chronic transfusion therapy child sickle cell disease recurrent acute chest syndrome. J Pediatr Hematol Oncol. 2005;27(3):158–61. doi: 10.1097 /01.mph.0000157789.73706.53 . 86 Davis BA, Allard S, Qureshi A, Porter JB, Pancham S, Win N, et al. Guidelines red cell transfusion sickle cell",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b1c09d13-89e7-4f9d-9a9d-533a3e8adf39",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": ", Qureshi A, Porter JB, Pancham S, Win N, et al. Guidelines red cell transfusion sickle cell disease Part II: indication transfusion. Br J Haematol. 2017;176(2):192–209. doi: 10.1111/bjh.14383 . 87 Vichinsky EP. Pulmonary hypertension sickle cell disease. N Engl J Med. 2004;350(9):857–9. doi: 10.1056/NEJMp038250 . 88 Koshy M, Burd L, Dorn L, Huff G. Frequency pain crisis pregnancy. Prog Clin Biol Res. 1987;240:305–11. doi: PMID: 3615495. 89 Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusion pregnant patient sickle cell disease. New Engl J Med. 1988;319(2):1447–52. doi: 10.1056/NEJM198812013192204 . 90 Malinowski AK, Shehata N, D’Souza R, Kuo KH, Ward R, Shah PS, et al. Prophylactic transfusion pregnant woman sickle cell disease: systematic review meta-analysis. Blood. 2015;126(21):2424–35; quiz 37. doi: 10.1182/blood-2015-06-649319 . 91 Oteng-Ntim E, Oakley LL, Robinson V, Brien S, Joseph J, Sharif J, et",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a38de82c-606f-46e5-bd42-75b68ff80f60",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": ".1182/blood-2015-06-649319 . 91 Oteng-Ntim E, Oakley LL, Robinson V, Brien S, Joseph J, Sharif J, et al. Prophylactic exchange transfusion sickle cell disease pregnancy: TAPS2 feasibility randomized controlled trial. Blood Adv. 2024;8(16):4359–69. doi: 10.1182/ bloodadvances.2024012923 . 92 Global status report blood safety availability. Geneva: World Health Organization; 2016 ( https://iris.who.int/ handle/10665/254987 , accessed 11 January 2025 ). 93 Agenda item 11.7, WHA 63.12. Availability, safety quality blood products. In: Sixty-third Word Health Assembly, Geneva, 17–22 May 2010. Geneva: World Health Organization; 2010. ( https://apps.who.int/gb/ebwha/pdf_files/WHA75/A75_40-en.pdf , accessed 21 November 2024) 94 Safe blood blood products. Geneva: World Health Organization; 2009. ( https://cdn.who.int/media/docs/default-source/ blood-transfusion-safety/guidelines-and-principles-for-safe-blood-transfudion-practice-module-1-.pdf?sfvrsn=afabe792_1 , accesse",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "717004be-1492-426f-b7d6-a12863c7ee96",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "elines-and-principles-for-safe-blood-transfudion-practice-module-1-.pdf?sfvrsn=afabe792_1 , accessed 21 November 2024 ). 95 Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) sickle cell disease. Cochrane Database Syst Rev. 2022;9(9):CD002202. doi: 10.1002/14651858.CD002202.pub3 . 96 Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect hydroxyurea frequency painful crisis sickle cell anemia. Investigators Multicenter Study Hydroxyurea Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317–22. doi: 10.1056/NEJM199505183322001 . 97 Chaube S, Murphy ML. effect hydroxyurea related compound rat fetus. Cancer Res. 1966;26(7):1448–57. doi: PMID: 5911587. 98 Wilson JG, Scott WJ, Ritter EJ, Fradkin R. Comparative distribution embryotoxicity hydroxyurea pregnant rat rhesus monkeys. Teratology. 1975;11(2):169–78. doi: 10.1002/tera.1420110205 . recommendations: Management sickle-cell",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d85cc641-b8c4-4b64-8702-2840c11ff855",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "gy. 1975;11(2):169–78. doi: 10.1002/tera.1420110205 . recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 99 Thauvin-Robinet C, Maingueneau C, Robert E, Elefant E, Guy H, Caillot D, et al. Exposure hydroxyurea pregnancy: case series. Leukemia. 2001;15(8):1309–11. doi: 10.1038/sj.leu.2402168 . 100 Kroner BL, Hankins JS, Pugh N, Kutlar A, King AA, Shah NR, et al. Pregnancy outcome hydroxyurea use woman sickle cell disease. J Hematol. 2022;97(5):603–12. doi: 10.1002/ajh.26495 . 101 Ballas SK, McCarthy WF, Guo N, DeCastro L, Bellevue R, Barton BA, et al. Exposure hydroxyurea pregnancy outcome patient sickle cell anemia. J Natl Med Assoc. 2009;101(10):1046–51. doi: 10.1016/s0027-9684(15)31072-5 . 102 Ware R. Hydroxyurea Exposure Limiting Pregnancy Follow-Up Lactation (HELPFUL). 2019. Children’s Hospital Medical Center, Cincinnati. NCT04093986. ( https://clinicaltrials.gov/stud",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "419c636d-9584-4442-bf8a-7840643088c7",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "019. Children’s Hospital Medical Center, Cincinnati. NCT04093986. ( https://clinicaltrials.gov/study/NCT04093986 . accessed 28 February 2025 ). 103 Shepard TH. “Proof” human teratogenicity. Teratology. 1994;50(2):97–8. doi: 10.1002/tera.1420500202 . 104 Stein PD, Beemath A, Meyers FA, Skaf E, Olson RE. Deep venous thrombosis pulmonary embolism hospitalized patient sickle cell disease. J Med. 2006;119(10):897 e7–11. doi: 10.1016/j.amjmed.2006.08.015 . 105 Novelli EM, Huynh C, Gladwin MT, Moore CG, Ragni MV. Pulmonary embolism sickle cell disease: case-control study. J Thromb Haemost. 2012;10(5):760–6. doi: 10.1111/j.1538-7836.2012.04697.x . 106 Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ, 3rd. Trends incidence venous thromboembolism pregnancy postpartum: 30-year population-based study. Ann Intern Med. 2005;143(10):697–706. doi: 10.7326/0003- 4819-143-10-200511150-00006 . 107 James AH, Jamison MG, Brancazio LR, Mye",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ffc2185b-5785-4617-a97d-5332ec00c54c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "97–706. doi: 10.7326/0003- 4819-143-10-200511150-00006 . 107 James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism pregnancy postpartum period: incidence, risk factors, mortality. J Obstet Gynecol. 2006;194(5):1311–5. doi: 10.1016/j.ajog.2005.11.008 . 108 Cresswell JA, Alexander M, Chong MYC, et., al. Global regional cause maternal death 2009-20: systematic analysis. Lancet Glob Health. 2025 Apr;13(4):e626-e634. doi: 10.1016/S2214-109X(24)00560-6. 109 Say L, Chou D, Gemmill A, Tuncalp Ö, Moller A-B, Daniels J, et al. Global cause maternal death: systematic analysis. Lancet Glob Health. 2014;2(6):e323–33. doi: 10.1016/S2214-109X(14)70227-X . 110 Inparaj S, Buckingham M, Oakley L, Seed PT, Lucas S, Oteng-Ntim E. Pulmonary complication woman sickle cell disease pregnancy: systematic review meta-analysis. Thorax. 2020;75(7):568–75. doi: 10.1136/thoraxjnl-2019-213796 . 111 Porter B, Key NS, Jauk VC, Adam S,",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3e703302-d973-4aec-ae07-3e75a66156cb",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "orax. 2020;75(7):568–75. doi: 10.1136/thoraxjnl-2019-213796 . 111 Porter B, Key NS, Jauk VC, Adam S, Biggio J, Tita A. Impact sickle hemoglobinopathy pregnancy-related venous thromboembolism. J Perinatol. 2014;31(9):805–9. doi: 10.1055/s-0033-1361931 . 112 Seaman CD, Yabes J, Li J, Moore CG, Ragni MV. Venous thromboembolism pregnant woman sickle cell disease: retrospective database analysis. Thromb Res. 2014;134(6):1249–52. doi: 10.1016/j.thromres.2014.09.037 . 113 Kane EV, Calderwood C, Dobbie R, Morris C, Roman E, Greer IA. population-based study venous thrombosis pregnancy Scotland 1980–2005. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):223–9. doi: 10.1016/j.ejogrb.2013.03.024 . 114 Liu S, Rouleau J, Joseph KS, Sauve R, Liston RM, Young D, et al. Epidemiology pregnancy-associated venous thromboembolism: population-based study Canada. J Obstet Gynaecol Can. 2009;31(7):611–20. doi: 10.1016/S1701-2163(16)34240-2 . 115 Knight M, UKOSS. Antena",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5122415c-abf0-42d6-ba57-f4905d265271",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "et Gynaecol Can. 2009;31(7):611–20. doi: 10.1016/S1701-2163(16)34240-2 . 115 Knight M, UKOSS. Antenatal pulmonary embolism: risk factors, management outcomes. BJOG. 2008;115(4):453–61. doi: 10.1111/j.1471-0528.2007.01622.x . 116 Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- postnatal risk factor venous thrombosis: hospital-based case-control study. J Thromb Haemost. 2008;6(6):905–12. doi: 10.1111/j.1538-7836.2008.02961.x . 117 Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism pregnancy puerperium: incidence additional risk factor London perinatal database. BJOG. 2001;108(1):56–60. doi: 10.1111/j.1471-0528.2001.00004.x . 118 Larsen TB, Sorensen HT, Gislum M, Johnsen SP. Maternal smoking, obesity, risk venous thromboembolism pregnancy puerperium: population-based nested case-control study. Thromb Res. 2007;120(4):505–9. doi: 10.1016/j. thromres.2006.12.003 . 119 Lindqvist P , Dahlbäck B, Marŝál K.",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d347872e-eb05-4b3d-8555-81b197da7078",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "s. 2007;120(4):505–9. doi: 10.1016/j. thromres.2006.12.003 . 119 Lindqvist P , Dahlbäck B, Marŝál K. Thrombotic risk pregnancy: population study. Obstet Gynecol. 1999;94(4):595–9. doi: 10.1016/s0029-7844(99)00308-7 . 120 Anderson FA, Jr., Spencer FA. Risk factor venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I9–16. doi: 10.1161/01. CIR.0000078469.07362.E6 . Summary management declared interest GDG member 57 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 58121 Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk first venous thromboembolism pregnant woman hospital: population based cohort study England. BMJ. 2013;347:f6099. https://doi.org/10.1136/bmj.f6099 . 122 Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk first venous thromboembolism around pregnancy: population-based cohort study. Br J Haematol. 2012;",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9df5a546-4b94-465d-8578-9741c54513eb",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "nous thromboembolism around pregnancy: population-based cohort study. Br J Haematol. 2012;156(3):366–73. doi: 10.1111/j.1365-2141.2011.08956.x . 123 Bröms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Complications inflammatory bowel disease pregnancy delivery. Clin Gastroenterol Hepatol. 2012;10(11):1246–52. doi: 10.1016/j.cgh.2012.08.018 . 124 HS, Kim DY, Yang MS, Lee SJ, Shin H-H, Park JB. Pregnancy-induced hypertension, gestational diabetes mellitus, risk factor venous thromboembolism pregnancy. Korean Circ J. 2011;41(1):23–7. doi: 10.4070/kcj.2011.41.1.23 . 125 Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence risk pattern venous thromboembolism pregnancy puerperium--a register-based case-control study. J Obstet Gynecol. 2008;198(2):233 e1–7. doi: 10.1016/j.ajog.2007.08.041 . 126 Areia AL, Mota-Pinto A. Experience direct oral anticoagulant pregnancy - systematic review. J Perinat Med",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "31095df6-b97e-4d4d-bae8-58b2347c75d2",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "A. Experience direct oral anticoagulant pregnancy - systematic review. J Perinat Med. 2022;50(4):457–61. doi: 10.1515/jpm-2021-0457 . 127 Ng AP , Verma A, Sanaiha Y, Williamson CG, Afshar Y, Benharash P. Maternal fetal outcome pregnant patient mechanical bioprosthetic heart valves. J Heart Assoc. 2023;12(10):e028653. doi: 10.1161/JAHA.122.028653 . 128 Flessa HC, Kapstrom AB, Glueck HI, JJ. Placental transport heparin. J Obstet Gynecol. 1965;93(4):570–3. doi: 10.1016/0002-9378(65)90518-1 . 129 Clark NP , Delate T, Witt DM, Parker S, McDuffie R. descriptive evaluation unfractionated heparin use pregnancy. J Thromb Thrombolysis. 2009;27(3):267–73. doi: 10.1007/s11239-008-0207-0 . 130 Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P , Burrows R. Heparin therapy pregnancy. Risks fetus mother. Arch Intern Med. 1989;149(10):2233–6. PMID: 2802889 . 131 Forestier F, Daffos F, Capella-Pavlovsky M. Low molecula",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "57939c59-ff0c-4a4a-93a0-1513e1f8e5e7",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": ". 1989;149(10):2233–6. PMID: 2802889 . 131 Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) cross placenta second trimester pregnancy study direct fetal blood sampling ultrasound. Thromb Res. 1984;34(6):557–60. doi: 10.1016/0049- 3848(84)90260-3 . 132 Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (CY 216) cross placenta third trimester pregnancy. Thromb Haemost. 1987;57(2):234. PMID: 3603416. 133 Peeters LL, Hobbelen PM, Verkeste CM, Vogel GM, Hasenack HG, Meuleman DG, et al. Placental transfer Org 10172, low- molecular weight heparinoid, awake late-pregnant guinea pig. Thromb Res. 1986;44(3):277–83. doi: 10.1016/0049- 3848(86)90002-2 . 134 Henny CP , ten Cate H, ten Cate JW, Prummel MF, Peters M, Buller HR. Thrombosis prophylaxis III deficient pregnant woman: application low molecular weight heparinoid. Thromb Haemost. 1986;55",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "32073e7a-00f4-4dc7-bc55-a812ab2af138",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "deficient pregnant woman: application low molecular weight heparinoid. Thromb Haemost. 1986;55(2):301. PMID: 3715796. 135 Greinacher A, Eckhardt T, Mussmann J, Mueller-Eckhardt C. Pregnancy complicated heparin associated thrombocytopenia: management prospectively vitro selected heparinoid (Org 10172). Thromb Res. 1993;71(2):123–6. doi: 10.1016/0049- 3848(93)90178-q . 136 Lindhoff-Last E, Kreutzenbeck H-J, Magnani HN. Treatment 51 pregnancy danaparoid heparin intolerance. Thromb Haemost. 2005;93(1):63–9. https://doi.org/10.1160/th04-06-0345 . 137 Warkentin TE, Levine MN, Hirsh J, Horsewood P , Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia patient treated low-molecular-weight heparin unfractionated heparin. N Engl J Med. 1995;332(20):1330–5. doi: 10.1056/ NEJM199505183322003 . 138 Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337(10):688–98. doi: 10.1056/NEJM199709043371007 . 139 Lim W, Dentali F, Eikelboo",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8fe759c3-6a36-48d4-a70f-202fbda162e0",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "N Engl J Med. 1997;337(10):688–98. doi: 10.1056/NEJM199709043371007 . 139 Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin bleeding patient severe renal insufficiency. Ann Intern Med. 2006;144(9):673–84. doi: 10.7326/0003-4819-144-9-200605020-00011 . 140 Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance treatment prevention obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):92–128. doi: 10.1007/s11239-015-1309-0 . 141 recommendation antiplatelet agent prevention pre-eclampsia. Geneva: World Health Organization; 2021. (https://iris.who.int/handle/10665/350190 , accessed 28 February 2025). recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 142 Ramakrishnan M, Moïsi JC, Klugman KP , Iglesias JMF, Grant LR, Mpoudi-Etame M, et al. Increased risk invasive bacterial infection African people wi",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5e92e4ec-4f72-44ef-b6f2-fbbd79e65a2e",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ant LR, Mpoudi-Etame M, et al. Increased risk invasive bacterial infection African people sickle-cell disease: systematic review meta-analysis. Lancet Infect Dis. 2010;10(5):329–37. doi: 10.1016/S1473-3099(10)70055-4 . 143 Bruno D, Wigfall DR, Zimmerman SA, Rosoff PM, Wiener JS. Genitourinary complication sickle cell disease. J Urol. 2001;166(3):803–11. PMID: 11490223 . 144 Darbari DS, Wang Z, Kwak M, Hildesheim M, Nichols J, Allen D, et al. Severe painful vaso-occlusive crisis mortality contemporary adult sickle cell anemia cohort study. PLoS One. 2013;8(11):e79923. doi: 10.1371/journal.pone.0079923 . 145 Salari N, Khoshbakht Y, Hemmati M, Khodayari Y, Khaleghi AA, Jafari F, et al. Global prevalence urinary tract infection pregnant mothers: systematic review meta-analysis. Public Health. 2023;224:58–65. doi: 10.1016/j.puhe.2023.08.016 . 146 Daw NC, Wilimas JA, Wang WC, Presbury GJ, Joyner RE, Harris SC, et al. Nasopharyngeal carriage",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "74e09f5c-f4ff-47a5-8054-60e6742de527",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "46 Daw NC, Wilimas JA, Wang WC, Presbury GJ, Joyner RE, Harris SC, et al. Nasopharyngeal carriage penicillin-resistant Streptococcus pneumoniae child sickle cell disease. Pediatrics. 1997;99(4):E7. doi: 10.1542/peds.99.4.e7 . 147 Dayie NTKD, Tetteh-Ocloo G, Labi AK, Olayemi E, Slotved H-C, Lartey M, et al. Pneumococcal carriage among sickle cell disease patient Accra, Ghana: Risk factors, serotypes antibiotic resistance. PLoS One. 2018;13(11):e0206728. doi: 10.1371/journal. pone.0206728 . 148 WHO. Antimicrobial resistance [website]. Geneva:World Health Organization; 2023 ( https://www.who.int/news-room/fact-sheets/ detail/antimicrobial-resistance , accessed 12 January 2025 ). 149 AWaRe (Access, Watch, Reserve) antibiotic book. Geneva: World Health Organization; 2022. ( https://iris.who.int/ handle/10665/365237 , accessed 28 February 2025 ). 150 Ballas SK, Lusardi M. Hospital readmission adult acute sickle cell painful episodes: frequency, etiology,",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "134f612d-dfa1-4636-8624-82d73b4a29cb",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "Lusardi M. Hospital readmission adult acute sickle cell painful episodes: frequency, etiology, prognostic significance. J Hematol. 2005;79(1):17–25. doi: 10.1002/ajh.20336 . 151 Powars DR, Sandhu M, Niland-Weiss J, Johnson C, Bruce S, Manning PR. Pregnancy sickle cell disease. Obstet Gynecol. 1986;67(2):217–28. doi: 10.1097 /00006250-198602000-00012 . 152 Martin JN, Jr., Martin RW, Morrison JC. Acute management sickle cell crisis pregnancy. Clin Perinatol. 1986;13(4):853–68. PMID: 3539455 . 153 Bisson DL, Newell SD, Laxton C, behalf Royal College Obstetricians Gynaecologists. Antenatal postnatal analgesia: Scientific impact paper No. 59. BJOG. 2019;126(4):e114–e24. doi: 10.1111/1471-0528.15510 . 154 Chen X, Yang Y, Chen L, Wang K. Pregnancy outcome birth defect offspring following Non-steroidal anti-inflammatory drug exposure pregnancy: systematic review meta-analysis. Reprod Toxicol. 2024;125:108561. doi: 10.1016/",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e3d93dca-c1a2-4e7c-9b10-902fb9c5ce0c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ing pregnancy: systematic review meta-analysis. Reprod Toxicol. 2024;125:108561. doi: 10.1016/j. reprotox.2024.108561 . 155 Joint Formulary Committee. BNF 81 (British National Formulary) March–September 2021. Pharmaceutical Press; 2021. ( https:// www.nice.org.uk/bnf-uk-only , accessed 28 February 2025). 156 Han J, Saraf SL, Lash JP , Gordeuk VR. Use anti-inflammatory analgesic sickle-cell disease. J Clin Pharm Ther. 2017;42(5):656- 60. doi: 10.1111/jcpt.12592 . 157 Macey-Stewart KV, Louie K. Using individualized pain management plan African American adult sickle cell disease. J Assoc Nurse Pract. 2023;35(7):434–40. doi: 10.1097 /JXX.0000000000000885 . 158 Krishnamurti L, Smith-Packard B, Gupta A, Campbell M, Gunawardena S, Saladino R. Impact individualized pain plan emergency management child sickle cell disease. Pediatr Blood Cancer. 2014;61(10):1747–53. doi: 10.1002/pbc.25024 . 159 Della-Moretta S, Delatore L, Purcell M, Huang",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e1369a6b-642f-4494-bb42-25a8a5546e13",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "r. 2014;61(10):1747–53. doi: 10.1002/pbc.25024 . 159 Della-Moretta S, Delatore L, Purcell M, Huang Y, Heinlein M, Adkins E, et al. effect use individualized pain plan sickle cell patient presenting emergency department. Ann Emerg Med. 2020;76(3S):S21–S7. doi: 10.1016/j. annemergmed.2020.08.008 . 160 Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: critical reappraisal. Blood. 2012;120(18):3647–56. doi: 10.1182/ blood-2012-04-383430 . 161 Pandey S, Tan EFS, Bellamkonda A, Aryal B, Karki S, Boddu G, et al. Intravenous hydration associated outcome patient sickle cell disease admitted vaso-occlusive crises: systematic review. Cureus. 2024;16(2):e54463. doi: 10.7759/ cureus.54463 . 162 Gaartman AE, Sayedi AK, Gerritsma JJ, de Back TR, van Tuijn CF, Tang MW, et al. Fluid overload due intravenous fluid therapy vaso-occlusive crisis sickle cell disease: incidence risk factors. Br J Haematol. 2021;194(5):899–907. doi: 10.1111/bj",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c3086839-3c22-4c5a-92c4-330a57c34f0f",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "sickle cell disease: incidence risk factors. Br J Haematol. 2021;194(5):899–907. doi: 10.1111/bjh.17696 . Summary management declared interest GDG member 59 recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period 60163 Carden MA, Brousseau DC, Ahmad FA, Bennett J, Bhatt S, Bogie A, et al. Normal saline bolus use pediatric emergency department associated poorer pain control child sickle cell anemia vaso-occlusive pain. J Hematol. 2019;94(6):689–96. doi: 10.1002/ajh.25471 . 164 Carden MA, Fay ME, Lu X, Mannino RG, Sakurai Y, Ciciliano JC, et al. Extracellular fluid tonicity impact sickle red blood cell deformability adhesion. Blood. 2017;130(24):2654–63. doi: 10.1182/blood-2017-04-780635 . 165 Bookchin RM, Balazs T, Landau LC. Determinants red cell sickling. Effects varying pH increasing intracellular hemoglobin concentration osmotic shrinkage. J Lab Clin Med",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "af93c120-da03-41e6-8b65-63b5b4c515cd",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ng pH increasing intracellular hemoglobin concentration osmotic shrinkage. J Lab Clin Med. 1976;87(4):597–616. PMID: 5563 . 166 Crozier T. Fluid management complicated obstetric patient. In: Lapinsky S, editor. Principles practice obstetric high- dependency critical care. Global Library Women’s Medicine; 2021. ( https://www.glowm.com/womens-medicine-series- obstetric/heading/vol-9--principles-and-practice-of-obstetric-highdependency-and-critical-care/id/409263 , accessed 1 March 2025). 167 Okomo U, Meremikwu MM. Fluid replacement therapy acute episode pain people sickle cell disease. Cochrane Database Syst Rev. 2017;7(7):CD005406. doi: 10.1002/14651858.CD005406.pub5 . 168 Jordan Bruno X, Koh I, Lutsey PL, Walker RF, Roetker NS, Wilkinson K, et al. Venous thrombosis risk medical surgical hospitalizations: medical inpatient thrombosis hemostasis (MITH) study. J Thromb Haemost. 2022;20(7):1645– 52. doi: 10.111",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0581be25-2e34-48da-9d54-611af303b9ff",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "inpatient thrombosis hemostasis (MITH) study. J Thromb Haemost. 2022;20(7):1645– 52. doi: 10.1111/jth.15729 . 169 Malinowski AK, Dziegielewski C, Keating S, Parks T, Kingdom J, Shehata N, et al. Placental histopathology sickle cell disease: descriptive hypothesis-generating study. Placenta. 2020;95:9–17. doi: 10.1016/j.placenta.2020.04.003 . 170 Wright E, Audette MC, Ye XY, Keating S, Hoffman B, Lye SJ, et al. Maternal vascular malperfusion adverse perinatal outcome low-risk nulliparous women. Obstet Gynecol. 2017;130(5):1112–20. doi: 10.1097 /AOG.0000000000002264 . 171 Mongelli M, Ek S, Tambyrajia R. Screening fetal growth restriction: mathematical model effect time interval ultrasound error. Obstet Gynecol. 1998;92(6):908–12. doi: 10.1016/s0029-7844(98)00349-4 . 172 Leung KY. Applications advanced ultrasound technology obstetrics. Diagnostics (Basel). 2021;11(7). doi: 10.3390/ diagnostics11071217 . 173 Milner J, Arezina J. accurac",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "620f8fb5-1c3c-49cf-aff6-d0b797400edb",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "ostics (Basel). 2021;11(7). doi: 10.3390/ diagnostics11071217 . 173 Milner J, Arezina J. accuracy ultrasound estimation fetal weight comparison birth weight: systematic review. Ultrasound. 2018;26(1):32–41. doi: 10.1177/1742271X17732807 . 174 recommendation induction labour, beyond term. Geneva: World Health Organization; 2022 ( https://iris.who.int/ handle/10665/363138 , accessed 12 January 2025 ). 175 Moncrieff G, Finlayson K, Cordey S, McCrimmon R, Harris C, Barreix M, et al. First second trimester ultrasound pregnancy: systematic review metasynthesis view experience pregnant women, partners, health workers. PLoS One. 2021;16(12):e0261096. doi: 10.1371/journal.pone.0261096 . 176 statement caesarean section rates. Geneva: World Health Organization; 2015. ( https://www.who.int/publications/i/item/ WHO-RHR-15.02 , accessed 21 November 2024 ). 177 Colomar M, Opiyo N, Kingdon C, Long Q, Nion S, Bohren MA, et",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "23334b5e-ffc9-476d-9f1e-7e2f3e14ac89",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "02 , accessed 21 November 2024 ). 177 Colomar M, Opiyo N, Kingdon C, Long Q, Nion S, Bohren MA, et al. woman prefer caesarean sections? qualitative evidence synthesis view experiences. PLoS One. 2021;16(5):e0251072. doi: 10.1371/journal.pone.0251072 . 178 Poliektov NE, Vuncannon DM, Ha TK, Lindsay MK, Chandrasekaran S. association sickle cell disease postpartum severe maternal morbidity. J Perinatol. 2024. doi: 10.1055/s-0044-1786174 . 179 Medical eligibility criterion wheel contraceptive use 2015. Geneva: World Health Organization; 2015 ( https://iris.who.int/ handle/10665/173585 , accessed 12 January 2025 ). 180 Nnodu OE, Sopekan A, Nnebe-Agumadu U, Ohiaeri C, Adeniran A, Shedul G, et al. Implementing newborn screening sickle cell disease part immunisation programme Nigeria: feasibility study. Lancet Haematol. 2020;7(7):e534–e40. doi: 10.1016/ S2352-3026(20)30143-5 . 181 Ware RE, Marahatta A, Ware JL, McElhinney K, Dong M, V",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fa89aec1-61b7-4c19-8bac-04c9605567a4",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "40. doi: 10.1016/ S2352-3026(20)30143-5 . 181 Ware RE, Marahatta A, Ware JL, McElhinney K, Dong M, Vinks AA. Hydroxyurea Exposure Lactation: Pharmacokinetics Study (HELPS). J Pediatr. 2020;222:236–9. doi: 10.1016/j.jpeds.2020.02.002 . 182 Standards improving quality maternal newborn care health facilities. Geneva: World Health Organization; 2016. (https://iris.who.int/handle/10665/249155 , accessed 12 January 2025 ). recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period recommendations: Management sickle-cell disease pregnancy, childbirth interpregnancy period World Health Organization Department Sexual Reproductive Health Research 20 Avenue Appia 1211 Geneva 27 Switzerland Email: srhhrp@who.int Website: https://www.who.int/teams/sexual-and-reproductivehealth-and-research-(srh)/ www.who.int",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7b211bc3-b163-4812-bd0a-55eb69a48a7c",
        "title": "Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period",
        "body": "h)/ www.who.int",
        "source": "WHO Guidelines: Management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "07aea1c0-a9c0-461a-b864-db76f0e8d686",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "Clinical management infection prevention control mpox Living guideline May 2025 Clinical management infection prevention control mpox Living guideline May 2025 © World Health Organization 2025 right reserved. work available Creative Commons Attribution- NonCommercial -ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by -nc-sa/3.0/igo ). term licence, may copy, redistribute adapt work non-commercial purposes, provided work appropriately cited, indicated below. use work, suggestion endorses specific organization, product services. use logo permitted. adapt work, must license work equivalent Creative Commons licence. create translation work, add followi ng disclaimer along su",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9735a9d0-29c1-40f3-b127-4e4e09c92373",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "f create translation work, add followi ng disclaimer along suggested citation: “This translation created World Health Organization (WHO). responsible content accuracy translation. original English edition shall binding authentic edition”. mediation relating dispute arising licence shall conducted accordance mediation rule World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/ ). Suggested citation . Clinical management infection prevention control mpox: living guideline, May 2025 . Geneva: World Health Organization; 2025 . https://doi.org/10.2471/B09434 . Licence: CC BY-NC-SA 3.0 IGO. Cataloguing -in-Publication (CIP) data. CIP data available https://iris.who.int/ . Sales, right licensing. purchase publications, see https://www.who.int/publications/book -orders . submit r",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c21ec9dd-f142-4462-a15f-3cf91b69608d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "sing. purchase publications, see https://www.who.int/publications/book -orders . submit request commercial use query right licensing, see https://www.who.int/copyright . Third -party materials. wish reuse material work attributed third party, tables, figure images, responsibility determine whether permission needed reuse obtain permission copyright holder. risk claim resulting infringement third- party -owned component work rest solely user. General isclaimers. designation employed presentation material publication imply expression opinion whatsoever part concerning legal status country, territory, city area authorities, concer ning delimitation frontier boundaries. Dotted dashed line map represent approximate bord",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "548144e0-6ba0-40e2-8d11-d0f815d1b828",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "mitation frontier boundaries. Dotted dashed line map represent approximate border line may yet full agreement mention specific company certain manufacturers’ product imply endorsed recommended preference others similar nature mentioned. Errors omission excepted, name proprietary product distinguished initial capital letter reasonable precaution taken verify information contained publication. However, published material distributed without warranty kind, either expressed implied. responsibility interpretation use material lie reader. event shall liable damage arising use. Contents 1. Executive summary ................................................................................ xviii 1.1 Clinical question: Wha",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "645624a1-6f7f-481a-9cd9-33d89effaa60",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "................................................................ xviii 1.1 Clinical question: clinical IPC intervention use caring patient mpox? ......................................................................................................................... xviii 1.2 New infection prevention control recommendation .................................................. xviii 1.3 New clinical management recommendation ............................................................................xix 2. Introduction ................................................................................................ 1 2.1 Mpox clade ............................................................................................................................................. 1 2.1.1 Update mpox outbreak virus clade using evidence available January 2025 ..........................................................",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2274a12f-03bb-4992-aa50-608e7671d95b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "evidence available January 2025 ...................................................................................................................................... 1 2.1.2 Clade Ia MPXV ...................................................................................................................... 1 2.1.3 Clade Ib MPXV ..................................................................................................................... 2 2.1.4 Clade IIa MPXV ..................................................................................................................... 3 2.1.5 Clade IIb MPXV .................................................................................................................... 3 2.2 Natural history ........................................................................................................................................ 4 2.3 Signs symptom ..................................................",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b6c53a35-d11c-4956-b890-e1b743ad0993",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ".................... 4 2.3 Signs symptom ............................................................................................................................ 4 2.3.1 Severe disease complication ................................................................................. 6 2.4 Laboratory finding ............................................................................................................................... 6 2.5 Differential diagnosis ............................................................................................................................ 6 2.6 Pregnant people postpartum period ..................................................................................... 7 2.7 Mid-and-long-term effect ................................................................................................................. 8 2.8 Transmission viral shedding ..........................................................",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9c55a82b-f835-4990-a3fa-30d22fe5b955",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "8 2.8 Transmission viral shedding ...................................................................................................... 8 2.8.1 Infectious period ................................................................................................................ 10 2.8.2 Children ................................................................................................................................ 11 2.8.3 Wastewater surveillance ................................................................................................. 11 3. recommendation apply to? ............................................. 12 3.1 Risk factor severe disease ......................................................................................................... 12 3.2 Prognosis ................................................................................................................................................ 15 3.2.1 Risk",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f87ab1f0-49b3-436d-b204-06d15930dbe3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "............................................................................. 15 3.2.1 Risk adverse outcome ............................................................................................. 15 3.3 Rate complication ......................................................................................................................... 15 ii 3.3.1 Rate complication ...................................................................................................... 15 4. Recommendations mpox care pathway ....................................... 17 4.1 Screening triage ........................................................................................................................... 17 4.1.1 Screening ............................................................................................................................. 17 4.1.2 Triage ...............................................................................",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "718710f2-4100-42ae-ad82-7b7851b442bc",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ". 17 4.1.2 Triage ..................................................................................................................................... 18 4.2 Testing mpox ................................................................................................................................... 20 5. Recommendations patient mild uncomplicated mpox (home - based care) ................................................................................................ 21 5.1 Infection prevention control (IPC) consideration home -based care ................. 21 5.1.1 Infection prevention control measure ............................................................ 22 5.1.2 Isolation patient mpox ................................................................................... 25 5.1.3 Symptomatic management ........................................................................................... 31 6. Recommenda",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "81f2ce04-037a-4b05-b2c2-43eb9c0db9ef",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ".................................................................................. 31 6. Recommendations patient high risk complication severe mpox ......................................................................................... 37 6.1 Infection prevention control health facility (New recommendations) ............. 37 6.1.1 Infection prevention control consideration ................................................. 39 6.1.2 Visitors isolated mpox patient .............................................................................. 46 6.1.3 Optimized supportive care ............................................................................................ 46 6.2 Timing ART initiation people living HIV (New recommendation ) .................. 48 6.2.1 Rapid ART initiation standard care ........................................................... 48 6.2.2 Mpox ART initiation",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4bc76eff-ae80-479f-a8f8-c1f416540eef",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "care ........................................................... 48 6.2.2 Mpox ART initiation ................................................................................................. 48 6.3 Breastfeeding mpox (New recommendation) ................................................................... 53 6.3.1 Breastfeeding ..................................................................................................................... 53 6.3.2 Resuming breastfeeding ................................................................................................ 60 6.4 Caring people mpox pregnancy .................................................. 64 6.4.1 Place care pregnancy ................................................................................... 64 6.4.2 Care pregnancy ................................................................................................... 64 6.4.3 Mode b",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4252b622-87a7-4cf7-99f1-7e07d8d100ad",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ".............................................................................. 64 6.4.3 Mode birth ..................................................................................................................... 65 6.4.4 Pregnancy postpartum period ............................................................................ 66 iii 6.5 Caring infant young child mpox .................................................................. 67 6.5.1 Monitoring newborn infant ................................................................................... 67 6.6 Recommendations patient mpox sexually active .................................. 68 6.6.1 Sex close physical contact .................................................................................... 68 6.6.2 Use barrier contraception ........................................................................................ 69 6.7 Recommendations ca",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c21a8573-3486-4e02-baee-29aa57f288f4",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "................................................................... 69 6.7 Recommendations caring mpox patient acute infection ............................ 70 6.7.1 Follow -up care ................................................................................................................... 70 6.8 Recommendations antiviral therapy (under revision) .............................. 70 6.9 Recommendation mental psychosocial support patient mpox .......... 70 6.9.1 Anxiety depressive symptom ............................................................................. 70 6.9.2 Sleep problem .................................................................................................................. 73 6.10 Recommendation deceased patient management ............................................................ 74 6.10.1 Handling human remains .............................................",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5579b1d6-5eef-45bc-a8cf-602a46fffe0a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ".............. 74 6.10.1 Handling human remains ......................................................................................... 74 6.11 Recommendations health care worker occupational exposure mpox 75 6.11.1 Occupational exposure mpox ................................................................................. 75 7. Methods: guideline created ............................................... 76 7.1 Types statement ............................................................................................................................ 77 7.1.1 Recommendations ........................................................................................................... 77 7.1.2 Good practice statement implementation consideration ...................... 77 7.2 Step-wise approach - application GRADE methodology ................................................. 78 7.2.1 Step 1: Evidence monitoring",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3a5d70e8-1189-49da-96bd-7c0a88c335f1",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "thodology ................................................. 78 7.2.1 Step 1: Evidence monitoring mapping triggering evidence synthesis 78 7.2.2 Step 2: Convening GDG .......................................................................................... 79 7.2.3 Step 3: Evidence synthesis assessment ............................................................ 80 7.2.4 Step 4: Recommendations ............................................................................................ 80 7.2.5 Step 5: External internal review ........................................................................... 81 7.3 GDG topic -specific working group ............................................................................................. 81 7.3.1 Infection prevention control technical working group .............................. 82 7.3.2 Breastfeeding technical working group pre-GDG discussion ........................... 83",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "54ce0f0a-6c92-41a8-8bdb-1d399fd2547d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "7.3.2 Breastfeeding technical working group pre-GDG discussion ........................... 83 7.3.3 HIV antiretroviral technical working group pre-GDG discussion ..................... 85 iv 7.4 Risk factor severe disease prognosis methodology .............................................. 86 8. access use guideline ........................................................ 88 8.1 access guideline ............................................................................................................ 88 8.2 navigate guideline ....................................................................................................... 88 8.3 Additional educational module implementation tool health worker .......... 89 8.4 Collection standardized data Clinical Platform ....................................... 90 9. Uncertainties, emerging evidence future research .....",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9c0b63ed-575c-4a4e-8b79-a4f00d2c576e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "............................... 90 9. Uncertainties, emerging evidence future research ............................ 91 9.1 Transmission .......................................................................................................................................... 91 9.2 Clinical management .......................................................................................................................... 91 9.3 Infection prevention control .................................................................................................... 92 9.4 Methods question ............................................................................................................................. 92 10. References ................................................................................................. 93 Tables Table 1. Risk factor clinical finding described associated severe disease poor outcome (based",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b4c6c799-0051-424a-99a7-d6e3f3547d00",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ical finding described associated severe disease poor outcome (based small, uncontrolled observational studies) (Published 2022) ....................................................................................................................................................................................... 12 Table 2. Risk factor associated severe disease hospitalization .............................................. 13 Table 3. Risk factor associated mortality ............................................................................................. 14 Table 4. Baseline risk adverse outcome patient mpox ..................................................... 15 Table 5. Baseline risk complication mpox ........................................................................................ 15 Table 6. Readership cue used statement guideline .............................",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e1629818-bcb7-425d-8404-1ffccdae5483",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "15 Table 6. Readership cue used statement guideline ............................................................. 78 Table 7. Levels certainty evidence .......................................................................................................... 80 v Acknowledgements World Health Organization (WHO) would like thank collaborative effort involved making process efficient, trustworthy transparent. following group contributed version guideline. coordination team Janet Diaz, Marta Lado, Jamie Rylance, Julie Viry, Daniel Youkee (Clinical Management Operations, Health Emergencies Programme, Geneva, Switzerland); April Baller, Hannah Hamilton Hurwitz, Nosheen Usman, Victoria Willet (Infection Prevention Control Water Sanitation Hygiene, Health Emergencies Programme, Geneva, Switzerland). Steering Committee mpox Steering Committe",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3289233e-3384-43bf-914a-f1e58026b20b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "cies Programme, Geneva, Switzerland). Steering Committee mpox Steering Committee mpox includes representative department regional office headquarters, including specialty technical input fully responsible decision guidance production convening Guideline Development Group (GDG). Hana Bekele (Nutrition Physical Activity, Regional Office Africa); Mercedes Bonet Semenas (Sexual Reproductive Health Research, Geneva, Switzerland); Giorgio Cometto (Health Workforce, Geneva, Switzerland); Ana Pau la Coutino Rehse (Infection Prevention Control, Regional Office Europe); Queen Dube (Newborn Health, Geneva, Switzerland); Lennox Ebbarnezh (Acute Events, Geneva, Switzerland); Fahmy Hanna (Department Mental Health Substance Abus e, Geneva, Switzerland); Iman Heweidy (Infection Prevention Control, Regional Office Eastern Mediterranean); Ana Hoxha (Acu",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e6bdd170-f68b-469f-8daf-4191eb89cfa3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "nfection Prevention Control, Regional Office Eastern Mediterranean); Ana Hoxha (Acute Events, Geneva, Switzerland); Landry Kabego (Infection Prevention Control, Regional Office Afr ica); Rashidatu Kamara (Clinical Management, Regional Office Africa); Janet Kayita (Child Adolescent Health, Regional Office Africa); Chiori Kodama (Clinical Management, Regional Office Eastern Mediterranean); Rosamund Lewis (Global Infectious Hazard Preparedness/Emerging Zoonotic Diseases, Geneva, Switzerland); Zhao Li (Infection Prevention Control, Regional Office Western Pacific); Tamano Matsui (Clinical Management, Regional Office Western Pacif ic); Sandra Milena (Infection Prevention Control, Pan American Health Organization [PAHO]); Lorenzo Moja (Essentials Medicines, Geneva, Switzerland); Thomas Moran (Risk Communication, Community Engagement Infodemic Management, vi Geneva, Switze",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "36b64805-1f0d-4174-a390-ffcd019bf42d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "Moran (Risk Communication, Community Engagement Infodemic Management, vi Geneva, Switzerland); Dorthy Ngailo (Occupational Health, Geneva, Switzerland); Adelheid Onyango (Healthier Populations Cluster, Regional Office Africa); Remco Peters (Global HIV, Hepatitis STIs Programmes, Geneva, Switzerland); Dina Pf eifer (Clinical Management, Regional Office Europe); Angel Rodriguez (Clinical Management, PAHO); Giovanni Satta (Infection Prevention Control Unit Hub, Geneva, Switzerland); Aparna Shah (Infection Prevention Control, Regional ffice South -East Asia); Nosheen Usman (Infection Prevention Control Water Sanitation Hygiene, Geneva, Switzerland); Wilson (Maternal, Newborn, Child Adolescent Health, Geneva, Switzerland); Pushpa Wijesinghe (Clinical Manag ement, Regional Office South- East Asia). Guideline Development Group Pierre Abi Hanna (Rafik Hariri University Hospital,",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "761a9e4b-6bf8-406a-aa96-f2fec79d2a30",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "th- East Asia). Guideline Development Group Pierre Abi Hanna (Rafik Hariri University Hospital, Lebanon); Mary Adanma Alex-Wele (University Port Harcourt University Port Harcourt Teaching Hospital, Nigeria); Meaghen Allen (Canadian Institute Public Health Inspectors, Canada); Bartholome w Boniface Ochonye (Heartland Alliance International, Nigeria); Andre Bulabula (Africa Centres Disease Control Prevention, Ethiopia); Shama Cash - Goldwasser (Pox Rabies Branch, United States Centers Disease Control Prevention [CDC], Unit ed States America); Mark Cotton (University Cape Town, South Africa); Henry DeVries (Amsterdam University Medical Centre, Kingdom Netherlands); Jake Dunning (Royal Free London HHS Foundation, United Kingdom Great Britain Northern Irelan d); Carole Fry (UK Health Security Agency, United Kingdom); Michelle Giles (University Melbourne, Australia); Beatriz Grinsztejn (Fiocruz, Brazil); Ahmed Hakawi (Ministr",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cb9d47b4-10d5-4f64-97f4-7ecbdf163bfe",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "e (University Melbourne, Australia); Beatriz Grinsztejn (Fiocruz, Brazil); Ahmed Hakawi (Ministry Health, Saudi Arabia); Lisa Hensley (United States Department Agriculture) [ participated 2025]; Prince Imani - Musimwa (University Goma, Democratic Republic Congo); Yuguo Li (Department Mechanical Engineering, University Hong Kong, Hong Kong SAR, China); Kushlani Jayatilleke (Sri Jayewardenepura General Hos pital, Sri Lanka); Nagwa Khamis (Children’s Cancer Hospital Egypt Shams University); Jason Kindrachuk (University Manitoba, Canada); Kalisvar Marimuthu (Communicable Diseases Agency, Singapore National Centre Infectious Diseases, Singapore); Geeta Mehta (Journal Patient Safety Infection Control, India); Graeme Meintjes (University Cape Town, South Africa); Sharon Nachman (Stony Brook Children’s Hospital, United States America); Grace Ndeezi (Makerere University Health Sciences, Uganda); Chloe Orkin (Quee",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2c90ca36-ca7f-4452-beb6-9c82d559f6ed",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "States America); Grace Ndeezi (Makerere University Health Sciences, Uganda); Chloe Orkin (Queen Mary University, London, United Kingdom); Diamantis Plachouras (European Centre Disease Prevention Control, Sweden); vii Priscilla Rupali (Christian Medical College Vellore Tamil Nadu, India); Nadia Sam - Agudu (Institute Human Virology, Nigeria); Beate Sander (University Health Network, Canada); Mark Sobsey (University North Carolina Chapel Hill United States Amer ica); Shalini Sri Ranganathan (University Colombo, Sri Lanka); Joseph Tannous (Emirates Health Services, United Arab Emirates); Valdilea Veloso (Fiocruz, Brazil); Mija Ververs (Center Humanitarian Health, Johns Hopkins Bloomberg School Public Hea lth Baltimore, United States America); Ian Wolley (Monash Health, Australia). Methodologists: Gordon Guyatt (McMaster University, Canada); Manya Prasad (Institute Liver Biliary Sciences, India). Clinical Chair: Tom Fletcher (Live",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a1fc5b38-ef0a-4415-b7f2-c28e538a72c5",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "anya Prasad (Institute Liver Biliary Sciences, India). Clinical Chair: Tom Fletcher (Liverpool School Tropical Medicine, United Kingdom). Infection Prevention Control Chair: Tochi Okwor (Nigeria Centre Disease Control, Nigeria). External reviewers: Chedly Azzouz (Infection Control African Network, Tunisia); Amy Elizabeth Barrera -Cancedda (Resolve Save Lives, United States America); Daniela Garone (Médecins Sans Frontières International, Belgium); Richard Kojan (Alliance Internationale Medi cal Action, Democratic Republic Congo). Systematic review team Risk factor severe disease: Ya Gao Qiukui Hao (McMaster University, Canada). Breastfeeding infant mother mpox: Kerry Dwan (Liverpool School Tropical Medicine, United Kingdom). Infection prevention control: Collaborating Centre Infection Prevention Control Anti -Microbial Resistance supervision Dr Majid Alshamrani (Infe",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "95e9d24d-52b7-48f1-87be-0890a61f1517",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ntion Control Anti -Microbial Resistance supervision Dr Majid Alshamrani (Infection Prevention Control Department, King Abdulaziz Medical City Hospital, Saudi Arabia); support from: Sarah Alfayez, Maher Alharbi, Kholoud Ameer, Wafaa Al Nasser, Mohammed Al Zunitan Mohammed Abalkhail, Aiman El -Saed, Fayssal Farahat, Syed Nazeer, Fatmah Othman. Technical Working Group HIV: Andrea Antinori (National Institute Infectious Diseases Lazzaro Spallanzani [IRCCS], Rome, Italy); Alexandre Calmy (University Geneve, Geneve, Switzerland); Mohamed Chakroun (University Monastir, Monastir, Tunisia); Mark Cotton (Stellenbosch Uni versity, Cape Town, South Africa); Peter Elyanu (Baylor College Medicine Children’s Foundation, Kampala, Uganda); Beatriz viii Grinsztejn (Oswaldo Cruz Foundation [FIOCRUZ], Rio de Janeiro, Brazil); Nagalingeswaran Kumarasamy (Voluntary Health Services Hospital, Chennai, India); Michael Marks (London School Hygien",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e6af8d5a-65d9-469a-bc5e-7d54802699e6",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "rasamy (Voluntary Health Services Hospital, Chennai, India); Michael Marks (London School Hygiene & Tropical Medicine, London, United Kingdom Great Britain Northern Ireland); Nick Medland (University New South Wales, Sydney, Australia); Graeme Meintjes (University Cape Town, Cape Town, South Africa); Oriol Mitja (Hospital Universitari Germans Trías Pujol, Badalona, Spain); Sharon Nachman (Department pediatrics, Renaissance School Medicine, New York, USA); Hideta Nakamura (University Ryukyus Graduate School Medicine, Nishihara -cho, Japan); Jeremy Nel (University Witwatersrand, Johannesburg, South Africa); Adesola Yinka -Ogunleye (Nig eria Centre Disease Control, Abuja, Nigeria); Chloe Orkin (Queen Mary University London, London, United Kingdom Great Britain Northern Ireland); Shama Cash -Goldwasser (Centers Disease Control Prevention, Atlanta, Georgia, United State America); Marcia Wong (New York City Department",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9ec4f847-2503-411e-a140-eb5a9d7e20ea",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "nd Prevention, Atlanta, Georgia, United State America); Marcia Wong (New York City Department Health Mental Hygiene, New York, United States America) Technical Working Group Infant feeding : Ebun Adejuyigbe (Obafemi Awolowo University Ile -Ife, Nigeria; Najwa Al Dheed (UNICEF, New York, United States America); Brooke Bauer (Save Children International, United Kingdom Great Britain Northern Ireland); Lars Bode (University California San Diego, United States America); Bindi Borg (Emergency Nutrition Network [ENN], United Kingdom Great Britain Northern Ireland); Erin Boyd (Tufts University, Boston, Massachusetts, United States America); Jodine Chase (SafelyFed Canada, Canada); Anne Detjen (UNICEF, New York, United States America); Alessandro Iellamo (FHI 360, Washington DC, United States America); Raoul Kamadjeu (UNICEF, New York, United States America); Marie McGrath (UK Emergenc Nutrition Network [ENN], United Kingd",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fdc15d08-509e-42fa-a701-4aa53c8e0f97",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "York, United States America); Marie McGrath (UK Emergenc Nutrition Network [ENN], United Kingdom Great Britain Northern Ireland); Grace Ndeezi (Makerere University College Health Sciences, Uganda); Philippe van de Perre (University Montpellier, France); Roberta Petrucci (Médecins Sans Frontières [ MSF], Geneva, Switzerland); Nadia Sam -Agudu (Institute Human Virology Nigeria (IHVN), Nigeria); Fatmata Fatima Sesay (UNICEF, New York, United States America); Mija -Tesse Ververs (Johns Hopkins Bloomberg School Public Health Baltimore, United Stat e America) . Additionally, would also like thank contributed first (interim) guideline development process 2022 [1]. coordination team member (2022) ix Vanessa Cramond (Clinical Management Operations, Geneva, Switzerland); Kathleen Dunn (Infection Prevention Controland Water Sanitation Hygiene, Geneva, Switzerland); Krutika Kuppalli (Emerging Diseases",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2b4cee7a-a39c-4837-b800-c726561dad34",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "land Water Sanitation Hygiene, Geneva, Switzerland); Krutika Kuppalli (Emerging Diseases Zoonoses Unit, Geneva, Swi tzerland); Hibak Osman Mahamed (Infection Prevention Control Water Sanitation Hygiene, Geneva, Switzerland). Steering Committee member (2022) Benedetta Allegranzi (Infection Prevention Control Unit Hub, Geneva, Switzerland); Lisa Askie (Quality Assurance Norms Standards Department, Geneva, Switzerland); Silvia Bertagnolio (Communicable Noncommunicable Diseases, Gen eva, Switzerland); Astrid Chojnacki (Infection Prevention Control, Regional Office Western Pacific); Jane Cunningham (Emerging Diseases Zoonoses Unit, Geneva, Switzerland); Kirrily De Polnay (Food Nutrition Action Health Sy stem); Meg Doherty (Global HIV, Hepatitis STIs Programmes); Marjam Esmail (UNICEF); Melinda Frost (Risk Communication Community Engagement, Geneva, Switzerland); Luca Fon",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4de1a39f-a254-4cd5-bc64-cac8854bcc96",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "CEF); Melinda Frost (Risk Communication Community Engagement, Geneva, Switzerland); Luca Fontana (Health Technical Logistics, Geneva, Switzerland); Ivan Ivano v (Occupational Workplace Health, Geneva, Switzerland); Kathryn Johnston (Infectious Hazard Management, PAHO); Manish Kakkar (WHO Regional Office South -East Asia); Edna Karra (Sexual Reproductive Health Research); Benjamin Kung (Infection Prevention Control, Regional Office Western Pacific); Cleiton Euzebio de Lima (UNAIDS); Moe Masunaga (WHO Regional Office South- East Asia); Virginia Macdonald (WHO Regional Office Western Pacific); Stacey Mearns (United Kingdom P ublic Health Rapid Support Team, seconded Infection Prevention Control, Health Emergencies Programme); Antons Mozalevskis (Global HIV, Hepatitis STIs Programmes); Deus Mubangizi (Regulations Prequalification, Geneva, Switzerland) ; Takeshi Nishijima (WHO Regional Office f",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a8cfec69-a725-4f71-b1dd-3d097d0cb321",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "gulations Prequalification, Geneva, Switzerland) ; Takeshi Nishijima (WHO Regional Office Western Pacific); Pilar Ramon Pardo (Department Communicable Diseases Environmental Determinants Health, PAHO); Mark Perkins (Epidemic Pandemic Preparedness Prevention, Geneva, Switzerl and); Jerome Pfaffmann (UNICEF); Moustafa Ramadan (Infection Prevention Control, Regional Office Eastern Mediterranean); Kamara Rashidatu (WHO Regional Office Africa); Ludovic Reveiz (Department Evidence Intelligence Action alth, PAHO); Jilian Sacks (Epidemic Pandemic Preparedness Prevention, Geneva, Switzerland); Alice Simniceanu (Emerging Diseases Zoonoses Unit, Geneva, Switzerland); Valeska Stempliuk (Infection Prevention Control PAHO); Omar Sued (Clinical Management, PAHO); Maha Talaat (Infection x Prevention Control, Regional Office Eastern Mediterranean); Joao Paulo Toledo (Infection P",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ab5b948d-f41c-429f-b7f3-36c5197f3b1c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ion Control, Regional Office Eastern Mediterranean); Joao Paulo Toledo (Infection Prevention Control Unit Hub, Geneva, Switzerland); Teodora Wi (Global HIV, Hepatitis STIs Programmes, Geneva, Switzerland); Williba ld Zeck (United Nations Population Fund). Guideline Development Group member (2022) Rodrigo Angerami (Hospital de Clínicas University Campinas/UNICAMP, Brazil); Nawal Al-Kaabi (Sheikh KhalifaMedical City, United Arab Emirates); Javier Bellocq (Community Representative, Argentina); Enrique Castro -Sánchez (University West London, Imperial College London; Universitat Oberta de Catalunya, Spain); Nizam Damani (Southern Health Social Care Trust, United Kingdom; Sindh Institute Urology Transplant Centre, Pakistan); Candida Fernandes (Centro Hospitalario Universitário de L isboa Central, Portugal); Esther Freeman (Global Health Dermatology Massachusetts General Hospital, Harvard Medical School, United State",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d14f19cc-db27-4a18-99e3-43b3eaf83637",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "(Global Health Dermatology Massachusetts General Hospital, Harvard Medical School, United States America); Sanjay Jain (Postgraduate Institute Medical Education Research, Chandigarh, India); Thierry Kal onji, (Ministry Health, Kinshasa, Democratic Republic Congo); Aaron Kofman (CDC, United States America); Brett Kurpiel (community representative, United States America); Laurens Liesenborghs (Belgian Institute Tropical Medicine, Belgium); Placide Mbala (National Institute Biomedical Research, Democratic Republic Congo); Geeta Mehta (Lady Hardinge Medical College, New Delhi, India); Marc Mendelson (Groote Schuur Hospital, University Cape Town, South Africa); Emmanuel Nakoune ( Pasteur Institute Bangui University Bangui, Central African Republic); Pius Okong (Health Service Commission, Uganda); Anne Rimoin (UCLA Jonathan Karin Fielding School Public Health Infectious Disease Division David Geffen School",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3f07e466-7193-4414-a296-34f054180165",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "arin Fielding School Public Health Infectious Disease Division David Geffen School Medicine, United States America); Mitchell J Schwaber (National Center Infection Control, Israel Ministry Health,Israel); Elena Sendagorta (University Hospital La Paz, Spain); Julian Tang (University Hospitals Leicester, United Kingdom); Margarida Tavares (São João University Hospital Centre, National Programme Sexually Transmitted Infections HIV Infection, Spain); Monica Thormann (Ministry Public Health, Dominican Republic); Philippe Van de Perre (University Montpellier, France ); Tania Villa Reyes (General Directorate Epidemiology, Mexico); Laura Waters (University College London, United Kingdom); Adesola Yinka (Nigeria Centre Disease Control, Nigeria). External reviewer (2022) xi Aula Abbara (Operational Centre Amsterdam, Médecins Sans Frontières, Kingdom Netherlands); Carlos Alvarez (Universidad Nacional de Colombia, Clinica Colsani",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7d03cd8e-353c-49fb-8750-628e2fdce2e9",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "es, Kingdom Netherlands); Carlos Alvarez (Universidad Nacional de Colombia, Clinica Colsanitas, Colombia); Francisco Bartolome (Médecins Sans Frontières, Spain);Anita Desai (National nstitute Mental Health Neurosciences, India); Marcio da Fonseca (Access Campaign, Médecins Sans Frontières, Kingdom Netherlands); Masahiro Ishikane (National Center Global Health Medicine, Japan); Richard Kojan (Alliance Internati onal Medical Action, Democratic Republic Congo); Buyiswa Lizzie Mazibuko (Independent Infection Prevention Control Specialist, Zimbabwe). Special thanks Strategic Health Operations Centre providing support meeting (Acute Emergency Management, Health Emergencies Programme). xii Abbreviations ABCD airway, breathing, circulation, disability ACH air change per hour AGP aerosol -generating procedure AIIR airborne infection isolation room ALT alanine transaminase ARDS acute resp",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "706ec858-c20c-4d19-98a3-7363f1f1c0f4",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ting procedure AIIR airborne infection isolation room ALT alanine transaminase ARDS acute respiratory distress syndrome ART antiretroviral therapy AST aspartate aminotransferase AVPU alert, voice, pain, unresponsive (scale) BMI body mass index BUN blood urea nitrogen CA-MRSA community -acquired methicillin -resistant Staphylococcus aureus CBT cognitive behavioural therapy CDC Centers Disease Control Prevention (United States America) CFR case fatality ratio CSF cerebrospinal fluid DGI disseminated gonococcal infection DOI declaration interest EMA European Medicines Agency FFR filtering facepiece respirator GDG Guideline Development Group GRADE Grading Recommendations Assessment, Development Evaluation HAI heath care -associated infection HR hazard ratio HSV herpes simplex virus IDP internally displaced person IFRC International Federation Red Cross Red Crescent Societies IITT Interagency Integrated Triage",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "43ef8b51-7912-4d5e-9a7a-286821291efb",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "nternational Federation Red Cross Red Crescent Societies IITT Interagency Integrated Triage Tool (WHO/IFRC) IO intraosseous IPC infection prevention control IRIS Immune reconstitution inflammatory system IRP infectious respiratory particle IV intravenous LGV lymphogranuloma venereum xiii MDR multidrug -resistant MEURI Monitored Emergency Use Unregistered Investigational Interventions mpox mpox preferred term synonym monkeypox MPXV monkeypox virus MSSA methicillin -sensitive Staphylococcus aureus MUAC mid-upper arm circumference (in children) NIOSH National Institute Occupational Safety Heal th (United States America) odds ratio PAHO Pan American Health Organization PCR polymerase chain reaction PEP post-exposure prophylaxis PPE personal protective equipment PTSD post-traumatic stress disorder RR relative risk RT-PCR real-time polymerase chain reaction STI sexually transmitted infect",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7901c890-2d60-4941-8642-0352d0e36c8e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "r RR relative risk RT-PCR real-time polymerase chain reaction STI sexually transmitted infection US FDA United States Food Drug Administration VIG vaccinia immune globulin VZV varicella zoster virus WBC white blood count World Health Organization xiv Definitions Aerosol -generating procedures: Medical procedure reported aerosol generating consistently associated increased risk pathogen transmission. current list procedure recognized aerosol generating includes aspiration open suctioning respiratory tract specimens, bronchoscopy, intubation, cardiopulmonary resuscitation, manual ventilation intubation, sputum induction using nebulized hypertonic saline, dentistry autopsy procedure [2 ,3]. Airborne infection isolation room (AIIR): room high ventilation rate controlled direction airflow used contain airborne infection acute r",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ed33517f-b1be-42bb-bc77-764bad04e33c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "nd controlled direction airflow used contain airborne infection acute respiratory infection caused novel agent potential pose public health risk. room naturally mechanically ventilated [2]. • Naturally ventilated airborne precaution room: airflow directed area free transit, permit rapid dilution contaminated air surrounding area open air; average ventilation rate 160 L / per patient. • Mechanically ventilated airborne precaution room: negative pressure created control direction airflow; ventilation rate least 12 air change per hour (ACH). room equivalent “airborne infection isolation room” described United States Centers Disease Control Prevention (CDC). Airborne transmission/inhalation (formerly airborne transmission): Occurs infectious respiratory particle (IR",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3675c90d-241a-434d-8dba-5baa31f1b8ec",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "sion/inhalation (formerly airborne transmission): Occurs infectious respiratory particle (IRPs) expelled air enter, inhalation, respiratory tract another person. form transmission occur IRPs travelled either short long distance infectious person. portal entry IRP respiratory tract tissue airborne transmission theoretically occur point along human respiratory tract, prefer red site entry may pathogen specific. noted distance travelled depend multiple factor including particle size, mode expulsion environmental condition (such airflow, humidity, temperature, setting, ventilatio n, etc.) [4] Care workers: People provide direct personal care service home, health care residential setting, assisting routine task daily life performing task simple routine na",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2865d320-9deb-495f-b4df-b31fc5e85430",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "assisting routine task daily life performing task simple routine nature. term comprises [5 ,6]: xv • Health care assistants: institution -based, personal care worker provide direct personal care assistance activity daily living patient resident variety health care settings, hospitals, clinic residential nurs ing care facilities. generally implement established care plan practice direct supervision medical, nursing health professional associate professionals. • Home -based personal care workers: provide routine personal care assistance activity daily living person need care due effect ageing, illness, injury physical mental conditions, private home independent residential settings. Contact transmission: spread infectious agent caused physical contact susceptible ho",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "62ec774c-1366-42eb-a73c-a5f1c99a6418",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ct transmission: spread infectious agent caused physical contact susceptible host people object [7]. • Direct contact transmission involves direct body -surface -to-body - surface contact physical transfer micro -organisms infected colonized person susceptible host [2 ,7]. addition, direct contact transmission occur infectious person directly transfer infectious pathogen respiratory tract, via IRPs, another person direct contact person ( e.g., via handshake), directly transfer IRPs mouth, nose eye [4]. • Indirect contact transmission involves contact susceptible host contaminated intermediate object ( e.g., contaminated hands) carry transfer micro -organisms [2,7]. Contaminated surface also created IRPs expelled air settle surface, infected person transfer",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "081cec1c-d0ca-4602-bc23-64f579072eb9",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "created IRPs expelled air settle surface, infected person transfer infectious respiratory secretion first touching mouth, nose eye touching surface shaking hands. Infectious pathogen contaminated surface transf erred another person touch contaminated surface mouth, nose eye [4]. Direct deposition (formerly droplet transmission): Occurs IRPs expelled air following short -range semi -ballistic trajectory, directly deposited exposed facial mucosal surface (mouth, nose eyes) another person, thus, entering human respiratory tract via portal potentially causing infection [4]. Filtering facepiece respirator (FFR respirator): Filtering facepiece respirator (FFRs respirators) offer balance filtration, breathability fit. Whereas xvi medical mask filter 3 -micrometre droplets, N95 -ra",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "26425949-b7e9-49c3-b78e-14138731e744",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "tration, breathability fit. Whereas xvi medical mask filter 3 -micrometre droplets, N95 -rated FFP2-rated FFRs must filter challenging 0.075-micrometre particle particulate must across entire surface respirator result fitted design. European FFP2 FFRs, according EN 149 standard, filter least 94% sodium chloride (NaCl) salt particle paraffin oil droplets. United States America's N95 FFRs, according National Institute Occupational Safety Health (NIOSH) NIOSH 42 CFR P art 84, filter least 95% NaCl salt particle [8,9]. Health worker: Health care worker people community hospitals, primarily engaged action primary intent enhancing health. includes health service providers, doctors, nursing midwifery professionals, public health p rofessionals, technician (laboratory, health, medical non-medical), personal care workers, h",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7c6771da-d3ce-46f8-a4be-5bbc401bdcae",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "fessionals, technician (laboratory, health, medical non-medical), personal care workers, healer practitioner traditional medicine. also includes health management support workers, cleaners, drivers, hospital administrator s, district health managers, social worker occupational group health -related activity [ 6,10].This document us combined term health care worker cover role settings. Infectious respiratory particles: Pathogens, contained within particle (known “infectious particles”), travel air infectious particle carried expired airflow enter human respiratory tract deposited mucosa mouth, nose eye another person [4]. Isolation: separation infected people contagious disease people infected [11]. Screening: process individual evaluated see whether person mee",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "824cdaf6-555e-4243-8f86-1f05fab88230",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "11]. Screening: process individual evaluated see whether person meet standardized case definition. Screening typically require close physical contact clinical expertise [12 ,13]. Standard precautions: Aim protect health worker patient reducing risk transmission micro-organism recognized unrecognized sources. minimum standard infection prevention control (IPC) practice used health care workers, care patients, times, settings. applied consistently, standard precaution prevent transmission microorganism patients, health worker envir onment [14]. Transmission -based precautions: Transmission -based precaution used addition standard precaution patient known suspected infection xvii colonization transmissible and/or epidemiologically significant pat",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "022370f2-cc87-4a41-bc9e-714bbd5543e6",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "suspected infection xvii colonization transmissible and/or epidemiologically significant pathogens. type transmission -based precaution assigned patient depends transmission route micro-organism: contact, droplet airborne [7]. Triage: process sorting patient category based need time - sensitive treatment using validated tools. Triage identifies require immediate medical intervention, safely wait. Triage may occur health post, prim ary health centre, clinic emergency unit. typically requires close physical contact (within 1 metre) patient assessment [12, 13]. Clinical management infection prevention control mpox xviii 1. Executive summary 1.1 Clinical question: clinical IPC intervention use caring patient mpox? Target audience: document public health specialists, health emergency responde",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f671f9bb-13a9-4cd2-8831-01c1d59606f2",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "mpox? Target audience: document public health specialists, health emergency responders, clinicians, health facility managers, health care worker IPC practitioner including limited working primary care clinics, sexual health clinics, emergency departments, dental practices, infectious disease clinics, genitourinary clinics, maternity services, paedia trics, obstetrics gynaecology acute care facility provide care patient suspected confirmed mpox. Context: Since publication th e interim mpox guideline 2022 [1] mpox virus, also known monkeypox virus (MPXV), outbreak associated continued evolve. Prior 2022, case primarily reported Central West Africa. 2022, global outbreak clade IIb declared continues affect numerous countries. Subsequently, outbreak associated clade Ia Ib, primarily affecting Dem",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "109a0df9-25bf-4c94-85ad-c760e1649cef",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "bsequently, outbreak associated clade Ia Ib, primarily affecting Democratic Republic Congo neighbouring African countries. Since August 2024, increasing number MPXV case Africa detection clade Ib beyond African continent, led second declaration Director General public health emergency international concern rela ted epidemic risk widespread transmission MPXV. person mpox acute infection patient risk complications, managed health facility setting supportive care. mild, non-complicated case mpox managed home -based care. 1.2 New infection prevention control recommendation • Infection prevention control measure including hand hygiene, dedicated personal items, appropriate handling linen laundry, cleaning disinfection environment, waste manageme",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9030f2a6-cba4-41d9-bcdc-a97f93236761",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "te handling linen laundry, cleaning disinfection environment, waste management followed person mpox community lesion healed.* (Good practice statement) • suggests person mild, uncomplicated mpox infection cared home required isolate** provided lesion covered wear well -fitting medical mask close proximity others lesion healed. * (Conditional recommendation, low certainty evidence) Executive summary xix • patient suspected confirmed mpox infection, suggests health care worker use contact droplet precaution .*** (Conditional recommendation, low certainty evidence) * Healed lesions: lesion crusted, scab fallen fresh layer skin formed underneath. ** Isolation mean separation infected people contagious disease people infected. *** Cont",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6d176600-0878-49a1-935a-7c528befa090",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "eparation infected people contagious disease people infected. *** Contact precaution include following personal protective equipment (PPE): gloves, gown. Droplet precaution include following PPE: medical mask consider eye protection based upon risk assessment. 1.3 New clinical management recommendation • recommends rapid initiation antiretroviral therapy (ART) people mpox infection HIV ART naïve prolonged interruption ART. (Strong recommendation, moderate certainty evidence) • suggests mother mpox continue breastfeeding whilst limiting direct contact non- infected infant. (Conditional recommendation, low certainty evidence) • suggests mother recover mpox infection withheld breastfeeding direct contact, resume breastfeeding direct contact infant soon lesion healed.* (Conditional recommendation,",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5ef34393-1c17-40f5-b141-4e34704c74ba",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "g direct contact infant soon lesion healed.* (Conditional recommendation, low certainty evidence) * Healed lesions: lesion crusted, scab fallen fresh layer skin formed underneath. triggered guideline: spread current global outbreak (since 2022 present) sustained human -to-human transmission occurring close contact including sexual contact. 10 March 2025, total 129 172 confirmed cases, including 283 deaths, reported 130 Member States/territories across six region [23]. need evidence- based clinical guidance become apparent case mpox arisen context limited direct experience patient management compared prior outbreaks. mpox Steering Committee Guideline Development Group (GDG) previously made initial recommendation interim guidance [1]. guideline: living g",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a19feb4a-ac41-4fe8-a50d-2240cbf0e11e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "viously made initial recommendation interim guidance [1]. guideline: living guideline incorporates new evidence dynamically update recommendation clinical management IPC mpox infection. GDG typically evaluates intervention judge sufficient evidence available make recom mendation. GDG take individual patient Clinical management infection prevention control mpox xx perspective making recommendations, also considers resource implications, acceptability, feasibility, equity human rights. IPC intervention listed good practice statement formulated according principle outlined GRADE (Grading Recommendations Assessment, Development Evaluation) framework described Methods section document. updated version guideline developed according standard method trustworthy guidelines.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8fa0808c-a7ed-465e-b1eb-000a1cc3d7de",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ion guideline developed according standard method trustworthy guidelines. Statements 2022 interim guidance clinical care IPC measure patient mpox infection prioritized review GDG chairs, methodologist subsequently reviewed Steering Committee panel. GRADE framework generate evidence -based recomm endations applied recommendation table version prior recommendation imported. remaining prior recommendation future recommendation reviewed according prioritization evidence becomes available future update guideline. information around methodology followed bring recommendation updated guideline found Methods: guideline created. Introduction 1 2. Introduction 2.1 Mpox clade Mpox virus (MPXV) belongs Orthopoxvirus g",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4b1b8ae2-7363-446d-a0a3-18dc6a3a7d03",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ntroduction 1 2. Introduction 2.1 Mpox clade Mpox virus (MPXV) belongs Orthopoxvirus genus Poxviridae family. human disease first identified 1970 9-month-old boy Democratic Republic Congo. 2022, case reported Central West Afri ca [15 ,16]. two distinct clade MPXV [17] • clade (a, b), previously known Central African (Congo basin) clade; • clade II (a, b), previously known West African clade; subclade IIb group variant circulating part 2022 global outbreak. Historically, clade considered virulent, case fatality ratio (CFR) ranging 1% 10% [16, 18,19], clade IIa associated overall lower mortality rate < 3% [19, 20]. However, emergence clade IIb global expansion 2022, well historic increase Clade mpox case 2023 2024, made virulence difference l",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cca234f5-d626-4d4a-b022-46babd859a8b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "historic increase Clade mpox case 2023 2024, made virulence difference less clear. detail virulence different clade described [21 ,22]. December 2024, total 124 753 confirmed cases, including 272 deaths, reported 128 Member States/territories across six region [23]. 2.1.1 Update mpox outbreak virus clade using evidence available January 2025 section provides overview major mpox outbreak MPXV subclade. 2.1.2 Clade Ia MPXV Clade Ia MPXV found primarily Democratic Republic Congo, affect endemic province increasingly found previously unaffected province recent years, including capital, Kinshasa. Sporadic case continue reported neighbouring Central African Republic Republic Congo. Democratic Republic Congo Central African Republic report Clinic",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d5db75a7-df13-476a-aae3-8dff069ea161",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "lic Congo. Democratic Republic Congo Central African Republic report Clinical management infection prevention control mpox 2 higher proportion child among cases, Republic Congo, case among adults. Previously, genomic sequencing analysis indicated clade Ia MPXV typically emerged human population zoonotic exposure, leading limited human-to -human transmission. Current epidemiological data phylogenetic analysis still suggest many outbreak mpox due clade Ia MPXV result zoonotic spillover secondary human-to -human transmission. 2.1.3 Clade Ib MPXV Clade Ib MPXV predominantly spreading Democratic Republic Congo, neighbouring country east, community transmission reported Burundi Uganda, cluster case reported Kenya Rwanda, mostly travel -related case country detected.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b635a719-78d9-4092-aab2-2d6129a95c76",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "n Kenya Rwanda, mostly travel -related case country detected. human case substantively linked suspected animal exposure clade yet, current genomic sequencing data suggest transmitted human - to-human contact [24 ,25]. Democratic Republic Congo, found eight provinces: South Kivu, North Kivu, Kinshasa, Kasai, Tshopo, Tanganyika, Haut-Katanga Mai -Ndombe, fastest expanding MPXV strain. affected country frica Burundi Uganda, transmission ongoing since end 2024 early 2025; smaller cluster reported Kenya Rwanda, extent undetected transmission unknown. Zambia Zimbabwe reported trave l- related case limited secondary transmission. Outside Africa, imported travel -related case also detected (in order reporting) Sweden, Thai",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0e3ee084-85aa-4c10-bf9a-f4591951ff69",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ica, imported travel -related case also detected (in order reporting) Sweden, Thailand, India, Germany, United Kingdom, United States America, Canada, Pakistan, Belgium, China France. Secondary transmission case reported United Kingdom, Germany, Belgium, China France. Imported mpox case among adult travelled incubation period early symptom diagnosed arrived country. Often, reported prior sexual contact person known mpox infection someone sign symptom suggestive mpox. initial cluster mpox due clade Ib MPXV expand outbreak progresses, transmission pattern appear evolve, spread within households, leading progressive shift age ex distribution, rising proportion case among children. multi -country outbreak mpox driven clade IIb MPXV Introducti",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc076494-0e6c-4291-9ba0-4a90b000dca6",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "case among children. multi -country outbreak mpox driven clade IIb MPXV Introduction 3 began 2022 showed sexual contact sustain community transmission MPXV. Likewise, subclades Ia Ib also spreading sexual contact, much remains understood transmissibility sustainability transmission throug h nonsexual direct physical contact clades. setting transmission persists, likely driven combination sexual, household community contact. 2.1.4 Clade IIa MPXV 2024, Côte d'Ivoire, Guinea Liberia reported mpox linked clade IIa MPXV. country shown evidence sustained community transmission strain, case dispersed wide geographical areas. Outbreaks clade IIa MPXV c oncerning new phenomenon human-to -human transmission clade reported 2024 [21]. Furthermore, co -circulation clade IIa clade IIb MPX",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e394c47b-554e-42b2-9471-d3e97d895890",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "reported 2024 [21]. Furthermore, co -circulation clade IIa clade IIb MPXV reported first time, Côte d'Ivoire Liberia. Mpox linked clade IIa MPXV reported adult children, many lacking known epidemiological link, suggesting ongoing, largely undetected community transmission. Limited epidemiological investigation constrained understanding mode transmission outbreak clade IIa MPXV remains least described MPXV strain scientific literature. documented evidence sexual contact transmission strain, form close contact likely contribute spread, documented first time 2024. 2.1.5 Clade IIb MPXV mpox outbreak part West, North Southern Africa part world due clade IIb MPXV, continuation multi -country outbreak began 2022. region report",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "44284ab7-a546-4012-a3be-865705d4316e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "de IIb MPXV, continuation multi -country outbreak began 2022. region report circulation clade IIb lineage B.1, l ineage A.1 continues circulate Nigeria country Eastern Mediterranean Region. affected population outside Africa continues men sex men, primarily exposed sexual contact [26, 27]. instance others affected, woman children, led sustained transmission, unlike observed clade MPXV African context. Australia seen unprecedented rising trend case recent month reporting country reported ongoing low -level transmission mainly population risk. Clinical management infection prevention control mpox 4 2.2 Natural history incubation period mpox usually 3 17 day following exposure MPXV [28]. Although people recover within 1",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bbbe6234-f787-432b-968f-244df38b0618",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "usually 3 17 day following exposure MPXV [28]. Although people recover within 1 2 weeks, severe complication sequela reported common among unvaccinated smallpox compared w ith vaccinated (74% v 39.5%) [29], although overall evidence inconsistent uncertain (see Table 2). Clinical evaluation underway generate real -world evidence effect. unclear waning immunity smallpox vaccination time; however, study indicate smallpox vaccination approximately 85% effective preventing mpox [30,31]. Evidence prior vaccination smallpox typically found scar upper arm. Individuals born smallpox eradication 1980 unlikely vaccinated, although laboratory personnel health care worker ay received vaccine date [15]. date, reported death occurred babies, infant imm",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d6ef6698-74d9-41cc-bf2a-4c8956afead9",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ccine date [15]. date, reported death occurred babies, infant immunocompromised individuals, poorly controlled HIV infection [20,29,32]. study Democratic Republic Congo reported cohort 216 patients, three death patient < 12 year age. compared survivors, patient fatal disease higher amount mpox virus DNA blood , higher maximum skin lesion count, raised liver enzyme (aspartate aminotranferase [AST] alanine tranaminase [ALT]) initial presentation [33]. Mortality rate decrease access good supportive care, individual better background health nutrition [34]. 2.3 Signs symptom Descriptions outbreak prior 2022 described two phases, initial 1 5 day illness characterized fever, headache, back pain, muscle aches, lack energy lymphadenopathy [33], followed appe",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9a865082-3369-4391-b911-9618f0ad5a4e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "r, headache, back pain, muscle aches, lack energy lymphadenopathy [33], followed appearance rash [31, 35,36]. rash typically presented sequential stage – macules, papules, vesicles, pustules, umbilication crusting desquamating period 2 3 weeks. However, 2022 clade IIb outbreak, 52–64% patient skin lesion before, time of, systemic symptom [37, 38,39]. Furthermore, lesion always present sequentially. example, initial lesion might pseudopustule ulcer without going typical progression, multiple type lesion may co-exist simultaneously [37]. Introduction 5 prior outbreaks, mpox noted spread centrifugally, starting face extending towards palm sol [16, 29,40]. 2022 clade IIb outbreak, many 70–78% participant lesion (and primarily first lesion) groin, perineum peri -anal",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d19767d3-0134-4ec0-b894-03e3741b8027",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "participant lesion (and primarily first lesion) groin, perineum peri -anal region, 43% oral peri -oral area [37, 38]. rash distribution may influenced nature transmission event (sexual transmission) site body significant expo sure lesion infected person (potential primary inoculation sites) [41]. (92%) patient fewer 20 skin lesions, significant minority (39%) patient 1 5 total lesions, though possible several hundred several thousand number [15]. distinct primary presentation proctitis without perianal lesion [42]. Patients may develop lymphadenopathy – described 98.6% cohort 200 patient mpox Democratic Republic Congo recorded 2007 2011 [16, 33]. recent series, like clade IIb outbreak 2022, lymphadenopathy seem less",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fb6a431c-910c-45a5-9d5d-7fa2cf151046",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "33]. recent series, like clade IIb outbreak 2022, lymphadenopathy seem less common (around half) [43]. Oral ulcer common may affect patient’s ability eat drink leading dehydration malnutrition [35, 44]. Also described clade IIb outbreak case series, pharyngeal, conjunctival nd genital mucosa also occur [35 ,45]. large prospective observational study describing natural history 216 patient mpox Democratic Republic Congo described common clinical symptom rash (96.8%), malaise (85.2%) sore throat (78.2%). common finding physical examination classic mpox rash (99.5%); lymphadenopathy (98.6% – cervical region frequently affected [85.6%], followed inguinal region [77.3%]); mouth/throat lesi ons (28.7%) [33]. 2022 mpox clade IIb outbreak, noted people living HIV disproportionately affected mpox. Pres",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "045b89f4-5332-4492-824a-d4a7353862d4",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "b outbreak, noted people living HIV disproportionately affected mpox. Presently, 38–50% individual diagnosed mpox living HIV [46]. Co -infection HIV associated frequent p erianal lesions, higher rash burden [47]. Atypical, large severe skin lesion wound noted immunocompromised individuals, especially living inadequately controlled HIV [48]. one global case series, noted ndividuals low CD4 count high viral load greatest disease severity, hospitalization mortality [46]. Clinical management infection prevention control mpox 6 2.3.1 Severe disease complication Though uncommon, patient mpox may develop severe life -threatening complications. example, confluent skin lesion increased risk bacterial skin soft tissue infection cellulitis, abscesses, necrotizing soft tissue infection",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "183a6625-f615-43df-9fb9-37e808a7c7ab",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "l skin soft tissue infection cellulitis, abscesses, necrotizing soft tissue infection requiring meticulous local wound care; subcutaneous accumulation fluid crusting phase leading intravascular depletion shock; exfoliation resulting area skin may require surgical debridement grafting [35,36,44]. ther rarer complication include severe pneumonia respiratory distress, infection cornea part eye may lead vision loss, loss appetite, vomiting diarrhoea may lead severe dehydration, electrolyte abnorma lities shock, cervical lymphadenopathy oropharynx involvement may lead retropharyngeal abscess respiratory compromise, sepsis, septic shock, encephalitis, proctitis, rectal perforation, myocarditis death [20, 29,32,33,35,36,45,49]. recently, two systematic review conducted September 2024 (data mostly 2022 global outbreak) u",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3e835e4c-bf3c-4283-9b95-0f448dc930b1",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ematic review conducted September 2024 (data mostly 2022 global outbreak) understand prognosis, complication risk factors. search strategy returned 3606 results; screening, 130 study (19 f risk factors) included, including 89 722 patient male percentage ranging 42.9–100% median age range 6.9 43 year [49]. Limited data available child pregnant woman inform systematic review. curren ongoing outbreak African Region, systematic review need updated comparison clade mode transmission considered. 2.4 Laboratory finding Small study looking laboratory abnormality patient mpox indicate leucocytosis, elevated liver transaminases, low high blood urea nitrogen hypoalbuminemia common feature illness, lymphocytosis thrombocyt openia seen one -third patient ev",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ff634965-c55f-4492-9a50-29fe64c1446a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ness, lymphocytosis thrombocyt openia seen one -third patient evaluated [16, 33,44]. 2.5 Differential diagnosis rash develops mpox may resemble rash caused infectious disease conditions, including primary varicella zoster virus infectious (VZV, chickenpox), herpes simplex virus infection (HSV), primary secondary syphilis, dis seminated gonococcal infection (DGI), foot mouth disease, Introduction 7 chancroid, lymphogranuloma venereum (LGV), granuloma inguinale, molluscum contagiosum, measles, scabies, rickettsia pox, chikungunya, Zika virus, dengue fever, vasculitis bacterial skin soft tissue infection [50,51,52]. Disseminated cryptococcosis skin lesion may resemble mpox circumstances. Guidelines diagnosing, preventing managing cryptococcal disease among adults, adolescent child living HIV found here: https://www.who.int/publicati",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9c4ea8a8-acd0-44ca-a58c-9f5bb4068ed8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ", adolescent child living HIV found here: https://www.who.int/publications/i/item/9789240052178 [53] Often, rash caused VZV confused mpox may distinguished VZV rash generally progress rapidly, centrally located centrifugal distribution mpox, patient usually classically lesion palm sol [16, 29]. Additionally, patient VZV typically lymphadenopathy, hallmark mpox [29]. recent publication case South Kivu, Democratic Republic Congo (Brosius et al., 2025), lymphadeno pathy differed significantly age groups, common adult (82%) child 5–14 year old (69%), less frequent child less 5 year old (16%). adults, inguinal lymphadenopathy primarily affected, whereas children, submandibular node commonly involved [54]. Despite clini",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "04644e2b-8691-44dc-b336-604d9478d9ed",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "whereas children, submandibular node commonly involved [54]. Despite clinical difference two diseases, study Democratic Republic Congo reported polymerase chain reaction (PCR) - confirmed co -infection mpox VZV, incidence 10 –13% [55, 56]. Patients co -infection reported fatigue, chills, headache myalgias. individual less likely report signs/symptoms oral sores, axillary lymphadenopathy, cough sore throat. Patients co -infection higher lesion burden seen VZV alone lower rash burden seen mpox alone raising suggestion co -infection two virus could modulate severity overall infection – area investigation [55, 56]. co -infections occur, mpox syphilis gonorrhoea, mainly sexual transmission. 2.6 Pregnant people postpartum period Mpox affect pregnant pers",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "09924bcd-6e23-404d-a826-9f8f320a356a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "en sexual transmission. 2.6 Pregnant people postpartum period Mpox affect pregnant person fetus [57]. utero transmission mpox documented, well transmission mother child via direct contact [58, 59,61]. former longitudinal case series reported outcome four pregnant persons: one delivered healthy baby, two early Clinical management infection prevention control mpox 8 miscarriage one fetal death stillborn covered diffuse rash virologic confirmation mpox. suggests mpox infection may lead adverse outcome fetus, death spontaneous abortion [33 ,59]. 2024 systematic review seven study identified 32 pregnant people clade IIb MPXV infection 6 31 week gestation; 3 12 pregnancy reported gestational outcomes, half resulted intrauterine fetal demise [ 60]. assoc iation betw",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3e75a153-1836-4d65-94af-84a14c06f1b3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "stational outcomes, half resulted intrauterine fetal demise [ 60]. assoc iation severity maternal illness outcome unclear [59,62]. 2.7 Mid-and- long- term effect information needed clinical characterization mid - long -term effect mpox. One study reported > 90% mpox survivor complications, regardless smallpox vaccination status [35]. develop long -term co mplications, common sequela disfiguring scarring skin blindness [29, 35,63]. Pitted scar pockmark develop [29, 35]. Data also suggest patient may risk developing mental health complication [36]. 2.8 Transmission viral shedding MPXV DNA detected wide variety clinical samples, including faeces, saliva, skin mucosal lesions, well semen, urine blood [64,65,66,67]. Replication -competent virus isolated skin lesion swabs, orophar",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5ae3ea36-7b00-4415-8b34-04b149b1ebe3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "lood [64,65,66,67]. Replication -competent virus isolated skin lesion swabs, oropharyngeal swabs, anal swabs, urethral swabs, conjunctival swab semen [64]. Studies shown skin lesions, anorectal lesion saliva contain highest concentrat ion viral DNA [64,65,66,67]. data describing mpox transmission viral shedding show transmission occur animal human, human animal, human human, contaminated environment human [90]. Previously, available information derived fr om 2022 global mpox outbreak clade IIb MPXV, predominantly affected gay, bisexual men sex men. early 2024, new MPXV strain, subclade Ib identified Democratic Republic Congo neighbouring countr ies. Since publication 2022 interim guideline two systematic review commissioned transmission route [68] latest review incl",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fc0410f5-703f-454f-b2de-10170f545ffb",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "atic review commissioned transmission route [68] latest review including literature published September 2022 September 2024 (review unpublished time writing guideline information available upon request). review found limited data Introduction 9 transmission mpox clade, specifically clade Ia clade Ib MPXV study found reporting clade IIa [68]. MPXV transmitted infected animal human via indirect direct contact [31]. Transmission may occur bite scratches, activity hunting, skinning, trapping, cooking, playing carcass eating animals, terrestrial rodents, non -human primates, antelope gazelle tree squirrel [35]. Human -to-animal mpox transmission documented close contact [69]. extent viral circulation animal population entirely known fur ther study underway",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "61bb3d01-5258-4766-a17e-9049a9966779",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "viral circulation animal population entirely known fur ther study underway [29,70]. Current evidence strongly suggests 2022 2024 multi -country outbreak driven animal -to- human transmission, rather sustained human-to -human transmission [71,72]. Human -to-human transmission occur direct physical contact infectious lesion skin mucous membranes, contact fluid exudate lesion IRPs [11,16,73,72]. 2024 review found one report single case self -reported “droplet exposure” 32 317 case reported route transmission data (unpublished data). single case one 12 breakthrough infection post -exposure vaccination mpox (the study defined droplet transmiss ion occurring presence exposed person without mask less 2 metre least 3 hour PCR -confirmed mpox patient) [74].",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e78751c2-f854-48dd-a25f-d66fe0ae4236",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "mask less 2 metre least 3 hour PCR -confirmed mpox patient) [74]. reported inhalation exposures. study published May 2022 clinical characte rization 216 patient diagnosed 2007 2011 Democratic Republic Congo suggested MPXV DNA blood upper respiratory tract may detected prior onset rash peak viral load may occur early di sease course [75]. study shown detection MPXV DNA air sample [76,77], replicant -competent virus bedding change one United Kingdom hospital - based study [77], epidemiological evidence date airborne/inhalation transmission. 2022 multi -country mpox outbreak, transmission reported primarily occurring close physical, sexual contact (oral, vaginal, anal) [47]. Subsequent literature review conducted September 2022 Sept",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "49b0278a-6a32-4520-a41e-805322e042a5",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "(oral, vaginal, anal) [47]. Subsequent literature review conducted September 2022 September 2024 supported fin ding [11]. 2024 systematic review non -comparative study (222 study describing transmission route 32 317 case mpox) identified intimate physical contact (sexual contact suspected sexual contact) Clinical management infection prevention control mpox 10 primary mode transmission (95.4%) followed close (non-sexual) contact (2.9%). Therefore, contact transmission represented 98.3% 32317 case mpox reviewed. infected pregnancy, MPXV cross placenta leading intrauterine exposure fetus risk congenital infection infant [78]. Environment -to-human transmission occur contact MPXV contaminated objects, fabric surface (also described fomite indirect contact transmission) [79,80,81]. Pox virus generally resistant",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e9aa5de8-e99a-4a65-bb2c-5fc2214b8465",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "fomite indirect contact transmission) [79,80,81]. Pox virus generally resistant environmental condition show high environmental stability [48 ,49,82,83]. Studies conducted health care facility household settings, show MPXV DNA found several surface environment [43,45,84,85,86,87]. study shown MPXV also p ersist environment several day patient mpox left space [46, 47]; however, transmission percutaneous injury contaminated object, fomite, transplacental animal product uncommon, accounting approximately 1.8%. 24 study reviewed 2022 –2024 describing 3331 household exposures,134 person infected (secondary infection rate 4.02%) route transmission described mainly close contact (non -sexual sexual). Based global surveillance data, less 1% reported case attributed fomite",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bbf37358-00d2-42db-a414-a1bdc2102c6e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "Based global surveillance data, less 1% reported case attributed fomite transmission [88,89]. risk infection contact contaminated material low, implausible [86,87]. Contaminated clothing linen disperse MPXV shaken [77,91]. recent systematic review conducted 2024 (see detail Methods section – data yet published) find health worker infection reported exposure contaminated bed linen patient mpox. Mpox transmission percutaneous injury contaminated sharp object documented health care worker specimen collection [92] well community settings, particular tattoo parlour [93]. review conducted 2024 found 29 study examined exposure among health care workers. 1738 exposure reported, 14 became infected. Ten infection indicated percutaneous injury route tr",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5a6e9255-2d20-483d-8201-67fe05ef6e3d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ted, 14 became infected. Ten infection indicated percutaneous injury route transmission. 2.8.1 Infectious period Mpox infectious period vary, typically begin onset symptom patient considered infectious new lesion stopped appearing, Introduction 11 existing lesion crusted, scab fallen lesion formed scabs, fresh, healthy skin seen lesion used be. may generally take 2 4 weeks, patient found persistent lesion much longer [46 ,54]. study also suggested patient might infectious symptom onset [75 ,94,95,96]. potential pre - symptomatic transmission remains unclear research needed. 2.8.2 Children Historically, mpox infection country Central Africa afflicted primarily child (under 18 year old) younger age adults, mainly thought becau",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "eaa17817-2921-4ecb-bd36-1ec16b5fa3b5",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "fflicted primarily child (under 18 year old) younger age adults, mainly thought older generation smallpox vaccine -cross protection. 2022 outbreak, dom inated clade IIb MPXV mostly affected gay, bisexual men sex men, child represented approximately 1.3% total reported global case [97]. Since 2023, Democratic Republic Congo Central African R epublic report higher proportion child among case mpox due clade Ia MPXV [98]. Studies shown difference exposure characteristic younger child older child mpox. Children age 0 –12 year old often acquired infection direct skin - to-skin contact caregiver household member mpox; whereas child age 13 –17 year old similar exposure characteristic commonly reported among adult ( i.e., sexual contact) [",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c0b8eea6-1586-4c2f-8de0-5a0f61050864",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ar exposure characteristic commonly reported among adult ( i.e., sexual contact) [97 ,99,100]. 2.8.3 Wastewater surveillance MPXV detected wastewater guidance wastewater environmental surveillance MPXV available [101]. virus present mucosal skin lesion released grey water activity including brushing teeth, hand washing, bathing, excretion toilet [72]. known case mpox infection resulting contact contaminated wastewater date [72] detection replication -competent MPXV wastewater yet reported [102 ,103]. 3. recommendation apply to? guideline applies patient mpox infection cared community, home health facility. Recommendations may differ based severity MPXV defined clinical assessment patients: presence risk factor severe disease, danger sig",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e877f16a-7439-4bf4-9000-cfbee8e15ee8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ned clinical assessment patients: presence risk factor severe disease, danger sign complications. classification severity mpox disease different pathway according it: • Non-severe mpox: home-based care • Severe complicated mpox: admission health facility closer monitoring clinical care Table 1. Risk factor clinical finding described associated severe disease poor outcome (based small, uncontrolled observational studies) (Published 2022) Patient group higher risk severe disease complication Children, pregnant women, person immunosuppressed person living HIV poorly controlled disease historically risk group (low CD4 cell count ) [106, 18,45,29,32,46]. Though data lacking, patient chronic skin condition (e.g. atopic dermatitis), acute skin condition (i.e. burns) may also higher risk complic",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6e5c57ff-0a90-431d-8c93-d21cea4dd870",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ". atopic dermatitis), acute skin condition (i.e. burns) may also higher risk complications, bacterial infection. Results recent systematic review found next chapter. Clinical sign symptom complication Nausea vomiting [29,40], painful cervical lymphadenopathy causing dysphagia, poor oral intake, eye involvement: eye pain, vision abnormalities, hepatomegaly, sepsis, dehydration, respiratory distress/ pneumonia, and/or confusion. Results recent systematic review found next chapter. Laboratory abnormality Elevated hepatic transaminase (AST and/or ALT), low high blood urea nitrogen (BUN), low albumin, elevated white blood count (WBC), low platelet count [40]. Skin lesion severity score smallpox experience [59,107]: Mild (< 25 skin lesions) Moderate (25–99 skin lesions) Severe (100– 250 skin lesions) severe (> 250 skin lesions). 3.1 Risk factor",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2e8c89ef-b1f9-4875-bf98-b9d8701c0de7",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "lesions) Severe (100– 250 skin lesions) severe (> 250 skin lesions). 3.1 Risk factor severe disease Risk factors: recently, systematic review conducted September 2024 [49] (data mostly 2022 global outbreak) understand prognosis, recommendation apply to? 13 complication risk factors. search strategy returned 3606 results; screening, 130 study (19 risk factors) included, including 89 722 patient male percentage ranging 42.9% 100% median age range 6.9 43 years. Limited data available child pregnant woman inform systematic review. current ongoing outbreak African Region, systematic review need updated comparison clade mode transmis sion considered. Using previously agreed upon thresholds, discussion methodology chair, subsequently confirmed GDG, determin",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3c042653-3a0c-4398-8414-3b1090f77218",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ", discussion methodology chair, subsequently confirmed GDG, determined criterion determining whether risk factor significant predicting hospitalization patient non- severe disease review observational data, risk factor odds ratio (OR) greater 2.0 least moderate certainty evidence. Additional, less impactful, risk factor noted least moderate certainty evidence 1.7 2.0. low low certainty evidence less 1.7 considered significant risk factor severe disease. Thus, major factor noted meet specified criterion significant risk factor patient non -severe mpox infection developing severe disease hospitalization (see Table 2) are: • HIV positive • HIV (CD4 < 350 cells/mm 3) next section show result recent system",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c0de9b71-a633-49bd-9a00-802347318f2a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "V positive • HIV (CD4 < 350 cells/mm 3) next section show result recent systematic review data published September 2024 [49]. Table 2. Risk factor associated severe disease hospitalization Risk factor Study result measurement Certainty evidence Summary Age (per 10 year increase) Odds ratio: 0.88 (95% CI 0.63 1.23) Based data 16 939 participant 6 study Low Due serious inconsistency, Due serious imprecision Age may associated little increase severe disease. Sex (males v females) Odds ratio: 0.78 (95% CI 0.34 1.78) Based data 5501 participant 3 study Low Due serious inconsistency; Due serious imprecision Males may associated little increase severe disease compared females. HIV (positive v negative) Odds ratio: 1.79 (95% CI 1.07 3.00) Moderate Due serious inconsistency HI",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "35e77c84-541e-4861-9e7b-fba4a9e22732",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "negative) Odds ratio: 1.79 (95% CI 1.07 3.00) Moderate Due serious inconsistency HIV probably associated increased odds severe disease. Clinical management infection prevention control mpox 14 Based data 9883 participant 7 study HIV (CD4 < 350 cells/mm3 v HIV negative) Odds ratio: 2.45 (95% CI 1.19 5.02) Based data 2321 participant 2 study High Patients CD4 < 350 cells/ mm3 associated increased odds severe disease compared HIV negative patients. HIV (CD4 ≥ 350 cells/mm3 v HIV negative) Odds ratio: 0.82 (95% CI 0.55 1.22) Based data 2321 participant 2 study Low Due serious inconsistency, Due serious imprecision Patients CD4 ≥ 350 cells/mm3 may associated little increase severe disease compared HIV negative patients. Vaccination (mpox smallpox) Odds ratio: 0.88 (95% CI 0.57 1.36)",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0d8f28b7-e5a1-491a-bba1-d44320ada97e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "negative patients. Vaccination (mpox smallpox) Odds ratio: 0.88 (95% CI 0.57 1.36) Based data 7400 participant 7 study Low Due serious inconsistency; Due serious imprecision Mpox smallpox vaccination may associated little decrease severe disease. Vaccination (childhood prior smallpox) Odds ratio: 0.96 (95% CI 0.61 1.51) Based data 7032 participant 6 study Low Due serious inconsistency; Due serious imprecision Childhood prior smallpox vaccination may associated little decrease severe disease. one major factor noted meet specified criterion significant risk factor patient non severe mpox infection death (see Table 3) are: • HIV (positive) Table 3. Risk factor associated mortality Risk factor Study result measurement Certainty evidence Summary HIV (positive v negative) Odds",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "21515371-7529-49de-9632-793c78c7b754",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ults measurement Certainty evidence Summary HIV (positive v negative) Odds ratio: 10.81 (95% CI 9.80 11.92) Based data 3377 participant 2 study High HIV associated increased odds -cause mortality. Age (per year) Odds ratio: 0.90 (95% CI 0.82 0.97) Based data 86 participant 1 study low Due extremely serious imprecision uncertain whether age associated increased odds all-cause mortality. Sex (males v females) Odds ratio: 3.59 (95% CI 0.54 23.60) Based data 86 participant 1 study low Due extremely serious imprecision uncertain whether male associated increased odds all-cause mortality compared females. recommendation apply to? 15 3.2 Prognosis 3.2.1 Risk adverse outcome Table 4 show baseline risk estimate systematic review. non - severe co",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b2e5b90a-6045-4a92-9c20-81bff208a23e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "come Table 4 show baseline risk estimate systematic review. non - severe cohort rate hospitalization 4% (39 42) low mortality. Whereas, patient severe cohort, already hospitalized, rate death estimated 4.6% (36 58). Table 4. Baseline risk adverse outcome patient mpox Outcomes Event rate (95% CI per 1000) Non-severe cohort* Severe cohort* Overall Hospitalization 40 per 1000 (39 42) NA 42 per 1000 (40 43) ICU admission 0.3 per 1000 (0.1 0.7) 49 per 1000 (33 68) 0.4 per 1000 (0.1 0.9) Mechanical ventilation 8 per 1000 (1 19) 55 per 1000 (34 80) 26 per 1000 (16 39) All-cause mortality 0 per 1000 (0 <0.001) 46 per 1000 (36 58) 0 per 1000 (0 <0.001) * review team used 50% threshold categorize study severe non -severe. Studies fewer 50% participant classified severe mpox hospitalized",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7cd65869-9743-4b66-8a34-585bc46e69fb",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "e. Studies fewer 50% participant classified severe mpox hospitalized treatment categorized non -severe; study 50% categorized severe. 3.3 Rate complication 3.3.1 Rate complication Table 5 show rate complication reported mpox patients. Overall, complication uncommon (< 10%) significant variation observed non-severe severe cohort patients. severe cohort, complication commonly reported (>10%) included: secondary bacterial infection (21%), gastroenteritis (13%), severe pain (27%), cellulitis (15%), proctitis (24%), urethritis (17%) rectal bleeding (16%). data systematic review included study published September 2024. current ongoing outbreak African Region, systematic review need updated comparison bet ween clade mode transmission considered. Table 5. Baseline ri",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2c34a1be-74e0-4846-8370-556991175262",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "pdated comparison bet ween clade mode transmission considered. Table 5. Baseline risk complication mpox Outcomes Event rate (95% CI per 1000) Non-severe cohort* Severe cohort* Overall Clinical management infection prevention control mpox 16 Acute kidney injury NA 14 per 1000 (2 34) 14 per 1000 (2 34) Secondary bacterial infection 75 per 1000 (69 84) 210 per 1000 (188 232) 92 per 1000 (86 99) Respiratory failure NA 37 per 1000 (21 56) 37 per 1000 (21 56) Sepsis 0.3 per 1000 (0 1.5) 38 per 1000 (23 55) 2 per 1000 (0.3 3) Pneumonia 3 per 1000 (1 6) 32 per 1000 (8 67) 4 per 1000 (1 7) Gastroenteritis 12 per 1000 (0.2 35) 125 per 1000 (37 248) 23 per 1000 (6 48) Encephalitis 0 per 1000 (0 0.2) 3 per 1000 (0 9) 0 per 1000 (0 0.2) Severe pain 24 per 1000 (19 29) 273 per 1000 (243 303) 51 per 1000 (45 58) Cellulitis 42 per 1000 (35 51) 15",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2805ed61-779a-44d7-a703-af2c2e4bd7aa",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "19 29) 273 per 1000 (243 303) 51 per 1000 (45 58) Cellulitis 42 per 1000 (35 51) 153 per 1000 (102 211) 46 per 1000 (38 55) Keratitis 63 per 1000 (30 106) 32 per 1000 (16 52) 39 per 1000 (24 58) Conjunctivitis 38 per 1000 (33 43) 20 per 1000 (13 30) 34 per 1000 (30 39) Abscess 27 per 1000 (18 38) 17 per 1000 (7 31) 24 per 1000 (16 32) Myocarditis 0 per 1000 (0 0.01) NA 0 per 1000 (0 0.01) Epiglottitis 1 per 1000 (0 7) NA 1 per 1000 (0 7) Tonsillitis 30 per 1000 (23 37) 70 per 1000 (40 107) 32 per 1000 (26 39) Pharyngitis 56 per 1000 (33 84) 71 per 1000 (21 146) 58 per 1000 (37 84) Urinary retention 7 per 1000 (0.2 19) 18 per 1000 (0 75) 7 per 1000 (0.5 19) Proctitis 67 per 1000 (62 72) 235 per 1000 (177 298) 69 per 1000 (64 74) Urethritis 11 per 1000 (8 14) 167 per 1000 (88 263) 12 per 1000 (8 15) Rectal bleeding 26 per 1000 (8",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d03ea6cf-68cc-457c-9e72-e62e623eddb8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "000 (8 14) 167 per 1000 (88 263) 12 per 1000 (8 15) Rectal bleeding 26 per 1000 (8 51) 160 per 1000 (111 215) 74 per 1000 (50 101) Penile edema 45 per 1000 (35 56) NA 45 per 1000 (35 56) Paraphimosis 9 per 1000 (6 12) NA 9 per 1000 (6 12) * review team used 50% threshold categorize study severe non -severe. Studies fewer 50% participant classified severe mpox hospitalized treatment categorized non -severe; study 50% categorized severe. Recommendations mpox care pathway 17 4. Recommendations mpox care pathway following section guideline provides recommendation screening, triage testing patient suspected mpox. See figure 1 (Annex 4) visual description care pathway. 4.1 Screening triage 4.1.1 Screening Interim guidance (Published 10 June 2022) recommends, first point co",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "19205287-284d-4792-a37a-cc28b3a53ca2",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "1 Screening Interim guidance (Published 10 June 2022) recommends, first point contact health system, screening triage performed person present rash fever and/or lymphadenopathy, according locally adapted case definition, identify individual suspected confirmed mpox infection. • Persons symptom meet case definition suspected mpox [108] (see Annex 1: case definition mpox outbreak non-endemic countries) enter mpox clinical care pathway immediately given well -fitting medical mask isolated well -ventilated single room. well -ventilated single room available, group patient similar clinical diagnosis based epidemiological risk factors, spatial separation (at least 1 metre patients). • Suspected case cohorted together confirmed cases. 4.1.1.1 Practical info • simplif",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8e4b341d-0761-42e6-844c-f313809f3be2",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "case cohorted together confirmed cases. 4.1.1.1 Practical info • simplified questionnaire screening protocol based case definition adapted local epidemiology implemented point entry health care (or contact tracing) screen patient based case definition local epidemiology. example, outbreak, done primary care clinics, sexual health clinics, emergency departments, infectious disease clinics, genitourinary clinics, dermatology clinics, maternity paediatrics clinic s. Clinical management infection prevention control mpox 18 • Depending national (local) coordination pathways, telemedicine may considered mean screening patients. • Medical mask alcohol -based hand sanitizer available patient presenting screening areas. Signs posted respiratory hygiene hand hygiene instr",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ee611774-37f1-4369-89d0-e3eeb16a7b2c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "screening areas. Signs posted respiratory hygiene hand hygiene instruction put well -fitting medical mask. • Screening activity conducted maintaining distance least 1 patient using “no touch” approach. measure cannot implemented maintained facility conduct risk assessment determine level PPE required according IPC recommendation health facility context mpox. Health care worker performing screening follow 5 moment hand hygiene [14 ,109,110]. • waiting, crowding prevented patient distance least 1 maintained patient [110]. • Consider implementing -patient surveillance mpox depending upon local epidemiology. 4.1.2 Triage Interim guidance (Published 10 June 2022) recommends screening isolation, patient suspected",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3217ce94-54cc-4a63-9ae0-cde249543c1a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "(Published 10 June 2022) recommends screening isolation, patient suspected mpox infection triaged using standardized triage tool (e.g. WHO/International Federation Red Cross Red Cre scent Societies (IFRC) Interagency Integrated Triage Tool), evaluated determine risk factor presence severe disease. • Triage refers sorting patient priority screening, based specific criterion (e.g. severity) performed point access health care system, including pre -health care facility -based setting [111] hospital wards, monitoring patients. • Acuity based triage action sorting prioritizing patient based estimation severity. used identify patient require immediate medical intervention safely wait may need transported specific destination based condition [111]. Recomm",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5e0b4039-88f1-4907-a822-3cbf7a4ddfad",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "may need transported specific destination based condition [111]. Recommendations mpox care pathway 19 • Interagency Integrated Triage Tool (IITT) novel triage tool developed provide integrated set protocol routine triage adult children. tool focus three -tier triage system found Clinical care severe acute respiratory infection toolkit [111]. • Clinical assessment focus identifying sign symptom severe complicated disease higher risk severe disease (see Table 5). Clinical management infection prevention control mpox 20 4.2 Testing mpox Interim guidance (Published 10 June 2022) recommends test monkeypox virus patient suspected mpox • Testing mpox virus conducted soon possible confirm diagnosis [106]. • Early HIV testing conducted patient present wi",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "33f231f7-ceda-4789-be7a-8ae14852e032",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ible confirm diagnosis [106]. • Early HIV testing conducted patient present suspected confirmed mpox infection [107]. • area endemic infection cause rash fever lymphadenopathy, patient risk factor diseases, part screening, febrile patient tested treated per routine protocol (e.g. STIs syphilis, HSV HIV, malaria testing endemic area patient fever, infectious disease per clinical context local epidemiology). Recommendations patient mild uncomplicated mpox (home- based care) 21 5. Recommendations patient mild uncomplicated mpox (home- based care) one updated IPC recommendation one new best practice recommendation section. 5.1 Infection prevention control (IPC) consideration home -based care Public health emergency often begin end communities; therefore, ef",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4e73f13a-5d5d-4f80-b7ec-f6baf004ffa9",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "n home -based care Public health emergency often begin end communities; therefore, effective emergency response always includes community interests. requires multifaceted approach includes, limited to, risk communication community engagement strategies, public health social measures, vaccination strategies, environ mental service adequate water sanitation infrastructure, application IPC measure [114, 115,116,117]. Health ministry intersectoral partner national subnational level engage community actor identify provide resource needed, implement risk communication strategy [118, 119] provide support, look context possible solution ensure IPC measure met provide safe care setting patient cared [120]. context emergency response, crucial community IPC WASH",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc8339af-8ebc-41cb-82c9-490b2d5fed3f",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ared [120]. context emergency response, crucial community IPC WASH measure implemented mitigate control transmission high -risk settings, household suspected cases, congregate settings, includes internally dis placed person (IDP) refugee camp ensure continuity service schools. Infection prevention control measure hand hygiene, dedicated personal items, handling linen laundry, environmental cleaning disinfection waste management, applied adapted applied community setting mitigate control transmission mpox. Previous guidance (2022) advised person mpox recovering home isolate themselves. Given evolving evidence perceived value preference person mpox avoid home isolation, updated recommendation GDG reflects shi ft away isolation home -based care, provided IPC measure",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e3d7b867-7ab0-4227-a02d-2503fae1c2f2",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "GDG reflects shi ft away isolation home -based care, provided IPC measure implemented maintained. research need IPC Clinical management infection prevention control mpox 22 home -based care listed section Uncertainties, emerging evidence future research. 5.1.1 Infection prevention control measure Good practice statement (Published May 2025) Infection prevention control measure including hand hygiene, dedicated personal items, appropriate handling linen laundry, cleaning disinfection environment, waste management followed person mpox community lesion healed.* * Healed lesions: lesion crusted, scab fallen fresh layer skin formed underneath. 5.1.1.1 Practical info 5.1.1.1.1 Implementation consideration • person mpox infection wear well -fitting medical mask cove",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dd51cec6-2c75-4073-a2b9-76f07eae8d97",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "consideration • person mpox infection wear well -fitting medical mask cover lesion close proximity others existing lesion crusted, scab fallen lesion formed scabs, fresh, healthy skin seen lesion used be. • person mpox infection recovering home able manage self- care identify designated caregiver, preferably someone good health, underlying health condition previous smallpox mpox vaccination MPXV infection (see conditional recommendation home care detail caregivers). activity undertaken caregiver may include preparing meals, going grocery store, getting medications, etc. • person mpox infection recovering home refrain contact wild domestic animal avoid infecting animal. includes keeping possibly infectious contaminated materi",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2b78a3e2-d640-4ebe-8eed-178dd1e7d5aa",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "l avoid infecting animal. includes keeping possibly infectious contaminated material, linens, towel clothing away pet animals. Another person take care domestic animal throughout illness. • health care worker required provide care patient mpox home, wear appropriate PPE (gloves, gown, eye protection medical mask), perform hand hygiene (according 5 moment Recommendations patient mild uncomplicated mpox (home- based care) 23 putting removing PPE) clean disinfect patient care equipment used. 5.1.1.1.2 Hand hygiene • Persons mpox infection, caregiver contact practice frequent hand hygiene [121]. includes: 1) preparing food; 2) eating feeding/breastfeeding; 3) using toilet handling human and/or animal faeces; 4) coughing, sneezing and/or di",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "07424e03-b8a3-412e-ac44-2cb5162b8a73",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ter using toilet handling human and/or animal faeces; 4) coughing, sneezing and/or disposing tissue; 5) time come contact lesions; 5) hand visibly dirty. • Alcohol -based hand rub soap water used hand hygiene. • person mpox soap share household members. 5.1.1.1.3 Personal belonging • person mpox family household member implement following measures: • Avoid sharing personal item eating utensils, linens, towels, electronic devices. • Avoid sharing bed sleeping area people animals. • Avoid direct contact upholstered furniture, couch chairs. Consider covering furniture clean sheet laundered. 5.1.1.1.4 Handling linen, laundry • person mpox dedicated caregiver handle launder bedding, clothing et",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "62ccdc07-0c1d-4e76-8e8e-490c4010da2b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "e person mpox dedicated caregiver handle launder bedding, clothing etc. • Linens bedding carefully lifted rolled prevent dispersion infectious particle lesion body fluids. shaken. • Linens, towels, clothing patient MPXV laundered separately household laundry reused washing (manually machine) detergent preferably hot water (> 70°C) chlorine (a minimum 0.05% ) hot water available [122]. 5.1.1.1.5 Environmental cleaning • person mpox dedicated caregiver clean disinfect environment objects/surfaces. Clinical management infection prevention control mpox 24 • Dishes utensil household surfaces, furniture, beds, toilet floors, location patient contact cleaned water soap disinfected r",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "966a87fa-66fe-4254-9f3b-4d1a5b00203a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "location patient contact cleaned water soap disinfected regularly. • Common household disinfectant sodium hypochlorite (household bleach) product may used [123, [124, 125,126]. Disinfectants prepared applied surface according manufacturers’ instructions. • One study found use minimum 0.05% sodium hypochlorite solution 70% ethanol efficacious MPXV wiped common non-porous surface low -resource setting 1-minute contact time [123]. • Use damp mopping, avoid dry sweeping prevent dispersion particles. • Carpeting household furnishing steam cleaned possible. Avoid vacuuming. 5.1.1.1.6 WASH waste management • Authorities ensure access safe water, sanitation, hygienic supply (soap water) waste collection disposal person mpox infection family member home -based care. •",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "814caf0c-7d58-4082-8a0f-f8fe3d6aaab7",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "disposal person mpox infection family member home -based care. • Waste generated caring patient MPXV, bandage PPE, placed strong bag securely tied disposal eventual collection municipal waste services[127]. • municipal waste service available, interim measure according local policies, safely burying controlled burning waste may performed sustainable environmentally friendly measure made available local co ntexts. 5.1.1.2 Justification GDG emphasized critical role applying IPC principle community level reduce community MPXV transmission. Members GDG highlighted importance implementing IPC measure cohesive package interventions, ensuring multi -pronged approach minimizing spread virus. GDG acknowledged primary route transmission contact",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b73507e5-3d87-4433-b1b3-e368eff64cc4",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "imizing spread virus. GDG acknowledged primary route transmission contact (sexual non-sexual) skin lesions, fluid exudate lesion individual infected MPXV. Given possible contamination surface object well potential infectious respiratory particles, risk indirect contact transmission direct deposition cannot excluded. Standard transmission -based precaution describe measure reduce route transmission Recommendations patient mild uncomplicated mpox (home- based care) 25 widely used health care. use standard transmission -based precaution cornerstone IPC measure GDG noted applied wherever human -to-human transmission [7 ,,103]. GDG member also noted important role ministry health implementing partner national subnational level play engaging communi",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1e89483b-cbf6-478e-a7ca-be1ad834441c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "f health implementing partner national subnational level play engaging community identify provide resource needed, implement risk communication strategy provide solution ensure IPC measure met. 5.1.2 Isolation patient mpox Conditional recommendation for, low certainty evidence (published May 2025) suggests person mild, uncomplicated mpox lesion cared home required isolate* provided lesion covered wear well -fitting medical mask close proximity others lesion healed.** • Persons mpox unable comply covering lesion wearing medical mask isolated home. • IPC measure reduce environmental contamination home implemented. * Isolation: separation infected people contagious disease people infected. ** Healed lesions: lesion hav",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "30d0d239-0940-47ab-ae22-806fd0df41b8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "people contagious disease people infected. ** Healed lesions: lesion crusted, scab fallen fresh layer skin formed underneath. 5.1.2.1 Practical info 5.1.2.1.1 Implementation consideration information implementing IPC measure home/household setting refer good practice statement implementation considerations. person mpox recovering home without implementing isolation, following measures, addition IPC measure described good practice statement, followed: • Persons mpox recovering home wear medical mask (if medical mask available, fabric mask may worn [118]) cover lesion near others. Clinical management infection prevention control mpox 26 • Covering lesion done use bandaging and/or wearing clothing comfortably cover lesions. • Clinica",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e7d99e0a-5869-4bfd-afc0-a9b30d68a8c0",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "th use bandaging and/or wearing clothing comfortably cover lesions. • Clinical follow -up conducted using method -person visit (e.g. telemedicine, telephone). • Regular cleaning disinfection environment person mpox occupies frequently touched surface implemented. • Individuals mpox limit traveling outside home. • person mpox leaf home wear well -fitting medical mask ensure lesion covered. • leave home ideally use private transportation ensure proper ventilation vehicle, open window feasible. • person mpox leaf home seek medical attention, inform health practitioner facility visit advance arrival (so facility implement transmission -based precautions). • person recovering home able manage",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "00564b79-23d2-4823-8874-e9fc6143c9cd",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "plement transmission -based precautions). • person recovering home able manage self -care identify designated caregiver, preferably someone good health, underlying health condition previous smallpox mpox vaccination MPXV infection (fo r example, may include preparing meals, going grocery store, getting medications, etc.). • designated caregiver maintain distance least 1 person mpox. • distance cannot maintained, conducting activity assisting laundry, cleaning environment, designated caregiver wear well -fitting medical mask disposable gloves.* • Caregivers clean hand either soap water alcohol - based hand sanitizer, contact person mpox environment putting removing gloves. event per",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0b193a6f-b002-4dcd-82c4-80b1a5656890",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "environment putting removing gloves. event person mpox cannot comply wearing mask covering lesion therefore required isolate home should: • Designate one person facilitate self -care: preferably someone good health, underlying health condition previous smallpox mpox vaccination mpox virus infection. example, may include preparing meals, goin g grocery store, getting medications, etc. • person mpox designated person facilitating self -care counselled regarding risk transmission. Recommendations patient mild uncomplicated mpox (home- based care) 27 • person mpox stay dedicated, well -ventilated room (e.g. window opened frequently) separate others household. addition, household member avoid entering ro",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b6ef43de-bd3b-43db-a13c-5c41ba4ee646",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "separate others household. addition, household member avoid entering room. • designated person facilitating self -care need enter isolation area, ideally ensuite toilet shower, refrain close contact person mpox. • distance cannot maintained, designated caregiver wear well-fitting medical mask disposable gloves.* clean hand either soap water alcohol -based hand sanitizer, contact pers mpox surrounding environment putting removing gloves. • person mpox cover lesion (if tolerable) wear well -fitting medical mask proximity others, moving outside designated isolation area (e.g. use toilet). • adequate isolation IPC measure cannot ensured home, isolation may need arranged,",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b6852823-b9e8-499e-b274-6863b0196689",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "equate isolation IPC measure cannot ensured home, isolation may need arranged, informed consent person mpox agreement caregiver member household, health care facility designated facility. * information implementation resource- limited setting refer Infection prevention control water, sanitation hygiene measure home care isolation mpox resource -limited settings: interim operational guide (2024) [ 119]. Benefits harm use isolation home may reduce potential contact protect household member vulnerable people community however insufficient evidence determine this. hand, isolation lead mental health challenge loneliness, anxiety depression, amplify stigmatization impose economic burden due absence work daily activity [122]. Based available",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "11f09610-aaaa-43ef-a316-8208b3861232",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ose economic burden due absence work daily activity [122]. Based available data evidence mode transmission mpox, GDG determined harm outweigh benefits. Certainty evidence Low certainty evidence judged low rated indirectness risk bias. GDG noted randomized observational randomized study isolation versus isolation Clinical management infection prevention control mpox 28 home, inference impact isolation could made basis epidemiological finding route transmission. 200 study 32000 patient identified primary mode transmission sexual (95.4%) non -sexual close contact (2.9%). Values preference Substantial variability expected uncertain GDG acknowledged many individual (the person mpox) would prefer",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8f86d17f-2609-4a46-a1d1-be79f4702ae3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "cted uncertain GDG acknowledged many individual (the person mpox) would prefer implement isolation negative mental health, social economic consequences. Values preference may vary family member community depending level fear getting mpox person isolated. Resources consideration use isolation home may require significant operational financial cost support affected person mpox, family/caregiver health system. may cost resource implication person mpox health system ensure access medical mask material cover lesion isolation implemented. Equity GDG acknowledged may inequity managing isolation home, particular low - middle -income country support may available including social financial stigmatization may",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "eb0ad2c0-c18c-4c65-9714-442353c129f0",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "untries support may available including social financial stigmatization may increased. Acceptability GDG noted situations, person mpox family member may prefer utilize home isolation potentially reduce transmission within household. However, others may find isolation unacceptable difficult implement. Feasibility GDG acknowledged may issue feasibility isolation home well wearing mask covering lesions. Recommendations patient mild uncomplicated mpox (home- based care) 29 5.1.2.2 Justification GDG noted randomized observational randomized study isolation versus isolation home low certainty evidence, inference impact isolation could made basis transmissi route. 200 study 32 000 patient identified primary mode",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0fd0b730-025f-4cac-b350-c40e407de321",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "transmissi route. 200 study 32 000 patient identified primary mode transmission close contact (sexual non-sexual) (data yet published available upon request). review found amongst 3331individuals documented exposed household, 13 4 infected (4.02% secondary infection rate) reported non -sexual close contact sexual contact. Similarly, amongst 3643 individual documented exposed community congregate settings, 91 infected (2.5% secondary infection rate), reported non-sexual close contact sexual contact. clear many study wh protective measures, any, taken. possible route transmission described. GDG noted limited study available describe different MPXV clade concern possible impact transm ission may differ depending upon clade.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "edbbf09c-5575-478a-935b-a0740425e526",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "concern possible impact transm ission may differ depending upon clade. available evidence 2023 2024 systematic review presented human-to -human transmission support close contact (sexual non-sexual) lesion infected person as, overwhelmingly, primary mode transmission [66]. GD G acknowledged main route transmission direct contact (sexual non -sexual) skin lesion (with fluid exudate lesion individual infected MPXV), possible environmental contamination well potential IRP cannot excluded. GDG determined IPC measure prevent close contact would paramount transmission prevention including additional measure isolation home could cause undue hardship. IPC measure clude avoiding direct contact lesions, use source control measure IRP, mitigating environmental c",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ee023dfe-5ad3-42e6-9567-0e97b5f28a2e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ntact lesions, use source control measure IRP, mitigating environmental contamination use cleaning disinfection. Based discussion evidence, benefit harm associated isolation home, well concern regarding resource, equity, feasibility acceptability, GDG formulated conditional recommendation includes covering le ion wearing medical mask, addition IPC measures, prevent environmental contamination rather isolation individual. Clinical management infection prevention control mpox 30 5.1.2.3 Clinical question/ PICO • Population: Person non-severe mpox cared home • Intervention: Mpox patient isolated lesion fully healed • Comparator: Mpox patient isolate non -healed lesion covered wear medical mask 5.1.2.4 Summary systematic review conducted two phase (see",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "49be345e-92b3-4ebb-a82e-ff7504fe8ab3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "wear medical mask 5.1.2.4 Summary systematic review conducted two phase (see Annex 5 details) data yet published available. Summary Findings table based non-comparative study identified indirectly inform IPC PICO question. study described route transmission suspected confirmed mpox cases. Based studies, ten mpox transmission ro ute identified amongst 32 317 case MPXV infection reported studies: confirmed sexual contact(65.1% mpo x cases),, suspected sexual contact (30.3%)close contact (non - sexual)( 2.9%), fomite/environment (0.36%), transplacental (0.01%), percutaneous injury (0.09%), direct deposition (formerly droplet) (0.003%),inhalation (0%), animal/animal product (0.48%) multiple route (0.83%)[26, 27,47,57,86,87,97,102,103,128,130,131,132]. Close contact predominate route transmission (95.3 %). Transmission route",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dee55c8d-d8f3-4dab-81bc-4a79e36d272d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "Close contact predominate route transmission (95.3 %). Transmission route including percutaneous injury contaminated object, fomite transplacental animal product uncommon, accounting approximately 1.8%. additional sub -analysis conducted assess route transmission mpox clade: Clade I, Clade Ib, Clade IIb. 29 222studies reported clade information, covering 24% patients. case Clade IIa reported literature. Among 10788 patient clade identified, case clade Ib IIb MPXV infection describe close contact (confirmed sexual, suspected sexual non -sexual) primary route transmission. clade 1a otal 218cases identified. Amongst cases, route transmission primarily described 40.6% (205) multiple routes, 30.9% (156 cases) exposure animal /animal products, 17% (86 cases) close",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "56665b6b-ba17-4640-9dd6-e527a338bb1d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "multiple routes, 30.9% (156 cases) exposure animal /animal products, 17% (86 cases) close contact (non - sexual) 11.5% (58 c ases) route transmission. description droplet inhalation transmission 29 clade specific studies. finding align previous systematic review [68]. Recommendations patient mild uncomplicated mpox (home- based care) 31 Lastly review also looked secondary infection reported amongst 8712 patient exposure setting, specifically health care setting amongst health care workers, household exposure congregate/community setting (including amongst community c ontacts, flight attendants, workplace, gay -oriented festivals, piercing tattooing services, person students). total 3331 individual documented exposed household, 134 infected (4.02% secondary infection rate), reported non-sexual close contact.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "db3638da-625d-407a-a5d1-6259849b5683",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "134 infected (4.02% secondary infection rate), reported non-sexual close contact. 3643 individual documented exposed community congregate settings, 91 infected (2.5% secondary infection rate), reported non-sexual close contact sexual con tact. Amongst 1738 health care worker documented exposed mpox 13 infected (0.8% secondary infection rate), three probable exposure primarily described due unspecified occupational exposure 10 (71.4%) case invo lved percutaneous (needlestick) injuries. Outcome Timeframe Study result measurement Comparator Covered lesions, medical mask, isolation Intervention Isolation lesion fully healed Certainty evidence (Quality evidence) Summary Mpox infection inferred transmission route frequency data (Observational (non - randomized)) 31 742 reported case transmission",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b6428692-a6b1-4f51-85c8-f019087b5a5c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "e frequency data (Observational (non - randomized)) 31 742 reported case transmission result close contact 32 318 patient (210/222 studies). disaggregated as: 21 025 case due confirmed sexual contact; 9788 case due suspected sexual contact; 930 due non- sexual close contact. Inferred odds: 1 Low Due serious risk bias, Due serious indirectness 1 Isolating patient probably prevent transmission mpox compared isolating patient provided lesion covered, medical mask worn physical contact others avoided. Risk Bias: serious. Inconsistency: serious. Indirectness: serious. Imprecision: serious. Publication bias: serious. 5.1.3 Symptomatic management 5.1.3.1 Pain fever management Interim guidance (Published 10 June 2022) recommends patient mpox given symptomatic treatment antipyretic fever analgesia pain",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "36b318f3-f000-440e-b9a1-81f2182eb93e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ents mpox given symptomatic treatment antipyretic fever analgesia pain. Clinical management infection prevention control mpox 32 5.1.3.1.1 Practical info • See Annex 2 recommendation symptomatic care. • Headache pain skin rash, oral, ocular genital lesions, swollen lymph node generalized muscle ache common. • Pruritic lesion itching also bothersome. • oral lesions, rinse mouth clean, salt water least four time day [135]. Consider use oral antiseptic keep lesion clean (e.g. chlorhexidine mouthwash) local anaesthetic (e.g. viscous lidocaine) [136] [137]. • genital anorectal lesion warm sitz bath (warm bath made water baking soda epsom salt heal cleanse perineal, perianal, penile vulvar area) and/or topical lidocaine may offer symptomatic relief [135]. 5.1.3.2 Nutrition Interim guidance (Published 10 June 2022)",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "93bd6a2b-64d4-47ec-9ae5-d4b1130b7b4a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "offer symptomatic relief [135]. 5.1.3.2 Nutrition Interim guidance (Published 10 June 2022) recommends patient mpox assessed nutritional status given adequate nutrition appropriate rehydration. • Symptomatic supportive care essential maintain good nutrition hydration. 5.1.3.2.1 Practical info Key actions: • Assess nutritional hydration status patient mpox whether admission health facility seen community. Nutritional intake compromised due oropharyngeal lesion and/ painful cervical lymphadenopathy. Nutritional support described important intervention [33]. • Adults: history reduced appetite weight loss, body weight, height, calculation body mass index (BMI), look sign malnutrition (e.g. muscle wasting, nutritional oedema etc.); standardized tool used (e.g. Malnutrition Universal Screening Tool [138]). • Children: ab",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5d612c20-42d8-4381-9cb0-ac3c2ad9cc13",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "dized tool used (e.g. Malnutrition Universal Screening Tool [138]). • Children: plus mid -upper arm circumference (MUAC) (6 –59 months). nutrition specialist trained clinician evaluate child severe malnutrition [139]. Recommendations patient mild uncomplicated mpox (home- based care) 33 • Oral nutrition encouraged daily, patient need sufficient energy (kcal) essential nutrients, addition fluid electrolyte [140]. patient well enough oral food intake, offer nutrient dense therapeutic foods; especial ly child risk malnutrition per Pocket book hospital care child [141]. • food intake tolerated, evaluate reason treat appropriately. example, poor feeding result nausea vomiting, antiemetic medication improve intake ability; due weakness, patient assisted feeding",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9aa52129-482a-433c-a988-ccc97829e474",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "n improve intake ability; due weakness, patient assisted feeding health care provider; or, tolerated, due pain oral lesion cervical adenopathy, treat pain. • Provide vitamin supplement according standard recommendations, especially child recently received dose. play important role stage wound healing eye health [142]. 5.1.3.3 Monitoring sign symptom complication Interim guidance (Published 10 June 2022) recommends counsel patient mild mpox sign symptom complication prompt urgent care. 5.1.3.3.1 Practical info • Communication patient trained health workers, established duration home -based care period. • Monitoring patient caregiver home done trained community worker outreach team telephone, telemedicine email initially daily ba",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e4d4ab52-a34e-45ae-a616-291d4e185194",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ed community worker outreach team telephone, telemedicine email initially daily basis (when possible) considered clinically necessary initial assessments. pa tient’s willingness engage medical assessment also considered. • Patients mpox infection family counselled sign symptom complication recognize deterioration health status requires medical attention. example, patient informed cont act health worker immediately lesion get worse increase quantity, develop worsening pain, persistent fever, nausea vomiting decreased oral intake, visual symptoms, difficulty breathing dizziness confusion. Clinical management infection prevention control mpox 34 • pregnant person chosen cared home, counsel person maternal, fetal newborn sign seek care",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "972ed47f-af33-4033-8eab-9ab9027da4ce",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "cared home, counsel person maternal, fetal newborn sign seek care develop worsening illness danger signs. Self -care intervention encouraged. • Counsel healthy behaviour including diet, physical activity, intake micronutrients, tobacco alcohol substance use, per recommendation antenatal [143] postnatal [144] care. • people requiring abortion services, consider alternative mode service delivery, including self -management medical abortion 12 weeks’ gestation, access accurate information health care provider stage process, per Abortion care guideline [145]. 5.1.3.4 General skin care Interim guidance (Published 10 June 2022) recommends conservative treatment rash lesions, dependent stage, aim relieve discomfort, speed healing prevent complications, secondary infection exfoliation.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "30e35cd6-bcd4-4e34-accd-604bcbbdf976",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "discomfort, speed healing prevent complications, secondary infection exfoliation. • Patients instructed avoid scratching skin keeping skin lesion clean dry prevent bacterial infection. instructed wash hand soap water use alcohol -based hand sanitizer touching skin rash lesion prevent infecti on. Lesions may cleaned gently sterile water antiseptic solution (see poster Care skin lesion mpox Infection, [242]). • Healing lesion would promoted uncovered exposed air possible. However, proximity people, lesion covered reduce risk transmission. • complication skin lesions, exfoliation suspicion deeper soft tissue infection (pyomyositis, abscess, necrotizing infection), consider consultation appropriate specialist (i.e. wound care specialist, ID specialist,",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "80b776e8-627f-4a88-9fbd-65404855d77a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "consider consultation appropriate specialist (i.e. wound care specialist, ID specialist, and/or surge on). Debridement skin done unless performed expert wearing appropriate PPE [156]. 5.1.3.4.1 Justification Optimal management skin lesion uncertain need research. Recommendations patient mild uncomplicated mpox (home- based care) 35 5.1.3.5 Antimicrobial therapy prophylaxis Interim guidance (Published 10 June 2022) recommends antibiotic therapy prophylaxis used patient uncomplicated mpox. However, lesion monitored secondary bacterial infection (i.e. cellulitis, abscess) present treated antibiotic activity normal skin flora, including Streptococcus pyogenes methicillin -sensitive Staphylococcus aureus (MSSA). • decision initiate antimicrobial therapy based individual clinical assessment loc",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8a6f6989-b9d8-4b69-ab80-947882579ebb",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "decision initiate antimicrobial therapy based individual clinical assessment local antimicrobial resistance patterns. patient improve clinically infection continues spread, reassess patient antibiotic regimen consider adjustment necessary. See Essential Medicines List: antibiotic book information regarding selection antimicrobial appropriate use [147] (see Annex 3. Antimicrobial recommendation dosage secondary bacterial skin infection). 5.1.3.5.1 Practical info • skin lesion patient mpox may inflamed causing mild erythema and/or skin hyperpigmentation – need treated antimicrobial therapy [45]. Empiric prophylactic use antibiotic discouraged, increase risk emergence transmission multidrug - resistant (MDR) bacteria place individual risk possible side - effect antibiotic",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "673f6da3-d3c4-40a2-9162-f1120e031822",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "tant (MDR) bacteria place individual risk possible side - effect antibiotic Clostridium difficile associated diarrhoea. Infections MDR bacteria difficult treat, associated increased morbidity mortality [147, 148,149]. • Secondary bacterial infection skin lesion reported common complication mpox patient monitored closely [45 ,32,40,146]. swab superficial skin infection unlikely helpful unless patient prolonged hospitalization concern MDR organism. Signs bacterial infection include erythema, induration, warmth, worsening pain, purulent drainage, malodorous discharge recurrence fever. See Annex 3 oral option antibiotics. selected case based individual risk factors, known colonization local prevalence, consideration may given initiate Clinical management infection prevention control mpox 36",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b21501fe-5793-4ac6-9d0e-def1c53b4f4b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "may given initiate Clinical management infection prevention control mpox 36 treatment community -acquired methicillin -resistant Staphylococcus aureus (MRSA). • Patients bacterial superinfection mpox rash may develop abscess collection pu within dermis subcutaneous tissue commonly due bacteria skin ( Streptococcus spp. Staphylococcus spp.) [150]. abscess may appear painful, red, shiny nodule without fluctuance. may associated surrounding cellulitis, fever worsening pain site infection. • Treatment abscess incision drainage done sterile aseptic technique qualified health worker using appropriate IPC measures, prevent complication related untreated abscess osteomyelitis, septic arthritis, pyomyositis, sepsis shock. Depending location body (e.g. adjacent major blood vessels), size compl",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d8570f82-409e-4f2a-b67a-9d1a0eb32b6b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "shock. Depending location body (e.g. adjacent major blood vessels), size complexity abscess, incision drainage may need performed operating theatre. Fluid aspirated sent microbiology culture help target antimicrobial therapy [150]. Recommendations patient high risk complication severe mpox 37 6. Recommendations patient high risk complication severe mpox one updated IPC (Infection prevention control health facilities) two new clinical management recommendation (Timing ART initiation people living HIV Breastfeeding mpox) section focused patient high risk developing severe mpox. 6.1 Infection prevention control health facility (New recommendations) Implementation appropriate IPC measure essential mitigate control risk transmission mpox health c",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "16719019-72cf-4105-8e8e-50c3e0c9bfbf",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ropriate IPC measure essential mitigate control risk transmission mpox health care facility community setting [109, 151]. Implementing hierarchy control [152] central reducing risk exposure mpox within health care settings. such, consideration application engineering administrative control use PPE integrated throughout recommendation outlined. critical ensure basic IPC standard put place national health facility level provide adequate protection patients, health workers, caregiver visitor thereby protect community. provides guidance minimum requirement [153] IPC national level health care facilities. Achieving IPC minimum requirement robust comprehensive IPC programme based Guidelines core component infection prevention control programme national acute",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0849d2c4-1ade-47fe-a2eb-48993e1cd461",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ines core component infection prevention control programme national acute health care facility level across health system essential sustaining effort control emerging infectious diseases, health care -associated infection (HAIs) antimicrobial resistance [151]. Health care worker always follow standard precaution perform risk assessment evaluate need use transmission -based precautions. Standard precaution summarized aide -memoire [14]. Infection prevention control crucial mitigating containing spread MPXV. appropriate IPC measure taken, transmission amplified via health care -associated (nosocomia) [153]) infection and/or health care worker infection within health -care setting [154]. result spread Clinical management infection prevention control mpox 38 community across borders, resulting increas",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "00d54a2e-5c8c-4ad4-aca2-ba8b32cf4a01",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "infection prevention control mpox 38 community across borders, resulting increased morbidity mortality. Public health official ensure robust IPC measures, environment infection control practice accompanied WASH service place health care settings, well communities, mitigate impacts. outbreak, support IPC include relevant point health-seeking practice within local context, including government health facilities, private facilities, traditional healer facility mpox treatment centre established manage care patient suspected confirmed pathogen interest outbreak. Strengthening IPC preparedness operational readiness lead robust responses, contain outbreak prevent health system becoming overwhelmed. Existing IPC capacity mapped assessed (e.g. using Health Emerge",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3e15f28a-4874-4094-a5b8-eeec944173d8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ming overwhelmed. Existing IPC capacity mapped assessed (e.g. using Health Emergency Readin es Response Operations Capabilities checklist [HERO] tool), identifying critical area missing need development. Additional information found Framework toolkit infection prevention control outbreak preparedness readiness response National Level [154] Framework toolkit infection prevention control outbreak preparedness, readiness response health -care facility level [ 155]. Outbreak management optimal established national subnational IPC programme exist, dedicated support trained IPC team national, local health care facility level. Although MPXV specific IPC considerations, standard transmission -based precaution followed caring suspected confirmed mpox patients. patient mpox receive",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "59d3b03d-700d-4171-9649-f0b22666f569",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "lowed caring suspected confirmed mpox patients. patient mpox receive respectful, patient -centred care respect promotes gender equity, maintains dignity, privacy confidentiality [1]. research need IPC focusing understanding transmission route IPC measure health care setting listed section Uncertainties, emerging evidence future research. Recommendations patient high risk complication severe mpox 39 6.1.1 Infection prevention control consideration Conditional recommendation , low certainty evidence (published May 2025) patient suspected confirmed mpox, suggests health care worker use contact droplet precautions.* • Consider using respirator ventilation poor unknown based upon risk assessment (e.g. immunocompromised status presence mucosal lesions). • Airborne precaution implemen",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2aae61c8-7a95-4f2c-8ac9-dc3105634e5c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "mmunocompromised status presence mucosal lesions). • Airborne precaution implemented varicella zoster virus (i.e. chickenpox) measles suspected excluded. • Airborne precaution implemented performing aerosol - generating procedure (AGPs). • single room available limited supply, cohort confirmed patient prioritize single room suspect probable patients. * Contact precaution include following PPE: gloves, gown. Droplet precaution include following PPE: medical mask, consider eye protection based upon risk assessment. ** Confirmed mpox mean via laboratory confirmation; probable meet clinical sign symptom epidemiological link. 6.1.1.1 Practical info 6.1.1.1.1 Implementation consideration • Contact droplet precaution used health care worker providing direct indirect care (e.g. cleaning environment, handling linen",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "76ef8183-a2c0-4606-9f9e-bf0e3389d1bb",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "h care worker providing direct indirect care (e.g. cleaning environment, handling linen waste) patient mpox. • addition droplet contact precautions, standard precaution followed patient times. measure described provide additional consideration implementing droplet contact precaution [7] context mpo x. • Health care worker trained use standard transmission -based precaution contact droplet precaution proper use PPE. Clinical management infection prevention control mpox 40 6.1.1.2 Risk assessment • Health care worker conduct risk assessment determine additional PPE required, respirator rather medical mask eye protection. risk assessment take consideration: 1) ventilation rate room AGP performed; 2) activity ta",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "85b1094b-0609-4e15-b240-dfb54579a79a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ") ventilation rate room AGP performed; 2) activity taking place may increase presence risk infectious respiratory particles, changing bed linen patient suspect confirmed mpox; 3) patient’s condition (e.g. number lesions, location, i.e. mucosal, patient's immune status). 6.1.1.2.1 Hand hygiene • Hand hygiene performed according 5 moment hand hygiene[240]. 6.1.1.2.2 Patient placement • Place patient contact droplet precaution mpox single room. • single room available single room limited: • Patients suspected mpox patient deemed probable mpox case prioritized single rooms; • Consider cohorting patient confirmed mpox. • Physically separate patient least 1 metre (3 feet) draw privacy curtains. • Whenever others room transpor",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f6980319-5006-48c2-b859-527595c2583c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "east 1 metre (3 feet) draw privacy curtains. • Whenever others room transport necessary: • Cover wound lesion patient’s body though use bandages, clothing and/or sheet comfortably cover lesions. • patient wear wear medical mask (if able tolerates) follow respiratory hygiene cough etiquette. 6.1.1.2.3 Personal protective equipment • Contact droplet precaution include following PPE: gown, gloves, medical mask eye protection based upon risk assessment. • Consider respirator instead medical mask based risk assessment (details above). • Use dedicated footwear decontaminated. Disposable shoe cover recommended [171, 172,173]. 6.1.1.2.4 Safe injection sharp injury prevention • Follow standard precaution safe injection sharp injury prevention. Recommendations patient high risk complication severe",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9c0f0e70-1368-4e93-b690-2976fb82ab6e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "jury prevention. Recommendations patient high risk complication severe mpox 41 • Avoid use sharp instrument specimen collection. Lesions swabbed. Follow guidance diagnostic testing MPXV. 6.1.1.2.5 Environmental cleaning disinfection • Increase cleaning disinfection mpox patient care area least twice daily well immediate cleaning disinfection surface visibly soiled blood body fluids. • frequent cleaning disinfection performed frequently touched surface including toilets, latrine showers. • Clean first detergent water disinfect surface chemical disinfectant allow disinfectant remain untouched surface contact time recommended manufacturer. Alternatively, combined detergent- disinfectant product ( available) used perform cleaning disinfection single step, provid",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "839360a1-474b-4356-a143-001817773034",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ct ( available) used perform cleaning disinfection single step, provided effective targeted pathogens. • Use product disinfecting environment approved environmental cleaning health care virucidal activity (follow national facility guideline) damage surface equipment. • Disinfectants prepared applied surface according manufacturers’ instruction: • One study found use 0.05% 0.5% sodium hypochlorite solution 70% ethanol efficacious MPXV wiped common non- porous surface low -resource setting 1 minute contact time [117] • Quaternary ammonium compound found achieve sufficient log reduction MPXV non-porous surface contact time 1 –10 minute (not porous surface wood) [117]. 6.1.1.2.6 Handling transport linen • Handle soiled linen patient",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4d7e7d90-f75d-4aa8-9f82-8f391c867839",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "wood) [117]. 6.1.1.2.6 Handling transport linen • Handle soiled linen patient mpox carefully (with minimal manipulation agitation) prevent personal contamination transfer patients. • Carefully lift roll linens. shake linen laundry. • Linens carefully placed designated container bag transport laundry services. • Remove heavily soiled material (e.g. faeces) linen, wearing appropriate PPE, placing laundry bag. Clinical management infection prevention control mpox 42 • Laundry linen may decontaminated manual machine washing least 20 minute hot water (70°C, hot water mixed detergent hot water mixed low -concentration sodium hypochlorite solution (0.05%) [116]. 6.1.1.2.7 Decontamination reprocessing reusable patient care item equipment • Use disposable dedicated patient care equipment. • Clea",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4611a31e-76e1-4349-8354-090faaa26761",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "patient care item equipment • Use disposable dedicated patient care equipment. • Clean disinfect equipment use patients. • Clean disinfect sterilize reusable equipment/devices according manufacturer’s instructions, national international standards, using efficient method based intended use. 6.1.1.2.8 Waste management • Handle treat bodily fluid solid waste patient mpox infectious waste. • Segregate waste according standard precaution (general waste, infectious waste sharps) place appropriate bin point use. • Management disposal waste (including PPE) performed accordance local regulation infectious waste. Evidence decision Benefits harm Small net benefit , little difference alternative GDG assessed benefit harm respirator use; public health perspective, GDG felt important",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2c429d37-0155-4e66-8457-233c10b750de",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "harm respirator use; public health perspective, GDG felt important reserve respirator situation respirator known make difference. GDG also highlighted potential challenge availability, particularly low - middle -income countries. Limited access setting may reduce supply area respirator essential. GDG member noted potential harm include possible mental health consequence anxiety stress related wearing respirators. Certainty evidence Low Recommendations patient high risk complication severe mpox 43 certainty evidence judged low rated indirectness risk bias. use respirator possibly make little difference prevention MPXV transmission compared medical mask. Values preference Substantial variability expected uncertain",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1e77e0b1-021c-424e-96ca-64a111c1cfaa",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "medical mask. Values preference Substantial variability expected uncertain GDG anticipated although health care worker caring patient mpox place priority safety, evidence support effectiveness intervention, use respirators, would decline use intervention. GDG acknowledged uncertainty likelihood va riability value preference health care workers. Furthermore, GDG placed high value avoiding wasteful expenditure intervention unlikely effective thus preserving resource intervention higher certain ty benefit. Resources consideration Resources GDG anticipated use respirator care patient mpox health care facility requires additional investment financial logistical resource (including fit testing), particularly impacting low - middle -in",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f884b0a5-fe38-4f67-bf75-939145b90f0d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ncial logistical resource (including fit testing), particularly impacting low - middle -income countries. Equity GDG acknowledged health care worker believe safety priority respirator available, however, low -resource setting supply may limited respirator need prioritized pathogen known th ey required. Acceptability health care worker may like wear respirator may prefer use medical mask. Use respirator associated report communication barrier (verbal non-verbal). Feasibility GDG expressed concern supply chain implication availability respirator needed used pathogen evidence Clinical management infection prevention control mpox 44 suggests possibly make little difference prevention compared medical mask. 6.1.1.3 Justificat",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "15aecc17-c1e1-4bdf-9425-e3f5e3ecbcd0",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ibly make little difference prevention compared medical mask. 6.1.1.3 Justification GDG noted among 32 000 case infection report transmission inhalation, one case self -reported droplet exposure, thus concluded use respirator possibly make little difference n prevention MPXV transmission compared medical mask. Amongst 1738 health care worker documented exposure mpox, 14 infections, 10 case (71.4%) identified related percutaneous injury (needlesticks), one ocula r exposure three due unspecified factors. may situation use respirator required AGP varicella zoster virus (chickenpox) measles suspected excluded. GDG stressed health care worker conduct risk assessment determine need respirator additional",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "560bdd19-7917-436c-9e41-297172d9e188",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "worker conduct risk assessment determine need respirator additional PPE (e.g. eye protection). area ventilation poor unknown possible ensure adequate ventilation respirator may preferred. GDG also highlighted importance assessing risk transmission related status patient, noting patient’s condition (number location lesions, immune status) may increase risk transmission taken consideration risk assessment determine use respirator. Given primary mode transmission described close contact (sexual non- sexual) conditional recommendation mpox considered context accepted practice (transmission -based precautions) IPC. GDG acknowledged main route transmission direct contact (sexual non-sexual) skin lesion (with fluid exudate tho",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "667a209a-6877-4fa8-a6a7-665036639e12",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "direct contact (sexual non-sexual) skin lesion (with fluid exudate lesion individual infected MPXV), possible environmental contamination well potential IR Ps cannot excluded. conditional recommendation made implement droplet contact precaution interacting patient mpox environment, addition use standard precautions. PPE, including gown, glove eye pro tection (based risk assessment), must worn per contact droplet precautions. Recommendations patient high risk complication severe mpox 45 6.1.1.4 Summary systematic review conducted two phase (see Annex 5 details) data yet published available. Summary Findings table based non-comparative study identified indirectly informs IPC PICO question. study described route transmission suspected",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "154e0dee-0574-481a-858e-bf34ed79743c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ly informs IPC PICO question. study described route transmission suspected confirmed mpox cases. Based studies, ten mpox transmission route identified amongst 32317 case MPXV infection reported studies: confirmed sexual contact(65.1% mpo x cases), suspected sexual contact(30.3%), close contact (non - sexual)(2.9%), fomite/environment (0.36%), transplacental (0.01%), percutaneous injury (0.09%),direct deposition(formerly droplet) (0.003%), inhalation (0%) animal/animal product (0.48%) multiple route (0.83%) [26,27,47,57,86,87,97,102,103,128,130,131,132].Close contact (sexual /nonsexual) predominate mode transmission (95.3 %). Transmission percutaneous injury contaminated object, fomite transplacental animal product uncommon, accounting approximately 0.1%. one case self - reported droplet exposure 32, 317 case reported route transmissi",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "60033f3f-7276-47e7-9136-b3bbaa75d0fc",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "case self - reported droplet exposure 32, 317 case reported route transmission data [74]. single case one 12 breakthrough infection postexposure vaccination mpox. study defined droplet transmission occurring presence exposed person without mask less two meter least three hour PCR -confirmed mpox patient [74]. reported inhalation exposures. additional sub -analysis conducted assess route transmission mpox clade: Clade I, Clade Ib, Clade IIb. 29 222 study reported clade information, covering 23.6% patients. case Clade IIa reported literature. Among 10788 patient clade identified, case clade Ib IIb MPXV infection describe close contact (confirmed sexual, suspected sexual non -sexual) primary mode transmission. clade 1a total 218 ca",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "33043b4d-e067-4eb9-9852-e0f32e10e68c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "l non -sexual) primary mode transmission. clade 1a total 218 case identified. Amongst cases, mode transmission primarily described 40.6% (205 cases) multiple routes, 30.9% (156 cases) exposure animal /animal products, 17% (86 cases) close contact (non-sexual) 11. 5% (58 cases) route transmission. description droplet inhalation transmission 29 clade specific studies. finding align previous systematic review [68] Clinical management infection prevention control mpox 46 Outcome Timeframe Study result measurement Comparator Respirators addition contact droplet precaution Intervention Medical mask part contact droplet precaution Certainty evidence (Quality evidence) Summary Mpox infection inferred transmission route frequency data (Observational (non - randomized))",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8c7b8824-25a8-4ec2-a216-3f406e23ffeb",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "pox infection inferred transmission route frequency data (Observational (non - randomized)) 1 reported case transmission droplet 32318 patient (1/270 studies) Inferred odds ratio: 1 Low Due serious indirectness, Due serious risk bias 1 use respirator probably make little difference preventing mpox transmission compared medical mask 1 Risk Bias: serious. Inconsistency: serious. Indirectness: serious. Imprecision: serious. Publication bias: serious. 6.1.2 Visitors isolated mpox patient Interim guidance (Published 10 June 2022) recommends patient isolated mpox measure put place support patient interaction family visitor promote well -being • Visitors caregiver perform appropriate hand hygiene entering/exiting patient room, receive instruction closely supervised use (putting removal) PPE contac",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fcbc72bb-cbe7-4ca3-8f6b-e7b900f11373",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "receive instruction closely supervised use (putting removal) PPE contact droplet precautions. • Vulnerable high -risk individual counselled regarding risk order make informed decision whether visit patient. • Alternate mode communication videoconference offered. 6.1.3 Optimized supportive care 6.1.3.1 Admission hospital Interim guidance (Published 10 June 2022) Recommendations patient high risk complication severe mpox 47 recommends patient high risk complication (i.e. young children, pregnant person immunosuppressed) severe complicated mpox admitted hospital closer monitoring clinical care appropriate isolation precaution prevent transmission mpox virus detail systematic evaluation, see [1]. 6.1.3.1.1 Practical info job aid de",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ee44c9a3-465e-4236-9b47-61bc4dc895ed",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "detail systematic evaluation, see [1]. 6.1.3.1.1 Practical info job aid describing systematic monitoring patient attached Annex 7. 6.1.3.2 Optimised supportive care Interim guidance (Published 10 June 2022) recommends patient mpox develop complication severe disease managed optimized supportive care interventions. 6.1.3.2.1 Practical info table describing optimized supportive care measure patient complication severe disease found Annex 6. Clinical management infection prevention control mpox 48 6.2 Timing ART initiation people living HIV (New recommendation) 6.2.1 Rapid ART initiation standard care strongly recommends rapid ART initiation (≤ 7 day HIV diagnosis) adults, adolescent children, including offer -day start. guidance based high-certainty evidence adult adolescents, l",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d2507100-b1e7-4c26-8c6d-a59750e699a7",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "-day start. guidance based high-certainty evidence adult adolescents, low -certainty evidence c hildren (WHO consolidated guideline HIV prevention, testing, treatment, service delivery monitoring (2021) [160]). Three randomized clinical trial showed strong mortality benefit rapid ART compared delayed ART (RR 0.47, 95% CI 0.24–0.93) well positive impact frequency ART initiation, retention care suppression viral load 12 months. recommendation rapid ART initiation acknowledges concern paradoxical immune reconstitution inflammatory system (IRIS) context immunosuppression. Restoration immune function ART considered important intervention management opportunistic infections, especially effective treatment unavailable. However, infection central nervous system involvement TB cryptococcal meningitis, case TB, targe",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d214f68e-0231-4497-a716-60bc71d93efc",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "central nervous system involvement TB cryptococcal meningitis, case TB, targeted antimicrobial treatment de lay ART week recommended reduce likelihood paradoxical IRIS adverse outcomes. 6.2.2 Mpox ART initiation currently randomized clinical trial comparing early v delayed ART initiation people HIV mpox. One observational study 19 patient HIV mpox showed uncertain effect delaying ART initiation; showed higher rate hospitalization compared early ART initiation group. low -certainty evidence initiation ART late stage HIV infection may increase hospitalization mpox patient ART (5 non-randomized studies, 2037 participants, = 4.19, 95% CI 2.11–8.34). Mpox IRIS following ART initiation may occur, frequency uncertain. Differentiating mpox IRIS progressive mpox complica",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "418a2ed1-90ce-428c-8b4b-8cd1f5c4d7e9",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "frequency uncertain. Differentiating mpox IRIS progressive mpox complicated given lack clear case definition overlapping manifestations. technical meeting organized WHO, expert consensus general mortality reduction benefit rapid ART initiation extend patient mpox, Recommendations patient high risk complication severe mpox 49 accepting risk paradoxical IRIS, noting delaying ART initiation may possibly harmful. conclusion based lack available evidence - based effective therapy mpox, continued mpox viral replication disease progression patient immunosuppression, estimation mpox central nervous system manifestation uncommon, concurrence opportunistic infection mpox would benefit rapid ART initiation. People symptom mpox access health service HIV testing",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3b0b1027-6b27-46f8-b194-2809049af7a0",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "rapid ART initiation. People symptom mpox access health service HIV testing early reduce risk severe mpox disease. Strong recommendation for, moderate certainty evidence (published May 2025) recommends rapid initiation ART people mpox HIV ART naïve prolonged interruption ART (Strong recommendation, moderate certainty evidence) • Early HIV testing conducted patient present suspected confirmed mpox infection. • patient referred appropriate service ART initiation soon possible, aiming provide therapy within 7 day HIV diagnosis including offer same-day start. • people already ART undetectable viral load, ART regimen continued without interruption change. viral load test result less 1 year old; not, new viral load test conducted. 6.2.2.1 Practical info l",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2ed17600-ea32-41e8-b814-eedb4b6c0378",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "1 year old; not, new viral load test conducted. 6.2.2.1 Practical info latest guidance HIV prevention, testing, treatment, service delivery monitoring found here: https://www.who.int/publications/i/item/9789240031593 .[160] Disseminated cryptococcosis skin lesion may resemble mpox circumstances. Guidelines diagnosing, preventing managing cryptococcal disease among adults, adolescent child living HIV found here: https://www.who.int/publications/i/item/9789240052178 .[53] Clinical management infection prevention control mpox 50 6.2.2.2 Evidence decision Benefits harm Substantial net benefit recommended alternative high -quality indirect evidence mortality benefit initiating antiretrovirals (ART) soon possible. absence effective mpox - specific treatment lower viral load, panel judged lit",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "96f62b42-3c13-49ee-87c1-b4a1896a9924",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "effective mpox - specific treatment lower viral load, panel judged little benefit delay ing ART initiation. panel judged harm delay ART initiation. Immune recovery central viral control recovery disease, treatment delay likely delay immune recovery. panel judged harm delay likely, including reduced linkage retention care, progression mpox viral replication. Despite absence direct evidence patient mpox, harm uncontrolled, progressive mpox infection context advanced immunosuppression well documented fatal. panel judged harm likely outweigh potential harm arising IRIS. Certainty evidence Moderate Current recommendation rapid ART initiation based high -quality evidence three randomized controlled trial , 7418 patient inferred mortality benefits.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ef0e4105-0bb4-466d-be4b-7c3b07e36a91",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "e three randomized controlled trial , 7418 patient inferred mortality benefits. study population within trial include mpox patients, therefore, due indirectness, certainty mortality benefit assessed moderate. IRIS severe occurs due opportunistic infections, occurrence rate uncertain mpox. Values preference substantial variability expected GDG inferred HIV patient mpox would place higher value mortality benefit initiating antiretrovirals (ART) soon possible possible increased risk developing IRIS. Resources consideration important issue recommended alternative Resources Recommendations patient high risk complication severe mpox 51 issue system already provides antiretrovirals. Equity issue system already provides antiretrovirals.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b53b7b3b-c3e5-497a-9141-6ac1ceba157e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "provides antiretrovirals. Equity issue system already provides antiretrovirals. Acceptability issue system already provides antiretrovirals. Feasibility issue system already provides antiretrovirals. 6.2.2.3 Justification Currently, contrast opportunistic infection delayed ART recommended, direct evidence regarding timing ART mpox low certainty. low -certainty evidence comparison uncontrolled versus controlled HIV mpox delayed ART may increase hospitalization mpox patient (5 non -randomized studies, 2037 participants, = 4.19, 95% CI 2.11–8.34). low-certainty evidence regarding impact early treatment versus delay occurrence effect IRIS mpox/ HIV co-infected patients. GDG considered evidence people mpox would pertain (with high -quality evidenc",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fb24e436-fd43-4532-96a1-4cfcef5c2b61",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ce people mpox would pertain (with high -quality evidence rated indirectness, therefore overall moderate certainty evidence benefit mpox). value preferences, panel judged almost HIV patient mpox would place higher value likely mortality benefit initiating ART soon possible possible increased risk developing IRIS. panel acknowledged strong recommendation would reduce likelihood accrual direct evidence pertaining PICO. However, observational data clinical case series would allow estimation incidence IRIS. 6.2.2.4 Clinical question/ PICO Population: HIV Mpox Intervention: Delayed ART Comparator: Early ART Clinical management infection prevention control mpox 52 Outcome Timeframe Study result measurement Comparator Early ART Intervention Delayed ART",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c0524b14-b20b-4125-a16c-87355c36a1e8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "Timeframe Study result measurement Comparator Early ART Intervention Delayed ART Certainty evidence (Quality evidence) Summary Mortality (high risk) Odds ratio 2.08 (CI 95% 1.08 — 3.99) Based data 7418 participant 3 studies. (Randomized controlled) 46 per 1000 91 per 1000 Moderate Due serious indirectness1 Delayed ART probably increase mortality mpox patient inferred comparison delayed versus early ART HIV 45 per 1000 (CI 95% 3 – 115 more) Mortality (low risk) Odds ratio 2.08 (CI 95% 1.08 — 3.99) Based data 7418 participant 3 studies. (Randomized controlled) 3 per 1000 6 per 1000 Moderate Due serious indirectness2 Delayed ART probably increase mortality mpox patient inferred comparison delayed versus early ART HIV 3 per 1000 (CI 95% 0 fewer – 9 more) Hospitalization Odds ratio 7 (CI 95% 0.29 — 167.93) Based data fr",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f7d8fc1e-79d6-405d-8dc3-a58ef9d8c09e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "CI 95% 0 fewer – 9 more) Hospitalization Odds ratio 7 (CI 95% 0.29 — 167.93) Based data 19 participant 1 studies. (Observational (non - randomized)) 82 per 1000 385 per 1000 low Due serious risk bias, Due serious imprecision 3 uncertain effect delayed versus early ART initiation mpox hospitalisation 303 per 1000 (CI 95% 57 fewer – 856 more) IRIS Odds ratio 1.13 (CI 95% 0.06 — 21.09) Based data 19 participant 1 studies. (Observational (non - randomized)) 100 per 1000 112 per 1000 low Due serious risk bias, Due serious imprecision4 uncertain effect delayed versus early ART initiation mpox occurrence IRIS 12 per 1000 (CI 95% 93 fewer – 601 more) 1, 2. Inconsistency: serious. Indirectness: serious. Downgraded indirectness population include mpox cases. Imprecision: serious. Publication bias: serious.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1172fccf-1df5-4dde-9d44-66bdc2039206",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "population include mpox cases. Imprecision: serious. Publication bias: serious. 3. Risk Bias: serious. Unadjusted estimate. Inconsistency: serious. Indirectness: serious. Imprecision: serious. One study events. Publication bias: serious. 4. Risk Bias: serious. Unadjusted estimate. Inconsistency: serious. Indirectness: serious. Imprecision: serious. Downgraded risk bias estimate unadjusted, downgraded imprecision one study events. Pu blication bias: serious. Recommendations patient high risk complication severe mpox 53 6.3 Breastfeeding mpox (New recommendation) current recommendation breastfeeding outside mpox context summarized, technical working group (see Methods section) provide foundational evidence mpox guideline development. noted existing guideline pertained, specifically",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "36a3cbc0-212a-4596-94b7-93ed426f69f5",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "pox guideline development. noted existing guideline pertained, specifically Recommendations postnatal care mother newborn (2013) [161]. • recommends “All baby exclusively breastfed birth 6 month age. Mothers counselled provided support exclusive breastfeeding postnatal contact (Strong recommendation, based moderate quality evidence). • Remarks: • recommendation applicable settings. • Exclusive breastfeeding promoted antenatal postnatal care contact. • Particular support exclusive breastfeeding provided mother caesarean section baby born preterm. • low -birth -weight feeding guideline LMIC recommend exclusive breastfeeding preterm low -birth -weight infant (https://www.who.int/publications/i/item/9789241548366 ).[162] • GDG reviewed evidence neonatal ou",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "48ec2580-880e-4a7f-8b85-205eb2ed45fa",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "/www.who.int/publications/i/item/9789241548366 ).[162] • GDG reviewed evidence neonatal outcomes; 6 -month duration exclusive breastfeeding based existing recommendation updated Cochrane review. technical group structured PICOs address separately risk mother child transmission mpox two potential routes, via breastmilk via direct contact. final PICO address whether mother recover mpox withheld breastfeeding direct contact, resume breastfeeding direct contact infant. 6.3.1 Breastfeeding Conditional recommendation for, low certainty evidence (published May 2025) Clinical management infection prevention control mpox 54 suggests mother mpox continue breastfeeding, whilst limiting direct contact non -infected infant, lesion fully resolved (lesions crusted, scab lesion fallen",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b08157fc-0d9f-45e2-bdab-6ee4237e9e27",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "nt, lesion fully resolved (lesions crusted, scab lesion fallen fresh layer intact skin formed underneath). (Conditional recommendation, low certainty evidence) • breastfeeding continued suspected confirmed mother mpox non -infected infant, IPC measure must established including limited contact mother infant except breastfeeding coverage active lesion ot part body whilst breastfeeding. • presence areolar lesion prompt careful consideration mother use breast breastfeed infant. case unilateral lesions, lesion healed per criterion (lesions crusted, scab lesion fallen fresh layer intact skin formed underneath), breastfeeding may take place unaffected breast whilst covering active lesions. • Health care worker inform mother th",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0ae35806-c274-486b-9715-00aff54f0c2b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "st whilst covering active lesions. • Health care worker inform mother risk infection infant whilst breastfeeding availability appropriate alternatives. • Context drive feasibility, availability safety alternative breast feeding. Whenever safe feasible, expressed breastmilk milk substitute direct contact, may pursued reduce transmission. 6.3.1.1 Practical info Additional guidance breastfeeding found Recommendations postnatal care mother newborn accessed here: https://www.who.int/publications/i/item/9789241506649 .[161] General protective IPC measure taken mother mpox handling feeding infants, e.g. washing hand feeding, wearing medical mask covering lesion areola area direct contact infant. Alternatively, one breast lesions,",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4a6c9d26-649e-4e28-bd10-46fc9c2e57ae",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "n area direct contact infant. Alternatively, one breast lesions, mother express/pump breast lesion areola discard milk feed non-affected breast. cases, monitor mother -infant pair closely dev elopment sign symptom mpox treat accordingly. Infants mother mpox closely monitored sign symptom main goal early supportive care prevent development severe disease poor outcomes. Recommendations patient high risk complication severe mpox 55 event replacement feeding breastmilk substitute, essential track infant’s growth, development illness well sign symptom mpox. 6.3.1.2 Evidence decision Benefits harm benefit continuing breastfeeding based moderate quality evidence exclusively breastfed neonate",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f71e669c-e393-4292-a916-366c59fdc8f6",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "uing breastfeeding based moderate quality evidence exclusively breastfed neonate lower risk -cause mortality infection -related mortality first month life compared partially breastfed neonates. Also, low -quality evidence exclusively breastfed neonate lower risk sepsis, acute respiratory infection diarrhoea first month life compared partially breastfed neonates. Harms continuing breastfeeding include risk transmission infection infant contact lesion expressed milk. evidence available transmission expressed milk (with contact) due presence viable virus milk limited. Certainty evidence Low certainty evidence ranged moderate low. Aside indirect evidence regarding impact breast feeding, seven publication providing potentially direct evidence identified;",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d6ab08e3-cb8d-4fdd-aae0-a0508919f437",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "mpact breast feeding, seven publication providing potentially direct evidence identified; five case report two case series. However, none study clarity th e existence lesion specifically breasts. Six study report breastfeeding direct contact. five studies, infant infected compared infant infected one study reported breastfeeding contact. moderate certainty evidence breastfeeding direct contact mother mpox lesion breast probably resulted infection infants. However, less clarity frequency event. was, however, low certainty evidenc e magnitude increase mpox infection infant result breastfeeding direct contact mother mpox lesion breasts. Regarding hospitalization infant due mpo",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "973e6383-8746-4c7c-b6d7-f1dff13e32dd",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "th mother mpox lesion breasts. Regarding hospitalization infant due mpox infection, four six infant breastfed close contact hospitalized compared Clinical management infection prevention control mpox 56 breastfeeding direct contact (the case hospitalized group breastfeeding direct contact monitor infant infection). Concerning mortality, one death breastfeeding direct contact group compared breastfeeding direct contact. low certainty evidence breastfeeding direct contact increase infant mortality low certainty regarding magnitude increase infant death may occur result breastfeeding direct contact mother mpox, lesion breast infant. one case report described breastfeeding",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "917b3448-c646-4569-8c87-b5fbe77166d5",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "esions breast infant. one case report described breastfeeding direct contact. certainty evidence rated low due lack clarity breastfeeding direct contact (e.g. expressed milk) affect risk infection, hospitalization mortality infant. adverse event reported studies. study reported infant mother confirmed mpox infection lesion breasts. Therefore published evidence effect breastfeeding close contact infant mother lesion breasts. Values preference Substantial variability expected uncertain likely substantial variability value preference mothers, related availability safety resource use milk substitutes, well beliefs, religion, culture family traditions. formal study",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "394e4f89-54a6-4766-b8ec-f0dfde71822b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "substitutes, well beliefs, religion, culture family traditions. formal study available inform patient value preference mpox. Nevertheless , panel inferred parent generally strongly wish avoid harm babies. time, experience Ebola virus disease mpox outbreak Democratic Republic Congo reported panel member suggests faced competing priority harm reduction desirability breastfeeding, mother valued breastfeeding highly. setting alternative breastfeeding (appropriate milk substitutes) feasible, available safe, panel inferred parent would place higher value possible beneficial effect breastfeeding direct contact Recommendations patient high risk complication severe mpox 57 expressed milk (no direct contact) eliminating uncertain magnitude risk",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6fd8b7a1-f28b-449b-bac5-133b9b712e6d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "mpox 57 expressed milk (no direct contact) eliminating uncertain magnitude risk infant getting infected mpox. Resources consideration Important issues, potential issue investigated Resources affordability alternative breastfeeding many context may limited, cost likely fall family health care system. GDG noted complexity providing safe breastmilk substitute including requirement available safe water equipment provide it. significant resource required term IPC measure irrespective choice breastfeeding not. PALM007 study Democratic Republic Congo, breastmilk substitute provided part research, apart support, mother would usually access it. Outside research settings, downstream event occ urring result -breastfeeding may sig",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d2b37c7b-faaa-4e9e-9fbb-9e2c38aed867",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "f research settings, downstream event occ urring result -breastfeeding may significant cost resource implication especially following diarrhoeal disease malnutrition. Equity Increasing cost associated use alternative breastfeeding could drive inequity increase pre - existing inequities. Acceptability Breastfeeding accepted promoted setting environment best option infant feeding. Feasibility large heterogeneity accessibility alternative breastfeeding (see Resources, above). Specifically, potential pasteurize breastmilk also noted, felt feasible many contexts. 6.3.1.3 Justification Overall, certainty evidence breastfeeding mother mpox infant rated moderate low. GDG felt strong recommendation could made given certainty evidence available. Clinical management infection p",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "66b25e18-847d-40e8-a5bb-42a1b6f80da6",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "could made given certainty evidence available. Clinical management infection prevention control mpox 58 GDG considered benefit continuing breastfeeding mother mpox infection based moderate certainty evidence exclusively breastfed neonate lower risk -cause mortality infection -related mortality first onth life compared partially breastfed neonates. GDG also considered deliberation alternative breastfeeding may feasible safe expose infant harm. setting alternative breastfeeding (appropriate milk substitutes) feasible, available safe, panel inferred parent would place higher value possible beneficial effect breastfeeding direct contact expressed milk (no direct contact) eliminating uncertain magnitude risk infant getting infected w ith mpox via breastfeedin",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "38c5e580-043d-4872-b6fd-cd55cee2359b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "eliminating uncertain magnitude risk infant getting infected w ith mpox via breastfeeding. GDG also noted little research available parent preference highlighted area research. considering harm risks, GDG also reflected pre -symptomatic stage, lesion emerge mother presented treatment, infant may already already exposed. case, may little benefit subsequent avoidance breastfeeding. Additionally, lesion part body, context intimate care infant may make isolated recommendation breastfeeding little impact likelihood infant infected. consideration support conditional recommendation continuing breastfeeding. 6.3.1.4 Clinical question/ PICO Population: People suspected confirmed mpox without lesion breast ar",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a174264e-af6b-496a-8058-6ec95d6f2719",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "/ PICO Population: People suspected confirmed mpox without lesion breast breastfeeding infant Intervention: Continue breastfeeding direct contact Comparator: Stop breastfeeding direct contact Outcome Timefram e Study result measurement Comparator breastfeedin g + contact Intervention Breastfeed + contact Certainty evidence Summary Mpox disease infant Based data 7 participant 5 0 83 per 100 Moderate transmission (due Breastfeeding direct contact mpox infected mother Recommendations patient high risk complication severe mpox 59 studies. (Observational (non- randomized)) extensive evidence transmission). low magnitude increase (due serious risk bias imprecision) 1 lesion breast probably result infection infants. uncertain magnitude increase",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d7cdb521-2a4a-4596-8211-3df4fdafade3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "bly result infection infants. uncertain magnitude increase mpox infection infant result breastfeeding direct contact mpox infected mother lesion br east infant. Hospitaliza tion infant due mpox Based data 6 participant 5 studies. (Observational (non- randomized)) 0 67 Moderate transmission (due extensive evidence transmission). low magnitude increase (due serious risk bias imprecision) Breastfeeding direct contact mpox infected mother lesion breast infant, probably result hospitalization uncertain magnitude hospitalization infant occurs result breastfeeding direct contact mother lesion breast infant. Infant mortality Based data 6 participant 5 studies. (Observation",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "34c46bf3-7ba1-4245-8837-37d8c56c2a99",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "infant. Infant mortality Based data 6 participant 5 studies. (Observational (non- randomized)) 0 17 Low infant mortality (due serious risk bias imprecision). low magnitude increase (due serious risk bias serious imprecision) Breastfeeding direct contact mpox infected mother lesion breast infant, may increase infant mortality uncertain magnitude increase infant death may occur result breastfeeding nd direct contact mpox infected mother lesion breast infant Adverse event breastfeedi ng infant mother reported included study Clinical management infection prevention control mpox 60 Adverse event breastfeedi ng infant mother reported included study 1. Risk Bias: serious. due risk bias",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4fa4edfe-9518-4631-93a9-46a526907eb8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ther reported included study 1. Risk Bias: serious. due risk bias reporting case- report case- series. 6.3.1.5 Clinical question/ PICO Population: People suspected confirmed mpox lesion breast breastfeeding infant Intervention: Continue breastfeeding direct contact (expressed milk) Comparator: Stop breastfeeding direct contact Outcome Timeframe Study result measurement Comparator breastfeeding + contact Intervention Breastfeed + contact Certainty evidence Summary Mpox disease infant (Observational (non - randomized)) studies. know effect. Hospitalization infant due mpox (Observational (non - randomized)) studies. know effect. Infant mortality (Observational (non - randomized)) studies. know effect. Adverse event breastfeeding infant",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "80c9d889-c3d8-49ea-afa7-d4deb0d0b1f3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "studies. know effect. Adverse event breastfeeding infant mother reported included study Adverse event breastfeeding infant mother reported included study 6.3.2 Resuming breastfeeding Conditional recommendation for, low certainty evidence (published May 2025) Recommendations patient high risk complication severe mpox 61 suggests mother recover mpox withheld breastfeeding direct contact, resume breastfeeding direct contact infant soon lesion fully resolved (lesions crusted, scab lesion fallen f fresh layer intact skin formed underneath). (Conditional recommendation, low certainty evidence) • recommendation applies mother confirmed mpox withheld breastfeeding close contact infant. • mother need supported",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6f7647c5-4734-4791-8ce7-43d81e800b25",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "withheld breastfeeding close contact infant. • mother need supported continue express milk breastfeeding maximize likelihood reinitiating breastfeeding recovers avoid complication (e.g. mastitis). 6.3.2.1 Practical info Additional guidance breastfeeding found recommendation postnatal care mother newborn (2013) accessed here: https://www.who.int/publications/i/item/9789241506649 [233]. 6.3.2.2 Evidence decision Benefits harm Substantial net benefit recommended alternative benefit resuming breastfeeding based moderate quality evidence exclusively breastfed neonate lower risk -cause mortality infection -related mortality first month life compared partially breastfed neon ates. Also, low quality evidence exclusively breastfed neonate lower risk sepsis, acute respira",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6139adce-b867-4c48-8318-bf136d4adbe8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "low quality evidence exclusively breastfed neonate lower risk sepsis, acute respiratory infection diarrhoea morbidity first month life compared partially breastfed neonates. Harms resuming breastfeeding recovery include risk transmission infection infant persistence virus breastmilk recovered mothers. Evidence around presence viable virus milk limited. Certainty evidence low evidence low certainty, including infection, hospitalization infant mortality endpoints, derived two case reports. One report Clinical management infection prevention control mpox 62 context less 2 weeks' post resolution lesion 2 weeks' post lesion resolution. event either group infection, hospitalization mortality infant. Adverse event report",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2dc47b52-b196-4d5d-b4b1-9b230d22663b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "group infection, hospitalization mortality infant. Adverse event reported. Values preference Substantial variability expected uncertain likely substantial variability value preferences, closely related available resources. data available literature inform patients' value preference mpox specifically. panel noted parent generally strongly wish avoid harm babies. Experience Ebola virus disease mpox outbreak Democratic Republic Congo reported panel member suggests circumstances, mother valued breastfeeding despite known potential transmission disease. parent would place higher value possible beneficial effect breastfeeding direct contact reducing uncertain magnitude risk infant getting infected mpox possible serious consequence w",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f6d1ed1b-4ac3-4205-8c17-39def6154040",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "tain magnitude risk infant getting infected mpox possible serious consequence feeding infant exp ressed milk (no direct contact). Resources consideration Important issue r potential issue investigated Resources affordability alternative breastfeeding questioned many contexts, cost likely fall family health care system. complexity providing safe breastmilk substitute include requirement available safe water equipment provide it. significant resource required term IPC irrespective choice breastfeeding not. noted PALM007 study Democratic Re[ublic Congo, breastmilk substitute provided part research, apart support, mother would usually access it. Outside research settings, downstream event occurring result breastf",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "69fed137-368f-44af-bd7d-d18b67a41f58",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "access it. Outside research settings, downstream event occurring result breastfeeding may Recommendations patient high risk complication severe mpox 63 significant cost resource implication especially following diarrhoeal disease malnutrition occurs. Equity Increasing cost associated alternative breastfeeding could drive inequity Acceptability Breastfeeding accepted promoted setting environment best option infant feeding. Feasibility large variability access alternative breastfeeding (see Resources, above). 6.3.2.3 Justification Overall low certainty evidence precluded strong recommendation. GDG discussed alternative ascertainment time point breastfeeding might reinitiated. Two week used initial practical threshold considering ability maintain lactation expressio",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "41caa6e2-770a-4af2-be12-e6c28d679022",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ed initial practical threshold considering ability maintain lactation expression breastmilk lesion resolut ion. However, GDG agreed adopt dermatological definition recovery: “when lesion crusted over, scab fallen new layer skin formed underneath, lesion eye body (in mouth, throat , eyes, vagina anus) healed” clinical progression may vary individual patient level. Recommencing breastfeeding benefit mother infant infection infant lesion healed lesion likely low. Clinical management infection prevention control mpox 64 6.4 Caring people mpox pregnancy 6.4.1 Place care pregnancy Interim guidance (Published 10 June 2022) recommends pregnant recently pregnant person mild uncomplicated mpox may require acute care hospital monit",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bb4a7b02-2fca-45cd-9966-cfc95128f677",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "pregnant person mild uncomplicated mpox may require acute care hospital monitoring health facility may preferred; severe complicated disease admitted health facili ty care require optimized supportive care and/or intervention improve maternal fetal survival. 6.4.1.1 Practical info Counsel patient healthy diet, mobility exercise, intake micronutrient infant, tobacco use second - hand smoke exposure, use alcohol substances, per recommendation antenatal care positive p regnancy experience recommendation maternal newborn care positive postnatal experience [143, 144]. 6.4.1.2 Justification Limited data suggest mpox virus infection pregnant woman may lead vertical transmission well adverse outcome fetus, spontaneous abortion stillbirth [33, 78,59,62,60]. 6.4.2 Care",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "023c9e45-a55b-4e76-8e47-0d338787e5a0",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "tcome fetus, spontaneous abortion stillbirth [33, 78,59,62,60]. 6.4.2 Care pregnancy Interim guidance (Published 10 June 2022) recommends pregnant recently pregnant person mpox access patient-centred, respectful, skilled care, including midwifery, obstetric, gynaecological, fetal medicine neonatal care, well mental health psychosocia l support, readiness care maternal neonatal complications. Recommendations patient high risk complication severe mpox 65 6.4.2.1 Practical info • Patient-centred, respectful, skilled care refers care organized provided patient manner maintains dignity, privacy confidentiality, ensures freedom harm mistreatment, enables informed choice. • labour childbirth includes companion choice, pain relief, mobility labour birth position choice.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "062b5728-f4a5-497f-8452-1123f3f59a7e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "includes companion choice, pain relief, mobility labour birth position choice. Screen birth companion using case definition mpox. • companion suspected confirmed mpox, arrange alternative, healthy birth companion consultation woman. • Emphasize companion importance IPC measure labour, childbirth woman’s newborn’s postnatal stay health facility. Include appropriate training use PPE limit movement health care fa cility. • pregnant person chosen cared home, counsel woman maternal, fetal newborn sign seek care develop worsening illness danger signs. Self -care intervention encouraged. • Counsel patient healthy behaviour including diet, physical activity, intake micronutrients, tobacco alcohol substance use, per recommendation antenatal",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b8e98589-8a5a-4712-a205-b72dec2da59a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ke micronutrients, tobacco alcohol substance use, per recommendation antenatal postnatal care [143, 144]. patient requiring abortion services, consider alternative mode service delivery, including self - management medical abortion 12 weeks’ gestation, woman access accurate information health care provider stage process, per Abortion care guideli ne [145]. 6.4.3 Mode birth Interim guidance (Published 10 June 2022) recommends mode birth individualized, based obstetric indication mother’s preferences. recommends induction labour caesarean section undertaken medically justified based maternal fetal condition. • Interventions accelerate labour childbirth (e.g. augmentation, episiotomy, operative vaginal birth) undertaken medically justified based maternal fetal clinica",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cd0a19d5-8c8a-4b16-b1d8-07366fae7d9a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "nal birth) undertaken medically justified based maternal fetal clinical condition per recommendation intrapartum care [163]. Clinical management infection prevention control mpox 66 • Delayed umbilical cord clamping (not earlier 1 minute birth) recommended improved maternal infant health nutrition outcomes. evidence delaying cord clamping increase possibility viral transmission mother newborn. proven benefit 1 –3 minute delay, least, clamping cord outweigh theoretical, unproven, harms. • Individualized decision taken postponing planned (elective) induction caesarean section pregnant person suspected confirmed mild mpox [171]. • Placenta pregnancy related tissue fluids, amniotic fetal tissue fluid, must disposed following specific IPC protocol potentially infectio",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bb6f44e2-c0d7-4aac-bd64-f6de0b780919",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "fetal tissue fluid, must disposed following specific IPC protocol potentially infectious materials. 6.4.3.1 Justification Emergency decision childbirth pregnancy termination complex depend various factors, including gestational age, severity maternal condition, fetal viability well-being, well regulatory legal barrier country state. 6.4.4 Pregnancy postpartum period Interim guidance (Published 10 June 2022) recommends pregnant recently pregnant person recovered mpox enabled encouraged receive routine antenatal, postpartum abortion care, appropriate. Additional care provided complications. • Pregnant person recovering mpox provided information related potential risk adverse pregnancy outcome offered counselling request desire it. Closer follow recommen",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bf27da97-0d1a-45ab-b947-36e9664758cf",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "nancy outcome offered counselling request desire it. Closer follow recommended, higher risk stillbirth/pregnancy loss. • Pregnant person mpox informed unknown whether transmission occur others exposed pregnancy -related fluid tissues, amniotic fluid, placenta fetal tissue. Instructions provided handle potentially infectious specimens. Recommendations patient high risk complication severe mpox 67 • pregnant person confirmed mpox infant followed national registry sign complications. • Patient’s choice right sexual reproductive health care respected, including access contraception safe abortion per Abortion care guideline [145]. • Counsel pregnant person safe sexual practices. 6.4.4.1 Justification Limited data suggest mpox virus",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1b041c4d-8e3f-48f0-bf5f-6de65041edae",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "person safe sexual practices. 6.4.4.1 Justification Limited data suggest mpox virus infection pregnant person may lead vertical transmission well adverse outcome fetus, spontaneous abortion stillbirth [33, 78,59,62,60]. 6.5 Caring infant young child mpox 6.5.1 Monitoring newborn infant Interim guidance (Published 10 June 2022) recommends newborn infant mother mpox monitored closely evidence potential congenital perinatal infection. Mothers infant young child also exposed close contact. • Children sleep room bed drink/eat utensil individual mpox. • Young child isolated alone. one person (parent caregiver), healthy high risk, providing care child mpox appropriate IPC measures. • Young child may considered",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc966a5d-d711-457f-be61-45d439f1d560",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ng care child mpox appropriate IPC measures. • Young child may considered care health facility monitor disease progression, occur recognize treat complication optimized supportive care. Clinical management infection prevention control mpox 68 6.6 Recommendations patient mpox sexually active 6.6.1 Sex close physical contact Interim guidance (Published 10 June 2022) recommends patient advised abstain sex close physical contact skin lesion mpox crusted, scab fallen fresh layer skin formed underneath. • patient sexually active: among person presenting rash skin lesion suspected mpox, co - infection STIs also considered. patient following assessment: • Thorough sexual history. • Full physical examinatio",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "83dcca8f-1eb8-4427-928e-994424321f0a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ient following assessment: • Thorough sexual history. • Full physical examination using appropriate IPC measure special attention examination for: lymphadenopathy; rash skin lesion oral mucosae, genitals, anogenital region, part skin. • Testing performed HIV, syphilis, genital HSV, screening STIs managed per Guidelines management symptomatic sexually transmitted infection [184]; patient encouraged use condom consistently sexual activity prevention HIV STIs made aware use condom alone cannot offer protection acquisition transmission diseases. • person living HIV, particularly poorly controlled disease, mpox may greater risk severe disease [46]. Data suggest may risk genital ulcers, secondary bacterial infection prolonged duration illne s [32].",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0e46d2ec-6ea0-42df-9a19-0d0a864d33ee",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "risk genital ulcers, secondary bacterial infection prolonged duration illne s [32]. • person living HIV diagnosed mpox, continue ART (see recommendation rapid initiation ART people mpox HIV ART naïve prolonged interruption ART) [185]. People lower CD4 count greater risk complication related mpox prioritized starting ART [32]. Recommendations patient high risk complication severe mpox 69 • person diagnosed mpox HIV time, address urgent issue treatment mpox consider drug- drug interactions. 6.6.1.1 Justification GDG acknowledged risk transmission direct contact infected skin mucocutaneous lesion amplify transmission, thus abstaining sexual activity infectious period would curtail transmission.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "604268f6-ac72-49fe-bbc9-e6afc6457f3e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "thus abstaining sexual activity infectious period would curtail transmission. well, potential sexual transmission unknown subject research. Note: recommendation based existing recommendation Clinical management infection prevention control monkeypox: interim rapid response guidance (June 2022) [1]. 6.6.2 Use ba rrier contraception Interim guidance (Published 10 June 2022) Based precautionary principle, suggests use condom consistently sexual activity (receptive insertive oral/anal/vaginal) 12 week recovery prevent potential transmission mpox. • available data recovery sexual mpox transmission, precautionary principle applied public health intervention. information becomes available understanding related transmission improves guidance updated accordingl",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8a5f0ecf-b7a7-43bd-8a27-7996a209327d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ble understanding related transmission improves guidance updated accordingly. 6.6.2.1 Justification Small case series reported mpox virus DNA detection bodily fluid healing skin lesions; raise uncertainty persistence mpox virus bodily fluid semen, vaginal fluids, saliva blood, risk onward transmission. emergency guidance produced quickly evolving situation precautionary principle applied public health intervention. information becomes available understanding related transmission impr oves guidance updated accordingly. Clinical management infection prevention control mpox 70 6.7 Recommendations caring mpox patient acute infection 6.7.1 Follow-up care Interim guidance (Published 10 June 2022) recommends patient suspected confirmed mpox access f",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6d50a8da-fac4-4840-84b3-671942d41da1",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "June 2022) recommends patient suspected confirmed mpox access follow -up care. patient mpox (and caregivers) counselled monitor persistent, new changing symptoms. occurs, seek medical care according national (local) care pathways. • National (local) coordinated care pathway established include primary care provider (e.g. general practitioners), relevant specialist (e.g. sexual health, infectious diseases, dermatologist, surgeons, wound care specialists), mental health psychosocial providers, nutritionist social care service patient families. • Management tailored according patient need coordinated. Management intervention may entail education, advice self - management strategies, caregiver support education, peer -to-peer groups, stress management, stigma mitigation home medication, and/or specialty",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0f2a5f42-fc91-4017-b582-b1995bdfa6e5",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "eer -to-peer groups, stress management, stigma mitigation home medication, and/or specialty management. 6.8 Recommendations antiviral therapy (under revision) revision[164, 165,166,167,168,169,170]. antiviral therapeutic section guideline updated following systematic review meta-analysis multiple ongoing therapeutic trials. 6.9 Recommendation mental psychosocial support patient mpox 6.9.1 Anxiety depressive symptom Interim guidance (Published 10 June 2022) Recommendations patient high risk complication severe mpox 71 recommends prompt identification assessment anxiety depressive symptom context mpox initiate basic psychosocial support strategy first-line intervention management new anxiety depressive symptoms. • Patients mpox receive compassionate, respectful, people -centred ca",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e6ed974a-56e8-4fbc-9b99-79f591f1676c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ssive symptoms. • Patients mpox receive compassionate, respectful, people -centred care consistently, ensuring appropriate adequate protection household members, visitor health workers. • patient mpox arrives health facility, patient family member informed mpox encouraged remain calm. informed disease transmitted educated precaution b e taken prevent disease spreading. Families updated patient’s condition provided additional information. • Ideally, psychologist, social worker nurse psychosocial provider fluent local language involved onset disease counsel patient happen isolation. possible, general nurse health centre trained supervised provide basic psychological support, using stand",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4a3dbd1f-d333-4edf-92dd-1eef7a092d03",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "health centre trained supervised provide basic psychological support, using standardized resources. • people experiencing symptom depression, brief psychological intervention based principle cognitive behavioural therapy (CBT), problem management relaxation training considered [173]. Consider using remote mental health support (i.e. telephone therapy) access regular service disrupted. • person’s anxiety depressive symptom persist beyond recovery mpox, underlying anxiety depressive disorder may suspected, mental health professional consulted, condition managed appropriately. Refer mhGAP humanitarian intervention guide mental, neurological substance use disorder non- specialized health setting [174, 175]. Clinical management infection prevention control mpox 72 • important ask thought act",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4d88d826-0d0d-4840-8fbc-e2cc56d08db3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "infection prevention control mpox 72 • important ask thought act self -harm, particularly mpox, due risk factor self -harm suicide sense isolation, loss loved one, job, financial loss hopelessness. Remove possible mean self-harm , activate psychosocial support, follow person consult mental health professional necessary. Refer mhGAP humanitarian intervention guide mental, neurological substance use disorder non-specialized health setting [174 ,175]. • ensure comprehensive care based initial assessment, following discharge, link person employment, education, social service (including housing) relevant sector [176]. • CBT trauma focus, eye movement desensitization reprocessing stress management considered adult post-traumatic stress disorder (PTSD) [174, 177]. 6.9.1.1 Practical info •",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7ed81da2-1512-483c-8fdb-ca05c60463b8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ed adult post-traumatic stress disorder (PTSD) [174, 177]. 6.9.1.1 Practical info • Psychological first aid: guide field worker Inter -Agency Standing Committee guidance basic psychosocial skill [177, 178] promote care according following principles: • Provide non-intrusive, practical care support. • Assess need concerns. • Help address basic need (food, water, information). • Listen patient families, pressure talk. • Provide accurate information patient’s condition treatment plan easily understood non-technical language, lack information major source stress. • Help people address urgent need concern help decision - making necessary. • Comfort patient family helping feel calm. Inform vast majority mpox patient survive, sure communicate patient family recovery expe",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c5001974-3ff3-431e-a3fd-bad7203870f4",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ox patient survive, sure communicate patient family recovery expected. • Help people connect information, service social supports. Information mpox important help dispel myths, share clear message healthy behaviour improve understanding disease. • Encourage patient caregiver use evidence -based stress management self -help tool stress management guide Problem management plus (PM+) [179]. Recommendations patient high risk complication severe mpox 73 • Following recovery, patient may suffer lingering scar disfigurement psychological distress result. Psychological social care included follow -up care plan part multidisciplinary team care. 6.9.1.2 Justification mpox outbreak lead significant mental psychosocial effects, similarly observed COVID -19 EVD, [178,",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7fa4c611-84d5-4975-9cf0-eeaccb89512b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "significant mental psychosocial effects, similarly observed COVID -19 EVD, [178, 179] [180], including: • Fear disease death, loss sense meaning life, loss faith. • Physical social isolation family community. • Stigma associated diagnosis returning community. • Scarring disability (e.g. blindness) associated disease. Basic psychosocial support skill essential management patient represent integral part care provided all. 6.9.2 Sleep problem Interim guidance (Published 10 June 2022) recommends psychosocial support strategy first -line intervention management sleep problem context acute stress. • Sleep hygiene advice (including avoiding use psychostimulants caffeine, nicotine alcohol) stress management (including relaxation technique mindfulness practices) effective red",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "13ff4122-bc43-4ca7-ae68-dff36e4602fd",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "stress management (including relaxation technique mindfulness practices) effective reducing sleep problem may offered. Psychological intervention based principle CBT may also considered. • people hospitalized mpox, additional cause insomnia may include environmental factor (e.g. excessive light noise night), anxiety, persistent cough, delirium, agitation pain. Identifying promptly addressing underlying caus e prioritized using pharmacological sleep aids. Clinical management infection prevention control mpox 74 6.10 Recommendation deceased patient management 6.10.1 Handling human remains Interim guidance (Published 10 June 2022) recommends handling human remains deceased individual mpox done appropriate IPC measures. • Handling deceased kept minimum. • Perform hand hygiene wear PPE accordi",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "03c97faf-d74f-402e-8d88-7cd4c16605d8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "Handling deceased kept minimum. • Perform hand hygiene wear PPE according contact droplet precaution (gloves, gown, medical mask eye protection based risk assessment) patient rash healed may still infectious virus. • Airborne precaution implemented performing AGPs. (This section modified interim guidance reflect current recommendations) 6.10.1.1 Practical info • Ensure leakage body fluid contained. • body wrapped cloth shroud transferred mortuary soon possible. • dignity dead, cultural religious traditions, family respected protected. Family friend may view body prepared burial, accordance local customs. touch k iss body clean hand soap water alcohol -based hand san",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "09960875-d7a6-4896-8675-2345b4c42928",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "touch k iss body clean hand soap water alcohol -based hand sanitizer viewing [136, 147] 6.10.1.2 Justification recommendation derives Clinical management infection prevention control monkeypox: interim rapid response guidance (2022) [1], recommended use airborne precaution addition droplet contact precautions. line change guidance , recommendation revised interim guidance remove stipulation airborne precautions. Recommendations patient high risk complication severe mpox 75 6.11 Recommendations health care worker occupational exposure mpox 6.11.1 Occupational exposure mpox Interim guidance (Published 10 June 2022) recommends staff occupational exposure mpox assessment management plan • Health care worker notify infection contro",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8947823b-37b9-434d-ad83-7216e8f7bacd",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "assessment management plan • Health care worker notify infection control, occupational health public health authority possible exposure receive medical evaluation instruction follow up. • Health care worker exposure person confirmed mpox undergo medical evaluation consideration possible intervention (vaccination post -exposure prophylaxis [PEP]) prospective data collection protocol clinical trial. • Health care worker occupational exposure (i.e. wearing appropriate PPE) need excluded work asymptomatic, undergo active surveillance symptom 21 day post -exposure instructed work vulnerable patients. 6.11.1.1 Practical info plan accordance national subnational policies. term national describes government entity national level subnation",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "861ae6ee-97d4-40f2-97be-6b86034f8ed3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ubnational policies. term national describes government entity national level subnational describes government entity national level (regardless political, financial administrative design country) involved management health worker context mpox. Clinical management infection prevention control mpox 76 7. Methods: guideline created guideline developed according standard method described Handbook guideline development [181]. initial content derived Clinical management infection prevention control monkeypox: interim rapid response guidance [1]; undergo formal Grading Recommendations Assessment, Development Evaluation (GRADE) process, given written rapid guidance context first mpox Public Health Emergency International Concern (2022). topical area updated Cl",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bf6fb72e-a0fb-4286-a8cc-3c5e3211ce11",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "pox Public Health Emergency International Concern (2022). topical area updated Clinical management infection prevention control monkeypox: interim response guidance (10 June 2022) revised based priority identified mpox Steering Committee Safe Scalable Care Cl uster Mpox Incident Management Support Team, established Public Health Emergency International Concern declared 1 4August 2024 [105]. prioritized questions, GRADE approach used rate strength direction evidence, produce recommendation (see Stepwise approach - application GRADE methodology). Several interim statement 2022 guidance subject systematic reviews, technical team determined approp riate inclusion updated document good practice statement (following GRADE methodology), implementation considerations, updated",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e1874ab5-36c0-4ef4-a17f-0fb14d3c4682",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "e statement (following GRADE methodology), implementation considerations, updated later date. interim statement reviewed categorized collaboration meth odologist, technical unit GDG co-chairs. presented GDG member review inclusion. convened technical meeting expert 15 November 2024 discus interpret available evidence ART initiation people living HIV mpox [188].. Additionally, convened technical meeting expert 26 Novembe r 2024 discus interpret available evidence breastfeeding mpox. 12 December 2024, GDG convened make recommendation breastfeeding ART initiation presentation consideration summarized technical groups. 27 November 2024, 10 December 2024 21 January 2025, GDG convened make recommendation transmission-based precaution hom",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "156a6595-477f-4465-8b02-db620fe0af3b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "21 January 2025, GDG convened make recommendation transmission-based precaution home isolation. Methods: guideline created 77 Steering Committee GDG member agreed retain many interim recommendation ensure consolidated single - sourced guideline, supporting comprehensive emergency response. new recommendation categorized either strong conditional recommendation (for against), good practice statements. interim statement remain tagged such. 7.1 Types statement 7.1.1 Recommendations Formal recommendation actionable statement choice two intervention specific population relevant, specific setting. based best available evidence follow transparent methodology considers certainty evidence determines strength recommendation following evidence decision framew ork, see",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "180f2421-a957-4fb5-951d-c174c0baba22",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "nd determines strength recommendation following evidence decision framew ork, see Table 6. 7.1.2 Good practice statement implementation consideration Good practice statement necessary, actionable clear guideline statement important warrant formal rating evidence quality. Formulating good practice statement includes adhering five principles: 1) collecting summarizing evidence poor use panel's limited time, energy resources? 2) message necessary health care practice? 3) implementing good practice statement unequivocally result net positive consequence? 4) well -documented clear rationale connecting indirect evidence? 5) statement clear actionable? Statements document IPC identified good practice statement reviewed methodologist GDG chair determine met criterion go",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7a4a0822-3693-4092-a0d4-9d6d375d2460",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "reviewed methodologist GDG chair determine met criterion good practice statement according identified principles. statement categorized meeting criterion presented panel discussion consensus. Implementation consideration support implementation recommendation statement describe “who, what, how” implementing Clinical management infection prevention control mpox 78 recommendation. may include tool strategy relevant supporting implementation intervention may clear link evidence. translate standard transmission -based precaution practical guidance managing mpox [7]. Many consideration derived document Transmission -based precaution prevention control infections: aide -memoire [7] Standard precaution prevent",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "91606a2c-64e1-494c-8821-13cf64d3a2d6",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "evention control infections: aide -memoire [7] Standard precaution prevention control infections: aide -memoire [14] along generic recommendation adapted mpox transmission modes. validated GDG. Table 6. Readership cue used statement guideline Interim purple “interim” indicated statement retained Clinical management infection prevention control monkeypox: interim rapid response guidance (10 June 2022). Strong recommendation green “strong recommendation” indicates updated/new statement Conditional recommendation yellow “conditional recommendation” indicates updated/new statement Good practice statement blue “good practice statement” indicates updated/new statement 7.2 Step-wise approach - application GRADE methodology GRADE process followed iteration interim guidance.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "aaeb34c0-749a-4afb-bf90-3427143e2625",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "RADE methodology GRADE process followed iteration interim guidance. 7.2.1 Step 1: Evidence monitoring mapping triggering evidence synthesis Guidelines periodically updated assess data undergone peer review intervening period new data. practice -changing evidence, increasing international interest, identified, mpox Steering Committee trigger guideline development process. trigger producing updating specific recommendation based following (any three may initiate recommendation): • likelihood change practice; • sufficient data inform high -quality evidence synthesis; • relevance global audience. Methods: guideline created 79 guideline formulated “living” guideline\", meaning revision update occur ongoing basis based availability new evidence evolving issue th",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "22af6d6c-f557-4d72-b8af-65da7feb3f41",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ur ongoing basis based availability new evidence evolving issue field leading new PICOs. factor may inform need update guideline include change transmission intensity, change epidemiology and/or health systems' capacity respond new epidemiological scenarios. 7.2.2 Step 2: Convening GDG selected GDG member ensure global geographical representation, gender balance, appropriate technical clinical expertise, community representatives. intervention, technical unit collected managed declaration interest (D OIs) found GDG member co-chairs conflict interest prevented limited participation. addition distribution DOI form, meeting, Secretariat described DOI process, opportunity given GDG member declare interest provided written form. verbal conflict",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e3886f3d-8f74-433e-bf4d-b1a073e1e020",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "en GDG member declare interest provided written form. verbal conflict declared. Web search identify additional interest could perceived affect individual’s objectivity independence development recommendations. One member found affiliation company make sell simple, field usable test detect quantify fecal bacteria drinking water; however, since mpox pathogen transmitted co ntaminated drinking water, conflict interest identified. GDG (see Acknowledgments) convened review analyses, including pre - specified subgroup analysis presented summary finding tables. making recommendations, GDG primarily took individual patient perspective secondarily populati on, public health, system perspective. Issues feasibility specific proposed intervention particularly relevant latter perspective.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "917f2b17-b61e-42dd-b503-7ed86478f699",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ility specific proposed intervention particularly relevant latter perspective. GDG considered issue GRADE evidence decision framework formulating recommendati ons. Given scope guideline, GDG divided four sections: clinical management, IPC, breastfeeding initiation ART HIV patients. GDG member relevant expertise contributed recommendation (e.g. IPC GDG formulate IPC recommendations, clinical management GDG made decision clinical management). detail specific subgroups, see section GDG topic -specific working groups. Clinical management infection prevention control mpox 80 7.2.3 Step 3: Evidence synthesis assessment independent systematic review team conducted rapid systematic review published literature examined benefit harm interventions. team includes systematic review, clinical expert",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c98098f9-81e1-4098-a51b-5885f8ec4262",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "enefits harm interventions. team includes systematic review, clinical expert biostatisticians. technical unit colle cted managed DOIs found systematic review team member conflict interest. certainty evidence question assessed using GRADE outlined handbook guideline development, 2nd edition (Table 7 provides definition four level certainty evidence). GRADE assessment considers risk bias/study limitations, inconsistency, imprecision, indirectness publication/reporting bias [182]. Table 7. Levels certainty evidence High confident true effect lie close estimate effect. Moderate moderately confident effect estimate: true effect likely close estimate effect, possibility substantially different. Low confidence effect e",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fdd426f4-c4ae-4975-a3a3-99fc65a8cbc1",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "possibility substantially different. Low confidence effect estimate limited: true effect may substantially different estimate effect. low little confidence effect estimate: true effect likely substantially different estimate effect. 7.2.4 Step 4: Recommendations GRADE approach provided framework establishing evidence certainty generating direction strength recommendations. Methods clinical co -chairs facilitated deliberation reach final recommendations. GDG member invited participate contribute discussion GDG meetings. Decisions made via consensus amongst GDG member identified relevant recommendation. consensus achieved, GDG member specific pertinent topic would b e asked vote. following key factor informed transparent",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ffc8ebcd-9d80-4de5-a28e-6428c1c1d498",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ic pertinent topic would b e asked vote. following key factor informed transparent trustworthy recommendations: • absolute benefit harm patient-important outcome structured evidence summary (e.g. GRADE summary finding tables) include effect estimate confidence interval outcome, associated rating certainty evidence findings. data available, GDG review narrative summary [183]; Methods: guideline created 81 • quality/certainty evidence [184, 185]; • value preference patient [186]; • resource consideration (including consideration cost, feasibility, applicability, equity) [186]; • recommendation rated either conditional strong, defined GRADE. GDG member disagree regarding evidence assessment strength recommendations, apply voting according established rule [186]. pre -",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "76b839e9-9069-4888-ab55-af833cd3e9dc",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "strength recommendations, apply voting according established rule [186]. pre - specified decis ion rule making strong recommendation 70% eligible GDG member place. 7.2.5 Step 5: External internal review external review group reviewed final guideline document identify factual errors, comment clarity language, contextual issue implication implementation. technical unit collected managed DOIs external reviewer found external reviewer conflict interest. However, certain therapeutics, pharmaceutical company technical representative may asked comment new drug industry perspectives, line handbook guideli ne development, comment individual organization draft guideline may helpful anticipating dealing controversy, identifying factual error promoting engagement stakeholder",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7578b68f-0944-425e-aa57-f4ceb17a25c0",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "dealing controversy, identifying factual error promoting engagement stakeholders. Comments contextual issue considered considering interests. affiliation individual appears Acknowledgement section. guideline finally reviewed approved Guideline Review Committee. 7.3 GDG topic -specific working group process develop updated guideline based structure consisted two working group functioned GDG: Clinical Management Infection Prevention Control, engaged specifically consider recommendation within domain expertise, i.e. IPC working group primarily formulated IPC recommendations, clinical management working group focused clinical management. Besides, two technical groups: one HIV one Breastfeeding. included GDG member several additional topical expert GDG member (see",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b191cd0e-62a6-4b01-816d-8c97f0d4b182",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "uded GDG member several additional topical expert GDG member (see Acknowledgements); worked bringing Clinical management infection prevention control mpox 82 consideration topic presented GDG member responsible making final recommendation guidelines. perspective viewpoint welcome discussions, formulation recommendation IPC made specifically respective IPC GDG members; Clinical Management GDG meeting Clinical Management GDG member responsible making recommendations. 7.3.1 Infection prevention control technical working group IPC working group member convened three separate meeting (27 November 2024, 10 December 2024 21 January 2025) review available evidence formulate recommendations, good practice statement implementation consideration contained",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc334fca-8b78-418b-b729-e515be4b102e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "formulate recommendations, good practice statement implementation consideration contained document. 7.3.1.1 Evidence synthesis commissioned systematic review underpins current guideline update previously published systematic literature review. systematic review performed 2023 assessed publication including September 2022. subsequent review commissioned 2024 given evolution new MPXV clades. review synthesize update evidence three research question outlined developed consultation GDG following publication interim guidance 2022. 1) use respirator versus medical mask interacting patient suspected confirmed mpox infectious period (as defined footnote) reduce occurrence mpox health care worker household, congregate livi ng health care setting? 2) use airborne",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f8bd2f7b-c411-402b-9a18-25936b17456f",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "orkers household, congregate livi ng health care setting? 2) use airborne precaution room versus adequately ventilated room health care facility patient mpox infectious period (as defined footnote) reduce occurrence mpox health care workers? 3) event person non-severe mpox cared home, isolating person non-severe mpox lesion fully healed reduce occurrence mpox person contacts, compared isolating patien wear medical mask, cover unhealed lesions, refrain close contact share material could contaminated? Methods: guideline created 83 review occurred two stages. first stage appraised available evidence comparative interventional trials, yielded evidence. absence data, second stage preformed synthesize evi",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2652dfb1-3aa5-401b-80d2-9ceb1f9d699f",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "yielded evidence. absence data, second stage preformed synthesize evidence reported route MPXV infection using non-comparative study design indirectly inform three IPC intervention review questions. Details search strategy key terminology found Annex 5: Search strategy terminology reported route MPXV fection. Throughout discussions, research gap identified, prompting development IPC research agenda ongoing research prioritization effort (see: Uncertainties, emerging evidence future research). 7.3.2 Breastfeeding technical working group pre-GDG discussion convened technical meeting expert 26 November 2024 guide review relevant evidence support update recommendation concerning breastfeeding mpox. technical working group included external expert experience infant feeding nutrition, paediatric c",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4059b24b-1adb-49c7-8ade-3f39b9b03adb",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "rking group included external expert experience infant feeding nutrition, paediatric care, wide geographical representation gender balance. full meeting report found [187]. summary synthesized evidence following PICO question relate breastfeeding recovery mpox infection presented discussed: • mother suspected/confirmed mpox lesion breast continue breastfeeding direct contact non -infected infant? • mother confirmed mpox active lesion breast continue breastfeeding direct contact non -infected infant? • recovery confirmed mpox (after stopping breastfeeding close contact) mother resume breastfeeding direct contact non-infected infant? • pasteurization inactivate mpox breastmilk allow feeding infant expressed milk without direct contact wi",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "16679581-a592-43c1-a2e5-1357bbe22ee4",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ctivate mpox breastmilk allow feeding infant expressed milk without direct contact mother mpox? Overall study answer four PICO questions. Identified study mostly observational, non - comparative study design significant methodological limitations. Clinical management infection prevention control mpox 84 meeting point summarized below, presented GDG discussion interpretation. 7.3.2.1 Routes transmission TWG reiterated guidance breastfeeding infant contact mpox infection need differentiate following potential MPXV route transmission mother child: • breastmilk (presence viability virus breastmilk unknown) • direct contact process breastfeeding (from breast) • direct contact infant (not breast) care • air droplet • saliva thr",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8d02aafb-7c55-41bd-876c-66e6be3e6c9f",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "direct contact infant (not breast) care • air droplet • saliva kissing. 7.3.2.2 evidence gaps? • still unknown MPXV secreted milk although laboratory experiment shown viable milk. thought first critical question study show breastmilk contain MPXV, would help answer question breastfeeding recommended how? • mpox transmitted via breastmilk, would need additional PICO, whether heat treatment expressed breastmilk make safe [?] feasibility intervention individual population level. 7.3.2.3 implementation considerations? • need involve, possible, another caregiver take care infant particularly mother isolation limit duration contact",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f76f6435-a178-4ddc-bb75-c3de51ecd519",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "particularly mother isolation limit duration contact infant mother mpox. • duration infant -to-mother contact vary depending age. Early initiation breastfeeding requires longer contact, later infant may need shorter contact breastfeeding. newborn (up 2, 6 even 8 weeks) usually need constant access breast successfully breastfeed. • lesion areola would make breastfeeding painful, therefore breast health, mother express breast order prevent engorgement mastitis preserve lactation later resumption breastfeeding. Methods: guideline created 85 • Alternative milk substitute may readily available, affordable, safe many locations. 7.3.3 HIV antiretroviral technical working group pre-GDG discussion convened technical meeting expert 15 November 2024",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "edc87af6-49eb-4a4e-bece-ee740b68c657",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "king group pre-GDG discussion convened technical meeting expert 15 November 2024 discus interpret available evidence ART initiation people living HIV mpox. Participants included HIV medicine experts, infectious disease specialists, programme manager significant mpox experience; full list participant meeting report accessed [188]. technical meeting led independent chair. objective meeting identify evidence source would best inform GDG place context current guideline include strong recommendation rapid ART initiation, option - day initiation, people living HIV. facilitate discussions, literature review compiled technical staff summarized available direct indirect evidence. meeting reported following findings, presented GDG discussion",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6c89d1ef-71d0-461c-a232-a152afc114fd",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "meeting reported following findings, presented GDG discussion interpretation. 7.3.3.1 ART initiation people living HIV mpox • ART life -saving intervention people living HIV, without mpox virus infection. • Rapid ART initiation (within 7 day HIV diagnosis) -initiation standard care people living HIV ART -naive interrupted ART (WHO, strong recommendation). includes people opportunistic infection tuberculosis central nervous system infections. • Immune restoration effective ART important control MPXV delay ART initiation may potentially harmful. • uncertainty incidence mpox IRIS; mpox IRIS may occur difficult distinguish progressive mpox given lack clear case definition, delayed clinical presentation concurrence (opportunistic) infections. • C",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "108fd021-85bf-458b-b007-d445c469361b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "definition, delayed clinical presentation concurrence (opportunistic) infections. • Central nervous system manifestation mpox estimated uncommon based clinical expertise reason delay ART initiation provided assessment etiology conducted. Clinical management infection prevention control mpox 86 • expert group proposed value preference statement “Most HIV patient mpox would place higher value mortality reduction benefit initiating ART soon possible possible increased risk developing IRIS”. 7.3.3.2 evidence gaps? • Lack direct evidence comparing rapid v delayed ART initiation people living HIV mpox. one small cohort study directly addressed question timing ART initiation identified; study show difference outcomes. • Understanding progressive mpox, mpox IRIS associate",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d3f3170b-bcef-400e-946f-453c9764598b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "show difference outcomes. • Understanding progressive mpox, mpox IRIS associated morbidity mortality. limited evidence viral pathogenesis, immune response disease progression people without ART initiation HIV. 7.3.3.3 implementation considerations? • Ensure patient presumed confirmed mpox receive HIV testing first presentation health care providers. • Ensure individual engage health care service early stage mpox symptom avoid disease progression late ART initiation. • Ensure clinical assessment conducted patient prior ART initiation ensure comprehensive care people living HIV, particular advanced HIV disease. 7.4 Risk factor severe disease prognosis methodology provide GDG comprehensive understanding mpox prognosis, systematic review observational study published 20 September",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f01a8fb6-2d4f-4a6a-bf6e-9db43c55b791",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "anding mpox prognosis, systematic review observational study published 20 September 2024, conducted. review aimed to: 1) establish baseline risk estimation clinical adverse outcome s, including limited hospitalization mortality, patient mpox, differentiating severe non -severe case defined literature; 2) identify adjusted risk factor associated mpox prognosis [49]. assistance expert librarian, review team searched MEDLINE, Embase, CENTRAL, CINAHL, Global Health, medRxiv, bioRxiv, SSRN inception September 2024, using search term including \"mpox\", ”cohort”, \"case -control \", \"observational study\", “cross-sectional”, “epidemiologic”, “population surveillance”, Methods: guideline created 87 \"retrospective\", “prospective” ”randomized controlled tria”\". identify additional eligible studies, review team screened reference list included",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "baedb128-fb3c-4480-856a-7572f96f7aa9",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ". identify additional eligible studies, review team screened reference list included study relevant systematic reviews. review included study patient laboratory -confirmed mpox virus infection reported rate clinical adverse outcome adjusted risk factor adverse outcomes. estimate pooled baseline risk associated 95% confidence interval adverse outcome, review team conducted meta-analyses proportion using fixed effect models. review team performed analysis patients, severe patient non-severe patient separately. every candidate risk factor, eligible study reported odds ratio (OR) measure association, study reported relative risk (RRs) hazard ratio (HRs), review team converted ORs pooled ORs using random effect model. review team examined different threshold classify study reporting severe diseas",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d6b5deee-5b72-4938-8bd7-092bceb12467",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "l. review team examined different threshold classify study reporting severe disease non -severe disease decided 50% threshold categorize study severe disease non -severe disease. Studies fewer 50% participant classified severe mpox hospitalized treatment categorized non -severe; study 50% categorized severe. Clinical management infection prevention control mpox 88 8. access use guideline living guideline WHO. recommendation included updated, new recommendation added time: 8.1 access guideline • website: full read MAGICapp content without reliable web access. also downloaded directly MAGICapp (see cogwheel top right). • MAGICapp online, multilayered format : fullest version guideline, detailed belo",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "88b1d68e-3e4d-4dfb-89b0-863fd66d796f",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "pp online, multilayered format : fullest version guideline, detailed below. 8.2 navigate guideline guideline written, disseminated updated MAGICapp, format structure ensures user -friendliness ease navigation [168]. accommodates dynamic updating evidence recommendation focus new keeping existing recommendations, appropriate, within guideline. purpose online format additional tools, infographics, make easier navigate make use guideline busy clinical practice. online multilayered format designed allow end-users find recommendati ons first drill find supporting evidence information pertinent applying recommendation practice, including tool shared decision -making ( clinical encounter decision aid ) [168] online multilayered format",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f78c0e02-0503-4862-8267-4f6a7f5b647f",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "decision -making ( clinical encounter decision aid ) [168] online multilayered format designed allow end-users find recommendation first drill find supporting information pertinent applying recommendation practice. End -users also need understand meant strong conditional recommendation (displayed immediately below) certainty evidence (the extent estimate effect research represent true effect treatment). recommendation additional information available following tabs: access use guideline 89 • Research evidence: Readers find detail research evidence underpinning recommendation GRADE Summary Findings table narrative evidence summaries. • Evidence decision: absolute benefit harm summarized, along factor value preference patients, practical issue aro",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d0c8ee53-5874-425f-b26a-0e2238602eed",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "zed, along factor value preference patients, practical issue around delivering treatment well consideration concerning resources, applicability, f easibility, equity human rights. latter factor particularly important need adapting guideline national local context. • Justification: Explanation GDG considered integrated evidence decision factor creating recommendations, focusing controversial challenging issues. • Practical information: example, dosing, duration administration drugs, apply test identify patient practice. • Decision aids: Tools shared decision -making clinical encounters. 8.3 Additional educational module implementation tool health worker • Essential item estimator tool (https://partnersplatform.who.int/tools/essentialitemsestimator) assist governments, partner st",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "58a27418-7ec1-48ba-a22d-cc687521da77",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "partnersplatform.who.int/tools/essentialitemsestimator) assist governments, partner stakeholder forecast necessary volume PPE, diagnostic test equipment, consumable medical supplies, biomedical equipment case management, essential drug supportive care treatment COVID -19. • website mpox clinical management ( https://www.who.int/teams/health - care-readiness/clinical- management-of -monkeypox ) includes multiple tool infographics clinical diagnosis management patient mpox. Atlas mpox lesions: tool clinical researchers, poster screening, triage differential diagnosis, skin care, etc. patient mpox infection. Also, includes link Global Clinical Data Platform Mpox. • Interim practical manual designing, setting assessing health facility context mpox outbreak (2024) (https://iris.who.int/handle/10665/380532 ). • Health emergenci",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dbb0c153-5d7a-41a9-8b89-f3285585901d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "e context mpox outbreak (2024) (https://iris.who.int/handle/10665/380532 ). • Health emergency - infection prevention control water sanitation hygiene ( https://www.who.int/teams/health - care-readiness/infection -prevention - and- Clinical management infection prevention control mpox 90 control#:~:text=Infection%20prevention%20and%20control%20%28IPC%29%20a nd%20water,%20sanitation,%20and%20hygiene ). 8.4 Collection standardized data Clinical Platform cluster mpox case continues expand country across region important understand clinical features, prognostic factor outcome patient better inform clinical management guideline inform pub lic health. Global Clinical Platform collect patient -level anonymized clinical data used understand various emerging pathogens. work understand current cases, developed",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d6034294-b714-4eee-8ecf-b48b799aa226",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "iou emerging pathogens. work understand current cases, developed case report form mpox, nd invite Member States contribute data platform. objective platform are: • describe clinical characteristic mpox. • assess variation clinical characteristic mpox. • identify association clinical characteristic mpox symptoms. • describe temporal trend clinical characteristic mpox. details, please see Global Clinical Platform mpox website [link] [189]. statistical analysis plan available [link] [190]. Uncertainties, emerging evidence future research 91 9. Uncertainties, emerging evidence future research formulating recommendation prioritizing question guideline, GDG identified key area uncertainty, felt research would enable future recommendation made higher certainty. 9.1",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4e2510d1-9286-4fb9-bf04-3619c8b93248",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ich felt research would enable future recommendation made higher certainty. 9.1 Transmission • Limited epidemiological evidence pre -symptomatic asymptomatic phase disease. • Routes human- human transmission, including viral dynamic trajectory correlate viral culture various bodily fluid impact transmission, infectious periods, subgroup disease manifestation disease severity. • Potential reverse zoonosis spillback events. • Natural history disease: disease severity risk factor severe, disease different subpopulation (neonates, child young people, immunosuppressed, pregnant woman older persons). • Difference similarity transmissibility clade (a b), clade II (a b). • Risks related particle aerosol -generating activity (e.g. shaking linen). • Infectious dose MPXV humans. • Characterization viral evolution.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc5b65dd-235a-4a19-908c-80665b64afd6",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ".g. shaking linen). • Infectious dose MPXV humans. • Characterization viral evolution. • Wastewater sampling predicting trend outbreak response. 9.2 Clinical management • Establish disease severity classification risk factor severity. • Co-infection: virus (varicella zoster [VZV], HIV), STIs (such herpes simplex virus [HSV], syphilis, chancroid, lymphogranuloma venereum [LGV]), others, parasitic infection (malaria, dengue, filariasis) etc. Understand co - infection impact disease severity. • Clinical management patient advanced HIV mpox. • incidence IRIS contribution morbidity mortality. • Racial ethnic disparity incidence access countermeasure care. • Best symptomatic care skin care, rash management, nutrition. Clinical management infection prevention control mpox 92 • Best optimized care package complication ocular central ner",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d391975d-c432-4d3c-afc8-e945e6aa2570",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "control mpox 92 • Best optimized care package complication ocular central nervous system complications. • Long -term outcome recovered patients, including mother babies, immunosuppressed patients. Evidence post viral syndrome clinical presentation. • Efficacy safety therapeutics, including pregnant breastfeeding mother children. • Presence transmission mpox breastmilk. Measures inactivate mpox virus make breastmilk safe (e.g. pasteurization).[129] 9.3 Infection prevention control • Description close proximity impact transmission. • Effectiveness covering lesion impact fomite/environmental contamination. • Health worker exposure risk category post-exposure prophylaxis (PEP). • Susceptibility mpox virus disinfectant virucidal property (i.e. active ingredient concentrations, contact time). • Stability virus environ",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3dc61c61-582a-45c6-b01d-8ed136eec86b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "(i.e. active ingredient concentrations, contact time). • Stability virus environment surfaces. • Optimal ventilation reduce disease transmission. • Duration transmission-based precaution maintain patient isolation (when transmission -based precaution lifted). • Effects home -based care (what learned, model care, etc.). • Effectiveness isolation home prevent transmission. 9.4 Methods question • Value preference survey affected populations. References 93 10. References 1. World Health Organization. Clinical management infection prevention control monkeypox: interim response guidance. 2022. https://www.who.int/publications/i/item/WHO- MPX -Clinical -and-IPC-2022.1 2. World Health Organization. Infection prevention control epidemic -and pandemic -prone acute respiratory infection health care. 2014. https://www.who.int/publications/i/item/infection -prevention -a",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "87968bfc-4ff6-41bc-bd93-33fdb744fa83",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "infection health care. 2014. https://www.who.int/publications/i/item/infection -prevention -and-control -of-epidemic -and- pandemic- prone -acute -respiratory -infections -in-health -care 3. World Health Organization. Infection prevention control context coronavirus disease (COVID -19): living guideline, 25 April 2022: updated chapter: mask use, part 1: health care settings. 2022. https://iris.who.int/bitstream/handle/10665/353565/WHO -2019- nCoV -ipc- guideline -2022.2-eng.pdf 4. World Health Organization. Global technical consultation report proposed terminology pathogen transmit air. https://www.who.int/publications/m/item/global- technical- consultation -report -on-proposed -terminology -for-pathogens -that-transmit-through- the-air 5. International Labour Organization. International Standard Classification Occupations (ISCO 2008). https://isco.ilo.org/en/ 6. World Health Organization. World Health Organization Health",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "eeb4bd2f-811c-4cb8-a01c-2617a0059a0d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "2008). https://isco.ilo.org/en/ 6. World Health Organization. World Health Organization Health Workforce -related terminology; Terminology work carried Language department request Health Workforce department. https://www.who.int/publications/m/item/health-workforce- terminology 7. World Health Organization. Transmission -based precaution prevention control infections. 2022. https://www.who.int/publications/i/item/WHO-UHL- IHS-IPC-2022.2 8. Atkinson J, Chartier Y, Pessoa- Silva CL, Jensen P, Li Y, Seto WH. Natural ventilation infection control health -care settings. Geneva: World Health Organization; 2009. Annex C, Respiratory droplets. 2020. https://www.ncbi.nlm.nih.gov/books/NBK143284/ 9. World Health Organization. Technical specification personal protective equipment COVID -19. 2020. https://iris.who.int/bitstream/handle/10665/336622/WHO -2019- nCoV - PPE_specifications -2020.1-eng.pdf 10. World Health",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "244ec112-2978-42a5-a2ec-e6f65f61fb4c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "itstream/handle/10665/336622/WHO -2019- nCoV - PPE_specifications -2020.1-eng.pdf 10. World Health Organization. world health report : 2006 : working together health. https://iris.who.int/bitstream/handle/10665/43432/9241563176_eng.pdf 11. U.S Department Health & Human Services. difference isolation quarantine?. 2022. https://www.hhs.gov/answers/public- health -and-safety/what- is-the- difference- -isolation -and-quarantine/index.html 12. World Health Organization. Operational consideration case management COVID -19 health facility community; Interim guidance. https://iris.who.int/bitstream/handle/10665/331492/WHO -2019- nCoV -HCF_operations -2020.1- eng.pdf 13. OpenWHO. Clinical management patient COVID -19: Initial approach h acutely ill patient. https://openwho.org/playlist/dedicated/500316/0_xfe055ah/0_sgcgs6yg 14. World Health Organization. Standard precaution prevention control",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fd0ce1a0-a79f-4d28-b01a-05e5f2c94ce8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "55ah/0_sgcgs6yg 14. World Health Organization. Standard precaution prevention control infections: aide-memoire. https://www.who.int/publications/i/item/WHO -UHL- IHS-IPC-2022.1 Clinical management infection prevention control mpox 94 15. Jezek Z., Grab B., Szczeniowski MV, Paluku KM, Mutombo . Human monkeypox: secondary attack rates. Bull World Health Organ 1988;66(4):465 -70 https://www.ncbi.nlm.nih.gov/pubmed/2844429 16. Brown K., Leggat PA. Human Monkeypox: Current State Knowledge Implications Future. Trop Med Infect Dis 2016;1(1) http://dx.doi.org/10.3390/tropicalmed1010008 17. Ulaeto D, Agafonov A, Burchfield J, Carter L, Happi C, Jakob R, et al. New nomenclature mpox (monkeypox) monkeypox virus clades. Lancet Infectious Disease 2023. https://www.thelancet.com/journals/lancet/article/PIIS1473 -3099(23)00055-5/fulltext 18. Li Y., Zhao H., Wilkins K., Hughes C., Damon IK. Real -time PCR assay speci",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "920d2782-7669-45b4-a007-b91d4156b00c",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "fulltext 18. Li Y., Zhao H., Wilkins K., Hughes C., Damon IK. Real -time PCR assay specific detection monkeypox virus West African Congo Basin strain DNA. J Virol Methods 2010;169(1):223 -7 http://dx.doi.org/10.1016/j.jviromet.2010.07.012 19. Beer EM, Rao VB. systematic review epidemiology human monkeypox outbreak implication outbreak strategy. PLoS Negl Trop Dis 2019;13(10):e0007791 http://dx.doi.org/10.1371/journal.pntd.0007791 20. Yinka -Ogunleye A., Aruna O., Dalhat M., Ogoina D., McCollum A., Disu Y., et al. Outbreak human monkeypox Nigeria 2017 -18: clinical epidemiological report. Lancet Infect Dis 2019;19(8):872- 879 http://dx.doi.org/10.1016/S1473- 3099(19)30294-4 21. Americo JL, Earl PL, Moss B. Virulence difference mpox (monkeypox) virus clade I, IIa, IIb.1 small animal model. Proceedings National Academy Sciences United States America 2023;120(8):e2220415120 http://dx.doi.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "26890ef4-7353-492e-a87f-709c9b09158e",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "National Academy Sciences United States America 2023;120(8):e2220415120 http://dx.doi.org/10.1073/pnas.2220415120 22. Bangwen E. Suspected confirmed mpox case DR Congo: retrospective analysis national epidemiological laboratory surveillance data, 2010 -23. Lancet 2025. http://dx.doi.org/10.1016/S0140-6736(24)02669-2 23. World Health Organization. Multi- country outbreak mpox, External situation report #48 - 10 March 2025. https://www.who.int/publications/m/item/multi- country -outbreak- of-mpox -- external -situation -report --48---10- march -2024 24. Kibungu EM, Vakaniaki EH, Kinganda -Lusamaki E, Kalonji -Mukendi T, Pukuta E, Hoff NA, et al. Clade -Associated Mpox Cases Associated Sexual Contact, Democratic Republic Congo. Emerging infectious disease 2024;30(1):172- 176 http://dx.doi.org/10.3201/eid3001.231164 25. Marsirika LM, Udahemuka JC, Martinez GS, Kelvin P, Nadine MB, Steeven BK, et al. FK. 2024. https://www",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c5f72de9-5759-47c8-b992-f0ec96766e46",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "rsirika LM, Udahemuka JC, Martinez GS, Kelvin P, Nadine MB, Steeven BK, et al. FK. 2024. https://www.medrxiv.org/content/10.1101/2024.03.05.24303395v1 26. Laurenson -Schafer H, Sklenovská N, Hoxha A, Kerr SM, Ndumbi P, Fitzner J, et al. Description first global outbreak mpox: analysis global surveillance data. Lancet. Global health 2023;11(7):e1012- e1023 http://dx.doi.org/10.1016/S2214- 109X(23)00198-5 27. Vaughan AM, Afzal M, Nannapaneni P, Leroy M, Andrianou X, Pires J, et al. Continued circulation mpox: epidemiological phylogenetic assessment, European Region, 2023 2024. Euro surveillance : bulletin Europeen sur le malady transmissibles = European communicable disease bulletin 2024;29(27) http://dx.doi.org/10.2807/1560- 7917.ES.2024.29.27.2400330 28. Centers Disease Control Prevention. MPOX: Clinical Recognition. 2023. https://www.cdc.gov/poxvirus/mpox/clinicians/clinical -recognition.html 29. McCollum AM, Damon IK. Human mon",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c1bff773-43a2-4ec4-8d21-62576e263e16",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ".cdc.gov/poxvirus/mpox/clinicians/clinical -recognition.html 29. McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis 2014;58(2):260 -7 http://dx.doi.org/10.1093/cid/cit703 References 95 30. World Health Organization. Multi- country outbreak mpox, External situation report # 18 -16 March. https://www.who.int/publications/m/item/multi -country- outbreak -of-mpox --external - situation -report --18---16- march -2023 31. Damon IK. Smallpox, Monkeypox, Poxvirus Infections. Goldman's Cecil Medicine, Twenty- fourth Ed.: Elsevier 2012;2117 -2121 https://www.sciencedirect.com/science/article/pii/B9781437716047003808?via%3Dihub 32. Ogoina D., Iroezindu M., James HI, Oladokun R., Yinka -Ogunleye A., Wakama P., et al. Clinical Course Outcome Human Monkeypox Nigeria. Clin Infect Dis 2020;71(8):e210 -e214 http://dx.doi.org/10.1093/cid/ciaa143 33. Pittman PR, Martin JW, Kingebeni PM, Tamfum J- JM, Wan Q, Reynolds MG, et al. Clinical characterization",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f302e416-434f-4e81-bb11-27c88c215446",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "n PR, Martin JW, Kingebeni PM, Tamfum J- JM, Wan Q, Reynolds MG, et al. Clinical characterization human monkeypox infection Democratic Republic Congo. medRxiv 2022;2022.05.26.22273379 http://dx.doi.org/10.1101/2022.05.26.22273379 34. PALM007. Detailed result PALM007 study: clinical impact tecovirimat mpox clade 1. IDweek2024 2025. https://i -base.info/htb/50006 35. Damon IK. Status human monkeypox: clinical disease, epidemiology research. Vaccine 2011;29 Suppl 4:D54- 9 http://dx.doi.org/10.1016/j.vaccine.2011.04.014 36. Adler H., Gould S., Hine P., Snell LB, Wong W., Houlihan CF, et al. Clinical feature management human monkeypox: retrospective observational study UK. Lancet Infect Dis 2022;22(8):1153- 1162 http://dx.doi.org/10.1016/S1473- 3099(22)00228-6 37. Prasad S, Galvan Casas C, Strahan AG, Fuller LC, Peebles K, Carugno A, et al. dermatologic assessment 101 mpox (monkeypox) case 13 country du",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "803d62ab-93a1-4bc6-ad8f-0c3a46a3bad4",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "K, Carugno A, et al. dermatologic assessment 101 mpox (monkeypox) case 13 country 2022 outbreak: Skin lesion morphology, clinical course, scarring. Journal Amer ican Academy Dermatology http://dx.doi.org/10.1016/j.jaad.2022.12.035 38. Català A., Muñoz -S antos C., Galván -C asas C., Roncero Riesco M., Revilla Nebreda D., Solá - ruyols A., et al. Cutaneous reaction SARS -C oV-2 vaccination: cross -s ectional Spanish nationwide study 405 cases*. British Journal Dermatology 2022;186(1):142- 152 h ttp://dx.doi.org/10.1111/bjd.20639 39. Tarín -Vicente EJ, Alemany A, Agud -Dios M, Ubals M, Suñer C, Antón A, et al. Clinical presentation virological assessment confirmed human monkeypox virus case Spain: prospective observational cohort study. Lancet (London, England) 2022;400( 10353):661- 669 http://dx.doi.org/10.1016/S0140-6736(22)01436-2 40. Weinstein RA, Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemer",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "eec9be9e-aa38-41a9-85e3-0e92bac093dd",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ".1016/S0140-6736(22)01436-2 40. Weinstein RA, Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence monkeypox: prevalence, diagnostics, countermeasures. Clinical infectious disease 2005;41(12):1765 - 1771 https://www. https://doi.org/10.1086/498155 41. Low N. Mpox virus transmission sexual contact: Defining research agenda. PLoS Med 2023. http://dx.doi.org/10.1371/journal.pmed.1004163 42. Bruzzesi E, Raccagni AR, Mileto D, Candela C, Canetti D, Castagna A, et al. Isolated monkeypox proctitis among men sex men. Infection 2023;51(5):1597 -1598 http://dx.doi.org/10.1007/s15010- 023-02051-6 43. Thornhill JP. Monkeypox Virus Infection Humans across 16 Countries - April -June 2022. New England Journal medicine 2022. http://dx.doi.org/10.1056/NEJMoa2207323 44. Huhn GD, Bauer AM, Yorita K., Graham MB, Sejvar J., Likos A., et al. Clinical characteristic human monkeypox, risk factor severe disease. Clin Infect",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "16af4bf0-a69b-4933-9c57-02b242ce4fa0",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "al. Clinical characteristic human monkeypox, risk factor severe disease. Clin Infect Dis 2005;41(12):1742- 51 http://dx.doi.org/10.1086/498115 Clinical management infection prevention control mpox 96 45. Petersen E., Kantele A., Koopmans M., Asogun D., Yinka -Ogunleye A., Ihekweazu C., et al. Human Monkeypox: Epidemiologic Clinical Characteristics, Diagnosis, Prevention. Infect Dis Clin North 2019;33(4):1027- 1043 http://dx.doi.org/10.1016/j.idc.2019.03.001 46. Mitja O, Alemany A, Marks M, Jezer M. Mpox people advanced HIV infection: global case series. Lancet 2023. https://www.thelancet.com/journals/lancet/article/PIIS0140 - 6736(23)00273-8/fulltext 47. Angelo KM, Smith T, Camprubí- Ferrer D, Balerdi -Sarasola L, Díaz Menéndez M, Servera -Negre G, et al. Epidemiological clinical characteristic patient monkeypox GeoSentinel Network: cross -sectional study. Lancet Infectious Diseases http://dx",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4231212d-3e64-4504-8b73-6b5b8e6f01de",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "pox GeoSentinel Network: cross -sectional study. Lancet Infectious Diseases http://dx.doi.org/10.1016/S1473-3099(22)00651-X 48. Miller M. Severe monkeypox hospitalized patient —United States, August 10 –october 10, 2022. Morbidity Mortality Weekly Report 2022. https://www.cdc.gov/mmwr/volumes/71/wr/mm7144e1.htm 49. Gao YA, Hao Q. Incidence risk factor adverse outcome complication among patient mpox: systematic review meta -analysis. Unpublished work 2025 (see Annex) 50. Gupta A.K . Differential diagnosis, prevention treatment mpox (monkeypox): review dermatologists. J Clin Dermatol 2023. http://dx.doi.org/10.1007/s40257-023- 00778-4 51. WHO. Atlas mpox lesions: tool clinical researchers, 28 April 2023, version 1.0. 2024. https://www.who.int/publications/i/item/WHO -MPX -Clinical- Lesions -2023.1 52. WHO. Infographic: Poster Differential diagnosis mpox lesions. 2024. https://www.who.int/teams/he",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "95029340-5140-4a6b-89dc-3595ba6fe8c3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "52. WHO. Infographic: Poster Differential diagnosis mpox lesions. 2024. https://www.who.int/teams/health- care-readiness/clinical -management -of-monkeypox 53. WHO. Guidelines diagnosing, preventing managing cryptococcal disease among adults, adolescent child living HIV. https://www.who.int/publications/i/item/9789240052178 54. Brosius I. Epidemiological clinical feature clade Ib South Kivu, Democratic Republic Congo: prospective cohort study. Lancet 2025. http://dx.doi.org/10.1016/S0140-6736(25)00047-9 55. Hughes CM, Liu L., Davidson WB, Radford KW, Wilkins K., Monroe B., et al. Tale Two Viruses: Coinfections Monkeypox Varicella Zoster Virus Democratic Republic Congo. J Trop Med Hyg 2020;104(2):604-611 http://dx.doi.org/10.4269/ajtmh.20- 0589 56. Hoff NA, Morier DS, Kisalu NK, Johnston SC, Doshi RH, Hensley LE, et al. Varicella Coinfection Patients Active Monkeypox Democratic Republic",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "df0f834b-3abf-4e36-ba4c-c2b42f30fac0",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "nsley LE, et al. Varicella Coinfection Patients Active Monkeypox Democratic Republic Congo. Ecohealth 2017;14(3):564- 574 http://dx.doi.org/10.1007/s10393- 017-1266-5 57. D'Antonio F, Pagani G, Buca D, Khalil A. Monkeypox infection pregnancy: systematic review metaanalysis. American journal obstetrics & gynecology MFM 2023;5(1):100747 http://dx.doi.org/10.1016/j.ajogmf.2022.100747 58. Hobson G., Adamson J., Adler H., Firth R., Gould S., Houlihan C., et al. Family cluster three case monkeypox imported Nigeria United Kingdom, May 2021. Euro Surveill 2021;26(32) http://dx.doi.org/10.2807/1560- 7917.ES.2021.26.32.2100745 59. Mbala PK, Huggins JW, Riu -Rovira T., Ahuka SM, Mulembakani P., Rimoin AW, et al. Maternal Fetal Outcomes Among Pregnant Women Human Monkeypox Infection Democratic Republic Congo. J Infect Dis 2017;216(7):824-828 http://dx.doi.org/10.1093/infdis/jix260 60. Nachega JB. Mpox pregnancy",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "783f8020-4a87-467e-b087-46a1c29fd68a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "Dis 2017;216(7):824-828 http://dx.doi.org/10.1093/infdis/jix260 60. Nachega JB. Mpox pregnancy: Risks, vertical transmission, prevention treatment. New England Journal medicine 2024. http://dx.doi.org/10.1056/NEJMp2410045 References 97 61. Brown SH., Goldfarb IT., Shenoy ES., Kwolek . Mpox Exposure Pregnancy. Journal General Internal Medicine 2023. https://link.springer.com/article/10.1007/s11606- 023-08226-z 62. Jamieson DJ, Jernigan DB, Ellis JE, Treadwell TA. Emerging infection pregnancy: West Nile virus, monkeypox, severe acute respiratory syndrome, bioterrorism. Clin Perinatol 2005;32(3):765- 76 http://dx.doi.org/10.1016/j.clp.2005.04.008 63. Hughes C., McCollum A., Pukuta E., Karhemere S., Nguete B., Shongo Lushima R., et al. Ocular complication associated acute monkeypox virus infection, DRC. International Journal Infectious Diseases 2014;21:276- 277 http://dx.doi.org/10.1016/j.ijid.2014.03.994 64. Centers Disease Con",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dbd0030f-82bf-4658-a452-4e3876bf4616",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "iseases 2014;21:276- 277 http://dx.doi.org/10.1016/j.ijid.2014.03.994 64. Centers Disease Control Prevention. Science Brief: Detection Transmission Mpox Virus. 2022. https://archive.cdc.gov/%23/details?url=https%3A//www.cdc.gov/poxvirus/mpox/about/science -behind- transmission.html 65. Li Z, Li XX, Chen Y, Ruan Q, Huang X, Zhu G, et al. Persistence monkeypox virus DNA clinical specimens. Journal infection 2022;85(6):702 -769 http://dx.doi.org/10.1016/j.jinf.2022.10.013 66. Meschi S, Colavita F, Carletti F, Mazzotta V, Matusali G, Specchiarello E, et al. MPXV DNA kinetics bloodstream body fluid samples. Scientific report 2024;14(1):13487 http://dx.doi.org/10.1038/s41598- 024-63044-5 67. Kim H, Kwon R, Lee H, Lee SW, Rahmati M, Koyanagi AI, et al. Viral load dynamic shedding kinetics mpox infection: systematic review meta -analysis. Journal travel medicine 2023;30(5) http://dx.doi.org/10.1093/jtm/taad111 68. Ku",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7017a0ca-0ce1-4d6e-9b24-235d00ca181a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ta -analysis. Journal travel medicine 2023;30(5) http://dx.doi.org/10.1093/jtm/taad111 68. Kuehn R, Fox T, Guyatt G, Lutje V, Gould S. Infection prevention control measure reduce transmission mpox: systematic review. PLOS global public health 2024;4(1):e0002731 http://dx.doi.org/10.1371/journal.pgph.0002731 69. Seang S, Burrel S, Todesco E, Leducq V, Monsel G, Le Pluart D. Evidence human- to-dog transmission monkeypox virus. Lancet 2022. https://www.thelancet.com/journals/lancet/article/PIIS0140 -6736(22)01487-8/fulltext 70. Islam M, Dutta P, .et al. Pathogenicity virulence monkeypox human- animal -ecology interface. Virulence 2023. http://dx.doi.org/10.1080/21505594.2023.2186357 71. World Health Organization. Surveillance, case investigation contact tracing mpox. 2022. https://www.who.int/publications/i/item/WHO -MPX -Surveillance -2022.4 72. World Health Organization. Surveillance, case investigation contact tr",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a33109df-b559-4948-9a86-27ab1bc43e18",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "rveillance -2022.4 72. World Health Organization. Surveillance, case investigation contact tracing mpox: interim guidance, 27 November 2024. 2024. https://iris.who.int/bitstream/handle/10665/379643/B09169-eng.pdf 73. Johnson RF, Dyall J., Ragland DR, Huzella L., Byrum R., Jett C., et al. Comparative analysis monkeypox virus infection cynomolgus macaque intravenous intrabronchial inoculation route. J Virol 2011;85(5):2112-25 http://dx.doi.org/10.1128/JVI.01931- 10 74. Thy M, Peiffer -Smadja N, Mailhe M, Kramer L, Ferré VM, Houhou N, et al. Breakthrough Infections Postexposure Vaccination Mpox. New England journal medicine 2022;387(26):2477-2479 http://dx.doi.org/10.1056/NEJMc2211944 75. Pittman PR, Martin JW, Kingebeni PM, Tamfum J- JM, Mwema G, Wan Q, et al. Clinical characterization placental pathology mpox infection hospitalized patient Democratic Republic Congo. PLoS neglected tropical disease 2023",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "71367d2d-eef4-4878-9c11-b79d8c6ee6a5",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "hospitalized patient Democratic Republic Congo. PLoS neglected tropical disease 2023;17(4):e 0010384 http://dx.doi.org/10.1371/journal.pntd.0010384 Clinical management infection prevention control mpox 98 76. Mellon G, Rubenstein E, Meghann A, Molina J -M, Delaugerre C, LeGoff J. Air detection monkeypox virus dedicated outpatient clinic room monkeypox infection diagnosis. Journal Infection 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546519/ 77. Gould S, Atkinson B, Onianwa O, Spencer A, Furneaux J, Grieves J, et al. Air surface sampling monkeypox virus UK hospital: observational study. Lancet Microbe. 2022. http://dx.doi.org/10.1016/S2666-5247(22)00257-9 78. Kisalu NK, Mokili JL. Toward Understanding Outcomes Monkeypox Infection Human Pregnancy. J Infect Dis 2017;216(7):795-797 http://dx.doi.org/10.1093/infdis/jix342 79. Salvato RS, Ikeda MLR, Barcellos RB, Godinho FM, Sesterhiem P, Bitencour",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3fd9e519-3c2e-42b0-8b2d-73cbcc6fe842",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "0.1093/infdis/jix342 79. Salvato RS, Ikeda MLR, Barcellos RB, Godinho FM, Sesterhiem P, Bitencourt LCB, et al. Possible Occupational Infection Healthcare Workers Monkeypox Virus, Brazil. Emerging Infectious Disease 2022. http://dx.doi.org/10.3201/eid2812.221343 80. Dominik. Evidence surface contamination hospital room occupied patient infected monkeypox, Germany, June 2022. https://icpcovid.com/sites/default/files/2022 -07/Ep 272- 7 Norz Surface contamination monkeypox hospital Eurosurv -27-26-1.pdf 81. Muller M, Mishra S, McGeer A, Patel S, Gubbay J, Hasso M, et al. Environmental Testing Surfaces Room Patient Mpox. Clinical Infectious Disease 2023. https://academic.oup.com/cid/article -abstract/76/1/179/6671583 82. Wood JP, Choi YW, Wendling MQ, Rogers JV, Chappie DJ. Environmental persistence vaccinia virus materials. Lett Appl Microbiol 2013;57(5):399-404 http://dx.doi.org/10.1111/lam.12126 83. Rheinbaben F",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9d17e81f-122e-447f-97a4-50d1c9d1b773",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ials. Lett Appl Microbiol 2013;57(5):399-404 http://dx.doi.org/10.1111/lam.12126 83. Rheinbaben FV, Gebel J, Exner M, Schmidt A. Environmental resistance, disinfection, sterilization poxviruses. Mercer AA, Schmidt A, Weber O, (Eds.), Poxviruses, null, Birkhäuser Basel 2007;397- 405 http://dx.doi.org/10.1007/978-3- 7643- 7557- 7_19 84. High -Contact Object Surface Contamination Household Persons Monkeypox Virus Infection — Utah, June 2022. http://www.cdc.gov/mmwr/volumes/71/wr/mm7134e1.htm 85. Morgan C, Whitehill F, Doty J, Matheny A, Stringer J, Delaney L, et al. Environmental Persistence Monkeypox Virus Surfaces Household Person Travel -Associated Infection, Dallas, Texas, USA, 2021. Emerging Infectious Disease 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514334/ 86. Hemati S, Mohammadi -Moghadam F. systematic review environmental perspective monkeypox virus. Reviews environmental health 2024;39(2):363- 370",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "10bacc3a-5a76-4e86-829b-a026fe72afff",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "nvironmental perspective monkeypox virus. Reviews environmental health 2024;39(2):363- 370 http://dx.doi.org/10.1515/reveh -2022- 0221 87. Pan D, Nazareth J, Sze S, Martin CA, Decker J, Fletcher E, et al. Transmission monkeypox/mpox virus: narrative review environmental, viral, host, population factor relation 2022 international outbreak. Journal medical virology 2023;95(2):e28534 http://dx.doi.org/10.1002/jmv.28534 88. 2022 Mpox (Monkeypox) Outbreak: Global Trends. 2023. https://worldhealthorg.shinyapps.io/mpx_global/ 89. Atkinson. Monkeypox virus contamination office -based workplace environment. Journal Hospital Infection 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428113/ 90. Isabel B, Christophe Van D, Jasmine C, Leen V, Eugene B, Fien V, et al. Pre - asymptomatic viral shedding high -risk contact monkeypox cases: prospective cohort study. medRxiv 2022. https://www.medrxiv.org/content/10.1101/2",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "131896f5-1c44-485f-9b70-fde781f20664",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "onkeypox cases: prospective cohort study. medRxiv 2022. https://www.medrxiv.org/content/10.1101/2022.11.23.22282505v1 91. Vaughan A., Aarons E., Astbury J., Brooks T., Chand M., Flegg P., et al. Human-to -Human Transmission Monkeypox Virus, United Kingdom, October 2018. Emerg Infect Dis 2020;26(4):782- 785 http://dx.doi.org/10.3201/eid2604.191164 References 99 92. Carvalho LB, Casadio LV, Polly M, Nastri AC, Turdo AC, de Araujo Eliodoro R, et al. Monkeypox Virus Transmission Healthcare Worker Needlestick Injury, Brazil. Emerging Infectious Disease journal 2022;28(11):2334 http://dx.doi.org/10.3201/eid2811.221323 93. Garia VDR, Palacios J, Morcillo A, Duran -Pla E, Rodriguez BS, Lorusso N. Monkeypox outbreak piercing tattoo establishment Spain. Lancet Infectious Diseases 2022. https://www.sciencedirect.com/science/article/pii/S1473309922006521?via%3Dihub& ! 94. Ward T, Christie R, Paton R, Cumming F, Overton C. Transmission dynamic mon",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ee7170fb-260b-4493-b953-2a621a92edaf",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "?via%3Dihub& ! 94. Ward T, Christie R, Paton R, Cumming F, Overton C. Transmission dynamic monkeypox United Kingdom: contact tracing study. BMJ 2022. https://www.bmj.com/content/379/bmj- 2022- 073153 95. Fuminari M, Jantien A. B, Gini van R, Roisin B, Stjin R, Mariska P, et al. Time scale human monkeypox transmission Netherlands. medRxiv 2022. https://www.medrxiv.org/content/10.1101/2022.12.03.22283056v1 96. Brosius I, Van Dijck C, Coppens J, Vandenhove L, Bangwen E, Vanroye F, et al. Presymptomatic viral shedding high -risk mpox contacts: prospective cohort study. Journal medical virology 2023;95(5):e28769 http://dx.doi.org/10.1002/jmv.28769 97. Hoxha A, Kerr SM, Laurenson- Schafer H, Sklenovská N, Mirembe BB, Nezu IH, et al. Mpox Children Adolescents Multicountry Outbreak, 2022 -2023. Emerging infectious disease 2023;29(10):2125- 2129 http://dx.doi.org/10.3201/eid2910.230516 98. World Health Organization. Multi- country",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b39afa71-c6c4-4da5-8b98-18d3e8ee4246",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "2125- 2129 http://dx.doi.org/10.3201/eid2910.230516 98. World Health Organization. Multi- country outbreak mpox, External situation report #47 13 February 2025. https://www.who.int/publications/m/item/multi-country- outbreak -of-mpox -- external -situation -report --47---13- february -2025 99. Epidemiologic Clinical Features Children Adolescents Aged <18 Years Monkeypox — United States, May 17 –September 24, 2022. https://www.cdc.gov/mmwr/volumes/71/wr/mm7144a4.htm 100. Monkeypox virus infection child Spain first month 2022 outbreak. https://www.thelancet.com/journals/lanchi/article/PIIS2352 -4642(22)00250-4/fulltext 101. World. Considerations wastewater environmental surveillance monkeypox virus: Interim guidance. https://www.who.int/publications/i/item/B09178 102. Oghuan J, Chavarria C, Vanderwal SR, Gitter A, Ojaruega AA, Monserrat C, et al. Wastewater analysis Mpox virus city low prevalence",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "24b59b1d-6ba6-4556-b76c-47d27bee144b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "Ojaruega AA, Monserrat C, et al. Wastewater analysis Mpox virus city low prevalence Mpox disease: environmental surveillance study. Lancet regional health. Americas 2023;28:100639 http://dx.doi.org/10.1016/j.lana.2023.100639 103. Wong CH, Zhang Z, Eid W, Plaza -Diaz J, Kabir P, Wan S, et al. Rapidly developed, optimized, applied wastewater surveillance system real -time monitoring low -incidence, high -impact MPOX outbreak. Journal Water & Health 2023. https://iwaponline.com/jwh/article/21/9/1264/97439/Rapidly -developed -optimized -and- applied -wastewater 104. World Health Organization. MPOX. 2024. https://www.who.int/news- room/fact - sheets/detail/mpox 105. World Health Organization. Second meeting International Health Regulations (2005) Emergency Committee regarding upsurge mpox 2024. 2024. https://www.who.int/news/item/28- 11-2024- second -meeting -of-the-international -health - regulation -%282005%29- emergency -commit",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "47181e34-8170-4eea-b032-b5b9009dd4a8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "11-2024- second -meeting -of-the-international -health - regulation -%282005%29- emergency -committee -regarding -the-upsurge- of-mpox -2024 106. Bunge E. changing epidemiology human monkeypox —A potential threat? systematic review. Plos Negl Trop Dis 2022. http://dx.doi.org/10.1371/journal.pntd.0010141 Clinical management infection prevention control mpox 100 107. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox eradication.1988;6 . https://iris.who.int/bitstream/handle/10665/39485/9241561106.pdf 108. WHO. Proposed case definition mpox WHO. 2025. https://cdn.who.int/media/docs/default- source/documents/emergencies/outbreak- toolkit/who -suggested -outbreak -case- definition3c9e12f0- d346- 4583- b34c -99c3a201aa1c.pdf?sfvrsn=521f7713_1 109. Adams, John, Bartram, Jamie & Chartier, Yves. (2008) . Essential environmental health standard health care / edited John Adams, Jamie Bartram, Yves Chartier. World Health Organ",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e734c6c3-09f7-43c1-b1a7-042ca254f982",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "standard health care / edited John Adams, Jamie Bartram, Yves Chartier. World Health Organization. https://iris.who.int/handle/10665/43767 110. World Health Organization. Strengthening infection prevention control primary care: collection existing standards, measurement implementation resources. 2021. https://www.who.int/publications/i/item/9789240035249 111. World Health Organization. Clinical care severe acute respiratory infection: toolkit: COVID- 19 adaptation. 2022. https://apps.who.int/iris/handle/10665/331736 112. WHO. Diagnostic testing monkeypox virus (MPXV): interim guidance, 10 May 2024. 2024. https://iris.who.int/handle/10665/379547 113. WHO. Consolidated guideline differentiated HIV testing services. 2024. https://www.who.int/publications/i/item/9789240096394 114. World Health Organization. Strengthening global architecture health emergency prevention, preparedness, response resilience. https://www.who.",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3b1cd8f2-53af-4d56-8784-f9d7cfd063e5",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "chitecture health emergency prevention, preparedness, response resilience. https://www.who.int/publications/m/item/strengthening -the-global -architecture -for-health - emergency -prevention --preparedness --response -and-resilience 115. World Health Organization. Infection prevention control water, sanitation hygiene measure home care isolation mpox resource -limited settings: interim operational guide. https://www.who.int/publications/i/item/9789240101654 116. Adams V, Song J, Shang J, McDonald M, Dowding D, Ojo M, et al. Infection prevention control practice home environment: Examining enablers barrier adherence among home health care nurses. American journal infection control 2021;49(6 ):721- 726 http://dx.doi.org/10.1016/j.ajic.2020.10.021 117. Brockhaus L, Lötscher C, Labhardt ND. Infection prevention practice home healthcare: mixed -method study two Swiss home healthcare organisations. BMC health serv",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3e8c9506-536b-4178-a916-d5245950b4e6",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "n home healthcare: mixed -method study two Swiss home healthcare organisations. BMC health service research 2024;24(1):657 http://dx.doi.org/10.1186/s12913- 024-11111-y 118. WHO. Risk communication community engagement (RCCE) monkeypox outbreaks: Interim guidance, 24 June 2022. 2022. https://www.who.int/publications/i/item/WHO -MPX - RCCE -2022.1 119. Public advice -mpox. https://www.who.int/news- room/public -advice 120. World Health Organization. Home care patient suspected confirmed COVID- 19 management contacts: interim guidance, 12 August 2020. 2020. https://www.who.int/publications/i/item/home- care-for- patient -with-suspected -novel - coronavirus- (ncov) -infection -presenting -with-mild-symptoms -and-management -of-contacts 121. MacLeod C, Braun L, Caruso BA, Chase C, Chidziwisano K, Chipungu J, et al. Recommendations hand hygiene community settings: scoping review current international guidelines. BMJ open 2023",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7da0ae69-9b83-4855-babd-aad9db0666aa",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "hygiene community settings: scoping review current international guidelines. BMJ open 2023;13(6):e068887 http://dx.doi.org/10.1136/bmjopen- 2022- 068887 122. Pitol AK, Richards S, Mirindi P, Mahamed HO, Baller A, Hughes GL, et al. Efficacy laundry practice eliminating monkeypox virus (MPXV) fabrics. Journal infectious disease 2024. http://dx.doi.org/10.1093/infdis/jiae606 References 101 123. Pitol AK, Richards S, Mirindi P, Mahamed HO, Baller A, Hughes GL, et al. Efficacy Disinfectants Monkeypox Virus Inactivation High Touch Surface Materials Low -Resource Settings. Environmental science & technology 2024;58(45):19981-19989 http://dx.doi.org/10.1021/acs.est.4c09821 124. Butcher W, Ulaeto D. Contact inactivation orthopoxviruses household disinfectants. Journal Applied Microbiology 2005. https://ami - journals.onlinelibrary.wiley.com/doi/abs/10.1111/j.1365- 2672.2005.02601.x 125. Gerba CP, Kennedy . Enteric virus sur",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4d303f61-c8ef-4944-89cd-064fab6bbe9d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ".wiley.com/doi/abs/10.1111/j.1365- 2672.2005.02601.x 125. Gerba CP, Kennedy . Enteric virus survival household laundering impact disinfection sodium hypochlorite. Appl Environ Microbiol 2007;73(14):4425-8 http://dx.doi.org/10.1128/AEM.00688-07 126. Rutala WA, Weber DJ. Uses inorganic hypochlorite (bleach) health -care facilities. Clin Microbiol Rev 1997;10(4):597- 610 http://dx.doi.org/10.1128/CMR.10.4.597 127. World Health Organisation . Standard precautions: waste management (OpenWHO). 2022. 128. Ianache I, Skrzat -Klapaczynska A, Jilich D, Fleischhans L, Gmizic I, Ranin J, et al. Mpox across country Central Eastern Europe - 2022 outbreak. Travel medicine infectious disease 2024;59:102719 http://dx.doi.org/10.1016/j.tmaid.2024.102719 129. Clark AE. Validating tool detect Inactivate Monkeypox virus Human milk. Breastfed Med 2023. http://dx.doi.org/10.1089/bfm.2023.0175 130. Thornhill JP, Palich R, Ghosn J, Walms",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "27719497-db1d-4902-b328-b2774bef8f2d",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "fed Med 2023. http://dx.doi.org/10.1089/bfm.2023.0175 130. Thornhill JP, Palich R, Ghosn J, Walmsley S, Moschese D, Cortes CP, et al. Human monkeypox virus infection woman non- binary individual 2022 outbreaks: global case series. Lancet (London, England) 2022;400(10367):1953-1965 http://dx.doi.org/10.1016/S0140- 6736(22)02187-0 131. Bragazzi NL, Woldegerima WA, Wu J, Converti M, Szarpak L, Crapanzano A, et al. Epidemiological Clinical Characteristics Mpox Cisgender Transgender Women Non-Binary Individuals Assigned Female Sex Birth: Comprehensive, Critical Global Perspective. Viruses 2024;16(3) http://dx.doi.org/10.3390/v16030325 132. Mirembe BB, Kerr SM, Ndumbi P, Ajong B, Le Polain de Waroux O, Pavlin BI, et al. MPOX infection among health worker global surveillance data, January 2022 -May 2023. Antimicrobial Resistance Infection Control Conference: 7th International Confe rence Prevention Infection C",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bf39a890-6f97-4c81-b7e5-4926fd768bdc",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "tance Infection Control Conference: 7th International Confe rence Prevention Infection Control, ICPIC 2023, 12(Supplement 1). 2023. https://aricjournal.biomedcentral.com/articles/supplements/volume -12-supplement -1 133. World Health Organization. Responding global mpox outbreak: ethic issue considerations: policy brief. https://www.who.int/publications/i/item/WHO- Mpox - Outbreak_response-Ethics- 2023.1 134. UK Health Security Agency . Monkeypox case confirmed England – latest updates. 2022. https://www.gov.uk/government/news/monkeypox- case -confirmed- in-england- latest -updates 135. Nigeria Centre Disease Control. National monkeypox public health response guidelines. 2019. https://ncdc.gov.ng/themes/common/docs/protocols/96_1577798337.pdf 136. France K., Villa . Acute Oral Lesions. Dermatol Clin 2020;38(4):441 -450 http://dx.doi.org/10.1016/j.det.2020.05.005 137. WHO. Care skin lesion mpox infection. 2025. https://www.wh",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "35030d1c-b9ed-47a7-8438-fed1a6dec880",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "/10.1016/j.det.2020.05.005 137. WHO. Care skin lesion mpox infection. 2025. https://www.who.int/multi- media/details/care -of-skin-lesions -in-mpox -infection -poster 138. Flynn M, Mercer D. Oxford Handbook Adult Nursing. 2018 . https://doi.org/10.1093/med/9780198743477.001.0001 Clinical management infection prevention control mpox 102 139. WHO. Guideline: update management severe acute malnutrition infant children. 2013. https://www.who.int/publications/i/item/9789241506328 140. World Health Organization. -ICRC Basic Emergency Care: approach acutely ill injured. 2018. https://www.who.int/publications/i/item/basic -emergency -care-approach -to-the- acutely -ill-and-injured 141. World Health Organization. Pocket book hospital care children: guideline management common childhood illnesses. 2013. https://www.who.int/publications/i/item/978 -92-4- 154837-3 142. Zinder R., Cooley R., Vlad LG, Mol",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dc386bff-37e1-4008-b1e6-255500b2f1f8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "tps://www.who.int/publications/i/item/978 -92-4- 154837-3 142. Zinder R., Cooley R., Vlad LG, Molnar JA. Vitamin Wound Healing. Nutr Clin Pract 2019;34(6):839- 849 http://dx.doi.org/10.1002/ncp.10420 143. World Health Organization. recommendation antenatal care positive pregnancy experience. 2016. https://www.who.int/publications/i/item/9789241549912 144. World Health Organization. recommendation maternal newborn care positive postnatal experience. 2022. https://www.who.int/publications/i/item/9789240045989 145. World Health Organization. Abortion care guideline. 2022. https://www.who.int/publications/i/item/9789240039483 146. Reynolds MG, McCollum AM, Nguete B., Shongo Lushima R., Petersen BW. Improving Care Treatment Monkeypox Patients Low -Resource Settings: Applying Evidence Contemporary Biomedical Smallpox Biodefense Research. Viruses 2017;9(12) http://dx.doi.org/10.3390/v9120380 147. World Health Orga",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "17babab3-8999-4c34-be8a-07ea632bc781",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "Biodefense Research. Viruses 2017;9(12) http://dx.doi.org/10.3390/v9120380 147. World Health Organization. AWaRe (Access, Watch, Reserve) antibiotic book. https://www.who.int/publications/i/item/9789240062382?%20utm_source=monthly - newsletter&utm_medium=email&utm_campaign=Feb -2022 148. Llor C., Bjerrum L. Antimicrobial resistance: risk associated antibiotic overuse initiative reduce problem. Ther Adv Drug Saf 2014;5(6):229- 41 http://dx.doi.org/10.1177/2042098614554919 149. Duncan H., Hutchison J., Parshuram CS. Pediatric Early Warning System score: severity illness score predict urgent medical need hospitalized children. J Crit Care 2006;21(3):271 -8 http://dx.doi.org/10.1016/j.jcrc.2006.06.007 150. Médecins Sans F rontières. Clinical guidelines: diagnosis treatment manual. 2021. https://medicalguidelines.msf.org/en/viewport/CG/english/cutaneous- abscess -18482406.html 151. World Health Organization. Guidelines core",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "06333183-70b8-413e-af4a-831558c7002a",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "/CG/english/cutaneous- abscess -18482406.html 151. World Health Organization. Guidelines core component infection prevention control programme national acute health care facility level. https://iris.who.int/handle/10665/331750 152. Centers Disease Control Prevention. Hierarchy Controls. 2023. https://www.cdc.gov/niosh/topics/hierarchy/default.html 153. World Health Organization. Minimum requirement infection prevention control programmes. https://iris.who.int/handle/10665/330080 154. World Health Organization. Framework toolkit infection prevention control outbreak preparedness, readiness response national level. 2021. https://iris.who.int/handle/10665/345251 155. World Health Organization. Framework toolkit infection prevention control outbreak preparedness, readiness response health care facility level. https://www.who.int/publications/i/item/9789240051027 References 10",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0156b163-b63c-45c0-9992-f6d85f30efb7",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "health care facility level. https://www.who.int/publications/i/item/9789240051027 References 103 156. World Health Organization. guideline hand hygiene health care . 2009. https://iris.who.int/handle/10665/44102 157. Antimicrobial Resistance Healthcare Associated Infection Scotland . Standard Infection Control Precautions Literature review - Footwear. 2021. https://www.nipcm.hps.scot.nhs.uk/media/1901/2021- 07-22-ppe-footwear- v30-final.pdf 158. Hall S., Poller B., Bailey C., Gregory S., Clark R., Roberts P., et al. Use ultraviolet -fluorescence - based simulation evaluation personal protective equipment worn first assessment care patient suspected high -consequence infectious disease. J Hosp Infect 2018;99(2):218- 228 http://dx.doi.org/10.1016/j.jhin.2018.01.002 159. Poller B., Hall S., Bailey C., Gregory S., Clark R., Roberts P., et al. 'VIOLET': fluorescence -based simulation exercise training healthcare worker",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cc43589f-d780-472e-84d8-8da3c6f03cf3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "P., et al. 'VIOLET': fluorescence -based simulation exercise training healthcare worker use personal protective equipment. J Hosp Infect 2018;99(2):229- 235 http://dx.doi.org/10. 1016/j.jhin.2018.01.021 160. World Health Organization. Consolidated guideline HIV prevention, testing, treatment, service delivery monitoring: recommendation public health approach. 2021. https://www.who.int/publications/i/item/9789240031593 161. recommendation Postnatal care mother newborn 2013. http://www.who.int/publications/i/item/9789241506649 162. WHO. Guidelines optimal feeding low birth -weight infant low - middle -income countries. https://www.who.int/publications/i/item/9789241548366 163. World Health Organization. recommendation intrapartum care positive childbirth experience. 2018. https://www.who.int/publications/i/item/9789241550215 164. Mbrenga F, Nakouné E, Malaka C, Bourner J, Dunning J, Vernet G, et",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8ae4a2df-929d-4a55-a058-d5d4e8da2dcc",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ns/i/item/9789241550215 164. Mbrenga F, Nakouné E, Malaka C, Bourner J, Dunning J, Vernet G, et al. Monkeypox treatment tecovirimat Central African Republic Expanded Access Programme. medRxiv 2022;2022.08.24.22279177 http://dx.doi.org/10.1101/2022.08.24.22279177 165. O'Laughlin K., Tobolowsky FA, Elmor R., Overton R., O'Connor SM, Damon IK, et al. Clinical Use Tecovirimat (Tpoxx) Treatment Monkeypox Investigational New Drug Protocol - United States, May -August 2022. MMWR Morb Mortal Wkly Rep 2022;71(37):1190- 1195 http://dx.doi.org/10.15585/mmwr.mm7137e1 166. SIGA . SIGA Receives Approval FDA Intravenous (IV) Formulation TPOXX® (tecovirimat). 2022. https://investor.siga.com/news- releases/news -release -details/siga -receives - approval -fda- intravenous -iv-formulation -tpoxxr 167. Fox T, Gould S, Princy N, Rowland T, Lutje V, Kuehn R . Therapeutics treating mpox humans. 2022. https://www.doi.org/10.1002/1",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8c913b52-5623-4dac-a5f2-294ed1c3f5d8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ", Lutje V, Kuehn R . Therapeutics treating mpox humans. 2022. https://www.doi.org/10.1002/14651858.CD015769 168. European Medicines Agency . EMA Tecovirimat -SIGA assessment report. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/tecovirimat- siga 169. GlobalNewswire. SIGA announces health Canada regulatory approval oral TPOXX® SIGA Technologies Inc. 2021. https://www.globenewswire.com/news- release/2021/12/01/2344305/9738/en/SIGA -Announces- Health -Canada- Regulatory -Approval - of-Oral-TPOXX.html 170. Mbrenga F, Nakouné E, Malaka C, Bourner J, Dunning J, Vernet G, et al. Monkeypox treatment tecovirimat Central African Republic Expanded Access Programme. medRxiv 2022;2022.08.24.22279177 http://dx.doi.org/10.1101/2022.08.24.22279177 171. World Health Organisation. recommendations: Induction labour beyond term. 2018;2018. https://iris.who.int/bitstream/handle/10665/363138/9789240052796-eng.pdf Clinical management",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a2032c27-26ab-4b9f-8d0d-f628c4d565ad",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "https://iris.who.int/bitstream/handle/10665/363138/9789240052796-eng.pdf Clinical management infection prevention control mpox 104 172. World Health Organization. Guidelines management symptomatic sexually transmitted infections. 2021. https://www.who.int/publications/i/item/9789240024168 173. World Health Organization. matter time stress: illustrated guide. 2020. https://www.who.int/publications/i/item/9789240003927 174. World Health Organization. mhGAP Humanitarian Intervention Guide (mhGAP -HIG): clinical management mental, neurological substance use condition humanitarian emergencies. 2015. https://www.who.int/publications/i/item/9789241548922 175. World Health Organization. mhGAP Intervention Guide - version 2.0. https://www.who.int/publications/i/item/9789241549790 176. World Health Organization. mhGAP training manual mhGAP intervention guide mental, neurological substance use disorder",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "06ab7a09-c185-4b26-acb1-eddebd654f4f",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ing manual mhGAP intervention guide mental, neurological substance use disorder non -specialized health settings. 2017. https://apps.who.int/iris/handle/10665/259161 177. World Health Organization. Psychological first aid: Guide field workers. 2011. https://www.who.int/publications/i/item/9789241548205 178. Inter-Agency Standing Committee (IASC) . IASC Guidance Basic Psychosocial Skills – Guide COVID -19 Responders. 2020. https://interagencystandingcommittee.org/iasc -reference- group- mental -health -and-psychosocial -support -emergency -settings/iasc -guidance -basic - psychosocial -skills -guide -covid -19-responders 179. World Health Organization. Problem Management Plus (PM+): Individual psychological help adult impaired distress community exposed adversity. 2016. https://www.who.int/publications/i/item/WHO -MSD -MER- 16.2 180. World Health Organization. Optimized supportive care Ebola virus disease: clinical mana",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5f08ebf3-1b8e-49e2-bf59-ebfdd1b184d7",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "180. World Health Organization. Optimized supportive care Ebola virus disease: clinical management standard operating procedures. 2019. https://apps.who.int/iris/handle/10665/325000 181. handbook guideline development, 2nd Edition. 2014. https://www.who.int/publications/i/item/9789241548960 182. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profile summary finding tables. Journal clinical epidemiology 2011;64(4):383- 94 http://dx.doi.org/10.1016/j.jclinepi.2010.04.026 183. Guyatt GH, Oxman AD, Kunz R, Falck -Ytter Y, Vist GE, Liberati A, et al. Going evidence recommendations. BMJ (Clinical research ed.) 2008;336(7652):1049-51 http://dx.doi.org/10.1136/bmj.39493.646875.AE 184. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck -Ytter Y, Alonso -Coello P, et al. GRADE: emerging consensus rating quality evidence strength recommendations. BMJ (Clinical research ed.)",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bf68017d-3bbd-474d-95ec-9c5b372422ca",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "onsensus rating quality evidence strength recommendations. BMJ (Clinical research ed.) 2008;336(7650):924- 6 http://dx.doi.org/10.1136/bmj.39489.470347.AD 185. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating quality evidence. Journal clinical epidemiology 2011;64(4):401 -6 http://dx.doi.org/10.1016/j.jclinepi.2010.07.015 186. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going evidence recommendation- determinant recommendation's direction strength. Journal clinical epidemiology 2013;66(7):726 -35 http://dx.doi.org/10.1016/j.jclinepi.2013.02.003 187. World Health Organization. Meeting Report Technical working group (TWG) meeting infant feeding direct contact Mpox infection. 2024. References 105 https://files.magicapp.org/guideline/7a056634- 975d -442c -9871- 57d650dd990d/files/TWG_report_infant_feeding_mpox_r817",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "655d51a8-3a56-42b9-b0e7-50fcbeb7d2a2",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "app.org/guideline/7a056634- 975d -442c -9871- 57d650dd990d/files/TWG_report_infant_feeding_mpox_r817816.pdf. 188. World Health Organization. Technical meeting report - Initiation antiretroviral therapy people HIV mpox. 2024 https://files.magicapp.org/guideline/7a056634- 975d -442c - 9871- 57d650dd990d/files/TWG_report_HIV_mpox_r817731.pdf. 189. Global Clinical Platform mpox. https://www.who.int/tools/global- clinical - platform/monkeypox 190. WHO. Clinical characterization mpox including monitoring use therapeutic interventions. Statistical plan 2023. https://iris.who.int/bitstream/handle/10665/373366/WHO - MPX -Clinical -Analytic_plan -2023.1-eng.pdf 191. WHO. Diagnostic testing monkeypox virus (MPXV): interim guidance, 10 May 2024. 2024. https://www.who.int/publications/i/item/WHO -MPX -Laboratory -2024.1 192. WHO. Essential Medicines List Antibiotic Book: improving antibiotic AWaReness. 2022- 11-19. https://www.who",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9829f073-376e-4778-8f10-e88063eea0e4",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ential Medicines List Antibiotic Book: improving antibiotic AWaReness. 2022- 11-19. https://www.who.int/publications/m/item/the-who- essential -medicines -list- antibiotic -book -improving -antibiotic -awareness 193. Altmann S., Brandt CR, Murphy CJ, Patnaikuni R., Takla T., Toomey M., et al. Evaluation therapeutic intervention vaccinia virus keratitis. J Infect Dis 2011;203(5):683 -90 http://dx.doi.org/10.1093/infdis/jiq103 194. Semba RD. ocular complication smallpox smallpox immunization. Arch Ophthalmol 2003;121(5):715-9 http://dx.doi.org/10.1001/archopht.121.5.715 Annex 1. case definition mpox outbreak non-endemic country Surveillance case definition case definition use outbreak may reviewed evidence becomes available. guidance testing please refer Laboratory testing monkeypox virus (MPXV): interim guidance 2024 [191]. Suspected case i) person contact",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "98e1a0e0-35d4-4e42-a04c-eabac4f02621",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "nkeypox virus (MPXV): interim guidance 2024 [191]. Suspected case i) person contact probable confirmed mpox case 21 day onset sign symptoms, present following: acute onset fever (> 38.5°C), headache, myalgia (muscle pain/body aches), back pain, profoun weakness fatigue. ii) person presenting since 1 January 2022 unexplained acute skin rash, mucosal lesion lymphadenopathy (swollen lymph nodes). skin rash may include single multiple lesion ano-genital region elsewhere body. Mucosal lesion may include single multiple oral, conjunctival, urethral, penile, vaginal ano -rectal lesions. Ano -rectal lesion also manifest ano -rectal inflammation (proctitis), pain and/or bleeding. following common cause acute rash skin lesion fully explain clinical picture: varicella zoster, herpes zoster, measles, herpes",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "aed88172-5bce-462f-9243-62fa2eec94d2",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "sion fully explain clinical picture: varicella zoster, herpes zoster, measles, herpes simplex, bacterial skin infections, disseminated gonococcus infection, primary secondary syphilis, chancroid, lymphogranuloma venereum, granuloma inguinale, molluscum contagiosum, allergic reaction (e.g. plants); locally relevant common cause papular vesicular rash. NB necessary obtain negative laboratory result listed common cause rash illness order classify case suspected. Further, suspicion mpox high due either history and/or clinical presentation possible exposure case, identification alternate pathogen cause rash illness preclude testing MPXV, co -infections identified. Probable case person presenting unexplained acute skin rash, mucosal lesion lymphadenopathy (swollen lymph nodes). skin rash may include single multiple lesio",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "173eb439-a0f2-416d-9a3e-59477c7201df",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "esions lymphadenopathy (swollen lymph nodes). skin rash may include single multiple lesion ano -genital region elsewhere body. Mucosal lesion may include single r multiple oral, conjunctival, urethral, penile, vaginal ano -rectal lesions. Ano-rectal lesion also manifest ano -rectal inflammation (proctitis), pain and/or bleeding. One following: • epidemiological link probable confirmed case mpox 21 day symptom onset. • Identifies gay, bisexual ci trans man sex men. • multiple and/or casual sexual partner 21 day symptom onset. • detectable level anti -orthopoxvirus (OPXV) IgM antibody (during period 4 –56 day rash onset); four -fold rise IgG antibody titer based acute (up day 5–7) convalescent (day 21 onwards) samples; absence recen smallpox/ mpox vaccination k",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7468d84a-4759-4009-831a-0ce72e90966f",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "lescent (day 21 onwards) samples; absence recen smallpox/ mpox vaccination known exposure OPXV. • positive test result orthopoxviral infection (e.g. OPXV -specific PCR without MPXV -specific PCR sequencing) . Confirmed case person laboratory -confirmed mpox virus infection detection unique sequence viral DNA real -time polymerase chain reaction (PCR) and/or sequencing. Discarded case suspected probable case laboratory testing lesion fluid, skin specimen crust PCR and/or sequencing negative mpox virus. Conversely, retrospectively detected probable case lesion testing longer adequate ly performed (i.e. crust fall off) specimen found PCR-positive, would remain classified probable case. suspected probable case discarded based negative result oropharyngeal, anal rectal swab blood te",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "54838a50-650d-4b14-ba2f-855ddcae0999",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "discarded based negative result oropharyngeal, anal rectal swab blood test alone. 1) person exposed probable confirmed mpox case. Please see definition contact. 2) Serology used retrospective case classification probable case specific circumstance diagnostic testing PCR skin lesion specimen possible, context research standardized data collec tion. primary diagnostic test mpox PCR skin lesion material specimen oral nasopharyngeal swab appropriate. Serology used first -line diagnostic test. 3) PCR blood specimen may unreliable also used alone first -line diagnostic test. blood PCR negative test done, sufficient discard case otherwise meet definition suspected fo r probable case. applies regar",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ae4039ef-417c-45c5-b491-5c499bd69084",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "rd case otherwise meet definition suspected fo r probable case. applies regardless whether blood PCR orthopox virus mpox virus -specific. Annex 2. Medications dosage symptomatic care Fever – paracetamol Adults: 1 g PO/IV every 6 –8 hours. Maximum dose 4 g every 24 hour (max 2 g/24 h history chronic liver disease). Neonates: Oral dose 10–15 mg/kg every 6 hours. Maximum dose 40 mg/kg/day; IV dose 7.5 mg/kg every 6 hours, maximum dose 30 mg/kg day. children: 10 –15 mg/kg every 6 hours, maximum dose 60 mg/kg /day. Mild pain control – paracetamol Adults: 1 g PO/IV every 6 –8 hours. Maximum dose 4 g every 24 hour (max 2 g/24 h history chronic liver disease). Children: Orally IV 10–15 mg/kg/dose every 4 –6 hour required, maximum usual dose 60 mg/kg/day, 90 mg/kg/day given short period medical supervision. Severe pain co",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "aa3a6d1f-0dfd-4c00-8f35-7e564fc22ed1",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "/kg/day, 90 mg/kg/day given short period medical supervision. Severe pain control – consider add tramadol (PO IV) Adults: 50–100 mg PO/IV every 4–6 hour needed, daily maximum 400 mg/day. Children > 6 months: 1 –2 mg/kg every 4–6 hours, maximum 400 mg/day. Severe pain control – consider replacing tramadol morphine (PO, IV, SC) (oral dose preferred patient tolerate; use immediate release tablet acute pain) Adults: Oral dose 10 mg every 4 hour needed; maximum dose 60 mg/day. IV dose 1–4 mg SQ/IV every 4 hour needed – monitor SBP RR prior administration morphine (hold low SBP respiratory rate). Children: Oral dose 0.2–0.4 mg/kg/dose every 4 hours. Titrate dose pain. IV dose 0.05–0.1 mg/kg/dose every 4–6 hour required. Antihistaminic itching Adults: Loratadine 10 mg PO daily. Children (> 30 kg): Loratadine 10 mg PO onc",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "74f04ad8-95ae-4fe5-981c-3accf785a433",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "itching Adults: Loratadine 10 mg PO daily. Children (> 30 kg): Loratadine 10 mg PO daily. Nausea vomiting Ondansetron (associated QT prolongation, thus important note medication may also prolong QT interval monitor regularly ECGs available). Adults: 8 mg PO every 12 hour 4 mg IV every 8 hour needed. Children: 0.15 mg/kg orally IV 0.15 mg/kg every 12 hours, maximum dose 8 mg. Promethazine adults: 12.5 –25 mg orally every 4–6 hour needed (can prolong QT interval). Dyspepsia Adult: Omeprazole 40 mg PO/IV every 24 hours. Child: Omeprazole: 5–10 kg: 5 mg daily; 10–20 kg: 10 mg daily; ≥ 20 kg: 20 mg daily. Diarrhoea Diarrhoea managed conservatively. use anti-motility agent generally recommended given potential ileus. Anxiety may symptom patient experience particularly relate",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "70cf0060-85d5-476b-8f6f-aa7cbed2d105",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "e potential ileus. Anxiety may symptom patient experience particularly related isolation due worsening symptoms. First-line therapy talk mental health counsellor. moderate severe anxiety, diazepam considered, evaluation patient’s mental status precede use. Benzodiazepines given patient altered mentation. Adults: Diazepam 5 –10 mg PO every 8 hour needed long mentation unaffected. Children: Diazepam 0.05– 0.1 mg/kg PO every 6 hour needed. Continual supervision health aid indicated keep child calm. Sedatives used necessary perform procedure give interventions. Agitation patient agitated becomes danger self, health care provider patients, consider pharmacotherapy. Adults: Diazepam 2–10 mg PO/IV every 6–8 hour needed long p",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6ba07b60-343c-4c6a-89e4-c06f5b979534",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ider pharmacotherapy. Adults: Diazepam 2–10 mg PO/IV every 6–8 hour needed long patient protect airway. Adults: Haloperidol 0.5–5 mg every 4–6 hours, needed. Children > 6 years: Haloperidol IM 1–3 mg every 4–8 hours, needed. Children 3–6 years: Haloperidol PO 0.01– 0.03 mg/kg daily. Haloperidol associated QT prolongation, thus important note medication may also prolong QT interval monitor ECG regularly available. Note: Avoid use salicylate (e.g. aspirin) child adolescent < 18 year age avoid development Reye’s Syndrome. Annex 3. Antimicrobial recommendation dosage secondary bacterial skin infection treatment impetigo, erysipelas cellulitis caused bacterial pathogen. excludes skin infection caused viral, fungal parasitic pathogens, necrotizing fasciitis, pyomyositis, se",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cebdc4a1-f428-468f-8236-445faa903612",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "n infection caused viral, fungal parasitic pathogens, necrotizing fasciitis, pyomyositis, severe infection sepsis surgical site infections. guidance recommendation antimicrobial therapy please consult Essential Medicines List antibiotic book: improving antibiotic AWaReness [147]and Essential Medicines List antibiotic book: infographics . [192] Adults Antibiotic Dose Cloxacillin (flucloxacillin) 500 mg orally every 8 hour Cephalexin 500 mg orally every 8 hour Amoxicillin -clavulanic acid 500–125 mg orally every 8 hour concern community acquired MRSA consider following treatment: Clindamycin 600 mg orally every 8 hour Trimethoprim -sulfamethoxazole 800–160 mg orally every 12 hour Doxycycline 100 mg orally every 12 hour Note: case penicillin beta -lactam allergy: use clindamycin trimethoprim -sulfamethoxazole. Children Weight Amoxicillin -clavulanic acid Cefale",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2d6b9111-cf32-4423-bcf4-5e7d2cf069a0",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "damycin trimethoprim -sulfamethoxazole. Children Weight Amoxicillin -clavulanic acid Cefalexin Cloxacillin (flucloxacillin) 40–50 mg/kg/dose amoxicillin component every 12 hour 30 mg/kg/dose every 8 hour orally 25 mg/kg/dose every 12 hour orally neonates: 25 –50 mg/kg/dose twice daily; children: 25 mg/kg/dose every 6 hour 3 < 6 kg 250 mg amoxicillin/dose twice daily 125 mg every 12 hour 125 mg every 6 hour 6 < 10 kg 375 mg amoxicillin/dose twice daily 250 mg every 12 hour 250 mg every 6 hour 10 < 15 kg 500 mg amoxicillin/dose twice daily 375 mg every 12 hour 375 mg every 6 hour 15 < 20 kg 750 mg amoxicillin/dose twice daily 500 mg every 12 hour 500 mg every 6 hour 20 < 30 kg 1000 mg amoxicillin/dose twice daily 625 mg every 12 hour 750 mg every 6 hour > 30 kg Use adult dose Use adult dose Use adult dose Note: concern community -acquired MRSA consider clindamycin",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2583bf72-acde-4682-aaa8-a4720680fee5",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "se adult dose Use adult dose Note: concern community -acquired MRSA consider clindamycin: neonate 5 mg/kg/dose every 8 hours; child 10 mg/kg/dose every 8 hours. Annex 4. Mpox care pathway Annex 5. Search strategy terminology reported route MPXV infection commissioned systematic 2024 review underpins current guideline update previously published review. synthesized updated evidence three research questions. review occurred two stages. first stage appraised available evidence comparative interventional trials, yielded evidence. absence data, second stage preformed synthesize evidence reported route MPXV infection using non-comparative study design indirect ly inform three IPC intervention review questions. Literature search strategy search done end September 2024 using broad search term including term",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8799cd94-cf72-495b-87da-486e6113722b",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "trategy search done end September 2024 using broad search term including term mpox -like viruses. search included following databases: MEDLINE (OVID), Embase (OVID), Biosis preview (Web Science), CAB Abstracts (Web Science) Global Index Medicus. Inclusion exclusion criterion study published English French September 2022 September 2024 presented data mpox mode transmission eligible included. comparative non -comparative study different setting (health care, households, congregate -living/community settings) included. followin g mpox study excluded; study without transmission data, study solely concerning animal-to -animal animal -to-human transmission, study solely examining laboratory transmission, non-original studies, study published language English French. Given potential varying interpretati",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "920d347a-96dd-48fb-af5e-0f1d9d6c3429",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ublished language English French. Given potential varying interpretation key terminology, following description used purpose systematic review: i) Fully healed: mpox lesion crusted, scab fallen fresh layer skin formed underneath. ii) Infectious period: mpox lesion crusted, scab fallen fresh layer skin formed underneath. iii) Isolation: separation infected people contagious disease people infected keeping separate room area within home. iv) Adequate ventilation single patient room: may achieved mechanical, natural hybrid ventilation. • Mechanical ventilation rate: six air change per hour room. • Natural ventilation rate: 60 L/sec per patient. • Hybrid (mixed mode) ventilation combination mechanical natural ventilation. relies natural driving force provide",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0da2c926-54ed-45c5-89cc-b22c939d68e8",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ination mechanical natural ventilation. relies natural driving force provide desired (design) flow rate. Mechanical ventilation used natural ventilation flow rate low . v) Airborne isolation room ventilation: mechanical ventilation meet criterion airborne precaution room: negative pressure created control direction airflow. ventilation rate least 12 ACH. Natural ventilation meet criterion airborne precaution room: airflow directed area free transit permit rapid dilution contaminated air surrounding area open air. average ventilation rate 160 litres/second per patient. data collected stage two, several subgroup analysis conducted based different contexts: • Setting: Review considered: household, congregate living, health care setting community settings. • Clade (where known presu",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "80957597-3483-4906-bfc3-e146e7f188e4",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "old, congregate living, health care setting community settings. • Clade (where known presumed) : analysis included Clade I, Clade II, subtypes Clade IIa Clade IIb (and sub lineages, including limited IIb.lineage A, IIb.lineage B, IIb.lineage C). • Route transmission: Transmission route analysed based information detailed paper(s). • Region and/or country : Data categorized regions, including African Region, Region Americas, South-East Asia Region, European Region, Eastern Mediterranean Region Western Pacific Region. • Context: Cases reported global mpox outbreak since 2022, categorized West African clade, classified likely Clade IIb unless evidence emerged contrary. review conducted 2024 followed similar search strategy one 2023, main difference extended timeframe. Annex 6. Optimized supportive care measur",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc02c673-9677-459a-ba7f-304a4e6007d7",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "main difference extended timeframe. Annex 6. Optimized supportive care measure Complication Treatment Skin exfoliation • Patients heavy rash burden may develop exfoliation (in severe case similar partial thickness burns), significant leading dehydration protein loss [146] . • Estimate percentage skin affected consider treatment like burns. • Minimize insensible fluid loss promote skin healing. • Ensure adequate hydration nutrition. • Obtain consultation appropriate consultant surgeon, dermatologist and/or wound care specialists. • Bedside surgical debridement needed. • Skin grafting rare severe case Necrotizing soft tissue infection • life-threatening condition deep soft tissue affect muscle fascia cause necrosis, tissue destruction systemic toxicity. Suspect patient develops oedema, crepitus,",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d7392a38-f8a2-47a0-9957-6cccd08d39ba",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "tissue destruction systemic toxicity. Suspect patient develops oedema, crepitus, malodorous discharge pain proportion appearance infection. Though caused mpox virus, consider bacterial pathogen well. Start broad spectrum antibiotic cover Staphylococcus sp . Streptococcus sp. Consult surgeon management. • See Essential Medicines List antibiotic book guidance correct antimicrobial selection appropriate use [192] . Pyomyositis • occurs pu develops within muscle suspected patient muscle tenderness. Though caused mpox virus, may also commonly caused skin flora Staphylococcus sp. Streptococcus sp. [141,192]. Ultrasound assist diagnosis. Collect blood cultures, start broad spectrum antibiotics, proceed surgical incision drainage. Send sample microbiology culture support antimic",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4a01b949-5acf-4457-9a2e-b25c6d8c3be3",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ceed surgical incision drainage. Send sample microbiology culture support antimicrobial therapy selection. • See Essential Medicines List antibiotic book guidance correct antimicrobial selection appropriate use [192] . Cervical adenopathy • occur 85% case lymphadenopathy [33]. • large cervical adenopathy combined multiple oropharyngeal lesion patient may risk complication respiratory compromise retropharyngeal abscesses. Patients also risk dehydration due decreased food water intake [33 ,146]. • Obtain consultation appropriate specialists, surgeon, ENT, anesthesiologist infectious disease clinicians. care, severe cases, steroid may used [33]. Ocular lesion • One significant sequela mpox corneal scarring loss vision [29,85 ,146,63 ,135]. • Patients may present",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "19e67032-1ee9-4691-8217-1bcf6d2a2d65",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "corneal scarring loss vision [29,85 ,146,63 ,135]. • Patients may present non-specific ocular symptom conjunctivitis. • Eye care ophthalmologist evaluation [135] . • Ophthalmic antibiotics/antivirals indicated co-infection. • Vitamin supplementation, especially malnourished child [141] . • Good eye care includes eye lubrication saline -soaked protective eye pad [141] . • Avoid steroid ointment (may prolong presence mpox virus ocular tissue) [146, 193]. • Trifluridine eye drop (sometimes used orthopoxviruses herpetic eye infections) may considered hasten resolution symptom prevent long-term damage scarring, available [146,63,193, 194]. Pneumonia • Manage according Clinical care severe acute respiratory infection toolkit [ 111] . • See Essential Medicines List antibiotic book guidance correct",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "010feb20-fd38-42bd-9424-4d95af485ca7",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "lkit [ 111] . • See Essential Medicines List antibiotic book guidance correct antimicrobial selection appropriate use [192] . Acute respiratory distress syndrome (ARDS) • Oxygen, non-invasive ventilation, mechanical ventilation. • Manage according Clinical care severe acute respiratory infection toolkit [111] . Severe dehydration • Severe dehydration hypovolemic shock seen patient mpox due intravascular volume loss due extensive rash and/or gastrointestinal loss due diarrhoea vomiting accompanied poor oral intake. • treatment severe dehydration resuscitation intravenous intraosseous (IV/IO) fluid, given one multiple bolus close monitoring fluid responsiveness. Adequate IV fluid intake refers volume correct sign hypovolemia. See Pocket book hospital care child [146, 141]. Sepsis septic shock • Seps",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5729545a-382e-4b6c-ae3d-5f7eff8f5126",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "lemia. See Pocket book hospital care child [146, 141]. Sepsis septic shock • Sepsis septic shock differ severe dehydration result immune response infection. Management sepsis requires early identification, management infection supportive care, including fluid resuscitation maintain organ perfusion reduce prevent organ injury; may also require vasopressor well control infection [146] . • See Clinical care severe acute respiratory infection toolkit information sepsis [111] . • See Essential Medicines List antibiotic book guidance correct antimicrobial selection appropriate use [192] . Encephalitis • Consider lumbar puncture cerebrospinal fluid (CSF) evaluation evaluate treatable conditions. • Monitor assess airway, breathing, circulation, disability (ABCD) give emergency tre",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "925f7b0a-41db-4f1d-b4ad-313929f92dd0",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "Monitor assess airway, breathing, circulation, disability (ABCD) give emergency treatments. • Monitor neurological status (AVPU). • Control seizure anti-epileptics [135] . • Antibiotics/antivirals indicated co-infections. • See Essential Medicines List antibiotic book guidance correct antimicrobial selection appropriate use [192] . Nutritional consideration • Assess nutritional status patients. food intake limited due weakness, patient assisted feeding health care provider. patient unable tolerate oral nutrition, consider enteral nutrition. placement nasogastric tube experienced provider could considered along nasogastric feeding. Always ensure proper placement nasogastric tube administering feed avoid r isk aspiration. Paediatric mpox patient diagnosed severe acute malnutrition treated according",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "38216934-4d43-46de-a583-38ddc1c84af6",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "Paediatric mpox patient diagnosed severe acute malnutrition treated according national protocol management severe acute malnutrition. • Take special care patient risk refeeding (critically unwell, low BMI, reduced food intake > 5 days, history alcohol abuse receiving following drugs: insulin, chemotherapy, antacid diuretics) start enteral feeding slowly close monitoring. • Patients reduced level consciousness risk aspiration forced eat. severe malnutrition present, refer published guideline [135 ,141]. Clinical management complication severe form mpox Annex 7. Systematic monitoring patient Vital sign pain assessment Temperature, heart rate, blood pressure, respiratory rate, peripheral oxygen saturation, level consciousness using alert, voice, pain, unresponsive scale (AVPU), point care glucose, body",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ef510a5e-f049-4708-aaf4-4d78ed132837",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "ciousness using alert, voice, pain, unresponsive scale (AVPU), point care glucose, body weight height calculate BMI children’s mid- upper arm circumference (MUAC) Pain scale General condition • patient able eat drink without support? • patient able sit walk independently? • patient recent weight loss since onset symptoms? Rash characterization • Stage rash: macules, papules, vesicles, pustules, crusted over, exfoliation • Location rash (face, arms, torso, genitals, legs, mucosa) • Number lesion [59 ,107]: • Mild (< 25 skin lesions) • Moderate (25 –99 skin lesions) • Severe (100 –250 skin lesions) • severe (> 250 skin lesions) • exfoliation present: % body affected (> 10% concerning) Presence bacterial secondary infection • Cellulitis, abscess, pyomyositis, necrotizing soft tissue infection Neurologic status • AVPU, seizures, coma Volume status • Presenc",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7be88503-c5d9-4e55-a2af-4afea4cae092",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": "otizing soft tissue infection Neurologic status • AVPU, seizures, coma Volume status • Presence dehydration: mild, moderate, severe Signs perfusion • Pulse rate, strength, capillary refill • Urine output (> 0.5 mL/kg/h = good adults; 1.0 mL/kg/h children) • Mottling skin Respiratory system • Respiratory rate, SpO2, sign respiratory distress Nutritional assessment • Change appetite, weight loss, body weight, height, calculation BMI, MUAC child • Signs malnutrition – use standardized tool (e.g. Malnutrition Universal Screening Tool ) Ophthalmologica l examination • One frequent complications, early diagnosis management Laboratory test • Hematology: white blood count, haemoglobin, platelet. Biochemistry: urea, creatinine, ALT, AST, glucose, albumin. Electrolytes: sodium, potassium, bicarbonate, calcium, chloride. Coagulation: prothrombin time/INR. Vital sign clinical feature monitor system",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0f82c1ad-d9f5-4c96-9233-c419fcc333cd",
        "title": "Clinical management and infection prevention and control for mpox",
        "body": ", chloride. Coagulation: prothrombin time/INR. Vital sign clinical feature monitor systematically (Source: table modified Optimized supportive care Ebola virus disease [180] includes information Pocket book hospital care child [141]). 121 Clinical practice guideline influenza World Health Organization Avenue Appia 20 1211 Geneva 27 Switzerland cmtm@who.int",
        "source": "WHO Guidelines: Clinical management and infection prevention and control for mpox.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6766678e-e127-4f3a-983b-0782ab61d20a",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "guideline treatment patient cystic echinococcosisWHO guideline treatment patient cystic echinococcosisWHO guideline treatment patient cystic echinococcosis ISBN 978-92-4-011047-2 (electronic version) ISBN 978-92-4-011048-9 (print version) © World Health Organization 2025 right reserved. work available Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). term licence, may copy, redistribute adapt work non-commercial purposes, provided work appropriately cited, indicated below. use work, suggestion endorses specific organization, product services. use logo permitted. adapt work, must license work equivalent Creative Commons licence. cre",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "07bde541-9550-4fb5-832f-13f7e911987b",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": ", must license work equivalent Creative Commons licence. create translation work, add following disclaimer along suggested citation: “This translation created World Health Organization (WHO). responsible content accuracy translation. original English edition shall binding authentic edition” . mediation relating dispute arising licence shall conducted accordance mediation rule World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. guideline treatment patient cystic echinococcosis. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data available https://iris.who.int/. Sales, right licensing. purchase publications, see https://www.who.int/publications/book",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7931ca1f-5fba-4a47-a214-eba555b8c69e",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "Sales, right licensing. purchase publications, see https://www.who.int/publications/book-orders. submit request commercial use query right licensing, see https://www.who.int/copyright . Third-party materials. wish reuse material work attributed third party, tables, figure images, responsibility determine whether permission needed reuse obtain permission copyright holder. risk claim resulting infringement third-party-owned component work rest solely user. General disclaimers. designation employed presentation material publication imply expression opinion whatsoever part concerning legal status country, territory, city area authorities, concerning delimitation frontier boundaries. Dotted dashed line map represent ap",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "462fadaf-2056-4ce0-be54-86e9660819f9",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "rning delimitation frontier boundaries. Dotted dashed line map represent approximate border line may yet full agreement. mention specific company certain manufacturers’ product imply endorsed recommended preference others similar nature mentioned. Errors omission excepted, name proprietary product distinguished initial capital letters. reasonable precaution taken verify information contained publication. However, published material distributed without warranty kind, either expressed implied. responsibility interpretation use material lie reader. event shall liable damage arising use. Design layout: Anne-Marie Labouche iiiContents Acknowledgements .....................................................................",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "65c0f756-a3f4-4b3c-973c-435506cb1d37",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "iiiContents Acknowledgements ............................................................................................................................................................... iv Abbreviations acronym ............................................................................................................................................... vi Glossary ................................................................................................................................................................................... vii Executive summary ............................................................................................................................................................... viii 1. Introduction .................................................................................................................................... 1 1.1 Background .......................................................................................",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fb413b5f-dd7d-49e6-84bb-7d0ea5c83552",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "Background ................................................................................................................................................................. 1 1.1.1 Epidemiology .................................................................................................................................................... 2 1.1.2 Diagnosis ........................................................................................................................................................... 2 1.1.3 Prevention ......................................................................................................................................................... 2 1.1.4 Treatment .......................................................................................................................................................... 2 1.2 Staging cystic echinococcosis cyst ......................................................................................",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cc2211ac-fef1-4828-88dd-e286c0d9a5b2",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "occosis cyst .................................................................................................................... 2 1.3 Objectives scope guideline .............................................................................................................. 5 1.4 Target audience ........................................................................................................................................................... 5 2. Guideline development process method ................................................................................. 5 2.1 guideline development process .................................................................................................................... 5 2.2 Contributors guideline development process .......................................................................................... 5 2.3 Declarations interest ...................................................................",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "da011cac-a5db-45cb-9e5d-2ff9e192be2e",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "5 2.3 Declarations interest ............................................................................................................................................ 5 2.4 Research question development ............................................................................................................................. 6 2.5 Evidence synthesis assessment ...................................................................................................................... 7 2.6 evidence recommendation ..................................................................................................................... 8 3. Evidence recommendation ...................................................................................................... 11 3.1 Recommendations clinical management uncomplicated hepatic CE cyst according classification ..........................................................................................",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "26d989e3-f05e-4b96-9329-ba78f6862718",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ification .............................................................................................................. 11 3.1.1 Uncomplicated hepatic cyst type CE1 CE3a < 5 cm ............................................................................ 11 3.1.2.Uncomplicated hepatic cyst type CE1 CE3a 5–10 cm ........................................................................ 12 3.1.3 Uncomplicated hepatic cyst type CE1 CE3a > 10 cm ......................................................................... 15 3.1.4 Uncomplicated hepatic cyst type CE2 CE3b ≤ 5 cm ........................................................................... 17 3.1.5 Uncomplicated hepatic cyst type CE2 CE3b > 5 cm ........................................................................... 18 3.1.6 Use praziquantel combined ALB post percutaneous/surgical procedure hepatic cyst type CE1, CE2, CE3a, CE3b .................................................................",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ac38336f-884a-4df0-bd61-77273a7a9356",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ic cyst type CE1, CE2, CE3a, CE3b ........................................................................ 21 3.2 Recommendations clinical management uncomplicated lung CE cyst ...................................... 22 4. Publication, dissemination, monitoring evaluation .................................................................. 24 4.1 Publication dissemination ................................................................................................................................ 24 4.2 Training derivative product ............................................................................................................................. 24 4.3 Essential Medicines List ............................................................................................................................................. 24 4.4 Adaptation ........................................................................................................................",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1c8082a2-d1e8-48e8-b23e-c755390b4a80",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "................................................................................................................................................ 24 4.5 Monitoring evaluating impact guideline ................................................................................ 24 5. Updating ......................................................................................................................................... 25 6. Research priority ........................................................................................................................... 25 References .......................................................................................................................................... 27 Annex. Contributors declaration interest .............................................................................. 29 Web Annex A. Reports systematic review, evidence summary including PICO questions, search strategies, finding",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0e53e286-d9c1-4668-bc76-c2f75302858c",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "t systematic review, evidence summary including PICO questions, search strategies, findings, GRADE tables, risk bias, excluded ongoing study (https://doi.org/10.2471/B09418) Web Annex B. Evidence-to-decision framework (https://doi.org/10.2471/B09415)ivAcknowledgements Global Neglected Tropical Diseases Programme World Health Organization (WHO/NTD) gratefully acknowledges contribution many individual organization development guidelines. Guideline Steering Group member Guideline Steering Group Bernadette Abela (Veterinary Public Health, Environment Vector Control unit (WHO/NTD)), Katrin Bote (Vector Borne Disease Control, Regional Office South-East Asia), Pauline Mwinzi (Expanded Special Project Elimination Neglected Tropical Diseases, Regional Office Africa), Andreas Alois Reis (Health Ethics Governance, WHO/TDR), Pryanka Relan (Health Care Readiness, Country",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "239a2e70-ad76-40fb-86ff-e979a76b3cb4",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "Reis (Health Ethics Governance, WHO/TDR), Pryanka Relan (Health Care Readiness, Country Readiness Strengthening), Teri Reynolds (Clinical Services Systems, Integrated Health Services), Kazim Sanikullah (Malaria Neglected Tropical Diseases, Regional Office Western Pacific), Vaseeharan Sathiyamoorthy (Research Health, Office Chief Scientist), Anthony Solomon (Office Director, WHO/NTD), Marco Vigilato (Zoonotic Diseases Veterinary Public Health, Regional Office Americas), Supriya Warusavithana (WHO Regional Office Eastern Mediterranean), Aya Yajima (WHO Regional Office South-East Asia). Guideline Development Group Guideline Development Group (GDG) chaired Timothy Pennel (University Cape Town Groote Schuur Hospital, South Africa) followed Peter Chiodini (Hospital Tropical Diseases London School Hygiene & Tropical Medicine, United Kingdom Great Britain Northern",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7d569a9f-d644-45f5-9383-6f4622c82915",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "as London School Hygiene & Tropical Medicine, United Kingdom Great Britain Northern Ireland) co-chaired Priscilla Rupali (Christian Medical College, Vellore, India). GDG member Okan Akhan (Hacettepe University Ankara, Türkiye), Jaime Altcheh (Ricardo Gutierrez Children’s Hospital, Multidisciplinary Institute Research Paediatric Pathologies (IMIP) CONICET , Buenos Aires, Argentina), Mohammad Sayed Behrad (Ghalib University Medical Science Faculty, Kabul, Afghanistan), Mustapha Benazzouz (Medical School, Rabat International University, Rabat-Salé, Morocco), Bolor Bold (Chinese Centre Tropical Diseases Research National Center Zoonotic Disease, Mongolia), Enrico Brunetti (University Pavia San Matteo Hospital Foundation, Italy), Peter Chiodini (Hospital Tropical Diseases London School Hygiene & Tropical Medicine, United Kingdom Great Britain Northern Ireland), Christina Coyle (Jacobi Medical Cen",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2d4a03bd-7acc-4e7b-a2f2-e67dacde3209",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "edicine, United Kingdom Great Britain Northern Ireland), Christina Coyle (Jacobi Medical Center Tropical Medicine Clinic Bronx Albert Einstein College Medicine, United States America), John Horton (Medical Practitioner, United Kingdom Great Britain Northern Ireland), Thomas Junghanss (Heidelberg University Hospital, Germany), Suneetha Narreddy (Apollo Health City Campus, Jubilee Hills, Hyderabad, India), Timothy Charles Pennel (University Cape Town Groote Schuur Hospital, South Africa), Marija Stojkovic (Heidelberg University Hospital, Germany), Francesca Tamarozzi (IRCCS Sacro Cuore Calabria Hospital, Negrar di Valpolicella, Verona, Italy), Leonardo Uchiumi (Ministry Health Rio Negro Province, Argentina), Ning Xiao (National Institute Parasitic Diseases National Center Tropical Diseases Research Chinese Center Disease Control Prevention, China). External Review Group following expert reviewed dra",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ab9e5345-6e4b-4eab-97de-f6000e21d485",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ease Control Prevention, China). External Review Group following expert reviewed draft guideline document provided valuable input: Karima Achour (University Hospital Lamine, Algeria), David Addiss (The Task Force Global Health, United States America), Moncef Belhassen Garcia (University Salamanca, Spain), Adriano Casulli (WHO Collaborating Centre Epidemiology, Detection Control Cystic Alveolar Echinococcosis, Italy), María Celina Elissondo (National Scientific Technical Research Council, Argentina), Majid Fasihi Harandi (Research Center vHydatid Disease, Kerman University Medical Sciences (KMU), Islamic Republic Iran), Ismailova Gulziya (Al- Farabi Kazakh National University, Kazakhstan), Jorge Gustavo Hernandez Cordova (Technological University Peru), Michael G. Kawooya (Mengo Hospital, Uganda), Rogelio López-Vélez (Hospital Ramón Cajal, Spain), Tommaso Manciulli (University Florence, Italy), Athman Mwato",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2d9973f8-61a4-4bcc-88bf-879b4505eafb",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ez (Hospital Ramón Cajal, Spain), Tommaso Manciulli (University Florence, Italy), Athman Mwatondo (Ministry Health, Kenya), Michael Ramharter (University Medical Centre Hamburg-Eppendorf Bernhard Nocht Institute Tropical Medicine, Germany), Peter Sauer (University Heidelberg, Germany), Kamenna Vutova (Medical University Sofia, Bulgaria), Tim Weber (Heidelberg University Hospital, Germany). Systematic Review Team following researcher conducted systematic review developed evidence profile GRADE (Grading Recommendations Assessment, Development Evaluation) tables: Rebecca Kuehn, Vittoria Lutje Paul Garner Systematic Review Production Management Team, Cochrane Infectious Diseases Group, Liverpool School Tropical Medicine, United Kingdom Great Britain Northern Ireland. Guideline methodologist Priscilla Rupali (Christian Medical College, Vellore, India) Writing team Meritxell Donadeu (WHO Consultant, Austra",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "02a2a45b-15fa-4a69-ab78-2ac1ff6bda81",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "(Christian Medical College, Vellore, India) Writing team Meritxell Donadeu (WHO Consultant, Australia); Bernadette Abela Katie Corridan (WHO/NTD); Priscilla Rupali, Hanna Alexander Jisha Sara John (Christian Medical College, Vellore, India); Rebecca Kuehn Paul Garner (Liverpool School Tropical Medicine, United Kingdom Great Britain Northern Ireland). Funding source Funding guideline provided WHO/NTD.viAbbreviations acronym ALB albendazole CE cystic echinococcosis CT computed tomography EtD evidence decision GDG Guideline Development Group GRADE Grading Recommendations Assessment, Development Evaluation ICU intensive care unit Mo-CAT modified catheterization technique MRCP magnetic resonance cholangiopancreatography MRI magnetic resonance imaging NTD neglected tropical disease PAIR Puncture, Aspiration, Injection, Re-aspiration PICO population, intervention, comparator, outcome PCR polymerase chain reaction RCT randomized",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "122e143f-9e24-4bc9-991c-2edf9094587d",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "PICO population, intervention, comparator, outcome PCR polymerase chain reaction RCT randomized controlled trial S-CAT standard catheterization World Health Organization WHO-IWGE Informal Working Group Echinococcosis viiGlossary definition given apply term used document. may different meaning contexts. active cyst Cysts biologically viable, evidenced integrity cyst wall layer presence cyst fluid cavities. complicated cyst cyst complication might include rupture (outside, internally structure infected organ); cyst causing clinically significant compression internal structure infected organ neighbouring organs, superinfection cyst bacteria fungi; anaphylactic reaction echinococcal antigen due loss integrity cyst wall. example, complicated hepatic cyst might present infection, rupture",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8008696f-14e8-415a-8686-98e2d55f0d04",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "grity cyst wall. example, complicated hepatic cyst might present infection, rupture abdominal cavity, fistula biliary tree migration thorax (pleura lung). complicated echinococcal lung cyst cyst ruptured bronchus pleural cavity, cyst infected. cystic echinococcosis Disease due E. granulosus sensu lato. fertile cyst Active cyst contain viable protoscoleces. health tier category treatment option patient CE depend capacity health facility deliver particular treatment option safely. Guideline Development Group defined surgical, radiological laboratory infrastructure well technical expertise required option part guideline process, defining four health tier category described Table 2. recommendation linked health tiers. inactive cyst Cysts biologically inactive (i.e. producing",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "41e66e19-3c44-49a5-a7d8-9254e6a07dd9",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "inked health tiers. inactive cyst Cysts biologically inactive (i.e. producing hydatid fluid). Inactive cyst solid content unlikely fertile. Egg-shell calcification cyst wall, complete calcification inactive (i.e. solid) cyst likely indicates non-viable cyst. modified catheterization technique (Mo-CAT) Procedure treatment CE cyst consists percutaneous placement catheter removal laminated germinal layer content, including daughter cyst present. non-radical surgery (in relation CE)Partial cystectomy. Surgical intervention remove content cyst (laminated germinal layer, cyst fluid, protoscoleces daughter cyst present) partially remove host tissue adventitial layer CE cyst. type surgery also includes “subtotal cystectomy” nearly total cystectomy incomplete removal adventitial layer",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "95bc0334-e0dd-4c43-9027-e3a52470786f",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "btotal cystectomy” nearly total cystectomy incomplete removal adventitial layer CE cyst. Puncture, Aspiration, Injection, Re-aspiration (PAIR)Minimally invasive therapeutic percutaneous drainage echinococcal cyst located liver abdominal location aim destroy germinal layer. involves: (i) percutaneous puncture cyst using ultrasonographic guidance, (ii) aspiration cyst fluid, (iii) injection protoscolecidal agent 10–20 min (iv) re-aspiration fluid (1). radical surgery (in relation CE) Total cystectomy. Complete removal CE cyst, including content (fluid, protoscoleces daughter cyst present) layer cyst (germinal laminated parasite layer host tissue adventitial layers). reactivation Appearance daughter cyst(s) solid matrix spontaneously inactivated CE4 cyst show evolution towards CE3b stage. recurrence Appearance ac",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2c83e838-3092-4a63-8834-fa912ee411ec",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "inactivated CE4 cyst show evolution towards CE3b stage. recurrence Appearance active CE cyst (stages CE1–3) location treated cyst located, independent type previous treatment. standard catheterization (S-CAT) Modification PAIR technique treatment selected CE cysts; includes insertion catheter, whether temporarily left cyst (2 ). uncomplicated cyst Cysts without complication (see complicated cyst). viable (metacestode, germinal layer, cyst, protoscoleces)Parasitic structure metacestode contains living cell able proliferate appropriate conditions. viiiExecutive summary Rationale target audience purpose document provide technical guidance treatment patient cystic echinococcosis (CE). aim ensure patient subjected unnecessary invasive procedures; procedure recommended",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9f211632-262a-4517-b545-66c85f6c364c",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ients subjected unnecessary invasive procedures; procedure recommended provided context infrastructure expertise sufficient ensure done safely. guideline intended clinicians, health facility manager health practitioner different level health service resource level (low, middle- high-income countries) provide care patient CE. also relevance health care policy-makers, health system administrator implementors neglected tropical disease (NTD) programmes. guideline cover liver lung CE cysts. liver CE cysts, guideline confined choice uncomplicated liver cysts. complicated CE liver cysts, expert opinion usually use open surgery service medical expertise carry safely. Pulmonary CE usually managed surgically; guideline evaluate treatment small (≤ 5 cm) lung cys",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "32404cc3-2f39-44a5-a5c7-f38f3da862ec",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "CE usually managed surgically; guideline evaluate treatment small (≤ 5 cm) lung cysts. Methods guideline developed accordance WHO’s procedure guideline development.1 process included developing algorithm help identify 11 priority question set using population, intervention, comparator, outcome (PICO) framework; retrieving evidence systematic review team; assessing synthesizing evidence using standard Cochrane “Risk Bias” tool, Review Manager (RevMan) software assess data, GRADE evidence profile system assess certainty evidence. Guideline Development Group (GDG) defined health service requirement various procedures, “tiers” , based technical expertise, laboratory capacity, radiological equipment surgical infrastructure formulate tier-specific recommendations. made sense so, assessment one PICO",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "430a8219-3e66-480c-8295-d893572b7a63",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "e tier-specific recommendations. made sense so, assessment one PICO question used produce recommendation. Summary recommendation Overall, comparative reliable research treatment option absent, decision based discussion expert develop consensus. guideline include seven new conditional recommendation corresponding research evidence assessed low certainty. cyst stage described section 1.2 Fig. 3. 1 guideline document, whatever title, containing recommendation health interventions, whether clinical, public health policy interventions. standard guideline produced response request guidance relation change practice, controversy single clinical policy area; expected cover full scope condition public health problem. recommendation provides information polic",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "147274fb-2008-4cc2-86ed-2a3b862e82ff",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "e condition public health problem. recommendation provides information policy-makers, health-care provider patient do; implies choice different intervention impact public health ramification use resources. publication containing recommendation approved Guideline Review Committee. ix ▶ Recommendations clinical management uncomplicated hepatic CE cyst according classification. Uncomplicated hepatic cysts: type CE1 CE3a < 5 cmRecommendation 1: patient uncomplicated hepatic cyst type CE1 CE3a < 5 cm, treatment albendazole (ALB) suggested. recommendation applicable tier. Conditional recommendation low certainty evidence. Uncomplicated hepatic cysts: type CE1 CE3a 5–10 cmRecommendation 2: patient uncomplicated hepatic cyst type CE1 CE3a 5–10 cm, PAIR (Puncture, Aspiration,",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2c485a53-9fdd-41bc-92c6-3b2022d7048b",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "n patient uncomplicated hepatic cyst type CE1 CE3a 5–10 cm, PAIR (Puncture, Aspiration, Injection, Re-aspiration) combined ALB suggested. PAIR used biliary communication present. recommendation requires tier 3 tier 4 settings. Conditional recommendation low certainty evidence. Uncomplicated hepatic cysts: type CE1 CE3a > 10 cmRecommendation 3: patient uncomplicated hepatic cyst type CE1 CE3a > 10 cm, percutaneous treatment combined ALB suggested. PAIR suggested rather standard catheterization surgery. PAIR used biliary communication present. recommendation requires tier 3 tier 4 settings. Conditional recommendation low certainty evidence (where relevant research), expert consensus (where relevant research). Uncomplicated hepatic cysts: type CE2 CE3b ≤ 5 cmRecommendation 4: patient uncomplicated hepatic cy",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a512ea64-6f8f-4ce9-9e27-13428962dc93",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "hepatic cysts: type CE2 CE3b ≤ 5 cmRecommendation 4: patient uncomplicated hepatic cyst type CE2 CE3b ≤ 5 cm, initial treatment ALB alone suggested. recommendation applicable tier. Conditional recommendation based expert consensus. Uncomplicated hepatic cysts: type CE2 CE3b > 5 cmRecommendation 5: patient uncomplicated hepatic cyst type CE2 CE3b > 5 cm, surgery combined ALB suggested. open surgery (in tier 2–4) laparoscopy (in tier 3–4). Conditional recommendation low certainty evidence (where relevant research), expert consensus (where relevant research). Use praziquantel combined ALB post-percutaneous/ surgical procedure hepatic cyst type CE1, CE2, CE3a, CE3bRecommendation 6: CE patient undergoing percutaneous surgical interventions, spillage suspected occurred, combination praziquantel ALB suggested. C",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "262f0f7d-e695-48a0-995e-66c48b3658df",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "spillage suspected occurred, combination praziquantel ALB suggested. Conditional recommendation based expert consensus.WHO guideline treatment patient cystic echinococcosisx ▶ Recommendations clinical management uncomplicated lung CE cyst < 5 cm Uncomplicated lung CE cyst ≤ 5 cmRecommendation 7: patient uncomplicated active lung CE cyst < 5 cm, surgery suggested. ALB given surgery. spillage suspected occurred, ALB surgery suggested. Lung surgery requires tier 4 settings. Conditional recommendation based expert consensus. Fig. 1. Algorithm first-line treatment uncomplicated liver CE cyst according different health tier based health provider resource capability Patients multiple hepatic cysts, hepatic cyst different stages, two organ involved (multi-organ involvement) require individualized manageme",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2cfff2df-9b1f-4457-99b4-c91a811361c4",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "two organ involved (multi-organ involvement) require individualized management. Fig. 1 summarizes recommendation first-line treatment uncomplicated hepatic cysts, relating tier specified recommendation option. Uncomplicated inactive cyst covered guidelines. Current practice “watch wait” , is, follow-up imaging (ultrasonography MRI). Surgery avoided far possible unless inactive cyst causing complication (e.g. cyst causing portal hypertension). Footnotes: Tiers (for full detail see Table 2, p.7): Tier 1: Medical doctor, basic laboratory capacity, ultrasound referral availability. Tier 2: Tier 1 plus general surgeon, anaesthetic operating theatre capacity, on-site ultrasonography. Tier 3: Tier 2 plus laparoscopic surgeon, physician trained PAIR, S-CAT , CT fluoroscopy capacity. Tier 4: Tier 3 plus thoracic surgery interventional radio",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e97af42e-5478-4a42-9b58-130d2158e1c5",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": ", S-CAT , CT fluoroscopy capacity. Tier 4: Tier 3 plus thoracic surgery interventional radiology capacity, MRI MRCP capacity, advanced laboratory capacity.Key: ALB: Albendazole PAIR: Puncture, Aspiration, Injection, Re-aspiration S-CAT: Standard Catheterization Diagnosis uncomplicated liver cystic echinoccocosisActive (CE1/CE2/ CE3a/CE3b) Inactive (CE4/CE5)CE1/ CE3a< 5 cm < 5 cm CE2/ CE3b> 5 cm < 10 cm > 10 cm > 5 cm Multiple cyst stagesFirst-line treatment recommendation Tier 1 Tier 2 Tier 3 Tier 4 ALB Refer Tier 3 4 PAIR ALB Refer Tier 3 4Percutaneous treatment ALB (PAIR preferred S-CAT) ALB Refer Tier 2 3 4Surgery ALB (open laparoscopy) Monitoring imaging («watch wait») Management recommendation individualized 11. Introduction 1.1 Background Human echinococcosis part parasitic disease group includes cystic echinococcosis (CE) caused Echinococcus granulosus sensu lato (s.l.),",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0007640c-822c-4290-a92b-475d0f0c7ada",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "oup includes cystic echinococcosis (CE) caused Echinococcus granulosus sensu lato (s.l.), alveolar echinococcosis (AE) caused E. multilocularis, neotropical echinococcosis caused E. oligarthrus E. vogeli. disease greatest relevance human health CE AE. guideline refer CE. E. granulosus s.l. genetically complex, involving numerous specie genotypes, cause infection humans. Two specie E. granulosus s.l. responsible almost recorded CE human infection (3): E. granulosus sensu stricto (s.s.; G1, G3) E. canadensis (G6, G7). guideline refer E. granulosus infections, convincing evidence different treatment strategy based infecting species. life cycle E. granulosus s.l. involves two animal host (Fig. 2): carnivorous definitive host (typically canids, mainly dogs) intermediate host (typically livestock, mainly sheep, although",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "79fd8cfb-e770-49c8-9939-822df7dbd088",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "canids, mainly dogs) intermediate host (typically livestock, mainly sheep, although animal cattle, goats, camels, yaks, pig wild herbivore also infected). Humans become infected accidentally ingesting parasite egg faeces infected definitive host. adult tapeworm (measuring 7 mm) resides definitive host’s small intestine, producing microscopic egg excreted faeces. egg contaminate environment (soil, grass, vegetables, water) ingested intermediate hosts, leading larval (hydatid metacestode echinococcal cysts) development body organs. Transmission definitive host occurs ingest infected intermediate host tissue containing fertile cyst (those containing viable protoscoleces), resulting development adult tapeworm (4). Human infection E. granulosus s.l. lead development one CE cyst located often live",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "17266617-2666-4cfa-9abf-09efcd39a001",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "E. granulosus s.l. lead development one CE cyst located often liver lungs, less frequently bones, kidneys, spleen, muscles, heart, central nervous system virtually body location. cyst may may fertile (contain protoscoleces). Larger cyst may develop secondary (daughter) cyst internal primary cyst. impact infection varies number, location size cyst and, symptomatic, manifest commonly pain compromised organ function, worsening cyst enlarge. asymptomatic incubation period last many months, year even lifelong, CE cyst grow extent trigger symptom signs. Untreated cyst might pose risk rupture, result severe complication anaphylactic shock, disseminated infection mortality. Intermediate host (larval stages)Deﬁnitive host (adult tapeworm) Cystic echinococcosisE. granulos",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cd80f8be-a49f-414a-b40a-6fc9b1d9b028",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "Intermediate host (larval stages)Deﬁnitive host (adult tapeworm) Cystic echinococcosisE. granulosus Fig. 2. Life cycle Echinococcus granulosus sensu latoINTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis2ntroduction1.1.1 Epidemiology CE represents substantial disease burden, especially pastoral rural community low-income upper-middle-income countries. significant public health problem large pastoral area South America, North Africa, Eastern mediterranean Europe, Middle East, Central Asia, Russian Federation China (5). Consistently, highest prevalence found among population involved sheep raising people close contact shepherd dogs. 1.1.2 Diagnosis diagnosis CE based imaging techniques, pri",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "220c5355-7cbb-4c52-bb73-2981f295542a",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "shepherd dogs. 1.1.2 Diagnosis diagnosis CE based imaging techniques, primarily ultrasound magnetic resonance imaging (MRI), computed tomography (CT) less reliable (6), complemented serology imaging conclusive. Contrast-enhancement imaging allows excluding CE diagnosis case cyst take contrast. antigen detection test commercially available. Antibody detecting serological test complement imaging findings, yet limitation warrant careful consideration. case sero-negativity, confirming presumptive diagnosis might involve demonstrating presence protoscoleces and/or hook microscopic examination cyst fluid, histology, polymerase chain reaction (PCR) cyst material (7) observation change cyst ultrasound appearance treatment, detachment parasite layer unilocular cyst (suspected CE1) percutaneous puncture administration ALB. Cu",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a7dd67c8-3c8b-4c36-95a2-6dfca01c6b4d",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "er unilocular cyst (suspected CE1) percutaneous puncture administration ALB. Currently, guideline diagnostic CE, identified key research priority (section 6). 1.1.3 Prevention main tool prevention transmission regular deworming dog praziquantel, vaccination sheep EG95 vaccine (8). Infected livestock organ disposed safely fed dog canids. Strategies prevention infection human include proper sanitation hygiene practices, emphasizing thorough handwashing contact dogs, faeces soil contaminated parasite’s eggs. at-risk areas, important wash vegetable eaten raw use safe water. 1.1.4 Treatment CE patient require treatment, require invasive treatment. Inappropriate treatment may lead iatrogenic complications. Howeve",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "947646ec-5ac0-42b7-8379-192a51a9d792",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "require invasive treatment. Inappropriate treatment may lead iatrogenic complications. However, CE may result severe complication disabling even life-threatening left untreated. suboptimal late treatment, patient often face reduced quality life. CE invariably expensive complicated treat, sometimes requiring extensive surgery and/or prolonged drug therapy. several option clinical management CE: (i) antiparasitic drug treatment; (ii) percutaneous treatment CE cyst PAIR (Puncture, Aspiration, Injection, Re-aspiration) technique, standard catheterization (S-CAT) modified catheterization technique (Mo-CAT); (iii) surgery; (iv) “watch wait” approach. clinical management approach primarily guided assessment sign symptom patient presentation involves patient factor age comorbidities, access health infrastructures. treatm",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0664b28c-2dbc-4277-b101-7cb2ddb3ca06",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "f patient factor age comorbidities, access health infrastructures. treatment choice uncomplicated CE primarily based imaging characteristic cyst, following stage-specific approach (when applicable), health care infrastructure human resource available (9). 1.2 Staging cystic echinococcosis cyst appropriateness various option treatment patient hepatic CE depends stage development parasitic cyst. Cyst stage first classified ultrasound imaging Gharbi et al (10) relation liver cysts, later modified Informal Working Group Echinococcosis (WHO-IWGE) described Brunetti et al (9). classification per se applies cyst describes morphology (except osseous CE, Introduction 3has infiltrative morphology, classification apply here). However, stage-specific treatment approach relates",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "eb2a7a76-3afc-4ae6-a41d-cad58925c331",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "classification apply here). However, stage-specific treatment approach relates hepatic CE necessarily apply locations. WHO-IWGE Imaging sub-panel, provided updated definition guidelines. comprise following stage (Fig. 3): Active cysts, likely contain viable protoscoleces: CE1. Active, unilocular, liquid contentWell-defined univesicular cyst, round oval shape, anechoic content, posterior acoustic enhancement, without low intensity floating echo upon decubitus change (moving “hydatid sand”) visible pathognomonic “double wall sign” consisting inner hyperechoic laminated layer outer hypoechoic adventitial layer. CE2. Active, multivesicular, liquid contentWell-defined multivesicular cyst, round oval shape, posterior acoustic enhancement, one daughter cyst filling part completely fluid-filled cyst; pathognomonic “honeycomb” appearance p",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8b3d48df-76a7-497a-aaaa-f766eca96759",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "filling part completely fluid-filled cyst; pathognomonic “honeycomb” appearance provided thin, regular, continuous avascular clearly distinguishable adjacent wall juxtaposed daughter cyst (giving septated appearance), without solid content. CE3a. Transitional unilocular, liquid content detached parasitic layersWell-defined univesicular cyst round oval shape, posterior acoustic enhancement, partial complete detachment laminated layer, visible hyperechoic thin regular layer floating anechoic cyst content, giving pathognomonic appearance, referred “water lily sign” . whole layer must identified continuous hyperechogenic structure, different views. Low-intensity floating echo upon decubitus change (moving “hydatid sand”) may present. CE3b. Active multivesicular cyst, partially solid content daughter cyst Well-defined multivesicular cyst round",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ac832dee-da29-4094-a3fb-a611d2008fc5",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "yst, partially solid content daughter cyst Well-defined multivesicular cyst round oval shape, posterior acoustic enhancement, heterogeneous structure, encompassing avascular solid component hypoechoic folded structure deriving degenerating layer one round daughter cyst anechoic content, giving pathognomonic “Swiss cheese” appearance. Inactive stages: CE4. Solid contentWell-defined round oval mass without posterior acoustic enhancement heterogeneous avascular solid content formed degenerated cyst layers, hypoechoic folded structure deriving degenerating layer mass giving pathognomonic “ball wool” “canalicular” “cerebroid” appearance. Unlikely contain viable protoscoleces. CE5. Solid content eggshell calcified wallWell-defined round oval mass posterior acoustic shadow deriving complete nearly complete egg-shell calcified wall,",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a30bc50e-5c2d-4df6-8b1d-7834baeb4245",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "h posterior acoustic shadow deriving complete nearly complete egg-shell calcified wall, heterogeneous avascular solid content (when acoustic shadow allows visualization) formed degenerated cyst layer hypoechoic folded structure deriving degenerating layer mass giving pathognomonic “ball wool” or” canalicular” appearance. Non-viable. NB: CE cyst stage show wall calcification, feature, per se, indicate viability non-viability cyst. WHO-IWGE Expert Consensus document (9) also included “cystic lesion (CL)” cyst. CL CE stage indicates cyst could suspected young echinococcal cyst. CL described unilocular cyst anechoic content, without double wall sign, evident sign non-parasitic aetiology (e.g. clear feature biliary cyst). serological and/or epidemiological criterion apply, suspected CE case. etiological diagnosis",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f8676323-1347-406c-8890-5f41afd54e94",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "al and/or epidemiological criterion apply, suspected CE case. etiological diagnosis CL cyst (CE biliary cyst) necessitates diagnostic step (11-13). INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis4Ultrasound imageParticulars pathognomonic signStage ViabilitybCystic echinococcal cyst CE1 Viable CE2 Viable CE3aViable non-viable CE3b Viable CE4Low viability non-viable CE5 Non-viableSuspected CL Fig. 3. Classification CE cyst description CLa (suspected case CE) CL: Cystic lesion visible pathognomonic feature E. granulosus s.l. aetiology. serological and/or epidemiological criterion apply, SUSPECTED CE case. diagnostic step required. b Viability refers metacestode containing living cell able",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ac31b0e8-cf1b-4434-ac26-b51feefd6a47",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "diagnostic step required. b Viability refers metacestode containing living cell able proliferate appropriate conditions. imply fertility (i.e. presence protoscoleces cyst, may cause secondary CE upon dissemination). © Francesca TamarozziIntroduction 51.3 Objectives scope guideline purpose guideline provide guidance choice treatment patient (adults children) CE cyst offered receive appropriate equitable treatment. aim ensure patient receive appropriate affordable management context infrastructure expertise sufficient ensure safety, without unnecessary invasive procedure treatment, avoid iatrogenic complication using invasive interventions. complicated CE liver cysts, surgery usually treatment choice, based best medical practice conveyed WHO-IWGE (9). guideline",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f9c64748-792e-4e07-8389-eac8045643a8",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "reatment choice, based best medical practice conveyed WHO-IWGE (9). guideline focused different choice uncomplicated liver cysts. Pulmonary CE usually managed surgical intervention, guideline evaluate option using ALB alone treat small pulmonary cysts. uncomplicated inactive cysts, recommendation guideline since current best medical practice follow-up imaging (ultrasonography, CT MRI), also known “watch wait” approach (9, 14). Surgery avoided far possible unless inactive cyst causing complication (e.g. cyst causing portal hypertension). 1.4 Target audience guideline developed clinicians, health facility manager health practitioner practising level health service (primary, secondary tertiary health care) resource level (low, middle- high-income countries) provide care patient w",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6bdada98-5235-448d-a503-f194bf3afa0f",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "nd resource level (low, middle- high-income countries) provide care patient CE. also developed inform health care policy-makers, health system administrators, insurance company NTD programme implementors. 2. Guideline development process method 2.1 guideline development process guideline developed accordance handbook guideline development (15) international standard generating evidence-based guidelines. process included: • identifying priority question using population, intervention, comparator outcome (PICO) framework; • retrieving evidence systematic review team; • assessing synthesizing evidence; • developing recommendations. 2.2 Contributors guideline development process contributor guideline include Guideline Steering Group, Systematic Review Team, Guideline Development Group (GDG), External",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0c06d0ac-b381-4953-aecb-d38da7608b21",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ne Steering Group, Systematic Review Team, Guideline Development Group (GDG), External Review Group Guideline Review Committee. GDG consisted 17 members, 11 male 6 female, representing different region world endemic CE. include patient representatives. 2.3 Declarations interest member GDG, non-WHO staff participating meeting guideline development external peer reviewer required submit Declarations Interest form confidentiality statement secretariat. reviewing declarations, secretariat Steering Group concluded conflict interest sufficient preclude member participating guideline development process.INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1605c24c-2eab-409a-93fc-d6231a7791b7",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "FERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis6The name affiliation contributor guideline confirmation absence significant conflict interest listed Annex document. 2.4 Research question development consultation discussion within GDG Systematic Review Team, 11 PICO question developed concerning area equipoise treatment people uncomplicated hepatic pulmonary CE. PICO question summarized Table 1, detailed PICO question included Web Annex A. Question development employed expert knowledge literature review relevant evidence, mapped clinical pathway algorithm identify area variation practice. methodology algorithm included Web Annex A. Table 1. PICO question used develop guideline (the element",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d83415a2-408c-4d75-87ee-019a1a08a63c",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "uded Web Annex A. Table 1. PICO question used develop guideline (the element PICO question included Web Annex A) Research (PICO) question P1 treating uncomplicated hepatic cyst type CE1 CE3a < 5 cm, PAIR combined ALB effective safe ALB alone? P2For treating uncomplicated hepatic cyst type CE1 CE3a 5–10 cm, PAIR combined ALB effective safe ALB alone? P3For treating uncomplicated hepatic cyst type CE1 CE3a 5–10 cm, surgery combined ALB effective safe PAIR combined ALB? P4For treating uncomplicated hepatic cyst type CE1 CE3a > 10 cm, standard catheterization combined ALB effective safe PAIR combined ALB? P5For treating uncomplicated hepatic cyst type CE1 CE3a > 10 cm, standard catheterization combined ALB effective safe compared surgery combined ALB? P6For treating uncomplicated hepatic cyst type CE2 CE3b ≤ 5 cm, su",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f88c89f4-8396-428d-9855-dd2d163b9056",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "surgery combined ALB? P6For treating uncomplicated hepatic cyst type CE2 CE3b ≤ 5 cm, surgery combined ALB effective safe ALB alone? P7For treating uncomplicated hepatic cyst type CE2 CE3b 5–10 cm, surgery combined ALB effective safe ALB alone? P8For treating uncomplicated hepatic cyst type CE2 CE3b size, laparoscopic surgery combined ALB effective safe open surgery combined ALB? P9For treating uncomplicated hepatic cyst type CE2 CE3b size, modified catheterization technique (Mo-CAT) combined ALB effective safe surgery combined ALB? P10Is praziquantel combined ALB effective safe ALB alone treating active cyst (cyst type CE1, CE2 CE3a, CE3b) given pre- post- percutaneous surgical interventions? P11For treating uncomplicated lung CE cyst ≤ 5 cm, ALB effective safe surgery combined ALB? GDG cognisant",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d4168b7e-1433-47a4-a2f2-8a24dcb10858",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ysts ≤ 5 cm, ALB effective safe surgery combined ALB? GDG cognisant safe delivery optimal treatment would depend available health care professional expertise health care facility resource (laboratory capacity, radiological equipment surgical infrastructure). GDG first examined health system classification, including Universal Health Coverage Service Planning Delivery & Implementation (SPDI) platform. SPDI platform provided overarching framework, treatment option CE specific requirement term health care professional Guideline development process method 7expertise health care resources. GDG developed health system tiers. required several meeting broader correspondence come consensus. treatment option mapped tier considered sufficient expertise resource deliver treatment option safely. tier wer",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ba3a9ee0-24b2-46eb-8468-85f7cfb117b4",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ed sufficient expertise resource deliver treatment option safely. tier categorized four, ranging least sophisticated (tier 1) sophisticated well-resourced category (tier 4). tier based health provider resource account patient’s financial resources, health insurance accessibility. tier mapped research question. tier described Table 2. Table 2. Health care system tier managing different treatment option CE, according available expertise resource TierHealth care worker technical expertise requiredSurgical infrastructure requiredRadiological capacity requiredLaboratory requiredIntervention(s) possible Tier 1 Medical doctor available Referral access ultrasonographyAccess facility complete blood cell count, liver function tests.Albendazole Tier 2General surgeon Anaesthesiologist Nursing careOperating theatre",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c52fdf37-e1c7-45a9-b27b-0519dcea507c",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "r function tests.Albendazole Tier 2General surgeon Anaesthesiologist Nursing careOperating theatre Inpatient facility monitoringUltrasound siteLaboratory test needed anaesthesia Tier 1 Surgery (non- radical only) Tier 3 (includes expertise facility available tier 2)Surgeon laparoscopic skill surgeon, radiologist physician relevant speciality trained PAIR S-CATGeneral surgery laparoscopic surgery facility Inpatient facility monitoring access ICUCT scan Fluoroscopy Laboratory test needed anaesthesiaTier 2 Surgery (radical non- radical) Laparoscopic Surgery PAIR Standard catheterization Tier 4 (includes expertise facility available tier 3)General laparoscopic surgeon Interventional Radiologists Thoracic SurgeonInterventional Radiology Facilities Procedure RoomMRI MRCPRoutine clinical pathology, biochemistry microbiologyTier 3 Modi",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0eb5f480-868c-4b5f-86de-e84a28456252",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "rocedure RoomMRI MRCPRoutine clinical pathology, biochemistry microbiologyTier 3 Modified Catheterization Technique Thoracic (lung) surgery CT: computed tomography, PAIR: Puncture-Aspiration-Injection-Re-aspiration, ICU: Intensive care unit, MRCP: Magnetic resonance cholangiopancreatography, MRI: Magnetic resonance imaging, S-CAT: Standard catheterization. 2.5 Evidence synthesis assessment Details literature search, including search strategies, study selection process results, given Web Annex A; also identifies study excluded, reason exclusion. outcome assessed inactivity cyst > 12 months, change symptoms, cyst recurrence, secondary dissemination, complication due disease progression, complication due intervention, duration hospital admission death within 28 days. Data extraction conducted Systematic Review Team, including characteristic study popula",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8d6089c6-cc79-439d-b06d-cabc1380c30c",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "traction conducted Systematic Review Team, including characteristic study population, intervention, comparator, outcomes. team conducted risk bias analysis using standard Cochrane Collaboration's “Risk Bias” tool (16). summary risk bias assessment INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis8of included study included Web Annex B. Data analysed using pair-wise comparison research question using Review Manager (RevMan) software Cochrane (17). GRADE (Grading Recommendations, Assessment, Development Evaluations) evidence profile system assessing certainty evidence applied recommended Cochrane handbook systematic review intervention (18). GRADE four level",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3a3d3c1e-7a96-4ce9-b977-9b251e5329b8",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ded Cochrane handbook systematic review intervention (18). GRADE four level evidence, also known certainty evidence: low, low, moderate high (Table 3). research evidence identified, expert consensus used formulate recommendation within evidence-to-decision framework (as explained below). Table 3. Certainty evidence used GRADE interpretation Certainty evidenceWhat mean High confident true effect lie close estimate effect. ModerateWe moderately confident effect estimate: true effect likely close estimate effect, possibility substantially different. LowOur confidence effect estimate limited: true effect may substantially different estimate effect. lowWe little confidence effect estimate: true effect likely substantially different fro",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cb644c9d-e123-4ccd-b749-6aacfb3cf584",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ttle confidence effect estimate: true effect likely substantially different estimate effect. Source: handbook guideline development (15). 2.6 evidence recommendation Evidence-to-decision framework used produce recommendation produced PICO question. included following criteria: benefit harm (desirable undesirable effects); certainty evidence effects, value preferences; balance effects; resource required; certainty evidence required resources; cost effectiveness; health equity; acceptability; feasibility. patient value preferences, qualitative literature review interview care provider people CE undertaken provide insight patient treatment preference (summary available Web Annex A). Evidence-to-decision evaluation summary judgement PICO question available Web Annex B.",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1fe5826d-a47c-4a40-910f-e552397944ca",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "valuation summary judgement PICO question available Web Annex B. recommendations, one PICO question used. Strength interpretation recommendation two type recommendations: strong recommendation GDG confident desirable effect (benefits) adherence recommendation outweigh undesirable consequence (harms); conditional weak recommendation GDG less certain balance benefit harm disadvantage implementing recommendation. interpretation different type recommendation different kind stakeholder shown Table 4 (15). Guideline development process method 9Table 4. Interpretation strong conditional recommendation intervention Audience Strong recommendation Conditional recommendation Patients individual situation would want recommended course action; onl",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "edb1a08f-9d30-4694-ba0d-5015f6827fbe",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "dation Patients individual situation would want recommended course action; small proportion would not. Formal decision aide likely needed help individual make decision consistent value preferences.Most individual situation would want suggested course action, many would not. Clinicians individual receive intervention. Adherence recommendation could used quality criterion performance indicator.Different choice appropriate individual patients, require assistance arriving management decision consistent value preferences. Decision aide may useful helping individual make decision consistent value preferences. Policy maker recommendation adopted policy situations.Policy-making require substantial debate involvement various stakeholders. Source:",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "946848e3-53bb-4741-bf2f-7313490689ef",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "Policy-making require substantial debate involvement various stakeholders. Source: handbook guideline development (15).INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWatching flock, Mongolia © European Union / Pierre Prakash; Licence CC BY-NC-ND 2.0 guideline treatment patient cystic echinococcosis 10113. Evidence recommendation 3.1 Recommendations clinical management uncomplicated hepatic CE cyst according classification 3.1.1 Uncomplicated hepatic cyst type CE1 CE3a < 5 cm Recommendation 1 patient uncomplicated hepatic cyst type CE1 CE3a < 5 cm, treatment ALB suggested. recommendation applicable tier. Conditional recommendation low certainty evidence. Background ALB accepted treatment early active cyst stages. PAIR available",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5b31f242-25f7-47da-83cc-5028fd777c1b",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "nty evidence. Background ALB accepted treatment early active cyst stages. PAIR available centre (tiers 3 4), without risk. Summary evidenceThis recommendation based PICO question 1 compared PAIR combined ALB use ALB alone small uncomplicated CE cysts. evidence limited single small randomized trial 20 participant published 1993 limited follow data concerning cyst < 5 cm could disaggregated data concerning larger cyst (19). GDG recognized risk possible complication using PAIR concluded limited feasibility acceptability intervention. Certainty evidenceThe overall certainty evidence low. Additional factor considered • Benefits harm GDG reviewed desirable undesirable effect came consensus balance effect favour ALB alone. • Health equity",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2127e512-178a-4b26-8cb8-14bc7c541836",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ect came consensus balance effect favour ALB alone. • Health equity ALB widely available listed Model List Essential Medicines low-cost medication settings. PAIR availability limited expensive due technical skilled expertise required. Recommending PAIR likely create inequity afford versus cannot, place available freely versus not. • Acceptability ALB considered acceptable people oral medication known safety profile. acceptability using PAIR combined ALB among different stakeholder likely vary. • Resource implication Health facility setting access ALB. low-resource intensive treatment. • Feasibility primary care setting resource limited settings, PAIR feasible. feasibility implementing intervention widely",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4ebf44e6-cf80-4f7e-ab4b-c9820085a5d8",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ce limited settings, PAIR feasible. feasibility implementing intervention widely varies depending country even health care setting. Implementation considerations1. ALB given orally, dosage 10–15 mg/kg/day two divided dos (up 400 mg twice day), fat rich meal increase bioavailability (9). administered continuously, without monthly treatment interruption recommended 1980s. treatment duration depends individual situation, stage size CE cyst. Current recommendation suggest continuous treatment 3–6 month (14). INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis12Implementation consideration (continued)important use high-quality ALB (branded generic)",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5e4283b5-ad3f-4722-877d-69cbfb3014fb",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "plementation consideration (continued)important use high-quality ALB (branded generic) contains required amount bioavailable drug. 2. ALB contraindicated cyst risk rupture first trimester pregnancy (9). Later pregnancy, potential benefit may warrant use ALB despite potential risks. Contraceptive measure necessary woman reproductive age long-term ALB. Benzimidazoles must used caution patient chronic hepatic disease avoided bone-marrow depression. Monitoring side-effects based liver enzyme hepatotoxicity blood cell count. 3. Follow-up imaging 3–6 month thereafter year minimum 5 consecutive year inactivation may help evaluate success treatment monitor recurrence cysts. 4. lack response defined absence cyst change 3 month treatment (detachment parasitic layer",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c9f76414-a86f-4820-901c-343e0c462594",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ined absence cyst change 3 month treatment (detachment parasitic layer outer cyst wall, size reduction, stage modification). Complete response evaluated earlier 12 month treatment end. Remarks Based expert opinion, lack response initial course ALB, repeat course ALB could considered. 3.1.2 Uncomplicated hepatic cyst type CE1 CE3a 5–10 cm Recommendation 2 patient uncomplicated hepatic cyst type CE1 CE3a 5–10 cm, PAIR combined ALB suggested. PAIR used biliary communication present. recommendation requires tier 3 tier 4 settings. Conditional recommendation low certainty evidence. Background Treatment option individual medium-sized active cyst stage CE1 CE3a include PAIR combined ALB surgery combined ALB. intervention require different level health professional expertise w",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e93dfb44-1337-44c3-8e61-c95d24836397",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "mbined ALB. intervention require different level health professional expertise well differing radiological surgical facilities. Summary evidenceThis recommendation based PICO question 2 3. comparison albendazole alone, evidence use PAIR ALB limited one randomized trial 20 participant 1993 limited follow-up disaggregated data outcome specifically cyst > 5 cm < 10 cm (19). comparison surgery, identified two small randomized controlled trial (RCTs) conducted India 20 year apart, including total 92 participants, surgery (combined ALB one study) compared PAIR another percutaneous method (the double percutaneous aspiration injection technique, DPAI) ALB (20, 21). Participants undergoing surgery study underwent open drainage simple cystectomy. older study report whether surgical group receiv",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9d1f94bf-8ae5-46e3-9477-b1d7dc5096ac",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "en drainage simple cystectomy. older study report whether surgical group received ALB, classified cyst either univesicular multivesicular. Outcome data study unable separated cyst stage size. mean follow-up time older study 17 month (20), 26 month high loss follow-up recent study (21). factor limit applicability evidence. GDG also recognized risk possible complication surgery cyst size > 5 cm < 10 cm. GDG also considered data summarized three observational single arm study regarding therapeutic application PAIR medium sized cyst (22-24). author reported cyst volume reduction, solidification low relapse rate (< 3.5%) PAIR. Evidence recommendation 13Certainty evidenceThe certainty evidence available use PAIR ALB low low. Additional factor consi",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e5066cf2-8e3e-4431-adb9-55bffadeeb14",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "nty evidence available use PAIR ALB low low. Additional factor considered • Benefits harm GDG agreed evidence limited and, based expert opinion, believed increased treatment success, reduced recurrence rate symptom improvement PAIR ALB surgery ALB. PAIR would provide shorter duration overall treatment, faster recovery would preferred clinician patient considering done expert physician technical support, success rate high, chance major complication low. However, important consider individual patient characteristic (location size cyst) available resource skill set determining appropriate treatment approach. undesirable effect percutaneous treatment surgical intervention vary term magnitude likelihood. Adverse event like anaphylax",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f1df04e8-723c-4d1d-8503-de4ae29653d3",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "l intervention vary term magnitude likelihood. Adverse event like anaphylaxis complication PAIR rare technique undertaken expert required facilities. GDG acknowledged possible long-term complication PAIR surgery could curative. • Health equity PAIR availability limited compared surgery; however, PAIR less expensive. may create inequity afford PAIR versus cannot, place available versus not. • Acceptability GDG considered PAIR acceptable patient clinicians. • Resource implication Either PAIR surgery could increase out-of-pocket cost related procedure, travel time hospital. • Feasibility feasibility implementing PAIR surgery widely varies depending country, health care setting, availability skilled manpower resources, infra",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "784ce43a-7841-4de5-b4e4-c7802b026891",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "country, health care setting, availability skilled manpower resources, infrastructure. Implementation considerations1. PAIR recommended biliary communication. bile- stained cyst fluid aspirated (the assessment made visual inspection aspirate bile contamination checking bilirubin aspirated cyst fluid) contrast observed biliary tract injected cyst planned PAIR procedure, strongly recommended injection protoscolecidal agent aspiration performed. alternative treatment percutaneous drainage (S-CAT) without injection protoscolecidal agent prolonging administration ALB 6 months. Surgery medical management also considered. 2. Standard practice give ALB 1–7 day prior PAIR continue 1–3 month post-PAIR (25), dose 10–15 mg/kg/day (up 400 mg twice day)",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "581b8943-4922-4545-b10e-ad129ae02d7f",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "continue 1–3 month post-PAIR (25), dose 10–15 mg/kg/day (up 400 mg twice day) two divided dos fat-rich meal increase bioavailability; duration extended considered appropriate. important use high-quality ALB (branded generic) contains required amount bioavailable drug. two-week post-procedure course praziquantel addition ALB may considered spillage cyst content (see recommendation 6). INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis14Implementation consideration (continued)3. larger hepatic CE cysts, especially CE1 cyst type prone ALB-related perforation, ALB given shorter period procedure (sometimes once) reduce risk per",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "475e7d3e-2479-4840-bde4-cc1e1c9ab5b5",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ould given shorter period procedure (sometimes once) reduce risk perforation. 4. PAIR, patient must closely monitored potential complication including anaphylaxis, infection bleeding. Monitoring adverse event ALB treatment also implemented (see 5 below). 5. ALB contraindicated cyst risk rupture first trimester pregnancy (9). Later pregnancy, potential benefit may warrant use ALB despite potential risks. Contraceptive measure necessary woman reproductive age long-term ALB. Benzimidazoles must used caution patient chronic hepatic disease avoided bone-marrow depression. Monitoring side-effects based liver enzyme hepatotoxicity blood cell-count. 6. case surgical intervention chosen individual uncomplicated CE1 CE3a cyst 5–10 cm size, surgical procedure performed eith",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ade55de9-a7d6-4714-adb0-4c2c9dfe903c",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "uncomplicated CE1 CE3a cyst 5–10 cm size, surgical procedure performed either open laparoscopic approach, depending location cyst, expertise surgical team availability resources. patient surgery option, individual patient factor general health, co- morbidity age considered final decision made. 7. Follow-up imaging 3–6 month thereafter year minimum 5 consecutive year inactivation may help evaluate success treatment monitor recurrence cysts. 8. lack response defined absence cyst change 3 month treatment (detachment parasitic layer outer cyst wall, size reduc - tion, stage modification). Complete response evaluated earlier 12 month treatment end.Evidence recommendation 153.1.3 Uncomplicated hepatic cyst type CE1",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "921c423b-812e-4fde-bfe2-329371c01f1f",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "month treatment end.Evidence recommendation 153.1.3 Uncomplicated hepatic cyst type CE1 CE3a > 10 cm Recommendation 3 patient uncomplicated hepatic cyst type CE1 CE3a > 10 cm, percutaneous treatment combined ALB suggested. PAIR suggested rather standard catheterization surgery. PAIR used biliary communication present. recommendation requires tier 3 tier 4 settings. Conditional recommendation low certainty evidence (where relevant research), expert consensus (where relevant research). Background Treatment option individual large, active CE1 CE3a cyst include percutaneous aspiration technique (either S-CAT PAIR) ALB, surgery ALB. intervention require different level health professional expertise well differing radiological surgical facilities. Summary evidenceThis recommendation based PICO question",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5e8dfcc9-aeec-4518-9eec-c315cb345f9c",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ical surgical facilities. Summary evidenceThis recommendation based PICO question 4 5. evidence compare PAIR ALB versus S-CAT ALB limited one randomized trial conducted Türkiye 38 participant (26). Data disaggregated cyst size reported; median cyst size 4 cm, suggesting evidence synthesis applicable smaller cysts. However, GDG judged evidence would likely also applicable larger cysts. Data reported recurrence, complication duration hospital admission. prospective comparative trial study comparing S-CAT ALB versus surgery ALB. GDG agreed health care centre S-CAT surgery available safe, S-CAT ALB would associated benefit lower costs, shorter duration hospital admission, fewer complication higher patient safety profile (including biliary communicati",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "42cef305-c229-4ffa-9d29-3aa120deb065",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ion, fewer complication higher patient safety profile (including biliary communication suspected). Certainty evidenceEvidence uncertain recurrence minor complication (very low certainty evidence) S-CAT ALB compared PAIR ALB. seemed trend towards longer hospital stay increased minor complication using S-CAT ALB, evidence uncertain. GDG agreed certainty evidence available favour PAIR ALB low. Additional factor considered • Benefits harm GDG favoured percutaneous approach, either PAIR S-CAT , ALB surgery. Centres proficient percutaneous technique generally opt PAIR. choice PAIR S-CAT varies depending location type cyst, capability experience clinician. Recurrence complication higher S-CAT duration hospitalization tends longer",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a3b537da-3e16-4033-8875-d9bb260d11e8",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ce complication higher S-CAT duration hospitalization tends longer compared PAIR. difference two method small, GDG emphasized need consider additional factor clinician patient preferences. GDG emphasized risk associated protoscolecidal agent PAIR case biliary communication. • Health equity Health equity would vary depending value preferences. • Acceptability GDG believed patient would likely opt procedure lower complication rate PAIR S-CAT would easier accept major abdominal surgery. INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis16Additional factor considered (continued) • Resource implication decision S-",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4b42c5d4-4878-42bd-b173-9f1b1a94e0d2",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "occosis16Additional factor considered (continued) • Resource implication decision S-CAT PAIR influenced experience clinician. Surgery also demand specific expertise hepatobiliary surgery. GDG agreed PAIR cost–effective, several GDG member opined cost higher S-CAT used centre used both. Experts anticipate longer hospital stay complication surgery, implying potential higher direct indirect costs. • Feasibility vary depending settings. PAIR practised widely S-CAT Implementation considerations1. Many health care setting may appropriate expertise resource available safely deliver PAIR, S-CAT surgery. settings, safest treatment option utilizing available expertise resource consideration patient treatment preference recommended. 2. PAIR recommended biliary commu",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "17e0b3e0-6372-4194-ae71-9aba96beb045",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "nt treatment preference recommended. 2. PAIR recommended biliary communication, cyst > 10 cm high risk fistulas, special care taken. bile- stained cyst fluid aspirated (the assessment made visual inspection aspirate bile contamination checking bilirubin aspirated cyst fluid) contrast observed biliary tract injected cyst planned PAIR procedure, strongly recommended injection protoscolecidal agent aspiration performed. alternative treatment percutaneous drainage (S-CAT) without injection protoscolecidal agent prolonging administration ALB 6 months. Surgery medical management also considered. 3. Standard practice give ALB 1–7 day prior percutaneous treatment continue 1–3 month post percutaneous treatment (25), dose 10–15 mg/kg/day",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6544ad5a-a2bc-43fc-8337-ab4f9f43720a",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "nt continue 1–3 month post percutaneous treatment (25), dose 10–15 mg/kg/day (up 400 mg twice day) two divided dos fat-rich meal increase bioavailability; duration extended considered appropriate. important use high-quality ALB (branded generic) contains required amount bioavailable drug. 2-week post- procedure course praziquantel addition ALB may considered spillage cyst content (see recommendation 6). 4. larger hepatic CE cysts, especially CE1 cyst type prone ALB- related perforation, ALB given shorter period procedure (sometimes once) reduce risk perforation. 5. percutaneous treatments, patient must closely monitored potential complication including anaphylaxis, infection bleeding. Monitoring adverse event ALB also implemented (see 6 below). 6. ALB contraindicate",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dbfb5f93-3166-4432-8717-5c2a8d4b51f7",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "toring adverse event ALB also implemented (see 6 below). 6. ALB contraindicated cyst risk rupture first trimester pregnancy (9). Later pregnancy, potential benefit may warrant use ALB despite potential risks. Contraceptive measure necessary woman reproductive age long-term ALB. Benzimidazoles must used caution patient chronic hepatic disease avoided bone-marrow depression. Monitoring side-effects based liver enzyme hepatotoxicity blood cell count. 7. case surgical intervention chosen individual uncomplicated CE1 CE3a cyst > 10 cm size, surgical procedure performed either open laparoscopic approach, depending location cyst, expertise surgical team availability resources. patient surgery option, individual patient factor general h",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a27676dc-6085-4a8a-ac65-f9d89eb2a5fe",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ources. patient surgery option, individual patient factor general health, co-morbidities age considered final decision made. Evidence recommendation 17Implementation consideration (continued)8. Follow-up imaging 3–6 month thereafter year minimum 5 consecutive year inactivation may help evaluate success treatment monitor recurrence cysts. 9. lack response defined absence cyst change 3 month treatment (detachment parasitic layer outer cyst wall, size reduction, stage modification). Complete response evaluated earlier 12 month treatment end. 3.1.4 Uncomplicated hepatic cyst type CE2 CE3b ≤ 5 cm Recommendation 4 patient uncomplicated hepatic cyst type CE2 CE3b ≤ 5 cm, initial treatment ALB alone suggested. recommendation applicable tier. Conditi",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "02887507-d5ee-4333-8225-90cf2d39baba",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "tial treatment ALB alone suggested. recommendation applicable tier. Conditional recommendation based expert consensus. Background Treatment option individual small medium active cyst stage CE2 CE3b include ALB alone surgery ALB. intervention require different level health professional expertise well differing radiological surgical facilities. Summary evidenceThis recommendation based PICO question 6. RCT non-randomized prospective comparative trial identified. GDG formulated recommendation based expert consensus, risk–benefit assessment, global applicability, consideration clinician expertise/skill, infrastructure capacity patient treatment preferences. GDG agreed surgery combined ALB would associated large cost possibly greater complication (inaccessible cyst deep parenchyma) compared ALB alone. Therefore, trial",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "17a2031d-1234-41b9-8372-e3c8034995a9",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "er complication (inaccessible cyst deep parenchyma) compared ALB alone. Therefore, trial ALB alone offered initially might prevent unnecessary surgical procedure. GDG also acknowledged relapse treatment failure higher ALB alone surgery ALB. Hence, though ALB may tried initially, response closely monitored escalated surgery combined ALB event treatment failure. Certainty evidenceThe recommendation formulated GDG using expert consensus within evidence-to-decision framework. Additional factor considered • Benefits harm GDG expressed view surgery may associated iatrogenic morbidity mortality ALB alone may effective proportion small cysts. • Health equity ALB low cost generally widely available medication. Surgery expensive intervention likely create inequity wh",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4754542b-f5dd-45f9-870f-7c488334189e",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "medication. Surgery expensive intervention likely create inequity afford cannot; place available freely place not. • Acceptability ALB considered generally acceptable patient oral medication known safety profile.INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis18Additional factor considered (continued) • Resource implication ALB treatment less invasive requires less resource implementation surgery. situation surgery required, resource requirement include cost associated surgery itself, hospitalization, transportation indirect expenses. • Feasibility Treatment ALB generally highly feasible implement. Impleme",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a6ae1e73-1a78-4262-8a92-c4667f1415fe",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ect expenses. • Feasibility Treatment ALB generally highly feasible implement. Implementation considerations1. ALB given orally, dosage 10–15 mg/kg/day two divided dos (up 400 mg twice day), fat-rich meal increase bioavailability (9). administered continuously, without monthly treatment interruption recommended 1980s. treatment duration depends individual situation, stage size CE cyst. Current recommendation suggest continuous treatment 3–6 month (14). important use high-quality ALB (branded generic) contains required amount bioavailable drug. 2. ALB contraindicated cyst risk rupture first trimester pregnancy (9). Later pregnancy, potential benefit may warrant use ALB despite potential risks. Contraceptive measure necessary woman reproductive age long-term ALB. Benzimidazoles must used",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5258c431-674d-43fb-9061-bc31a8a8c6b7",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "e necessary woman reproductive age long-term ALB. Benzimidazoles must used caution patient chronic hepatic disease avoided bone-marrow depression. Monitoring side-effects based liver enzyme hepatotoxicity blood cell count. 3. Follow-up imaging 3–6 month thereafter year minimum 5 consecutive year inactivation may help evaluate success treatment monitor recurrence cysts. 4. lack response defined absence cyst change 3 month treatment (detachment parasitic layer outer cyst wall, size reduction stage modification). Complete response evaluated earlier 12 month end treatment. Remarks Since ALB alone known higher risk relapse, event non- response 3 months, based expert opinion, surgery (non-radical radical approaches) offered along wi",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0ccb811f-febc-40b0-87ac-cd4306cbc88d",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "hs, based expert opinion, surgery (non-radical radical approaches) offered along continued ALB. patient surgery option, individual patient factor general health, co- morbidity age considered final decision made. 3.1.5 Uncomplicated hepatic cyst type CE2 CE3b > 5 cm Recommendation 5 patient uncomplicated hepatic cyst type CE2 CE3b > 5 cm, surgery combined ALB suggested. open surgery (in tier 2–4) laparoscopy (in tier 3–4). Conditional recommendation low certainty evidence (where relevant research), expert consensus (where relevant research). Background Treatment option individual active hepatic cyst stage CE2 CE3b include ALB alone, surgery ALB (laparoscopic open) modified catheterization technique (Mo-CAT) ALB. intervention require different level health professional exp",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "642f9870-ff90-4345-b80d-410852671980",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "echnique (Mo-CAT) ALB. intervention require different level health professional expertise well differing radiological surgical facilities.Evidence recommendation 19Summary evidenceThis recommendation based PICO question 7, 8 9. prospective comparative trial comparing ALB alone surgery combined ALB identified. evidence comparing laparoscopic surgery ALB, open surgery ALB, limited two trials: one RCT conducted Pakistan including 82 participants; one prospective comparative trial conducted Islamic Republic Iran including 73 participant (27, 28). trial Pakistan included cyst 5 cm greater diameter; follow-up time 12 months. trial Islamic Republic Iran report cyst stage included, participant received ALB conjunction surgery; data unable separated participant receipt ALB. RCT non-r",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bcd1d85f-caf0-4804-95bb-ba6159cb1fd9",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ction surgery; data unable separated participant receipt ALB. RCT non-randomized prospective comparative trial comparing Mo-CAT surgery identified. GDG acknowledged limited expertise Mo-CAT globally lack information regarding possible undesirable effects. Resource considerations, cost feasibility, underscore challenge associated implementing Mo-CAT even tier 4 settings. Certainty evidenceThe certainty evidence PICO question 8 low. GRADE method could applied PICO question 7 9 due lack evidence. recommendation formulated GDG using expert consensus within evidence decision framework. Additional factor considered • Benefits harm health care centre surgery ALB available safe, even associated larger costs, option would benefit lower relapse fewer complication c",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0f94e6bf-5918-4cad-bff3-d45c20aaf786",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "larger costs, option would benefit lower relapse fewer complication compared ALB alone. Surgical complication rare hand experienced surgeons, rare complication include risk intraoperative cyst rupture leading anaphylaxis dissemination, especially case multiple daughter cysts. enough research evidence desirable undesirable effect Mo- CAT procedures. • Values preference study evaluate patients’ value preferences, qualitative research undertaken evidence team reveals usually concern scar surgery young patient children. • Health equity Surgery combined ALB may unaffordable patient likely create inequity afford versus cannot; place free charge versus not. • Acceptability Surgery combined ALB generally",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0a3fbc52-91a4-47c0-b02f-d89e9c51b1a5",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "free charge versus not. • Acceptability Surgery combined ALB generally acceptable patient clinicians. • Resource implication Costs could higher open surgery laparoscopic surgery. Surgery familiar procedure many settings; laparoscopy available tier 3 4, Mo-CAT implemented tier 4, handful centre skilled personnel around world. • Feasibility Feasibility depend clinician preference health facility available. Mo-CAT procedure limited accrued experience settings, evidence emerging centre Asia.INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis20Implementation considerations1. patient invasive procedure, e",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4b5846bc-4c0d-4200-9fcb-ef8182a2a8f1",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "c echinococcosis20Implementation considerations1. patient invasive procedure, especially surgery, option, individual patient factor general health, comorbidities age considered final decision made. 2. choice open laparoscopic surgery depend setting infrastructure, availability laparoscopy, site cyst cyst characteristics, expertise experience local clinical team, surgeon’s preference patient choice. Laparoscopy favoured peripheral, superficial cysts, especially paediatric cases, open surgery chosen cyst deep complicated scenarios. 3. Surgical challenge include inaccessibility dealing small cyst deep within liver parenchyma, particularly segment 7 8, individual underlying comorbidities. 4. opting Mo-CAT , crucial reduce risk recurrence ensuring thoro",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4f42a6e1-5036-47a1-9865-1d257eaa97f2",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "dities. 4. opting Mo-CAT , crucial reduce risk recurrence ensuring thorough removal cyst content germinal layer. T2-weighted MRI addition ultrasound cavitography used monitor efficacy treatment sessions. 5. Standard practice give ALB 1–7 day prior surgical procedure continue 1–3 month post procedure, dose 10–15 mg/ kg/day (up 400 mg twice day) two divided dos fat-rich meal increase bioavailability; duration extended considered appropriate. important use high-quality ALB (branded generic) contains required amount bioavailable drug. two-week post-procedure course praziquantel addition ALB may considered spillage cyst content (see recommendation 6). 6. larger hepatic CE cysts, ALB given shorter period procedure (sometimes once) reduc",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e2320a0b-0b8e-4d62-a6bf-9b2af05d7d9a",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "CE cysts, ALB given shorter period procedure (sometimes once) reduce risk perforation. 7. surgery, patient must closely monitored potential complication including anaphylaxis, infection bleeding. Monitoring adverse event ALB also implemented (see 7 below). 8. ALB contraindicated cyst risk rupture first trimester pregnancy (9). Later pregnancy, potential benefit may warrant use ALB despite potential risks. Contraceptive measure necessary woman reproductive age long-term ALB. Benzimidazoles must used caution patient chronic hepatic disease avoided bone-marrow depression. Monitoring side-effects based liver enzyme hepatotoxicity blood cell count. 9. Follow-up imaging 3–6 month thereafter year minimum 5 consecutive year inactivation may help evaluate succe",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8bc4f628-394a-4154-8b76-12851c6f9b4e",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ter year minimum 5 consecutive year inactivation may help evaluate success treatment monitor recurrence cysts. 10. lack response defined absence cyst change 3 month treatment (detachment parasitic layer outer cyst wall, size reduction stage modification). Complete response evaluated earlier 12 month treatment end.Evidence recommendation 213.1.6 Use praziquantel combined ALB post percutaneous/surgical procedure hepatic cyst type CE1, CE2, CE3a, CE3b Recommendation 6 CE patient undergoing percutaneous surgical interventions, spillage suspected occurred, combination praziquantel ALB suggested. Conditional recommendation based expert consensus. Background ALB often used treatment CE, alone addition invasive interventions. Recently, attention given addition",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "497bda51-a6b5-4939-ab20-0e04b5021111",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "alone addition invasive interventions. Recently, attention given addition praziquantel pre- post-intervention, combined ALB. Summary evidenceThis recommendation based PICO question 10. trial identified. GDG formulated recommendation based pharmacological data, expert consensus, risk benefit assessment clinician experience. Praziquantel reported protoscolecidal effect parasiticidal cyst (14). Pharmacological data indicate combination praziquantel ALB enhances efficacy increasing ALB sulfoxide levels, pharmacologically active metabolite, resulting markedly increased protoscolecidal activity, enhancing efficacy treatment reducing risk recurrence complication associated spillage. Biological plausibility reported Cobo et al. (29). Certainty evidenceThere evidence available support",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1c67910d-cca3-4e02-b313-1b6d2ba2eaa5",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "rted Cobo et al. (29). Certainty evidenceThere evidence available support use praziquantel combined ALB performing invasive interventions. recommendation formulated GDG using expert consensus within evidence-to-decision framework. Additional factor considered • Benefits harm GDG acknowledges potential benefits, enhanced therapeutic activity, broader applicability risk mitigation, associated praziquantel ALB combination. concern raised include limited experience, cost issue uncertainty regarding specific outcomes. lack data regarding undesirable effects. • Health equity, acceptability, resource implications, feasibility high cost praziquantel country could potentially create access barriers, highlighting concern health equity, acceptability feasibility. Efforts made make praziquantel affordable accessible,",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f62e91e6-9e07-4c38-951d-f2fa0a4960e5",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ility feasibility. Efforts made make praziquantel affordable accessible, especially low- middle-income region CE endemic. Implementation considerations1. case suspected ascertained cyst fluid spillage, ALB given dose 10–15 mg/kg/day two divided dos (up 400 mg twice day) minimum 3 months, usually, 6–12 month intervention, considered appropriate clinician. 2. Praziquantel given dose 40–50 mg/kg/day divided two daily dos 2 week intervention. praziquantel effect cyst (as compared ALB), 2 week suggested. However, period increased maximum 4 week considered appropriate clinician. 3. ALB praziquantel given simultaneously fat-rich meal increase bioavailability. 4. clinician use praziquantel combination ALB 2 week prio",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "94e8acca-16f9-4116-ae76-a39fb01e86e8",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "bioavailability. 4. clinician use praziquantel combination ALB 2 week prior procedure (29). evidence needed make practice recommendation. INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis223.2 Recommendations clinical management uncomplicated lung CE cyst 3.2.1 Uncomplicated lung CE cyst ≤ 5 cm Recommendation 7 patient uncomplicated active lung CE cyst ≤ 5 cm, surgery suggested. ALB given surgery. spillage suspected occurred, ALB surgery suggested. Lung surgery requires tier 4 settings. Conditional recommendation based expert consensus. Background Pulmonary CE mainly managed surgical intervention. Pulmonary surgery requires high level health professional e",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4c15d14c-090d-4d43-bb53-7f1a86d8c48e",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ged surgical intervention. Pulmonary surgery requires high level health professional expertise well radiological surgical facilities. uncertain whether ALB alone 6 month effectively treat small pulmonary CE (≤ 5 cm). Summary evidenceThis recommendation based PICO question 11. trial identified. GDG formulated recommendation based expert consensus, risk benefit assessment, consideration clinician patient treatment preferences. recommendation surgery combined ALB rather ALB alone 6 month uncomplicated CE lung cyst ≤ 5 cm based potential risk complications, risk rupture. recommendation also supported concern relying solely ALB 6 month may result higher relapse treatment failure rates. Certainty evidenceThe recommendation formulated GDG using expert consensus within evidence-to-decision frame",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c1c58181-1430-45d6-9b35-1f47d679dd3d",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "commendation formulated GDG using expert consensus within evidence-to-decision framework. Additional factor considered • Benefits harm Uncomplicated lung CE cyst (≤ 5 cm) represent specific limited type. ALB given, chance cyst might rupture, whether exacerbated drug treatment not. Surgery useful preventing potential complications, risk rupture. However, GDG considered possibility morbidity mortality associated surgery. published data reporting follow-up post-surgery patient could identified. multiple cysts, surgery may challenging, depending skill experience surgeon location cysts. • Health equity Surgery expensive intervention compared ALB alone considered essential lung cysts. • Acceptability Acceptability may frequently dictated clinician preferences. Often, patie",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4b78c8cb-97a2-4b9b-bcf6-d21f2e88bbcd",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": ". • Acceptability Acceptability may frequently dictated clinician preferences. Often, patient might initially reluctant choose specialized thoracic surgery, perceived option manage disease oral medicine, risk recurrence opportunity achieving complete remission surgery make surgery best option. • Resource implication thoracic surgery required excise CE cyst requires high level skill specialized staff. • Feasibility intervention feasible health facility infrastructure technical expertise available.Evidence recommendation 23Implementation considerations1. Pulmonary CE primarily managed surgical intervention. Medical treatment ALB contemplated surgery medically contraindicated feasible due specific patient circumstances. medical treatment, regular monitoring secondary infection,",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "96b12454-1b83-4f7e-9193-6cb06eb542d2",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "fic patient circumstances. medical treatment, regular monitoring secondary infection, expectoration laminated layer, mandated. T2-weighted MRI applied monitor inactivation cyst time. 2. patient invasive procedure, especially surgery, option, individual patient factor general health, comorbidities age considered final decision made. 3. Standard practice give ALB prior surgical procedure due perceived risk rupture case lung cysts. concern intraoperative spillage, give ALB 1–3 month post procedure, dose 10–15 mg/kg/day (up 400 mg twice day) two divided dos fat- rich meal increase bioavailability; duration extended considered appropriate. important use high-quality ALB (branded generic), contains required amount bioavailable drug. 2-week post",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "444771e5-881b-4b4e-9043-00f64d5661e3",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ity ALB (branded generic), contains required amount bioavailable drug. 2-week post-procedure course praziquantel addition ALB may considered spillage cyst content (see recommendation 6). 4. surgery, patient must closely monitored potential complication including anaphylaxis, infection, prolonged air leak bleeding. Monitoring adverse event ALB also implemented (see 5 below). 5. ALB contraindicated first trimester pregnancy (9). Later pregnancy, potential benefit may warrant use ALB despite potential risks. Contraceptive measure necessary woman reproductive age long-term ALB. Benzimidazoles must used caution patient chronic hepatic disease avoided bone-marrow depression. Monitoring side- effect based liver enzyme hepatotoxicity blood cell count. 6. Follow-up imaging 3–6 month thereafter year",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "387fd601-7553-4f99-8bd0-13f1b8cb4daa",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "hepatotoxicity blood cell count. 6. Follow-up imaging 3–6 month thereafter year minimum 5 year inactivation may help evaluate success treatment monitor recurrence cysts. 7. lack response defined absence cyst change 3 month treatment (detachment parasitic layer surrounding lung tissue, size reduction morphological change). Complete response evaluated earlier 12 month treatment end. INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATING244. Publication, dissemination, monitoring evaluation 4.1 Publication dissemination disseminate guideline regional country offices, different collaborators, generate wide dissemination guidelines, including: • Publication website.",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d54a9d78-9391-49ed-83b9-deb8ebe297f5",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "generate wide dissemination guidelines, including: • Publication website. • Communication WHO’s regional country office health ministries, provincial health authorities, central urban district hospital health centre endemic country including supporting materials. • Dissemination regional subregional event well professional network associations. • Communication Collaborating Centres Echinococcosis NTDs. • Dissemination global subscribers, chief health executives, depository libraries, representatives, headquarters regional office libraries. • Publication synthesized result peer reviewed journal sharing URL published guideline key journal (international readership endemic countries). • Promotion guideline workshop scientific congresses. • Embedding guideline within",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "38041047-5b6a-484e-9382-00b11388e95b",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "n guideline workshop scientific congresses. • Embedding guideline within relevant disciplines, clinical service systems, safe surgery diagnostic imaging. 4.2 Training derivative product implement recommendations, training may required develop and/or increase required competence diagnostics, percutaneous treatment mitigating managing potential complication related procedure specific settings. OpenWHO course resource control management CE prepared remote learning tool targeted public professional audience well on-site training clinician health care providers. guideline important component course. 4.3 Essential Medicines List ALB praziquantel included 22nd (2021) Model List Essential Medicines (30) intestinal anthelminthic well cysticidal medicines. ALB curr",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "edda3032-6a81-4c01-b409-27af76821e93",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "Essential Medicines (30) intestinal anthelminthic well cysticidal medicines. ALB currently available donation health ministry (31). 4.4 Adaptation guideline developed considering different resource settings, adaptation, taking account local circumstance resource considerations, undertaken regional national levels. translated Chinese, French, Russian Spanish. Additional translation official language may considered depending demand. 4.5 Monitoring evaluating impact guideline evaluation made member Guideline Steering Group NTD programme managers. evaluation focus following aspects: • access target audience guidelines; • in-country acceptance application recommendations; • observed obstacle implementation.255. Updating per standards,",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4e0eebd9-ea79-449f-a199-58b169b08d66",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "commendations; • observed obstacle implementation.255. Updating per standards, guideline reviewed periodically currency ensure alignment current emerging evidence. Subject operational priorities, review new evidence published 7–10 years, unless significant new evidence mandating earlier revision becomes available date. future revisions, effort made include patient representatives. 6. Research priority Research priority 1 Prospective comparative trial update recommendations. 2 Health service research provision access service endemic areas. 3 Survey patient preference treatment management CE. 4 PICO question duration ALB regimen need assessed RCT . addition, procedure recommended, potential role combination praziquantel also need addressed proper RCT . 5",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c2252c76-db8e-4369-8fbb-d1216783b93a",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "potential role combination praziquantel also need addressed proper RCT . 5 Include additional question guideline management treatment failure PAIR. 6 Develop CE diagnostic guidelines. 7 Improved diagnostic tool specific use cases. Rec Research question per recommendation 1 large RCT comparing PAIR ALB v ALB alone hepatic CE cyst type CE1 CE3a < 5 cm. 2 large RCT comparing ALB alone versus PAIR ALB versus surgery ALB hepatic cyst type CE1 CE3a 5–10 cm. 3 large RCT comparing S-CAT ALB, PAIR ALB surgery ALB large hepatic cyst type CE1 CE3a (> 10 cm). 4 large RCT prospective trial comparing surgery combined ALB v ALB alone initial treatment hepatic cyst type CE2 CE3b ≤ 5 cm diameter. 5 large RCT comparing ALB, laparoscopic surgery combined ALB, non-laparoscopic surgery combined ALB Mo-CAT combined ALB hepatic cyst",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "df93e705-aee4-4e34-b82b-0a349a2a84c9",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ALB, non-laparoscopic surgery combined ALB Mo-CAT combined ALB hepatic cyst type CE2 CE3b (> 5 cm). 6 a) large comparative trial studying outcome cyst inactivity, recurrence, spillage complication people hepatic cyst type CE1, CE2, CE3a, CE3b (> 5 cm), undergoing procedure, combination praziquantel ALB compared ALB alone needed obtain evidence. b) Comparison addition praziquantel ALB pre-procedure; post-procedure; pre- post-procedure cyst type also needed. 7 large RCT comparing therapeutic trial ALB 6 month v surgery adjunctive ALB people lung CE cyst ≤ 5 cm. recent Cochrane Review treatment CE draw similar conclusion evidence synthesis informing guideline support identified research priority (32).INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREF",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3703375d-179c-4135-ad45-f5b5c3f6336c",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "32).INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGPeruvian farmer sheep © Shawn Harquail; Licence CC BY-NC-ND 2.0 guideline treatment patient cystic echinococcosis 2627References 1. PAIR: Puncture, Aspiration, Injection, Re-Aspiration: option treatment cystic echinococcosis. Geneva: World Health Organization; 2001 (https://iris.who.int/handle/10665/67207). 2. Vuitton DA, McManus DP , Rogan MT , Romig , Gottstein B, Naidich A, et al. International consensus terminology used field echinococcoses. Parasite. 2020;27:41. doi: 10.1051/parasite/2020024. 3. Alvarez Rojas CA, Romig , Lightowlers MW. Echinococcus granulosus sensu lato genotype infecting humans--review current knowledge. Int J Parasitol. 2014;44(1):9–18. doi: 10.1016/j.ijpara.2013.08.008. 4. Romig , Deplazes P , Jenkins D, Gira",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "164f35bf-b0cb-4d3c-885a-8c241efccc03",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "sitol. 2014;44(1):9–18. doi: 10.1016/j.ijpara.2013.08.008. 4. Romig , Deplazes P , Jenkins D, Giraudoux P , Massolo A, Craig PS, et al. Ecology life cycle pattern Echinococcus species. Adv Parasitol. 2017;95:213–314. doi: 10.1016/bs.apar.2016.11.002. 5. Deplazes P , Rinaldi L, Alvarez Rojas CA, Torgerson PR, Harandi MF, Romig , et al. Global distribution alveolar cystic echinococcosis. Adv Parasitol. 2017;95:315–493. doi: 10.1016/bs.apar.2016.11.001. 6. Stojkovic M, Rosenberger K, Kauczor HU, Junghanss , Hosch W. Diagnosing staging cystic echinococcosis: CT MRI perform comparison ultrasound? PLoS Negl Trop Dis. 2012;6(10):e1880. doi: 10.1371/journal.pntd.0001880. 7. Siles-Lucas M, Casulli A, Conraths F J, Muller N. Laboratory diagnosis Echinococcus spp. human patient infected animals. Adv Parasitol. 2017;96:159-257. doi: 10.1016/bs.apar.2016.09.003. 8. Craig PS, Hegglin D, Lightowlers MW, Torgerson PR, Wang Q. Echinococcosis:",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d8f65f84-b544-4c4a-bcce-1a88e135f87a",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "6/bs.apar.2016.09.003. 8. Craig PS, Hegglin D, Lightowlers MW, Torgerson PR, Wang Q. Echinococcosis: control prevention. Adv Parasitol. 2017;96:55-158. doi: 10.1016/bs.apar.2016.09.002. 9. Brunetti E, Kern P , Vuitton DA, Writing Panel WHO-IWGE. Expert consensus diagnosis treatment cystic alveolar echinococcosis humans. Acta Trop. 2010;114(1):1–16. doi: 10.1016/j. actatropica.2009.11.001. 10. Gharbi HA, Hassine W, Brauner MW, Dupuch K. Ultrasound examination hydatic liver. Radiology. 1981;139(2):459-63. doi: 10.1148/radiology.139.2.7220891. 11. Caremani M, Lapini L, Caremani D, Occhini U. Sonographic diagnosis hydatidosis: sign cyst wall. Eur J Ultrasound. 2003;16(3):217-23. doi: 10.1016/s0929-8266(02)00076-9. 12. Tamarozzi F, Akhan O, Cretu CM, Vutova K, Akinci D, Chipeva R, et al. Prevalence abdominal cystic echinococcosis rural Bulgaria, Romania, Turkey: cross-sectional, ultrasound-based, population study",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4a11dee5-ed66-4894-8f31-1b92d85408f7",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "rural Bulgaria, Romania, Turkey: cross-sectional, ultrasound-based, population study HERACLES project. Lancet Infect Dis. 2018;18(7):769-78. doi: 10.1016/S1473-3099(18)30221-4. 13. Solomon N, Kachani M, Zeyhle E, Macpherson CNL. natural history cystic echinococcosis untreated albendazole-treated patients. Acta Trop. 2017;171:52–7. doi: 10.1016/j. actatropica.2017.03.018. 14. Kern P , Menezes da Silva A, Akhan O, Mullhaupt B, Vizcaychipi KA, Budke C, et al. echinococcoses: diagnosis, clinical management burden disease. Adv Parasitol. 2017;96:259–369. doi: 10.1016/ bs.apar.2016.09.006. 15. handbook guideline development - 2nd ed. Geneva: World Health Organization; 2014 (https://iris. who.int/handle/10665/145714). 16. Higgins JPT , Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk bias randomized trial. In: Higgins JPT , Thomas J, Chandler J, Cumpston M, Li , Page MJ, et al., editors. Cochrane handbook fo",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d06b0778-d55f-483f-8140-b6c02eb22198",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ggins JPT , Thomas J, Chandler J, Cumpston M, Li , Page MJ, et al., editors. Cochrane handbook systematic review interventions, Version 61. Cochrane, 2020. 17. Cochrane Reviews. ReviewManager (RevMan web version 2.3.0) [Web page]. (https://training.cochrane.org/ online-learning/core-software; accessed 12 February 2025). 18. Schunemann HJ, Higgins JP , Vist GE, Glasziou P , Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary findings’ table grading certainty evidence. In: Higgins JPT , Thomas J, Chandler J, Cumpston M, Li , Page MJ, et al., editors. Cochrane handbook systematic review interventions, Version 61. Cochrane, 2020.INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis2819. Khuroo MS, Dar MY, Yattoo GN, Zargar SA, Javaid G, Khan BA, et al. Per",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6470a799-4f1e-4040-b58a-6b288b55a451",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "th cystic echinococcosis2819. Khuroo MS, Dar MY, Yattoo GN, Zargar SA, Javaid G, Khan BA, et al. Percutaneous drainage versus albendazole therapy hepatic hydatidosis: prospective, randomized study. Gastroenterology. 1993;104(5):1452-9. doi: 10.1016/0016-5085(93)90355-g. 20. Khuroo MS, Wani NA, Javid G, Khan BA, Yattoo GN, Shah AH, et al. Percutaneous drainage compared surgery hepatic hydatid cysts. N Engl J Med. 1997;337(13):881-7. doi: 10.1056/NEJM199709253371303. 21. Shera TA, Choh NA, Gojwari TA, Shera FA, Shaheen FA, Wani GM, et al. comparison imaging guided double percutaneous aspiration injection surgery treatment cystic echinococcosis liver. Br J Radiol. 2017;90(1072):20160640. doi: 10.1259/bjr.20160640. 22. Akhan O, Ozmen MN, Dincer A, Sayek I, Gocmen A. Liver hydatid disease: long-term result percutaneous treatment. Radiology. 1996;198(1):259-64. doi: 10.1148/radiology.198.1.8539390. 23. Ustunsoz B, Akhan O, Kamiloglu MA, Somuncu",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7c37f462-4bc2-4e39-96bf-cb1f998dd1be",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "98(1):259-64. doi: 10.1148/radiology.198.1.8539390. 23. Ustunsoz B, Akhan O, Kamiloglu MA, Somuncu I, Ugurel MS, Cetiner S. Percutaneous treatment hydatid cyst liver: long-term results. AJR J Roentgenol. 1999;172(1):91–6. doi: 10.2214/ajr.172.1.9888746. 24. Koroglu M, Erol B, Gurses C, Turkbey B, Bas CY, Alparslan AS, et al. Hepatic cystic echinococcosis: percutaneous treatment outpatient procedure. Asian Pac J Trop Med. 2014;7(3):212-5. doi: 10.1016/ S1995-7645(14)60023-7. 25. Akhan O, Yildiz AE, Akinci D, Yildiz BD, Ciftci . adjuvant albendazole treatment really needed PAIR management liver hydatid cysts? prospective, randomized trial short-term follow-up results. Cardiovasc Intervent Radiol. 2014;37(6):1568-74. doi: 10.1007/s00270-014-0840-2. 26. Akhan O, Erdogan E, Ciftci TT , Unal E, Karaagaoglu E, Akinci D. Comparison long-term result Puncture, Aspiration, Injection Re-aspiration (PAIR) catheterization tec",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f509d442-10ab-491c-8f49-71afa6cb4e78",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ng-term result Puncture, Aspiration, Injection Re-aspiration (PAIR) catheterization technique percutaneous treatment CE1 CE3a liver hydatid cysts: prospective randomized trial. Cardiovasc Intervent Radiol. 2020;43(7):1034-40. doi: 10.1007/s00270-020-02477-7. 27. Ahmad U, Anwar A, Khan SA, QU, Kamal M, Aman Z. Outcome laparoscopic versus open surgery patient hydatid cyst liver. Rawal Medical Journal. 2020;45(4):806–9. 28. Jabbari Nooghabi A, Mehrabi Bahar M, Asadi M, Jabbari Nooghabi M, Jangjoo A. Evaluation comparison early outcome open laparoscopic surgery liver hydatid cyst. Surg Laparosc Endosc Percutan Tech. 2015;25(5):403–7. doi: 10.1097/sle.0000000000000199. 29. Cobo F, Yarnoz C, Sesma B, Fraile P , Aizcorbe M, Trujillo R, et al. Albendazole plus praziquantel versus albendazole alone pre-operative treatment intra-abdominal hydatisosis caused Echinococcus granulosus. Trop Med Int Health. 1998",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cb5ebc87-6040-4eba-8806-b7dead212e14",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "eatment intra-abdominal hydatisosis caused Echinococcus granulosus. Trop Med Int Health. 1998;3(6):462–6. doi: 10.1046/j.1365-3156.1998.00257.x. 30. World Health Organization model list essential medicines: 22nd list (2021). Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/345533). 31. Neglected tropical diseases: GSK reaffirms longstanding commitment expands donation programme three diseases. WHO/News [website]. Geneva: World Health Organization; 2022 (www. who.int/news/item/23-06-2022-neglected-tropical-diseases--gsk-reaffirms-longstanding-commitment- and-expands-its-donation-programme-to-three-diseases; accessed 14 January 2025). 32. Kuehn R, Uchiumi LJ, Tamarozzi F. Treatment uncomplicated hepatic cystic echinococcosis (hydatid disease). Cochrane Database Syst Rev. 2024;10.1002/14651858.CD015573(7). doi: 10.1002/14651858. CD015573.29Annex. Contributors declaration interest Guideline Steering Group Name Cluster/D",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d6fcf229-a609-4192-bc04-1ad981cf611e",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "73.29Annex. Contributors declaration interest Guideline Steering Group Name Cluster/Department Area expertise/Role Bernadette Abela Veterinary Public Health Vector Control Neglected tropical disease veterinary public health Katrin Bote Regional Office South-East Asia Neglected tropical disease veterinary public health Pauline Mwinzi Regional Office Africa Parasitology immunology Andreas Alois Reis Health Ethics Governance Global health ethic Pryanka Relan Health Care Readiness Emergency medicine Teri Reynolds Integrated Health Services Emergency medicine Kazim Sanikullah Regional Office Western Pacific Neglected tropical infectious disease Vaseeharan Sathiyamoorthy Office Chief Scientist Infectious disease Anthony Solomon Director’s Office, Global NTD Programme Neglected tropical infectious disease Marco Vigilato Regional Office Americas Veterinary public health Supriya Warusavi",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "446e6019-59e7-4e71-9825-8818cc01d99b",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "eas Marco Vigilato Regional Office Americas Veterinary public health Supriya Warusavithana Regional Office Eastern Mediterranean Neglected tropical disease Aya Yajima Regional Office South-East Asia Neglected tropical disease Guideline Development Group Name AffiliationArea expertise/roleCountry/primary location [work]Declarations interest Interest identifiedManagement plan decision Okan Akhan Hacettepe University AnkaraRadiology Türkiye None Jaime Altcheh Ricardo Gutierrez Children’s Hospital Buenos AiresParasitology Argentina None Mohammad Sayed BehradGhalib University Medical Science Faculty KabulThoracic surgeryAfghanistan None Mustapha BenazzouzRabat Medical School, Mohamed V UniversityEndoscopy Morocco None Bolor Bold Chinese Centre Tropical Diseases Research National Centre Zoonotic Disease, Mongolia Epidemiology Mongolia China None INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECO",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "605d562b-825d-4f12-9a8c-d25d4e4e1e95",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "Epidemiology Mongolia China None INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGYoung boy sheep - Ethiopia, 2016 © ILRI / Camille Hanotte; Licence CC BY-NC-ND 2.0 guideline treatment patient cystic echinococcosis 30Annex 31Enrico Brunetti University Pavia San Matteo Hospital FoundationInfectious disease Italy None Peter Chiodini Hospital Tropical Diseases London School Hygiene & Tropical MedicineParasitology United Kingdom Great Britain Northern IrelandNone Christina Coyle Jacobi Medical Centre Tropical Medicine Clinic Bronx Albert Einstein College MedicineInfectious disease United States AmericaNone John Horton Pharmacology development consultant Pharmacology United Kingdom Great Britain Northern IrelandNone Thomas JunghanssHeidelberg University HospitalInfectiou",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8c5ee26f-c36e-4f2a-88c7-6113a453c338",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "Great Britain Northern IrelandNone Thomas JunghanssHeidelberg University HospitalInfectious diseasesGermany None Suneetha NarreddyApollo Health City Campus, Jubilee Hills, HyderabadInfectious diseasesIndia None Timothy Pennel University Cape Town Groote Schuur HospitalCardiothoracic surgerySouth Africa None Priscilla Rupali Christian Medical College, Vellore Methodologist India None Marija Stojkovic Heidelberg University HospitalInfectious disease Germany None Francesca TamarozziIRCCS Sacro Cuore Calabria Hospital, Negrar di ValpolicellaInfectious diseasesItaly None Leonardo UchiumiMinistry Health Río Negro ProvinceInfectious diseasesArgentina None Ning Xiao National Institute Parasitic Diseases National Center Tropical Diseases Research Chinese Center Disease Control PreventionInfectious diseasesChina None INTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "916e9477-89f1-4a3e-abb3-a5195905a4f2",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "ODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGWHO guideline treatment patient cystic echinococcosis32External Review Group Name Affiliation Area expertise/roleCountry/primary location [work]Declarations interest Interest identifiedManagement plan decision Karima Achour University Hospital Lamine Thoracic surgeryAlgeria None David Addiss Task Force Global HealthEthics Unites States AmericaNone Moncef Belhassen GarciaUniversity Salamanca Infectious tropical diseasesSpain None Adriano Casulli Collaborating Centre Epidemiology, Detection Control Cystic Alveolar EchinococcosisInfectious diseasesItaly None María Celina Elissondo National Scientific Technical Research Council,Parasitology Argentina None Majid Fasihi HarandiResearch Center Hydatid Disease, Kerman University",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cdff6260-0270-49a2-8a28-62f4d85ac66c",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "itology Argentina None Majid Fasihi HarandiResearch Center Hydatid Disease, Kerman University Medical Sciences (KMU)Parasitology Islamic Republic Iran Yes Declaration constitute conflict. Ismailova Gulziya Al-Farabi Kazakh National UniversityRadiologist Kazakhstan Yes Declaration constitute conflict. Jorge Gustavo Hernandez CordovaTechnological University PeruEpidemiology Peru None Michael G. KawooyaErnest Cook Ultrasound Research Education Institute, Mengo HospitalRadiology Uganda None Rogelio López- VélezHospital Ramón Cajal Infectious disease Spain Tommaso ManciulliUniversity Florence Infectious disease Italy Athman MwatondoMinistry Health, Kenya Zoonotic disease Kenya Michael RamharterUniversity Medical Centre Hamburg-Eppendorf Bernhard Nocht Institute Tropical MedicineNeglected tropical diseasesGermany None Peter Sauer University Heidelberg Interventional endoscopyGermany None",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1fbb4fe8-a10e-4443-abe1-f0098adc7acc",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "l diseasesGermany None Peter Sauer University Heidelberg Interventional endoscopyGermany None Kamenna Vutova Medical University Sofia Parasitology Bulgaria None Tim Weber Heidelberg University HospitalRadiology Germany None shepherd dog flock, Sardinia © Marshall Lightowlers. Annex 33Systematic Review Team Name Affiliation Area expertise/ roleCountry/ primary location [work]Declarations interest Interest identifiedManagement plan decision Paul Garner Cochrane Infectious Diseases Group, Liverpool School Tropical MedicineEmeritus Professor, Evidence synthesis global healthUnited Kingdom Great Britain Northern IrelandNone Rebecca Kuehn Cochrane Infectious Diseases Group, Liverpool School Tropical MedicineClinical research associate evidence synthesisUnited Kingdom Great Britain Northern IrelandNone Vittoria Lutje Cochrane Infectious Diseases Group, Liverpool School Tropical MedicineClinical research asso",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "21e0ddca-9ec7-4d2d-a27d-c7accfb4735c",
        "title": "Treatment of patients with cystic echinococcosis",
        "body": "e Cochrane Infectious Diseases Group, Liverpool School Tropical MedicineClinical research associate evidence synthesisUnited Kingdom Great Britain Northern IrelandNoneINTRODUCTION CONTENTSGUIDELINE DEVELOPMENTEVIDENCE RECOMMENDATIONSRESEARCH PRIORITIESREFERENCES ANNEXPUBLICATION, DISSEMINATION, MONITORING EVALUATIONUPDATINGFor information, contact: Global Programme Neglected Tropical Diseases World Health Organization 20 avenue Appia 1211 Geneva 27 Switzerland Website: https://www.who.int/teams/control-of-neglected-tropical-diseases",
        "source": "WHO Guidelines: Treatment of patients with cystic echinococcosis.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3e3dc7c9-b93f-44ae-98d1-b5acf2643afd",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Health system strengthening intervention improve health displaced migrant population context climate changeHealth system strengthening intervention improve health displaced migrant population context climate changeHealth system strengthening intervention improve health displaced migrant population context climate change (Global Evidence Review Health Migration (GEHM) series) ISBN 978-92-4-011245-2 (electronic version) ISBN 978-92-4-011246-9 (print version) © World Health Organization 2025 right reserved. work available Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). term licence, may copy, redistribute adapt work non-commercial purposes, provided work appropriately cited, indicated below. use work, shou",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "46545f11-7ec7-4de7-a4d9-54e38def8869",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": ", provided work appropriately cited, indicated below. use work, suggestion endorses specific organization, product services. use logo permitted. adapt work, must license work equivalent Creative Commons licence. create translation work, add following disclaimer along suggested citation: “This translation created World Health Organization (WHO). responsible content accuracy translation. original English edition shall binding authentic edition” . mediation relating dispute arising licence shall conducted accordance mediation rule World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. Health system strengthening intervention improve health displaced",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a53ac8fb-4893-48eb-b10f-256606e2ca7f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "uggested citation. Health system strengthening intervention improve health displaced migrant population context climate change. Geneva: World Health Organization; 2025 (Global Evidence Review Health Migration (GEHM) series). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data available https://iris.who.int/. Sales, right licensing. purchase publications, see https://www.who.int/publications/book-orders. submit request commercial use query right licensing, see https://www.who.int/copyright . Third-party materials. wish reuse material work attributed third party, tables, figure images, responsibility determine whether permission needed reuse obtain permission copyright holder. risk claim resulting infringement third-party-owned component work rest solely user.",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4d18fc42-53d0-4bc1-9266-beb65b0fb4e2",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "lting infringement third-party-owned component work rest solely user. General disclaimers. designation employed presentation material publication imply expression opinion whatsoever part concerning legal status country, territory, city area authorities, concerning delimitation frontier boundaries. Dotted dashed line map represent approximate border line may yet full agreement. mention specific company certain manufacturers’ product imply endorsed recommended preference others similar nature mentioned. Errors omission excepted, name proprietary product distinguished initial capital letters. reasonable precaution taken verify information contained publication. However, published material",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "99bc8561-9730-48b6-b136-076e1b3876ed",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ken verify information contained publication. However, published material distributed without warranty kind, either expressed implied. responsibility interpretation use material lie reader. event shall liable damage arising use. illustration page 1,7,17,32 generated using AI (MidJourney) combining original sketch illustrations. image refined using Photoshop. Introduction Contents Foreword ........................................................................................... Preface ............................................................................................... Acknowledgements .......................................................................... Abbreviations .................................................................................... Glossary .....................................................................",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "69d201c1-cda4-48d9-8aee-42b03a30ae84",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "..................... Glossary ............................................................................................. Executive summary ........................................................................... 1. Introduction................................................................................. 1.1 Focus review ................................................................ 1.2 Climate change, health, migration displacement ......... 1.3 Health system context climate change, migration displacement ................................................. 1.4 Health system strengthening ................................................. 1.5 Methodology ........................................................................... 2. Results ........................................................................................... 2.1 Governance............................................................................. 2.2 Health financing",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4f015e37-05cd-421e-a072-3aa28b3dd61e",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ce............................................................................. 2.2 Health financing...................................................................... 2.3 Health workforce..................................................................... 2.4 Medicines supplies........................................................... 2.5 Health information systems................................................... 2.6 Service delivery....................................................................... 3. Discussion ..................................................................................... 3.1 Strengths, limitation research gaps.............................. 3.2 Key finding evidence review.................................. 3.3 Policy considerations.............................................................. 3.4 Next step supporting migrant-inclusive climate- resilient health systems...............................................",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "13f55381-2ad2-4f1c-a0ea-395b487a1d10",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "clusive climate- resilient health systems........................................................... 4. Conclusions................................................................................... References......................................................................................... Annex 1. Search strategy.................................................................... Annex 2. Health system intervention identified reviewiv vi viii ix x xiii 1 1 2 3 4 6 8 12 14 15 17 18 18 22 22 25 27 29 32 33 44 53 iiiiv Foreword Globally, 1 billion people move, either migrating voluntarily forcibly displaced, within across borders. Behind movement economic, environmental, political conflict-related factors, among others, climate change increasingly emerging driver. Migration displacement broadly recognized key determinant health well-being. health migrants, refugee",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ef1c03ac-3c90-4f19-b612-b9e03cb5e247",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "recognized key determinant health well-being. health migrants, refugee displaced population shaped individual characteristics, place origin, journey policies, legislation health service origin, transit destination countries. context surrounding migration across phase profoundly affect health outcomes. Health system must, therefore, adaptive inclusive, integrating refugee migrant within broader health system response well within health system strengthening interventions. 14th General Programme Work emphasizes need address social, economic environmental determinant health strengthen prevention approach acting root cause ill health. underscore importance addressing health risk associated climate change developing climate-sensitive low-carbon health systems. effort cruc",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1892a326-2dc9-4398-8786-f77d46022539",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "limate change developing climate-sensitive low-carbon health systems. effort crucial promoting protecting health individuals, including displaced migrant populations. today's rapidly changing world, pace climate change environmental degradation accelerated, emerging escalating threat human health. Extreme weather event rising global temperature increasing frequency, intensity duration, disproportionately affecting region population vulnerable situation including refugees, migrant displaced groups. Climate hazard impact health directly indirectly, exacerbating noncommunicable diseases, increasing emergence spread climate-sensitive disease increasing health emergencies. Climate change risk multiplier, intensifying human migration displacement impacting population health stressor extreme weather, prolonged drought env",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1b98b0f1-8cc3-4af2-91d0-c6a88416fbb7",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "impacting population health stressor extreme weather, prolonged drought environmental degradation. projected sudden-onset extreme weather event droughts, cyclone flood internally displace 216 million people 2050. consequence climate change health depend resilience adaptability affected populations, including displaced migrant groups, well effectiveness action climate change. Climate change challenge health system straining health infrastructure, reducing workforce capacity undermining progress towards universal health coverage. compound existing disease burden heightens barrier accessing health services, often critical moment need.v urgency transformative action cannot overstated – effort taken reduce emission avoid crossing dangerous temperature threshold irreversible tipping point determine future hea",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bbf8bb85-50f0-4004-8d87-817aa6ef8bb7",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "sing dangerous temperature threshold irreversible tipping point determine future health well-being community worldwide. Embedding refugee migrant inclusivity within climate resilience framework crucial mitigating health risk ensuring health equity. Global Evidence Review Health Migration consolidates available evidence health system intervention address need climate-affected displaced migrant populations. outline priority action develop health system inclusive refugee migrant climate resilient. Achieving health face climate change requires transformative strategies, collective commitment sustained action. hoped report serve vital resource policy-makers, practitioner stakeholders, fostering informed decision collaborative effort ensure that, world evolves, one left behind. Dr Ailan Li",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6479dd33-c8f5-4b15-9ded-676ac7afc815",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "collaborative effort ensure that, world evolves, one left behind. Dr Ailan Li Former Assistant Director-General Division Universal Health Coverage/Healthier Populations World Health Organization Dr Jeremy Farrar Assistant Director-General Division Health Promotion, Disease Prevention Care World Health Organizationvi Preface interaction climate change, migration, displacement health complex. Yet urgent need address health implication population displaced changing climate, requires immediate attention action cross-sectoral interdisciplinary collaboration. Migration displacement key determinant health. many reason people migrate move, climate-related factor increasingly emerging driver movement. Climate change direct driver displacement migration intensifier environmental change (such de",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ab34dd65-8984-4b26-893b-cb3dbb0991bd",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "direct driver displacement migration intensifier environmental change (such deforestation, desertification, loss biodiversity) economic political instability. Environmental change caused climate change, rising temperatures, directly indirectly heighten health risks, including increased mortality, injury extreme weather event spread climate-sensitive disease vector- foodborne illnesses. threat environmental change extends beyond physical health, loss land, property livelihood significantly impact mental health well-being. displaced forced migrate new area climate change-related environmental threat mental health pressure ensuing loss community identity disruption social support networks. impact influenced diverse factor across broad cultural, social, economic political contexts, nec",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3e739619-b256-4fa9-8cb9-102a3ccd8de1",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "e influenced diverse factor across broad cultural, social, economic political contexts, necessitating cross-sectoral responses. Global Evidence Review Health Migration provides global overview existing evidence health system intervention aimed addressing health need displaced migrant population context climate change. Understanding social determinant health root cause ill health strengthening health system integrated approach essential achieving universal health coverage ensuring health changing climate. review designed practical tool policy-makers, presenting actionable strategy strengthen health systems, enhance care delivery support vulnerable population facing current future climate-related challenges. also identifies critical evidence gap – particularly regarding long-term health intervention climate-affected displaced",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5839e6d1-7de3-4182-8c72-41d5540be9da",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ce gap – particularly regarding long-term health intervention climate-affected displaced migrant populations, well integration climate mitigation strategy health system responses. Bridging evidence gap targeted research urgently needed guide informed effective policy practice.vii shift beyond short-term, reactive response essential establish refugee- migrant-inclusive, climate-resilient health system effective, sustainable accessible. Addressing longer-term health need community climate-conscious strategy critical ensuring global health equity. review also highlight innovative, adaptive cross-sectoral intervention inclusive refugee migrant climate resilient. Policy alignment meaningful inclusion climate-affected migrant health system planning development imperative building sustainab",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3cade5ed-2139-4c35-b8c0-d71e7333ba0b",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "te-affected migrant health system planning development imperative building sustainable, responsive health care services. Ensuring need displaced migrant group reflected national health policies, programme system essential delivering equitable accessible health care all. Dr Santino Severoni Director, Health MigrationDr Maria Purificacion Neira Director, Environment, Climate Change Health viii Acknowledgements Contributors Technical development, review publication coordination Technical conceptualization coordination publication process provided Health Migration (WHO headquarters) strategic lead supervision Santino Severoni, Director, technical lead Miriam Orcutt Sylvia Garry. publication developed close collaboration Environment, Climate Change Health Department (WHO headquarters), leadership Maria Ne",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "da88b146-02af-4753-aff5-d7ca78ba5b88",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ironment, Climate Change Health Department (WHO headquarters), leadership Maria Neira, Director, technical input Carlos Corvalan, Aderita Sena Christian Schweizer. Coordination consolidation input led Health Migration (WHO headquarters) Hams Bashir Claire Zhang, technical input Saverio Bellizzi Claudia Marotta input conceptualization phase Lucinda Hiam. Document production lead academic collaborator Renzo R Guinto (SingHealth Duke-NUS Global Health Institute, Duke-NUS Medical School, Singapore), supported Dominique Aluquin Tanisha Naqvi (SingHealth Duke-NUS Global Health Institute, Duke-NUS Medical School, Singapore) independent collaboration Karen Ceballos, Kent Tristan Esteban Joyce Hu library support Annelissa Chin (National University Singapore, Singapore). document reviewed Baltica Cabieses (Universidad Del Desarrollo, Chile),",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "22e1100d-62f4-408d-bce1-0cae50315a85",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ore, Singapore). document reviewed Baltica Cabieses (Universidad Del Desarrollo, Chile), Bernadette Kumar (Norwegian Institute Public Health, Norway) Ricardo Safra De Campos (University Exeter, United Kingdom Great Britain Northern Ireland). Valuable regional insight perspective provided focal point health migration across six regional offices. included Ernest Dabiré (WHO Regional Office Africa); Celso Bambaren Alatrista (WHO Regional Office Americas); Ali Ardalan, Lucia Barcellini Tonia Rifaey (WHO Regional Office Eastern Mediterranean); Palmira Immordino Kristina Mauer-Stender (WHO Regional Office Europe); Hiromasa Okayasu (WHO Regional Office Western Pacific). Additional support broader Health Migration team headquarters essential throughout development publication. Funding support document produced funding supp",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dc5a7e3f-8d78-4c66-a93a-90152156d3f4",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ut development publication. Funding support document produced funding support Institute Philanthropy; Ministry Health, Italy; Ministry Foreign Affairs International Cooperation, Italy; Ministry Health Welfare, Republic Korea. Declaration interest external expert participated individual capacity submitted declaration interest WHO, disclosing potential conflict might affect – reasonably perceived affect – objectivity independence regard subject matter report. reviewed declaration accordance corporate policy concluded none presented potential reasonably perceived conflict interest relation topic discussed meeting addressed guidance.ix Abbreviations COVID-19 coronavirus disease GEHM Global Evidence Review Health Migration (series) IDP internally displaced",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d87cfaf7-8904-4f1c-b93c-22c9a2b72d2c",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ru disease GEHM Global Evidence Review Health Migration (series) IDP internally displaced person IFRC International Federation Red Cross Red Crescent Societies IOM International Organization Migration mhGAP Mental Health Gap Action Programme MSF Médecins Sans Frontières NGO nongovernmental organization UNHCR United Nations High Commissioner Refugees UNICEF United Nations Children's Fund WASH water, sanitation hygienex Glossary Adaptation. \"In human systems, process adjustment actual expected climate effects, order moderate harm exploit beneficial opportunities. natural systems, process adjustment actual climate effects; human intervention may facilitate adjustment expected climate effects\" (1). Climate change. \"A change state climate identified (e.g. using statistical tests) change mean and/or variability property persi",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8265695e-8b0b-4739-9b3e-7b8d756a2bb5",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "g statistical tests) change mean and/or variability property persists extended period, typically decade longer. Climate change may due natural internal process external forcings modulation solar cycles, volcanic eruption persistent anthropogenic change composition atmosphere land use\" (1). Climate migration. \"The movement person group person who, predominantly reason sudden progressive change environment due climate change, obliged leave habitual place residence choose so, either temporarily permanently, within State across international border\" (2). Climate-resilient health systems. \"[t]hose capable anticipating, responding to, coping with, recovering adapting climate-related shock stress, bring sustained improvement population health, despite unstable climate\" (3). Climate-se",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c4b1e69e-d86c-46c6-8e48-0ac73856dca4",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ing sustained improvement population health, despite unstable climate\" (3). Climate-sensitive diseases. Special Programme Research Training Tropical Diseases describes climate-sensitive disease \"those impacted change environment climate. include infectious diseases, transmitted vector (mosquitoes, ticks, etc.), water (cholera, typhoid, etc.) animal (rabies, anthrax, etc.), well non-infectious disease affected temperature, humidity, rainfall, air quality extreme weather event (heat stroke, asthma, cardiovascular diseases, etc.)\" (4). Displacement. \"The movement person forced obliged flee leave home place habitual residence, particular result order avoid effect armed conflict, situation generalized violence, violation human right natural human-made disasters\" . intended cov",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4b251562-3020-47d4-b4f7-6411ae958c1f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "violence, violation human right natural human-made disasters\" . intended cover internal cross‐ border displacement population (2). Hazard. \"The potential occurrence natural human-induced physical event trend may cause loss life, injury health impacts, well damage loss property, infrastructure, livelihoods, service provision, ecosystem environmental resources\" (1). Health system. \"The health system comprises organizations, institutions, people, resource action whose primary purpose improve, restore maintain health. goal health system improving health health equity way responsive, financially fair make best efficient use available resources. Six health system building block together constitute complete health system – health service delivery; health workforce; health information; medical technologies; health financing; leade",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b28ab745-8ce7-47b3-a025-740df350e30f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "rvice delivery; health workforce; health information; medical technologies; health financing; leadership governance\" (5).xi Health system strengthening. \"[a]ny array initiative improve one function health system lead better health improvement access, coverage, quality efficiency\" (5). Internally displaced person (IDP). \"[a] person group person forced obliged flee leave home place habitual residence, particular result order avoid effect armed conflict, situation generalized violence, violation human right natural human-made disaster crossed internationally recognized State border\" (2). Migration. \"The movement person away place usual residence, either across international border within State\" (2). Migrant. \"An umbrella term, defined international law, reflecting common l",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9dce4fc5-4075-4517-8bc3-175e8b7bcfce",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "State\" (2). Migrant. \"An umbrella term, defined international law, reflecting common lay understanding person move away place usual residence, whether within country across international border, temporarily permanently, variety reasons\" (2). Migrant-sensitive health systems. \"[t]hose 'consciously systematically incorporate need migrant health financing, policy, planning, implementation evaluation'\" (6). Mitigation (of climate change). \"A human intervention reduce greenhouse gas emission enhance sink reduce greenhouse gases\" (1). Refugee. definition used International Organization Migration follows. \"A person who, owing well-founded fear persecution reason race, religion, nationality, membership particular social group political opinion, outside country nationality unable or, owing fear limitin",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a551e758-e491-4447-b1b3-0b2bbed506ad",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "opinion, outside country nationality unable or, owing fear limiting factors, either unable unwilling avail protection country; who, nationality outside country former habitual residence result events, unable or, owing fear, unwilling return it\" (2). Resilience. \"The capacity interconnected social, economic ecological system cope hazardous event, trend disturbance, responding reorganising way maintain essential function, identity structure. Resilience positive attribute maintains capacity adaptation, learning and/or transformation\" (1). Trapped populations. \"Populations migrate, yet situated area threat, … risk becoming 'trapped' stay behind, vulnerable environmental shock impoverishment\" (7).xii References",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cc74c061-45d7-486d-94f6-564a199ea44d",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": ", vulnerable environmental shock impoverishment\" (7).xii References1 1. Glossary [online database]. Geneva: Intergovernmental Panel Climate Change; 2025 (https://apps.ipcc.ch/glossary/). 2. Key migration term [website]. International Organization Migration; 2019 (https://www. iom.int/key-migration-terms). 3. Operational framework building climate resilient low carbon health systems. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/373837). Licence: CC BY- NC-SA 3.0 IGO. 4. EWARS-csd: overview [website]. TDR, Special Programme Research Training Tropical Diseases; 2025 (https://tdr.who.int/activities/ewars-csd). 5. 21st century health challenges: essential public health function make difference? Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/351510). Licence: CC BY-NC-SA 3.0 IGO. 6. Health migrants: way forward: report global consultation, Madr",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "52b28968-5b4c-48ca-8dec-928c518faf6a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": ": CC BY-NC-SA 3.0 IGO. 6. Health migrants: way forward: report global consultation, Madrid, Spain, 3–5 March 2010. Geneva: World Health Organization; 2010 (https://iris.who.int/ handle/10665/44336). Licence: CC BY-NC-SA 3.0 IGO. 7. Environmental migration [website]. International Organization Migration; 2025 (https://environmentalmigration.iom.int/environmental-migration#:~:text=Trapped%20 populations%20are%20those%20%E2%80%9Cwho,to%20environmental%20shocks%20 and%20impoverishment). 1 reference accessed 30 March 2025.xiii Executive summary health refugee migrant directly related access quality, effective appropriate health care along route travel. Refugees migrant face challenge accessing health care, including financial, legal cultural barriers, well documented. challenge vary according national regional legislation services. Additionally, global context inc",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "168f0429-dae3-438f-84f4-e4a9406313b2",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ording national regional legislation services. Additionally, global context increasingly affected changing climate, directly affect individual health also impact upon health system exacerbates health inequities. Climate change continues drive increasing migration population displacement directly indirectly affect health well-being displaced. Health system must increasingly urgently consider additional challenge presented climate change order effectively respond health need work towards universal health coverage health equity. literature considered within review, total 95 health system intervention identified, spanning six health system building blocks. majority (53%) focused service delivery, particularly context climate-related emergencies. included provision health immunization services, mental h",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "822c849a-1443-43a6-9725-b3f152f25047",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ate-related emergencies. included provision health immunization services, mental health intervention access safe water, sanitation hygiene services. Interventions pertaining governance health workforce constituted 37% total interventions. primarily focused inclusion climate-affected migrant policy plan governance, well enhancing capacity health workforce address health need displaced migrant populations. least represented intervention related health financing, medicine supplies, health information system, accounting approximately 10% intervention identified. included effort expand health coverage, ensure availability medical supply monitor climate-sensitive health risk within respective building block. Additionally, six health system intervention explicitly included climate mitigation strategies; r",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "57d67a1d-552f-4836-861e-344f04a0bdd7",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ally, six health system intervention explicitly included climate mitigation strategies; remainder focused climate adaptation, primarily response extreme weather events.xiv evidence review found innovative intervention emerging also many existing intervention adapted meet population needs. example identified demonstrate cross-sectoral interdisciplinary collaboration vital, engagement migrant community. review also highlighted possible evidence gap future research action. increasing need evidence amassed concerning longer-term sustainable interventions. include intervention covering climate mitigation; evaluating effectiveness impact intervention population outcomes; addressing less-documented building block health system (such health financing, medicine supplies, health information systems) cut across mu",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "82cc6777-828b-4f52-a0ce-77990b9a0d63",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "health financing, medicine supplies, health information systems) cut across multiple building block (health system-wide approaches); evidence less-represented regions, European, South-East Asia Western Pacific Regions, particularly particularly vulnerable climate change impacts. Moving forward, build migrant-inclusive climate-resilient health systems, evidence gap identified review must filled cross-sectoral interdisciplinary research action. ensure coherence across policies, programme frameworks, applying migration lens climate-resilient health system agenda climate lens migration health effort crucial. also important move beyond short-term reactive response consider longer-term health need climate-affected displaced migrant populations. Policy consideration strengthen adapt existing health system better address",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c7aa4710-27fb-4a9e-bcf6-ddb64de12bab",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "populations. Policy consideration strengthen adapt existing health system better address health need displaced migrant population context climate change, following policy consideration suggested based review findings. Move towards whole-of-route approach support continuity careThink beyond health system building block integrating essential public health function health system resilience considerationsEnsure inclusion migrant, refugee displaced population building health systemsEnsure meaningful inclusion engagement displaced migrant population policy planning deliveryAddress knowledge gap health system strengthening intervention context migration climate changeShift towards proactive long- term strategy designing planning health system migrant inclusive climate resilient1. Introduction 1.1 Focus rev",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2015da17-d983-4a89-9488-a55879bc9185",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "system migrant inclusive climate resilient1. Introduction 1.1 Focus review review Global Evidence Review Health Migration (GEHM) series address health system strengthening nexus health, climate change, migration displacement. Specifically, examines health system responding emerging health need displaced migrant population context climate change. review address following question: health system intervention improve health displaced migrant population context climate change? Glossary outline definition used review, includes working definition climate migrant set International Organization Migration (IOM) definition climate migration (\"for reason sudden progressive change environment due climate change\"); review also considers population mo",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2327c921-b566-43d1-b369-3f2e9943c8e5",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ange environment due climate change\"); review also considers population moved/been displaced reason (such conflict) exposed climate-sensitive health risk outcomes. GEHM, population identified climate migrant reported text referred generally climate affected identified displaced (irrespective reason) exposed climate- related health risks. evolving field research; therefore, definition may continue evolve. also discussed limitation (section 3.1.2). report, migrant-inclusive health system describes health system consciously systematically incorporate health wider need migrant policy, planning, implementation evaluation. includes considering epidemiological profiles, well relevant cultural, language socioeconomic factors. revie",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4bd6d961-dcff-4d8a-9262-aa011e6cd48e",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "demiological profiles, well relevant cultural, language socioeconomic factors. review included health system intervention population displaced migrate, across climate change-related event (both acute long term). search strategy outlined Annex 1. 12 Health system strengthening intervention improve health displaced migrant population context climate changeMany people situation face significant health risk along stage migration displacement, poor living working conditions, exposure pollution disease risk factor limited access health care (3). 1.2 Climate change, health, migration displacement Today, estimated 1 billion people globally refugees, migrant forcibly displaced home (1,2). Climate change affect health directly – example, direct exposure extreme heat – indirectly influencing di",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8f88c84a-9d91-46b4-bbda-09bb4313237a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "h directly – example, direct exposure extreme heat – indirectly influencing disease vector well social environmental determinant health (4). Climate hazard cyclone heat wave also disrupt health service affect health workers. Climate change risk multiplier. combined impact climate change stressors, extreme weather prolonged droughts, contributes human displacement, consequence population health (1,5). Climate-related displacement may happen within across borders. estimated that, 2050, climate change cause internal displacement 216 million people globally, migration hotspot rural, urban coastal area (7). Data cross-border movement challenging estimate, although data Central America, Sahel Pacific Islands (8). Displaced migrant group may exposed climate hazard point",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "46c203bd-83f5-409f-9c42-83a338308121",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Pacific Islands (8). Displaced migrant group may exposed climate hazard point along route, including departure, transit destination. Migrants may also move towards area climate change pose health risks, labour migrant facing heat stress risk various global contexts; example include migrant construction worker Middle East, migrant farmworkers 2023 alone, estimated 20.3 million people globally internally displaced sudden-onset extreme weather event droughts, cyclone flood (6). 3 Introductionin Americas migrant brick kiln worker India (9–13). Meanwhile, climate-affected population may trapped immobile (14). growing recognition importance understanding climate–migration–health nexus, particularly regarding health need affected (15–19). Studies investigated various health issue associated climate migratio",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5d7f97d0-8e7c-443e-9a73-3e73c9b6b048",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "affected (15–19). Studies investigated various health issue associated climate migration, including health access, food insecurity changing pattern communicable noncommunicable disease (20). Climate-affected displaced migrant population face physical, mental health social health challenges, women, child elderly people disproportionately vulnerable (21–23). 1.3 Health system context climate change, migration displacement Globally, health systems, particularly low- middle-income countries, confronted challenge achieving universal health coverage: ensure people access quality health service needed without financial burden (24). addition, health system must respond strengthen capacity adapt effect climate change (25). WHO’s Operational framework building climate resilient low carbon health system outline importance",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e803c16e-32a7-468c-8783-0f9ab6281afc",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "l framework building climate resilient low carbon health system outline importance adaptation climate risk also building resilience. includes managing climate-related health risks; developing health system capacity, long-term vision adaptive management; promoting whole-of-society action (26). health system country receive refugee migrant must also adapt changing health need number meeting need citizen resident (27). Climate change risk multiplier health system additional pressure along route migration displacement (28,29). region facing high level climate-related displacement, Africa, South-East Asia Western Pacific, noted increasing strain health systems; includes shortage financial resource medical supplies, well difficulty coordinating service among provider (30,31). addition, hea",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7e11bb07-767b-4f5d-aa54-6e60cc4f64f3",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "supplies, well difficulty coordinating service among provider (30,31). addition, health system responding migrant health need face risk disrupted changing climate: health service interrupted electricity grid damaged; medicine supply chain disrupted road flooded; health facility destroyed cyclones. looking develop climate-resilient health facilities, risk specifically identified hazard including floods, storm hurricanes, temperature extremes, well water shortage (32). Services serving displaced migrant population might greater risk hazards; example, delivered temporary semi-permanent structures, put place rapidly remote locations.4 Health system strengthening intervention improve health displaced migrant population context climate change1.4 Health system strengthening",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7133b685-8438-4431-9260-ba673073f108",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "isplaced migrant population context climate change1.4 Health system strengthening WHO’s framework guide health system strengthening (33) conceptualizes six building blocks: health system building block essential improving health displaced migrant populations, result review organized using framework. World report health refugee migrant outlined intervention building block framework build refugee- migrant-sensitive health system (3). Report also highlighted importance making health system inclusive need refugee migrant integrating patients, providers, facilitator decision-makers. increasing recognition health system need reduce greenhouse gas emission prepare health system health impact climate change, developed Operational framework building climate resilient",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3760fec1-180c-4d44-97a2-f24ab2b6bd78",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "impact climate change, developed Operational framework building climate resilient low carbon health system (26), identified 10 component (Fig. 1).leadership governance: ensuring effective leadership governance structure guide health system policy reforms; health financing: developing sustainable equitable financing mechanism ensure access health service without financial hardship; health workforce: ensuring adequate skilled workforce deliver health services; medicine supplies: ensuring access essential medical product technologies; health information systems: strengthening health information system research capacity inform policy practice; service delivery: ensuring health service accessible, equitable high quality. 45 Introduction advance agenda migrant-inclusive climate-resilient health systems, need identify evidence health system str",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "95bb26df-9d91-4a74-a1c6-bb7e925c629a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ive climate-resilient health systems, need identify evidence health system strengthening intervention respond health need climate-affected displaced migrant populations. Adopting health system strengthening approach key achieving health health equity.Fig. 1. Operational framework building climate resilient low carbon health system GHG: greenhouse gases. Source: (26).Leadership & governanceClimate- transformative leadership governanceClimate- smart health workforce Assessments climate health risk GHG emission Integrated risk monitoring, early warning, GHG emission tracking Health climate research Climate resilient low carbon infrastructures, technologies, supply chainManagement environmental determinant healthClimate-related emergency preparedness managementSustainable climate health financing Climate-informed health programme Service de",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "452866da-f637-47f3-8396-e4477ed56133",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "managementSustainable climate health financing Climate-informed health programme Service deliveryFinancingHealth workforce Health information system Essential medical product & technologiesBuilding block health systems6 Health system strengthening intervention improve health displaced migrant population context climate change1.5 Methodology scoping review peer-reviewed grey literature conducted covering period January 2014 June 2024, using English language study feasibility considerations. Peer-reviewed literature sourced PubMed Embase, grey literature sourced search engine United Nations agency International Labour Organization, IOM, United Nations Children's Fund (UNICEF), United Nations Office Drugs Crime, United Nations High Commissioner Refugees (UNHCR) WHO. database sourcing grey literature include Climate",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "47da5638-3e32-44b6-abf8-25057f872128",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "oner Refugees (UNHCR) WHO. database sourcing grey literature include Climate Change Human Health Literature Portal, Google Scholar, International Migration Institute website, OAIster, Science.gov, World Bank online database. full list database used search strategy given Annex 1. search strategy combined three key area interest: review included publication described specific health system intervention implemented response climate change generally specific climate hazard (sudden-onset event cyclones, flood wildfires, well slow-onset effect including rising sea level droughts) address health need refugees, migrant displaced population type (e.g. moved climate hazard exposed climate hazard regardless reason migration displacement). Publications excluded",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c622fa39-d829-4342-a227-6b5104d601d2",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "hazard regardless reason migration displacement). Publications excluded fit within criterion full text available. Inclusion exclusion criterion detailed Annex 1. comprehensive string relevant term spanning intersection climate change, migration health system developed peer-reviewed literature. initial set 4574 article identified; removal duplicate screening title abstract, 334 progressed full-text review; 22 article describing 38 intervention included data extraction. grey literature, simpler string applied 29 search engines, giving initial set 3928 documents, 393 document progressed full-text screening, 34 article describing 57 intervention included. Data extracted included bibliometric information; geographical focus; detailed description health system intervention;",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f38a0be3-2d93-4271-b841-1f8f1966e125",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "bliometric information; geographical focus; detailed description health system intervention; type climate hazard addressed intervention; type displaced migrant population. Interventions classified based three main criteria: main health system building block addressed intervention; whether refugees, migrant displaced populationsclimate change specific hazardshealth system building blocks. Introduction intervention reactive/short term (e.g. direct health response climate-related disaster) anticipatory/long term (e.g. building improving health infrastructure) nature; whether intervention primarily climate adaptation measure (reducing risk addressing impact climate change) mitigation measure (reducing greenhouse gas slow stop progression climate change). Within building block, intervention categorized",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "79fbb57f-f6cf-4464-9f19-8d5bf3f35ec1",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "progression climate change). Within building block, intervention categorized subcategories. phase research, two member research team involved reviewing article, extracting data categorizing interventions. categorizing interventions, one researcher performed initial data extraction charting, another researcher reviewed independently categorized them. discrepancy, third researcher made final decision. 7 8 Building block Intervention type Illustrative example literature Governance (n = 19)Including need climate-affected migrant climate health policy plan (n = 7) Enhancing coordination service across agency responding health need climate-affected displaced migrant population (n = 8) Involving displaced and/or relocated community planning implementation health intervention (n =",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9414c253-31b8-4efd-acfd-0805ede2ebc6",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "laced and/or relocated community planning implementation health intervention (n = 1) Including climate migrant health system receiving country (n = 3)The Government Vanuatu partner created National Policy Climate Change Disaster-induced Displacement population affected climate change; Policy’s strategic area 7 covered health, nutrition psychosocial well- being; main objective provide equal access health care climate-displaced migrant (34)2. Results review literature identified 56 relevant articles, described 95 health system interventions. health system intervention categorized according main health system building block addressed, following distribution: Table 1 outline intervention theme identified literature review, examples. Table 1. Key intervention theme identified literature review, including",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "53dddfcd-f4e7-4f99-b55a-1237f59b24dc",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "examples. Table 1. Key intervention theme identified literature review, including illustrative example intervention strengthen health system displaced migrant population context climate changegovernance (n = 19) medicine supply (n = 3)health financing (n = 3) health information system (n = 4)health workforce (n = 16) service delivery (n = 50). 9 ResultsBuilding block Intervention type Illustrative example literature Health financing (n = 3)Allocating additional budget improve health service infrastructure climate- affected displaced migrant population (n = 2) Improving breadth health insurance coverage include climate-affected displaced migrant population (n = 1)After Hurricane Katrina hit 2005, Government United States America implemented Section 1115 Medicaid Emergency Waivers, allowed United States expedite Medicaid coverage",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f35a70e9-4eae-4649-9e11-25db2045df61",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Medicaid Emergency Waivers, allowed United States expedite Medicaid coverage displaced individual streamlining documentation income requirements; Texas waiver programme TexKat largest programme, included urgent medical care delivery phase first month health care coverage phase next 5 month (35) Health workforce (n = 16)Training health worker building competency meet health need climate-affected migrant (n = 9) Expanding health workforce capacity response climate-related event emergency (n = 7)In Mali, climate change remains one leading driver conflict displacement Sahel, Government expanded health workforce availability incentivizing health worker assigned area dire need; cash incentive vary depend local ministry external assistance ( 36) Medicine supply (n = 3)Ensuring availabilit",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c6213399-bacc-4a8a-ac45-dc4ac067eedd",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "cal ministry external assistance ( 36) Medicine supply (n = 3)Ensuring availability medical supply climate-affected displaced migrant group (n = 3)Between May 2023 May 2024, IOM provided menstrual hygiene kit sanitary pad flood- displaced woman girl Danyar Refugee Camp Somalia ( 37) 10 Health system strengthening intervention improve health displaced migrant population context climate changeBuilding block Intervention type Illustrative example literature Health information system (n = 4)Establishing integrated surveillance system monitoring climate-sensitive health risk outcome among climate-affected displaced migrant population (n = 4)In 2021 International Centre Diarrhoeal Disease Research Bangladesh implemented waste-water surveillance programme refugee camp detect climate-sensitive infections, Vibrio cholerae Salmonel",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "69a892c6-c19c-484a-bf42-42c6ea6eb193",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "refugee camp detect climate-sensitive infections, Vibrio cholerae Salmonella typhi; programme expanded two city joint effort involving Government multilateral organization (38) Service delivery (n = 50)Providing humanitarian response health service climate-related emergency (n = 21) Ensuring access health service displaced population climate-affected protracted crisis (n = 6) Providing mental health intervention climate-affected displaced migrant population (n = 8) Improving WASH service climate-affected displaced migrant population (n = 13) Ensuring access vaccine recommended Essential Programme Immunization climate-affected displaced migrant population (n = 2)The Honduran Red Cross activated humanitarian service point point departure along route migrating caravan people vulnerable climate hazar",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "84fb8c68-bca3-4a72-a210-4b60daf37d88",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "departure along route migrating caravan people vulnerable climate hazards; point provided migrant water, face masks, prehospital care information safety, security coronavirus disease (COVID-19) prevention (39) Fifty-two intervention could described short-term reactive nature, responding abrupt shock extreme weather event. 43 intervention geared towards longer-term health system strengthening – example establishing mechanism (such disease surveillance system) remain sustained beyond single disaster event. Overall, 89 focused climate adaptation response health impacts, two addressed climate mitigation explicitly (i.e. reducing greenhouse gas emissions) four incorporated adaptation mitigation elements. note, intervention sustainable health care delivery (e.g. telemedicine, decentralized health care servic",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "126a853f-68ea-4bde-bd38-79f766146f8a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "tions sustainable health care delivery (e.g. telemedicine, decentralized health care services) may also indirect mitigation effect climate change.11 ResultsAlmost three quarter health intervention (n = 69) catered need population climate change identified publication driver population displacement. Nine intervention displaced conflict also risk climate hazards; six climate change conflict identified displacement drivers; 11 interventions, driver migration specified study. half (62%) intervention implemented internally displaced people (IDPs): 16% refugees, 4% hospital evacuees, 5% multiple migrant population (e.g. refugee IDPs) rest unspecified (12%). Climate hazard described study affected displaced migrant population included: tropical cyclone (26%) floo",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f1f9c7d4-061f-4ad5-9b67-a243d4563441",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "n study affected displaced migrant population included: tropical cyclone (26%) flood (19%) drought (12%) sea level rise (1%) wildfire (1%) multiple hazards, including heavy rains, mudslide rising temperature (14%). remaining publication referred climate change general. Health system intervention implemented variety actor (Fig. 2). Civil society nongovernmental organization Governments United Nations agency Health professional Academia Collaboration stakeholders, including private sector25% 20% 21%21% 10% 3%Fig. 2. Actors implementing health system intervention displaced migrant population affected climate change majority (n = 61) health system intervention identified implemented low- middle- income countries. example, seven intervention implemented Somalia, six implemented Ethiopia, South Sudan Yemen. Forty-three implem",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4ce05508-0765-4212-bf54-8030579521cb",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "lia, six implemented Ethiopia, South Sudan Yemen. Forty-three implemented fragile conflict-affected situation (40). Among high-income country (24 intervention identified), 12 Health system strengthening intervention improve health displaced migrant population context climate changeNot applicable 2.1 Governance Governance critical part health system heavily influence building blocks. Key component governance include oversight, agenda priority-setting, policy- decision- making, regulation, coalition building (33). 19 governance interventions, grouped four subcategories: include need climate-affected displaced migrant population climate health policy plan (n = 7) (34,39,41–45); enhance coordination service across agency responding health need climate-affected displaced migrant popula",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "60eb0dbf-11d0-48ab-93ee-621ecab714a1",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "across agency responding health need climate-affected displaced migrant population (n = 8) (46–51);interventions identified African Regioninterventions identified Region Americasin Eastern Mediterranean Regionin European Region South-East Asia Regionin Western Pacific Region 35 23175 64Fig. 3. Health system intervention across region Note: designation employed presentation material publication imply expression opinion whatsoever part concerning legal status country, territory, city area authorities, concerning delimitation frontier boundaries. Dotted dashed line map represent approximate border line may yet full agreement. Source: created GIS Centre Health DNA/DDI. © 2025; Licence: CC BY-NC-SA 3.0 IGO.18 intervention",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "883cd195-6a5f-4c69-9ad0-57657507419e",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "GIS Centre Health DNA/DDI. © 2025; Licence: CC BY-NC-SA 3.0 IGO.18 intervention United States America (Fig. 3). Four intervention explicitly specify country region, one implemented one region – governance intervention Namibia, Samoa Yemen (39).13 Results2.1.1 Include need climate-affected displaced migrant population climate health policy plan Several country international organization beginning recognize health need displaced migrant group affected climate change integrating issue national policy plans. example, Governments Ethiopia (41), South Sudan (42) Vanuatu (34) considered health well-being displaced population national climate change disaster plans. dedicated section health outline response health need displaced population",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4804d81c-ee04-4f83-a27b-984ee5fc0bf8",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "cated section health outline response health need displaced population context climate change, including strategy health system strengthening resilience building. Meanwhile, regional platform Regional Inter-Agency Standing Committee Southern Africa starting integrate migration displacement concept climate health response plans, recognizing climate change, driver migration, adverse effect displaced population (44). International organizations, including nongovernmental organization (NGOs), also collaborating government explore health need climate migrant assess well health need incorporated disaster response plan (39,44,45). 2.1.2 Enhance coordination service across agency responding health need displaced migrant population affected climate change Following extreme weather disaster",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "50f058dd-9ff9-4b4b-88c8-5dd5f079a03c",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "displaced migrant population affected climate change Following extreme weather disaster emergencies, coordination across agency stakeholder found essential managing health well-being need affected displaced migrant populations. intervention include activation emergency response plan forming coalition coordinate health response ( 46–50) . intervention focus strengthening collaboration governments, civil society organization international agency establish safe spaces, procure distribute medical supplies, reinforce human resources, connect displaced population affected climate change appropriate service ( 47–51) . 2.1.3 Involve displaced and/or relocated community planning implementation health intervention Here, term relocated community derived community relocation, defined permanent (or long",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "92a05bc9-213a-45bc-8da5-f8f9fd916a6a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ed community derived community relocation, defined permanent (or long-term) movement community (or significant part it) one location involve displaced and/or relocated community planning implementation health intervention (n = 1) (39); include climate migrant health system receiving country (n = 3) (50,52,53).14 Health system strengthening intervention improve health displaced migrant population context climate changeto another important characteristic original community, including social structures, legal political system worldviews, retained: community stay together destination social form similar community origin (54). Community engagement incorporating input displaced population essential ensuring health intervention designed tailored needs. humanit",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7f93c090-0b70-4995-b0d7-d57d08048c8b",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "al ensuring health intervention designed tailored needs. humanitarian response International Federation Red Cross Red Crescent Societies (IFRC), example, consider input displaced population better understand need following climate-related disasters, ensuring equitable access health, particularly among vulnerable group (e.g. elderly people people disabilities). Community engagement also led installation water system evacuation centre identified internally displaced community Samoa affected climate change (39). 2.1.4 Include climate migrant health system receiving country instance climate migrant cross national borders, government receiving country Ethiopia Malawi made effort include respective national health care systems, granting right access health care local citiz",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "379eb557-a2c7-4829-9265-256c3e7d4a90",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "national health care systems, granting right access health care local citizen (52,53). Health care services, including acute care, chronic disease care, sexual reproductive health services, mental health support vaccinations, provided displaced population upon arrival receiving area United States settlement camp Ethiopia (50,52). 2.2 Health financing Health financing vital ensure adequate funding health, allowing people access care need without facing financial hardship. well-designed health financing system raise necessary fund time high demand, reduce reliance out-of-pocket payment strengthen social protection system (33). Two health financing intervention identified review, could grouped as: allocate additional budget improve health service infrastructure climate-affected displaced migrant population (n = 2) (39,55)",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "00618b21-e35e-4d8b-bcea-c08e0d90becc",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "service infrastructure climate-affected displaced migrant population (n = 2) (39,55); improve breadth health insurance coverage include climate-affected displaced migrant population (n = 1) (35).15 Results 2.2.1 Allocate additional budget improve health service infrastructure climate-affected displaced migrant population International agency started allocating additional fund address health need displaced migrant population context climate change. UNHCR, example, launched Climate Resilience Fund increase availability environmentally sustainable resource displacement settings, clean energy power water system health infrastructure used refugee host community (55). Improving health infrastructure setting enhances availability quality health service displaced migrant population al",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc53a44a-64f3-49f3-a482-64248b528662",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "availability quality health service displaced migrant population also community host them. IFRC, Disaster Relief Emergency Fund, also made available additional fund improve health care service provision population displaced climate-related disaster address immediate health need (39). 2.2.2 Improve breadth health insurance coverage include climate-affected displaced migrant population Depending upon health financing structure, health insurance/financing mechanism may readily available population migrate displaced within country across borders. may consequence population displaced climate-related events, may require immediate health care service face financial repercussions. United States, Hurricane Katrina hit 2005, United States Government implemented waiver allowed state",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9f19e6b0-1f34-4fae-b756-1836cca256a0",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "rricane Katrina hit 2005, United States Government implemented waiver allowed state expedite provision health insurance displaced (35). 2.3 Health workforce health workforce consists \"all people engaged action whose primary intent protect improve health\" (33). includes health service provider (such midwives, nurses, physician others) health management support workers. public private sector; may paid unpaid (voluntary) include professional lay cadres. well-performing health workforce characterized available, competent, responsive productive health workers. Achieving requires opportunity capacity-building strengthening, well policy governing recruitment, retention labour migration management (33). review yielded 16 health workforce interventions, divided two groups: train health worker",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "43e094d6-af32-43e8-945c-bdbb291b60a7",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "health workforce interventions, divided two groups: train health worker build competency meet health need climate-affected migrant (n = 9) ( 38,39,56–62) ; expand health workforce capacity response climate-related event emergency (n = 7) (36,39,46,48–50,63).16 Health system strengthening intervention improve health displaced migrant population context climate change2.3.1 Train health worker build competency meet health need climate-affected displaced migrant population Building maintaining competence health worker essential provision high-quality responsive health services. achieved education training programme well capacity-building strengthening activity (33). important develop necessary skill address emerging climate-related health need (64). R efugee migrant toolki",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0ea18fd4-2e4c-413e-a195-c0de1a49c7fe",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ssary skill address emerging climate-related health need (64). R efugee migrant toolkit developed available governments, organization health care professional working refugee migrant health, module climate change risk among migrant (56). several regions, programme trained local community health care worker volunteer delivering community-based mental health psychosocial intervention displaced victim tropical storm flooding. resulted identifying medical need onward referral specialized mental health care facility appropriate (38,57). Pakistan, mobile application used aid local community health worker tracking, counselling referring individual mental health concern displaced flooding (57). Capacity-building programme identified address climate-related health outcomes. Globally, academic institution offer educational",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "01caf574-66a7-401c-8f08-9fc19e74db05",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ied address climate-related health outcomes. Globally, academic institution offer educational practical course medical student health professional provide training addressing health need displaced population climate- related disaster lead complex humanitarian emergency (61,62). national level, course included training health worker climate-affected displacement camp Somalia reduce neonatal maternal mortality (58) training blood smear preparation microfilaria detection health volunteer community displaced flooding Samoa (39). General medical training health care worker treat displaced population climate-affected area Brazil South Sudan also reported (59,60). 2.3.2 Expand health workforce capacity response climate-related event emergency Apart capacity-building health workers, ensuring availability ad",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f16215e2-ee82-48ce-9530-f26df4b113ee",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "emergency Apart capacity-building health workers, ensuring availability adequate number health worker essential ensuring continuous delivery health services. crucial disaster settings, resource capacity limited overstretched. Mali, like country Sahel region, severely affected climate change, leading displacement large number people. address emerging health needs, Government Mali implemented incentive programme encouraged health professional relocate practice climate-affected area (36). review found example hospital United States receiving influx migrant patient evacuee following climate-related disaster increased health care staff hiring extra qualified personnel, providing accommodation ensuring on-site availability. Displaced health care professional also able provide assistanc",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "787a0cdb-30e0-4b98-9a68-af7b24967945",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "uring on-site availability. Displaced health care professional also able provide assistance hospital support increased patient number (46,50). another example, health care professional volunteer international 17 Results agency neighbouring area also deployed climate-affected locality aid addressing health need displaced populations. example, medical team composed doctor nurse deployed provide medical assistance population displaced tropical storm torrential rain Italy (49), Mozambique (39) Nicaragua (48). Another example included mental health counsellor hired school provide counselling student displaced tornado United States (63). 2.4 Medicines supply High-quality well-functioning health system provide equitable access ensure availability, quality efficacy essential medicines, vaccines, diagnostics medic",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a7caf0eb-affa-4d67-857a-01e0f608d697",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "availability, quality efficacy essential medicines, vaccines, diagnostics medical technologies. Achieving requires robust system manufacturing, quality assurance, procurement, supply, storage distribution (33). three intervention related building block centred ensuring availability medical supply climate-affected displaced migrant population (37,44,48) . 2.4.1 Ensure availability medical supply climate-affected displaced migrant population Extreme weather, tropical storms, overwhelm health system disrupt supply essential medicine medical supplies. example, Nicaragua, medical supply distributed temporary shelter set hurricane response coronavirus disease (COVID-19) pandemic included prophylactic medicine climate- sensitive disease leptospirosis, personal protective equipment antigen",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "78b919f0-5517-4572-a386-2a3aaf8b732f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "climate- sensitive disease leptospirosis, personal protective equipment antigen polymerase chain reaction test COVID-19 (48). another example, sexual reproductive health need woman girl flood-displaced community Somalia South Sudan addressed distributing oral contraceptives, condoms, injectables menstrual hygiene kit (37,44).18 Health system strengthening intervention improve health displaced migrant population context climate change2.5 Health information system Health information system ensure production, analysis, dissemination use reliable timely health information aid decision-makers, implementers health professionals. Important component include robust disease surveillance systems, development standardized tool instruments, collation publication health statistic (33). Populations residing displacement camp tempor",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f05e5697-6d0c-4df3-a3e2-ced47ac09313",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "publication health statistic (33). Populations residing displacement camp temporary evacuation centre high risk contracting communicable disease issue overcrowding, poor sanitation, lack vaccination delayed health service delivery (65). Therefore, robust health information systems, including integrated surveillance systems, essential monitoring disease outbreak potential settings. literature revealed four intervention relating establishment integrated surveillance system monitoring climate-sensitive health risk outcome among climate-affected displaced migrant population (38,47,66,67). 2.5.1 Establish integrated surveillance system monitoring climate-sensitive health risk outcome among climate-affected displaced migrant population Following acute displacement due extreme weather events, government stakeholder Mozambique, Si",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "193b07a2-90a1-4cdf-a57b-7b097b9e034c",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "e displacement due extreme weather events, government stakeholder Mozambique, Sierra Leone Solomon Islands enhanced surveillance disease reporting established sentinel site evacuation camp (47,66,67). Emergency surveillance task force established monitor climate-sensitive disease disease high outbreak potential, dengue, cute watery diarrhoea cholera. Data surveillance effort used health programme planning well implementing water, sanitation hygiene (WASH) intervention health promotion strategy affected population (47,67). Integrated surveillance system implemented population protracted displacements, Rohingya residing camp Cox’s Bazar, Bangladesh. Collaboration academic institutions, government agency multilateral organization enabled monitoring detection climate-sensitive disease waste-water",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f036490f-6a59-4045-9a9c-ac34beba0bc2",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "organization enabled monitoring detection climate-sensitive disease waste-water low-resource settings, including refugee camp ( 38). 2.6 Service delivery According health system framework (33), \"g ood health service deliver effective, safe, quality personal non-personal health intervention need them, needed, minimum waste resources\" . include prevention, treatment rehabilitation services, may delivered home, community, workplace health facilities. building block involves input service organized managed ensure access, quality, safety continuity care across health condition setting time. organization management health provider networks, along adequate infrastructure logistics, essential effective health service delivery (33).19 ResultsA total 50 intervention involved",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "31bc68be-5e23-4cd1-a753-0631943b3f90",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "essential effective health service delivery (33).19 ResultsA total 50 intervention involved provision health service displaced population context climate change. classified five groups: 2.6.1 Provide humanitarian response health service climate-related emergency climate crisis increasing frequency intensity extreme weather events, country lacking preparedness resilience continue face worsening humanitarian need (94). Climate- related disaster disrupt delivery quality safe health care services, particularly among displaced population (95). response, government international agency IFRC, IOM, Médecins Sans Frontières (MSF) UNHCR provided primary health care services, including disease consultations, screening treatment common climate-sensitive disease (e.g. malaria, respiratory tract infection diarrhoea) displa",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e22ab6e6-bc14-4020-95b3-7c8858d6b31d",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "climate-sensitive disease (e.g. malaria, respiratory tract infection diarrhoea) displaced people evacuation camp area climate affected, including Mozambique, Somalia, South Sudan United States (39,60,68–72) . No-cost medicine distributed temporary evacuation centre housing displaced population Italy United States ( 49,71,72) . nutritional need internally displaced child pregnant lactating woman addressed systematic nutritional screening Somalia (68), high-nutrient feeding intervention took place Chad part Horn Africa refugee IDPs (73,74) . Emergency mental health psychosocial support routine vaccination communicable disease provided Chad Somalia, particularly among internally displaced child ( 68,74) . Emergency WASH service delivered Chad, Iraq, Germany, Mozambique, Namibia, Sierra Leone, South Sudan",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "337daa8c-a4e4-4e14-a9ed-8a1ffeeebf14",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "WASH service delivered Chad, Iraq, Germany, Mozambique, Namibia, Sierra Leone, South Sudan Yemen refugee IDPs. intervention include providing safe drinking-water, repairing rehabilitating existing water systems, distributing water treatment tablets, distributing body bags, emptying latrine setting sanitation hand-washing facility ( 39,47,69,73–75) .provide humanitarian response health service climate-related emergency (n = 21) (39,46,47,49,60,68–77) ; ensure access health service displaced population climate-affected protracted crisis (n = 6) (37,39,78–80) ; provide mental health intervention climate-affected displaced migrant population (n = 8) (47,49,59,63,81–85) ; improve WASH service climate-affected displaced migrant population (n = 13) ( 37,39,68, 73,86–92); ensure access vaccine climate-affected displaced migrant population (n = 2) (47,93).20 Health system strengthe",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8d0838ca-602f-4306-898c-b7b71d89fc68",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "e climate-affected displaced migrant population (n = 2) (47,93).20 Health system strengthening intervention improve health displaced migrant population context climate changeSome intervention involved establishing emergency medical facility deploying mobile health clinic provide emergency health service medicine displaced population Chad, Germany, Iraq, Sierra Leone, Somalia United States (39,46,47,49,71,72,74,77). anticipation large influx displaced patient extreme weather events, hospitals, New York City, United States, implemented preparatory measure ensure continuous provision health services, adjusting operating room schedules, ensuring early delivery supply maintaining adequate on-site staff (46). 2.6.2 Ensure access health service displaced population climate-affected protracted crisis Populations displaced due protracted",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "110b67ad-5f9a-49f8-8a18-a21541cf3092",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "pulations climate-affected protracted crisis Populations displaced due protracted crisis face long-term exposure climate health risks, particularly IDP refugee camp setting ( 96). Refugee settlement rarely based principle enhance well-being resilience refugee often contain adequate sanitation (97). situations, organization MSF shifted emergency care sustained health service meet ongoing need displaced population affected climate hazards. Free basic public health service provided clinic health post inside refugee IDP camp Chad, Somalia South Sudan (78–80). service include vaccinations, maternal care, health consultations, care service chronic disease HIV tuberculosis, psychological support. Referrals tertiary hospital also available. Health facility also enhanced newly established",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "302ef099-c567-4e48-abec-08428297d28a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "tiary hospital also available. Health facility also enhanced newly established accommodate climate-affected refugee protracted crises. example, humanitarian service point set along migration route caravan Central America provide health care (39), health facility refugee camp equipped solar power system ensure continued provision health care Bangladesh (59). 2.6.3 Provide mental health intervention climate-affected displaced migrant population Mental health psychosocial support service important displaced migrant population due risk developing mental disorder (98). Additionally, climate change climate-related disaster also found negatively affect mental health vulnerable populations, particularly displaced migrant group (99–101). Directly following extreme weather disasters, government international",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "451fd07f-6a6f-4f5b-8aed-e15bb9a6c3cb",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "migrant group (99–101). Directly following extreme weather disasters, government international agency supported deployment psychologist Canada, Italy, Sierra Leone United States provide psychological first-aid, counselling support displaced population (47,49,63,81) . Screening mental health outcome proper referral specialized mental health care also available countries, well Bangladesh (49,63,82,83). mental health programme also implemented, peer mentorship programmes, mindfulness psycho-educational programme Canada migration helplines India (82,84). Mental health also integrated community-based health 21 Resultsservices within basic health service refugee IDPs residing camp Bangladesh Burkina Faso according Mental Health Gap Action Programme (mhGAP) guideline (83,85). 2.6.4 Improve WASH service climate-affected displa",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2294c48d-e754-4a73-9939-88f4e59410fe",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Action Programme (mhGAP) guideline (83,85). 2.6.4 Improve WASH service climate-affected displaced migrant population Displaced population often live camp temporary shelter access clean water proper sanitation, increasing risk contracting communicable diseases. Women, example, impacted access adequate WASH service menstrual feminine hygiene product safe space ( 102) . WASH included role disease prevention health promotion, part integrated health service delivery. International organizations, including IFRC, IOM, UNHCR UNICEF, leading WASH intervention IDP refugee camp area affected water insecurity droughts. organization provided clean safe water population displaced due changing climate Afghanistan, Ethiopia, Mozambique, Pakistan, Somalia, Yemen part",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5c143311-bd11-4645-a401-e1b6577d9dc4",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "changing climate Afghanistan, Ethiopia, Mozambique, Pakistan, Somalia, Yemen part Africa establishing water rehydration points, constructing lead-line hand pumps, digging boreholes, repairing damaged water system providing water trucking (37,68,86–89). Solar-powered water system constructed Ethiopia, Mozambique Yemen (87,89–91), rainwater harvesting system installed Samoa (39) provide reliable economical access water without need rely expensive short-term emergency water intervention water trucking. Sanitation facilities, including latrines, handwashing stations, lavatory facility private spaces, constructed refugee IDP camp Ethiopia, Pakistan Somalia (37,86,87). Hygiene kit water treatment supply also distributed camp Ethiopia, Somalia Yemen (37,87,88). Hygiene promotion health education programme al",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4522dda5-d75a-448a-b968-4624e78de745",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "n Ethiopia, Somalia Yemen (37,87,88). Hygiene promotion health education programme also implemented camp Afghanistan, Ethiopia, Mozambique, Pakistan, Somalia Yemen, focus combating vaccine hesitancy, preventing acute watery diarrhoea cholera promoting proper handwashing (37,68,86–88,91). outbreak acute watery diarrhoea cholera occurred, Yemen, screening, treatment vaccination effort implemented (68). intervention Afghanistan, Bangladesh Somalia focused menstrual hygiene woman girl camp distributing gender-response hygiene kit communal female WASH unit private toilets, shower disposal system (37,88,92). 2.6.5 Ensure access vaccine climate-affected displaced migrant population Overcrowding poor sanitation refugee camp temporary shelter increase risk disease outbreaks, cholera. response outbrea",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "64d81a88-7249-4ceb-a77e-189cc8570718",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "temporary shelter increase risk disease outbreaks, cholera. response outbreak Malawi Sierra Leone, government implemented mass vaccination campaign administer oral cholera vaccine displaced population living temporary shelter following climate-related disaster IDP refugee camp case protracted displacement. Vaccination task force formed coordinate campaign activity vaccine distributed help community health worker ( 47,93) .22 3. Discussion 3.1 Strengths, limitation research gap 3.1.1 Strengths review identified 95 intervention across 56 publication focused strengthening health system displacement migration context climate change. health system building block framework used approach categorizing interventions. intervention classified intervention types, discussed detail",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0378c3e1-6336-4667-ae03-388cca96af23",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "e intervention classified intervention types, discussed detail Results. intervention type provide structured framework governments, policy-makers implementers address health system challenge faced climate–migration–health nexus. example, governance building block, four intervention type identified: including need climate-affected displaced migrant population climate health policy plans; enhancing coordination service across agency responding health need climate- affected displaced migrant populations; involving displaced and/or relocated community planning implementation health interventions; including climate migrant health system receiving countries. 3.1.2 Limitations review included reference English, peer-reviewed grey literature; consequently, intervention langu",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9033730c-4052-4e5f-afea-7d4cc80491d0",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "English, peer-reviewed grey literature; consequently, intervention language may missed. unavailability full text literature also posed limitation accessing potentially relevant different evidence. also gap intervention identified; might context labelled related climate change intervention used across contexts. review, intervention classified according main/primary building block addressed, based researchers’ judgement. Many intervention literature also addressed either second multiple building blocks. also variability migration term used literature, \"climate-affected migrants\" \"climate-induced migration\" . variability addressed interpreting wider report understand population referred to, terminology report",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5b021806-26ad-4487-94e4-8329c03e672f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "understand population referred to, terminology report aligned Glossary explanation beginning report.23 Discussion3.1.3 Research gap clear evidence gaps, detailed follows. Long-term intervention proactively address health need displaced population found scarce. majority intervention found short term reactive nature, often implemented response climate-related disaster emergency (e.g. tropical cyclone). example, service delivery building block comprised least half total interventions, focused activating emergency response protocol providing emergency health service displaced population directly following climate hazard (39,46–49,51,60,68–77) . intervention respond current urgent health risk important, need health system implement resilient, sc",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "02021334-d588-461b-9985-d9e021107855",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "nd urgent health risk important, need health system implement resilient, scalable sustainable intervention tackle climate health challenge long term. Long-term intervention proactively address health need displaced population found less frequently. include installing water system possible evacuation centre Samoa (39) establishing waste-water surveillance system Rohingya camp Bangladesh detect climate-sensitive disease prevent outbreak (38). latter example provided pathway enable government buy-in ownership. programme expanded two city joint effort involving five Government body multilateral organization following success camp (38). limited evidence intervention integrating climate mitigation. Climate action within health system two dimension – climate mitigation, aim reduce greenhouse ga",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "eaf99da6-9d93-47c2-9d2e-a0e8f52dbd20",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "within health system two dimension – climate mitigation, aim reduce greenhouse gas emission slow progression, climate adaptation, aim address reduce health impacts. review, around 90% intervention involved climate adaptation six found explicitly include mitigation principles. mitigation strategy found incorporated government plan (34,41–43) , UNHCR Climate Resilience Fund ( 55) Climate Change module Refugee migrant toolkit ( 56). full discussion climate mitigation beyond scope review. However, health system also contribute climate change – estimate show around 4–5% global greenhouse gas emission attributable health sector ( 103) . Hence, need also incorporate climate mitigation measures, even primary focus health system adaptation resilience climate change. Gaps evidence",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c2bfa02a-f942-450d-89bd-ac3bb9f51f2b",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "f primary focus health system adaptation resilience climate change. Gaps evidence synergy health system strengthening planning, resilience preparedness. Another evidence gap health system-wide approach cut across multiple building blocks. Certain health system building block underrepresented, 24 Health system strengthening intervention improve health displaced migrant population context climate changethe intervention area also limited scope. example, intervention medicine supply involved distribution medical health care supplies, despite building block also covering aspect supply chain (such manufacturing, quality control, storage distribution). Similarly, health financing building block three interventions, covered allocating additional budget health service infrastructure expanding healt",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "69d41dba-9db8-4784-a5a3-838d54bc49f3",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "hich covered allocating additional budget health service infrastructure expanding health insurance coverage. Additionally, intervention found health information system building block focused disease surveillance climate-related events, lacking function comprehensive information system collecting managing health data climate migrants. need variety intervention address different aspect building block. addition, effectiveness many included intervention explicit reports. included review documented implementation phase, seen evaluation component (36,38,48,57,66,76,82). thorough research need conducted regarding effectiveness, sustainability impact implemented interventions. geographical area underrepresented. term geographical distribution, health system inter",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "38738386-6187-4c09-8e6b-eb8608e0ad2f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "phical area underrepresented. term geographical distribution, health system intervention identified review mostly implemented low- middle-income countries, particularly African Region Eastern Mediterranean Region. large proportion intervention also implemented country fragile conflict-affected situations. small number intervention identified South-East Asia Region Western Pacific Region despite experience climate change migration ( 104,105) . European Region, also experience climate change related internal displacement ( 106) , also underrepresented current review. may linked limitation identified regarding unavailability full text published work inclusion English language study only. Understanding context-specific operationalization health sys",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0d134a63-2d96-47a1-8990-1f7ecf7eaf85",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "English language study only. Understanding context-specific operationalization health system intervention important support climate-affected displaced migrant population accessing health care. also help identify evidence, policy implementation gaps, could inform future research policy priority offer crucial guidance targeted support resource allocation future.25 Discussion3.2 Key finding evidence review three key finding review: intervention show extensive coordination humanitarian organizations, governments, academics, private sector community members; innovative intervention emerging; existing intervention adapted migrant inclusive climate resilient. 3.2.1 Interventions show extensive coordination humanitarian organizations, governments, academics, private sector community member climate–migration–health",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e6cc76ee-f86e-4d89-8150-b5104733c012",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "governments, academics, private sector community member climate–migration–health nexus present opportunity cross-sectoral interdisciplinary collaboration. review shown coordination across actor involved health wider response. example, response city Houston Orlando United States influx refugee displaced hurricanes, coordination health sector, local governments, private sector NGOs essential. Referral system point care made available migrant network stakeholder supported health sector (50). Coordination WASH sector also prominent, particularly emergency responses. Intersectoral collaboration needed create programme address overarching health need migrant population context climate change. half identified intervention supported population",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "00f5016d-2671-46b6-8c2c-a12e71ad63bd",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ntext climate change. half identified intervention supported population internally displaced. International refugee migrant may face additional legal social challenge destination countries, often face discrimination, possible abuse exploitation. Additionally, cross-border migrant may face barrier accessing essential health care legal status (107). Engaging displaced/or relocated population migrant also important ensure intervention tailored need contexts. example, IFRC gather input displaced community ensure humanitarian intervention evidence informed (39). Similarly, involving local community health worker volunteer delivering intervention displaced population also effective, case community-based mental health psychosocial intervention Myanmar following tropical cyclo",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3d924c1b-2786-43db-8e19-c9258a1f59fb",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "community-based mental health psychosocial intervention Myanmar following tropical cyclone (38) Pakistan following intense flooding (57). 26 Health system strengthening intervention improve health displaced migrant population context climate change3. 2.2 Innovative intervention emerging review yielded diverse array health system intervention aimed strengthening health system respond need displaced migrant population affected changing climate facing climate hazards. Innovative intervention address health need displaced population context climate change emerging. example, mPareshan application, used deliver mental health intervention facilitate referral population affected flood Pakistan, demonstrates technology incorporated community-based mental health response ( 57). Health system also beginning ado",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b4910357-0e68-48f6-b4a3-8a0cbe653fce",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "porated community-based mental health response ( 57). Health system also beginning adopt intervention incorporate climate-related considerations. Implementing climate-resilient environmentally sustainable technology electrifying health care facility essential ensure continuous operation clinics, particularly region vulnerable extreme weather event climate change ( 108) . Installing solar-powered water system community photovoltaic electrical system health facilities, example, allowed displaced population continuous access clean water electricity, thereby reducing reliance high-carbon-emitting fuel generator (59,87,89–91) . Climate-related displacement also served basis United States Government expedite Medicaid coverage affected Hurricane Katrina 2005 ( 35). example demonstrate importance innovative thinking health system strength",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4d6453d5-2c39-42d0-a604-83cb48459ac7",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "5 ( 35). example demonstrate importance innovative thinking health system strengthening, particularly context climate change migration. look promising, far between. 3.2.3 Existing intervention adapted migrant inclusive climate resilient Many intervention found familiar health system strategy new principle practice still effective context migrant population affected climate change. example, rehabilitating refurbishing water system (37,68,86–89) , deploying mobile health unit provide emergency health care ( 39,46,47,49,71,72,74,76) mass vaccination campaign (47,93) action implemented broad population groups. case, also applicable displaced population context climate change. Efforts focus innovation also strengthening improving system",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4e768f7a-7997-488e-84e1-9e6853d0f491",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "fort focus innovation also strengthening improving system already place improve climate resilience reduce greenhouse gas emission integration displaced migrant population within system support target universal health coverage. principle universal health coverage emphasizes making essential health service available accessible host migrant populations. involves making sure migrant access health service addressing specific barrier limit service utilization among migrants. Combining well-known strategy innovation allows well-rounded health system intervention support health climate-affected displaced migrant populations.27 Discussion 3.3 Policy consideration strengthen health system better address health need displaced populations, including refugee migrants, context c",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e6b699f0-70a0-487b-af64-b2806f0af35d",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "es health need displaced populations, including refugee migrants, context climate change, review identified following priorities. 3.3. 1 Ensure meaningful inclusion engagement displaced migrant population policy planning delivery Incorporating input displaced population essential ensuring health intervention designed group tailored needs. Integrating community perception support design implementation intervention hallmark feature government organization address health need climate-displaced populations. 3.3 .2 Address knowledge gap health system strengthening intervention context migration climate change Interventions address identified knowledge gap implemented policy programmes, ongoing evaluation. require transdisciplinary intersectional Move",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f0b8b0c5-0ba4-4c37-8b88-fe76e9e794ae",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "programmes, ongoing evaluation. require transdisciplinary intersectional Move towards whole-of-route approach support continuity careThink beyond health system building block integrating essential public health function health system resilience considerationsEnsure inclusion migrant, refugee displaced population building health systemsEnsure meaningful inclusion engagement displaced migrant population policy planning deliveryAddress knowledge gap health system strengthening intervention context migration climate changeShift towards proactive long- term strategy designing planning health system migrant inclusive climate resilient28 Health system strengthening intervention improve health displaced migrant population context climate changeresearch (109,110) build evidence health system-strengthening interven",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "30144113-48ef-463b-bcd0-61025d7f0e60",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "text climate changeresearch (109,110) build evidence health system-strengthening intervention effective sustainable. Implementation research must build existing good practice well embrace innovation designing new interventions. research needed understand key population geographical area focus. critical ensure context- specific adaptation localization, well dissemination scale-up diverse settings. 3.3.3 Shift towards proactive long-term strategy designing planning health system migrant inclusive climate resilient crucial move beyond short-term reactive response look longer-term health need climate-affected displaced migrant populations. focus must include proactive, long-term strategy designing planning health system migrant inclusive climate resilient. fa",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "70bc844e-af2c-4723-967e-c03887bdcc1e",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "designing planning health system migrant inclusive climate resilient. far, health system strengthening intervention identified reactive nature, implemented response specific climate hazard health emergencies. immediate short-term action necessary, designed sustainability scalability mind. built last expanded effectively, intervention contribute long-term improvement health system (26). 3.3.4 Move towards whole-of-route approach support continuity care additional health risk migrant face due climate change emphasize urgent need access, continuity safety health care often disrupted factor weak health system capacity barrier access (e.g. gender, cultural, financial, social, language) (21). many countries, health system access among climate-affected displaced migrant population",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "59a50dcc-cd7c-4c1c-b335-9b40f21dcf0d",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "n many countries, health system access among climate-affected displaced migrant population fragmentary, mostly limited emergency services, immunization mother child preventive service (31). whole-of-journey approach urgently needed considers migrants’ health service access, safety domestic gender-based violence safety climate hazard (21,79,110–112) . 3.3.5 Think beyond health system building block integrating essential public health function health system resilience consideration essential public health function form basis improving public health practice building resilient health system capable meeting universal health coverage goals. Essential public health function include health service equity quality; public health research, evaluation knowledge; access utilization health products; public health workforce development; community engagement social protection;",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7caba771-421b-472a-856c-3528196f581c",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "health products; public health workforce development; community engagement social protection; health promotion; disease prevention early detection; health protection; multisectoral planning, financing management public health; 29 Discussionpublic health stewardship; public health emergency management; public health surveillance monitoring (113) . review capture example critical intervention including intervention surveillance community engagement characteristic essential public health functions. integration essential public health function health system resilience consideration health system building block essential creating adaptable sustainable health care system capable anticipating, absorbing recovering chronic acute shock ensuring refugee- migrant-inclusive health system context climate change. widely used understood gl",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "50b0198c-6eba-4a5e-a7f8-d902fb651e5a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "rant-inclusive health system context climate change. widely used understood globally health stakeholders, including ministry health, health system building block framework may include complexity strengthening health systems: intervention health promotion education, information dissemination, occupational health initiative workplace intervention addressing social determinant health displaced populations. Examples include designing creating laundry bag improve menstrual hygiene privacy girl refugee camp (92) vector-control strategy prevent dengue outbreak following flood (66). beyond scope report, still relevant important enhance health displaced migrant population amidst climate crisis. addition, building block tend focus provider/supplier side rather demand/ac",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3585251b-02e2-4503-95b4-2f0111bee5c2",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ition, building block tend focus provider/supplier side rather demand/accessibility perspective. 3.3.6 Ensure inclusion migrant, refugee displaced population building health system building climate-resilient environmentally sustainable migrant-inclusive health systems, essential observe inclusion displaced migrant populations, climate change-related considerations. need synergy across policies, guidance monitoring frameworks, play role supporting implementation appropriate accessible health services. require including displaced population building climate-resilient environmentally sustainable health system including climate consideration effort addressing health need refugees, migrant displaced population humanitarian, emergency development settings. 3.4 Next step supporting migrant",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c045f27a-d74d-4d2b-b5af-c17ce5652352",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ulations humanitarian, emergency development settings. 3.4 Next step supporting migrant-inclusive climate-resilient health system review showcase opportunity migrant inclusivity embedded within climate resilience framework climate consideration included refugee migrant health system 30 Health system strengthening intervention improve health displaced migrant population context climate changeClimate-resilient low- carbon health systemsHealth system building blocksMigrant- refugee-inclusive health system context climate change Climate transformative leadership governanceGovernanceInclude need climate-affected migrant climate health policy plan Enhance coordination service across agency responding health need climate-affected displaced migrant population Involve displaced and/or relocated community planning",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7e5f98c0-1c4e-4a49-b665-883221848c9d",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "displaced migrant population Involve displaced and/or relocated community planning implementation health intervention Including climate migrant health system receiving country Sustainable climate health financingHealth financingAllocate additional budget improve health service infrastructure climate- affected displaced migrant population Improve breadth health insurance coverage include climate-affected displaced migrant populationsTable 2. Mapping finding Operational framework climate resilient low carbon health systemsstrengthening. Table 2 initial mapping incorporating migrant-inclusive approach climate- resilient environmentally sustainable health system incorporating climate perspective effort addressing health need refugees, migrant displaced populations. example, need train health worker build competencie",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7c6300e0-3323-47f3-8026-e0511423cd48",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "nd displaced populations. example, need train health worker build competency meet health need climate-affected displaced migrant population identified within review build upon need climate-smart health workforce, highlighted Operat ional framework climate resilient low carbon health system (26). Similarly, need establish integrated surveillance system monitoring climate- sensitive health risk outcome among climate-affected displaced migrant population brings together expands upon framework’s component health climate research, \"integrated risk monitoring early warning\" \"assessment climate health risks\" .31 DiscussionClimate-resilient low- carbon health systemsHealth system building blocksMigrant- refugee-inclusive health system context climate change Climate-smart health workforceHealth workforceTrain health worker build",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3d3768cb-4a41-472a-ba98-e8d273dbb8df",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "f climate change Climate-smart health workforceHealth workforceTrain health worker build competency meet health need climate-affected migrant Expand health workforce capacity response climate-related event emergency Climate-resilient low- carbon infrastructures, technology supply chainMedicine suppliesEnsure availability medical supply climate-affected migrant displaced people Health climate research Integrated risk monitoring, early warning greenhouse gas emission tracking Assessments climate health risk greenhouse gas emissionsHealth information systemsEstablish integrated surveillance system monitoring climate-sensitive health risk outcome among climate-affected displaced migrant population Climate-related emergency preparedness management Climate-informed health programme Management environmental determinant healthService deliveryProvide h",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ac83fafe-5c1a-4703-9ff6-abc06a726312",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "med health programme Management environmental determinant healthService deliveryProvide humanitarian response health service climate-related emergency Ensure access health service displaced population climate-affected protracted crisis Provide mental health intervention climate- affected displaced migrant population Improve WASH service climate-affected displaced migrant population Ensure access vaccine climate-affected displaced migrant population first step work might include mapping wider intervention migrant- refugee-inclusive health systems, well broadening model beyond building blocks. integrated health system strengthening approach crucial achieving universal health coverage health within changing climate.32 4. Conclusions report provides global, systematic overview health system intervention addressing heal",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "18ab9232-37a5-4b22-a7da-56b8478e7521",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "eport provides global, systematic overview health system intervention addressing health need displaced migrant population context climate change, spanning health system building blocks. review included peer-reviewed grey literature publication detailed specific health system intervention responding climate change generally specific climate hazard aimed addressing health need refugees, migrant displaced populations. many documented intervention familiar, demonstrate innovation. Building work, also need stronger focus integrated systemic approach effectively strengthen health system improve health displaced migrant population changing climate. Additionally, inclusion literature different language would help capture varied evidence. ensure migrant-inclusive climate-resilient health syst",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c2d67472-d6f3-4e0e-8552-f4597a5da0b3",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "help capture varied evidence. ensure migrant-inclusive climate-resilient health systems, evidence gap identified review must addressed cross-sectoral interdisciplinary research action. ensure coherence across policies, programme frameworks, crucial apply migration lens climate-resilient health system agenda climate lens migration health efforts. Finally, crucial move beyond short-term reactive response longer-term health need climate-affected displaced migrant population build effective, resilient, realistic accessible migrant-inclusive climate-resilient health systems. 3233 References1 1. World migration report 2020. Geneva: International Organization Migration; 2019 (https://publications.iom.int/system/files/pdf/wmr_2020.pdf ). Licence: CC BY-NC-ND 3.0 IGO. 2. Refugee data finder. In: Refugee population statistic [online database]. Geneva: Un",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e21d210e-ad68-4ea7-aa25-4d15b971287c",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "-ND 3.0 IGO. 2. Refugee data finder. In: Refugee population statistic [online database]. Geneva: United Nations High Commissioner Refugees; 2023 (https://www.unhcr.org/refugee-statistics). 3. World report health refugee migrants. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/360404). Licence: CC BY-NC-SA 3.0 IGO. 4. Haines A, Ebi K. imperative climate action protect health. N Engl J Med. 2019;380(3):263–73 (https://doi.org/10.1056/nejmra1807873). 5. Uddin R, Philipsborn R, Smith D, Mutic A, Thompson LM. global child health perspective climate change, migration human rights. Curr Probl Pediatr Adolesc Health Care. 2021;51(6):101029 (https://doi.org/10.1016/j.cppeds.2021.101029). 6. GRID 2024: global report internal displacement. Geneva: Internal Displacement Monitoring Centre; 2024 (https://api.internal-displacement.org/sites/default/files/publications/documents/ IDMC-GRID-2024-Global-Report-on-Internal-Displa",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4e965928-99b5-4ea0-8a85-bb3b99ca5e09",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ment.org/sites/default/files/publications/documents/ IDMC-GRID-2024-Global-Report-on-Internal-Displacement.pdf ). 7. Clement V, Rigaud KK, de Sherbinin A, Jones B, Adamo S, Schewe J et al. Groundswell part 2: acting internal climate migration. Washington, DC: World Bank; 2021 (https://openknowledge. worldbank. org/entities/publication/2c9150df-52c3-58ed-9075-d78ea56c3267). Licence: CC BY-4.0. 8. slow onset effect climate change human right protection cross-border migrants. Geneva: Office United Nations High Commissioner Human Rights; 2018 (https://www. ohchr.org/sites/default/files/Documents/Issues/Migration/OHCHR_slow_onset_of_ Climate_Change_EN.pdf ). Licence: CC BY-4.0. 9. Radhan B, Kjellstrom , Atar D, Sharma P , Kayastha B, Bhandari G et al. Heat stress impact cardiac mortality Nepali migrant worker Qatar. Cardiology. 2019;143(1–2):37–48 (https:// doi.org/10.1159/000500853). 10. Kjellstrom , Oppermann E,",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9aded3a4-11a6-4b1c-90b8-1e09a1abf2bd",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "2019;143(1–2):37–48 (https:// doi.org/10.1159/000500853). 10. Kjellstrom , Oppermann E, Lee JKW. Climate change, occupational heat stress, human health, socioeconomic factors. In: Theorell , editor. Handbook socioeconomic determinant occupational health: macro-level micro-level evidence. Cham: Springer International; 2020:71–89 (https://doi.org/10.1007/978-3-030-31438-5_37). 1 reference accessed 30 March 2025.34 Health system strengthening intervention improve health displaced migrant population context climate change11. El Khayat M, Halwani DA, Hneiny L, Alameddine I, Haidar MA, Habib RR. Impacts climate change heat stress farmworkers’ health: scoping review. Front Public Health. 2022;10:782811 (https://doi.org/10.3389/fpubh.2022.782811). 12. Bloss JE, LePrevost CE, Zahra AG, Firnhaber GC, Cofie LE, Zepeda R et al. Advancing health migrant seasonal farmworkers United States: identif",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4f403072-2325-4453-a99e-bf021543b4be",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "eda R et al. Advancing health migrant seasonal farmworkers United States: identifying gap existing literature, 2021. Health Promot Pract. 2022;23(3):432–44 (https://doi. org/10.1177/15248399211033308). 13. Lundgren-Kownacki K, Kjellberg SM, Gooch P , Dabaieh M, Anandh L, Venugopal V. Climate change- induced heat risk migrant population working brick kiln India: transdisciplinary approach. Int J Biometeorol. 2018;62(3):347–58 (https://doi.org/10.1007/s00484-017-1476-0). 14. Adams H. population persist: mobility, place attachment climate change. Popul Environ. 2016;37(4):429–48 (https://doi.org/10.1007/s11111-015-0246-3). 15. Nash SL. Cancun Paris: era policy making climate change migration. Glob Policy. 2018;9(1):53–63 (https://doi.org/10.1111/1758-5899.12502). 16. Abubakar I, Aldridge RW, Devakumar D, Orcutt M, Burns R, Barreto ML et al. UCL– Lancet Commission Migration Health: health world",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b524dda0-d74b-4e4b-b4ab-9f6736366dde",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "urn R, Barreto ML et al. UCL– Lancet Commission Migration Health: health world move. Lancet. 2018;392(10164):2606–54 (https://doi.org/10.1016/S0140-6736(18)32114-7). 17. Schütte S, Gemenne F, Zaman M, Flahault A, Depoux A. Connecting planetary health, climate change, migration. Lancet Planet Health. 2018;2(2):e58–9 (https://doi.org/10.1016/S2542-5196(18)30004-4). 18. McMichael C. Human mobility, climate change, health: unpacking connections. Lancet Planet Health. 2020;4(6):e217–18 (https://doi.org/10.1016/s2542-5196(20)30125-x). 19. Hunter LM, Koning S, Fussell E, King B, Rishworth A, Merdjanoff et al. Scales sensitivity climate vulnerability, displacement, health. Popul Environ. 2021;43(1):61–81 (https://doi.org/10.1007/s11111-021-00377-7). 20. Schwerdtle PN, McMichael C, Mank I, Sauerborn R, Danquah I, Bowen KJ. Health migration context changing climate: systematic literature assessment. E",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "98a29718-ec50-461e-8b75-8d3d9f037cf5",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "J. Health migration context changing climate: systematic literature assessment. Environ Res Lett. 2020;15: 103006 (https://doi.org/10.1088/1748-9326/ ab9ece). 21. Bellizzi S, Popescu C, Panu Napodano CM, Fiamma M, Cegolon L Global health, climate change migration: need recognition \"climate refugees\" . J Glob Health. 2023;13:103006 (https:// doi.org/10.7189/jogh.13.03011). 22. Mannanal MS, Mohan A. Unveiling health concern climate migrants: narrative review. Asian Res Arts Soc Sci. 2024;22(3):50–60 (https://doi.org/10.9734/ arjass/2024/v22i3522).35 References23. Anantapong K, Moura HF, Udomratn P , Persaud A, Javed A, Ramachandran P et al. Geopsychiatry: climate change, migration, mental health. Ind Psychiatry J. 2024;33 (suppl 1):S257–60 (https://doi.org/10.4103/ipj.ipj_33_24). 24. Universal health coverage [fact sheet]. World Health Organization; 2023 (https://www.who.int/ news-room/fact-sheets/detail/universal-health-coverage-",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "48ec2e5d-80f6-46bb-a4f8-3ecb95408746",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "lth Organization; 2023 (https://www.who.int/ news-room/fact-sheets/detail/universal-health-coverage-(uhc)). 25. Mosadeghrad AM, Isfahani P , Eslambolchi L, Zahmatkesh M, Afshari M. Strategies strengthen climate-resilient health system: scoping review. Glob Health. 2023;19(1):62 (https://doi.org/10.1186/s12992-023-00965-2). 26. Operational framework building climate resilient low carbon health systems. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/373837). Licence: CC BY-NC-SA 3.0 IGO. 27. Mapping health systems’ responsiveness refugee migrant health need Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/346682). Licence: CC BY-NC-SA 3.0 IGO. 28. Vearey J, Orcutt M, Gostin L, Braham CA, Duigan P . Building alliance global governance migration health. BMJ. 2019;366:l4143 (https:// doi.org/10.1136/bmj.l4143). 29. Darlington F, Norman P , Goules M. Health",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1fa6412c-0c2d-4108-871b-c9a5c2e10bac",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "366:l4143 (https:// doi.org/10.1136/bmj.l4143). 29. Darlington F, Norman P , Goules M. Health internal migration. In: Smith DP , Finney N, Halfacree K, Walford N, editors. Internal migration: geographical perspective processes. Farnham: Ashgate; 2016:113–28. 30. climate change exacerbates population displacement [news release]. ReliefWeb; 26 April 2024 (https://reliefweb.int/report/world/how-climate-change-exacerbates-population-displacement). 31. Negev M, Teschner N, Rosenthal A, Levine H, Lew-Levy C, Davidovitch N. Adaptation health system climate-related migration sub-Saharan Africa: closing gap. Int J Hyg Environ Health. 2019;222(2):311–14 (https://doi.org/10.1016/j.ijheh.2018.10.004). 32. Schwerdtle PN, Ngo TA, Hasch F, Phan TV, Quitmann Q, Montenegro-Quiñonez CA. Climate change resilient health facilities: scoping review case study low middle-income countries. Environ Res Lett. 2024;19:074041 (https://doi.org/10.1088/1748-9326/ad472",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8922d794-ec14-4136-99bb-3b837125c441",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "middle-income countries. Environ Res Lett. 2024;19:074041 (https://doi.org/10.1088/1748-9326/ad472b). 33. Everybody's business: strengthening health system improve health outcomes: WHO's framework action. Geneva: World Health Organization; 2007 (https://iris. who.int/ handle/10665/43918). Licence: CC BY-NC-SA 3.0 IGO. 34. Vanuatu: national policy climate change disaster-induced displacement. Port Villa: Vanuatu National Disaster Management Office; 2018 (https://ndmo.gov.vu/images/download/Vanuatu- National-Policy-on-Climate-Change-and-Disaster-Induced-Displacement-2018-published.pdf ). 35. Quast . Healthcare utilization child asthma displaced Hurricane Katrina. J Asthma. 2018;55(4):416–23 (https://doi.org/10.1080/02770903.2017.1339244).36 Health system strengthening intervention improve health displaced migrant population context climate change36. Forced displacement potential solution IDPs refugee Sa",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1ea209b7-946e-4526-8537-f8808de58bf8",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "climate change36. Forced displacement potential solution IDPs refugee Sahel: Burkina Faso, Chad, Mali, Mauritania, Niger. Washington, DC: World Bank Group; 2014 (https://documents1.worldbank.org/curated/en/229401467990086793/pdf/899510WP0Box380 splacement0study0WEB.pdf ). 37. Menstrual hygiene support woman girl Somalia: World Menstrual Hygiene Day [website]. International Organization Migration; 2025 (https://somalia.iom.int/stories/ menstrual-hygiene-support-women-and-girls-somalia-world-menstrual-hygiene-day). 38. Climate health solution space [website]. ClimaHealth; 2021 (https://climahealth.info/ climate-and-health-solutions-space/). 39. Displacement changing climate: localized humanitarian action forefront climate crisis. Geneva: International Federation Red Cross Red Crescent Societies; 2021 (https://www.ifrc.org/sites/default/files/2021-11/2021-Climate-Displacement-Report-Fina",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "54aaefac-0aa9-4f58-b5a6-96d224d222dc",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "2021 (https://www.ifrc.org/sites/default/files/2021-11/2021-Climate-Displacement-Report-Final.pdf ). 40. Classification fragile conflict-affected situation [website]. World Bank; 2025 (https://www.worldbank.org/en/topic/fragilityconflictviolence/brief/classification-of-fragile-and- conflict-affected-situations). 41. Ethiopia 2018: humanitarian disaster resilience plan. Addis Ababa: United Nations Office Coordination Humanitarian Affairs Government Ethiopia; 2018 (https://www.refworld.org/policy/legalguidance/ocha/2018/ en/121068). 42. Revised national development strategy 2021–2024: consolidate peace stabilize economy. Juba: Republic South Sudan United Nations Development Programme; 2022 (https://www.refworld.org/policy/strategy/natlegbod/2022/en/147818). 43. RIASCO action plan southern Africa: response plan El Niño-induced drought southern Africa May 2016–April",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0eaf7a33-4417-4c0c-9b2b-07fdf8356372",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "r southern Africa: response plan El Niño-induced drought southern Africa May 2016–April 2017. Geneva: Regional Inter-Agency Standing Committee; 2016 (https://library.alnap.org/help-library/riasco-action-plan-for-southern-africa-response-plan-for- the-el-nino-induced-drought-in). 44. Doherty P , Wheeler E, Mochache V, Mark J, Luttah G, Bero B et al. Considerations program manager improve sexual reproductive health service displaced populations. Glob Health Sci Pract. 2023;11(4):e2300036 (https://doi.org/10.9745/ghsp-d-23-00036). 45. Spickett J, Katscherian D, Brown H. Climate change, vulnerability health guide. Perth: Curtin University Collaborating Centre Climate Change Health Impact Assessment; 2015 (https://doi.org/10.17605/OSF.IO/K38SW). 46. Adalja AA, Watson M, Bouri N, Minton K, Morhard RC, Toner ES. Absorbing citywide patient surge Hurricane Sandy: case study accommodating multiple hospital evacuations. Ann Emerg",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "40420776-2675-400c-8c9b-f80da61e4085",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "e Hurricane Sandy: case study accommodating multiple hospital evacuations. Ann Emerg Med. 2014;64(1):66–73.e61 (https://doi.org/10.1016/j.annemergmed.2013.12.010).37 References47. Musoke R, Chimbaru A, Jambai A, Njuguna C, Kayita J, Bunn J et al. public health response mudslide Freetown, Sierra Leone, 2017: lesson learnt. Disaster Med Public Health Prep. 2020;14(2):256–64 (https://doi.org/10.1017/ dmp.2019.53). 48. Shultz JM, Berg RC, Kossin JP , Burkle Jr F, Maggioni A, Pinilla Escobar VA et al. Convergence climate-driven hurricane COVID-19: impact 2020 hurricane Eta Iota Nicaragua. J Clim Change Health. 2021;3:100019 (https://doi.org/10.1016/j.joclim.2021.100019). 49. Valente M, Zanellati M, Facci G, Zanna N, Petrone E, Moretti E et al. Health system response 2023 flood Emilia-Romagna, Italy: field report. Prehosp Disaster Med. 2023;38(6):813–17 (https://doi.org/10.1017/S1049023X23006404). 50. Clark-Ginsberg A, Becerr",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b4a5f8dd-3c21-4b7a-b703-b649b47220a7",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "er Med. 2023;38(6):813–17 (https://doi.org/10.1017/S1049023X23006404). 50. Clark-Ginsberg A, Becerra-Ornelas A, Chandra A. Capacities health system climate migrant receiving communities: insight US Gulf Coast. Washington, DC: Urban Institute; 2023 (https://issuelab.org/resources/43676/43676.pdf ). 51. Ashraf M, Shahzad S, Sequeria P , Bashir A, Azmat SK. Understanding challenge woman face flood-affected area access sexual reproductive health services: rapid assessment disaster-torn Pakistan. BioMed Res Int. 2024;(1):1113634 (https:// doi.org/10.1155/2024/1113634). 52. Ethiopia: refugee policy review framework update 30 June 2023. Geneva: United Nations High Commissioner Refugees; 2024 (https://data.unhcr.org/en/documents/details/107226). Licence: CC BY-4.0. 53. Support urgently needed avert deeper Sahel crisis, UNHCR’s protection chief warns [news release]. United Nations High Commissioner Refugees; 25 March 2024 (https://w",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d00ba841-ff8b-4a35-b4fa-9d5fdcabcc37",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "chief warns [news release]. United Nations High Commissioner Refugees; 25 March 2024 (https://www.unhcr. org/ news/press-releases/support-urgently-needed-avert-deeper-sahel-crisis-unhcr-s-protection-chief ). 54. Campbell J. International relocation Pacific Island countries: adaptation failure. In: Proceedings Environment, Forced Migration, Social Vulnerability International Conference, Bonn, Germany, 9–11 October 2008. Apia: SPREP; 2008 (https://library.sprep.org/sites/default/ files/644.pdf ). Licence: CC BY-NC-SA 4.0. 55. UNHCR launch fund shield refugee displaced people climate shock [news release]. United Nations High Commissioner Refugees; 24 April 2024 (https://www.unhcr.org/news/press- releases/ unhcr-launches-fund-shield-refugees-and-other-displaced-people-climate-shocks). 56. Module 3: tackling social determinant health workers’ occupational health safety; tool 10: climate change. In: Refugee migrant health",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2ea0971e-68ce-45fa-84ee-a88b289bd86d",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "orkers’ occupational health safety; tool 10: climate change. In: Refugee migrant health toolkit [online application]. World Health Organization; 2015 (https://www.who.int/tools/refugee-and-migrant-health-toolkit/ module-3/tool-10).38 Health system strengthening intervention improve health displaced migrant population context climate change57. Rabbani F, Siddiqui A, Merali Z. Responding mental health challenge flood-affected community technology-driven local solution Pakistan: mPareshan Project. Karachi: Brain Mind Institute Department Community Health Sciences, Aga Khan University; 2022 (https://hub.connectingclimateminds.org/research-and-action/case-studies/14). 58. Amsalu R, Schulte-Hillen C, Garcia DM, Lafferty N, Morris CN, Gee et al. Lessons learned helping baby survive humanitarian settings. Pediatrics. 2020;146 (suppl 2):S208–17 (https://doi.org/10.1542/peds.2020-016915L). 59. Clim",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e50427ed-7e03-4311-940f-3210754511cf",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Pediatrics. 2020;146 (suppl 2):S208–17 (https://doi.org/10.1542/peds.2020-016915L). 59. Climate change impact health: affecting development human mobility. Geneva: International Organization Migration; 2023 (https://www.iom.int/sites/g/files/tmzbdl486/files/ documents/2024-01/iom-health_climate-change_position-paper_21.12.2023.pdf ). Licence: CC BY-NC-ND 3.0 IGO. 60. Unshattered hope face adversity South Sudan [blog]. Médecins Sans Frontières; 15 November 2023 (https://www.msf.org/unshattered-hope-face-adversity-south-sudan). 61. Evans DP , Anderson M, Shahpar C, del Rio C, Curran JW. Innovation graduate education health professional humanitarian emergencies. Prehosp Disaster Med. 2016;31(5):532–8 (https://doi.org/10.1017/S1049023X16000650). 62. Williams H, Downes E. Development course complex humanitarian emergencies: preparation impact climate change. J Nurs Scholarsh. 2017;49(6):661–9 (https://do",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dc8a8576-2ed8-461c-b076-9fe2791fb68a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "impact climate change. J Nurs Scholarsh. 2017;49(6):661–9 (https://doi.org/10.1111/jnu.12339). 63. Kanter RK, Abramson D. School intervention Joplin tornado. Prehosp Disaster Med. 2014;29(2):214–17 (https://doi.org/10.1017/S1049023X14000181). 64. Sorensen CJ, Fried LP . Defining role responsibility health workforce respond climate crisis. JAMA Netw Open. 2024;7(3):e241435 (https://doi.org/10.1001/ jamanetworkopen.2024.1435). 65. Altare C, Kahi V, Ngwa MC, Goldsmith A, Hering H, Burton et al. Infectious disease epidemic refugee camps: retrospective analysis UNHCR data (2009–2017). J Glob Health Rep. 2019;3:e2019064 (https://doi.org/10.29392/joghr.3.e2019064). 66. Shortus M, Musto J, Bugoro H, Butafa C, Sio A, Joshua C. Vector-control response post-flood disaster setting, Honiara, Solomon Islands, 2014. Western Pac Surveill Response J. 2016;7(1):38–43 (https://doi.org/10.5365/wpsar.2015.6.3.004). 67.",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a23b604e-574a-459a-9d58-c10d1a5a8c02",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Western Pac Surveill Response J. 2016;7(1):38–43 (https://doi.org/10.5365/wpsar.2015.6.3.004). 67. Mugabe VA, Gudo ES, Inlamea OF, Kitron U, Ribeiro GS. Natural disasters, population displacement health emergencies: multiple public health threat Mozambique. BMJ Glob Health. 2021;6(9):e006778 (https://doi.org/10.1136/bmjgh-2021-006778).39 References68. Emergency health: 2023 global highlights. Geneva: International Organization Migration; 2023 (https://www.iom.int/sites/g/files/ tmzbdl486/files/documents/2024-05/iom-emergency-health- infosheet-2023_08.05.2024.pdf ). Licence: CC BY-NC-ND 3.0 IGO. 69. Benkritly M, Hujale M. Sudanese refugee fleeing conflict find safety South Sudan [news release]. United Nations High Commissioner Refugees; 27 June 2023 (https://www.unhcr.org/ news/stories/sudanese-refugees-fleeing-conflict-find-safety-south-sudan). 70. Hujale M. Displaced Somalis refugee struggle recover climate change brings new threat [news release].",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3e8df532-7328-41d2-9419-80178d2c3b62",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "laced Somalis refugee struggle recover climate change brings new threat [news release]. United Nations High Commissioner Refugees; 17 August 2012 (https://www.unhcr.org/news/stories/displaced-somalis-and-refugees-struggle-recover-climate- change-brings-new-threats). 71. Lien C, Raimo J, Abramowitz J, Khanijo S, Kritharis A, Mason C et al. Community healthcare delivery post-Hurricane Sandy: lesson mobile health unit. J Community Health. 2014;39(3):599–605 (https:// doi.org/10.1007/s10900-013-9805-7). 72. Sood RK, Bocour A, Kumar S, Guclu H, Potter M, Shah TB. Impact primary care access post-disaster: case study Rockaway Peninsula. Disaster Med Public Health Prep. 2016;10(3):492–95 (https://doi.org/10.1017/dmp.2016.80). 73. Horn Africa drought emergency [website]. United Nations High Commissioner Refugees; 2023 (https://www.unhcr.org/ uk/emergencies/horn-africa-drought-emergency). 74. Chad flood deepen humanitarian crisis high",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7aaa7210-f2b8-41f2-aa12-a745c1bf4b3a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "uk/emergencies/horn-africa-drought-emergency). 74. Chad flood deepen humanitarian crisis high risk disease outbreak [blog]. Médecins Sans Frontières; 5 December 2022 (https://www.msf.org/floods-n%E2%80%99djamena-chad-deepen- humanitarian-crisis-high-risk-disease-outbreaks). 75. People cut healthcare cyclone Freddy batter Malawi [news release]. Médecins Sans Frontières; 24 March 2023 (https://www.msf. org/people-cut-healthcare-after-cyclone-freddy- batters-malawi). 76. Kearns RD, Stringer L, Craig J, Godette-Crawford R, Black PS, Andra DL et al. Relying National Mobile Disaster Hospital business continuity strategy aftermath tornado: Louisville experience. J Bus Contin Emer Plan. 2017;10(3):230–48 (https://pubmed.ncbi.nlm. nih.gov/28222847/). 77. UNHCR ramp aid thousand displaced Somalia drought [news release]. United Nations High Commissioner Refugees; 11 March 2023 (https://www.unhcr.org/news/briefing-notes/ un",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a6a81ed9-ec54-40c6-b272-0ba888ab25e8",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ations High Commissioner Refugees; 11 March 2023 (https://www.unhcr.org/news/briefing-notes/ unhcr-ramps-aid- thousands-displaced-somalia-drought). 78. Soaring need persist Twic County one year [news release]. Médecins Sans Frontières; 17 May 2023 (https://www.msf.org/south-sudan-soaring-needs-persist- twic-county-one-year).40 Health system strengthening intervention improve health displaced migrant population context climate change79. Lindvall K, Kinsman J, Abraha A, Dalmar A, Abdullahi MF, Godefay H et al. Health status health care need drought-related migrant Horn Africa: qualitative investigation. Int J Environ Res. 2020;17(16):5917 (https://doi.org/10.3390/ijerph17165917). 80. Bourgois X. Dwindling rain northern Cameroon spark conflict displacement [news release]. United Nations High Commissioner Refugees; 10 November 2021 (https://www. unhcr.org/news/stories/dwindling-rains-northern-cameroon-spark-conflict",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d75e0b7e-d7a4-4433-b0de-3fe203752fac",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "November 2021 (https://www. unhcr.org/news/stories/dwindling-rains-northern-cameroon-spark-conflict-and-displacement). 81. Lalani N, Drolet JL, McDonald-Harker C, Brown MRG, Brett-MacLean P , Agyapong VIO et al. Nurturing spiritual resilience promote post-disaster community recovery: 2016 Alberta wildfire Canada. Front Public Health. 2021;9 (https://doi. org/10.3389/fpubh.2021.682558). 82. Taioli E, Tuminello S, Lieberman-Cribbin W, Bevilacqua K, Schneider S, Guzman et al. Mental health challenge experience displaced population following Hurricane Sandy Hurricane Harvey: need comprehensive intervention temporary shelters. J Epidemiol Community Health. 2018;72(10):867–70 (https://doi. org/10.1136/jech-2018–210626). 83. Alam F, Hossain R, Ahmed HU, Alam MT , Sarkar M, Halbreich U. Stressors mental health Bangladesh: current situation future hopes. BJPsych Int. 2021;18(4):91–4 (https://doi.org/10.119",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8bfcf965-ee58-459a-b221-0169735c6204",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "future hopes. BJPsych Int. 2021;18(4):91–4 (https://doi.org/10.1192/bji.2020.57). 84. Bharadwaj R, Huq S. Climate-induced migration health issues: toolkit policymakers. London: International Institute Environment Development; 2022 (https:// issuelab.org/ resources/43319/43319.pdf ). 85. Mental health climate change: policy brief. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/354104). Licence: CC BY-NC-SA 3.0 IGO. 86. Akbar M. Empowering woman girl water sanitation initiative post- flood Pakistan [news release]. International Organization Migration; 22 March 2024 (https://reliefweb.int/report/pakistan/empowering-women-and-girls-through-water-and- sanitation-initiatives-post-flood-pakistan). 87. Viray K. Solar energy delivers clean water drought-affected family Ethiopia [blog]. In: International Organization Migration Storyteller; 2024 (htt",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1508b5a9-c534-4c4f-9627-ef12f5e5757a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ed family Ethiopia [blog]. In: International Organization Migration Storyteller; 2024 (https://storyteller.iom.int/stories/ solar-energy-delivers-clean-water-drought-affected-families-ethiopia). 88. Global annual result report 2021: ensuring every child life safe clean environment. Goal Area 4: progress, result achieved lesson 2021 [website]. United Nations Children’s Fund; 2022 (https://www.unicef.org/reports/global-annual-results-2021-goal-area-4). 89. UNICEF DRR action: every country protected; every child resilient. New York: United Nations Children's Fund; 2022 (https://www.unicef.org/documents/unicef-drr-action-every-country- protected-every-child-resilient). Licence: CC BY-4.0.41 References90. Chiriac M. Ripples change: durable water solution reshape community along Yemen’s West Coast. International Organization Migration; 21 March 2024 (https://yemen.iom.int/stories/ ripples-change-durable-water-solutions-reshape-communities",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "69a5d7bd-0890-4517-9076-301a8827f540",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "arch 2024 (https://yemen.iom.int/stories/ ripples-change-durable-water-solutions-reshape-communities-along-yemens-west-coast). 91. Mohammed M. Green energy grant conflict-affected community Yemen access safe water [blog]. In: International Organization Migration Storyteller; 2024 (https://storyteller.iom.int/ stories/green-energy-grants-conflict-affected-communities-yemen-access-safe-water). 92. Hirani SAA. Barriers women’s menstrual hygiene practice recurrent disaster displacement: qualitative study. Int J Environ Res. 2024;21(2):153 (https://doi.org/10.3390/ ijerph21020153). 93. Msyamboza KP , M’Bang’ombe M, Hausi H, Chijuwa A, Nkukumila V, Kubwalo HW et al. Feasibility acceptability oral cholera vaccine mass vaccination campaign response outbreak flood Malawi. Pan Afr Med J. 2016;23:203 ( https://doi.org/10.11604/pamj.2016.23.203.8346). 94. Climate change [fact sheet]. World Health Organization; 12 October 2023",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1ef16de6-6483-44a8-976f-fe15216ed9c7",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "203.8346). 94. Climate change [fact sheet]. World Health Organization; 12 October 2023 (https://www.who.int/news-room/fact-sheets/detail/climate-change-and-health). 95. Salam A, Wireko AA, Jiffry R, Ng JC, Patel H, Zahid MJ et al. impact natural disaster healthcare surgical service low- middle-income countries. Ann Med Surg (Lond). 2023;85(8):3774–7 (https://doi.org/10.1097/ms9.0000000000001041). 96. Neef K, Jones E, Marlowe J. conflict, climate change, displacement nexus revisited: protracted Rohingya refugee crisis Bangladesh. J Peacebuild Dev. 2023;18(3):231–47 (https://doi.org/10.1177/15423166231190040). 97. Fransen S, Werntges A, Hunns A, Sirenko M, Comes . Refugee settlement highly exposed extreme weather conditions. PNAS. 2024;121(3):e2206189120 (https://doi.org/doi: 10.1073/ pnas.2206189120). 98. Mental health refugee migrants: risk protective factor access care. Genev",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "65d7c76c-5949-4779-a8a8-541795a94cdd",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "). 98. Mental health refugee migrants: risk protective factor access care. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/373279). Licence: CC BY-NC-SA 3.0 IGO. 99. Hayes K, Blashki G, Wiseman J, Burke S, Reifels L. Climate change mental health: risks, impact priority actions. Int J Ment Health Sys. 2018;12(1):28 (https://doi.org/10.1186/ s13033-018-0210–6). 100. Lebel L, Paquin V, Kenny TA, Fletcher C, Nadeau L, Chachamovich E et al. Climate change Indigenous mental health circumpolar north: systematic review inform clinical practice. Transcult Psychiatry. 2022;59(3):312–36 (https://doi.org/10.1177/13634615211066698).42 Health system strengthening intervention improve health displaced migrant population context climate change101. Middleton J, Cunsolo A, Jones-Bitton A, Wright CJ, Harper SL. Indigenous mental health changing climate: systema",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4f0cf40b-8960-460c-8b63-5e10a5ce5d84",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "itton A, Wright CJ, Harper SL. Indigenous mental health changing climate: systematic scoping review global literature. Environ Res Lett. 2020;15(5):053001 (https://doi.org/10.1088/1748-9326/ab68a9). 102. WASH? [news release]. Washington, DC: USA UNHCR UN Refugee Agency; 3 April 2024 (https://www.unrefugees.org/news/what-is-wash/). 103. Pichler P , Jaccard IS, Weisz U, Weisz H. International comparison health care carbon footprints. Environ Res Lett. 2019;14:064004 (https://doi.org/10.1088/1748-9326%2Fab19e1). 104. come fighting climate change, green golden [news release]. Asian Development Bank; 22 March 2023 (https://www.adb.org/news/features/when-it-comes-fighting-climate- change-green-golden). 105. Countries western Pacific frontlines climate crisis, say [news release]. World Health Organization; 7 April 2022 (https://www.who.int/westernpacific/news/item",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b09f460f-660f-4ff2-b679-a5330bae0251",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ew release]. World Health Organization; 7 April 2022 (https://www.who.int/westernpacific/news/item/07-04- 2022-countries-in-the-western-pacific-on-the-frontlines-of-the-climate-crisis--says-who). 106. Scissa C, Martin SF. Migration context climate environmental change within central Asia European Union Russian Federation. Geneva: International Organization Migration; 2024 (https://environmentalmigration.iom.int/sites/g/files/tmzbdl1411/files/ documents/2024-05/pub2023-041-el-migration-in-the-context-of-climate-ca-eu-rf_0.pdf ). Licence: CC BY-NC-ND 3.0 IGO. 107. critical challenge migration displacement. Statement ICRC President, Peter Maurer, National Autonomous University Mexico [news release]. International Committee Red Cross; 18 October 2017 (https://www.icrc.org/en/ document/speech- migration-and-internal-displacement-national-and-global-challenges). 108. WHO, World Bank, International Renewable",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "86a09725-5f8d-4957-9780-3ce92ba3663c",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ternal-displacement-national-and-global-challenges). 108. WHO, World Bank, International Renewable Energy Agency, Sustainable Energy All. Energizing health: accelerating electricity access health-care facilities. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/365657). Licence: CC BY-NC-SA 3.0 IGO. 109. Cundill G, Singh C, Adger WN, Safra de Campos R, Vincent K, Tebboth et al. Toward climate mobility research agenda: intersectionality, immobility, policy responses. Glob Environ Change. 2021;69:102315 (https:// doi.org/https://doi.org/10.1016/j.gloenvcha.2021.102315) 110. McMichael C, Yee M. 10 health consequence climate change migrant immobile populations. In: Andreas N, Natasha P , Bukola S, editors. De Gruyter handbook climate migration climate mobility justice. Berlin: De Gruyter; 2024:216–34 (https://doi.org/10.1515/9783110752144-011).43 References111. Bellizzi S,",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "731f9f53-adc3-41ba-8cb1-090992ed6e09",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "(https://doi.org/10.1515/9783110752144-011).43 References111. Bellizzi S, Molek K. high risk gender-based violence migrant woman girls. J Pediatr Adolesc Gynecol. 2021;35(3):265–6 (https://doi.org/10.1016/j.jpag.2021.12.008). 112. Anastario M, Shehab N, Lawry L. Increased gender-based violence among woman internally displaced Mississippi 2 year post-hurricane Katrina. Disaster Med Public Health Prep. 2009;3(1):18–26 (https://doi.org/10.1097/DMP .0b013e3181979c32). 113. Defining essential public health function service strengthen national workforce capacity. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/376579). Licence: CC BY-NC-SA 3.0 IGO.44 Annex 1. Search strategy Peer-reviewed literature peer-reviewed articles, PubMed (MEDLINE) Embase searched using comprehensive keyword list. MeSH Emtree term (subject headings) used ensure specificity search term yi",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "24643336-2db7-4b06-9ba4-189b81a36fee",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "MeSH Emtree term (subject headings) used ensure specificity search term yield manageable number results. Key word searched within title abstract, using filter year (2014–2024) language (English) included list exclusionary terms. predefined term combined using \"OR\" Boolean operator (within column Table A1.1); area interest combined using \"AND\" operator exclusionary term combined using \"NOT\" operator. second round automated exclusion applied using R filter remaining exclusionary terms. Table A1.1. Full list migration, climate health system term Migration term Climate term Health system term · \"migra*\" · \"immigra*\" · \"emigra*\" · \"refugee*\" · \"asylum seeker*\" · \"internally displaced\" · \"forcibly displaced\" · \"displaced\" · \"deport*\" · \"unaccompanied minor*\" · \"exodus\" · \"human traffick*\" · \"detention*\" · \"immobil*\" · \"trapped population\"",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a6c66df5-0134-4d70-9324-19c72f5b9684",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ccompanied minor*\" · \"exodus\" · \"human traffick*\" · \"detention*\" · \"immobil*\" · \"trapped population\" · \"cross-border\" · \"transient*\"· \"climatic\" · \"global warming\" · \"global heating\" · \"greenhouse effect\" · \"temperature\" · \"rapid onset event\" · \"extreme heat\" · \"typhoon\" · \"cyclone\" · \"hurricane\" · \"storm\" · \"wildfire\" · \"bushfire\" · \"fire\" · \"landslide\" · \"disaster*\" · \"slow onset event\"· \"healthcare\" · \"governance\" · \"health policy\" · \"information system\" · \"e-health\" · \"telehealth\" · \"early warning system\" · \"insurance\" · \"medicine*\" · \"pharmaceutical*\" · \"supply chain\" · \"supplies\" · \"emergency response\" · \"disaster response\" · \"Health\" · \"health strengthening\" · \"essential medicine\"45 Annex 1. Search strategyMigration term Climate term Health system term · \"relocat*\" · \"settle*\" · \"nomad*\" · \"detain*\" · \"resettle*\" · \"undocumented person*\" · \"IDP\" · \"forced displacement\" · \"internal displacement\" · \"cross-border\" · \"irregular migra*\" · \"returnee*\"· \"sea level rise\" · \"pollutio",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "50fdb109-f5f5-42e8-9ed4-c79fb810fbd1",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "rnal displacement\" · \"cross-border\" · \"irregular migra*\" · \"returnee*\"· \"sea level rise\" · \"pollution\" · \"air quality\" · \"haze\" · \"drought\" · \"desertification\" · \"extreme weather\" · \"climate\" · \"flood*\" · \"rainfall\" · \"rain\" · \"ocean acidification\"· \"screening\" · \"diagnosis\" · \"health resilience\" · \"financing\" · \"funding\" · \"physician*\" · \"nurse*\" · \"financial\" · \"emergency preparedness\" · \"health system*\" · \"health response\" full search string PubMed Embase follows. Removal duplicate completed using EndNote title abstract screening. PubMed ((\"climatic\"[Title/Abstract] \"global warming\"[Title/Abstract] \"global heating\"[Title/Abstract] \"greenhouse effect\"[Title/Abstract] \"temperature\"[Title/Abstract] (\"rapid\"[All Fields] \"rapidities\"[All Fields] \"rapidity\"[All Fields] \"rapidness\"[All Fields]) \"onset event\"[Title/ Abstract]) \"extreme heat\"[Title/Abstract] \"typhoon\"[Title/Abstract] \"cyclone\"[Title/ Abstract]",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6267023e-6c4f-4f42-aaf1-0f6291d3a2fb",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ract]) \"extreme heat\"[Title/Abstract] \"typhoon\"[Title/Abstract] \"cyclone\"[Title/ Abstract] \"hurricane\"[Title/Abstract] \"storm\"[Title/Abstract] \"wildfire\"[Title/Abstract] \"bushfire\"[Title/Abstract] \"fire\"[Title/Abstract] \"landslide\"[Title/Abstract] \"disaster*\"[Title/ Abstract] (\"slow\"[All Fields] \"onset event\"[Title/Abstract]) \"sea level rise\"[Title/ Abstract] \"pollution\"[Title/Abstract] \"air quality\"[Title/Abstract] \"haze\"[Title/Abstract] \"drought\"[Title/Abstract] \"desertification\"[Title/Abstract] \"extreme weather\"[Title/ Abstract] \"climate\"[Title/Abstract] \"flood*\"[Title/Abstract] \"rainfall\"[Title/Abstract] \"rain\"[Title/Abstract] \"ocean acidification\"[Title/Abstract]) (\"migra*\"[Title/Abstract] \"immigra*\"[Title/Abstract] \"emigra*\"[Title/Abstract] \"refugee*\"[Title/Abstract] \"asylum seeker*\"[Title/Abstract] \"internally displaced\"[Title/Abstract] \"forcibly displaced\"[Title/ Abstract] \"di",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "230c9a2b-d977-4451-a58b-a034d1b81f55",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "/Abstract] \"internally displaced\"[Title/Abstract] \"forcibly displaced\"[Title/ Abstract] \"displaced\"[Title/Abstract] \"deport*\"[Title/Abstract] \"unaccompanied 46 Health system strengthening intervention improve health displaced migrant population context climate changeminor*\"[Title/Abstract] \"exodus\"[Title/Abstract] \"human traffick*\"[Title/Abstract] \"detention*\"[Title/Abstract] \"immobil*\"[Title/Abstract] \"trapped population\"[Title/Abstract] \"cross-border\"[Title/Abstract] \"transient*\"[Title/Abstract] \"relocat*\"[Title/Abstract] \"settle*\"[Title/Abstract] \"nomad*\"[Title/Abstract] \"detain*\"[Title/Abstract] \"resettle*\"[Title/ Abstract] \"undocumented person*\"[Title/Abstract] \"IDP\"[Title/Abstract] \"forced displacement\"[Title/Abstract] \"internal displacement\"[Title/Abstract] \"cross-border\"[Title/ Abstract] \"irregular migra*\"[Title/Abstract] \"returnee*\"[Title/Abstract]) (\"healthcare\"[Title/ Ab",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5a420146-72cb-4311-87c8-44441b2730d0",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "t] \"irregular migra*\"[Title/Abstract] \"returnee*\"[Title/Abstract]) (\"healthcare\"[Title/ Abstract] \"governance\"[Title/Abstract] \"health policy\"[Title/Abstract:~3] \"information system\"[Title/Abstract] \"e-health\"[Title/Abstract] \"telehealth\"[Title/Abstract] \"early warning system\"[Title/Abstract] \"insurance\"[Title/Abstract] \"medicine*\"[Title/Abstract] \"pharmaceutical*\"[Title/Abstract] \"supply chain\"[Title/Abstract] \"supplies\"[Title/Abstract] \"emergency response\"[Title/Abstract] \"disaster response\"[Title/Abstract] \"Health\"[Title/ Abstract] \"health strengthening\"[Title/Abstract:~3] \"essential medicine\"[Title/Abstract] \"screening\"[Title/Abstract] \"diagnosis\"[Title/Abstract] \"health resilience\"[Title/Abstract:~3] \"financing\"[Title/Abstract] \"funding\"[Title/Abstract] \"physician*\"[Title/Abstract] \"nurse*\"[Title/Abstract] \"financial\"[Title/Abstract] \"emergency preparedness\"[Title/Abstract] \"health syst",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "38f0d4c9-7211-4ef4-9d66-3069d30c9d2e",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "bstract] \"financial\"[Title/Abstract] \"emergency preparedness\"[Title/Abstract] \"health system*\"[Title/Abstract] \"health response\"[Title/Abstract:~3])) (\"cellular migration\"[Title/Abstract] \"migraine\"[Title/Abstract] \"intracellular trafficking\"[Title/Abstract] \"membrane trafficking\"[Title/Abstract] \"gene migration\"[Title/Abstract] \"MRNA\"[Title/Abstract] \"DNA\"[Title/Abstract] \"RNA\"[Title/Abstract] \"Genetics\"[Title/Abstract] \"avian\"[Title/ Abstract] \"bird\"[Title/Abstract] \"animal\"[Title/Abstract] \"acupuncture\"[Title/Abstract] \"silica-immobilized\"[Title/Abstract] \"silica-immobilised\"[Title/Abstract] \"migrans\"[Title/ Abstract] \"coral\"[Title/Abstract] \"gardening\"[Title/Abstract] \"coral\"[Title/Abstract] \"nurse sharks\"[Title/Abstract] \"mouse\"[Title/Abstract] \"fish\"[Title/Abstract] \"mice\"[Title/Abstract] \"cellular\"[Title/Abstract] \"cell\"[Title/Abstract] \"mutation\"[Title/Abstract] \"silica\"[Title/",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "02ee0b9c-9e1b-4e9e-9fd0-650bc85bcd0c",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "llular\"[Title/Abstract] \"cell\"[Title/Abstract] \"mutation\"[Title/Abstract] \"silica\"[Title/ Abstract] \"soil\"[Title/Abstract] \"rabbit*\"[Title/Abstract] \"plant\"[Title/Abstract] \"in vitro\"[Title/Abstract] \"valve\"[Title/Abstract] \"aorta\"[Title/Abstract] \"rat\"[Title/Abstract] \"rats\"[Title/Abstract] \"beagle*\"[Title/Abstract] \"canine\"[Title/Abstract] \"equine\"[Title/ Abstract] \"murine\"[Title/Abstract] \"rodent*\"[Title/Abstract] \"animals\"[Title/Abstract] \"broiler\"[Title/Abstract] \"cadaver\"[Title/Abstract] \"piglet*\"[Title/Abstract] \"porcine\"[Title/ Abstract] \"pig\"[Title/Abstract])) (y_10[Filter]) (english[Filter])) Embase (climatic:ti,ab,kw 'global warming':ti,ab,kw 'global heating':ti,ab,kw 'greenhouse effect':ti,ab,kw temperature:ti,ab,kw 'rapid onset event':ti,ab,kw 'extreme heat':ti,ab,kw typhoon:ti,ab,kw cyclone:ti,ab,kw hurricane:ti,ab,kw storm:ti,ab,kw wildfire:ti,ab,kw bushfir",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1ff9967e-8b34-49cc-996a-42388071b2f1",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "i,ab,kw cyclone:ti,ab,kw hurricane:ti,ab,kw storm:ti,ab,kw wildfire:ti,ab,kw bushfire:ti,ab,kw fire:ti,ab,kw landslide:ti,ab,kw disaster*:ti,ab,kw 'slow onset event':ti,ab,kw 'sea level rise':ti,ab,kw pollution:ti,ab,kw 'air quality':ti,ab,kw haze:ti,ab,kw 47 Annex 1. Search strategyOR drought:ti,ab,kw desertification:ti,ab,kw 'extreme weather':ti,ab,kw climate:ti,ab,kw flood*:ti,ab,kw rainfall:ti,ab,kw rain:ti,ab,kw 'ocean acidification':ti,ab,kw) (healthcare:ti,ab,kw governance:ti,ab,kw (health NEAR/3 policy):ti,ab,kw) 'information system':ti,ab,kw 'e health':ti,ab,kw telehealth:ti,ab,kw 'early warning system':ti,ab,kw insurance:ti,ab,kw medicine*:ti,ab,kw pharmaceutical*:ti,ab,kw 'supply chain':ti,ab,kw supplies:ti,ab,kw 'emergency response':ti,ab,kw 'disaster response':ti,ab,kw health:ti,ab,kw (health NEAR/3 strengthening):ti,ab,kw) 'essential medicine':ti,ab,kw",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "85a3c880-0736-47af-a1d0-6c842b89cc6f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "kw health:ti,ab,kw (health NEAR/3 strengthening):ti,ab,kw) 'essential medicine':ti,ab,kw screening:ti,ab,kw diagnosis:ti,ab,kw (health NEAR/3 resilience):ti,ab,kw) financing:ti,ab,kw funding:ti,ab,kw physician*:ti,ab,kw nurse*:ti,ab,kw financial:ti,ab,kw 'emergency preparedness':ti,ab,kw 'health system*':ti,ab,kw (health NEAR/3 response):ti,ab,kw)) (migra*:ti,ab,kw immigra*:ti,ab,kw emigra*:ti,ab,kw refugee*:ti,ab,kw 'asylum seeker*':ti,ab,kw 'internally displaced':ti,ab,kw 'forcibly displaced':ti,ab,kw displaced:ti,ab,kw deport*:ti,ab,kw 'unaccompanied minor*':ti,ab,kw exodus:ti,ab,kw 'human traffick*':ti,ab,kw detention*:ti,ab,kw immobil*:ti,ab,kw 'trapped population':ti,ab,kw transient*:ti,ab,kw relocat*:ti,ab,kw settle*:ti,ab,kw nomad*:ti,ab,kw detain*:ti,ab,kw resettle*:ti,ab,kw 'undocumented person*':ti,ab,kw idp:ti,ab,kw 'forced displacement':ti,ab,kw",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "82de3604-7598-40dd-a479-1999a0f3833d",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "*:ti,ab,kw 'undocumented person*':ti,ab,kw idp:ti,ab,kw 'forced displacement':ti,ab,kw 'internal displacement':ti,ab,kw 'cross border':ti,ab,kw 'irregular migra*':ti,ab,kw returnee*:ti,ab,kw) ('cellular migration':ti,ab,kw migraine:ti,ab,kw 'intracellular trafficking':ti,ab,kw 'membrane trafficking':ti,ab,kw 'gene migration':ti,ab,kw mrna:ti,ab,kw dna:ti,ab,kw rna:ti,ab,kw genetics:ti,ab,kw avian:ti,ab,kw bird:ti,ab,kw animal:ti,ab,kw acupuncture:ti,ab,kw 'silica immobilized':ti,ab,kw 'silica immobilised':ti,ab,kw migrans:ti,ab,kw gardening:ti,ab,kw coral:ti,ab,kw 'nurse sharks':ti,ab,kw mouse:ti,ab,kw fish:ti,ab,kw mice:ti,ab,kw cellular:ti,ab,kw cell:ti,ab,kw mutation:ti,ab,kw silica:ti,ab,kw soil:ti,ab,kw rabbit*:ti,ab,kw plant:ti,ab,kw 'in vitro':ti,ab,kw valve:ti,ab,kw aorta:ti,ab,kw rat:ti,ab,kw rats:ti,ab,kw beagle*:ti,ab,kw canine:ti,ab,kw",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6368debe-d00a-490a-b5ff-0b26142029a6",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ti,ab,kw aorta:ti,ab,kw rat:ti,ab,kw rats:ti,ab,kw beagle*:ti,ab,kw canine:ti,ab,kw equine:ti,ab,kw murine:ti,ab,kw rodent*:ti,ab,kw animals:ti,ab,kw broiler:ti,ab,kw cadaver:ti,ab,kw piglet*:ti,ab,kw porcine:ti,ab,kw pig:ti,ab,kw) [english]/lim [2014-2024]/py.48 Health system strengthening intervention improve health displaced migrant population context climate changeGrey literature grey literature, general search engine Google, Google Scholar OAIster used alongside general institutional database may specialized content related climate change, migration health systems, World Bank Science.gov. climate-related database used included ClimaHealth Climate Change Human Health Literature Portal. Migrant-related repository used include IOM RefWorld websites. Health- focused database used inc",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "412888fc-f8d6-4cc5-ae08-3bddea2eac81",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "used include IOM RefWorld websites. Health- focused database used include United States National Institutes Health websites, well MedRxiv. Since search engine different search features, sort option filters, unique search strategy developed (Table A1.2). Table A1.2. Grey literature search engines, search term filter Database Search term Sort filter used Google (migrant refugee asylum seeker displace) climate \"health system\"Sorted relevance Google Scholar (migrant refugee asylum seeker displace) climate \"health system\"Date: 2014–2024 Sort relevance, type ReliefWeb (migrant refugee asylum seeker displace) climate \"health system\"Language: English, date: 17 June 2014 17 June 2024 RefWorld Climate, \"health system\" Language: English, date: 17 June 2014 17 June 2024 Climate migrant sort/filter Active Learning Net",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a1367f16-c85b-4386-afac-7382d4191d8e",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "sh, date: 17 June 2014 17 June 2024 Climate migrant sort/filter Active Learning Network Accountability Performancemigration, climate Sort relevance, date: 18 June 2014 18 June 2024 International Labour Organization Climate health Language: English, date: 2014– 2024, topic: labour migration IOM \"health\" \"climate\" Date: 2014–2024, sort latest49 Annex 1. Search strategyDatabase Search term Sort filter used UNHCR Health climate Date: 2014–2024, sort relevance IFRC Filters: climate change, migration, date: 17 June 2014 17 June 2024, sort relevance World Bank Climate health migrant Language: English, date: 2014– 2024, sort relevance OAIster \"climate\" \"health\" \"migrant Search result display: show Language: all, date: 2014–2024 Audience: audience Content type: content Searching databases: OAIster Science.gov Climate health migrant Date: 2014 – 2024, sort rank BMC Proceedings Climate, migrant",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c485a238-c6fc-4bbb-97a3-d82fd0b951a1",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ience.gov Climate health migrant Date: 2014 – 2024, sort rank BMC Proceedings Climate, migrant Sort newest first (manual cut 2013 earlier) Social Science Research NetworkClimate, migrant, health Search title, abstract key words, date displayed UNICEF Climate health Date: 7 March 2015 14 June 2024 Content: climate change, climate change impacts, displacement, health, internal displacement, migrant refugee crisis, migration, refugee Trip Pro Climate migrant Date: 2014–2024, sort relevance Open Science FrameworkClimate, migrant, health system Sort relevance National Institute HealthClimate migrant Date: fiscal year 2014–2024 (only kept recent iterations), project news tab MedRxiv Climate migrant Date: 2014–2024, sorted best match ClimaHealth Health migrant filter/sort50 Health system strengthening intervention improve health displaced migrant population context",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7987523d-612e-4da8-bcef-d3b33cbc0d8b",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ngthening intervention improve health displaced migrant population context climate changeDatabase Search term Sort filter used Climate Change Human Health Literature Portal migrant Date: 2014–2023 (no 2024 results); sort by: year (recent first) Connecting Climate MindsNo search bar document \"Research & Action\" tab GreenFILE Health migrant Date: 2014–2024, find search term Migrant Research HubHealth climate Date: 2014–2021, language: English International Migration Institute1. Climate, Health 2. Climate (articles published 2014 onwards) 3. Health (articles published 2014 onwards)No filter United Nations Office Drugs CrimeClimate, migrant, health system Sort date MSF Climate Sort recent IOM Policy DevelopmentClimate, Health Filter: content types, topic search prioritized general term \"migrant\" instead \"refugee\" simplify search process, given databases’ limi",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5c415cf4-c9ea-4669-8ed5-79feb0898626",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "neral term \"migrant\" instead \"refugee\" simplify search process, given databases’ limitation handling complex queries, ensuring efficient screening result 29 search engines. Despite limitation, available research able capture case study experience refugee IDPs many example coming MSF, IOM, United Nations Human Rights Council UNHCR’s RefWorld. search term adjusted depending database. example, migrant-related website searched using term related \"climate\" \"health\" . Conversely, term related \"climate\" \"migrants\" used health-related websites. searching diverse selection databases, grey literature different migrant types, climate hazard health care setting collected. However, migrant type international students, expatriate victim human trafficking appear searches. could due",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "945c8f53-f688-4fd5-b9f1-a83fe5aa75a3",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "expatriate victim human trafficking appear searches. could due limitation search term used database chosen. search engine, 200 entries, starting recently published, screened duplicate removed. Publications screened based title, abstract, summary and/or rapid keyword search full text accessible.51 Annex 1. Search strategyInclusion/exclusion criterion screening process Inclusion criterion were: · published since 2014 · published English language · type article (original article, review, commentary). Exclusion criterion were: · unavailable full text · describing specific health system intervention · refugees, migrant displaced population (of type) · climate change (general specific hazard). publication underwent screening two reviewers. Principal Investigator helped resolve discrepancy scr",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "98d4024d-8dd9-4227-9d66-a5bb645e87f2",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "rwent screening two reviewers. Principal Investigator helped resolve discrepancy screening outcome two reviewer make final decision regarding inclusion.52 Health system strengthening intervention improve health displaced migrant population context climate change Identification Included ScreeningRecords identified from: PubMed (n = 3155), Embase (n = 3826)Records identified database (n = 3928) Records screened (n = 3928) Reports sought retrieval (n = 384) Reports assessed eligibility (n = 377) Studies included review (n = 34) Interventions included review (n = 57)Records removed screening (n = 0) Records removed reason (n = 0) Records excluded (n = 3521) Duplicate record removed (n = 23) Reports retrieved (n = 7) Reports excluded: specific health system intervention (n = 220) climate change (general hazard) (n = 88) refugee",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "04a609b0-69d0-4d46-9c2f-2b2a8f78bc0e",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "vention (n = 220) climate change (general hazard) (n = 88) refugee migrant (of type) (n = 35)Records screened (n = 3255) Reports sought retrieval (n = 287) Reports assessed eligibility (n = 229) Studies included review (n = 22) Interventions included review (n = 38) Total study included review (n = 56) Total intervention included review (n = 95)Reports retrieved (n = 58) Reports excluded: specific health system intervention (n = 118) climate change (general hazard) (n = 60) refugee migrant (of type) (n = 29)Records removed screening: (n =0) Records removed using automatic deduplication using EndNote R (n = 3726) Records excluded (n = 2792) Duplicate record removed (n = 176)Identification study via database Identification grey literatureFig. A1.1. give PRISMA (Preferred Reporting Items Systematic Reviews Meta-Analyses) brea",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ee614f89-35f0-466c-932e-7a905f67a7ba",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "g. A1.1. give PRISMA (Preferred Reporting Items Systematic Reviews Meta-Analyses) breakdown result search peer-reviewed grey literature. Fig. A1.1. Search strategy53 Annex 2. Health system intervention identified review Intervention typeSource Country/ regionMigrant type Climate hazardBrief summary Governance (n = 19) Include need climate- affected displaced migrant population climate health policy plan (n = 7) Vanuatu National Disaster Management Office (1)Vanuatu Nonspecific Nonspecific Government Vanuatu partner created National Policy Climate Change Disaster-induced Displacement population affected climate change- related displacement; Policy’s strategic area 7 cover health, nutrition psychosocial well-being; main objective provide equal access health care climate-displaced population United Nations Office f",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7348ab68-1e5f-4923-b937-1a17e61b1385",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "vide equal access health care climate-displaced population United Nations Office Coordination Humanitarian Affairs Government Ethiopia (2)Ethiopia IDP Drought Ethiopia Humanitarian Disaster Resilience Plan (2018) addressed need nearly 1 million IDPs affected recurrent drought Key area focus included: · enhancing WASH service extending developing water networks; · expanding health service coverage; · enhancing emergency preparedness; · training community better manage water use54 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Governance (n = 19) Include need climate- affected displaced migrant population climate health policy plan (n = 7) Republic South Sudan United Nations Deve",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f242b8f2-870b-4ff6-9dee-6f4af744f23c",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "imate health policy plan (n = 7) Republic South Sudan United Nations Development Programme (3)South Sudan IDP , refugee Drought South Sudan’s Revised National Development Strategy 2021–2024 addressed gap policy implementation aid service ID Ps, refugee returnees focusing enhancing disaster management early warning system staff training; Strategy advocate increased funding Government stakeholder disaster preparedness response resettlement assistance Regional Inter-Agency Standing Committee (4)Angola, Lesotho, Madagascar, Malawi, Mozambique, Swaziland, ZimbabweIDP , refugee Drought Regional Inter-Agency Standing Committee developed Response Plan El Niño-related drought southern African countries, addressing humanitarian needs, resilience climate impact migration trends; recommendation focus water access,",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "79759452-10fb-4080-8e4b-305adc79d607",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ce climate impact migration trends; recommendation focus water access, WASH integration health services, disease screening vulnerable populations, maintaining supplies, health worker training, immunization services, multisectoral approach health nutrition emergency preparedness considering La Niño risks55 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Governance (n = 19) Include need climate- affected displaced migrant population climate health policy plan (n = 7) IFRC (5) Mozambique IDP Flood response flooding Mozambique, Mozambique Red Cross Society developed Early Action Plan Disaster Preparedness benefiting 7500 displaced affected people; activity include providing health care, distributing mosquito nets, chlorine item reduce outbreak",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "750435db-326d-40be-8ab8-bc1dec9bc73f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "viding health care, distributing mosquito nets, chlorine item reduce outbreak activating volunteer communication line Doherty et al. (6)Madagascar IDP Nonspecific Women’s Integrated Sexual Health programme collaborated Malagasy Government research climate change impact IDPs’ access se xual reproductive health fa mily planning service extent service incorporated disaster response plan Spickett et al. (7)No specified countryNonspecific Nonspecific guidance document produced assist decision-makers others undertake assessment potential health impact associated social implication arising climate change; section vector-borne disease considered refugee migrant vulnerable population health promotion, disease screening health education considered intervention them56 Health system strengthenin",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a8126bd1-277a-46db-ad20-c49a200ff0d2",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "health education considered intervention them56 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Governance (n = 19) Enhance coordination service across agency responding health need climate- affected displaced migrant population (n = 8) Adalja et al. (8)United States Hospital evacueeCyclone/ typhoon/ hurricane/ stormAs part New York hospital system response Hurricane Sandy, hospital activated incident command system participated citywide unified command structure; hospital also coordinated patient transfer disaster evacuation purpose 26 October, New York State Department Health New York City Department Health Mental Hygiene activated interagency Healthcare Facility Evacuatio",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5587f3f8-70f1-4288-9a7d-b378c69b8814",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Department Health Mental Hygiene activated interagency Healthcare Facility Evacuation Centre, involving agency fire department emergency medical service Musoke et al. (9)Sierra Leone IDP Mudslide, heavy rainFollowing mudslide occurred Freetown, Sierra Leone, 2017 due 3 day torrential rains, supported country’s P ublic Health Emergency Operations Centre Government, United Nations agency international N GOs coordinated health response disease surveillance, case management, procurement medical supply disease prevention activity affected displaced individuals57 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Governance (n = 19) Enhance coordination service across agency responding health need climate- affected displaced migrant popula",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0d7b7f41-b2e9-4d02-878e-d485c0a627e3",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "agency responding health need climate- affected displaced migrant population (n = 8)Shultz et al. (10)Nicaragua IDP Cyclone/ typhoon/ hurricane/ stormIn wake 2020 hurricane Eta Iota Nicaragua, disaster response logistics planning conducted Sistema Nacional para la Prevención, Mitigación Atención de Desastres, Nicaraguan Government’s disaster response agency Multiple United Nations agencies, fund programme international NGOs participated response (IOM, Plan International, Save Children, UNICEF, World Food Programme) Valente et al. (11)Italy IDP Heavy rain, floodFollowing intense rainfall Italy May 2023, emergency response plan activated coordination local governments, rescue corps, local police, volunteers, European Union neighbouring countries; worst-affected Emilia- Romagna Region activated seven rescue coordination centre 160 municipal",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e2d6314c-0001-4aa2-8dd4-6fa84caaa72d",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "st-affected Emilia- Romagna Region activated seven rescue coordination centre 160 municipal operation centres, utilized ambulance offered NGOs four helicopter emergency service employed specialized alpine rescue volunteers58 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Governance (n = 19) Enhance coordination service across agency responding health need climate- affected displaced migrant population (n = 8)Clark- Ginsberg et al. (12)United States IDP , refugee Cyclone/ typhoon/ hurricane/ stormIn response displacement people due hurricane (Katrina United States Maria Puerto Rico), Houston Orlando formed coalition stakeholder provide health care service affected migrants; coalition included core",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a5a78a71-4f08-4fd6-b3e2-255644fea77c",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "f stakeholder provide health care service affected migrants; coalition included core member health system, emergency response organization individual community member organization Clark- Ginsberg et al. (12)United States IDP , refugee Cyclone/ typhoon/ hurricane/ stormFor refugee migrant Houston Orlando (United States) displaced either Hurricane Katrina Maria, private sector organizations, mostly supported physical health needs, NGOs churches, provided mental health support, engaged support arriving refugee migrant Clark- Ginsberg et al. (12)United States IDP , refugee Cyclone/ typhoon/ hurricane/ stormGovernment agency United States set formal structure coordinate health service access refugee migrant displaced hurricane Florida, Hispanic Office Local Assistance connected migrant health care services; Louisiana, Depa",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "51ff0286-16c9-4e35-bd9a-32ca470ea923",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Office Local Assistance connected migrant health care services; Louisiana, Department Health designated lead coordination agency public health medical service emergency support function59 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Governance (n = 19) Enhance coordination service across agency responding health need climate- affected displaced migrant population (n = 8)Ashraf et al. (13)Pakistan IDP Flood response 2022 Pakistan floods, Khyber Pakhtunkhwa Department Health coordinated United Nations agency provide displaced woman maternal newborn child health service support, hygiene kit baby delivery kits; district health officer district coordinated local organization establish safe shelter space pregnant woman",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "74721885-d147-467a-9d57-500900097052",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "istricts coordinated local organization establish safe shelter space pregnant woman Involve displaced and/ relocated community planning implementation health intervention (n = 1) IFRC (5) Namibia, Samoa, Yemen IDP Drought, flood, cyclone/ typhoon/ hurricane/ stormThe IFRC engaged community across various humanitarian response Namibia Red Cross Society’s 2021 response worsening droughts, refugee migrant consulted ensure equitable access assistance, particularly vulnerable group Yemen, Yemen Red Cross Society integrated community perception view need assessments, ensuring community participation operation response severe flood 2021 Samoa, Samoa Red Cross Society involves household member preparation relocation site displaced tropical cyclone provides household training cleaning maintaining r ainwater h",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1f6f07fe-dce7-48ef-954a-81e4580617bc",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ed tropical cyclone provides household training cleaning maintaining r ainwater harvesting systems60 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Governance (n = 19) Include climate- displaced migrant health system receiving country (n = 3) UNHCR (14) Ethiopia IDP , refugee Drought Ethiopia host refugee IDPs impacted drought; refugee policy involves inclusion refugee national health care system national strategic health plans, access health service term Ethiopian nationals, access free service (TB, HIV leprosy treatment; sexual reproductive health services; vaccinations) public health facility camp setting continuity care secondary tertiary health service non- camp hospital",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9527f858-94b0-4dfb-8672-f5fc0855d85f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "setting continuity care secondary tertiary health service non- camp hospital UNHCR (15) Mali Refugee Nonspecific Facing influx climate- displaced refugee Burkina Faso Niger, Mali maintains open border offer registered refugee right Malians, including access health care education; UNHCR also work Malian organization provide refugee IDPs essential service shelter protection gender- based violence, health care access WASH facility improvements61 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Governance (n = 19) Include climate- displaced migrant health system receiving country (n = 3)Clark- Ginsberg et al. (12)United States IDP , refugee Cyclone/ typhoon/ hurricane/ stormHealth coalition Houston Orlando (United States) offered health service r",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "778c0c00-9a5f-42e1-b46d-1ad2e54bf22f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "icane/ stormHealth coalition Houston Orlando (United States) offered health service refugee migrant displaced hurricanes, including basic medication, diagnostic tests, acute care mental health services; Orlando, posttrauma service scaled provider operated airport support arriving refugee migrant Health financing (n = 3) Allocate additional budget improve health service infrastructure climate- affected displaced migrant population (n = 2)UNHCR (16) country specifiedIDP , refugee Nonspecific UNHCR Climate Resilience Fund launched 2024, aiming raise US$ 100 million end 2025 climate- affected refugee displaced communities; Fund increase sustainable energy displacement settings; support restoration; invest climate-resilient infrastructure livelihoods; reduce environmental impact humanitarian responses; priori",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dfab664c-a2a5-4080-9e66-3c4665981545",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "structure livelihoods; reduce environmental impact humanitarian responses; prioritizing local project involving affected communities62 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Health financing (n = 3) Allocate additional budget improve health service infrastructure climate- affected displaced migrant population (n = 2)IFRC (5) Yemen IDP Flood Disaster Relief Emergency Fund launched respective Red Cross Red Crescent society response disaster emergencies; funding able support Yemen Red Crescent Society 6 months, providing immediate need household material hygiene kit 1000 household affected floods, priority IDPs host community Improve breadth health insuranc",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6b76a5ad-ea43-4264-b3b0-229963aade3a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "floods, priority IDPs host community Improve breadth health insurance coverage include climate- affected displaced migrant population (n = 1)Quast (17) United States IDP Cyclone/ typhoon/ hurricane/ stormAfter Hurricane Katrina hit 2005, United States Government implemented Section 1115 Medicaid Emergency Waivers, allowed States expedite Medicaid coverage displaced individual streamlining documentation income requirements; Texas waiver programme (TexKat) largest programme, included urgent medical care delivery phase first month health care coverage phase next 5 months63 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Health workforce (n = 16) Train health worker build competency meet health need climate- affected",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9defdb32-d53f-45a6-ba7f-d788378f5fb6",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "n health worker build competency meet health need climate- affected displaced migrant population (n = 9) (18) country specifiedNonspecific Nonspecific Refugee migrant health toolkit designed used Member States, country offices, United Nations partners, nongovernmental actor health professional working refugee migrant health; toolkit includes module climate change (Tool 10) ClimaHealth (19)Myanmar IDP Cyclone/ typhoon/ hurricane/ storm PATH (international, not- for-profit global health organization) integrated climate health response Cyclone Mocha Myanmar emergency MHPSS service building mental health intervention capacity among local community- building organization training programmes, expected completed December 2023 training programme scalable model vulnerable community globall",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ca2cec73-4ca3-4e2f-8e7c-526215cf4f7a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "December 2023 training programme scalable model vulnerable community globally64 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Health workforce (n = 16) Train health worker build competency meet health need climate- affected displaced migrant population (n = 9) Rabbani et al. (20)Pakistan IDP Flood mPareshan intervention, feasibility study Aga Khan University 2021 2022, aimed improve mental health flood-displaced affected community Badin District, Pakistan, training female health worker supervisor communication counselling using WHO- adapted curriculum; second phase implemented digital app, mPareshan, provided psychoeducational counselling referral service Amsalu et al",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6293b19c-4081-4816-ad40-cbbc9ecfedb8",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "app, mPareshan, provided psychoeducational counselling referral service Amsalu et al. (21)Somalia IDP Nonspecific Save Children, coordination Puntland Ministry Health, facilitated 8-day Helping Babies Survive training course 2016 subsequent 14-day master trainer course 2019; health care provider Bossaso City, Somalia, trained maternal health, intrapartum care, supportive supervision health information system displaced populations65 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Health workforce (n = 16) Train health worker build competency meet health need climate- affected displaced migrant population (n = 9) IFRC (5) Samoa IDP Flood prevent vector-borne disease filariasis heavy flood Samoa 2016 2019, displaced many, vo",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fc11a2f7-458d-4108-ba48-41073c2298c7",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "filariasis heavy flood Samoa 2016 2019, displaced many, volunteer Samoa’s Red Cross Society captured mosquitos, removed potential breeding site trained blood sample collection microfilaria detection IOM (22) Brazil IDP , refugee Nonspecific Since 2023, IOM provided technical support training health care worker border municipality Brazil address climate change- related health risk among migrating groups; IOM also provided equipment supply municipality increased awareness prevention treatment climate-related health issue MSF (23) South Sudan IDP Flood 2023 MSF Academy Healthcare began training South Sudanese health care worker several state strengthen competency improve quality care area high displacement fragile health system aggravated violence severe floods66 Health system strengt",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0b729ce6-702b-4a5d-94b5-cca6379b6395",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ement fragile health system aggravated violence severe floods66 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Health workforce (n = 16) Train health worker build competency meet health need climate- affected displaced migrant population (n = 9) Evans et al. (24)United States Nonspecific Nonspecific Rollins School Public Health Emory University offer Graduate Certificate Humanitarian Emergencies, field practice programme complex humanitarian emergency fellowship prepare health care professional complex humanitarian emergencies, including climate-related disaster displacements; Certificate programme serf foundational training, field practice fellowship facilitate work experience compl",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "59a16131-17d4-494f-9a83-3be9a6a18f3e",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "undational training, field practice fellowship facilitate work experience complex humanitarian emergency setting Williams Downs (25)No country specifiedNonspecific Nonspecific Introduction Complex Humanitarian Emergencies course designed prepare nurse addressing health need displaced population following climate change, natural disaster conflicts; course developed using Sphere Humanitarian Charter Minimum Standards practical framework, consultation resettled refugee expert field humanitarian response67 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Health workforce (n = 16) Expand health workforce capacity response climate-related event emergency (n = 7)World Bank Group (26)Mali IDP Nonspecific Mali, climate change remains one lead",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ee1d5485-d3da-4a67-9810-764c25dc7abb",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "7)World Bank Group (26)Mali IDP Nonspecific Mali, climate change remains one leading driver conflict displacement Sahel region, Government incentivizes civil servant health worker assigned area dire need; cash incentive vary depending local ministry external assistance Clark- Ginsberg et al. (12)United States Refugee Cyclone/ typhoon/ hurricane/ stormIn response Orlando’s new refugee migrant population arriving Hurricane Maria 2017, staff change across Orlando’s health system made, qualified bilingual staff volunteer hired meet need new, predominantly Spanish- speaking population Puerto Rico Adalja et al. (8)United States Hospital evacueeCyclone/ typhoon/ hurricane/ stormIn response Hurricane Sandy, New York hospital focused augmenting supporting hospital staff manage increased influx evacuated patient creati",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "84354658-c369-4ef1-8ca5-ab8de750acaf",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ing supporting hospital staff manage increased influx evacuated patient creating sleeping quarter employees, organizing meal planning employee remain site 72 hours; facility received evacuated patient also used displaced health professional alleviate pressure patient surge68 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Health workforce (n = 16) Expand health workforce capacity response climate-related event emergency (n = 7)Shultz et al. (10)Nicaragua IDP Cyclone/ typhoon/ hurricane/ stormIn wake 2020 Hurricanes Eta Iota Nicaragua, Pan American Health Organization/ Regional Office Americas brought almost 20 medical team deployment Puerto Cabezas surrounding municipaliti",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9c39412f-5fcc-49af-a202-940aef49452b",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "brought almost 20 medical team deployment Puerto Cabezas surrounding municipality assist displaced, responding report low health workforce capacity IFRC (5) Mozambique IDP Cyclone/ typhoon/ hurricane/ stormA Red Cross field hospital deployed Mozambique provide health service displaced 2019 tropical Cyclone Idai; Red Cross doctor nurse worked local health provider strengthen district hospital capacity WASH, deliver supplies, support operating room maternal ward assist surgery Valente et al. (11)Italy IDP Heavy rain/ floodingFollowing intense rainfall occurred Italy May 2023, Crisis Unit Ferrara Province activated extra family community nurses, provided primary health care people displaced, alongside general practitioners, voluntarily provided extra support69 Annex 2. Health system intervention identified reviewInterv",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fe9a0f69-9362-4e6f-9b41-9cb037cde4cc",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "arily provided extra support69 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Health workforce (n = 16) Expand health workforce capacity response climate-related event emergency (n = 7)Kanter Abramson (27)United States IDP Cyclone/ typhoon/ hurricane/ stormResponding 2011 tornado Joplin (Missouri, United States), staff public private school trained reassurance techniques, classroom mental health intervention recognizing serious symptom referral; licenced mental health counsellor also hired support displaced schoolchildren Medicine supply (n = 3) Ensure availability medical supply climate- affected displaced migrant population (n = 3)Shultz et al. (10)Nicaragua IDP Cyclone/ typhoon/ hurricane/ stormIn response Hurricanes Eta Iota Nicaragua, UNICEF distributed nu",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f7e79752-8a1e-49a9-9ad6-cd5b5586f675",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "phoon/ hurricane/ stormIn response Hurricanes Eta Iota Nicaragua, UNICEF distributed nutritional supply kit personal protective equipment 1000 health workers, international NGOs provided chlorine, hygiene kits, water filter leptospirosis treatment displaced neighbouring Honduras, Pan American Health Organization/WHO Regional Office Americas donated 40 000 antigen test 300 000 polymerase chain reaction test improve early COVID-19 detection70 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Medicine supply (n = 3) Ensure availability medical supply climate- affected displaced migrant population (n = 3)Shultz et al. (10)South Sudan IDP Cyclone/ typhoon/ hurricane/ stormThe Women’s Integrated Sexual Healt",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "38474ef8-ed8d-45c7-9982-2ebd1c86d304",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "z et al. (10)South Sudan IDP Cyclone/ typhoon/ hurricane/ stormThe Women’s Integrated Sexual Health programme supported Boma Health Initiative community health worker South Sudan; flood-displaced woman girl Rubkona Aweil East given access oral pills, condoms, injectables referral long-acting reversible contraceptive Doherty et al. (6)Somalia IDP Flood May 2023 May 2024, IOM provided menstrual hygiene kit sanitary pad flood- displaced woman girl Danyar Refugee Camp Somalia Health information system (n = 4) Establish integrated surveillance system monitoring climate- sensitive health risk outcome among climate- affected displaced migrant population (n = 4) Shortus et al. (29)Solomon IslandsIDP Flood flash flood 2014 displaced people Solomon Islands, dengue outbreak increased; response, paper-based Early Warning Alert Response Ne",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6e6ffe4b-c2c0-4ac7-99ca-4cf3b88973ec",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "nds, dengue outbreak increased; response, paper-based Early Warning Alert Response Network established monitor diseases, National Surveillance Unit used syndromic surveillance collect data eight disease sentinel sites71 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Health information system (n = 4) Establish integrated surveillance system monitoring climate- sensitive health risk outcome among climate- affected displaced migrant population (n = 4)Musoke et al. (9)Sierra Leone IDP Mudslide, heavy rainIn response 2017 Freetown mudslide Sierra Leone, displaced 5000 people, Ministry Health, supported WHO, aimed improve weekly reporting priority disease Integrated Disease Surveillance Response system; nine health facility submitted daily report",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "48593c49-e429-41d4-8282-2524e4f8ce69",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ed Disease Surveillance Response system; nine health facility submitted daily report shared weekly epidemiological bulletin Public Health Emergency Operations Centre covered children’s diarrhoeal symptoms, suspected cholera typhoid fever Mugabe et al. (30)Mozambique IDP Cyclone/ typhoon/ hurricane/ stormIn response cholera outbreak following onslaught Cyclones Idai Kenneth Mozambique, multisectoral multidisciplinary task force formed carry active surveillance, case detection investigation, laboratory diagnosis management suspected cholera cases; surveillance combined WASH intervention social mobilization involved door-to-door health promotion education strategy regarding proper hygiene vaccination displaced populations72 Health system strengthening intervention improve health displaced migrant population context c",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e6c9ef32-7e96-4024-8124-f0294b610477",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "thening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Health information system (n = 4) Establish integrated surveillance system monitoring climate- sensitive health risk outcome among climate- affected displaced migrant population (n = 4)ClimaHealth (19)Bangladesh Refugee Nonspecific 2021 International Centre Diarrhoeal Disease Research Bangladesh implemented waste-water surveillance programme refugee camp detect climate- sensitive infections, Vibrio cholerae Salmonella typhi; programme expanded two city joint effort involving Government multilateral organization Service delivery (n = 50) Provide humanitarian response health service climate-related emergency (n = 21) IFRC (5) Mozambique IDP Cyclone/ typhoon/",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7f7e95bb-cd1a-481a-a922-080d4b41f16b",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "service climate-related emergency (n = 21) IFRC (5) Mozambique IDP Cyclone/ typhoon/ hurricane/ stormAfter tropical Cyclone Idai Mozambique 2019, Mozambique Red Cross Society managed cholera outbreak providing clean water, treating water sources, repairing hand pump building latrines; 36-bed cholera treatment unit established, serving 114 055 people emergency shelter kit supporting 28 712 IDPs camp WASH services73 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Provide humanitarian response health service climate-related emergency (n = 21) IFRC (5) Namibia Refugee Drought Namibia Red Cross Society distributed 20 000 water purification tablets, jerry cans, hand sanitizers hygiene kit Angolan refugee (displaced droughts) Namibia, 17",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f271c1ff-9bdc-49f7-88fa-f42ebd83139c",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "sanitizers hygiene kit Angolan refugee (displaced droughts) Namibia, 17 handwashing station set up; health education TB, malaria, COVID-19 communicable disease also provided IFRC (5) Yemen IDP Flood, heavy rainIn response 2021 rain floods, volunteer Yemen Red Crescent Society distributed food non- food item shelter kit personal hygiene kit affected people, including IDP families; volunteer also provided first aid, evacuation, ambulance service MHPSS service IFRC (5) Iraq IDP Drought 2021 Disaster Relief Emergency Fund approved targeting 43 116 people Iraq displaced climate-exacerbated water shortages; Iraqi Red Crescent Society deployed mobile health teams, providing medical supply health education 40 870 individual WASH intervention ensured clean water sanitation 7186 households, including displaced returnees",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f83f4ff9-d4ed-415f-a12b-633a577d8609",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ention ensured clean water sanitation 7186 households, including displaced returnees camps74 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Provide humanitarian response health service climate-related emergency (n = 21) IFRC (5) Germany IDP Flood, heavy rainResponding displacement July 2021 storms, German Red Cross provided drinking-water, food, accommodation, electricity, psychological help mobile clinic fully equipped emergency practice (two treatment rooms, laboratory sonography, capacity treat 100 patient day); German Red Cross established emergency waste-water treatment facility originally designed use Bangladesh modular facility providing shelter, electricity, WASH, commu",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f537a042-aa68-4af3-8463-58ac80681720",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "esigned use Bangladesh modular facility providing shelter, electricity, WASH, communication essential service IOM (31) Somalia IDP Flood 2023 IOM supported Somalian Ministry Health flash flood climate disaster increased displacement; seven health care facility 20 mobile clinic provided around 300 000 primary health care consultations, 73 000 routine vaccination child 260 000 systematic malnutrition screening child under-5 year pregnant lactating women75 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Provide humanitarian response health service climate-related emergency (n = 21) Benkritly Hujale (32)South Sudan Refugee Flood 2023 UNHCR worked South Sudan’s Government provide refugee emergency assistance transit",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "49218d4a-b490-4561-afe7-0f7ef0d85bea",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "orked South Sudan’s Government provide refugee emergency assistance transit centre near Sudan–South Sudan border, camp experience flood risks; assistance included water, food, sanitation facility primary health care Hujale (33) Somalia IDP Cyclone/ typhoon/ hurricane/ stormIn 2020 Cyclone Gati hit Bossaso, Somalia’s coastal settlement hosting IDPs facing extreme temperatures, water shortage floods; response, UNHCR airlifted relief item hard-hit area Bari Region MSF (23) South Sudan IDP Flood 2023 MSF team supported at-risk community (including flood-affected IDPs) South Sudan running health clinics, outreach disease prevention activity training community health care worker remote area Lien et al. (34) United States IDP Cyclone/ typhoon/ hurricane/ storm response Hurricane Sandy 2012, North Shore Long Island Jewish Health System launched mobile health unit",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "02723f48-4463-4c01-8fa0-e868fae8226a",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "andy 2012, North Shore Long Island Jewish Health System launched mobile health unit operation serve displaced population cost without requiring insurance; operating 64 days, mobile health unit included community need assessment, preparation, staff recruitment evaluation; pharmacy donated vaccine medical supplies76 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Provide humanitarian response health service climate-related emergency (n = 21) Sood et al. (35)United States IDP Cyclone/ typhoon/ hurricane/ stormAfter Hurricane Sandy New York, organization ensured continued access primary care mobile health clinics; 5 November 2012, Mayor’s administration deployed six mobile health clinic st",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6ff2fd69-f7c8-48cb-a00c-1fb0a41311c5",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "th clinics; 5 November 2012, Mayor’s administration deployed six mobile health clinic staffed primary care provider deliver free medical care prescription drug affected residents, supporting uninsured lost access medication evacuation Valente et al. (11)Italy IDP Heavy rain, floodResponding intense rainfall May 2023 Italy, general practitioner distributed free medicine evacuation centres, mobile clinic called Socio-Sanitary Assistance Posts offered nursing medical service health promotion leaflet distributed displaced; flooded areas, health institution monitored gastrointestinal, cutaneous respiratory infection authority recommended tetanus toxoid booster UNHCR (36) Horn Africa IDP , refugee Nonspecific region climate change exacerbates poor living condition refugee IDPs, UNHCR supported health facility enhance",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "848d3968-9886-4437-946b-91e1fd2ba282",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "erbates poor living condition refugee IDPs, UNHCR supported health facility enhance nutritional assistance woman child high-nutrient feeding medical treatment77 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Provide humanitarian response health service climate-related emergency (n = 21) MSF (37) Chad IDP Flood response 2022 flooding Chad, MSF collaborated Chad Ministry Health establish run mobile clinic displacement site support existing health centre people sought shelter; MSF provided basic health care, nutritional support, vaccinations, water supply, sanitation service consultation malaria, respiratory tract infection diarrhoea MSF (38) Malawi IDP Cyclone/ typhoon/ hurricane/ stormResponding aftermath Cyclone",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "de3d4359-07a4-4972-9474-cfdf0fa728bf",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "rhoea MSF (38) Malawi IDP Cyclone/ typhoon/ hurricane/ stormResponding aftermath Cyclone Freddy Malawi 2023, MSF provided support local hospital donating medical supply allocating staff treat patient undertake orthopaedic surgeries; evacuation camps, MSF provided clean water chlorine purify drinking- water, rehabilitated water networks, emptied latrine distributed blanket cooking equipment78 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Provide humanitarian response health service climate-related emergency (n = 21) Musoke et al. (9)Sierra Leone IDP Mudslide, heavy rainAs part Sierra Leone’s response 2017 Freetown mudslide displaced 5905 people, essential service provided",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9bc355ca-5a3b-4e44-b345-8d20eb3e2dae",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "onse 2017 Freetown mudslide displaced 5905 people, essential service provided cost clinic served affected population new clinic established IDP sites; service provided include reproductive health services, treatment children, TB HIV treatment, access safe drinking-water, water quality monitoring, hand washing station distribution body bag Musoke et al. (9)Sierra Leone IDP Mudslide, heavy rainFollowing mudslide occurred Freetown, Sierra Leone 2017 3 day torrential rains, additional clinic temporarily established site IDPS; partner agency organization supported provision health care temporary facility Kearns et al. (39)United States IDP Cyclone/ typhoon/ hurricane/ stormResponding 2014 tornado hit Louisville (United States), mobile hospital established could respond assist post disaster; included",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a93e2256-8530-4821-8949-b070b399f415",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "es), mobile hospital established could respond assist post disaster; included five-bed emergency department, 11-bed inpatient acute care unit, central medical supply, laboratory, pharmacy radiology unit79 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Provide humanitarian response health service climate-related emergency (n = 21) Adalja et al. (8)United States Hospital evacueeCyclone/ typhoon/ hurricane/ stormLearning Hurricane Irene, New York hospital anticipated request absorb limited number patient hospital within individual system responding Hurricane Sandy; precaution taken ensure hospital prepared shelter place receive evacuated patients; effort included proactive management in-hospital census, adjusting oper",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0ec08a62-45e7-4648-b248-ba6093261153",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "cuated patients; effort included proactive management in-hospital census, adjusting operating room schedules, enhancing security, scheduling supply delivery arrive early ensuring adequate staffing level accommodations; receiving hospital also suspended elective surgery approximately 2 day free operating room space Adalja et al. (8)United States Hospital evacueeCyclone/ typhoon/ hurricane/ stormTo meet need displaced resident New York, New York City Department Health Mental Hygiene opened eight medical shelter staffed volunteer health professionals80 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Provide humanitarian response health service climate-related emergency (n = 21) UNHCR (40) Somali",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c7b8f8dd-0e13-4a4c-b28a-f254f1b45f09",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "response health service climate-related emergency (n = 21) UNHCR (40) Somalia IDP Drought 2022 UNHCR humanitarian partner assisted drought-displaced population Somalia delivering shelter material hygiene items; separated unaccompanied child provided medical assistance, psychosocial support, counselling safe space protect forced child recruitment Ensure access health service displaced population climate- affected protracted crisis (n = 6)MSF (41) South Sudan IDP Flood South Sudan 2023, MSF shifted emergency care response comprehensive, decentralized medical care flood-affected IDPs 86-bed hospital, two health post four community site camps, providing outpatient consultations, emergency care, maternal care, chronic disease care (e.g. TB HIV) psychological support; consultation camp nearby health post w",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "385eea52-d18b-4410-99f5-f20c9c31515c",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "e.g. TB HIV) psychological support; consultation camp nearby health post provided Lindvall et al. (42)Somalia IDP Nonspecific IDPs displaced conflict climate change living camp Somalia full free access basic public health service vaccination maternal child care; however, tertiary specialized service surgery free81 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Ensure access health service displaced population climate- affected protracted crisis (n = 6)Lindvall et al. (42)Kenya IDP , refugee Drought Drought-displaced refugee migrant arriving formally designated camp Kenya undergo standardized health screening malnutrition disease (e.g. viral haemorrhagic fever, poliomyelitis) also asked",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "30121b19-a293-4292-8b43-b67d81e9370f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "rition disease (e.g. viral haemorrhagic fever, poliomyelitis) also asked vaccination status; ensure continuation care TB HIV, counsellor provide free treatment concerned individual Bourgois (43) Chad IDP , returnee Flood Due severe flood northern region Cameroon 2021, 12 500 people fled across Logone river Chad; 2 month this, 4000 returned close 9000 remained Chad; UNHCR United Nations Refugee Agency collaborated NGO partner Chadian authority provide IDPs returnees shelter, health care basic necessity IFRC (5) Guatemala, HondurasRefugee Nonspecific Honduran Red Cross activated humanitarian service point point departure along route migrating caravan people vulnerable climate hazards; point provided migrant water, face masks, prehospital care information safet",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f43b4c01-c298-476c-be6f-69cab452373f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "se point provided migrant water, face masks, prehospital care information safety, security COVID-19 prevention82 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Ensure access health service displaced population climate- affected protracted crisis (n = 6)IOM (22) Bangladesh Refugee Nonspecific IOM provided solar power system informal camp hosting Rohingya Cox’s Bazar, Bangladesh; IOM 27 facility equipped solar photovoltaic system Bangladesh, including four health facilities, woman girls’ safe space water supply network 100 climate-resilient community clinic Provide mental health intervention climate- affected displaced migrant population (n = 8) Kanter Abramson (27)United St",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "57172252-82ab-4f88-941a-d63b3e72ea22",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "climate- affected displaced migrant population (n = 8) Kanter Abramson (27)United States IDP Cyclone/ typhoon/ hurricane/ stormAfter schoolchildren displaced 2011 tornado Joplin (Missouri, United States), public school psychologist sent survey parent identify child needed counselling facilitated selective referral mental health provider child greatest need Valente et al. (11)Italy IDP Heavy rain, floodAs part Italy’s emergency response measure following intense rainfall May 2023, 120 psychologist specialize emergency mental care deployed offer psychological support displaced populations; psychological service subsequently expanded rest population83 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Provide mental health",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "615dbef0-1e7a-4c24-8586-a546f0cb79e5",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Provide mental health intervention climate- affected displaced migrant population (n = 8) Musoke et al. (9)Sierra Leone IDP Heavy rain, mudslideFollowing mudslide occurred Freetown, Sierra Leone 2017, supported 21 mental health nurse provided psychological first aid intensive listening forum displaced population front-line workers; teacher also trained support child distress Lalani et al. (44)Canada IDP Wildfire displacement 2016 wildfire Alberta, Canada, population Fort McMurray received young people family- focused mental health programmes, including peer mentorship, mindfulness counselling; programme taught coping strategy emotional regulation, alongside \"Journey Hope\" initiative support family children’s mental health Taioli et al. (45)United States IDP Cyclone/",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "de219de2-5258-4a3f-a5f6-34c2485c08a5",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ive support family children’s mental health Taioli et al. (45)United States IDP Cyclone/ typhoon/ hurricane/ stormProject Restoration provided mental health service displaced population Hurricane Sandy hit United States 2012; individual high-risk area Rockaways screened mental behavioural issue linked care Far Rockaway Treatment Centre84 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Provide mental health intervention climate- affected displaced migrant population (n = 8) Alam et al. (46)Bangladesh Refugee Flood, cyclone/ typhoon/ hurricane/ stormBangladesh face climate- related disasters, affecting Rohingya; mental health service integrated basic care following WHO’s mhGAP g",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "46743eb3-a89f-47be-8c14-3a1acf8f264b",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "fecting Rohingya; mental health service integrated basic care following WHO’s mhGAP guidelines; primary health care provider trained mhGAP method patient severe issue referred district hospital specialized care Bharadwaj Huq (47)India IDP Nonspecific migration helpline Jharkhand, India, helping climate-displaced migrant distress counselling (48) Burkina Faso IDP Nonspecific Integrated Production Diversification Nutritional Improvement programme Burkina Faso enhances food security raise awareness climate change resource management technique among IDPs; includes MHPSS service component address mental health stressors, establish community support groups, integrate basic mental health care nonspecialized setting promote right psychosocial disabilities85 Annex 2. Health system intervention identified reviewInterventio",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "940f0235-c8c4-4d2e-9462-aaba4c6b3481",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "sychosocial disabilities85 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Improve WASH service climate- affected displaced migrant population (n = 13)IOM (31) Somalia, YemenIDP , in-transit Drought, floodIn 2023 IOM provided essential health WASH service Somalia Yemen address acute watery diarrhoea cholera response prevention wake climate-related drought floods; included direct assistance hotspot 26 000 IDPs host community members, establishment 12 water point along refugee migrant routes, joint hygiene promotion solid waste management activities, oral cholera vaccination campaign cholera treatment kit Negussie (28) Somalia IDP Heavy rain, droughtIOM provided WASH service menstrual hygiene IDPs Danyar Refugee Camp, Somalia, whi",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "55771fe1-d89a-4335-ac91-940bbf143fb7",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "OM provided WASH service menstrual hygiene IDPs Danyar Refugee Camp, Somalia, experienced torrential rain drought; May 2023 May 2024, IOM distributed hygiene kit sanitary pad nearly 60 000 families, constructed nearly 2800 sanitary structure conducted reproductive health hygiene promotion awareness session nearly 700 000 people86 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Improve WASH service climate- affected displaced migrant population (n = 13)Akbar (49) Pakistan IDP , returnee Flood Responding Pakistan’s 2022 floods, destroyed house latrine fleeing flood, IOM constructed latrines, handwashing station lead-line hand pump affected village",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fdf0582a-14b6-48e4-a373-15fdb407b730",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "OM constructed latrines, handwashing station lead-line hand pump affected village conducted WASH awareness session hygiene technique waterborne disease risk returning home Viray (50) Ethiopia IDP Drought collaboration local water office drought-stricken community Ethiopia, IOM provided safe drinking- water 7500 individual constructing solar-operated water systems; IOM also provided potable drinking- water across Ethiopia emergency water trucking, constructing rehabilitating WASH facilities, distributing WASH item promoting hygiene awareness drought- affected population host community UNICEF (51) Ethiopia IDP Drought response Ethiopia’s drought, conflict COVID-19, 2021 UNICEF’s WASH programme reached 14 million people emergency water trucking, repairing water system providing hygiene kits; sanitation intervention mass handwashing",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "acd67dc0-2c2c-4956-994a-1a5aad99e915",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "pairing water system providing hygiene kits; sanitation intervention mass handwashing campaign supported displaced community transit centres87 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Improve WASH service climate- affected displaced migrant population (n = 13)UNICEF (51) Afghanistan IDP Drought 2021 UNICEF responded WASH intervention Afghanistan’s humanitarian crisis caused political situation coupled severe drought; intervention included support supply water system chlorination, water trucking, delivery water sanitation service school hygiene promotion nationally UNICEF (51) Yemen IDP Nonspecific 2021 UNICEF’s WASH programme Yemen targeted IDP camps, rehabilitating water sanitation systems, delivering gender-responsive hygiene ki",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0f9cccb7-f68e-4e42-b82c-b296dfe1bb17",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "IDP camps, rehabilitating water sanitation systems, delivering gender-responsive hygiene kit promoting handwashing COVID-19 cholera prevention; programme also trained 600 technician climate-resilient sanitation safeguard UNICEF (52) Mozambique IDP Drought response 2016–2017 Mozambique drought, UNICEF installed multiuse olar-powered water system 54 boreholes rehabilitated 98 boreholes, improving water access 95 000 people; 2019 system operated throughout cyclone period, supporting previously newly displaced community lost safe water access, without relying water trucking88 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Improve WASH service climate- affected displaced",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "383dfc76-1c5f-4673-80f5-28fb55c45041",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "rief summary Service delivery (n = 50) Improve WASH service climate- affected displaced migrant population (n = 13)UNHCR (36) Horn Africa IDP , refugee Nonspecific region climate change exacerbates living condition refugee IDPs, UNHCR provides access water water trucking, drilling additional boreholes rehabilitation existing water sanitation system Chiriac (53) Yemen IDP Nonspecific IOM helped rehabilitate water supply system Yakhtol, Yemen, constructing collective water tank, installing solar pumping unit generator setting equipment room; provided 14 000 people access clean water district; IDPs residing community faced disrupted access clean water due climate change land degradation Mohammed (54)Yemen IDP Drought IOM, collaboration local Water Corporation Turbah, Yemen, established solar power",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e1d830c2-3621-47ea-9cac-d375f30e0612",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "collaboration local Water Corporation Turbah, Yemen, established solar power system providing clean water community experiencing displacement drought; IOM team conducted cleaning awareness campaign resident organized operation management session water committee overseeing wells89 Annex 2. Health system intervention identified reviewIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Improve WASH service climate- affected displaced migrant population (n = 13)IFRC (5) Samoa IDP Heavy rain, sea level riseBuilding WASH rainwater harvesting experience 2009 tsunami, Samoa Red Cross Society become lead implementing agency national WASH sector rainwater harvesting; annually requested Government install household rainwater harvesting system ventilated latrine syste",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "86d5c977-c2a2-4073-8014-d8c86789c9fb",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Government install household rainwater harvesting system ventilated latrine systems; Society successfully advocated mandatory rainwater harvesting system new structure increase resilience relocated household Hirani (55) Bangladesh Refugee Nonspecific OXFAM (an NGO) constructed communal female WASH unit includes private toilets, shower laundering area provide privacy improve menstrual hygiene woman girl Rohingya camps, prone climate- exacerbated flood face difficulty waste disposal; unit innovative discrete chute system used dispose menstrual products90 Health system strengthening intervention improve health displaced migrant population context climate changeIntervention typeSource Country/ regionMigrant type Climate hazardBrief summary Service delivery (n = 50) Ensure access vaccine climate- affected displaced",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ccb26aad-4746-408a-84c9-db122047e1fe",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "f summary Service delivery (n = 50) Ensure access vaccine climate- affected displaced migrant population (n = 2)Mysamboza et al. (56)Malawi IDP Flood response Malawi’s 2014 cholera outbreak, mass campaign provide oral cholera vaccine conducted National Task Force involving Malawi’s Ministry Health partners; campaign comprised coordination monitoring workshop vaccine campaign targeting 160 000 flood-displaced camp resident surrounding community Nsanje district; health care community worker administered 91.9% received dos oral cholera vaccine Musoke et al. (9)Sierra Leone IDP Heavy rain, mudslideAs part Sierra Leone’s response 2017 mudslide, oral cholera vaccine campaign implemented among affected displaced population aged 1 year over; supported community health worker community leader administering 518 013 vaccine across tw",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6ad1aa95-25cf-4e96-a76a-128394b7d0e8",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "orted community health worker community leader administering 518 013 vaccine across two campaign MHPSS: mental health psychosocial support; TB: tuberculosis.91 Annex 2. Health system intervention identified reviewReferences1 1. Vanuatu: national policy climate change disaster-induced displacement. Port Villa: Vanuatu National Disaster Management Office; 2018 (https://www.refworld.org/policy/strategy/ natlegbod/2018/en/121425). 2. Ethiopia 2018: humanitarian disaster resilience plan. Addis Ababa: United Nations Office Coordination Humanitarian Affairs Government Ethiopia; 2018 (https://www.refworld.org/policy/legalguidance/ocha/2018/en/121068). 3. Revised national development strategy 2021–2024: consolidate peace stabilize economy. Juba: Republic South Sudan United Nations Development Programme; 2022 (https://www.refworld.org/policy/strategy/natlegbod/2022/en/147818). 4.",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ec8f2ca4-ef90-441b-b1fd-9a161687d211",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ogramme; 2022 (https://www.refworld.org/policy/strategy/natlegbod/2022/en/147818). 4. RIASCO action plan southern Africa: response plan El Niño-induced drought southern Africa May 2016–April 2017. Geneva: Regional Inter-Agency Standing Committee; 2016 (https://library.alnap.org/help-library/riasco-action-plan-for-southern-africa-response-plan-for- the-el-nino-induced-drought-in). 5. Displacement changing climate: localized humanitarian action forefront climate crisis. Geneva: International Federation Red Cross Red Crescent Societies; 2021 (https://www.ifrc.org/sites/default/files/2021-11/2021-Climate-Displacement-Report-Final.pdf ). 6. Doherty P , Wheeler E, Mochache V, Mark J, Luttah G, Bero B et al. Considerations program manager improve sexual reproductive health service displaced populations. Glob Health Sci Pract. 2023;11(4):e2300036 (https://doi.org/10.9745/ghsp-d-23-00036). 7. Spickett J, Kats",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6bb87757-8f24-47ce-bf12-90d8619ee921",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Health Sci Pract. 2023;11(4):e2300036 (https://doi.org/10.9745/ghsp-d-23-00036). 7. Spickett J, Katscherian D, Brown H. Climate change, vulnerability health guide. Perth: Curtin University Collaborating Centre Climate Change Health Impact Assessment; 2015 (https://doi.org/10.17605/OSF.IO/K38SW). 8. Adalja AA, Watson M, Bouri N, Minton K, Morhard RC, Toner ES. Absorbing citywide patient surge Hurricane Sandy: case study accommodating multiple hospital evacuations. Ann Emerg Med. 2014;64(1):66–73.e61 (https://doi.org/10.1016/j.annemergmed.2013.12.010). 9. Musoke R, Chimbaru A, Jambai A, Njuguna C, Kayita J, Bunn J et al. public health response mudslide Freetown, Sierra Leone, 2017: lesson learnt. Disaster Med Public Health Prep. 2020;14(2):256–64 (https://doi.org/10.1017/dmp.2019.53). 10. Shultz JM, Berg RC, Kossin JP , Burkle Jr F, Maggioni A, Pinilla Escobar VA et al. Convergence climate-driven hurricane COVID-19: impact 2020",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "62beb718-f648-4ea7-80fe-a2a748c6c3af",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Pinilla Escobar VA et al. Convergence climate-driven hurricane COVID-19: impact 2020 hurricane Eta Iota Nicaragua. J Clim Change Health. 2021;3:100019 (https://doi.org/10.1016/j.joclim.2021.100019). 1 reference accessed 30 March 2025.92 Health system strengthening intervention improve health displaced migrant population context climate change11. Valente M, Zanellati M, Facci G, Zanna N, Petrone E, Moretti E et al. Health system response 2023 flood Emilia-Romagna, Italy: field report. Prehosp Disaster Med. 2023;38(6):813–17 (https://doi.org/10.1017/S1049023X23006404). 12. Clark-Ginsberg A, Becerra-Ornelas A, Chandra A. Capacities health system climate migrant receiving communities: insight US Gulf Coast. Washington, DC: Urban Institute; 2023 (https://issuelab.org/resources/43676/43676.pdf ). 13. Ashraf M, Shahzad S, Sequeria P , Bashir A, Azmat SK. Understanding challenge woman face floo",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "433956eb-b3cf-469c-8545-f607c8170b0f",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": ". Ashraf M, Shahzad S, Sequeria P , Bashir A, Azmat SK. Understanding challenge woman face flood-affected area access sexual reproductive health services: rapid assessment disaster-torn Pakistan. BioMed Res Int. 2024;(1):1113634 (https://doi.org/10.1155/2024/1113634). 14. Ethiopia: refugee policy review framework update 30 June 2023. Geneva: United Nations High Commissioner Refugees; 2024 (https://data.unhcr.org/en/documents/details/107226). Licence: CC BY-4.0. 15. Support urgently needed avert deeper Sahel crisis, UNHCR’s protection chief warns [news release]. United Nations High Commissioner Refugees; 25 March 2024 (https://www.unhcr.org/ news/press-releases/support-urgently-needed-avert-deeper-sahel-crisis-unhcr-s-protection-chief ). 16. UNHCR launch fund shield refugee displaced people climate shock [news release]. United Nations High Commissioner Refugees; 24 April 2024 (https://www.unhcr.org/news/press- relea",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1c288930-35c6-4029-9500-29dd9e76979b",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "nited Nations High Commissioner Refugees; 24 April 2024 (https://www.unhcr.org/news/press- releases/unhcr-launches-fund-shield-refugees-and-other-displaced-people-climate-shocks). 17. Quast . Healthcare utilization child asthma displaced Hurricane Katrina. J Asthma. 2018;55(4):416–23 (https://doi.org/10.1080/02770903.2017.1339244). 18. Module 3: tackling social determinant health workers’ occupational health safety; tool 10: climate change. In: Refugee migrant health toolkit [online application]. World Health Organization; 2015 (https://www.who.int/tools/refugee-and-migrant-health-toolkit/ module-3/tool-10). 19. Climate health solution space [website]. ClimaHealth; 2021 (https://climahealth.info/ climate-and-health-solutions-space/). 20. Rabbani F, Siddiqui A, Merali Z. Responding mental health challenge flood-affected community technology-driven local solution Pakistan: mPareshan Project. Karachi: Brain",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "637d533b-2950-4f54-ba5a-595f9342af09",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "e technology-driven local solution Pakistan: mPareshan Project. Karachi: Brain Mind Institute Department Community Health Sciences, Aga Khan University; 2022 (https://hub.connectingclimateminds.org/research-and-action/case-studies/14). 21. Amsalu R, Schulte-Hillen C, Garcia DM, Lafferty N, Morris CN, Gee et al. Lessons learned helping baby survive humanitarian settings. Pediatrics. 2020;146 (suppl 2):S208–17 (https://doi.org/10.1542/peds.2020-016915L).93 Annex 2. Health system intervention identified review22. Climate change impact health: affecting development human mobility. Geneva: International Organization Migration; 2023 (https://www.iom.int/sites/g/files/tmzbdl486/files/ documents/2024-01/iom-health_climate-change_position-paper_21.12.2023.pdf ). Licence: CC BY-NC-ND 3.0 IGO. 23. Unshattered hope face adversity South Sudan [blog]. Médecins Sans Frontières; 15 November 2023 (https://www.msf.org",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e6c7896b-4395-4675-89c8-02a96a850b47",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "adversity South Sudan [blog]. Médecins Sans Frontières; 15 November 2023 (https://www.msf.org/unshattered-hope-face-adversity-south-sudan). 24. Evans DP , Anderson M, Shahpar C, del Rio C, Curran JW. Innovation graduate education health professional humanitarian emergencies. Prehosp Disaster Med. 2016;31(5):532–8 (https://doi.org/10.1017/S1049023X16000650). 25. Williams H, Downes E. Development course complex humanitarian emergencies: preparation impact climate change. J Nurs Scholarsh. 2017;49(6):661–9 (https://doi.org/10.1111/jnu.12339). 26. Forced displacement potential solution IDPS refugee Sahel: Burkina Faso, Chad, Mali, Mauritania, Niger. Washington, DC: World Bank Group; 2014 (https://documents1.worldbank. org/curated/en/229401467990086793/pdf/899510WP0Box380splacement0study0WEB.pdf ). 27. Kanter RK, Abramson D. School intervention Joplin tornado. Prehosp Disaster Med. 2014;29(2):",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f2f32ae3-4dff-4c6e-9c46-d967591484a9",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "er RK, Abramson D. School intervention Joplin tornado. Prehosp Disaster Med. 2014;29(2):214–17 (https://doi.org/10.1017/S1049023X14000181). 28. Menstrual hygiene support woman girl Somalia: World Menstrual Hygiene Day [website]. International Organization Migration; 2025 (https://somalia.iom.int/stories/ menstrual-hygiene-support-women-and-girls-somalia-world-menstrual-hygiene-day). 29. Shortus M, Musto J, Bugoro H, Butafa C, Sio A, Joshua C. Vector-control response post-flood disaster setting, Honiara, Solomon Islands, 2014. Western Pac Surveill Response J. 2016;7(1):38–43 (https://doi.org/10.5365/wpsar.2015.6.3.004). 30. Mugabe VA, Gudo ES, Inlamea OF, Kitron U, Ribeiro GS. Natural disasters, population displacement health emergencies: multiple public health threat Mozambique. BMJ Glob Health. 2021;6(9):e006778 (https://doi.org/10.1136/bmjgh-2021-006778). 31. Emergency health: 2023 global highlights. Geneva: International Organization",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "350f080e-3528-4fa3-bfb8-7870ee8b2815",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "h-2021-006778). 31. Emergency health: 2023 global highlights. Geneva: International Organization Migration; 2023 (https://www.iom.int/sites/g/files/tmzbdl486/files/documents/2024-05/iom-emergency-health- infosheet-2023_08.05.2024.pdf ). Licence: CC BY-NC-ND 3.0 IGO. 32. Benkritly M, Hujale M. Sudanese refugee fleeing conflict find safety South Sudan [news release]. United Nations High Commissioner Refugees; 27 June 2023 (https://www.unhcr.org/ news/stories/sudanese-refugees-fleeing-conflict-find-safety-south-sudan). 33. Hujale M. Displaced Somalis refugee struggle recover climate change brings new threat [news release]. United Nations High Commissioner Refugees; 17 August 2012 (https://www.unhcr.org/news/stories/displaced-somalis-and-refugees-struggle-recover-climate- change-brings-new-threats).94 Health system strengthening intervention improve health displaced migrant population context climate change34. Lien C, Raimo J,",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c58a83ce-ec54-48e3-940d-75ddda5f152b",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "e health displaced migrant population context climate change34. Lien C, Raimo J, Abramowitz J, Khanijo S, Kritharis A, Mason C et al. Community healthcare delivery post-Hurricane Sandy: lesson mobile health unit. J Community Health. 2014;39(3):599–605 (https://doi.org/10.1007/s10900-013-9805-7). 35. Sood RK, Bocour A, Kumar S, Guclu H, Potter M, Shah TB. Impact primary care access post-disaster: case study Rockaway Peninsula. Disaster Med Public Health Prep. 2016;10(3):492–95 (https://doi.org/10.1017/dmp.2016.80). 36. Horn Africa drought emergency [website]. United Nations High Commissioner Refugees; 2023 (https://www.unhcr.org/uk/emergencies/horn-africa-drought-emergency). 37. Chad flood deepen humanitarian crisis high risk disease outbreak [blog]. Médecins Sans Frontières; 5 December 2022 (https://www.msf.org/floods-n%E2%80%99djamena-chad-deepen- humanitarian-crisis-high-risk-disease-outbreaks). 38. People cut",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c20f66b3-ac41-401e-9e57-8882d66b36e4",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "%99djamena-chad-deepen- humanitarian-crisis-high-risk-disease-outbreaks). 38. People cut healthcare cyclone Freddy batter Malawi [news release]. Médecins Sans Frontières; 24 March 2023 (https://www.msf.org/people-cut-healthcare-after-cyclone-freddy- batters-malawi). 39. Kearns RD, Stringer L, Craig J, Godette-Crawford R, Black PS, Andra DL et al. Relying National Mobile Disaster Hospital business continuity strategy aftermath tornado: Louisville experience. J Bus Contin Emer Plan. 2017;10(3):230–48. (https://pubmed.ncbi.nlm.nih.gov/28222847/). 40. UNHCR ramp aid thousand displaced Somalia drought [news release]. United Nations High Commissioner Refugees; 11 March 2023 (https://www.unhcr.org/news/briefing-notes/ unhcr-ramps-aid-thousands-displaced-somalia-drought). 41. Soaring need persist Twic County one year [news release]. Médecins Sans Frontières; 17 May 2023 (https://w",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "151e139a-7e4b-4ec8-b058-de3c10f63bea",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "persist Twic County one year [news release]. Médecins Sans Frontières; 17 May 2023 (https://www.msf.org/south-sudan-soaring-needs-persist-twic-county-one-year). 42. Lindvall K, Kinsman J, Abraha A, Dalmar A, Abdullahi MF, Godefay H et al. Health status health care need drought-related migrant Horn Africa: qualitative investigation. Int J Environ Res. 2020;17(16):5917 (https://doi.org/10.3390/ijerph17165917). 43. Bourgois X. Dwindling rain northern Cameroon spark conflict displacement [news release]. United Nations High Commissioner Refugees; 10 November 2021 (https://www. unhcr.org/news/stories/dwindling-rains-northern-cameroon-spark-conflict-and-displacement). 44. Lalani N, Drolet JL, McDonald-Harker C, Brown MRG, Brett-MacLean P , Agyapong VIO et al. Nurturing spiritual resilience promote post-disaster community recovery: 2016 Alberta wildfire Canada. Front Public Health. 2021;9 (https://doi.org/10.3389/fpubh.2021.682558). 45. Ta",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "605731f6-3322-4653-96ae-8bbf4cb881c3",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "wildfire Canada. Front Public Health. 2021;9 (https://doi.org/10.3389/fpubh.2021.682558). 45. Taioli E, Tuminello S, Lieberman-Cribbin W, Bevilacqua K, Schneider S, Guzman et al. Mental health challenge experience displaced population following Hurricane Sandy Hurricane Harvey: need comprehensive intervention temporary shelters. J Epidemiol Community Health. 2018;72(10):867–70 (https://doi.org/10.1136/jech-2018–210626).95 Annex 2. Health system intervention identified review46. Alam F, Hossain R, Ahmed HU, Alam MT , Sarkar M, Halbreich U. Stressors mental health Bangladesh: current situation future hopes. BJPsych Int. 2021;18(4):91–4 (https://doi.org/10.1192/bji.2020.57). 47. Bharadwaj R, Huq S. Climate-induced migration health issues: toolkit policymakers. London: International Institute Environment Development; 2022 (https://issuelab.org/ resources/43319/43319.pdf ). 48. Mental",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d792531b-1736-4641-9de3-76b0fe1968e3",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "Environment Development; 2022 (https://issuelab.org/ resources/43319/43319.pdf ). 48. Mental health climate change: policy brief. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/354104). Licence: CC BY-NC-SA 3.0 IGO. 49. Akbar M. Empowering woman girl water sanitation initiative post- flood Pakistan [news release]. International Organization Migration; 22 March 2024 (https://reliefweb.int/report/pakistan/empowering-women-and-girls-through-water-and- sanitation-initiatives-post-flood-pakistan). 50. Viray K. Solar energy delivers clean water drought-affected family Ethiopia [blog]. In: International Organization Migration Storyteller; 2024 (https://storyteller.iom.int/stories/ solar-energy-delivers-clean-water-drought-affected-families-ethiopia). 51. Global annual result report 2021: ensuring every child life safe clean environment. Goal Area 4: progress, result achieve",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "34a46b49-e12d-4d62-b995-4347d1aac28e",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ring every child life safe clean environment. Goal Area 4: progress, result achieved lesson 2021. [website]. United Nations Children’s Fund; 2022 (https://www.unicef.org/reports/global-annual-results-2021-goal-area-4). 52. UNICEF DRR action: every country protected; every child resilient. New York: United Nations Children's Fund; 2022 (https://www.unicef.org/documents/unicef-drr-action-every-country- protected-every-child-resilient). Licence: CC BY-4.0. 53. Chiriac M. Ripples change: durable water solution reshape community along Yemen’s West Coast. International Organization Migration; 21 March 2024 (https://yemen.iom.int/stories/ ripples-change-durable-water-solutions-reshape-communities-along-yemens-west-coast). 54. Mohammed M. Green energy grant conflict-affected community Yemen access safe water [blog]. In: International Organization Migration Storyteller; 2024 (https://storyteller.iom.int/ stories/green-energy-grants-confli",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2a0a126f-b874-4adb-9951-5fea1d67ff31",
        "title": "Health system strengthe Health of displaced and migrant populations in the context of climate change",
        "body": "ion Migration Storyteller; 2024 (https://storyteller.iom.int/ stories/green-energy-grants-conflict-affected-communities-yemen-access-safe-water). 55. Hirani SAA. Barriers women’s menstrual hygiene practice recurrent disaster displacement: qualitative study. Int J Environ Res. 2024;21(2):153 (https://doi.org/10.3390/ ijerph21020153). 56. Msyamboza KP , M’Bang’ombe M, Hausi H, Chijuwa A, Nkukumila V, Kubwalo HW et al. Feasibility acceptability oral cholera vaccine mass vaccination campaign response outbreak flood Malawi. Pan Afr Med J. 2016;23:203 (https://doi.org/10.11604/ pamj.2016.23.203.8346).WHO Health Migration World Health Organization 20, Avenue Appia, 1211 Geneva 27, Switzerland healthmigration@who.int www.who.int",
        "source": "WHO Guidelines: Health system strengthe Health of displaced and migrant populations in the context of climate change.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c64d9341-832c-4aa2-b75f-2224676d99c2",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Guidelines management asymptomatic sexually transmitted infectionsGuidelines management asymptomatic sexually transmitted infectionsGuidelines management asymptomatic sexually transmitted infection ISBN 978-92-4-010490-7 (electronic version) ISBN 978-92-4-010491-4 (print version) © World Health Organization 2025 right reserved. work available Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). term licence, may copy, redistribute adapt work non-commercial purposes, provided work appropriately cited, indicated below. use work, suggestion endorses specific organization, product services. use logo permitted. adapt work, must license work equivalent Creative Commons l",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "03a163dc-2be1-43d9-9ebc-a082ee3c905d",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "adapt work, must license work equivalent Creative Commons licence. create translation work, add following disclaimer along suggested citation: “This translation created World Health Organization (WHO). responsible content accuracy translation. original English edition shall binding authentic edition” . mediation relating dispute arising licence shall conducted accordance mediation rule World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/ rules/). Suggested citation. Guidelines management asymptomatic sexually transmitted infections. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data available https://iris.who.int/. Sales, right licensing. purchase publications, see https://www.",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7fbbaa12-2b28-46c6-81dd-fc9299ddee63",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "https://iris.who.int/. Sales, right licensing. purchase publications, see https://www.who.int/publications/book- orders. submit request commercial use query right licensing, see https://www.who.int/ copyright . Third-party materials. wish reuse material work attributed third party, tables, figure images, responsibility determine whether permission needed reuse obtain permission copyright holder. risk claim resulting infringement third- party-owned component work rest solely user. General disclaimers. designation employed presentation material publication imply expression opinion whatsoever part concerning legal status country, territory, city area authorities, concerning delimitation frontier boundaries. Dotted dashed",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "93226539-749d-44f1-9e43-d0cc86b32a2f",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "authorities, concerning delimitation frontier boundaries. Dotted dashed line map represent approximate border line may yet full agreement. mention specific company certain manufacturers’ product imply endorsed recommended preference others similar nature mentioned. Errors omission excepted, name proprietary product distinguished initial capital letters. reasonable precaution taken verify information contained publication. However, published material distributed without warranty kind, either expressed implied. responsibility interpretation use material lie reader. event shall liable damage arising use. Design layout: Studio FFFOG.iii Acknowledgements v Executive summary vii Summary recommendation viii",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f64f1e8c-8d5b-4397-afb3-1c0212f8ab73",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "yout: Studio FFFOG.iii Acknowledgements v Executive summary vii Summary recommendation viii 1. Introduction 1 1.1 Epidemiology global target 2 1.2 Rationale new updated recommendation 3 1.3 Objectives 3 1.4 Target audience 4 1.5 Guiding principle 4 1.6 Structure guideline 5 2. Methods 6 2.1 Overview 7 2.2 Roles group involved developing guideline 7 2.3 Scope question 8 2.4 Reviews evidence modelling inform guideline 9 2.5 Assessment presentation evidence 9 2.6 Making recommendation 10 2.7 Managing conflict interest 11 3. Updated new recommendation 12 3.1 Pregnant woman 13 3.2 Adolescents young people 14 3.3 Sex worker 15 3.4 Men sex men 16 3.5 Research need 17 4 recommendation related asymptomatic screening STIs 18 4.1 Syphilis 19Contentsiv Guidelines management asymptomatic sexually transmitted infections5. Implement",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "abc010b1-da51-4036-9da3-89e93fd31fe4",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Contentsiv Guidelines management asymptomatic sexually transmitted infections5. Implementation consideration management asymptomatic STIs 20 5.1 Definition screening 21 5.2 Rationale objective establishing screening programme asymptomatic STIs 21 5.3 Ethical consideration 22 5.4 Selecting diagnostic test screening asymptomatic STIs 23 5.5 Acceptable performance characteristic screening test 23 5.6 Treatment, antibiotic consumption preparedness screening programme 24 5.7 Screening integrated prevention intervention 24 5.8 Ensuring early effective treatment 25 5.9 STI service key populations, adolescent young people 25 5.10 Antenatal screening pregnant woman 26 6. Disseminating updating guideline 27 6.1 Dissemination 28 6.2 Updating STI guideline user feedback 28 References 29 Annex 1. Contributors guideline 35 Annex 2. Declarations conflic",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9d688c09-9c1a-4496-872e-1015047d5f97",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "back 28 References 29 Annex 1. Contributors guideline 35 Annex 2. Declarations conflict interest 40 Web annexes: Evidence-to-decision framework systematic review management asymptomatic sexually transmitted infections, https://doi.org/10.2471/B09199. Web Annex A. Evidence-to-decision framework asymptomatic screening pregnant woman Web Annex B. Evidence-to-decision framework asymptomatic screening sexually active adolescent young people Web Annex C. Evidence-to-decision framework asymptomatic screening sex worker Web Annex D. Evidence-to-decision framework asymptomatic screening men sex men Web Annex E. Systematic review screening approach management asymptomatic sexually transmitted infection Web Annex F. Modelling screening approach management asymptomatic sexually transmitted infectionsv Department Global HIV, Hepatitis",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "76bb0b40-d5f6-45ca-b4a7-25085da5f3c2",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "f asymptomatic sexually transmitted infectionsv Department Global HIV, Hepatitis Sexually Transmitted Infections Programmes grateful thanks individual organization contributed developing guidelines. appreciates support Secretariat Guidelines Review Committee guideline development process. Methodologist systematic reviewer GRADE methodologist: Farid Foroutan (Ted Rogers Centre Health Research, Canada). Systematic reviewer modelers: Mary Ashley Keene, Krishnan Puri-Sudhir Katy Turner (Aquarius Public Health, United Kingdom Great Britain Northern Ireland) Nancy Santesso (Michael G. DeGroote Cochrane Canada Centre, McMaster University, Canada). Guideline Development Group member Guideline Development Group (Annex 1) provided invaluable guidance comment development guideline virtual meeting comment correspond",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "27e7e975-0956-41d9-9568-de5dd14043aa",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ents development guideline virtual meeting comment correspondence. meticulous attention detail, expert comment feedback ensured consistency relevance guidelines. Members: Laith Abu-Raddad (Weill Cornell Medical College, Qatar), Yaw Adu-Sarkodie (Kwame Nkrumah University Science Technology, Ghana), Jamila Al-Abri (Ministry Health, Oman), Zeyana Al-Habsi (Ministry Health, Oman), Mircea Betiu (Nicolae Testimitanu State University Medicine Pharmacy, Republic Moldova), Catriona Bradshaw (Monash University, Australia), Xiang-Sheng Chen (National Center AIDS/STD Control Prevention, China), Irith De Baetselier (Institute Tropical Medicine, Belgium), Chido Dziva Chikwari (Biomedical Research Training Institute, Zimbabwe), Amina El Kettani (Ministry Health, Morocco), Patricia Garcia (Cayetano Heredia University, Peru), William M. Geisler (University Alabama Birmingham, Un",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6cc8a135-a80e-456e-a923-411c6673f528",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ia (Cayetano Heredia University, Peru), William M. Geisler (University Alabama Birmingham, United States America), Kimberly Green (PATH, Viet Nam), Somesh Gupta (All India Institute Medical Sciences, India), Edward W. Hook III (University Alabama Birmingham, USA), Rena Janamnuaysook (Institute HIV Research Innovation, Thailand), Nathalie Kapp (International Planned Parenthood Federation, United Kingdom), Hamida Khattabi (independent consultant, Morocco), Rossaphorn Kittyaowamarn (Ministry Public Health, Thailand), Jeffrey D. Klausner (University Southern California, USA), Ranmini Kularatne (Awanui Labs, New Zealand), Peter Kyambadde (Ministry Health, Uganda), David Lewis (Western Sydney Sexual Health Centre, Australia), Philippe Mayaud (London School Hygiene Tropical Medicine, United Kingdom), Saiqa Mullick (Wits RHI, University Witwatersrand, South Africa), Francis Ndowa (Skin Genito-Urinary Medicine Clinic, Zimbabwe), Lilan",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0b268731-9569-4352-88be-68308ba0951c",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "watersrand, South Africa), Francis Ndowa (Skin Genito-Urinary Medicine Clinic, Zimbabwe), Lilani Rajapaksa (Ministry Health, Sri Lanka), Kees Rietmeijer (Denver Public Health Department, USA), Danvic Rosadiño (LoveYourself Inc., Philippines), Jonathan Ross (Birmingham University Hospitals NHS Trust, United Kingdom), Lon Sayheng (National Center HIV/AIDS, Dermatology STD, Cambodia), Anna Shapiro (Global Network Sex Work Projects, United Kingdom), Daniel Simões (Coalition Plus, Portugal), Jane Thiomi (LVCT Health, Kenya), Jane Tomnay (University Melbourne, Australia), Magnus Unemo (Örebro University Hospital, Sweden) Judith Wasserheit (University Washington, USA). External Review Group Members: Henry J.C. de Vries (Amsterdam Sexual Health Clinic, Netherlands [Kingdom the]), Kristina Grabbe (Jhpiego, USA), Hans Benjamin Hampel (University Zurich, Switzerland), Kausar Jabeen (Aga Khan Foundation, Pakistan), Monica Lahra (Prince Wales Hospital,",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "122d7960-b803-4dca-9240-5de6f6f356f0",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "witzerland), Kausar Jabeen (Aga Khan Foundation, Pakistan), Monica Lahra (Prince Wales Hospital, Australia), Pham Thi Lan (National Hospital Dermatology Venerology, Viet Nam), Ahmed Latif (public health consultant, Australia), Ioannis Mameletzis (consultant, Ukraine), Angelica Espinosa Miranda (Ministry Health, Brazil), Koleka Mlisana (National Health Laboratory Service, South Africa), Lori Newman (Gates Foundation, USA), Catherine Ngugui (Ministry Health, Kenya), Reshmie Ramautarsing (Institute HIV Research Innovation, Thailand), Pachara Sirivongrangson (Ministry Public Health, Thailand) Janet Wilson (International Union Sexually Transmitted Infections, United Kingdom). Acknowledgmentsvi Guidelines management asymptomatic sexually transmitted infectionsObservers Francis Kakooza (Makerere University, Uganda), Otilia Mardh (European Centre Disease Prevention Control, Sweden), Fernando Pascal Martinez (Global Antibiotic",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "74f72fa5-6cdf-443d-a4af-667e186aae48",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Centre Disease Prevention Control, Sweden), Fernando Pascal Martinez (Global Antibiotic Research Development Partnership, Spain) Tim Sladden (United Nations Population Fund, USA). Secretariat consultant Overall coordination Teodora Wi led development guideline support Ismail Maatouk Daniel McCartney (Department Global HIV, Hepatitis Sexually Transmitted Infections Programmes) leadership Meg Doherty (Director, Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes). Steering Committee Department Global HIV, Hepatitis Sexually Transmitted Infections Programmes: Maeve Brito de Mello, Cheryl Johnson, Ismail Maatouk, Antons Mozalevskis, Morkor Newman, Remco Peters, Jane Rowley, Annette Verster, Marco Vitoria Teodora Wi. headquarters staff members: Benedikt Huttner (Department Access Medicines Health Products), Ozge Tunçalp (Department Maternal,",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cf5bff80-c882-45c0-979c-ac65c5e84886",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "tner (Department Access Medicines Health Products), Ozge Tunçalp (Department Maternal, Child Adolescent Health), Anne-Laure Page (Department Regulation Prequalification), Avni Amin, Sami Gottlieb, James Kiarie, Gitau Mburu Igor Toskin (Department Sexual Reproductive Health Research) Arif Al-Hamad Daniel Marcano- Zamora (Department Surveillance, Prevention Control). regional offices: Akudo Ezinne Ikpeazu (Regional Office Africa), Monica Alonso (Regional Office Americas), Polin Chan (Regional Office South-East Asia), Stela Bivol (Regional Office Europe), Joumana Hermez (Regional Office Eastern Mediterranean) Kiyohiko Izumi (Regional Office Western Pacific). Funding source Department Global HIV, Hepatitis Sexually Transmitted Infections Programmes provided funding guidelines.vii global burden sexually transmitted infection (STIs) high,",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "438459b1-c822-4e91-9ebb-db050071db4d",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "e guidelines.vii global burden sexually transmitted infection (STIs) high, 30 pathogens, including bacteria, virus parasites, known transmitted sexual contact. estimate 2020 indicate 374 million new case curable STIs (gonorrhoea, chlamydia, syphilis trichomoniasis) among people 15–49 year old. includes 156 million new case trichomoniasis, 128.5 million new case chlamydia, 82.4 million new case gonorrhoea 7.1 million new case syphilis, amounting 1 million new curable STIs every day. 2022, number new syphilis case increased 8.0 million.1 Chlamydia, caused Chlamydia trachomatis, gonorrhoea, caused Neisseria gonorrhoeae, common bacterial STIs worldwide result substantial morbidity economic costs. Syphilis bacterial STI caused Treponema pallidum result substantial morbidity mortality. addition, cong",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f9152d69-ff43-4fb6-835c-484d2684c919",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "caused Treponema pallidum result substantial morbidity mortality. addition, congenital syphilis devastating fetus infection pregnancy detected treated sufficiently early pregnancy. set ambitious target recent global health sector strategy HIV, viral hepatitis STIs. achieve targets, 90% reduction gonorrhoea syphilis infection 2030, strategy emphasizes importance improving access prevention, diagnostic treatment service people STIs. guideline support management asymptomatic STIs. One challenge responding burden STIs infection asymptomatic large variable extent. individuals, biological women, gonococcal chlamydial infection cervix asymptomatic 50–97% cases. anatomical site urethra cervix, anorectal",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "61a43e91-637a-45da-9146-671672327853",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "50–97% cases. anatomical site urethra cervix, anorectal oropharyngeal sites, symptom usually minimal absent 85% cases. Further, treatment people STIs complicated rapidly changing antimicrobial susceptibility pattern various sexually transmitted pathogens, N. gonorrhoeae Mycoplasma genitalium, available antibiotics, concern eventual development untreatable infection serious sexual reproductive health consequences. Asymptomatic STIs, especially pharynx rectum, may reservoir selection antimicrobial resistance antimicrobial agent given condition minimal inhibitory concentration pre-existing STI pathogens. Antimicrobial resistance N. gonorrhoeae emerged every drug available empirical first-line treatment, extended-spectrum cephalosporin, ceftriaxone,",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f6ad5205-5579-4665-834b-d4bba56a81fc",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ailable empirical first-line treatment, extended-spectrum cephalosporin, ceftriaxone, currently last option countries. Certain antibiotics, including azithromycin, relatively high risk selection bacterial resistance, use need reserved certain pathogens, including M. genitalium. guideline focus management people asymptomatic STIs providing evidence-informed recommendation screen N. gonorrhoeae C. trachomatis. recommendation complement guideline syphilis screening among pregnant women, sex worker men sex men, syphilis self-testing treponemal non-treponemal testing; guideline STI partner services; guideline treatment people specific STIs (N. gonorrhoeae, C. trachomatis, M. genitalium, T. pallidum, Trichomonas vaginalis, bacterial vaginosis, Candida albicans, herpes simplex virus, human papillomavirus [genital warts]) gui",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "01c3f323-4c65-4734-bf5c-a7f8c48f87cf",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "al vaginosis, Candida albicans, herpes simplex virus, human papillomavirus [genital warts]) guideline management symptomatic STIs. guideline included forthcoming consolidated guideline STI prevention care. objective guideline are: • provide evidence-informed recommendation screening people asymptomatic STIs; • support country national programme developing national guideline management STIs towards reaching 2030 global sector strategy target STIs. guideline intended policy-makers, programme managers, health-care worker public health professional responsible planning implementing STI service (stand-alone integrated health services). guideline also resource donor development agencies, 1 up-to-date STI estimate always available page Global Sexually Tr",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ffce8bee-a28e-4d0a-a405-886878dc9151",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "1 up-to-date STI estimate always available page Global Sexually Transmitted Infections Programme’s website: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/stis/strategic-information. Executive summaryviii Guidelines management asymptomatic sexually transmitted infectionsinternational, nongovernmental, civil society community-based organization well working led key population community affected STIs, including HIV. guideline developed following method outlined 2014 handbook guideline development. Systematic review modelling conducted address guideline objectives. Guideline Development Group reviewed evidence made recommendations. Grading Recommendations Assessment, Development Evaluation (GRADE) approach used assess evidence formulate recommendations. External Review Group",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4e78736a-bbbc-43fe-9963-def96762aa23",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "roach used assess evidence formulate recommendations. External Review Group reviewed guideline submitted Guidelines Review Committee. Summary recommendation guideline provide recommendation asymptomatic screening Neisseria gonorrhoeae Chlamydia trachomatis. recommendation apply pregnant women, sexually active adolescent young people, sex worker men sex men (Table 1). recommendation based combined prevalence N. gonorrhoeae C. trachomatis population level. sexually active adolescent young people, high prevalence setting suggested 15–20% combined infections. pregnant women, due adverse health effect infants, combined prevalence 10% setting may considered high. Decision-makers may access prevalence data countries, programme clinics, used",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5c07a1f4-3d61-4c1b-918a-4f7c6180854b",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "r may access prevalence data countries, programme clinics, used determine whether screening implemented population addressed recommendation. Note recommendation intended applied based population-level prevalence involve assessment individual’s risk infection. frequency screening depend sexual exposure, rate partner exchange transmission cost test. balanced cost, number case detected consequence screening. sex worker men sex men, screening advised least annually every six months. Recommendations Strength recommendation certainty evidence Pregnant woman suggests pregnant woman symptom sexually transmitted infection accessing health-care service antenatal visit screened N. gonorrhoeae and/or C. trac",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1cd13ef0-28df-4501-91bd-7290d07014b9",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "e accessing health-care service antenatal visit screened N. gonorrhoeae and/or C. trachomatis setting prevalence high resource capacity available. Recommendations management symptomatic sexually transmitted infection continue followed.a Remarks: • recommendation applies population-level prevalence rather individual risk assessments, shown lack accuracy. recommendation also applies screening either quality-assured molecular assay, nucleic-acid amplification testing rapid test minimum sensitivity 80% specificity 90%, treatment available. • Screening voluntary informed consent. Treat N. gonorrhoeae and/or C. trachomatis based result quality-assured test using national treatment guidelines. Sexual partner people testing positive also tested treated, positive.Conditional r",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5b1b95f4-c001-4777-be54-35b2a9fd3c3e",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "al partner people testing positive also tested treated, positive.Conditional recommendation, low certainty evidence effect (new 2024)Table 1. Summary new updated recommendation screening asymptomatic sexually transmitted infection (see detail Chapter 3)ix Recommendations Strength recommendation certainty evidence Adolescents young people suggests sexually active adolescent young people (10–24 year old) symptom sexually transmitted infection accessing health-care service screened N. gonorrhoeae and/or C. trachomatis setting prevalence high resource capacity available. Recommendations management symptomatic sexually transmitted infection continue followed.a Remarks: • balancing resource benefit screening, adolescent girl young woman may prioritized. recommendation applies populat",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0cf74a4c-a13b-40d9-8195-a3342c88839b",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ening, adolescent girl young woman may prioritized. recommendation applies population-level prevalence rather individual risk assessments, shown lack accuracy. However, exploring sexual activity past 12 month prior screening essential. recommendation also applies screening either quality-assured molecular assay, nucleic-acid amplification testing, rapid test minimum sensitivity 80% specificity 90%, treatment available. • Screening voluntary informed consent. Treat N. gonorrhoeae and/or C. trachomatis based result quality-assured test using national treatment guidelines. Sexual partner people testing positive also tested treated, positive.Conditional recommendation, low certainty evidence effect (new 2024) Sex worker suggests sex worker accessing health-care service symptom",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1d8585c9-430f-42d5-aea7-2762595a5cb4",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "4) Sex worker suggests sex worker accessing health-care service symptom sexually transmitted infection screened N. gonorrhoeae and/or C. trachomatis. Recommendations management symptomatic sexually transmitted infection continue followed.a Remarks: • recommendation applies screening either quality- assured molecular assay, nucleic-acid amplification testing, rapid test minimum sensitivity 80% specificity 90%, treatment available. anatomical site depends sexual behaviour, pooling sample reduce cost increase yield, depending resource available. • Screening voluntary informed consent. Treat N. gonorrhoeae and/or C. trachomatis based result quality-assured test using national treatment guidelines. Sexual partner people testing positive also tested treated, positive.Conditional r",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c4ab24b6-66b8-4191-9328-e51b46932d1e",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "l partner people testing positive also tested treated, positive.Conditional recommendation, low certainty evidence effect (updated 2024)x Guidelines management asymptomatic sexually transmitted infectionsRecommendations Strength recommendation certainty evidence Men sex men suggests men sex men accessing health-care service symptom sexually transmitted infection screened N. gonorrhoeae and/or C. trachomatis. Recommendations management symptomatic sexually transmitted infection continue followed.a Remarks: • recommendation applies screening either quality- assured molecular assay, nucleic-acid amplification testing, rapid test minimum sensitivity 80% specificity 90%, treatment available. anatomical site depends sexual behaviour, pooling sample reduce cost increase yi",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d7f51a35-6436-41f2-b986-5696a8fcf576",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "e anatomical site depends sexual behaviour, pooling sample reduce cost increase yield, depending resource available. • Screening voluntary informed consent. Treat N. gonorrhoeae and/or C. trachomatis based result quality-assured test using national treatment guidelines. Sexual partner people testing positive also tested treated, positive.Conditional recommendation, low certainty evidence effect (updated 2024) Guidelines management symptomatic sexually transmitted infections. Geneva: World Health Organization; 2021 (https://iris. who.int/handle/10665/342523). Licence: CC BY-NC-SA 3.0 IGO.1. Introduction2 Guidelines management asymptomatic sexually transmitted infections1.1 Epidemiology global target Sexually transmitted infection (STIs) major public health problem worldwide, reducing quality life causing serious morbidity mortality. STIs direc",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "31114d8c-87aa-40e8-924e-88572d0ff023",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "problem worldwide, reducing quality life causing serious morbidity mortality. STIs directly affect reproductive child health causing infertility, cancer pregnancy complications, indirectly facilitate sexual transmission HIV; therefore, addition affecting health, STIs also affect national economy individual finances. Chlamydia, caused Chlamydia trachomatis , gonorrhoea, caused Neisseria gonorrhoeae , two common bacterial STIs result substantial morbidity economic cost worldwide. estimate that, 2020, 128.5 million (90.0 million–173.8 million) new case chlamydia 82.4 million (47.7 million–130.4 million) new case gonorrhoea occurred among people 15–49 year old worldwide (1). burden chlamydia fall primarily women, higher rate disease men among cause pelvic inflammatory disease, tubal factor infertility poor birth outcom",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b161da7c-17f0-4718-9b27-97d15e4229a5",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "nd among cause pelvic inflammatory disease, tubal factor infertility poor birth outcome (2,3) . three biovars C. trachomatis , consisting several serovars genotypes, cause genital infections, lymphogranuloma venereum (LGV) trachoma (eye infection). Men higher rate gonococcal infection, complication disproportionally affect woman include pelvic inflammatory disease, ectopic pregnancy, infertility increased HIV acquisition (4–6) . Syphilis bacterial STI caused Treponema pallidum lead significant morbidity mortality. estimate 2022, 8.0 million (5.6 million–10.4 million) new case occurred among adolescent adult aged 15–49 year worldwide (7) . Syphilis transmitted sexual contact infectious lesion mucous membrane abraded skin, blood transfusion across placenta pregnancy. Without treatment, syphilis cause serious health complications,",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f033f853-5e8f-4082-8ffc-5e27ef5290ec",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "placenta pregnancy. Without treatment, syphilis cause serious health complications, including neurological problems. Congenital syphilis result wide range adverse birth outcomes. Global estimate 2022 indicate 150 000 early fetal death stillbirths, 70 000 neonatal death 55 000 preterm low-birthweight birth (8) . However, syphilis easily cured treatment, risk adverse outcome minimal infection detected treated sufficiently early pregnancy. Population group especially vulnerable STIs include sex worker clients, men sex men, trans gender-diverse people, people inject drugs, people prisons, young people, mobile population people affected conflict civil unrest (1) . set ambitious target within Global health sector strategy HIV, viral hepatitis sexual transmitted infection period 2022–2030 , including 90% reduct",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "97449895-f284-44b3-bfd4-0fa554678a22",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "viral hepatitis sexual transmitted infection period 2022–2030 , including 90% reduction gonorrhoea syphilis infection elimination congenital syphilis public health problem (defined less 50 case per 100 000 live births) 2030 (9) . achieve targets, strategy STIs highlight importance enabling people STIs risk STIs easily access prevention, diagnostics, treatment care.1. Introduction3 1.2 Rationale new updated recommendation reduce STIs prevent complications, high-quality STI prevention care service essential. Many STIs transmitted people unaware infections, either lack knowledge awareness symptom sign STIs lack symptoms. requires developing evidence-informed guideline STI treatment comprehensive case management, including screening, diagnosis, treatment care. Correct",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "adc48b0c-265c-4be0-a477-f798621e1e15",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ent comprehensive case management, including screening, diagnosis, treatment care. Correct effective treatment people STIs, ideally given taken day first contact patient health-care providers, important public health measure controlling STIs since endeavour break chain transmission infection without delay. Since publication Guidelines management sexually transmitted infection 2003 (10), change epidemiology STIs progress prevention, diagnosis treatment STIs HIV necessitated change approach STI prevention management. 2021, published Guidelines management symptomatic sexually transmitted infection evidence-informed recommendation improve quality STI case management people symptomatic STIs, including aetiological diagnosis syndromic management (11) . Syndromic management",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "933bf716-f83d-47af-b136-b2e84d3d7b56",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "atic STIs, including aetiological diagnosis syndromic management (11) . Syndromic management widely used manage symptomatic people STIs. resource- limited settings, syndromic management flowchart still standard care, laboratory diagnosis available available result available day. Although shortcoming related STI syndromic approach, remains essential component management symptomatic STIs. guideline aim raise quality STI case management symptomatic people STIs providing evidence-informed recommendation address symptomatic STIs. Many STIs, gonococcal infection, chlamydial infection, syphilis HIV may asymptomatic many infected people, therefore may aware infected. accurate identification asymptomatic symptomatic STIs depends availability diagnostic test scree",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4880d235-cb46-4ac5-8993-91100db0298c",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "asymptomatic symptomatic STIs depends availability diagnostic test screening strategy. Although high-quality diagnostic test STIs available, often expensive, frequently labour intensive and, stage, often suitable use rapid point-of-care tests. Traditionally, diagnostic test STIs used address STI prevention control following areas: • provide definitive diagnosis aetiology-guided treatment; • provide screening service asymptomatic individual risk infection; • provide statistical information prevalence various infections; • determine antimicrobial susceptibility causative organisms; • assist management sexual partners. area remain important supporting national programme know burden infection settings, set evidence-informed target control infection community determin",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "94ec0438-1754-4633-9aa8-5db595a48e78",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ngs, set evidence-informed target control infection community determine trend time. end, updated manual Laboratory point-of-care diagnostic testing sexually transmitted infections, including HIV (12) . 1.3 Objectives objective guideline are: • provide evidence-informed recommendation screening people asymptomatic STIs, specifically N. gonorrhoeae C. trachomatis ; • support country national programme developing national guideline management STIs towards reaching 2030 global health sector strategy target STIs. 1. Introduction4 Guidelines management asymptomatic sexually transmitted infections1.4 Target audience guideline intended STI prevention control programme manager national level frontline health-care provider primary, secondary tertiary health-care facility involved treating",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "eb3d44e9-d663-464f-8beb-7a51120a40b1",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ealth-care provider primary, secondary tertiary health-care facility involved treating managing people STIs. recommendation guidance also important health-care workers, including lay provider community health workers, responsible offering performing STI services. guideline relevant implementers STI services, including HIV, sexual reproductive health service maternal child health services. also relevant nongovernmental community-based organizations, including working led key population HIV epidemic, service provider user pre-exposure prophylaxis (PrEP) HIV. guideline able support planning, implementation monitoring evaluation services, used advocacy tool seeking financial human resource required deliver adequate, acceptable equitable STI care everyone need",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "932dc566-7770-40ae-9cdf-659a9eec06c9",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "man resource required deliver adequate, acceptable equitable STI care everyone need STI services. recommendation also important people greater risk acquiring STIs, including HIV, member key populations, people use HIV PrEP vulnerable population groups, pregnant women, adolescent setting high HIV STI burden, indigenous population migrants. 1.5 Guiding principle following principle informed development guideline guide implementation recommendations. • guideline contribute achievement key global goals, including Sustainable Development Goals, relevant national-level goal targets. • guideline based public health approach scaling provision service care people STIs, aim reaching everyone, including vulnerable population key populations, relevant",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a22d8d2e-911e-40f2-836e-2d967eef0ddc",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "h aim reaching everyone, including vulnerable population key populations, relevant interventions, including, example, targeted screening N. gonorrhoeae antimicrobial resistance monitoring (in accordance guidance). • adaptation implementation guideline accompanied effort promote protect human right people receiving STI services, including preventing stigma discrimination, promoting gender equity ensuring use service always voluntary never mandatory coerced. • implementation recommendation guideline informed local context, including epidemiology STIs, availability resource commodity diagnosis treatment STIs, capacity health system anticipated cost– effectiveness various interventions. • adaptability built guideline intended promote accessibility, acce",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7a73879d-217b-4cde-aac1-e2b31206265d",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "tions. • adaptability built guideline intended promote accessibility, acceptability effectiveness STI service public private health-care systems, including community health centre primary care facility providing service STIs, clinic maternal child health, antenatal care, family planning sexual reproductive health services. such, guideline form part broader package service delivery approaches, including linkage prevention, testing, treatment care services. • guideline provide direction acceptable effective STI service population identified especially vulnerable higher risk STIs, including living HIV infection, aim improve health outcome population level. • guideline follow guideline principle Model List Essential Medicines, including prevent emergence",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7faf62e4-16db-49a4-8e7e-99de64375536",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ne principle Model List Essential Medicines, including prevent emergence spread antibiotic resistance, parsimony, feasibility alignment List Critically Important Antimicrobials Human Medicine, including AWaRe (access, watch, reserve) categorization antibiotic (13,14) .5 1. Introduction1.6 Structure guideline guideline provide evidence-informed recommendation screening asymptomatic STIs intended become subsection forthcoming consolidated guideline prevention, diagnosis, treatment care STIs. Chapter 3 present new updated recommendation screening asymptomatic N. gonorrhoeae C. trachomatis among pregnant women, sexually active adolescent young people, sex worker men sex men. recommendation based recent evidence. guideline provide direction country develop national recom",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fe2a31d5-f970-4434-9b5b-66df57dc18e3",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "st recent evidence. guideline provide direction country develop national recommendations; however, national guideline also consider local prevalence health service capacity resources. Chapter 4 present existing recommendation related asymptomatic screening T. pallidum (syphilis) along implementation consideration management asymptomatic STIs Chapter 5.2. Methods7 2.1 Overview guideline developed accordance procedure handbook guideline development (15). Guideline Development Group identified key question screening asymptomatic STIs 2020. systematic review conducted modelling work completed. Evidence summary developed question evidence assessed according Grading Recommendations Assessment, Development Evaluation (GRADE) approach. Guideline Development Group developed recommendation considering",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9fdb2873-32e5-4fb8-b064-fbc89db5ce57",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "tion (GRADE) approach. Guideline Development Group developed recommendation considering certainty evidence effects, balance desirable undesirable effects, value preferences, acceptability, feasibility resource need across variety settings. Information aspect included evidence-to-decision tables, shared advance electronically via GRADEpro application Guideline Development Group feedback used meeting support judgement Guideline Development Group make recommendations. Consistent previous guidelines, guideline based public health approach. following section provide detail aspect guideline development process. 2.2 Roles group involved developing guideline Five main group formed guide implement guideline development process, coordinated WHO. group play",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "52bbfc78-431b-4d9a-b42b-513b7d9feec3",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ormed guide implement guideline development process, coordinated WHO. group played specific role, described below. Annex 1 list member group contributor affiliations. 1. Steering Committee. group, responsible overall coordination guideline development process, led Department Global HIV, Hepatitis Sexually Transmitted Infections Programmes. Participants included unit staff member Department Global HIV, Hepatitis Sexually Transmitted Infections Programmes, Department Sexual Reproductive Health Research, Department Surveillance, Prevention Control Department Access Medicines Health Products. Steering Committee also included technical staff member every region. 2. Guideline Development Group. group comprised non-United Nation non-WHO experts, health professional",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b94e4eed-ca34-40f6-a26a-9393ae6ba8bf",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "elopment Group. group comprised non-United Nation non-WHO experts, health professional representative group affected recommendation guidelines. 37 Guideline Development Group member formulated recommendation good practice statements, including implementation service delivery considerations. also reviewed approved final content guidelines. composition Guideline Development Group represented six region balanced across gender backgrounds, including academia research, programme implementation policy community organization networks. member selected coordination Steering Committee country regional offices. Steering Committee reviewed curriculum vitae, declaration-of-interest form confidentiality agreements. proposed membership list posted public review comment finalized. 3.",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6046736c-a2fd-478c-a412-12505dbe77b0",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ents. proposed membership list posted public review comment finalized. 3. External Review Group. member responsible peer reviewing guidelines, including updated new recommendations. group selected consultation Steering Committee assure geographical gender balance. comprised 15 peer reviewer academia, policy research institutions, programme implementation community organization representative network key vulnerable populations.2. Methods8 Guidelines management asymptomatic sexually transmitted infections4. External evidence reviewer modellers, led methodologist. independent team external expert conducted systematic review effect intervention based selected key question guidelines. addition, evidence value preferences, feasibility cost– effectiveness compiled summarized questi",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7bcdf3cf-470b-4cfd-bcb8-cb4ce42f6156",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ues preferences, feasibility cost– effectiveness compiled summarized question. 5. External observers. Representatives European Centre Disease Prevention Control (ECDC), Global Antibiotic Research Development Partnership (GARDP), United Nations Population Fund (UNFPA) attended Guideline Development Group meeting observers. organization long history collaboration Department Global HIV, Hepatitis Sexually Transmitted Infections Programmes. member Guideline Development Group, External Review Group non-WHO staff participating meeting and/or guideline development process submitted declaration-of- interest form confidentiality statement WHO. reviewed declarations, conflict interest sufficient preclude Guideline Development Group member participating fully development guideline found. Annex",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7f6fa573-86c3-45e5-bcac-ad2599ea25d0",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "pment Group member participating fully development guideline found. Annex 2 provides full compilation summary declaration interests. 2.3 Scope question December 2013, first Guideline Development Group meeting held agree scope STI guideline identify different phase developing various component guidelines. December 2020, Guideline Development Group met determine population, intervention, comparison, outcome (PICO) question management asymptomatic STIs. population identified included adult special populations: adolescents, pregnant women, people living HIV population disproportionately affected STIs, men sex men sex workers. Specific question developed using PICO element outlined Table 2.1, following format: • screening [using strategy] versus screening N. gonorrhoe",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7e9c7179-7f95-4622-8832-f70d6eef5b92",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "1, following format: • screening [using strategy] versus screening N. gonorrhoeae C. trachomatis infection used [population] symptom STI accessing health-care services? Population Intervention comparator Outcomes (in order importance) Screening Treatment based diagnosis Women men without STI symptom high risk infection • Sexually active • People living HIV • Sex worker • Men sex men • Adolescents young people • Pregnant woman • Family planning attendee Settings: • Low prevalence • High prevalence • Primary health care health-care facility • Community centreSTIs: chlamydial infection gonorrhoea laboratory test • Nucleic acid amplification test gonorrhoea, chlamydia trichomoniasis • Culture sensitivity (gonorrhoea) • Rapid syphilis test • Microscopy • Risk assessment, genital examination • screening Frequency screeningDiagnosis treatment",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "82718591-4b60-4309-a383-fcb22bbf88a6",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "• Risk assessment, genital examination • screening Frequency screeningDiagnosis treatment based specific aetiology • Gonorrhoea • Chlamydial infection• STI incidence prevalence • Adverse birth outcome pregnant woman (miscarriage, stillborn, preterm, low birthweight • Pelvic inflammatory disease, chronic pelvic pain infertility • Antimicrobial resistance • Adverse drug treatment effect • Stigma • Treatment infected partner • Microbiological cure • HIV transmission acquisition Table 2.1 Population, intervention, comparator outcome (PICO) component prioritized guidelines9 2.4 Reviews evidence modelling inform guideline 2.4.1. Reviews evidence systematic review screening approach management asymptomatic STIs conducted PubMed July 2022 study published English (Web Annex E). Studies study design reporting outcome (including acceptability, feasibility,",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "077b91b0-6c33-4b64-a7be-95a7dc17ada1",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "nex E). Studies study design reporting outcome (including acceptability, feasibility, resource equity indicators) screening people symptom unknown symptom status STI low- middle-income country included. search primary study updated April 2024 Ovid Medline Embase low- middle-income country high-income country language. Targeted search key guideline published high- income country also conducted determine evidence supporting recommendations. study found measuring important outcomes, data pooled statistically across studies. Individual study summarized narratively, one study contributed data outcome result pooled range. Studies reported prevalence STI (not measured follow-up) used input decision-tree model. 2.4.2. Modelling decision-tree model u",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fd0451aa-08f8-46b1-9715-47fc01f7e3bc",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "llow-up) used input decision-tree model. 2.4.2. Modelling decision-tree model used explore health-care outcome cost screening asymptomatic individual N. gonorrhoeae C. trachomatis. model provided framework considering clinical economic impact alternative screening approach asymptomatic individual different populations. based model commissioned inform symptomatic STI case management guideline (see Web Annex F). model used explore different scenario included combination approach managing asymptomatic infections. included screening treatment, screening laboratory-based nucleic- acid amplification test (sensitivity 95% specificity 98%), screening high-performance point-of-care test (90% 95%), screening lower-performance point-of-care test (80% 90%), screening Gram stain use risk assessment befor",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9a3be526-45e9-408a-a0ec-bd957f6cffe1",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "rmance point-of-care test (80% 90%), screening Gram stain use risk assessment test. impact scenario assessed using several outcome indicator nine populations. Web Annex B describes assumption structure model detail . Briefly, model operates static manner therefore assess evolving impact screening initiative time population level. N. gonorrhoeae C. trachomatis treated single entity infection testing purposes. model assumes uniformity probability symptom development infections. probability clinical outcome men women, regardless infecting pathogen, equivalent. Additionally, model assumes people screened treated treatment successful. 2.5 Assessment presentation evidence certainty evidence outcome review primary study th",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3b4556af-9a2f-4d89-9f78-e9e8e54c56b2",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "dence certainty evidence outcome review primary study model assessed separately using GRADE approach based domain risk bias, inconsistency, indirectness, imprecision, publication bias, effect size, dose response opposing confounding (15,16). Certainty evidence effect assigned one four grade evidence defined GRADE Working Group: • high certainty: confident true effect lie close estimate effect; • moderate certainty: moderately confident effect estimate; true effect likely close estimate effect, possibility substantially different; • low certainty: confidence effect estimate limited; true effect may substantially different estimate effect; • low certainty: little confidence effect estimate; tru",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cdc81fc0-8200-4801-b6b8-8dee23358a49",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "effect; • low certainty: little confidence effect estimate; true effect likely substantially different estimate effect. Evidence summary-of-findings table (also called evidence profiles) evidence-to-decision framework (tables facilitate decision-making updated recommendations) drafted Guideline Development Group meeting using GRADEpro software (17) (see Web Annexes A–D evidence-to-decision framework recommendation). 2. Methods10 Guidelines management asymptomatic sexually transmitted infections2.6 Making recommendation complexity developing recommendations, several subgroup virtual meeting initiated 2022 review evidence. Guideline Development Group subgroup proposed collecting additional evidence, including risk factor N. gonorrhoeae C. trachomatis infection asymptomatic symptomatic gono",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "86cbb4b2-b6ac-464a-9f66-1bc6c876982e",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "risk factor N. gonorrhoeae C. trachomatis infection asymptomatic symptomatic gonococcal chlamydial infection model cost effectiveness different strategy diagnosing N. gonorrhoeae C. trachomatis infection 2023. series virtual meeting followed discus evidence propose draft recommendation various syndromes. virtual Guideline Development Group meeting organized April 2024 support development recommendations. meeting, draft recommendation evidence-to-decision table circulated Guideline Development Group via GRADEpro application obtain feedback. April 2024, Guideline Development Group reviewed feedback, evidence-to-decision table summary evidence make judgement effect screening strategy different population decide whether make strong conditional recommendation ag",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bae7e9fb-90cf-462c-9bd3-b3a4c091bc26",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "different population decide whether make strong conditional recommendation screening. Guideline Development Group agreed consensus, disagreement requiring voting. recommendation evidence-to-decision table finalized electronically via GRADEpro June 2024. According GRADE approach, strength recommendation rated either strong conditional. strength recommendation reflects degree confidence Guideline Development Group desirable consequence (such beneficial health outcomes) recommendation outweigh undesirable consequence (such adverse effects) considers criteria, resources, acceptability, equity feasibility. According assessment, strength recommendation graded two categories. 1. strong recommendation one Guideline Development Group confident desirable c",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9dfb4a4d-8917-43f5-a70f-40c6999b3eca",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "g recommendation one Guideline Development Group confident desirable consequence adhering recommendation outweigh undesirable consequences. 2. conditional recommendation one Guideline Development Group concluded desirable consequence adhering recommendation probably outweigh undesirable consequence confident trade-off (15). Table 2.2 explains implication differing strength recommendation patients, clinician policy-makers. Remarks added recommendation explain recommendation and/or describe relevant conditions. Implementation consideration added provide information possible application recommendation. drafted full guideline circulated electronically Steering Committee, Guideline Development Group External Review Group comment feedback.",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7f0fcbc9-79f4-4441-b9f0-3a88703e054e",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ommittee, Guideline Development Group External Review Group comment feedback. input considered guideline revised. External peer review completed June 2024, text edited, neither process affected recommendation formulated.11 2.7 Managing conflict interest Managing conflict interest key priority throughout process developing guidelines. guideline declaration interest expert implemented. Declaration interest statement obtained member Guideline Development Group External Review Group assumed roles. beginning Guideline Development Group meetings, including subgroup meetings, member disclosed declared interest new ones. Annex 2 summarizes declaration interest statements. Eleven member Guideline Development Group declared interests.",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e149d5c6-fd95-44cc-8f15-4bf85c0a7cd6",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "n interest statements. Eleven member Guideline Development Group declared interests. deemed able fully participate since conflict related diagnostics screening asymptomatic infections. 2. MethodsImplications Strong recommendation recommends…Conditional recommendation suggests… patient individual situation would want recommended course action, small proportion would not.Most individual situation would want suggested course action, would not. clinician individual receive recommended course action. Adherence recommendation according guideline could used quality criterion performance indicator. Formal decision aid likely needed help individual make decision consistent value preferences.Clinicians recognize different choice appropriate individu",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3050ed0d-992c-4630-afc3-9d52a64d9890",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "eferences.Clinicians recognize different choice appropriate individual clinician must help individual arrive management decision consistent individual’s value preferences. Decision aid may useful help individual make decision consistent value preferences. policy- makersThe recommendation adopted policy situations. Policy-making require substantial debate involvement various stakeholders.Table 2.2. Implications differing strength GRADE recommendation Source: handbook guideline development (15).3. Updated new recommendations13 3. Updated new recommendation section provides recommendation screening N. gonorrhoeae C. trachomatis pregnant women, adolescent young people, sex worker men sex men, symptom STI accessing health-care service. recommendation",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5d8831f5-f860-4b22-bd18-f3cebe17db4b",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "th men, symptom STI accessing health-care service. recommendation based combined prevalence N. gonorrhoeae C. trachomatis population level. sexually active adolescent young people, high prevalence setting suggested 15–20% combined infections. pregnant women, adverse health effect infants, combined prevalence 10% setting may considered high. Decision-makers may access prevalence data countries, programme clinics, used determine whether screening implemented population addressed recommendation. Note recommendation intended applied based population-level prevalence involve assessment individual’s risk infection. 3.1 Pregnant woman Summary evidence Overall, certainty evidence low small moderate benefit trivial harm dif",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "915accb6-4fd6-49a8-9ba0-3409ad474676",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Overall, certainty evidence low small moderate benefit trivial harm different screening strategy screen pregnant woman symptom STI accessing health- care service antenatal visit (see evidence-to-decision table Web Annex A). evidence benefit harm based search evidence April 2024 (see Web Annex E systematic review literature) result decision model (see Web Annex F). found randomized controlled trial (18) non-randomized study (19,20) used result decision model. primary study occurred low- middle-income countries, prevalence STIs 23% 25%. Guideline Development Group judged likely little difference premature birth and/or low birthweight screening point-of-care test screening. Based modelled results, critical benefit scree",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0bacfadf-6dc4-49fd-ac05-9aff42b72ba0",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "point-of-care test screening. Based modelled results, critical benefit screening (and greatest value placed) reducing transmission N. gonorrhoeae C. trachomatis infants, lead conjunctivitis pneumonia. setting prevalence high (such greater 20%), screening could lead significant reduction infection 3. Updated new recommendationsRecommendation (new 2024) suggests pregnant woman symptom sexually transmitted infection accessing health-care service antenatal visit screened N. gonorrhoeae and/or C. trachomatis setting prevalence high resource capacity available. Recommendations management symptomatic sexually transmitted infection continue followed.a Conditional recommendation, low certainty evidence effect Remarks: recommendation applies population-level prevalence rath",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e6dfe064-9c79-4b07-9bf4-25f7c7fe068a",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "inty evidence effect Remarks: recommendation applies population-level prevalence rather individual risk assessments, shown lack accuracy. recommendation also applies screening either quality-assured molecular assay, nucleic-acid amplification testing rapid test minimum sensitivity 80% specificity 90%, treatment available. Screening voluntary informed consent. Treat N. gonorrhoeae and/or C. trachomatis based result quality-assured test using national treatment guidelines. Sexual partner people testing positive also tested treated, positive. aGuidelines management symptomatic sexually transmitted infection (11).14 Guidelines management asymptomatic sexually transmitted infections(about 25 per 1000 fewer). However, reduction smaller prevalence lower (about 12 per 1000 fewer). remains uncer",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "844307e0-66b5-4ba8-b085-72b35b58cf68",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": ", reduction smaller prevalence lower (about 12 per 1000 fewer). remains uncertainty whether antimicrobial resistance may slightly increase (due higher antibiotic consumption) long-term consequence asymptomatic infections. review acceptability feasibility rapid screening treatment pregnant woman STIs six low- middle-income country found acceptability ranged 85% 99% feasibility 91% 100% (21). Barriers access acceptability include logistical barrier knowledge STIs stigma (22). Guideline Development Group agreed screening probably acceptable pregnant woman feasible. However, resource cost nucleic-acid amplification test point-of-care test screen moderate, test may available settings. Guideline Development Group therefore agreed may greater benefit undesirable conse",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6973c689-7839-4077-a5c8-ed095576f842",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "deline Development Group therefore agreed may greater benefit undesirable consequence setting prevalence greater 20%, prevalence lower, benefit may outweigh cost required resources. Summary evidence Overall, certainty evidence low moderate benefit small harm screening strategy screen sexually active adolescent girl young woman young people symptom STI low trivial benefit small harm adolescent boy young men (see evidence-to-decision table Web Annex B). evidence benefit harm based search evidence April 2024 (see Web Annex E systematic review literature) result decision model (see Web Annex F). found systematic review (23) four randomized controlled trial two recently published studies, one case series low- middle-income country",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f5e35f66-b91d-42f2-992e-1a494f49da21",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "lled trial two recently published studies, one case series low- middle-income country (24) one randomized controlled trial (25). prevalence N. gonorrhoeae C. trachomatis combined 10.4% males, 20.5% female case series low- middle-income country 20% model. benefit male female could include reducing transmission STIs could reduce incidence, evidence reporting outcome. males, Guideline Development Group agreed infection may cause little difference incidence epididymitis based modelled evidence (8 fewer per 1000). females, model estimated risk pelvic inflammatory disease may reduced 20 people per 1000, review randomized controlled trial found 2 fewer. estimate model found infertility may reduced 5 per 1000. recently published randomized contr",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1956f554-f9ad-4b18-a385-ef0626deba00",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "e model found infertility may reduced 5 per 1000. recently published randomized controlled trial found prevalence may slightly reduced (0.5%). Guideline Development Group agreed stigma consequence may small harm male females. also uncertainty long-term consequence asymptomatic infection whether antibiotic resistance caused greater 3.2 Adolescents young people Recommendation (new 2024) suggests sexually active adolescent young people (10–24 year old) symptom sexually transmitted infection accessing health-care service screened N. gonorrhoeae and/or C. trachomatis setting prevalence high resource capacity available. Recommendations management symptomatic sexually transmitted infection continue followed.a Conditional recommendation, low certainty evidence effect Remarks: balancing re",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0f30bbad-548a-4a0a-8850-0cb6011d6e79",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "lowed.a Conditional recommendation, low certainty evidence effect Remarks: balancing resource benefit screening, adolescent girl young woman may prioritized. recommendation applies population-level prevalence rather individual risk assessments, shown lack accuracy. However, exploring sexual activity past 12 month prior screening essential. recommendation also applies screening either quality-assured molecular assay, nucleic-acid amplification testing, rapid test minimum sensitivity 80% specificity 90%, treatment available. Screening voluntary informed consent. Treat N. gonorrhoeae and/or C. trachomatis based result quality-assured test using national treatment guidelines. Sexual partner people testing positive also tested treated, positive. aGuidelines management symptomatic sexually",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "576b4d56-fdbc-4519-a1c4-2adac83dde29",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ould also tested treated, positive. aGuidelines management symptomatic sexually transmitted infection (11).15 3. Updated new recommendationsantibiotic consumption may slightly increased screening. Guideline Development Group placed greatest value potential reducing transmission STIs adverse outcome therefore agreed benefit would outweigh harm, especially females. review four study reporting acceptability found testing probably acceptable, barriers, cost, lack knowledge risk embarrassment (24,26,27). resource cost nucleic-acid amplification test point-of-care test screen large, especially considering large number adolescent young people would need screened. Screening test (molecular assay nucleic-acid amplification testing rapid tests) may available countries, potentially",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "af5befd4-d902-4930-8753-624f86e10c53",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "c-acid amplification testing rapid tests) may available countries, potentially reducing equity. Consequently, screening may feasible many countries. Guideline Development Group agreed may greater benefit undesirable effect setting prevalence greater 20%, adolescent girl young women, given priority screening resource capacity could available. 3.3 Sex worker Recommendation (updated 2024) suggests sex worker accessing health-care service symptom sexually transmitted infection screened N. gonorrhoeae and/or C. trachomatis. Recommendations management symptomatic sexually transmitted infection continue followed.a Conditional recommendation, low certainty evidence effect Remarks: recommendation also applies screening either quality-assured molecular assay, nucleic-acid amplifica",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "972725e6-f08a-4cac-bd16-058b5b15913f",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "applies screening either quality-assured molecular assay, nucleic-acid amplification testing, rapid test minimum sensitivity 80% specificity 90%, treatment available. anatomical site depends sexual behaviour pooling sample reduce cost increase yield, depending resource available. Screening voluntary informed consent. Treat N. gonorrhoeae and/or C. trachomatis based result quality-assured test using national treatment guidelines. Sexual partner people testing positive also tested treated, positive. aGuidelines management symptomatic sexually transmitted infection (11). Summary evidence Overall, certainty evidence low moderate benefit (such reduction STI transmission) trivial harm screening strategy screen sex worker symptom STI (see evidence- to-decision table Web",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "691089af-8384-4354-8ab0-7c5e017d8147",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "e screen sex worker symptom STI (see evidence- to-decision table Web Annex C). evidence assessed applicable sex worker defined female, male, trans gender-diverse adult (18 year age older) receive money good exchange sexual services, either regularly occasionally. evidence benefit harm based search evidence April 2024 (see Web Annex E systematic review literature) result decision model (see Web Annex F). found recent randomized controlled trial (28) review evidence previously published guideline 2012 (29). Evidence 2012 guideline included eight non- comparative study one randomized controlled trial reported HIV, N. gonorrhoeae C. trachomatis acquisition screening provided combination intervention (such condom promotion, education STI treatment). study foun",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "62d795d2-4ebc-41ee-bce0-39af53f32253",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "intervention (such condom promotion, education STI treatment). study found reduction prevalence infection time. recent randomized controlled trial low- middle-income country found prevalence C. trachomatis lower 3.7% N. gonorrhoeae 0.7% screening versus screening. benefit female sex worker estimated model included reduction pelvic inflammatory disease (20 fewer per 1000) infertility (5 fewer per 1000). Guideline Development Group placed greatest value potential reduce onward transmission STIs, although measured studies. uncertainty harm (such whether antibiotic resistance may slightly increased greater antibiotic consumption long-term consequence asymptomatic infection). Overall, health benefit screening outweighed harm sex workers.16 Guidelines mana",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "35c5129d-7b3e-44d2-be84-19e9f763b29f",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "verall, health benefit screening outweighed harm sex workers.16 Guidelines management asymptomatic sexually transmitted infectionsOther factor change favouring screening population. found systematic review 14 study low- middle-income country high-income country assessing facilitator barrier screening female sex worker (30). found greater number sex client partners, awareness STIs, trained peer emotional support may increase uptake testing. Barriers may lack awareness risk STIs availability testing, time constraint long waiting lists, cost, judgemental attitude health-care providers, stigma criminalization sex work. Guideline Development Group agreed screening probably acceptable female sex workers, may experience multiple barriers. Guideline Development Group also agreed resource cost",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ea4b1b73-9f89-4390-a44f-fbaf4fc8442a",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "xperience multiple barriers. Guideline Development Group also agreed resource cost nucleic-acid amplification test point-of-care test screen moderate, screening may feasible many country currently tests. 3.4 Men sex men Recommendation (updated 2024) suggests men sex men accessing health-care service symptom sexually transmitted infection screened N. gonorrhoeae and/or C. trachomatis. Recommendations management symptomatic sexually transmitted infection continue followed.a Conditional recommendation, low certainty evidence effect Remarks: recommendation applies screening either quality-assured molecular assay, nucleic-acid amplification testing, rapid test minimum sensitivity 80% specificity 90%, treatment available. anatomical site depends sexual behavio",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a1a7d969-4aaa-42e6-939f-7241a5f9ca36",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "specificity 90%, treatment available. anatomical site depends sexual behaviour, pooling sample reduce cost increase yield, depending resource available. Screening voluntary informed consent. Treat N. gonorrhoeae and/or C. trachomatis based result quality-assured test using national treatment guidelines. Sexual partner people testing positive also tested treated, positive. aGuidelines management symptomatic sexually transmitted infection (11). Summary evidence Overall, certainty evidence low small benefit trivial harm screening strategy screen men sex men symptom STI (see evidence-to-decision table Web Annex D). evidence benefit harm based search evidence April 2024 (see Web Annex E systematic review literature) result decision mo",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1f9b652d-ad0e-4b20-833d-8d447d678b05",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "2024 (see Web Annex E systematic review literature) result decision model (see Web Annex F). found systematic review 12 non-randomized study (31), recently published study men sex men using HIV PrEP high-income country (32) evidence previously published guideline (33). Evidence guideline included five observational study low- middle- income country providing data sensitivity specificity different test prevalence urethral rectal N. gonorrhoeae C. trachomatis measure outcome effect screening. systematic review found prevalence N. gonorrhoeae C. trachomatis various site increased unchanged 10 reduced six site time screening. Incidence reported randomized controlled trial found little difference (0.5 infection per 1000 person-days). Guideline Development Grou",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3fb728ac-2d5a-4f35-83dc-ef0637574577",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "found little difference (0.5 infection per 1000 person-days). Guideline Development Group agreed benefit screening may trivial, HIV acquisition transmission heterosexual population measured studies. Given increased risk HIV acquisition STIs risk transmission heterosexual populations, Guideline Development Group agreed benefit small. Regarding harm, uncertainty whether antibiotic resistance may slightly increased greater antibiotic consumption long-term consequence asymptomatic infection.17 3. Updated new recommendations3.5 Research need address gap certainty evidence effect asymptomatic screening STIs, particularly N. gonorrhoeae C. trachomatis, randomized controlled trial and/or hybrid efficacy implementation science study essential, especially low- middle-income cou",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cd7b80b6-d6e7-49f2-abf4-52c83cd42346",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "efficacy implementation science study essential, especially low- middle-income country among diverse populations. study aim measure asymptomatic screening affect outcome transmission, including onward STI transmission, HIV acquisition transmission, adverse event associated infection among pregnant non-pregnant people broader impact incidence population health. Implementation outcome also documented asymptomatic screening procedure incorporated clinical services. Antimicrobial resistance represents significant area concern given priority research effort detect rise resistance among pathogen screened. Collaborative effort sector also monitor antimicrobial resistance non-STI-related organisms. study necessary elucidate role asymptomatic STIs transmission sexual partner",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "72ef09e7-6d18-4551-9af2-c228b1dd998a",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "tudies necessary elucidate role asymptomatic STIs transmission sexual partner associated morbidity untreated infections. addition, development low-cost, rapid point-of-care test high specificity sensitivity critically needed. Implementation research focused use point-of-care nucleic-acid amplification test screening vital optimize approaches. Emerging testing technology rigorously evaluated incorporated screening programme learn-as-you-go approach. screening programme asymptomatic infection implemented, gathering data potential harm, acceptability feasibility within various setting population crucial. Moreover, research explore sustainability programmes, identifying factor contributing discontinuation inefficacy screening strategies, especially fail achieve high coverage reach inten",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bef284c9-4d29-4bee-a256-987065d683b0",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "cacy screening strategies, especially fail achieve high coverage reach intended populations.Two study (32,34) assessed acceptability screening found mixed reaction screening: wanted treat infection prevent infections; others wanted asymptomatic infection treated. Evidence frequency screening also considered systematic review 46 study (35), none directly compared less frequent frequent. Although fewer people tested positive screened every 2–3 month every 4–6 months, confounding population could responsible difference. Guideline Development Group agreed screening probably acceptable feasible men sex men. resource cost nucleic-acid amplification test point-of-care test screen asymptomatic men sex men moderate, screening may feasible many country curr",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e03321e5-36b5-48d7-8095-83df614425a3",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "n sex men moderate, screening may feasible many country currently test available.4. recommendation related asymptomatic screening STIs19 4. recommendation related asymptomatic screening STIs4. recommendation related asymptomatic screening STIs Box 4.1. Existing recommendation screening asymptomatic syphilis infection Pregnant woman (37,38) • Recommendation: recommends screening pregnant woman syphilis least early possible, ideally first antenatal care visit (strong recommendation, moderate-certainty evidence). Key population (39) • Recommendation: Offering periodic serological testing asymptomatic syphilis infection men sex men trans gender-diverse people strongly recommended offering screening (strong recommendation, moderate certainty evidence). • Recommendation: suggests offering",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3c8b6fef-d312-4c18-a840-43ca7349852d",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ng (strong recommendation, moderate certainty evidence). • Recommendation: suggests offering periodic screening asymptomatic syphilis infection sex worker (conditional recommendation, low certainty evidence). People STI symptom (11) • Good practice statement: people symptom of: (1) urethral discharge penis; (2) vaginal discharge; (3) lower abdominal pain (among sexually active women); (4) genital ulcer (including anorectal ulcers); (5) anorectal discharge, good practice includes offering HIV syphilis testing.4.1 Syphilis Syphilis bacterial STI caused T. pallidum transmitted sexual direct contact infectious lesion organism penetration intact mucous membrane abraded skin, via blood transfusion trans-placentally (vertically) pregnant woman fetus (congenital syphilis). Vertical transmission devastating fetus maternal infection detected treate",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "89708e44-a8ee-48d2-8c4f-beed1a678319",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "cal transmission devastating fetus maternal infection detected treated sufficiently early pregnancy. Syphilis, treated, result substantial morbidity mortality. Syphilis pregnancy, untreated, lead stillbirth, neonatal death, prematurity, low birthweight, malformation bone serious neurological issues. untreated among sexually active people, disease last many year divided stages. Early syphilis consists primary syphilis, secondary syphilis early latent syphilis, late syphilis comprises late latent syphilis tertiary syphilis (neurosyphilis, ocular syphilis gumma). Sexual transmission typically occurs early syphilis. Syphilis also increase risk HIV infection, facilitated syphilitic ulcer (36). Syphilis diagnosis complex. usually based combination clinical history, physical examination, laboratory testing sometimes radiology",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "db9c85df-ea44-4dd6-9d47-8b8b6fec92c0",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "combination clinical history, physical examination, laboratory testing sometimes radiology. Although laboratory test exist, serological test commonly used support diagnosis. Serological test include treponemal test detect antibody T. pallidum infection non-treponemal test use indirect marker infection. information syphilis diagnosis available Laboratory point-of-care diagnostic testing sexually transmitted infections, including HIV (12). number existing recommendation screening asymptomatic syphilis different population (Box 4.1).5. Implementation consideration management asymptomatic STIs21 5. Implementation consideration management asymptomatic STIs5. Implementation consideration management asymptomatic STIs 5.1 Definition screening context screening asymptomatic STIs, especially N. gonorrhoeae, C. tracho",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a978108a-d5d8-4c3f-be65-205e39a4ae74",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "creening context screening asymptomatic STIs, especially N. gonorrhoeae, C. trachomatis, syphilis HIV, person screened would well unaware may infection. Screening, therefore, defined presumptive identification unrecognized infection disease applying tests, examination procedure applied rapidly sort apparently well people probably infection disease probably not. Broadly, three type screening exist: • mass screening, selection population, checking infant hearing problems; • selective screening, categorized, example, age, sex sexual risk specific infection; • multi-phased screening, performed periodically, annual health examinations. STIs, depending infection screened for, latter two type screening may appropriate. example, generally accepte",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b09b7c7d-f5dc-47be-beaa-35ffe6b7a83d",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "or, latter two type screening may appropriate. example, generally accepted C. trachomatis prevalent adolescent young people, would, therefore, appropriate target population pathogen. Key populations, men sex men sex workers, may also offered screening STIs including syphilis HIV. pregnant women, important exclude syphilis HIV or, detected, offered prompt treatment prevent adverse pregnancy outcome reduce risk infant infection. pregnant women, screening may multi-phased conducted first trimester near delivery exclude, pick up, infection may acquired nine month pregnancy. 5.2 Rationale objective establishing screening programme asymptomatic STIs Justifying screening strategy requires infection question constitute significant public health",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a0eeacfe-1ee6-468f-b182-ccdfd567f564",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "screening strategy requires infection question constitute significant public health problem term morbidity mortality may cause amenable effective treatment available accessible potential cure. People may common bacterial viral STIs (C. trachomatis, N. gonorrhoeae, HIV, herpes simplex virus human papillomavirus) Trichomonas vaginalis without symptoms. individuals, biological women, may asymptomatic gonococcal chlamydial infection cervix 50–97% case (40,41). anatomical site urethra cervix, anorectal oropharyngeal sites, symptom usually minimal absent 85% case (42). Asymptomatic infections, especially anatomical site pharynx rectum, may reservoir selection antimicrobial resistance antimicrobial agent taken conditi",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "85ea97a9-269e-47ae-a120-c7d5832e8646",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "selection antimicrobial resistance antimicrobial agent taken condition minimal inhibitory concentration pre-existing STI pathogen (43). Since 50–97% STI infection may asymptomatic, people symptomatic infection represent tip iceberg. Ignoring asymptomatic infection imprudent since people infected without symptom documented transmit STI pathogen sexual partner (44,45). Asymptomatic STIs cause significant ill health mortality precursor cancer, including cervical, penile, anal hepatic cancer. Further, untreated asymptomatic infection result increased risk transmitting acquiring HIV.22 Guidelines management asymptomatic sexually transmitted infectionsBefore screening programme introduced asymptomatic STIs national level, common agreement objective interventi",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "25af4434-a145-43ab-9f5d-12bc903073a7",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ic STIs national level, common agreement objective intervention, screening test used, population screened pathogen screened for. Considerations population (such pregnant woman adolescent young people) screen depend prevalence, value placed outcome screening (such infertility among young women, adverse pregnancy outcome increased STI transmission) cost test. population screening implemented known high prevalence N. gonorrhoeae C. trachomatis. Screening may cost-effective target population subgroup higher risk based available surveillance data. frequency screening depend sexual exposure, rate partner exchange transmission cost test. frequency screening balanced cost number case det",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7c1d85cc-841f-45f5-a882-6630e9d9ae76",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "test. frequency screening balanced cost number case detected consequence screening. Based evidence frequency screening among men sex men, fewer people test positive screened every 2–3 month 4–6 months, confounded population (34). However, frequent screening cost more. Sex worker men sex men screened least annually every six months. main objective screening programme asymptomatic STIs are: • detect infection stage treatment given person develops signs, symptom complications; • interrupt chain transmission STIs impact incidence prevalence STIs community. 5.3 Ethical consideration Since screening conducted healthy people, ethic health care must given priority. following ethical principle observed: •",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ce358bea-c17e-4341-a97f-ae667ad96bd5",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ic health care must given priority. following ethical principle observed: • autonomy: moral, political, bioethical philosophy, people must capacity make informed uncoerced decision regarding whether undertake screening test; • non-maleficence: principle causing harm evil people must upheld; • beneficence: process conducted intent good; • justice: fairness must ensured everyone involved treated. People also mental risk associated learning STI, especially sexually active adolescents. Minimizing social risk ensuring confidentiality result essential. addition, sexually active adolescents, like sex worker men sex men, may vulnerable coercion undue influence. Procedures place ensure people population receive proper education screening informed c",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a0e08d2e-6780-45d2-bcc5-2cff8b7ef2ad",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ure people population receive proper education screening informed consent obtained. People positive STI result receive counselling trained personnel. Adolescents counselled potential benefit risk disclosing positive STI status empowered supported decide whether, when, disclose status.23 5.4 Selecting diagnostic test screening asymptomatic STIs Screening test intended determine whether asymptomatic person infection recognized lack symptoms. accurate identification asymptomatic STIs depends availability accurate diagnostic test sound screening strategy. following guidance adhered selecting test used: • validity: test able detect many possible infection asymptomatic state, determined performance charac",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "56e08c86-da70-477d-99bc-c780b8589251",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "possible infection asymptomatic state, determined performance characteristic test term sensitivity specificity; • reliability: test give consistent result random errors; • acceptability accessibility: test cause least discomfort person affordable cost individual and/or government; • testing linked care, treatment follow-up. High-quality diagnostic test STIs available currently expensive, frequently labour intensive currently suitable use rapid point-of-care tests. screening strategy therefore need established determine targeted population specific pathogen screened. setting screening syphilis HIV already established, assessment made determine whether screening additional pathogen integrated population. 5.5",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8809ffd9-6420-41bf-8313-4554c258ec47",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "etermine whether screening additional pathogen integrated population. 5.5 Acceptable performance characteristic screening test ensure sustainability screening programme, test used inexpensive easy administer cause discomfort would deter person tested. Further, test widely available accessible target population. test serve purpose adequately, acceptably good sensitivity specificity. sensitivity screening test ability detect true positive: correctly identifying infection among everyone infected. specificity screening test ability detect true negative: correctly identifying people infection. predictive value probability infection given result test. Positive predictive value probability person positive te",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "41ad767b-ff47-429c-9db6-97068e2f63be",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "e result test. Positive predictive value probability person positive test result infection, whereas negative predictive value probability person negative test result truly free infection. Predictive value determined sensitivity specificity test prevalence infection population tested. screening programme, specificity especially important health-care provider positive test reduces likelihood person tested free infection. prevalence infection low, positive predictive value also low, even test high sensitivity high specificity. Increasing positive predictive value screening programme therefore requires targeting high risk infection. sensitivity specificity test evaluated gold standard reference standard test, pol",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "85cbb40d-8fae-47f2-ac15-e8b7ec45f5d5",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "icity test evaluated gold standard reference standard test, policy-makers ensure information selecting screening test screening programme. Currently, gold standard diagnostic screening test STIs molecular- based testing, real-time polymerase chain reaction (PCR). highly sensitive test asymptomatic infection would mean number people asymptomatic infection diagnosed test decreases. test would pick high proportion infected may also false positives. highly specific test would produce small percentage false-positive results. screening programme, high specificity may desired sensitivity, especially cost overtreatment need avoided, including unnecessary use antibiotic 5. Implementation consideration management asymptomatic STIs24 Guidelines managem",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a5b634b3-3300-4f81-aceb-5e9b62227b19",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": ". Implementation consideration management asymptomatic STIs24 Guidelines management asymptomatic sexually transmitted infectionsdevelopment antimicrobial resistance. However, indicated above, predictive value depend prevalence infection community tested. Nevertheless, since specificity may never 100%, tested person informed negative screening result mean infection present but, rather, likelihood infection present low. Similarly, highly sensitive screening test unlikely produce false-negative results, people test negative kind screening test therefore unlikely infected. However, false positives, even fewer, borne mind. Screening test reliable reproducible. important point-of-care test used screening since traffic people tested may high test",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3a733d93-a76a-4757-84db-13c7f68762f6",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "test used screening since traffic people tested may high test may performed rush different health-care personnel self-test. frequent cause variability result usually following: • anatomical site sample taken; • intraobserver variability difference interpretation test different times; • interobserver variability variation interpretation test two health-care providers. Therefore, regardless test selected screening, training conducted, standard operating procedure established covering preparation person anatomical site tested, collecting processing specimen, conducting test interpret result. 5.6 Treatment, antibiotic consumption preparedness screening programme people testing positive STI treated based national guid",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ab3b6b31-043c-46c9-b533-7ac753744ff8",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ing programme people testing positive STI treated based national guidelines. addition, since screening programme also constitute part prevention strategy, sexual partner people testing positive also tested treated, positive. Testing sexual partner ensures antibiotic use rational adheres principle antimicrobial stewardship. effective successful screening programme detect infection requiring treatment option previously obtained management symptomatic infections. 5.7 Screening integrated prevention intervention Screening asymptomatic STIs implemented part integrated prevention intervention panacea ending STI burden own. general population population selected targeted STI screening, prevention intervention enhanced scaled maximum",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b59873eb-b0f8-4b3e-8ce9-4f895887ef71",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "targeted STI screening, prevention intervention enhanced scaled maximum coverage impact. prevention package STIs includes following intervention (46): • information, education communication activity aimed fostering participants' knowledge STIs safer sex; • use male female condoms; • vaccines, currently human papillomavirus hepatitis B; • voluntary medical male circumcision; • suppressive therapy genital herpes, may prevent transmission herpes simplex virus 2 (HSV-2).25 5.8 Ensuring early effective treatment prevention intervention screening service implemented conjunction accessible acceptable STI service treatment care general population, adolescent key population ensure following process: • promoting good STI health care–seeking behaviour; • providing high-quality care STIs, ensures immediate tr",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ae0860b6-5b1f-4924-a86c-720393ad4610",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "TI health care–seeking behaviour; • providing high-quality care STIs, ensures immediate treatment; • ensuring universal access STI care everyone need service thus putting service scale adequate coverage maximum impact. 5.9 STI service key populations, adolescent young people adaptation implementation guideline accompanied effort promote protect human right people requiring STI care services. includes ensuring stigma discrimination prevented service provision promoting gender equity ensuring use service voluntary. Since key population disproportionately affected STIs, critical increase access STI service key population people living HIV, including adolescent young people. many settings, people key population may disclose identity behaviour, particularly con",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a8969299-841c-4c17-9f95-4f0f59537258",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "gs, people key population may disclose identity behaviour, particularly context sex work certain sexual activity criminalized. Therefore, service designed accessible non-discriminatory, ensuring confidentiality protection legal social repercussions. Consolidated guideline HIV, viral hepatitis STI prevention, diagnosis, treatment care key population provide recommendation guidance (39). addition, following guidance publication offer implementation consideration increasing access delivering STI service key populations: • Implementing comprehensive HIV STI programme sex workers: practical approach collaborative intervention (47); • Implementing comprehensive HIV STI programme men sex men: practical guidance collaborative intervention (48); • Implementing comprehensive HIV STI programme",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7434d3bb-727b-4f45-8bd2-72094470f905",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ance collaborative intervention (48); • Implementing comprehensive HIV STI programme transgender people: practical guidance collaborative intervention (49); • Implementing comprehensive HIV HCV programme people inject drugs: practical guidance collaborative intervention (50). Adolescent-friendly health service provided, ensuring meet specific need adolescent community-based approach training health-care providers. Services maintain confidentiality, privacy non-judgemental attitude create supportive environment seeking care. Additional guidance providing high-quality health-care service adolescent available following publications: • Global standard quality health-care service adolescents: guide implement standards- driven approach improve quality health-care service adolescent (51); • Adolescent-friendly",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8e07d2b6-3eb2-4443-bd11-870cedacc1c7",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "oach improve quality health-care service adolescent (51); • Adolescent-friendly health service adolescent living HIV: theory practice (52). 5. Implementation consideration management asymptomatic STIs26 Guidelines management asymptomatic sexually transmitted infections5.10 Antenatal screening pregnant woman recommendation antenatal care positive pregnancy experience (53) recommend maternal assessment detect various condition pregnancy. include anaemia, asymptomatic bacteriuria, intimate partner violence, gestational diabetes mellitus, tobacco use, substance use, HIV, syphilis tuberculosis. pregnant woman tested HIV, well syphilis hepatitis B virus, least early possible pregnancy (38). setting high prevalence infection (exceeding 15–20%), also recommends integrate screening N. gonorrhoeae C.",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc80b998-f16b-4a8e-98c1-d8ed2694b0ea",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "nfections (exceeding 15–20%), also recommends integrate screening N. gonorrhoeae C. trachomatis maternal assessment prevent adverse maternal newborn outcome gonococcal chlamydial infections.6. Disseminating updating guidelines28 Guidelines management asymptomatic sexually transmitted infections6. Disseminating updating guideline 6.1 Dissemination guideline made available website https://www.who.int/health-topics/sexually- transmitted-infections – click “Guidelines” (there also link supporting documents). headquarters work regional office country office ensure country receive support adapting, implementing monitoring utility guidelines. Every level (headquarters, regional office country offices) work regional national partner – including United Nations Population Fund (UNFPA), th",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3f29e935-8b2d-47c9-b21e-e94bc293e3e9",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "work regional national partner – including United Nations Population Fund (UNFPA), United Nations Children’s Fund (UNICEF), Joint United Nations Programme HIV/AIDS (UNAIDS), nongovernmental organization agency implementing HIV, STI sexual reproductive health service ensure integrated approach preventing controlling STIs. advocate external partner support dissemination implementation guidelines. guideline also disseminated conference related HIV, STIs sexual reproductive health electronic media. recommendation also included WHO’s forthcoming consolidated guideline prevention, diagnosis, treatment care STIs. 6.2 Updating STI guideline user feedback system monitoring relevant new evidence updating recommendation guideline established mechanism disseminating",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fe1c94e7-bcb3-452b-80ae-c0dda7db3410",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ating recommendation guideline established mechanism disseminating new information put operation. mechanism electronic communication. electronic follow-up survey key end-users guideline conducted disseminated one year. result survey used identify challenge barrier uptake guidelines, evaluate usefulness improving service delivery STIs identify topic gap treatment need addressed future editions.References30 Guidelines management asymptomatic sexually transmitted infections1. Global progress report HIV, viral hepatitis sexually transmitted infections, 2021: accountability global health sector strategy 2016–2021: action impact. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/341412). Licence: CC BY-NC-SA 3.0 IGO. 2. Adachi",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9ced72a2-15b7-49d8-a3b0-ed852e6573de",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "nization; 2021 (https://iris.who.int/handle/10665/341412). Licence: CC BY-NC-SA 3.0 IGO. 2. Adachi K, Nielsen-Saines K, Klausner JD. Chlamydia trachomatis infection pregnancy: global challenge preventing adverse pregnancy infant outcome sub-Saharan Africa Asia. Biomed Res Int. 2016;2016:9315757 (https://doi.org/10.1155/2016/9315757). 3. Hoenderboom BM, van Benthem BHB, van Bergen J, Dukers-Muijrers N, Gotz HM, Hoebe C et al. Relation Chlamydia trachomatis infection pelvic inflammatory disease, ectopic pregnancy tubal factor infertility Dutch cohort woman previously tested chlamydia chlamydia screening trial. Sex Transm Infect. 2019;95(4):300–6 (https://doi.org/10.1136/sextrans-2018-053778). 4. Wi , Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P et al. Antimicrobial resistance Neisseria gonorrhoeae: global surveillance call international collaborative action. PLoS Med. 2017;14(7):e1002344 (https://doi.org",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "028b41a3-db20-401d-a855-8638db702cd2",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "e call international collaborative action. PLoS Med. 2017;14(7):e1002344 (https://doi.org/10.1371/journal.pmed.1002344). 5. Unemo M, Seifert HS, Hook EW 3rd, Hawkes S, Ndowa F, Dillon JR. Gonorrhoea. Nat Rev Dis Primers. 2019;5(1):79 (https://doi.org/10.1038/s41572-019-0128-6). 6. Unemo M, Lahra MM, Cole M, Galarza P , Ndowa F, Martin et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review new data evidence inform international collaborative action research efforts. Sex Health. 2019;16(5):412–25 (https://doi. org/10.1071/SH19023). 7. Implementing global health sector strategy HIV, viral hepatitis sexually transmitted infections, 2022–2030: report progress gap 2024. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/378246). Licence: CC BY-NC-SA 3.0 IGO. 8. Global Sexually Transmitted Infections Programme: Strategic information [website]. Geneva: World Health",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "afce9ff5-35ec-4ba2-9e6c-2f3b86204152",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Sexually Transmitted Infections Programme: Strategic information [website]. Geneva: World Health Organization; 2024 (https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/stis/strategic- information). 9. Global health sector strategy on, respectively, HIV, viral hepatitis sexually transmitted infection period 2022-2030. Geneva: World Health Organization; 2022 (https://iris.who.int/ handle/10665/360348). Licence: CC BY-NC-SA 3.0 IGO. 10. Guidelines management sexually transmitted infections. Geneva: World Health Organization; 2003 (https://iris.who.int/handle/10665/42782). 11. Guidelines management symptomatic sexually transmitted infections. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/342523). Licence: CC BY-NC-SA 3.0 IGO. 12. Laboratory point-of-care diagnostic testing sexually transmitted infections, including HIV. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/3",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7170717a-4940-4440-a21d-1f31b5719a41",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ctions, including HIV. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/374252). Licence: CC BY-NC-SA 3.0 IGO. 13. AWaRe (access, watch, reserve) antibiotic book. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/365237). Licence: CC BY-NC-SA 3.0 IGO. 14. AWaRe Antibiotic Categorization [website]. World Health Organization; 2025 (https://aware.essentialmeds. org/groups).References2 2 reference accessed 2 January 2025.31 References15. handbook guideline development. 2nd edition. Geneva: World Health Organization; 2014 (https://iris.who.int/handle/10665/145714). 16. Brozek JL, Canelo-Aybar C, Akl EA, Bowen JM, Bucher J, Chiu WA et al. GRADE Guidelines 30: GRADE approach assessing certainty modeled evidence – overview context health decision- making. J Clin Epidemiol. 2021;129:138–50 (https://doi.org/10.1016/j.jclinepi.2020.09.018). 17. GRADEpro Guideline Development Tool (GDT)",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fe83caf1-6bfe-4711-b991-322422a2f698",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "8–50 (https://doi.org/10.1016/j.jclinepi.2020.09.018). 17. GRADEpro Guideline Development Tool (GDT) [Software]. McMaster University Evidence Prime; 2024 (https://www.gradepro.org ). 18. Riddell MA, Vallely LM, Mengi A, Badman SG, Low N, Wand H et al. Point-of-care testing treatment sexually transmitted genital infection improve birth outcome high-burden, low-resource setting (WANTAIM): pragmatic cluster randomised crossover trial Papua New Guinea. Lancet Glob Health. 2024;12(4):e641–51 (https://doi.org/10.1016/S2214-109X(24)00004-4). 19. Wynn A, Mussa A, Ryan R, Babalola CM, Hansman E, Ramontshonyana K et al. Evaluating Chlamydia trachomatis Neisseria gonorrhoeae screening treatment among asymptomatic pregnant woman prevent preterm birth low birthweight Gaborone, Botswana: secondary analysis non-randomised, cluster-controlled trial. BJOG. 2024;131(9):1259–69 (https://doi.org/10.1111/1471- 0528.17775). 20. Mussa A, Wynn A,",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "90008c48-2259-463d-9cd7-4e16fb8db454",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "trial. BJOG. 2024;131(9):1259–69 (https://doi.org/10.1111/1471- 0528.17775). 20. Mussa A, Wynn A, Ryan R, Babalola C, Simon S, Ramontshonyana K et al. High cure rate among pregnant woman Chlamydia trachomatis Neisseria gonorrhoeae testing treatment intervention study Gaborone, Botswana. Sex Transm Dis. 2023;50(2):124–7 (https://doi.org/10.1097/OLQ.0000000000001725). 21. Shannon CL, Bristow C, Hoff N, Wynn A, Nguyen M, Medina-Marino et al. Acceptability feasibility rapid chlamydial, gonococcal, trichomonal screening treatment pregnant woman 6 low- middle-income countries. Sex Transm Dis. 2018;45(10):673–6 (https://doi.org/10.1097/ OLQ.0000000000000832). 22. Canada’s Drug Agency. Screening Chlamydia trachomatis Neisseria gonorrhoeae pregnancy: health technology assessment. Ottawa: Canadian Agency Drugs Technologies Health; 2018 (https://www.cda-amc.ca/sites/default/files/pdf/feedback/DRAFT_HT0023-report.pdf ).",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "17429d72-e060-4584-b505-e07a8ec67ae6",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Health; 2018 (https://www.cda-amc.ca/sites/default/files/pdf/feedback/DRAFT_HT0023-report.pdf ). 23. Low N, Redmond S, Uuskula A, van Bergen J, Ward H, Andersen B et al. Screening genital chlamydia infection. Cochrane Database Syst Rev. 2016;9(9):CD010866 (https://doi.org/10.1002/14651858.CD010866. pub2). 24. Chikwari CD, Simms V, Kranzer K, Dauya E, Bandason , Tembo et al. Evaluation community- based aetiological approach sexually transmitted infection management youth Zimbabwe: intervention finding STICH cluster randomised trial. EClinicalMedicine. 2023;62:102125 (https:// doi.org/10.1016/j.eclinm.2023.102125). 25. Hocking JS, Temple-Smith M, Guy R, Donovan B, Braat S, Law et al. Population effectiveness opportunistic chlamydia testing primary care Australia: cluster-randomised controlled trial. Lancet. 2018;392(10156):1413–22 (https://doi.org/10.1016/S0140-6736(18)31816-6). 26. Jiang TT , Han Y, Cao NX, Yin YP , Chen XS. Knowle",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c4af5bc3-3816-4da7-89f5-dc8600e53d47",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "tps://doi.org/10.1016/S0140-6736(18)31816-6). 26. Jiang TT , Han Y, Cao NX, Yin YP , Chen XS. Knowledge Chlamydia trachomatis acceptance testing among young student China. Sex Transm Dis. 2023;50(4):236–40 (https://doi.org/10.1097/ OLQ.0000000000001756). 27. Marcus R, C P , Gill K, Smith P , Rouhani S, Mendelsohn et al. Acceptability, feasibility cost point care testing sexually transmitted infection among South African adolescent syndromic management standard care. BMC Health Serv Res. 2023;23(1):1078 (https://doi.org/10.1186/s12913- 023-10068-8). 28. Garcia P J, Holmes KK, Carcamo CP , Garnett GP , Hughes JP , Campos PE et al. Prevention sexually transmitted infection urban community (Peru PREVEN): multicomponent community-randomised controlled trial. Lancet. 2012;379(9821):1120–8 (https://doi.org/10.1016/S0140-6736(11)61846-1). 29. Prevention treatment HIV sexually transmitted infection sex work",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7da3614a-b4dd-4479-820a-75e07ed16acf",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "61846-1). 29. Prevention treatment HIV sexually transmitted infection sex worker low- middle-income countries: recommendation public health approach. Geneva: World Health Organization; 2012 (https://iris.who.int/handle/10665/77745). 30. Xu W, Liang P , Wang C. Facilitators barrier chlamydia gonorrhea testing female sex workers: scoping review. Open Forum Infect Dis. 2023;10(8):ofad397 (https://doi.org/10.1093/ofid/ofad397).32 Guidelines management asymptomatic sexually transmitted infections31. Tsoumanis A, Hens N, Kenyon CR. screening chlamydia gonorrhea men sex men associated reduction prevalence infections? systematic review observational studies. Sex Transm Dis. 2018;45(9):615–22 (https://doi.org/10.1097/OLQ.0000000000000824). 32. Vanbaelen , Tsoumanis A, Florence E, Van Dijck C, Huis 't Veld D, Sauvage et al. Effect screening Neisseria gonorr",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8e8253c4-b8fa-47f4-8485-4f4437a664d5",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "rence E, Van Dijck C, Huis 't Veld D, Sauvage et al. Effect screening Neisseria gonorrhoeae Chlamydia trachomatis incidence infection men sex men transgender woman taking HIV pre-exposure prophylaxis (the Gonoscreen study): result randomised, multicentre, controlled trial. Lancet HIV. 2024;11(4):e233–44 (https://doi. org/10.1016/S2352-3018(23)00299-0). 33. Prevention treatment HIV sexually transmitted infection among men sex men transgender people: recommendation public health approach. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/44619). 34. Wardley AM, Williams H, Coombe J, Caddy C, Fairley CK, Hocking JS. Would men sex men support less frequent screening asymptomatic chlamydia gonorrhoea improve antibiotic stewardship? qualitative study. Sex Health. 2023;20(2):148–57 (https://doi.org/10.1071/SH22139). 35. Kim CM, Zhao V",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "56a8feb4-3752-4e5f-887a-dd2702f637c2",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "alitative study. Sex Health. 2023;20(2):148–57 (https://doi.org/10.1071/SH22139). 35. Kim CM, Zhao V, Brito De Mello M, Baggaley R, Johnson CC, Spielman E et al. Determining screening frequency sexually transmitted infection people use HIV pre-exposure prophylaxis: systematic review meta-analysis. Int J Infect Dis. 2023;129:181–7 (https://doi.org/10.1016/j. ijid.2023.01.007). 36. Wu MY, Gong HZ, Hu KR, Zheng HY, Wan X, Li J. Effect syphilis infection HIV acquisition: systematic review meta-analysis. Sex Transm Infect. 2021;97(7):525–33 (https://doi.org/10.1136/ sextrans-2020-054706). 37. guideline syphilis screening treatment pregnant women. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/259003). Licence: CC BY-NC-SA 3.0 IGO. 38. Consolidated guideline HIV testing services, 2019. Geneva: World Health Organization; 2020 (https:// iris.who.int/handle/10665/336323). License: CC BY-NC-SA 3.0 IGO 39. Conso",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ad942a65-cd47-4865-bcf7-95e62aaba83d",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ganization; 2020 (https:// iris.who.int/handle/10665/336323). License: CC BY-NC-SA 3.0 IGO 39. Consolidated guideline HIV, viral hepatitis STI prevention, diagnosis, treatment care key populations. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/360601). Licence: CC BY-NC-SA 3.0 IGO. 40. Martin-Sanchez M, Fairley CK, Ong JJ, Maddaford K, Chen MY, Williamson DA et al. Clinical presentation asymptomatic symptomatic woman tested positive genital gonorrhoea sexual health service Melbourne, Australia. Epidemiol Infect. 2020;148:e240 (https://doi.org/10.1017/ S0950268820002265). 41. Martin K, Olaru ID, Buwu N, Bandason , Marks M, Dauya E et al. Uptake factor associated testing sexually transmitted infection community-based setting among youth Zimbabwe: mixed-methods study. Lancet Child Adolesc Health. 2021;5(2):122–32 (https://doi.org/10.1016/S2352- 4642(20)30335-7). 42. Kent CK, Chaw JK,",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e5a2d9f7-7e0c-401b-82c6-a993ea654755",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Health. 2021;5(2):122–32 (https://doi.org/10.1016/S2352- 4642(20)30335-7). 42. Kent CK, Chaw JK, Wong W, Liska S, Gibson S, Hubbard G et al. Prevalence rectal, urethral, pharyngeal chlamydia gonorrhea detected 2 clinical setting among men sex men: San Francisco, California, 2003. Clin Infect Dis. 2005;41(1):67–74 (https://doi.org/10.1086/430704). 43. Hahn A, Frickmann H, Loderstadt U. Testing prevention resistance bacteria causing sexually transmitted infection – population-based model Germany. Antibiotics (Basel). 2021;10(8):929 (https://doi.org/10.3390/antibiotics10080929). 44. Rieg G, Lewis RJ, Miller LG, Witt MD, Guerrero M, Daar ES. Asymptomatic sexually transmitted infection HIV-infected men sex men: prevalence, incidence, predictors, screening strategies. AIDS Patient Care STDS. 2008;22(12):947–54 (https://doi.org/10.1089/apc.2007.0240). 45. Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "053ed997-8091-42a2-893a-1f6e8283a171",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "i.org/10.1089/apc.2007.0240). 45. Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: case screening. Prev Med. 2003;36(4):502–9 (https://doi.org/10.1016/s0091-7435(02)00058-0). 46. Marrazzo JM, Cates W. Interventions prevent sexually transmitted infections, including HIV infection. Clin Infect Dis. 2011;53(Suppl. 3):S64–78 (https://doi.org/10.1093/cid/cir695).33 References47. WHO, UNFPA, UNAIDS, World Bank, Global Network Sex Work Projects. Implementing comprehensive HIV/STI programme sex workers: practical approach collaborative interventions. Geneva: World Health Organization; 2013 (https://iris.who.int/handle/10665/90000). 48. UNFPA, Global Forum MSM HIV, UNDP , UNAIDS, WHO, USAID et al. Implementing comprehensive HIV STI programme men sex men: practical guidance collaborative interventions. New York: United Nations Population Fund; 2015 (https://www.unfpa.org/publications/ implementing-comp",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "32cf72ec-b397-4f9a-a806-63a0904cdbc2",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ew York: United Nations Population Fund; 2015 (https://www.unfpa.org/publications/ implementing-comprehensive-hiv-and-sti-programmes-men-who-have-sex-men). 49. UNDP , IRGT: Global Network Trans Women HIV, UNFPA, UCSF Center Excellence Transgender Health, Johns Hopkins Bloomberg School Public Health, et al. Implementing comprehensive HIV STI programme transgender people: practical guidance collaborative intervention (TRANSIT). New York: United Nations Development Programme; 2016 (https://www.undp.org/ publications/implementing-comprehensive-hiv-and-sti-programmes-transgender-people). 50. UNODC, International Network People Use Drugs, UNAIDS, UNDP , UNFPA, et al. Implementing comprehensive HIV HCV programme people inject drugs: practical guidance collaborative interventions. Vienna: United Nations Office Drugs Crime; 2017 (https://www.undp. org/publications/implementing-comprehensive-hiv-and-hcv-programmes-peo",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6fb15cfc-8f0a-47eb-8d69-53fa6c18a607",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "rime; 2017 (https://www.undp. org/publications/implementing-comprehensive-hiv-and-hcv-programmes-people-who-inject-drugs). 51. WHO, UNAIDS. Global standard quality health-care service adolescents: guide implement standards-driven approach improve quality health-care service adolescents. Geneva: World Health Organization; 2015 (https://iris.who.int/handle/10665/183935). 52. Adolescent-friendly health service adolescent living HIV: theory practice, December 2019: technical brief. Geneva: World Health Organization; 2019 (WHO/CDS/HIV/19.39 (https://iris.who.int/ handle/10665/329993). Licence: CC BY-NC-SA 3.0 IGO. 53. recommendation antenatal care positive pregnancy experience. Geneva: World Health Organization; 2016 (https://iris.who.int/handle/10665/250796).Annex 1. Contributors guidelines35 Annex 1. Guideline Development GroupAnnex 1. Contributors guideline Laith Abu-Raddad Director, Collaborating",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "22d1935c-9d3b-42d3-9d2c-64b903399ba7",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "elopment GroupAnnex 1. Contributors guideline Laith Abu-Raddad Director, Collaborating Centre Disease Epidemiology Analytics HIV/AIDS, STIs, Viral Hepatitis Weill Cornell Medical College Doha, Qatar Yaw Adu-Sarkodie Professor Clinical Microbiology Kwame Nkrumah University Science Technology Kumasi, Ghana Jamila Al-Abri Director, Woman Child Health Department Ministry Health Oman Zeyana Al-Habsi Head, HIV/STI Hepatitis Section Ministry Health Oman Mircea Betiu Associate Professor Nicolae Testimitanu State University Medicine Pharmacy Chisinau, Republic Moldova Catriona Bradshaw Professor Sexual Health Melbourne Sexual Health Centre School Translational Medicine Monash University Alfred Hospital Melbourne, Australia Xiang-Sheng Chen Deputy Director National Center AIDS/STD Control Prevention Nanjing, China Irith De Baetselier Coordinator, National Reference Centre STIs Institute Tropical Medicine Antw",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c10779a9-e190-439d-a41c-912f6c9dd49f",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "th De Baetselier Coordinator, National Reference Centre STIs Institute Tropical Medicine Antwerp, BelgiumChido Dziva Chikwari Assistant Professor Epidemiology London School Hygiene & Tropical Medicine Health Research Unit Zimbabwe Biomedical Research Training Institute Harare, Zimbabwe Amina El Kettani Medical Officer Direction de l’Epidémiologie et de Lutte Contre le Maladies Ministry Health Rabat, Morocco Patricia Garcia Professor Universidad Peruana Cayetano Heredia Lima, Peru William M. Geisler Professor Assistant Dean Physician Scientist Development University Alabama Birmingham Birmingham, USA Kimberly Green Global Program Director, Primary Health Care PATH Hanoi, Viet Nam Somesh Gupta Dermatologist India Institute Medical Sciences New Delhi, India Edward W. Hook III Director, Division Infectious Diseases University Alabama Birmingham Birmingham, USA Rena Janamnuaysook Program Manager, Implementation Science Institute",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d0696757-6a39-4ac5-a666-5b3d8fb07b14",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Birmingham Birmingham, USA Rena Janamnuaysook Program Manager, Implementation Science Institute HIV Research Innovation Bangkok, ThailandGuideline Development Group36 Guidelines management asymptomatic sexually transmitted infectionsNathalie Kapp Chief Medical Adviser International Planned Parenthood Federation London, United Kingdom Hamida Khattabi Medical Officer, Service de MST-Sida Direction de l'Epidémiologie et de Lutte Contre le Maladies Ministry Health Rabat, Morocco Rossaphorn Kittyaowamarn Chief Bangrak STIs Center Bureau AIDS, TB STIs Department Diseases Control Ministry Public Health Nonthaburi, Thailand Jeffrey D. Klausner Professor Medicine Public Health University Southern California Los Angeles, USA Ranmini Kularatne Clinical Head, Microbiology Infectious Serology Awanui Labs Auckland, New Zealand Peter Kyambadde Executive Director Risk Populations Initiative (MARPI) National Coordinator, Key Populati",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a7389418-7a45-4205-afba-4011bbc71cd7",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "de Executive Director Risk Populations Initiative (MARPI) National Coordinator, Key Populations/STI Program Ministry Health Kampala, Uganda David Lewis Director Western Sydney Sexual Health Centre Sydney, Australia Philippe Mayaud Professor Infectious Diseases Reproductive Health London School Hygiene Tropical Medicine London, United Kingdom Saiqa Mullick Director, Implementation Science Wits RHI University Witwatersrand Johannesburg, South Africa Francis Ndowa Physician Skin Genito-Urinary Medicine Clinic Harare, Zimbabwe Lilani Rajapaksa Consultant Venereologist Ministry Health Colombo, Sri Lanka Kees Rietmeijer Medical Director Denver STD Prevention Training Center Denver Public Health Department Denver, USA Danvic Rosadiño Program Innovations Director LoveYourself Inc. Manila, Philippines Jonathan Ross Consultant Physician University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom Lon Sayheng Head STD Unit Nation",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e2920d29-4d82-4600-a2ab-497f3c35595d",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "tals Birmingham NHS Foundation Trust Birmingham, United Kingdom Lon Sayheng Head STD Unit National Center HIV/AIDS, Dermatology STD Phnom Penh, Cambodia Anna Shapiro Policy Manager Global Network Sex Work Projects Edinburgh, United Kingdom Daniel Simões Strategic Information Manager Coalition Plus Lisbon, Portugal Jane Thiomi GBV HIV Prevention Manager LVCT Health Nairobi, Kenya Jane Tomnay Director Centre Excellence Rural Sexual Health University Melbourne Melbourne, Australia Magnus Unemo Associate Professor Medical Microbiology Molecular Biology Örebro University Hospital Örebro, Sweden Judith Wasserheit Professor Global Health Medicine University Washington Seattle, USA37 Annex 1. Guideline Development GroupFrancis Kakooza Head, Global Health Security Department Infectious Diseases Institute Makerere University Kampala, Uganda Otilia Mardh Medical Epidemiologist European Centre Disease Prevention Control Stockholm, SwedenFernan",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e573d424-56b9-4615-ba99-ab26699e8a8b",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "dh Medical Epidemiologist European Centre Disease Prevention Control Stockholm, SwedenFernando Pascal Martinez Research Development Access Development Lead Global Antibiotic Research Development Partnership Barcelona, Spain Tim Sladden Senior Advisor, Sexual Reproductive Health United Nations Population Fund New York, NY, USA Henry J.C. de Vries Amsterdam Sexual Health Clinic Amsterdam, Netherlands (Kingdom the) Hans Benjamin Hampel University Zurich Zurich, Switzerland Kausar Jabeen Professor Consultant Microbiologist, Pathology Laboratory Medicine Aga Khan University Karachi, Pakistan Monica Lahra Collaborating Centre STIs Antimicrobial Resistance Prince Wales Hospital Sydney, Australia Pham Thi Lan National Hospital Dermatology Venereology Hanoi Medical University Hanoi, Viet Nam Ahmed Latif Public health consultant Brisbane, Australia Ioannis Mameletzis Consultant Kyiv, UkraineAngelica Espinosa Miranda Coordinator",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "30fc53fb-b193-4676-83d7-4826706b0d0b",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "ane, Australia Ioannis Mameletzis Consultant Kyiv, UkraineAngelica Espinosa Miranda Coordinator Surveillance STIs Ministry Health Brasília, Brazil Koleka Mlisana Executive Manager, Academic Affairs, Research Quality Assurance National Health Laboratory Service Johannesburg, South Africa Lori Newman Deputy Director STI Gynecology Gates Foundation Washington, DC, USA Catherine Ngugui Head, National AIDS STI Control Ministry Health Nairobi, Kenya Reshmie Ramautarsing Physician Institute HIV Research Innovation Bangkok, Thailand Pachara Sirivongrangson Ministry Public Health Bangkok, Thailand Janet Wilson Consultant, Genito-Urinary Medicine Leeds Teaching Hospitals NHS Trust Leeds, United KingdomObservers External Review Group38 Guidelines management asymptomatic sexually transmitted infectionsHeadquarters Arif Al-Hann Technical Officer Department Surveillance, Prevention Control Antimicrobial Resistance Division Avni Amin Technical",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3cd10ada-3aae-4087-83a1-24c15933b7fc",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "nt Surveillance, Prevention Control Antimicrobial Resistance Division Avni Amin Technical Officer Department Sexual Reproductive Health Research Maeve Brito de Mello Technical Officer Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes Meg Doherty Director Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes Sami Gottlieb Medical Officer Department Sexual Reproductive Health Research Benedikt Huttner Team Lead Department Access Medicines Health Products Cheryl Johnson Technical Officer Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes James Kiarie Unit Head Department Sexual Reproductive Health Research Ismail Maatouk Technical Officer Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes Daniel Marcan-Zamora Technical Officer Department Surveillance, Prevention Control Antimicrobial Resistance Division Gitau Mburu",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d59a2931-1b7e-47c0-9bd1-2b8007fbf88e",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "er Department Surveillance, Prevention Control Antimicrobial Resistance Division Gitau Mburu Scientist Department Sexual Reproductive Health ResearchDaniel McCartney Consultant Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes Antons Mozalevskis Technical Officer Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes Yamuna Mundade Programme Manager Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes Morkor Newman Owiredu Medical Officer Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes Anne-Laure Page Scientist Regulation Prequalification Remco Peters Medical Officer Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes Jane Rowley Technical Officer Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes Özge Tuncalp Medical Officer Maternal, Child Adolescent Health Igor Toskin Scien",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6c5ffe3b-1d5b-4173-b6ea-ff694cdd29d9",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "tion Programmes Özge Tuncalp Medical Officer Maternal, Child Adolescent Health Igor Toskin Scientist Department Sexual Reproductive Health Research Annette Verster Technical Officer Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes Marco Vitoria Medical Officer Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes Teodora Wia Lead, Sexually Transmitted Infections Department Global HIV, Hepatitis Sexually Transmitted Infection Programmes aOverall coordinator guidelines.WHO Steering Committee39 Annex 1. Guideline Development GroupRegional office Polin Chan Regional Advisor, Hepatitis, HIV STIs Regional Office South-East Asia Viatcheslav Grankov Unit Lead, Joint Infectious Diseases Regional Office Europe Joumana Hermez Regional Adviser Regional Office Eastern Mediterranean Kiyohiko Izumi Medical Officer Regional Office Western Pacific Ruben Mayorga Sagast",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "00945546-798e-485d-bc8c-886695964327",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "nean Kiyohiko Izumi Medical Officer Regional Office Western Pacific Ruben Mayorga Sagastume Unit Chief, HIV, Hepatitis, Tuberculosis STIs Regional Office Americas Agnes Shetty Medical Officer, HIV/AIDS Treatment Care Regional Office Africa Methodologist evidence review team Methodologist Farid Foroutan Ted Rogers Centre Health Research Canada Systematic review modelling team Nancy Santesso Michael G. DeGroote Cochrane Centre Canada Katy Turner, Krishnan Puri-Sudhir Mary Ashley Keene Aquarius Public Health United KingdomAnnex 2. Declarations conflict interest41 Annex 2. Declarations conflict interestName 1. Employment consulting2. Research support 3. Investment interests4. Intellectual property5. Public statement positions6. Tobacco productsConflicts management plan Laith Abu-Raddad (Weill Cornell Medical College, Qatar)- - - - - - Full participation Yaw Adu-Sarkodie (Kwame Nkrumah University",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "45e700fd-e2d0-4f16-8ee0-0eba5f8a7ae3",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "l Medical College, Qatar)- - - - - - Full participation Yaw Adu-Sarkodie (Kwame Nkrumah University Science Technology, Ghana)- - - - - - Full participation Jamila Al-Abri (Woman Child Health Department, Ministry Health, Oman)- - - - - - Full participation Zeyana Al-Habsi (HIV/STIs & Hepatitis Section, Ministry Health, Oman)- - - - - - Full participation Mircea Betiu (Nicolae Testimitanu State University Medicine Pharmacy, Republic Moldova)- - - - - - Full participation Catriona Bradshaw (Monash University Alfred Hospital, Australia)Funding Abbott support development STI testing recommenda- tions country across Asia-Pacific region (3800 Australian dollars).Australian Research Council Grant Monash University contains contribution government, two diagnostic company (Speedx Cepheid) NGOs including Global Antibiotic Research Development Partnership (GARDP) support work",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "25dd5086-b785-4ef1-bb3d-2c84e141ea52",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "nd NGOs including Global Antibiotic Research Development Partnership (GARDP) support work development resistance diagnostics antimicrobial resistance (1.5 million Australian dollars). Diagnostic kit GeneXpert platform donated use specific investigator-initiated research.- - - - Declare. Direct finance significant. Full participation Xiang-Sheng Chen (National Center AIDS/STD Control Prevention, China)- - - - - - Full participation Irith De Baetselier (Institute Tropical Medicine, Belgium)- - - - - - Full participationGuideline Development Group members42 Guidelines management asymptomatic sexually transmitted infectionsName 1. Employment consulting2. Research support 3. Investment interests4. Intellectual property5. Public statement positions6. Tobacco productsConflicts management plan Chido Dziva Chikwari (Biomedical Research Training Institute, Zimbabwe)- - - - - - Full participati",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a2a5c367-7016-4e71-839c-9fc8f764db2b",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Dziva Chikwari (Biomedical Research Training Institute, Zimbabwe)- - - - - - Full participation Amina El Kettani (Ministry Health, Morocco)- - - - - - Full participation Patricia Garcia (Universidad Peruana Cayetano Heredia, Peru)- - - - - - Full participation William M. Geisler (University Alabama Birmingham, USA)Consulting C. trachomatis vaccine Sanofi (ceased 2023), consulting STI point-of-care test Visby (ceased 2023).Research support Hologic study M. genitalium prevalence resistance USA (ceased 2023), speaking honorarium related M. genitalium Hologic, Roche Molecular Systems, Abbott (ceased 2023).- - - - Declare. None active. Full participation Kimberly Green (PATH, Viet Nam)- Support Hepatitis Fund triple elimination, including syphilis screening (US$ 50,000).- - - - Declare. Finance significant. Full participation Somesh Gupta (All India Institute Medical Scienc",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0b49ae4e-6ab0-409f-afc2-667b99f22680",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Finance significant. Full participation Somesh Gupta (All India Institute Medical Sciences, India)- - - - - - Full participation Edward W. Hook III (University Alabama Birmingham, USA)- Member advisory board Visby Diagnostics (US$ 10 000) Talsis Diagnostics.- - - - Declare. Finance significant. Full participation Rena Janamnuaysook (Institute HIV Research Innovation, Thailand)- - - - - - Full participation43 Annex 2. Declarations conflict interestName 1. Employment consulting2. Research support 3. Investment interests4. Intellectual property5. Public statement positions6. Tobacco productsConflicts management plan Nathalie Kapp (International Planned Parenthood Federation, United Kingdom)- - - - - - Full participation Hamida Khattabi (Ministry Health, Morocco)- - - - - - Full participation Rossaphorn Kittyaowamarn (Ministry Public Health, Thailand)- Multi-centre randomized, open-label, non-inf",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5cdb9ded-efe5-45d9-8dc4-252b553a4811",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Kittyaowamarn (Ministry Public Health, Thailand)- Multi-centre randomized, open-label, non-inferiority trial evaluate efficacy safety single oral dose zoliflodacin treatment patient uncomplicated gonorrhoea (GARDP).- - - - Full participation – related STI screening Jeffrey D. Klausner (University Southern California, USA)Consulting technical adviser Visby Medical (ceased 2023), Biofire (ceased 2023), Cepheid (ceased 2022), Roche (ceased 2021).- - - - - Declare. None active. Full participation Ranmini Kularatne (Awanui Labs, New Zealand)- - - - - - Full participation Peter Kyambadde (Ministry Health, Uganda)- - - - - - Full participation David Lewis (Western Sydney Sexual Health Centre, Australia)Consultancy GSK relating gepotidacin treatment gonorrhoea (review Phase 3 results, Advisory Board meetings).- - - - - Full participation – related STI screening44 Guidelines",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6bdecc4f-54c9-4b3b-8d60-b2c50e8c51b3",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "visory Board meetings).- - - - - Full participation – related STI screening44 Guidelines management asymptomatic sexually transmitted infectionsName 1. Employment consulting2. Research support 3. Investment interests4. Intellectual property5. Public statement positions6. Tobacco productsConflicts management plan Philippe Mayaud (London School Hygiene Tropical Medicine, United Kingdom)- Research support Abbott Diagnostics sample collection development N. gonorrhoeae C. trachomatis diagnostic test (ceased 2023).- - - - Declare. None active. Full participation Saiqa Mullick (Wits RHI, University Witwatersrand, South Africa)- - - - - - Full participation Francis Ndowa (Skin Genito-Urinary Medicine Clinic, Zimbabwe)- - - - - - Full participation Lilani Rajapaksa (Ministry Health, Sri Lanka)- - - - - - Full participation Kees Rietmeijer (Denver Public Health Department, USA)Past consul",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b7a663cf-e9ea-420f-b277-bcd3d3447039",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": ")- - - - - - Full participation Kees Rietmeijer (Denver Public Health Department, USA)Past consulting Sentient (ceased 2023), (ceased 2022).- - - - - Declare. None active. Full participation Danvic Rosadiño (LoveYourself Inc., Philippines)- - - - - - Full participation Jonathan Ross (Birmingham University Hospitals NHS Trust, United Kingdom)Consultancy advice relation clinical trial (GSK Pharma).Research payment employer role principal investigator clinical trial (purified protein derivative).Investments (self wife) GSK Pharma AstraZeneca.- - - Declare. Finance significant. Full participation Lon Sayheng (National Center HIV/AIDS, Dermatology STD, Cambodia)- - - - - - Full participation Anna Shapiro (Global Network Sex Work Projects, United Kingdom)- - - - - - Full participation45 Annex 2. Declarations conflict interestName 1. Employment consulting2. Research support 3.",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f4ad5d81-64a3-4f05-810b-0e650eb5ce0c",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "x 2. Declarations conflict interestName 1. Employment consulting2. Research support 3. Investment interests4. Intellectual property5. Public statement positions6. Tobacco productsConflicts management plan Daniel Simões (Coalition Plus, Portugal)Employed GAT Portugal.Member Country Support core team (trainer) CHIP (Center Excellence Health Immunity Infections) European AIDS Clinical Society. Member Regional Office Europe’s European Laboratory Initiative, Co-chair EuroTest Initiative, Member European Union’s Drugs Agency review panel updated guidance people inject drugs.- - - - Full participation Jane Thiomi (LVCT Health, Kenya)- - - - - - Full participation Jane Tomnay (University Melbourne, Australia)- - - - - - Full participation Magnus Unemo (Örebro University Hospital, Sweden)- - - - - - Full participation Judith Wasserheit (University Washington, USA)- - - - - - Full",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "de5fab45-bcb8-4f82-8041-49e8916e673f",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "- - - - - - Full participation Judith Wasserheit (University Washington, USA)- - - - - - Full participation46 Guidelines management asymptomatic sexually transmitted infectionsName 1. Employment consulting2. Research support 3. Investment interests4. Intellectual property5. Public statement positions6. Tobacco productsConflicts management plan Francis Kakooza (Makerere University, Uganda)- - - - - - Nil Otilia Mardh (European Centre Disease Prevention Control, Sweden)- - - - - - Nil Fernando Pascal Martinez (Global Antibiotic Research Development Partnership, Spain)- - - - - - Nil Tim Sladden (United Nations Population Fund, USA)- - - - - - Nil Name 1. Employment consulting2. Research support 3. Investment interests4. Intellectual property5. Public statement positions6. Tobacco productsConflicts management plan Henry J.C. de Vries (Amsterdam Sexual Health Clinic, Netherlands [Kingdom the])- - - - - - Fu",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5439750f-2deb-4ae8-b474-5e8835a13127",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Henry J.C. de Vries (Amsterdam Sexual Health Clinic, Netherlands [Kingdom the])- - - - - - Full participation Kristina Grabbe (Jhpiego, USA)- - - - - - Full participation Hans Benjamin Hampel (University Zurich, Switzerland)- - - - - - Full participation Kausar Jabeen (Aga Khan Foundation, Pakistan)- - - - - - Full participation Monica Lahra (Prince Wales Hospital, Australia)- - - - - - Full participationExternal Review Group membersObservers47 Annex 2. Declarations conflict interestName 1. Employment consulting2. Research support 3. Investment interests4. Intellectual property5. Public statement positions6. Tobacco productsConflicts management plan Pham Thi Lan (Institute Dermatology Venerology, Viet Nam)- - - - - - Full participation Ahmed Latif (public health consultant, Australia)- - - - - - Full participation Ioannis Mameletzis (consultant, Ukraine)- - - - - - Full participation Angelica Espinosa Miranda (Ministry",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a01d770e-21f7-4e38-93a3-657666f24f99",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "eletzis (consultant, Ukraine)- - - - - - Full participation Angelica Espinosa Miranda (Ministry Health, Brazil)- - - - - - Full participation Koleka Mlisana (National Health Laboratory Service, South Africa)- - - - - - Full participation Lori Newman (Gates Foundation, USA)- - - - - - Full participation Catherine Ngugui (Ministry Health, Kenya)- Research support GARDP , Drugs Neglected Diseases Initiative (DNDI) Ministry Health study prevalence C. trachomatis N. gonorrhoeae infection among pregnant woman key population Kenya (US$ 40 000; ceased 2022).- - Former Director National AIDS STI Control Kenya.- None active. Full participation Reshmie Ramautarsing (Institute HIV Research Innovation, Thailand)- - - - - - Full participation Pachara Sirivongrangson (Ministry Public Health, Thailand)Consulting work GARDP (US$ 10 000).- - - - - Full participation Janet Wilson (Lee",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e73a2c9d-35af-41c7-9f8f-42398a00fdd1",
        "title": "Management of asymptomatic sexually transmitted infections",
        "body": "Thailand)Consulting work GARDP (US$ 10 000).- - - - - Full participation Janet Wilson (Leeds Teaching Hospitals NHS Trust, United Kingdom)- - - - - - Full participationFor information, please contact: World Health Organization Global HIV, Hepatitis Sexually Transmitted Infections Programmes 20 Avenue Appia 1211 Geneva 27 Switzerland Email: hiv-aids@who.int Website: www.who.int/teams/global-hiv-hepatitis-and-stis-programmes www.who.int",
        "source": "WHO Guidelines: Management of asymptomatic sexually transmitted infections.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "156f348d-acd8-4c7b-865b-124d700189e3",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever ISBN 978-92-4-011111 -0 (electronic version) ISBN 978 -92-4-011112 -7 (print version) © World Health Organization 2025 right reserved. work available Creative Commons Attribution -NonCommercial - ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by -nc-sa/3.0/i go). term licence, may copy, redistribute adapt work non -commercial purposes, provided work appropriately cited, indicated below. use work, suggestion endorses specific organization, product services. use logo",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "852ab961-5a2d-4a08-b192-b2e57c83df57",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "stion endorses specific organization, product services. use logo permitted. adapt work, must license work equivalent Creative Commons licence. create translation work, add th e following disclaimer along suggested citation: “This translation created World Health Organization (WHO). responsible content accuracy translation. original English edition shall binding authentic edition”. mediation relating dispute arising licence shall conducted accordance mediation rule World Intellectual Property Organization ( http: //www.wipo.int/amc/en/mediation/rules/ ). Suggested citation . guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever . Geneva: World Health Organization; 2025 . Licence: CC BY-NC-SA 3.0 IGO . Catalo",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "733ec845-5bee-4fa3-843a-b69e4113bd24",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "yellow fever . Geneva: World Health Organization; 2025 . Licence: CC BY-NC-SA 3.0 IGO . Cataloguing -in-Publication (CIP) data. CIP data available https://iris.who.int/ . Sales, right licensing. purchase publications, see https://www.who.int/publications/book -orders . submit request commercial use query right licensing, see https://www.who.int/copyright . Third -party materials. wish reuse material work attributed third party, tables, figure images, responsibility determine whether permission needed th reuse obtain permission copyright holder. risk claim resulting infringement third -party - owned component work rest solely user. General isclaimers. designation employed presentation th e material publication imply expression opinion whatsoever part con",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "336f74a8-1bb8-4da3-872b-e4c497522570",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "al publication imply expression opinion whatsoever part concerning legal status country, territory, city area authorities, concerning delimitation frontier boundary . Dotted dashed line map represent approximate border line may yet full agreement. mention specific company certain manufacturers’ product imply endorsed recommended preference others similar nature mentioned. Errors omission excepted, name proprietary product distinguished initial capital letters. reasonable precaution taken verify information cont ained publication. However, published material distributed without warranty kind, either expressed implied. responsibility interpretation use material lie reader.",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d43c0efa-3434-44d1-9b8d-7e673ab66948",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "mplied. responsibility interpretation use material lie reader. event shall liab le damage arising use. Design: Jamie Rylance Contents Acknowledgments ................................ ................................ ................................ ... vi 1 Executive summary ................................ ................................ ............................ 1 2 Introduction ................................ ................................ ................................ ....... 3 2.1 Background ................................ ................................ ................................ ...................... 3 2.2 Dengue ................................ ................................ ................................ ............................ 6 2.3 Chikungunya ................................ ................................ ................................ ....................",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "36ea9504-1a95-4ec4-85e0-5ad2bced43e2",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "............ ................................ ................................ .................... 8 2.4 Zika ................................ ................................ ................................ ................................ .. 9 2.5 Yellow fever ................................ ................................ ................................ .................... 10 2.6 Laboratory confirmation ................................ ................................ ................................ . 12 2.7 Identifying severe arboviral disease ................................ ................................ ................. 13 2.8 Purpose ................................ ................................ ................................ ......................... 14 2.9 Scope target audience ................................ ................................ ............................. 15 3 Guideline development implementation ....................",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9fcbab34-fe91-4773-a20c-a4cbace48e77",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "............................. 15 3 Guideline development implementation ................................ ..................... 16 3.1 triggered update ................................ ................................ .............................. 16 3.2 Guideline development process ................................ ................................ ...................... 16 3.3 Managing declaration interest ................................ ................................ ................... 23 4 Recommendations patient non -severe, suspected confirmed, arboviral disease ................................ ................................ ............................ 24 4.1 Oral rehydration ................................ ................................ ................................ ............. 24 4.2 Symptom control ................................ ................................ ................................ ............",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "99f87bde-111e-4ed4-a079-810a71bc948c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "................... ................................ ................................ ............ 28 4.3 Corticosteroids (for non -severe arboviral disease) ................................ ........................... 42 5 Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) ................................ ................................ ......... 46 5.1 Choice intravenous fluid ................................ ................................ ............................. 46 5.2 Guiding administration intravenous fluid volume ................................ .................... 50 5.3 Corticosteroids (for severe disease) ................................ ................................ ................ 70 5.4 Immunoglobulins ................................ ................................ ................................ ........... 74 5.5 Platelet transfusion ................................ ..",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "38568ca1-154b-4464-b74c-dff2bb2835a3",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "..................... ........... 74 5.5 Platelet transfusion ................................ ................................ ................................ ........ 77 5.6 Specific management yellow fever ................................ ................................ .............. 81 6 access use guideline ................................ ................................ . 91 7 Guideline -relevant research need limitation ................................ ............ 92 ii 8 Publication, dissemination, monitoring evaluation ................................ ...... 94 References ................................ ................................ ................................ ............. 95 Annex 1. Declarations Interest ................................ ................................ ........... 101 Annex 2. Arbovirus baseline risk estimate survey ................................ ................. 102 Annex 3. Prot",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3db5a2e6-15af-4628-95c9-734b250e3001",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "eline risk estimate survey ................................ ................. 102 Annex 3. Protocol systematic review inform clinical practice guideline management arboviral disease ................................ .......................... 106 iii Tables Table 2 -1 Clinical manifestation dengue, chikungunya Zika differentiate cause febrile illness1 ................................ .............................. 4 Table 2 -2. Clinical manifestation dengue, chikungunya Zika might differentiate other1 ................................ .............................. 5 Table 3 -1.Minimally important difference outcome interest ................................ .. 19 Table 3 -2. Assumed absolute risk prioritized outcome ................................ ............. 20 Table 3 -3. Implications strong conditional recommendation different user guid",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d92b34ad-89bc-4563-92be-84aac34d7965",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "20 Table 3 -3. Implications strong conditional recommendation different user guideline ................................ ................................ ................................ . 22 Table 4 -1. Summary finding protocolized oral fluid treatment compared non - protocolized oral fluid treatment patient non - severe arboviral disease ................................ ................................ ................................ ................ 27 Table 4 -2. Dosing Paracetamol (acetaminophen) treatment ................................ ... 30 Table 4 -3. Dosing Paracetamol patient renal impairment .............................. 31 Table 4 -4. Summary finding use paracetamol (acetaminophen) treatment pain and/or fever patient suspected confirmed non - severe arboviral disease ................................ ................................ ............ 32 Table 4 -",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9f7d5b5b-fe1a-478a-8585-be4931111708",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "sease ................................ ................................ ............ 32 Table 4 -5. Dosing metamizole treatment ................................ ............................... 35 Table 4 -6. Summary finding use metamizole (dipyrone) treatment pain and/or fever patient suspected confirmed non -severe arboviral disease ................................ ................................ ................................ ..... 37 Table 4 -7. Summary finding use non -steroidal anti -inflammatory medication (NSAIDs) patient acute suspected confirmed arboviral disease, irrespective severity ................................ ................................ ............... 41 Table 4 -8. Summary finding corticosteroid treatment compared corticosteroid treatment patient acute non -severe arboviral disease 45 Table 5 -1. Choice intravenous fluid assessed ...............",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9365bc19-ab17-4c7f-9443-39e8a0286dde",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "non -severe arboviral disease 45 Table 5 -1. Choice intravenous fluid assessed ................................ ............................ 48 Table 5 -2. Summary finding administration crystalloid fluid rather colloid fluid patient require intravenous fluid treatment severe arboviral disease ................................ ................................ ................................ ..... 49 Table 5 -3. Summary finding capillary refill time -guided resuscitation compared standard care patient suspected confirmed arbovirus infection receiv e intravenous fluid infusion ................................ .................. 55 Table 5 -4. Summary finding capillary refill time -guided resuscitation compared lactat e-guided resuscitation patient suspected confirmed arbovirus infection ................................ ................................ ............................",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e7f3c1f8-3714-4cc7-9a6c-d710219ac3b2",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "tion ................................ ................................ ................................ ... 56 Table 5 -5. Summary finding lactate -guided resuscitation compared Central Venous Oxygen saturation -guided resuscitation patient suspected confirmed arbovirus infection receive intravenous fluid infusion ...... 61 iv Table 5 -6. Summary finding lactate -guided resuscitation compared standard care patient suspected confirmed arbovirus infection receive intrave nous fluid infusion. ................................ .............................. 62 Table 5 -7. Summary finding cardiac output response leg raise test (LRT) bolus infusion -guide resuscitation compared standard care patient suspected confirmed arbovirus infection receive intravenous fluid infusion ................................ ................................ .....................",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "052915ea-6b20-46c2-8fa5-1746777d0453",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "infusion ................................ ................................ ................................ .... 67 Table 5 -8. Summary finding cardiac output response leg raise test (LRT) guided resuscitation compared standard care patient suspected confirmed arbovirus infection receive intravenous fluid fusion. ..... 68 Table 5 -9. Summary finding corticosteroid compared standard care patient acute severe arbovira l disease ................................ ............................ 72 Table 5 -10. Summary finding Intravenous immunoglobulin compared standard care patient acute arboviral disease ................................ ........... 76 Table 5 -11. Summary finding platelet transfusion compared platelet transfusion patien t confirmed suspected dengue fever thrombocytopenia. ................................ ..............................",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0f96dad5-9ef0-43dc-91e8-f8d9f1ac927f",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "dengue fever thrombocytopenia. ................................ ................................ .................... 79 Table 5 -12. N -acetylcysteine dosing ................................ ................................ .............. 83 Table 5 -13. Summary finding N -acetylcysteine compared standard care patient acute liver failure caused infectious disease ..................... 84 Table 5 -14. Summary finding yellow fever -specific monoclonal antibody TY014 compared placebo patient yello w fever ................................ ... 88 Table 5 -15. Summary finding Sofosbuvir compared standard care patient yellow fever ................................ ................................ ........................ 90 v Figures Figure 2 -1. course dengue illness day onset ................................ ............. 7 Figure 5 -1. Suggested way measure standardiz",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ce3307c3-0526-473f-87ee-6c79538667bb",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "................................ ............. 7 Figure 5 -1. Suggested way measure standardized capillary refill time (67) .................... 54 Figure 5 -2. Suggested way perform standardized passive leg raise test ........................ 65 vi Acknowledgments World Health Organization (WHO) gratefully acknowledges contribution many individual organization made development guidelines. Steering Committee Steering Committee included representative departm ents Regional Offices headquarters, including specialty technical input. Lisa Askie (Methods Standards Unit, Science Division, WHO, Geneva, Switzerland), Laurence Cibrelus Health Emergencies Programme, WHO, Geneva, Switzerland), Jane Cunningh (Health Emergencies Programme, WHO, Geneva, Switzerland), Janet Diaz (Health Emergencies Programme, WHO, Geneva, Switzerland), Caron Rahn Kim (Department Reproductive Health Rese",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "013bacdf-b763-4e29-9d04-34a34cdbe306",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e Programme, WHO, Geneva, Switzerland), Caron Rahn Kim (Department Reproductive Health Research, WHO, Geneva, Switzerland), Jean -François (Jeff) Lemaire (Immun ization Vaccines Biologicals department, WHO, Geneva, Switzerland), Mick Mulders (Immunization Vaccines Biologicals department, WHO, Geneva, Switzerland), Ingrid Rabe (Health Emergencies Programme, WHO, Geneva, Switzerland), Marie -Eve Raguenaud (He alth Emergencies Programme WHO, Geneva, Switzerland), Andreas Reis (Ethics Division, WHO, Geneva, Switzerland), Diana Rojas Alvarez (Health Emergencies Programme, WHO, Geneva, Switzerland), Jamie Rylance (Health Emergencies Programme, WHO, Geneva, Switzerland), Atsushi Samura (Health Emergencies Programme, WHO, Geneva, Switzerland), Nicoline Schiess (Mental Health, Brain Health Substance Use Department, WHO, Geneva, Switzerland), Maria Van Kerkhove (Health Emergencies Programme, WHO, Geneva, Swi tzerland), Raman Velayudhan (Neglected Tropical Diseases",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d7ec88c5-c0a5-420b-91e7-66974cf08938",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "th Emergencies Programme, WHO, Geneva, Swi tzerland), Raman Velayudhan (Neglected Tropical Diseases department, WHO, Geneva, Switzerland), Gamaliel Gutierrez Castillo (Neglected Tropical Diseases department, Regional Office Americas), Jairo Andres Mendez Rico (Health Emergencies Program me, Regional Office Americas), Belinda Herring (Health Emergencies Programme, Regional Office Africa), James Kelley (Communicable Disease Control Programme , Regional Office Western Pacific), Chiori Kodama (Health Emergencie Programme, Regional Office Eastern Mediterranean), Pushpa Ranjan Wijesinghe (Health Emergencies Programme, Regional Office South -East Asia). Interns: Romina Rios Blanco (Arboviruses Team, Health Emergencies Programme, WHO, Geneva, Swi tzerland) , Taudgirdas Persaud (Arboviruses Team, Health Emergencies Programme, WHO, Geneva, Switzerland). Project officer: Julie Viry (Clinical Management Team, Heal",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9c9528f1-27c9-4a6b-9aa3-58bfad4b2af9",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Programme, WHO, Geneva, Switzerland). Project officer: Julie Viry (Clinical Management Team, Health Emergencies Programme, WHO, Geneva, Switzerland). vii Technical responsible unit: Clinical anagement Team , Health Emergencies Programme, WHO, Geneva, Switzerland: Janet Diaz (Lead), Jamie Rylance. Guideline Development Group (GDG) Tajeldin Mohammedein Abdallah (University Kassala Kassala Teaching Hospital, Kassala, Sudan); Ashutosh Biswas (Department Medicine, AIIMS Delhi, India); Lucy Lum Chai See (University Malaya, Kuala Lumpur, Malaysia), Orlando Cuellar Cuellar (Hospital San Juan de Dios, Santa Cruz, Bolivia (Plurinational State of) ); Ismael Diallo (Yalgado Ouedraogo University Hos pital, Joseph KI -Zerbo University, Ouagadougou, Burkina Faso); Cristina Domingo Carrasco (Robert Koch Institute, Centre International Health Protection, Berlin, Germany); P. S. Indu (Department Community Medicine, Govt Medical College, Kollam, Keral Universi",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e259d3d3-47c2-4911-8c96-5b3c69cfafd4",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "many); P. S. Indu (Department Community Medicine, Govt Medical College, Kollam, Keral University Health Sciences, India); Emilie Javelle (French Armed Forces Health Services (SSA), French Armed Forces Biomedical Research Institute (IRBA), 2MI department, Laveran Military Hospital, Marseille, France); Mikaila Kabore (Regional Hospital f Ziniaré, Ziniaré, Burkina Faso); Yee -Sin Leo (National Centre Infectious Diseases, National Healthcare Group, Singapore); Pisake Lumbiganon (Faculty Medicine Khon Kaen University, Khon Kaen, Thailand); Kleber Giovanni Luz (Federal University Rio Grande Norte, Brazil), Carlos Pardo -Villamizar (Neurology Pathology (Neuropathology), Johns Hopkins University School Medicine, Baltimore, United States America); Mostafa Salehi - Vaziri (Department Arboviruses Viral Hemorrhagic feve rs, Pasteur Institute Iran, Tehran, Iran); Michel Van Herp (Doctors Without Borders, Brussels, Belgium); Maria Esterlita Vi",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "76981490-3624-47e7-9eab-e67bc8c032a0",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "n, Tehran, Iran); Michel Van Herp (Doctors Without Borders, Brussels, Belgium); Maria Esterlita Villanueva Uy (Institute Child Health Human Development, National Institutes Health, University Philippines, Manila , Philippines); Liya Wassie (Armauer Hansen Research Institute AHRI, Addis Ababa, Ethiopia). Methodologist: Gordon Guyatt (McMaster University, Canada). Clinical Chair: Marta Lado Castro -Rial (Partners Health). Co-chair: Erin Staples (C enters Disease Control Prevention, United States America) [collaboration preceded 20 January 2025]. Systematic reviewers: Ariel Izcovich (GRADE Cono Sur). Special thanks external reviewers: Claudia Mello (Instituto de Infectologia Emílio Ribas, São Paulo, Brazil), André Ricardo Ribas Freitas (Epidemiologist Professor Public Health, Faculdade São Leopoldo Mandic, Campinas, São Paulo, Brazil); Liliana Sanchez - Gonzalez (Centers Disease Control Prevention, United States",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "19da177a-d567-46bc-b92c-be2f9f5c059f",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": ", Brazil); Liliana Sanchez - Gonzalez (Centers Disease Control Prevention, United States America) [colla boration preceded 20 January 2025] ; Sophie Yacoub (Oxford University Clinical Research Unit, Viet Nam), Hasitha Tissera (Ministry Health, Sri Lanka). viii guideline developed financial support United States Centers Disease Contro l Prevention cooperative agreement Grant GH19 1967 CDC PMS U2GGH002225 [collaboration preceded 20 January 2025] , Bill Melinda Gates Foundation award 72295 VCS BMGF PREP RESP YF WRLDW, Global Neglected Tropical Diseases progr amme fund systematic review, support French Government award 76465 WHO's Contingency Funds Emergencies (for dengue grade 3 emergency declared December 2023) fund convening GDG in-person meeting Geneva fee associated methodological support. ix Abbr",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c7ecbea7-fb47-4fa8-99ca-ac4acf17f12d",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "in-person meeting Geneva fee associated methodological support. ix Abbreviations CI confidence interval CRT capillary refill time DOI declaration interest GDG Guideline Development Group GRADE Grading Recommendations Assessment, Development Evaluation IV intravenous IVIG intravenous immunoglobulin ICU intensive care unit MAP mean arterial pressure MID minimally important difference NSAIDs non -steroidal anti -inflammatory drug PLR passive leg raise test PICO population, intervention, comparison, outcome RCT randomized controlled trial World Health Organization Executive summary 1 1 Executive summary Scope : purpose guideline assist health care provider caring patient suspected confirmed arboviral disease caused dengue, chikungunya, Zika yellow fever viruses. guideline includes recommendation management p atients admitted health care",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e2a0ad36-afa9-4eef-80cd-36901597af26",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ses. guideline includes recommendation management p atients admitted health care facility (defined purpose guidance “severe disease”) seen outpatient facility (defined purpose guidance “non -severe disease”). Target audience : guideline design ed primarily health care provider manage patient clinically apparent arboviral infections. guideline applied level health system, including community -based care, primary care, emergency department hospital ward s. guideline also serve reference source policymakers, health manager health facility administrator support development national, regional local guideline epidemic pandemic preparedness. guideline provi de recommendation following: • treatment severe non -severe arboviral disease • choice fluid management measuremen",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d1e732f3-2e9f-4464-be90-3d8f8060c413",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ment severe non -severe arboviral disease • choice fluid management measurement guide fluid administration. • treatment adjunctive therapy patient yellow fever Knowledge gap highlighted priority area future research. Recommendations summary Recommendations patient non -severe, suspected confirmed arboviral disease (dengue, chikungunya, Zika yellow fever): • suggest use protocolized os l fluid treatment compared non - protocolized oral fluid treatment patient suspected confirmed non -severe arboviral disease. [Conditional recommendation, low certainty evidence] • suggest use paracetamol treatment pain and/or fever patient suspected confirmed non -severe arboviral disease. [Conditional recommendation, low certainty evidence] • suggest use metamizole treatment pain and/or f ever patient suspected",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a34244df-ee6e-4611-9d8e-5d46f7b57647",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "suggest use metamizole treatment pain and/or f ever patient suspected confirmed non -severe arboviral disease. [Conditional recommendation, low certainty evidence] • recommend use non -steroidal anti -inflammatory medication (NSAIDs) patient acute suspected conf irmed arboviral disease, irrespective severity. [Strong recommendation, low certainty evidence] guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 2 • suggest using corticosteroid treatment patient acute suspected confirmed non -severe arboviral disease [Conditional recommendation, low certainty evidence] Recommendations specific patient severe (hospitalized) , suspected confirmed arboviral disease (dengue, chikungunya, Zika yellow fever): • suggest using crystalloid fluid rather colloid fluid patient require intravenous flu",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e9fe8254-1e12-4210-8d8c-af565f6efb82",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "suggest using crystalloid fluid rather colloid fluid patient require intravenous fluid treatment suspected confirmed severe arboviral disease . [Conditional recommendation, low certainty evidence] • recommend use capillary refill tim e guide intravenous fluid management patient suspected confirmed severe arboviral disease. [Strong recommendation, low certainty evidence] • recommend use lactate measurement addition standard care guide intravenous fluid management patient suspected confirmed severe arboviral disease. [Strong recommendation, moderate certainty evidence] • suggest use passive leg raise test patien t shock, suspected confirmed arboviral disease, clinician uncertain intravenous fluid administration warranted. [Conditional recommendation, low certainty evidence] • suggest use systemic corticoster oids",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1d3b79e8-9144-4566-a2b3-8dbbb5ce7e87",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ommendation, low certainty evidence] • suggest use systemic corticoster oids treatment patient suspected confirmed severe arboviral disease . [Conditional recommendation, low certainty evidence] • suggest use immunoglobulin treatment patient suspected confirmed severe arboviral disease . [Conditional recommendation, low certainty evidence] • suggest use prophylactic platelet transfusion patient suspected confirmed severe arboviral disease platelet count <50,000 platelets/microlitre active bleeding. [Conditional recommendation, low certainty evidence] • suggest use intravenous N -acetylcysteine treatment patient liver failure due suspected confirmed yellow fever. [Conditional recommendation, low -certainty evidence] • recommend use monoclonal immunoglobulin TY014",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6fb1c6e2-95a4-407d-ac86-17029ab64f9e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "low -certainty evidence] • recommend use monoclonal immunoglobulin TY014 treatment patient yellow fever research settings. [Use research] • recommend use sofosbuvir treatment patient yellow fever research settings. [Use research] guideline updated according emerging evidence. Introduction 3 2 Introduction 2.1 Background Arthropod -borne virus (arboviruses) dengue, chikungunya Zika virus transmitted Aedes (Stegomyia ) specie mosquitoes. mosquito also transmit yellow fever virus urban settings. Aedes -borne arbovirus currently pose public health threat area approximately 3.9 billion people live. Although Aedes aegypti Aedes albopictus mo quitoes abundant tropical subtropical temperate climates, geographic scope expanding risk introduction",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5fd3c942-ad73-4bfa-8d84-3bf75a2dbead",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "temperate climates, geographic scope expanding risk introduction spread virus transmit. simultaneous circulation, frequency, magnitude outbreak arbovirus increasing globally, fuelled convergence ecologic, economic social factors, consequent expansion area case occur. increasing incidence endemic area occurrence imported autochthonous (sometimes refer red indigenous ) disease case new area require clinician awareness recognize disease manage case according evidence -based guidance, task complicated challenge differentiating clinically infections, particularly early phase illness. preparation 2022 Pan American Health Organization Guidelines Clinical Diagnosis Treatment Dengue, Chikungunya, Zika , systematic review conducted using various electron",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d9856e86-de23-4b9e-94fa-399c4dcae554",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "atment Dengue, Chikungunya, Zika , systematic review conducted using various electronic database manual search (1). Among research questions, review aimed determine clinical finding basic complementary study differentiate disease caused arbovirus febrile diseases. synthesis evidence profile developed using Grading Recommendations Assessment, Development Evaluation ( GRADE ) approach, recommendation agreed upon panel arbovirus experts. methodology guideline followe guideline development methods. Updated search formally undertaken , recent large -scale study known panel ; finding incorporated aid end -users refining clinical judgements, formal recommend ations made. detailed methodology information, please refer document (2). gui",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4190b3c2-dc84-4f67-b1a2-7be7eef4bb64",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "made. detailed methodology information, please refer document (2). guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 4 Tables 1.1 1.2 detail clinical laboratory finding potentially useful guiding diagnosis suspected arbovirus infection based systematic review Pan American Health Organization guidelines. subsequent publication multicentre, prospective, observational study early diagnostic indicator dengue versus febrile illness Asia Latin America, platelet count, white blood cell count change count prev iou day illness, well bleeding, anorexia, skin flushing identified significant predictor dengue , cough rhinitis negative predictor dengue (3). Table 2-1 Clinical anifestations dengue, chikungunya Zika differentiate fro",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a4dedf2d-d587-431f-8799-64575aba520e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "). Table 2-1 Clinical anifestations dengue, chikungunya Zika differentiate cause febrile illness1 Certainty evidence Manifestations arbovirus HIGH (findings differentiate them) Rash Conjunctivitis Arthralgia (dengue chikungunya) Myalgia bone pain (dengue chikungunya) Haemorrhage , including bleeding skin, mucous membranes, (dengue chikungunya) Thrombocytopenia (dengue) Progressive increase haematocrit (dengue) Leukopenia (dengue) Headache (dengue) Pruritus (Zika) MODERATE (findings probably differentiate hem) Fluid accumulation Arthritis (chikungunya) Chills (dengue chikungunya) Dysgeusia (dengue) LOW (findings may differentiate them) Asthenia Retro -ocular pain 1Adapted Pan American Health Organization guideline diagnosis treatment dengue, chikungunya, zika Region Americas Introduction",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "09982646-7a46-48a8-9ece-091a35cc2fa4",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "treatment dengue, chikungunya, zika Region Americas Introduction 5 Table 2-2. Clinical anifestations dengue, chikungunya Zika might differentiate other1 Certainty evidence Manifestations dengue Manifestations chikungunya Manifestations Zika HIGH (findings differentiate them) Thrombocytopenia Progressive increase haematocrit Leukopeni Arthralgia Pruritus MODERATE (findings probably differentiate them) Anorexia Vomiting Abdominal pain Chills Haemorrhage (includes bleeding skin, mucous membranes, both) Rash Conjunctivitis Arthritis Myalgia bone pain Rash Conjunctivitis LOW (findings may differentiate them) Retro -ocular pain Hepatomegaly Headache Diarrhoea Dysgeusia Cough Elevated transaminase Positive tourniquet test Haemorrhage (includes bleeding skin, mucous membranes, both) Adenopath",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9b8a1d13-180f-48e8-a581-fc297b1948bc",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "iquet test Haemorrhage (includes bleeding skin, mucous membranes, both) Adenopath Pharyngitis odynophagia 1Adapted Pan American Health Organization guideline diagnosis treatment dengue, chikungunya, zika Region Americas guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 6 2.2 Dengue Dengue caused infection one dengue virus ( Orthoflavivirus dengue , serotypes 1 -4), belonging family Flaviviridae (4). Although people infected dengue virus symptoms, typically experience abrupt onset high fever, body aches, arthralgia, retro -orbital headache, rash, nausea. symptom occur, usually begin 4 –10 day infection last 2 –7 day , starting febrile phase, patient recover (Figure 2-1)(5). pa tients , often increased capillary p",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d9f689c1-0546-417d-a07b-1b7327eb7365",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "h patient recover (Figure 2-1)(5). pa tients , often increased capillary permeability , enter critical phase around time defervescence (fever reduction) 4th-5th day illness , warning sign become evident worsening symptom , organ dysfunction , occasion ally severe bleeding occur ; however, patient severe dengue warning sign . Severe dengue fatal , patient need care hospital careful fluid management address complication infection (6). Following critical phase, patient typically enter recovery phase reabsorption extravascular fluid. patient recover 1–2 weeks. risk developing severe dengue increase person infected second dengue virus serotype month year initial infection. Risk also increased patient concomitant comorbidities condition",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "11cd0c97-a555-4bc0-a0f8-37fd0d8feaa5",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "on. Risk also increased patient concomitant comorbidities condition pregnancy, young age (particularly infant young children) advanced age. known specific antiviral treatment dengue virus infections. Medications used manage pain fever . However, non -steroidal anti -inflammatory drug typically avoided risk bleeding complications. Prevention engue hinge avoidance mosquito bite community -level mosquito vector reduction. Vaccines developed received stringent regulatory approvals. Use vaccines, however, limited date (7). Reported dengue case increased markedly past decade, case roughly doubling annually since 2021. Globally, 136 country territory reported current prior autochthonous dengue transmission. 2024, 14.2 million dengue case reported , including 7.5 million confirmed c",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dee6c377-0c4d-4d6e-af0e-11642735ccc3",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": ". 2024, 14.2 million dengue case reported , including 7.5 million confirmed cases, 52 000 severe case 10000 death (8). case report ed Region Americas arbovirus surveillance consistent robust Regions four dengue subtypes circulate (9). case reported Brazil, member state except Canada reported prior autochthonous dengue transmission. Introduction 7 Figure 2-1. course dengue illness day onset Source : updated Yip, 1980 (2). Notes: IgM = immunoglobulin M. Temperature data illustrative represent typical febrile non -febrile phases. Sepsis critical illness may associated hypothermia. Hematocrit value depend significantly fluid therapy. IgM kinetics variable may depend primary vs. secondary infection. Hemocrit platelet data https://pmc.ncbi.nlm.nih.gov/ar",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "058086b1-5c53-4cec-a4a2-09f6549860e7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "n primary vs. secondary infection. Hemocrit platelet data https://pmc.ncbi.nlm.nih.gov/articles/PMC6114047 . Viral count data https://elifesciences.org/articles/92606 . NS1 data https://www.embopress.org/doi/pdf/10.15252/embr.202153600 . African Region, evidence autochthonous transmission 30 countries, 19 reporting transmission 2024. Eastern Mediterranean Region, seven country h ave reported autochthonous transmission 2024 ; dengue transmission Region compounded fragile, weakened health care systems, conflicts, floods. South -East Asia Region, dengue endemic ten country . 2022 -2023, significant increase dengue case observed Bangladesh Thailand , 2024 highest case number reported Indonesia Ind ia. Dengue endemic 23 country Western Pacific Region recent large outbreak Malaysia",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "65baf037-ff4d-450c-b97f-26af26da63cd",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "endemic 23 country Western Pacific Region recent large outbreak Malaysia Viet Nam 2023 -2024 . Although previously documented, large outbreak reported Pacific Island Countries territory rece nt years. Sporadic autochthonous dengue case limited dengue outbreak reported European Region since 2010 France, Italy, Spain, Portugal (Madeira) Croatia. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 8 2.3 Chikungunya Chikungunya caused infection chikungunya virus (Alphavirus chikungunya) , belonging family Togaviridae. half patient chikungunya virus infection experience symptom typically include fever severe , sometimes incapacitating arthralgia . symptomat ic patients, disease onset typically 4 – 8 day (range 2 – 12 days) bite infected mosquito. patient",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6e060fe8-e260-473f-ab15-dc1529b3a731",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "typically 4 – 8 day (range 2 – 12 days) bite infected mosquito. patient develop severe chikungunya, fatal , particularly underlying medical conditions, elderly person neonate infected around time delivery presence maternal viraemia soon birth infected mosquito bites. Severe complications, including cardiovascular, neurological multiorgan involvement, may require intensive medical care (8 – 10). known specific antiviral treatment chikungunya virus infections. Medications used manage pain fever. one vaccine approved United States America Europe use traveller laboratory worker , vaccine widely available public health use endemic outbreak settings. Chikungunya virus first identified United Republic Tanzania 1952, sporadic case outbreak reported",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0198bd8e-8e34-44fd-aa5d-52cc1db89382",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ied United Republic Tanzania 1952, sporadic case outbreak reported Africa Asia 1950s nd 1960s, respectively (13). Since 2004 outbreak become frequent widespread spread virus non -immune population associated, outbreaks, viral adaptation facilitate transmission Aedes albopictus mosquitoes. Autochthonous chikungunya virus transmission identified 119 country across regions. 2024, 460 000 suspected case chikungunya reported globally. case reported Region Americas, systematic chikungunya surveillance place across Member States Territ ories. Since 2018, chikungunya case reported 14 -15 country region annually transmission 2023 marked geographic expansion reported cases, including large outbreak Paraguay, resumption transmission Arg",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "65b45381-495f-4cc2-861d-25f3ef87ef79",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ansion reported cases, including large outbreak Paraguay, resumption transmission Argentina first recorded autochthonous transmission Uruguay. African Region, limited outbreak sporadic case recorded periodically since 1950s, marked increase starting 2004 outbreak Keny a, spread Indian Ocean island . Outbreaks reported country across African Region since time. Chikungunya transmission reported six country Eastern Mediterranean Region, outbreak activity reported Pakistan 2024. South -East Asia Region, case reported mostly India inist ry Health Family Welfare website (14) around 100 000 case occurred annually since 2020, increase noted 2024; country Region also experienced cyclical outbreak within past two decade (15). Periodic chikungunya outbreaks, introduc",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "79253055-4039-43a6-a449-23434537aff0",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "nced cyclical outbreak within past two decade (15). Periodic chikungunya outbreaks, introduc ed viraemic traveller , reported Italy France (European Region) 2007 2017. 2024, single Introduction 9 autochthonous chikungunya case reported mainland France, along ten case La Réunion, France. Autochthonous transmiss ion reported 20 country Western Pacific Region , large outbreak chikungunya reported several Pacific Island country 2011 -2017. 2.4 Zika Zika caused infection Zika virus ( Orthoflavivirus zikaense ), belonging family Flaviviridae . people Zika virus infection develop symptom . typically symptom including rash pruritus , conjunctivitis, fever, myalgia , arthralgia , malaise, headache last 2 – 7 days. Although primarily transmitted Aedes specie mosquitoes, Zika virus also b",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc8dd84c-3f71-4939-9863-465d485e16ec",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "2 – 7 days. Although primarily transmitted Aedes specie mosquitoes, Zika virus also transmitted mother foetus pregnancy, sexual contact, transfusion blood blood product organ transpl antation. 2016, declared public health emergency international concern due association Zika virus infection cluster microcephaly neurological disorder Guilla in-Barré syndrome ( GBS ), encephalitis myeliti (16). vaccine antiviral yet available prevention treatment Zika virus infection, remains active area research. Cases Zika virus disease declined 2017 onwards globally , many country instituted surveillance public health em ergency ceased testing monitoring transmission since th en. However, Zika virus case still reported low level several country Region Americas ot",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7e6463da-95cc-4947-8b93-e6dac3340776",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "as still reported low level several country Region Americas endemic region , including outbreak India Thailand . date, total 92 country territory reported evidence mosquit o- transmitted Zika virus infection (17,18). 2024, 30 000 Zika case reported , Region Americas, good surveillance disease (9). African Region, country conducting testing Zika; transmission reported multiple country prior 2024 typically sporadic case detected research project (19). South -East Asia Region, autochthonous transmission Zika occurs low level several country periodic outbreak reported , including India (Maharashtra Karnataka states) Thailand . European Region, Zika virus autochthonous transmission reported sin",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "059529b8-e4d4-41a3-b76e-aa6a156de407",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": ". European Region, Zika virus autochthonous transmission reported single instance France 2019 yet reported Eastern Mediterranean Region. Spor adic Zika case reported mainland country Western Pacific Region . Although first recorded Zika outbreak occurred Micronesia (Federated States of) 2007, followed large outbreak French Polynesia , France, 2013 , case reported Pacific Island country remained low since 2016. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 10 2.5 Yellow fever Yellow fever caused infection yellow fever virus ( Orthoflavivirus flavi ) belonging family Flaviviridae . transmitted bite infected mosquitoes, primarily Aedes, Haemagogus Sabethes species. ellow fever disease affect human non -human primates.",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5a3cd38e-d1b1-4878-b2e6-2396cb9c256b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "magogus Sabethes species. ellow fever disease affect human non -human primates. Many infected people experience symptoms. symptomatic, symptom appear incubation period typically 3-6 day following bite infected mosquito. common symptom fever, muscle pain prominent backach e, headache, loss appetite nausea vomiting. cases, symptom disappear 3 – 4 days. small percentage patient enter second, toxic phase within 24 hour recovering initial symptoms. High fever return several bo dy system affected, usually liver kidneys. phase, people likely develop jaundice, dark urine, abdominal pain vomiting. Bleeding occur mouth, nose, eyes, stomach. Half patient die within 7 – 10 days. severe case confused severe malaria, leptospirosis, viral hepatitis (especially fulmina",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5738a7b5-8eaa-47ec-86a1-cf84d51ff01c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "evere case confused severe malaria, leptospirosis, viral hepatitis (especially fulminant forms), haemorrhagic fevers, infection flavivirus (including dengue ) poisoning. Vaccination effective preve ntive measure, providing lifelong immunity cases. Yellow fever transmitted three distinct cycles: (1) sylvatic ( jungle) ; (2) intermediate savannah yellow fever; (3) urban yellow fever . urban cycle involves transmission virus human Aedes aegypti mosquito densely populated areas, potentially leading large epidemics. 2023, 34 country Africa 13 country Central South America either endemic for, region endemic for, yellow fever. threat yellow fever outbreak continues affect country regions. past ix years, explosive outbreak seen yellow fever re-emerge major international pu",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c91166ab-d0a6-4a8a-abb6-42e8fa5fb5ba",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "past ix years, explosive outbreak seen yellow fever re-emerge major international public health threat endemic areas, fuelled insufficient vaccination coverage, climate factors, population growth urbanization (20,21). 2023, African Region experienced yellow fever outbreak urban setting across three countries, case epidemic potential three additional country sporadic case eight countries. transmission pattern 2023 highlight ongoing risk due sylvatic transmission, spillover, amplification susceptible populations. 2023, Region Americas, case exposure sylvatic enviro nment reported four country (22). long -term Eliminate Yellow fever Epidemics (EYE) strategy (2017 -2026) developed partner respond increasing risk large urban yellow fever outbreak risk international spread threat global health securi",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6c320ac9-9853-4ffc-96ec-ac3f80759088",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e urban yellow fever outbreak risk international spread threat global health security (23). EYE Strategy work Introduction 11 across full continuum prevention, preparedness, outbreak response. effort partnership 377 million people Africa , 2024, protected life vaccination campaign routine immunization since 2017. resource • Global Dengue Surveillance dashboard (8) • Global distribution Chikungunya virus (24) • Countries territory current previous Zika virus transmission (25) • Yellow fever case distribution (26) guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 12 2.6 Laboratory confirmation Aedes -borne arbovirus infection often cannot distinguished clinically becau se share non -specific clinical feature . Laboratory confirmation therefore needed differentiate",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c92a8e67-35ff-4284-8213-89d2ad3c910e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e non -specific clinical feature . Laboratory confirmation therefore needed differentiate infection circulating arboviral non -arboviral pathogens. However, testing readily available many part world Aedes -borne arbovirus circulate , leading frequen misdiagnoses, clinical management guided clinical syndrome prevailing epidemiology. Laboratory testing arbovirus accomplished either direct detection method virus isolation, molecular detection nucleic acid antigen testing including rapid diagnostic test (RDTs ) within first week illness onset, indirect detection method IgM IgG antibody ELISAs RDTs end first week illness onset first three month year later (27,28). Antigenic similarity within viral family cause cross -reactivity serologic testing notable",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "24d2b2ef-9d81-44b9-b489-2ba8b55775a5",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "milarities within viral family cause cross -reactivity serologic testing notable among flavivirus , particularly Zika dengue virus (29). Serologic cross -reactivity also noted lphaviruses including c hikungunya , Mayaro virus (Alphavirus mayaro ) Americas O’nyong ’nyong virus ( Alphavirus onyong ) Africa . Laboratory guidance diagnosis dengue outbreak setting development , update planned Zika chikungunya diagnostic testing . guide country selection diagnostic tests, Expert Reviews Procurement Diagnostics progress dengue. Existing guideline laboratory diagnosis found at: • Laboratory manual yellow fever (2024) (30) • Recommendations Laboratory Detection Diagnosis Arbovirus Infections Region Ame ricas (2023) (31) • Laboratory testing Zika virus dengue virus infections: interim gu",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f3a52e49-872d-446d-a5c9-a1467d618372",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Ame ricas (2023) (31) • Laboratory testing Zika virus dengue virus infections: interim guidance (2022) (32) • Dengue guideline diagnosis, treatment, prevention control: new edition (2009) (33) Introduc tion 13 2.7 Identifying severe arboviral disease Dengue, chikungunya, Zika yellow fever unique case definitions, accompanied classification severity. dengue severity classification outlined 2009 Dengue guideline diagnosis, treatment, prevention, control includes category non -severe (with without warning signs) severe dengue (33). case definition chikungunya proposed expert panel convened 2015 included definition acute disease severe acute disease (34). proposed case case definition Zika surveillance case definition yellow fever include categorization severe non -severe disease : Zika,",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8c95337f-4d22-4fd0-9805-a26784fca2eb",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "yellow fever include categorization severe non -severe disease : Zika, severe disease manifestation ar e rare outside congenital disease neurological syndrome (which case definition ) (35); yellow fever case definition includes organ dysfunction (hepatic) resulting jaundice implies severe disease (36). Pan American Health Organization recently issued updated dengue, chikungun ya Zika case definition dengue severity classification Americas based systematic review clinical feature differen tiating arboviral infection conducted 2022 (12). Definitions non -severe severe arboviral disease guideline heterogeneity available case definition classification across viral disease variation case definition classification across Regions Member States necessitated development working definition purpo",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6a6f7886-14b6-4f3f-8c7c-5f9f849943f0",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "s Regions Member States necessitated development working definition purpose evaluating evidence developing clinical recommendations. Consequently, purpose clarity guideline, following terminology used . Severe disease : patient clinician assess requiring hospitalization base clinical evaluation includes assessment presence warning sign existing complications. Non -severe disease : feature severe disease managed -patient basis. Based literature rev iew 2022 Pan American Health Organization guidelines, following criterion identified might encourage clinician hospitalize patient dengue . • Dengue warning sign : abdominal pain: progressive continuous sustained intense, end febrile stage sensory disorder: irritability, drowsiness,",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5e8e1b85-73af-4867-b215-8bb1a2258780",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "nd intense, end febrile stage sensory disorder: irritability, drowsiness, lethargy mucosal bleeding: bleeding gum , epistaxis, vaginal bleeding associated menstruation menstrual bleeding usual haematuria hepatomegaly: 2 cm costal margin abrupt onset guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 14 vomiting: persistent (three episode one hour four episode six hours) progressive increase haematocrit: least two consecutive measurement patient monitoring. • dengue criterion severe disease, according 2009 definition • oral intolerance • difficulty breathing • narrowing pulse pressure • arterial hypotension • acute renal failure • prolonged capillary refill time • pregnancy • coagulopathy addition, clinician setting may elect admit hospital",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3b13034e-9a82-4a70-8f52-7faf67c3904a",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "gnancy • coagulopathy addition, clinician setting may elect admit hospital patient risk factors, patient extreme age (elderly, neonates) underlying medical condition high risk adverse disease outcomes. Zika, chikungunya, yellow fever, need hospitalization require individual assessment clinician . 2.8 Purpose 2.8.1 guideline's objectives? • Describe standard clinical care improve patient management therefore clinical outcomes. • Identify important uncertainty require research investigation. 2.8.2 Guideline principle • Taking patient perspective outcome , entail prioritizing patient -important outcome assessing certainty evidence making recommendations. • Recommendations pertain across area arbovirus transmission globally . • Recommendations inclusive spe",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fb008ca5-98e9-4d3f-88ca-1b950b1f04db",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "across area arbovirus transmission globally . • Recommendations inclusive speak need vulnerable populations. Introduction 15 2.9 Scope target audience Scope : purpose guideline assist health worker caring patient suspected confirmed arboviral disease caused dengue, chikungunya, Zika, yellow fever virus es. guideline include recommendation management patient admitted health care facility (defined purpose guidance “severe disease”) seen outpatient facility (defined purpose guidance “non -severe disease”). guideline intended exhaustive clinical manual read implemented context local clinical system arb ovirus treatment practices. Prior guidance includes detailed information clinical management (5,33). specific recommendation within guideline",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bbc406da-8f35-4113-ac29-eaa87216b78c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "led information clinical management (5,33). specific recommendation within guideline supersede previous documents. Target audience : guideline designed primarily health care provider manage patient clinically apparent arboviral infection. guideline applied level health system including community -based care, primary care, emergency department hospital wards. guideline also serve reference source policymakers, health manager health facility administrator support development national, regional, local guideline epidemic pandemic preparedness. guideline provide recommendation following: • Supportive symptomatic reatment non -severe severe arboviral infection. • Fluid management , including administration monitoring oral intravenous fluids. • Specific adjunctive therapy patient yellow",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "72b0eee7-d7ff-4401-ae48-b389643c3b7a",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ng oral intravenous fluids. • Specific adjunctive therapy patient yellow fever. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 16 3 Guideline development implementation 3.1 triggered update Prior guidance clinical management dengue, chikungunya, Zika yellow fever based mostly expert opinion, clinical practice experience review available evidence without applying GRADE methodology . 2022, Pan American Health Organization Member States developed published guideline emanating first GRADE -type evaluation clinical management dengue, chikungunya Zika region (2). However, consideration pertinent PAHO recommendation specific Region Americas . thus need similar process conducted global level context, considering",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "08f0117f-6ca5-400e-9f43-2a88f3a638d4",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "need similar process conducted global level context, considering region Member States e ndemic transmission introduction likely occur time. country subnational area Aedes -borne arboviral disease detected first time, clinician may particular need guidance bec ause lack prior experience caring patient conditions. health care resource planning preparedness perspective, increasing size frequency arbovirus epidemic placing additional strain available facili tie personnel , capaci ty improve patient outcome reduced hospital admission shorter duration hospital stay becoming ever important. 3.2 Guideline development process Introduction development guideline adheres standard trustworthy guidelines, including United",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "40e131f2-6401-4d1d-a168-658575fbce41",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "guideline adheres standard trustworthy guidelines, including United States Institute Medicine (37), (38) GRADE working group (39,40). Timeline May 2022, Steering Committee group assembled (see authorship , contribution acknowledgement section ), priority clinical question related arbovir al disease management identified. April 2023, written plan development integrated clinical guidance dengue, Zika, chikungunya yellow fever submitted Guidelines Review Committee (GRC) f approval included proposed population, intervention, comparison, outcome ( PICO ) question Guideline Development Group (GDG) member . plan approved one revision May 23, 2023. 2023, Steering Committee appointed convened GDG clinical guidance arbovirus approved GRC (see Authorship, contributions, Guideline devel",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c7750338-b17a-4ef6-ba52-f9ac182111bf",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "l guidance arbovirus approved GRC (see Authorship, contributions, Guideline development implementation 17 acknowledgement section) . GDG multidisciplinary group comprised 17 individual regions, including tech nical expert arbovirus, researchers, primary care clinicians, paediatrician , emergency doctors, haematologist , neurologists, patient representative stakeholders. guideline, GDG also included specialist ethics. also ensured GDG balanced gender representation regions. initial meeting GDG held online July 2023. initial meeting chair co-chairs proposed elected member GDG initial PICO question discussed. GDG convened person July 2024 review data gathered systematic review address PICO questions. 3.2.1 Scope formul ation PICOs",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6297d34d-be5b-494c-888d-4ab26aeb8fee",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "n systematic review address PICO questions. 3.2.1 Scope formul ation PICOs population interest included person suspected confirmed arboviral disease. Disease caused infection following arbovirus considered: • dengue • Zika • chikungunya • yellow fever Steering Committee GRC reviewed revised list determined clinical priorit y scope initial guideline. Questions codified using PICO framework, identifies population, intervention, comparator outcome interest. ques tions refined methodologist, technical team, clinical chairs. outcome interest chosen based perceived importance patients, agreed upon GDG. 3.2.2 Evidence identification synthesis 3.2.2.1 Identification exis ting evidence independent methodologist reviewed proposed PICO question advised",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "75b707c4-6fd6-49d7-92b7-66d3673737ee",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ting evidence independent methodologist reviewed proposed PICO question advised refinement terminology parameter optimal sequential ordering . PICOs previously framed diagnostic identification arbovirus illness compared febrile illness differentiation arbovirus excluded systematic review , since content covered recent literature review conducted development PAHO guidance (2) preceded global guideline . 2023 , independent research group specializing systematic review application GRADE methodology commissioned perform systematic review randomized controlled study (RCTs) clinical diagnosis treatment arboviral diseases. systematic review team analysed RCTs major database , database inception 30 guideline clinical management arboviral diseases: dengue, chikungunya, Zika ye",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "36e59c3e-2df0-457b-8df9-acbd964180b4",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "30 guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 18 April 2024 enrolled patient suspected confirmed diagnosis arboviral disease (chikungunya, dengue, yellow fever Zika) compared intervention aga inst placebo, standard care, alternative interventions. PICOs RCTs identified specifically addressed question patient Zika , chikungunya yellow fever . Studies patient dengue assessed indirect evidence arboviral diseases. Similarly , PICOs addressing fluid management patient severe disease, indirect evidence could obtained study patient sepsis (6). GDG considered indirectness evidence part GRADE evaluation. 3.2.2.2 Additional evidence synthesis De novo review undertaken required using pre -defined protocol search st",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9fb2dcee-218a-4e9b-898b-7468816617a1",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ynthesis De novo review undertaken required using pre -defined protocol search strategy. Evidence certainty assessed using GRADE methodology (38). 3.2.3 Values preference insufficient evidence -based descriptio n patient experience value preference regarding decision treatment based literature search. GDG, therefore, relied judgment well -informed patient would value balancing benefits, harms, burden treatment. Judgements value preference crucially informed experience former patient represented GDG. GDG agreed following value preference would typical well -informed patients: • “Most patient suffering non -severe disease, given good prognosis, would reluctant use intervention uncertain would receive n overall benefit.” • “Most patient suffering sev",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3450243e-3c65-4bad-8f12-72b651eac1a7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "uncertain would receive n overall benefit.” • “Most patient suffering severe disease, given poor prognos is, would wish use intervention even uncertain whether n overall benefit.” addition taking individual patient perspective, GDG also considered population perspective feasibility, acceptability, equit y, cost important considerations. Specific deliberation value preference associated feasibility resource - related consideration presented recommendation. 3.2.4 Priority outcome minimal important difference 3.2.4.1 Priority outcome GDG identif ied patient -important critical important outcome structured online survey asked assign relative important . pooled analysi mandatory survey presented panel highlighting frequently identified . discussion",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3bea2931-e857-4ed4-804c-556632e64f2a",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "rvey presented panel highlighting frequently identified . discussion de -emphasised proxy endpoint limited list eight Guideline development implementation 19 outcomes. GDG collectively agreed list endpoint presented evidence summary . Outcomes critical interest identified follows: • duration symptom • hospitalization • length hospital stay • mechanical ventilation • organ failure • major bleeding • severe adverse event • mortality. 3.2.4.2 Minimal important difference (MID) MID defined smallest difference outcome informed patient would perceive significant, whether beneficial harmful. intervention impact less MID would usually prompt use patient management (41). MIDs already frequent use clinical panel presented GDG ratification. case org",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6f18020c-104d-40bc-a9b6-8cbaee79642b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ent use clinical panel presented GDG ratification. case organ failure severe bleeding , previous explicit MID used. GDG polled using questionnaire assessed threshold importance. result presented GDG ratification. final MIDs agreed according Table 3.1. Table 3-1.Minimally important difference outcome interest Outcome MID Length hospital stay 1 day Hospitalization 15 per 1000 Duration symptom 1 day Mortality 3 per 1000 Mechanical ventilation 15 per 1000 Organ failure 15 per 1000 Severe adverse event 15 per 1000 3.2.5 Defining baseline risk provide absolute risk estimate benefit alternative interventions, guideline used harmonized baseline rate prioritized outcomes. evidence obtained study involving participant dengue, rate outcome lower c",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bbe4a64d-decd-4eb7-8fbd-efb29de7cde5",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "study involving participant dengue, rate outcome lower chikungunya Zika, similar higher yellow fever . However, following assumption many patient unknown aetiology time presentation, guideline us estimate dengue. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 20 extr act these, systematic review obtained estimate baseline absolute risk observational study “mortality ,” “bleeding” “hospitalization”. provided wide range estimates. focus single point, GDG panel surveyed usin g discrete choice bounded outer estimate observational study (Annex 2). Using survey, consensus absolute risk obtained agreed meeting, described Table 3.2. yellow fever specific PICOs, baseline risk primary evidence used. Table",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f7f518b3-b050-475f-ae68-27e281eaaa64",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "3.2. yellow fever specific PICOs, baseline risk primary evidence used. Table 3-2. Assum ed absolute risk prioritized outcome Outcome Non -severe disease (per 1000 patients) Severe disease (per 100 0 patients) Mortality 1 20 Bleeding 5 25 Admission hospital 50 N/A Organ failure N/A 50 N/A: applicable 3.2.6 GDG meeting: GRADE consideration evidence decision making recommendation GDG member (see authorship , contribution acknowledgement ) convened online meeting starting July 2023. July 2024, hybrid (face -to-face virtual) GDG meeting held , Geneva , Switzerland , review result systematic review conducted consultant review team formulate recommendation (Annex 3 ). meeting GRADE methodology used assess overall certainty evidence, w hich could higher lowest certainty rating outcome consi",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "376dae1a-1504-42b0-8abf-18bb4b41e5b8",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ty evidence, w hich could higher lowest certainty rating outcome considered critical informing recommendation. Standard approach lowering raising level certainty confidence used, including risk bias, inconsistency, indirectness, imprecision, publication bias, confounding bias, dose response large effect (42). GRADE methodologist present July 2024 meeting advise GDG member adher ence methodology. GDG decided priori consider cost determining strength direction recommendation , since cost -effectiveness analysis performed. Nonetheless, cost intervention resource required application guideline discussed GDG member , feasibility important component evidence -to- decision framework. Guideline development implementation 21 GDG noted intervention evide",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "271b51b8-1706-4669-a78c-312f02d4455c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Guideline development implementation 21 GDG noted intervention evidence originates research patient dengue, making evidence largely indirect chikungunya, Zika yellow fever. Furthermore, PICOs regarding fluid administration, eligi ble study identified patient arboviral infections, evidence studie patient sepsis considered , also indirect. 3.2.7 GDG decision -making making recommendations, GDG considered magnitude benefit harms, certainty evidence (very low , low, moderate high) supporting estimate magnitude benefit harm belief regarding value preference stakeholder (in particular, patient arboviral disease s). Interpretations strong conditional recommendation perspective patients, clinician policymakers appear Table 3.3. guid",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7101e687-9b7d-4374-8653-7936deaf70a4",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "perspective patients, clinician policymakers appear Table 3.3. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 22 Table 3-3. Implications strong conditional recommendation different user guideline Implications for… Strong recommendation “WHO recommends …” Conditional recommendation “WHO suggests …” Patients individual situation would want recommended course action; small proportion would not. Formal decision aide likely needed help individual make decision consistent value preferences. ind ividuals situation would want suggested course action, many would not. Clinicians individual receive intervention. Adherence recommendation could used quality criterion performance indicator. Differen choice appropriate individu",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3afe483b-fbf9-4da5-9688-047796dac8e6",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "quality criterion performance indicator. Differen choice appropriate individual patients, require assistance arriving management decision consistent value preferences. Decision aide may useful helping individual make decision consistent th eir value preferences. Policymakers recommendation adopted policy situations. Policymaking require substantial debate involvement various stakeholders. detail information, please refer Handbook guideline development (38). Deliberations direction strength recommendation facilitated methodologist clinical chairs. priori voting rule (of 70% consensus) informed procedure GDG failed reach consensus discussion, chair absented voting. following factor informed formulation recommendations: • absolute benefit har",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1fe84462-cc73-4b44-88cd-b755c69919b2",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "following factor informed formulation recommendations: • absolute benefit harm patient -important outcome structured evidence summary ( e.g., GRADE summary finding table including effect estimate confidence interval narrative summaries) • certainty evidence • value preference patient • resource consideration (including consideration feasibility, applicability, equity). Guideline development implementation 23 Consistent recent advic e guideline panels, GDG attempted make recommendation even limited evidence face considerable uncertainty. Whenever possible, GDG used research evidence inform discussion around key factors. absenc e evidence, discussion factor informed expert opinion GDG members. Discussions rationale, feasibility accessibility, equity implication (if",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bb2db0b6-db39-4f37-bd39-7b015c574a3b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "f GDG members. Discussions rationale, feasibility accessibility, equity implication (if any) implementation consideration also documented. Equity implication included qualitative discussion feasibility implication recommendation favour intervention constrained health care system context health care need (such supportive care) population interest. derive empirical evidence likely impact, principle human right maximising public health impact . recommendation made consensus . Polling used trigger guide ongoing debate used decide recommendation. 3.2.8 Peer review approval guideline external review group reviewed final guideline document identify, correct clarify errors, contextual issues, implication implementation. guideline reviewed approved WH",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dc70934e-c01b-417e-bd0b-f2fe2120733d",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ues, implication implementation. guideline reviewed approved Guideline Review Committee. 3.3 Managing declaration interest technical unit collected managed written statement declaration interest (DOI) (Annex 1 ). DOI form reviewed Secretariat. Consultation Quality Norms Standards team Ethics team obtained, necessary. Conflicts interest declared three pane l member related institutional research funding deemed ground panel ineligibility. start meeting, Secretariat described DOI process GDG member asked verbally update DOI; verbal conflict declared. Web search identify additional interest would likely affect members' independence. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 24 4 Recommend",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7d6df952-8b73-48dc-8b59-63610419c29e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "nical management arboviral diseases: dengue, chikungunya, Zika yellow fever 24 4 Recommendations patient non - severe, suspected confirmed, arboviral disease many settings, patient symptom common co-circulating arbovir al disease present clinician often access reliable diagnostic test , including conducted point care , differentiate them. Thus, despite differ ences pathophysiology arboviral infection diseases, clinician often managing patient without certainty aetiology . (43,44). intervention thus need considered term benefit harm across arboviral disease included differential diagnosis. 4.1 Oral rehydration Conditional recommendation suggests use protocoli zed oral fluid treatment compared non - protocoli zed oral fluid treatment patient suspected confirmed non",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6ab82562-1ec6-4973-8f2e-d7ac91d3f2c4",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "compared non - protocoli zed oral fluid treatment patient suspected confirmed non - severe arboviral disease. [Conditional recommendation, low certainty evidence ]. • Monitoring hydration , prevention dehydration , performed patients. C linician provide cup mean measuring oral intake give advice record amount taken . • Volumes fluid admi nistered depend age (children v adults) underlying medical condition (e.g. congestive heart failure, chronic kidney disease). 4.1.1 Evidence decision Benefits harm Benefits : patient non -severe disease, documenting use protocoli zed oral liquid intake may reduce hospital admission (22 fewer hospital admission per 1000 , 95% confidence interval ( CI) 38 fewer 15 more). Harms : Specific group known intolerance fluid (for example chronic kidney disease chronic cardiac di",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8d00e4fa-72fa-4d7a-8c59-4317fa037d35",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "th known intolerance fluid (for example chronic kidney disease chronic cardiac disease) may risk harm fluid. Recommendations patient non -severe, suspected confirmed, arboviral disease 25 Certainty evidence Research evidence limited dengue. evidence indirectly applied arboviral infections. single RCT involved patient population inferred non -severe. population included 53.8% confirmed dengue cases, 11.2% probable dengue fever cases, 24.3% case febrile illness 10.5% undetermined cases. evidence non -dengue arbovirus infection indirect. Values preference overall summary expected value preference given section 3.2.3. Given possib le benefit minimal harm associated intervention ost patient , GDG felt patient non -severe disease would choose use protocolized oral fl",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "df2bf5b3-3f8b-484a-8a54-7b6d54cbb4f4",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "GDG felt patient non -severe disease would choose use protocolized oral fluid treatment . Resources consideration Equity: simplicity intervention likely promote accessible equitability. Acceptability: intervention simple non -invasive, therefore likely acceptable. Feasibility: potential positive impact intervention early treatment pathway felt high. GDG con curred intervention would expected similar benefit pregnan woman child recommendation apply groups. 4.1.2 Justification Durin g dengue, chikungunya, Zika outbreak s, patient population important high proportion individual presenting non -severe disease. substantial public health implications, especially hospital service may overwhelmed. recommendation applies patient n",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0a339a98-ccb5-4f68-814e-f4278679e23d",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "pecially hospital service may overwhelmed. recommendation applies patient require intravenous fluid resuscitation shock dehydration treatment. GDG concluded balance benefit harm would favour intervention, risk -hydration oral fluid would low, monitoring intake would enable careful fluid balance, patient would typically take less fluid would optimal using protoco lized oral fluid treatment. type fluid specified RCT contributing data -to-evidence summary. mean 24 -hour fluid intake 2500 l control group 3,000 l intervention group. intervention control group told optimize hydration (take five cups). intervention provided, additionally: guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 26 • mean measuring volume",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "088adb0c-197b-4b35-b5e0-e2249f6d736d",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "boviral diseases: dengue, chikungunya, Zika yellow fever 26 • mean measuring volume administering fluid (a 200 l cup). • Advice recording volume administered. Although data predominantly patient dengue , GDG noted early disease, differentiation would difficult impossible concluded risk: benefit consideration would apply similarly arboviral infections. 4.1.3 Practical info rmation • oral hydrat ion possible, preferred infusion intravenous fluid (45). oral fluid prescribed, must taken sufficient amount address fluid deficit ongoing need . (See Table 4.1 summary findings.) • replace fluid loss fever vomiting, encourage frequent small amount oral fluids, especially experi encing nausea anorexia. • Record review oral fluid intake daily ambulatory setting. Provide cup othe",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3f8960a5-8436-412e-94c4-617890a27bbf",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "exia. • Record review oral fluid intake daily ambulatory setting. Provide cup mean measuring volume ensure accurate fluid intake. Advise patient caregiver record volume fluid administered noting amount given time totalling end day. Review record daily ensure adequate hydration . • Adequate oral fluid intake result urination least four six time per day. Patients aim threshold monitor urination frequency. notice significant deviation pattern, promptly contact health care provider guidance. • Water alwa y main source fluids. Choose fluid based availability ensure come safe source drinking water. information fluid selection, please refer guideline (46). • Using standardised oral rehydration solution practical way ensu",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9b6725bb-0a48-416c-a26d-7bb83838cf61",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ther guideline (46). • Using standardised oral rehydration solution practical way ensuring appropriate electrolyte replacement. absence ORS, fluid locally available may used addition water, including soup s, unsweetened fluid juice, coconut water, yogurt drinks, water used cooking rice grains. • Avoid commercial carbonated drink exceed isotonic level (5% sugar) may exacerbate hyperglycaemia related physiological stress fro dengue diabetes mellitus. Examples include commercial carbonated beverages, commercial fruit juice sweetened tea (5,45). • detailed information fluid therapy, please refer guideline (45). Recommendations patient non -severe, suspected confirmed, arboviral disease 27 Table 4-1. Summary finding protocoli zed oral fluid treatment compared non - protocoli zed oral fluid treatment patient non - severe",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "27fe72ba-ad91-48e9-a920-9c253b9eabf7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "fluid treatment compared non - protocoli zed oral fluid treatment patient non - severe arboviral disease Clinical question/ PICO • Population: patient require intravenous resuscitation • Intervention: protocoli zed oral hydration • Comparator: non-Protocoli zed oral hydration Outcome Study result measurement Absolute effect estimate Certainty evidence Summary Non - Protocoli zed oral hydration Protocoli zed oral hydration Hospital admission Relative risk: 0.55 (CI 95% 0.23 -1.3) Based data 143 participant 1 study patient dengue Follow -up 60 day 50 per 1000 28 per 1000 Low Due serious risk bias, due serious imprecision1 Protocoli zed oral hydration may reduce hospital admission Difference: 22 fewer per 1000 (CI 95% 38 fewer - 15 more) 1. Risk bias: serious . Inadequate/lack blinding participant personnel, resulting potential performance bias",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3f9f2b57-0080-4293-a6a1-6f866157b633",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "dequate/lack blinding participant personnel, resulting potential performance bias ; inadequate/lack blinding outcome assessors, resulting potential detection bias; imprecision: serious : 95% CI includi ng harm guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 28 4.2 Symptom control Pain fever common symptom across four arboviral infections. Effective management symptom important ensuring patient wellbeing/comfort . 4.2.1 Paracetamol /acetaminophen Conditional recommendation suggests use paracetamol (acetaminophen) treatment pain and/or fever patient suspected confirmed non -severe arboviral disease. [Conditional recommendation, low -certainty evidence ] • recommendation apply yellow fever • Use paracetamol (acetaminophen) caution patient pre -existing newly developin",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e3400a87-6a52-4209-983a-24bb1864ba86",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "• Use paracetamol (acetaminophen) caution patient pre -existing newly developing liver disease transaminitis . 4.2.1.1 Evidence decision Benefits harm Benefits : absolute benefit paracetamol assess ed; panel examined comparative data alternative therapies. Paracetamol (acetaminophen) probably little impact length hospital stay (0.1 fewer day length stay, 95% CI 1.11 fewer day 0.91 days). may less efficacious fever reduction NSAIDs indirect population (children undifferentiated fe ver), low -certainty evidence. Harms : patient non -severe disease, uncertain whether paracetamol (acetaminophen) increase decrease severe bleeding acute kidney injury. low certainty e vidence liver failure inferred elevated liver enzyme resulting paracetamol (192 case standard care, 95% CI 4 716 mo",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "06470ec9-ada1-45d8-80d8-cb6e9bf27cec",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ver enzyme resulting paracetamol (192 case standard care, 95% CI 4 716 more) , possibly little impact duration illness (0.2 day duration illness, 95% CI 0.2 fewer 0.6 more). Certainty evidence Research evidence limited dengue. evidence indirectly applied arboviral infections. single RCT assessed length hospital stay 123 dengue patient (moderate certainty, graded serious imprecision ). Based data 587 participant 5 studies, paracetamol (acetaminophen) may less efficacious reducing fever NSAIDs (low certainty due imprecision indirectness applying evidence child younger 2 year old fever various causes). Recommendations patient non -severe, suspected confirmed, arboviral disease 29 single small study 89 subject provided low certainty adverse event related paracetamol -",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "32b788b1-fea8-44f3-a777-a573af60a1dd",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "mall study 89 subject provided low certainty adverse event related paracetamol - (acetaminophen ) related severe bleeding acute kidney injury . RCT evidence 88 participant one study provided low c ertainty evidence paracetamol (acetaminophen) might elevate liver enzyme compared standard care (RR 2.92, 95% CI 1.04 -8.16 , serious imprecision, serious indirectness ). Evidence one RCT (n=123) follow -up period seven day suggested probably little impact paracetamol duration symptom (moderate certainty due serious imprecision ). Values preference overall summary expected value preference given section 3.2.3 . GDG considered patient would choose use medication pain fever. Given alternatives, patient might choose paracetamol treatment due accessib ility . Resources consideration Equity accepta",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1cd29525-5c1b-4a07-9a19-96a8436edb79",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "treatment due accessib ility . Resources consideration Equity acceptability: equity, availability cost issue identified, paracetamol (acetaminophen) widely available low cost. Feasibility: Paracetamo l (acetaminophen) included Essential Medicines List (47). 4.2.1.2 Justification overall body evidence paracetamol (acetaminophen) considered moderate low certainty, primarily due imprecision indirectness. panel considered paracetamol might increase risk severe bleeding acute kidney injury given recommend ed doses, although may elevate liver enzymes. Mild rise liver function test dengue may indicate significant liver injury, holistic assessment guide choice analgesia. GDG inferred paracetamol (acetaminophen) f ew safety concern used symptomatic control pain fever. pan",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5f9f1331-e93a-459a-9e4b-98487f269886",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "inophen) f ew safety concern used symptomatic control pain fever. panel noted point presentation, might impossible distinguish dengue arbovir al disease potential harm related platelet inhibition caused NSAIDs made paracetamol (acetaminophen) safer alternative , despite low certainty evidence might less effective . guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 30 4.2.1.3 Practical info Mechanism action Understanding mechanism action paracetamol (acetaminophen ) remains incomplete appears derived mostly action central nervous system. Hypotheses include: 1) inhibition cyclooxygenase (COX) enzyme analgesic antipyretic ef fects similar nonsteroidal anti -inflammatory drug (without anti -inflammatory anti -coagulat ion effec",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f8935d3b-4cf6-491b-8f84-ba78b5bc000b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "nonsteroidal anti -inflammatory drug (without anti -inflammatory anti -coagulat ion effects); 2) inhibition L -arginine -nitric oxide pathway reinforcement descending inhibitory serotonergic pain pathways; 3) effe ct cannabinoid receptor active metabolites. Potential indication contraindication arboviral infection Pain fever. Route, dosage, duration Paracetamol (acetaminophen) given orally dose, based age body weight, Table 4.2. available tablet 500 mg oral powder reconstitution oral suspension. Indirect evidence multiple systematic review show effective pain (except chronic lower back pain) , adverse event significantly higher placebo (48). Table 4-2. Dosing Paracetamol (acetaminophen) treatment Age Body weight Dose duration non/severe, suspected confirmed, arboviral disease Adults >",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b137516d-a20d-4767-a397-8dc0a3196cab",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "dy weight Dose duration non/severe, suspected confirmed, arboviral disease Adults > 50 kg 500 mg – 1 g every 4 -6 hour (maximum daily dose: 4 g) Paediatrics 10-15mg/kg every 4-6 hour (maximum daily dose: 60 mg/kg) repeat dose frequently every 4 hour . Maximum daily dose avoid hepatic toxicity based route administration product containing paracetamol (acetaminophen ) (49). Dose adjustment Renal impairment: recommended giving paracetamol patient renal impairment, reduce dose increase minimum interval administration least 6 hour unless directed otherwise physician (49), Table 4.3. Recommendations patient non -severe, suspected confirmed, ar boviral disease 31 Table 4-3. Dosing Paracetamol patient renal impairment Glomerular filtration rate Dose 10-50 ml/min 500 mg every 6 hour <10 ml",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b4feffbf-6b87-4770-987a-b155cf9ed071",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "th renal impairment Glomerular filtration rate Dose 10-50 ml/min 500 mg every 6 hour <10 ml/min 500 mg every 8 hour Hepatic impairment: Reduce dose prolong dosing interval patient hepatic impairment Gilbert's Syndrome ; daily dose exceed 2g/day unless directed physician (49). dos repeated frequently every four six hour four dos given 24 -hour period. consideration Children: Children given paracetamol (acetaminophen) three day without consulting doctor (49). Pregnancy: large amount data pregnant woman indicate neither malformative r foetal /neonatal toxicity. Epidemiological study neurodevelopment child exposed paracetamol utero show inconclusive results. clinically needed, use paracetamol pregnancy lowest effective dose, shortest possible time",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "94cff21e-4754-424b-9c23-cb92c66e1ee0",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "paracetamol pregnancy lowest effective dose, shortest possible time lowest possible frequency. Breastfeeding: Following oral administration, small amount paracetamol excreted breast milk . However , clinically significant. date, known undesirable effect side effect breast -feeding. Paracetamol administered lactation therapeutic doses. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 32 Table 4-4. Summary finding use paracetamol (acetaminophen) treatment pain and/or fever patient suspected confirmed non -severe arboviral disease Clinical question/ PICO • Population: patient su spected confirmed dengue fever • Intervention: paracetamol (acetaminophen) • Comparator: standard care Outcome timeframe Study result measurement Absolute effect",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "07447870-ec11-4b3b-a4dc-3785af7ed845",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "mparator: standard care Outcome timeframe Study result measurement Absolute effect estimate Certainty evidence Summary SOC Paracetamol Duration symptom Measured by: day scale: - lower better Based data 123 participant 1 study Follow 7 day 4.8 Mean 5 Mean Moderate Due serious imprecision1 Paracetamol (acetaminophen) probably little impact duration illness Difference: MD 0.2 (CI 95% 0.2 fewer - 0.6 more) Length hospital stay Measured by: day scale: - lower better Based data 123 participant 1 study Follow -up 7 day 3.9 Mean 3.8 Mean Moderate Due serious imprecision2 Paracetamol (acetaminophen) probably little impact length hospital stay Difference: MD 0.1 fewer (CI 95% 1.11 fewer - 0.91 more) Reduction fever , inferred comparison NSAID fever cause young child Relative risk: 0.54 (CI",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0431b654-0489-4176-8eaa-df2f510937a3",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "comparison NSAID fever cause young child Relative risk: 0.54 (CI 95% 0.29 – 0.99) Based data 587 participant 5 study 536 per 1000 NSAIDs 289 per 1000 paracetamol Low Due concern imprecision indirectness3 Paracetamol (acetaminophen) may less efficacious reducing fever NSAIDs Difference: 247 fewer per 1000 (CI 95% 381 fewer – 5 fewer) Severe bleeding Relative risk: 4.18 (CI 95% 0.21 – 84.5) Based data 89 participant 1 study Follow -up 7 day 5 per 1000 21 per 1000 low Due extremely serious imprecision4 uncertain whether paracetamol (acetaminophen) increase decrease severe bleeding Difference: 16 per 1000 (CI 95% 15 fewer - 98 more) Acute kidney injury Relative risk: 2.51 (CI 95% 0.1 – 59.8) Based data 89 participant 1 study Follow -up 7 day 12 per 1000 30 per 1000 low Due extrem",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4799815a-daf0-42d5-a44b-ec26516bf5d2",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "participant 1 study Follow -up 7 day 12 per 1000 30 per 1000 low Due extremely serious imprecision5 uncertain whether paracetamol (acetaminophen) increase de crease acute kidney injury Difference: 18 per 1000 (CI 95% 19 fewer - 61 more) Liver failure inferred elevated liver enzyme (RCT) Relative risk: 2.92 (CI 95% 1.04 – 8.16) Based data 88 participant 1 study Follow 7 day 100 per 1000 292 per 1000 Low Due serious imprecision serious indirectness6 Paracetamol (acetaminophen) may increase elevated liver enzyme Difference: 192 per 1000 (CI 95% 4 - 716 more) 1. Imprecision: serious. 123 patient 2. Imprecision: serious. 123 patient 3. Indirectness: serious. Different population (young child fever causes); imprecision: serious. 95% CI including absence important differences. 4. Imprecision: extremely serious. 2 event ove",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d6acaa37-b631-4909-b3a5-5570adc8800a",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "CI including absence important differences. 4. Imprecision: extremely serious. 2 event overall 5. Imprecision: extremely serious. 1 event overall 6. Imprecision: serious. Optimal information size met, 18 event overall Recommendations patient non -severe, suspected confirmed, arboviral disease 33 4.2.2 Metamizole /dipyrone Conditional recommendation suggests use metamizole (dipyrone) treatment pain and/or fever patient suspected confirmed non -severe arboviral disease. [ Conditional recommendation, low certainty evidence ] • Metamizole limited geographic availability regulatory approval . 4.2.2.1 Evidence decision Benefits harm Benefits: Metamizole (dipyrone) cause similar fever reduction NSAIDs (moderate certainty due indirectness patient population ); child undifferentiated fever effect 0.03°C lower temperature, 95% CI 0.2",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d5c5b9b0-f659-4c04-94d5-5024dfd6530f",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ion ); child undifferentiated fever effect 0.03°C lower temperature, 95% CI 0.29°C lower 0.24°C higher. uncertain whether metamizole (dipyrone) improves symptom control ; 52 patient improved intervention, 95% CI 151 fewer 335 more. Harms: Metamizole (dipyrone) probably little impact aplastic aemia (1/1,000,000 fewer cases, 95% CI 3 fewer 23 , low certainty ) compared baseline estimate 3 per million case aplastic aemia ( 0.5 per million agranulocytosis) . data derive review available evidence effect largest published multicentre study three Latin American country , researcher initially conducted broad active search case April 2002 -April 2003 determine background population incidence agranulocytosis aplastic anaemia, multicentre case -control study defined research sited identify incident case",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8af6a1ea-bb1e-400c-9cc4-ffc032e304e9",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "multicentre case -control study defined research sited identify incident case risk factor development (50,51). patient non -severe, suspected confirmed arboviral disease , uncertain whether metamizole (dipyrone) increase severe bleeding (3 severe bleeding cases, 95% CI 3 fewer 23 more). Certainty evidence Research evidence limited dengue. evidence indirectly applied arboviral infections. certainty evidence impr ovement symptom control also rated low, supported one observational study serious risk bias serious imprecision. However, certainty evidence improvement fever rated moderate. rating supported hree RCTs identified indirect evidence, based comparison use NSAIDs young child fever cause, imprecision. guideline clinical management ar",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "99862736-c8a4-458a-9d02-2f230d29802c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "g child fever cause, imprecision. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 34 systematic review rate bone marrow suppression performed , GDG noted multiple different estimate exist. GDG considered one large observational study, certainty evidence agranulocytosis rated low due risk bias indirect evidence patient without arboviral disease . However, high certainty low baseline risk. Based three non -RCTs involving 1568 participants, certainty evidence severe bleeding rated low. downgra de due inappropriate adjustment potential confounders, resulting serious risk bias serious imprecision. GDG concluded metamizole (dipyrone) might associated major complication agranulocytosis evere bleeding. evidence",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a0315957-eb73-40ee-b56b-a69eaea223cf",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "associated major complication agranulocytosis evere bleeding. evidence suggested effect fever comparable NSAIDs. Values preference Applying agreed upon value preference (see 3.2.3) patient non -severe disease, GDG inferred patient would use metamizole good evidence symptomatic benefit. Resources consideration Metamizole (dipyrone) included Essential Medicines List (47). Metamizole limited geographic availability licencing. Concerns safety etamizole (dipyrone) , particularly respect inducing agranulocytosis, prompted market withdrawal several country past four decade including United Kingdom Great Britain Northern Ireland, Canada, United States, Finland, Denmark , Sweden , recently, India . Metamizole remains readily available Spain, Russia, Israel,",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "113d6560-a948-4ff7-89c8-51edd4b3f484",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "den , recently, India . Metamizole remains readily available Spain, Russia, Israel, many cou ntries Latin America ; Germany access medication restricted -the-counter requiring medical prescription . Primary research study meta - analysis yielded wide range estimate ncidence metamizole induced agranulocytosis , 1.5-40 time common used v , author concluded meaningful difference overall rate adverse event compared ther widely used analgesic (52,53). 4.2.2.2 Justification Research evidence derived study addressing patient dengue . GDG feel indirectnes significant enough rate down. panel noted metamizole (dipyrone) may increase risk severe bleeding agranulocytosis . aplastic anaemia, baseline risk estimate derived observational study",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b00eba77-b321-4fe4-8407-fd4b4547041b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "tosis . aplastic anaemia, baseline risk estimate derived observational study Latin America (where metamizole widely used) found 3 Recommendations patient non -severe, suspected confirmed, arboviral disease 35 case per 1 million (50). panel recognised different regulatory approach metamizole, above. inferred effect fever similar NSAIDs patient non -severe arboviral disease. Therefore, panel considered metamizole (dipyrone) alternative paracetamol country approved symptomatic control pa fever patient non -severe, suspected confirmed arboviral disease. 4.2.2.3 Practical info Mechanism action Metamizole (dipyrone ) classified atypical non -steroidal anti -inflammatory drug used n antipyretic analgesic. h lower anti -inflammatory anti -thrombotic activity conventional non",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f62c1f5e-5908-4e93-9b4f-a21004866dae",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "nd analgesic. h lower anti -inflammatory anti -thrombotic activity conventional non -steroidal anti -inflammatory drugs. Research suggests metamizole (dipyrone) inhibits COX -3 higher affinity compared COX -1 COX -2. Special consideration adverse event related metamizole (dipyrone) Health care provider inform patient benefit potential side effects, agranulocytosis, clinical decision -making process help make informed choice regardi ng treatment plan. choice medication depends local epidemiology resources, including availability monitoring facilities. Route, dosage, duration Metamizole (dipyrone) given orally dose based age body weight, Table 4.5. available tablet 500 mg oral powder reconstitution oral suspension. route administration available. Table 4-5. Dosing",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "10018ea6-064f-4805-8a1e-5600634aad53",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "titution oral suspension. route administration available. Table 4-5. Dosing metamizole treatment Age category Body weight Single dose Daily maximum dose kg tablet mg tablet mg Adults adolescent (≥ 15 years) > 53 1–2 500 –1000 8 4000 Children adolescent (up 14 year old) 10 mg/kg ½–1 250 –500 4 2000 Administer treatment early possible (50,54). guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 36 Dose adjustment Renal hepatic impairment: Avoid multiple high dos renal hepatic function impaired, elimination rate reduced. date, insufficient experience long -term use metamizole (dipyrone) patient severe hepatic renal impairment. consideration Children: child adolescent 14 year age 8 –16 mg metamizole (dipyrone) per kg body weight given",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "884d17e9-d587-43a0-9eec-c83af3ba440e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "lescents 14 year age 8 –16 mg metamizole (dipyrone) per kg body weight given single dose. dose 10 mg /kg body weight suggested fever. single dose taken 4 time daily interval 6 –8 hours. Age - appropriate formulation (oral drops, solution injection) available. Pregnancy: Although data limited, evidence show teratogenic embryotoxic effect metamizole (dipyrone) used first trimester. However, evidence indicates fetotoxi city , foetal renal impairment ductus arteriosus constriction, used third trimester. Therefore, European Medicines Agency (EMA) considers metamizole contraindicated third trimester (55,56). Breastfeeding: Avoid using metamizole breastfeeding relative infant dose may high , overall evidence scarce. Use b etter investigated characterized analgesic advised (56). Recommendati",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "22d8f8ea-1b21-4f05-aa79-b6f840919211",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "scarce. Use b etter investigated characterized analgesic advised (56). Recommendations patient non -severe, suspected confi rmed, arboviral disease 37 Table 4-6. Summary finding use metamizole (dipyrone) treatment pain and/or fever patient suspected confirmed non -severe arboviral disease Clinical question/ PICO • Population: patient suspected confirmed dengue fever • Intervention: metamizole (Dipyrone) • Comparator: standard care Outcome timeframe Study result measurement Absolute effect estimate Certainty evidence Summary SOC Metamizole (dipyrone) Improvement symptom control Relative risk: 1.08 (CI 95% 0.77 – 1.51) Based data 110 participant 1 non -RCT 656 per 1000 708 per 1000 low Due serious risk bias, due serious imprecision1 uncertain whether metamizole (dipyrone) improves symptom control Differe",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9e981d76-9f5c-49f9-af57-823a3c068b0e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "u imprecision1 uncertain whether metamizole (dipyrone) improves symptom control Difference: 52 per 1000 (CI 95% 151 fewer - 335 more) Reduction fever inferred comparison NSAID fever cause young child Measured by: °C Lower better Based data 547 participant 3 RCTs 37°C Mean NSAID arm 37°C Mean dipyrone arm Moderate Due concern imprecision indirectness2 probably little difference fever reduction metamizole (dipyrone) compared NSAID treatment . Difference: MD 0.03 °C lower (CI 95% 0.29 °C lower 0.24 °C higher) Severe bleeding Relative risk: 1.61 (CI 95% 0.46 - 5.59) Based data 1568 participant 3 non-RCTs Follow 4.5 day 5 per 1000 8 per 1000 low Due serious risk bias, due serious imprecision3 uncertain whether metamizole (dipyrone ) increase severe bleeding Difference: 3 per",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "29a599c7-a289-438c-8dbe-1b4f26d89e9b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "uncertain whether metamizole (dipyrone ) increase severe bleeding Difference: 3 per 1000 (CI 95% 3 fewer - 23 more) Aplastic anaemia Relative risk: 0.8 (CI 95% 0.54 – 1.14) Based data 1568 participant without arbovir u disease 1 observational study 3 per 1 million 2 per 1 million Low Due concern indirectness risk bias, upgraded due high certainty low baseline risk4 Metamizole (dipyrone ) probably little impact aplastic anaemia. Difference: 1 fewer per 1 million (CI 95% 2 fewer - 1 more) 1. Risk bias: serious: non -RCT inappropriate adjustment potential confounders; imprecision: serious: 95% CI including important benefit harm 2. Indirectness: serious: different population (Young child fever cause); imprecision: serious: OIS met. 3. Risk bias: serious: non -RCT inappropriate adjustment potential confounders;",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bda77ba5-7436-4376-8827-2343c89d0634",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": ". 3. Risk bias: serious: non -RCT inappropriate adjustment potential confounders; imprecision: serious; 95% CI including important harm 4. Risk bias: non -RCT; indirectness: Patients without arboviral disease; large magnitude effect: high certainty low baseline risk guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 38 4.2.3 Non -steroidal anti -inflammatory drug (NSAIDs ) Strong recommendation recommends use non -steroidal anti -inflammatory medication (NSAIDs) patient acute suspected confirmed arboviral disease, irrespective severity . [Strong recommendation, low certainty evidence ] • patient established NSAID therapy (for example ischaemic heart disease inflammatory arthropathies), decision continue made according anticipated risk /benefit balance . • recommendation apply",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "02738df1-5127-4fae-9811-7a01013623d5",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "uld made according anticipated risk /benefit balance . • recommendation apply confirmed chikungunya confirmed Zika NSAID treatment may considered arthralgia inflammation. 4.2.3.1 Evidence decision Benefits harm Benefits: NSAIDs probably improve fever compared standard care (0.45°C lower temperature, 95% CI 1°C lower 0.11°C , moderate certainty ). Harms: Whether NSAIDs treatment increase severe bleeding patient non -severe arbovirus disease uncertain (1 case per 1000 patient , 95% CI 1 fewer 3 , low certainty ). uncertain whether NSAIDs increase blood p roduct requirement (2 more, 95% CI 2 fewer 12 , low certainty ). Certainty evidence Research evidence limited dengue. evidence indirectly applied arboviral infections. moderate certainty evidence fever improvement (0.45°C fewer temperature",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0bebbf17-e7ad-49cc-b92d-ffb0c3b4093a",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ons. moderate certainty evidence fever improvement (0.45°C fewer temperature standard care) based two study 287 patient respiratory viral infections, consideration indirect evidence (as study involve patient arbovirus disease) imprecision. Four non -RCTs involving patient arbovirus disease identified. Additionally, three RCTs 34 participant one non -RCT 2285 participant provided indirect evidence based bleeding haemophilic patients. several source bias studies, including indirect ness (the RCTs involve patient arbovirus disease) lack adjustment confounding variable non -RCTs. Recommendations patient non -severe, suspected confirmed, arboviral disease 39 single non -RCT 642 participant evaluated blood product requirement. certainty evidence rated low (observati",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e1934007-2cf6-4ab9-ad14-8c1d43459072",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "evaluated blood product requirement. certainty evidence rated low (observational data) low due inappropriate adjustment potential confounder s. Values preference Applying agreed -upon value preference (see 3.2.3), patient non -severe disease, GDG inferred patient suffering non -severe disease, given good prognosis, would reluctant use NSAIDs concern harm alternative treatment option . GDG considered patient would choose avoid NSAID treatment precaution potential risk related bleeding although low uncertain frequency , could severe occur . Resources consideration None noted . 4.2.3.2 Justification GDG panel decided despite low certainty evidence, strong concern around possibility NSAIDs, anti -platele",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b5c40ac4-1c0a-40d9-ae5c-e4847e42aa06",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "idence, strong concern around possibility NSAIDs, anti -platelet action, could contribute mortality dengue resulting severe bleeding. panel reasoned many circumstance acute presentation, differentiation causative aetiology would possible. time prescription, therefore, unless dengue could ruled out, would safer alternative available (paracetamol metamizole) . Despite low certainty evidence, panel issued strong recommendation basis similar benefit fewer risk according rationale outlined GRADE framework (38,57). patient already taking non -steroidal anti -inflammator medication anti - platelet effect - example , receiving aspirin coronary heart disease - GDG noted risk benefit would need assessed individu al basis. panel acknowledged w aeti",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4fd98488-d425-46c1-a702-cdc2417dfb8a",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "would need assessed individu al basis. panel acknowledged w aetiology known , clinician might use NSAIDs, example inflammatory arthralgia arthritis caused chikungunya . guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 40 4.2.3.3 Practical information Mechanism action NSAIDs include drug like aspirin, ibuprofen, ketorolac, indomethacin, naproxen, others, influence enzyme cyclo -oxygenase (COX) responsible produc ing prostaglandins. least two isoforms COX enzyme exist, coded separate genes. Th e constitutive isoform (COX -1) multiple actions, including , example , production prostacyclin , cytoprotective effect gastric mucosa. inducible isoform (COX -2) upregulated produced response inflammatory stim uli cytokine migratory cells. Effect platelets:",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "10ac0043-1773-4273-b817-56cb51ab4cbc",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "esponse inflammatory stim uli cytokine migratory cells. Effect platelets: Aspirin NSAIDs inhibit platelet activation, aggregation, secretion reducing production thromboxane A2 (TxA2). Recommendations patient non -severe, suspected confirmed, arboviral disease 41 Table 4-7. Summary finding use non -steroidal anti -inflammatory medication (NSAIDs) patient acute suspected confirmed arboviral disease, irrespective severity Clinical question/ PICO • Population: patient suspected confirmed dengue fever • Intervention: non -steroidal anti -inflammatory drug • Comparator: standard care Outcome Timeframe Study result measurement Absolute effect estimate Certainty Evidence Summary SOC NSAIDs Fever reduction Measured by: °C Scale: Lower better Based data 287 participant 2 stud y 37.5°C Mean 37°C Mean Moderate",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "86477591-c2de-40b4-a173-05aaf7d0d013",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "better Based data 287 participant 2 stud y 37.5°C Mean 37°C Mean Moderate Due concern indirectness imprecision1 NSAIDs probably reduce fever compared standard care Difference: MD 0.45°C fewer (CI 95% 1°C less – 0.11°C more) Severe bleeding Relative risk: 1.14 (CI 95% 0.85 – 1.53) Based data 2247 participant 4 non-RCT Follow -up 3.5 day 5 per 1000 6 per 1000 low Due serious risk bias2 uncertain whether NSAIDs increase severe bleeding Difference: 1 per 1000 (CI 95% 1 fewer – 3 more) Blood product requirement Relative risk: 1.48 (CI 95% 0.65 – 3.38) Based data 642 participant 1 non-RCT 5 per 1000 7 per 1000 low Due serious risk bias, due serious imprecision3 uncertain whether NSAIDs increase blood product requirement Difference: 2 per 1000 (CI 95% 2 fewer – 12 more) Severe bleeding (indirect evidence",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "48e1ae11-4149-4055-8d45-31156b5df7b2",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Difference: 2 per 1000 (CI 95% 2 fewer – 12 more) Severe bleeding (indirect evidence bleeding haemophilic patients) RCTs4 Relative risk: 1 (CI 95% 0.02 – 47.7) Based data 34 participant 3 study Follow -up 12 16 week 5 per 1000 5 per 1000 low Due serious imprecision, due serious indirectness4 uncertain whether NSAIDs increase severe bleeding Difference: 0 fewer per 1000 (CI 95% 217 fewer – 217 more) Severe bleeding (indirect evidence bleeding haemophilic patients) non-RCT Hazard ratio: 0.8 (CI 95% 0.3 – 2.2) Based data 2285 participant 1 study Follow -up 17.4 month 5 per 1000 4 per 1000 low Due serious risk bias, Due serious indirectness5 uncertain whether NSAIDs increase severe bleeding Difference: 1 fewer per 1000 (CI 95% 3 fewer - 6 more) 1. Imprecision: 95% CI including temperature reduction ; indirectness: di",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9598ed09-dd17-424a-8103-93f87c6452f5",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "% 3 fewer - 6 more) 1. Imprecision: 95% CI including temperature reduction ; indirectness: different population (patients acute viral respiratory infection). 2. Risk bias: serious : non-RCT inappropriate adjustment potential confounders 3. Risk bias: serious : Non-RCT Inappropriate adjustment potential confounders; imprecision: serious : 95% CI including important harm 4. Imprecision: serious : 2 event 34 participants; indirectness: serious : subject without arbovir u disease 5. Risk bias: serious : non-RCT inappropriate adjustment potential confounders; imprecision: serious ; 95% CI includes important harms, 42 events; indirectness: serious ; different population (patients haemophilia ) guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 42 4.3 Corticosteroids (for non -severe arboviral disease) Conditional recommendation W",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e8a82b2b-7734-4a99-bd2f-69ae25be731f",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "42 4.3 Corticosteroids (for non -severe arboviral disease) Conditional recommendation suggests using corticosteroid treatment patient acute suspected confirmed non -severe arboviral disease. [Conditional recommendation, low certainty evidence] • patient established corticosteroid therapy, decision continue made according anticipated risk: benefit balance. 4.3.1 Evidence decision Benefits harm Benefits : low certainty evidence benefit corticosteroid non - severe arboviral disease (18 fewer hospital admissions, 95% CI 35 fewer 18 more) . Harms: Corticosteroids probably little impact gastrointestinal bleeding. uncertain cause severe bleeding . Certainty evidence single randomized trial assessed corticosteroid use 179 dengue outpatient , hospital admission could extracted systematic review pu",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6bf4b111-47d5-49fe-aa7a-dc53c16482de",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "dengue outpatient , hospital admission could extracted systematic review publication , low certainty evidence. Indirect data adverse event participant without arboviral disease provided data 245 participant two randomized controlled trial gastrointestinal bleeding, 33 253 participant 159 randomized controlled trial (moderate certaint effect) severe bleeding (very low certainty due serious imprecision) . median duration corticosteroid treatment 8.5 day (IQR 3.3 –28.0), appreciation short longer cour se steroid might different adverse event contributed low certainty rating. Values preference Applying agreed upon value preference (see 3.2.3), patient non -severe disease, GDG inferred patients, given good prognosis, would reluctant use corticosteroid uncertain wou",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5fd8932e-403e-47a0-bda9-cc67ed54c9a8",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "en good prognosis, would reluctant use corticosteroid uncertain would receive n overall benefit. Recommendations patient non -severe, suspected confirmed, arboviral disease 43 Resources consideration Corticosteroids widely available low cost worldwide, particular ly oral preparations. Multiple corticosteroid included Essential Medicines List (47), dexamethasone, hydrocortisone, prednisolone. 4.3.2 Justification Due low certainty evidence , acknowledging lack direct research finding inform , panel argu ed principle non -maleficence would justify recommendation use corticosteroids. Two panel member felt recommendation b e “strongly ,” specifically dengue based putative harm immunosuppression acute infectious disease ; conditional recommendation made",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "892bc96d-1280-43a5-a2ac-32f0fe8c9bdf",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "harm immunosuppression acute infectious disease ; conditional recommendation made consensus concern noted. patient already corticosteroid therapy time infection, individualized clinical determination risk benefit balance required . panel intended recommendation apply chikungunya, dengue, yellow fever Zika. GDG noted compared dengue, arbov iral infection (e.g. chikungunya yellow fever) may frequently associated complication uveitis, myocarditis, severe pruritus , use corticosteroid may indicated, although patient complication wou ld likely classified severe disease. 4.3.3 Practical info rmation Mechanism action Corticosteroids bind glucocorticoid receptor mediating change gene expression lead multiple downstream effect hour days. Non -genomic effect throu",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "71d5874a-1d71-4cec-b4d3-29b6dbdf34df",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "expression lead multiple downstream effect hour days. Non -genomic effect interaction intracellular glucocorticoid receptor membrane -bound glucocorticoid receptor result change shorter timeframes. Corticosteroids broad activity, including alteration immune cel l function reducing neutrophil apoptosis demargination; reduction arachidonic acid derivative inhibition phospholipase A2; inhibition transcription factor NF -κB AP-1, multiple subsequent change gene expre ssion; promotion anti - inflammatory gene interleukin -10. Lower dos corticosteroid tend anti -inflammatory effect, higher dos profoundly immunosuppressive, example inhibiting production B cell cell (58). short -term effect corticosteroid decreased vasodilation permeability capillaries, well decreased",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1fcd7a3a-c4ce-4354-8aff-be394a223f74",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "f corticosteroid decreased vasodilation permeability capillaries, well decreased leukocyte migration site inflammation. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 44 Corticosteroids also exhibit mineraloc orticoid activity, impacting water, salt, mineral homeostasis. Adverse event profile Adverse effect due corticosteroid dose duration dependent affect multiple body system . incidence severity adverse event also affected patient age, underlying medical condition (such diabetes mellitus) concomitant medication use. systematic review 22 RCTs child received ≤14 day systemic corticosteroid published 2016 described vomiting, behavioura l changes, sleep disturbance common adverse event reported , increased susceptibility infection serious (59). Although measured patien",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "96716250-f0d9-4c74-845a-bca4c25d98a8",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ncreased susceptibility infection serious (59). Although measured patients, 43 53 patient demonstrated hypothalamic -pituitary -adrenal axis suppression. adult treated ≤ 30 day corticosteroid , common adverse event noted large retrospective cohort sel f-controlled case series United States included sepsis, venous thromboembolism , fracture (60). Recommendations patient non -severe, suspected confirmed, arboviral disease 45 Table 4-8. Summary finding corticosteroid treatment compared corticosteroid treatment patient acute non -severe arboviral disease Clinical question/ PICO • Population: patient acute arboviral disease (non -severe) • Intervention: corticosteroid • Comparator: standard care Outcome timeframe Study result measurement Absolute effect estimate Certainty Evidence Summary SOC Steroids Hospital adm",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e4f5862c-9aac-4a73-9031-72401087b137",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ents Absolute effect estimate Certainty Evidence Summary SOC Steroids Hospital admission Relative risk: 0.63 (CI 95% 0.36 – 1.08) Based data 179 participant 1 RCT 50 per 1000 32 per 1000 low Due risk bias, due serious imprecision1 uncertain whether corti costeroids increase decrease hospitalization Difference: 18 fewer per 1000 (CI 95% 32 fewer - 4 more) Severe bleeding Relative risk: 1.13 (CI 95% 0.07 – 17.61) Based data 245 participant 2 RCTs 5 per 1000 6 per 1000 low Due serious risk bias, due serious imprecision, due concern indirectness2 uncertain whether cortico steroid increase decrease severe bleeding Difference: 1 per 1000 (CI 95% 26 fewer - 28 more) Gastro - intestinal bleeding Relative risk: 1.43 (CI 95% 1.22 – 1.66) Based data 33 253 participant 159 study RCTs 5 per 1000 7 per 1",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b2f291e8-8f8d-47b1-9af1-c294f80bff07",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "5% 1.22 – 1.66) Based data 33 253 participant 159 study RCTs 5 per 1000 7 per 1000 Moderate Due serious indirectness3 Corticosteroids probably little impact gastrointestinal bleeding Difference: 2 per 1000 (CI 95% 1 - 3 more) 1. Imprecision: serious. 95% CI including absence benefit ; 24 event overall, risk bias: serious : complete risk bias assessment possible full text unavailable 2. Risk bias: serious : inadequate/lack blinding participant personnel, resulting potential performance bias ; inadequate/lack blinding outcome assessors, resulting potential detection bias; imprecision: serious : 95% CI including important benefit harms; indirectness: different population (severe patients) 3. Indirectness: different population (patients without arbovir al disease ) guideline clinical management arboviral diseases: dengue, chikungunya,",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "28712e7b-2ce0-4504-9f97-26eb23647115",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "al disease ) guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 46 5 Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) Clinical management based suspected aetiology patient’s needs. definition severe disease used guideline, refer section 2.6. approach treat severe case must involve thorough training health care personnel. Practices may differ among regions, standardization procedure hospitalized patient best option ensure consistent effective care. Users guideline strongly encouraged educate patient recognize warning sign present health care facility quickly occur . 5.1 Choice intravenous fluid Conditional recommendation suggests using crystalloid fluid rather colloid fluid patient require intravenous flu",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "18c18f6e-1bfe-4fa9-ab00-9ba7700db473",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "uggests using crystalloid fluid rather colloid fluid patient require intravenous fluid treatment suspected confirmed severe arboviral disease. [Conditional recommendation, low certainty evidence ] • Clinicians must personalise treatment decision due c omplex fluid resuscitation requirements, dynamic nature severe arboviral disease . applies particularly choice fluid subsequent initial resuscitation . 5.1.1 Evidence decision Benefits harm Benefits : patient severe, suspected, confirmed arboviral disease requiring hospitalization, colloid may little impact mortality (no difference two intervention groups, 95% CI 24 fewer 24 more) . low certainty evidence compared crystalloids, colloid impact organ failure (2 fewer case organ failure per 1000 patients, 95% CI 17 fewer 22 more), clinical bleeding, defined",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f1e0ce4d-553b-488f-9b4b-c96d9859e40b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "organ failure per 1000 patients, 95% CI 17 fewer 22 more), clinical bleeding, defined mucosal major soft -tissue bleeding (3 case bleeding per 1000 patients, 95% CI 15 fewer 53 more). Colloids probably little impact hospital length stay (no difference two intervention groups, 95% CI 0.47 fewer 0.47 more). Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 47 Harms : Colloids may increase severe adverse events, infusion reaction (27 case severe adverse events, 95% CI 1 180 more). Adverse event associated colloid (dextran) typified rigor temperature usually occurring within 6 hour starting study fluid. Certainty evidence Research evidence limited dengue. evidence indirectly applied arboviral infections. Three RCTs involving 313 participant evaluated mortality",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "405a3ce5-7022-4a10-ab14-b3ac8d654303",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ed arboviral infections. Three RCTs involving 313 participant evaluated mortality organ failure among chi ldren dengue receiving intravenous fluid infusion , providing low certainty evidence due serious imprecision (the confidence interval includes important benefit harm ). single RCT 383 participant evaluated clinical bleeding child ren dengue (low certainty due serious imprecision ). certainty evidence length hospital stay rated moderate due serious risk bias. Children dengue receiving intravenous fluid infusion similar average hospital stay four days, regardless whether treated crystalloids colloid . Three study involving 658 child dengue evaluated serious adverse event . certainty evidence rated low due serious imprecision, event occurred intervention group, control group. Absolute effect esti",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "404fdf70-eea0-4fcb-adc8-8538346db482",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "n, event occurred intervention group, control group. Absolute effect estimate 27 case severe adverse event per 1000 patient colloid group compared crystalloid group (95% CI 1 180 more) . Values preference Applying agreed -upon value preference (see 3.2.3) severe disease, GDG inferred patients, given uncertain benefit colloid possibility harm , would choose receive crystalloids . Resources consideration Equity: Colloids expensive crystalloids, although panel insufficient quantitative information , believed single universal estimate would apply regions. Equity concern ar ose colloid increased costs. Acceptability: intervention judged likely acceptable. Feasibility: Crystalloids frequently available colloids. guideline clinical mana",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4c751975-1d76-4f60-81da-f4df0a732fe2",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ibility: Crystalloids frequently available colloids. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 48 5.1.2 Justification Research evidence limited dengue. evidence indirectly applied arboviral infections. study conducted hospitalized children, encompassing following number patients. preference crystalloids driven mostly based higher rate severe adverse event colloids, absence evidence benefit. GDG panel appreciated heterogeneity colloid intervention tested, would situation initial choice one intravenous fluid might changed diffe rent fluid later, driven individualized patient -clinician decisions. Table 5-1. Choice intravenous fluid assessed Interventions assessed Studies Patients Balanced crystalloids (Ringer’s lactate) 7 484 De",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "79aa850d-7571-4368-87ee-797e4dbc986c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Interventions assessed Studies Patients Balanced crystalloids (Ringer’s lactate) 7 484 Dextran (dextran 40 – 10% 70 – 6% variously) 5 577 Starch (hydroxyethyl starch 3%, 6% 10% variously) 5 388 Isotonic saline (0.9% w/v sodium chloride) 3 266 Gelatins (gelafu sine 3% 4% variously) 2 207 Hypertonic saline (hypertonic lactated saline) 1 48 Albumin 0 0 GDG judged recommendation apply similarly adult , pregnancy , child . Similarly, recommendation would also apply arboviral disease dengue. 5.1.3 Practical info rmation manufacturer’s summary product characteristic provides additional detail contraindications, special warnings, precaution use interaction medicinal product (61,62). Recommendations specific pa tients severe, suspected confirmed, arboviral disease (hospitalized) 49 Table 5-2. Summary finding administratio",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c3187643-9a3e-4ce0-a6f7-b301356c8a79",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "confirmed, arboviral disease (hospitalized) 49 Table 5-2. Summary finding administration crystalloid fluid rather colloid fluid patient require intravenous fluid treatment severe arboviral disease Clinical question/ PICO • Population: patient suspected confirmed arbovirus infection receive intravenous fluid infusion • Intervention: colloid • Comparator: crystalloids Outcome timeframe Study result measurement Absolute effect estimate Certainty evidence Summary Crystalloids Colloids Mortality Relative risk: 1 (CI 95% 0.11 – 9.6) Based data 313 participant 3 study child dengue Follow -up 30 day 20 per 1000 20 per 1000 Low Due serious imprecision1 Colloids may little impact mortality Difference: 0 fewer per 1000 (CI 95% 24 fewer - 24 more) Organ failure Relative risk: 0.96 (CI 95% 0.65 – 1.44) Based data 311",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "33672fa5-e831-4794-be22-70aac466d417",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "er - 24 more) Organ failure Relative risk: 0.96 (CI 95% 0.65 – 1.44) Based data 311 participant 3 study child dengue Follow -up 30 day 50 per 1000 48 per 1000 Low Due serious imprecision2 Colloids may little impact organ failure Difference: 2 fewer per 1000 (CI 95% 17 fewer - 22 more) Clinical bleeding (mucosal major soft - tissue bleeding) Relative risk: 1.1 (CI 95% 0.39 –3.11) Based data 383 participant 1 study child dengue Follow -up 7 day 25 per 1000 28 per 1000 Low Due serious imprecision3 Colloids may little impact severe bleeding Difference: 3 per 1000 (CI 95% 15 fewer - 53 more) Severe adverse event (mostly infusion reactions) Relative risk: 7.75 (CI 95% 1.31 – 46.0) Based data 658 participant 3 study child dengue Follow -up 7 day 4 per 1000 31 per 1000 Low Due se",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2e1ee8b2-e4d4-41e9-9e91-49999494a460",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "tudies child dengue Follow -up 7 day 4 per 1000 31 per 1000 Low Due serious imprecision4 Colloids may increase severe adverse event Difference: 27 per 1000 (CI 95% 1 - 180 more) Hospital length stay Measured by: Days Scale: lower better Based data 383 participant 1 study child dengue Follow -up 7 day 4 Mean 4 Mean Moderate Due serious risk bias5 Colloids probably little impact hospital length stay Difference: MD 0 fewer (CI 95% 0.47 fewer - 0.47 more) 1. Imprecision: serious ; 95% CI including important benefit harm (0 event overall) ; 2. Imprecision: serious. ; 95% CI including important benefit harm (70 event overall) 3. Imprecision: serious ; 95% CI including important benefit harm 4. Imprecision: serious ; 18 event overall ; intervention arm. 5. Risk bias: serious; possible selective repor",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "50d04110-17b2-4936-b6b7-c84b485cf38f",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "18 event overall ; intervention arm. 5. Risk bias: serious; possible selective reporting one trial reported outcome . guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 50 5.2 Guiding administration intravenous fluid volume purpose fluid resuscitation shock improve oxygen delivery vital organ . Briefly, hock may hypovolemic (loss intravascular volume, resulting low cardiac preload ), distributive (pathological reduction systemic vascular resistance due vasodilatation ), cardiogenic (reduction systolic diastolic cardiac function ), obstructive (physical obstruction great vessel heart , either internally within vessel self extrinsic compression) . (63,64) Dengue plasma leakage patient dengue experience clinically significant degree plasma leakage due increased vascular pe",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3d48a20b-729a-45d8-ab16-6743ace256c2",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "h dengue experience clinically significant degree plasma leakage due increased vascular permeability , manifest fluid accumulation intravascular fluid depletion, critical phase. typically occurs around day 4 –6 illness often coincid ing defervescence (65). phase typically improves spontaneously 48–72 hour (66). Differences management arbovirus Pathophysiological difference rbovir al disease require adaptation clinical approaches. example, plasma leakage dengue may profound require significant initial volume intravenous fluid , subsequent de-escalation minimise accumulation interstitial fluid . contrast, chikungunya lead myocarditis cardiac insufficiency , especially infant older adult , making iatrogenic pulmonary oedema likely ; although myocarditis occur dengue, th rare comparison rate dengue",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2106fbb1-c7da-4538-8c29-e45e04beb159",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "; although myocarditis occur dengue, th rare comparison rate dengue related shock . case, monitoring effect intravenous fluid administration performed maximise benefit minimise harm. Patient monitoring Routine patient monitoring fluid balance includes regular frequent monitoring physiological variable , urine output, laboratory value (notably haematocrit ) (5). Clinical measure response include blood pressure (including pulse pressu mean arterial pressure), heart rate , urine output mental status . Imminent worsening respiratory compromise, pulmonary oedema, may detected rising respiratory rate and/or decreasing oxygen saturation. Fluids given improve target perfusion, volume rate may modified based age , weight, clinical biological condition (such acid -base balance) concomitant therapy . Careful monito",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "14b7bfde-c412-43cc-87aa-2df1aea5e3c9",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "cal biological condition (such acid -base balance) concomitant therapy . Careful monitoring essential. Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 51 5.2.1 Current guideline fluid volume administration GDG acknowledged heterogeneity across Regions regarding practice current guidelines. Clinicians encouraged use appropriate guideline based Regional national expe rience. • World Health Organization: a. Dengue guidelines, diagnosis, treatment, prevention control • Pan American Health Organization/Regional Office Americas World Heal th Organization: a. Guidelines Clinical Diagnosis Treatment Dengue, Chikungunya Zika - PAHO/WHO | Pan American Health Organization b. Algorithms Clinical Management Dengue Patients - PAHO/WHO | Pan American Health Organization c. Tool diagnosi",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "264d3e40-d106-420c-bf45-7930f3314c3d",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "agement Dengue Patients - PAHO/WHO | Pan American Health Organization c. Tool diagnosis care patient suspected arboviral disease d. Clinical Management Yellow Fever Region Americas. Experiences Recommendations Health Services • Regional Office South -East Asia: a. Comprehensive Guideline Prevention Control Dengue Dengue Haemorrhagic Fever. Revised expanded edition b. Guidelines Clinical Management Chikungunya Fever c. SEARO MAI district clinician manual: hospital care adolescent adults: guideline management illness limited - resources. • Regional Office Western Pacific: a. Dengue clinical management: facilitator's training manual guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 52 5.2.2 Capillary refill time Strong recommendation recommends use capillary refill time",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b21b6d7b-a092-4442-941b-00c1ae0f0ff1",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "apillary refill time Strong recommendation recommends use capillary refill time guide intravenous fluid management patient suspected confirmed arboviral disease addition standard care/monitoring . [Strong recommendation, low certainty evidence ] 5.2.2.1 Evidence decision Benefits h arm Benefits : two RCTs involving total 466 participants, high -certainty evidence capillary refill time ( CRT )-guided resuscitation increase mortality compared l actate -guided resuscitation (2 fewer death per 1000 patient lact ate; 95% CI 6 fewer 2 more). Harms : one RCT involving 30 participants, fluid replenishment guided using fluid challenge followed reassessment. Peripheral perfusion monitored using CRT parameters. approach compared standard care group fluid administration followed fixed clinical guidelines. outcome mortality (3",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ebbfe011-5e42-4586-962b-bc1b53fc2df1",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "group fluid administration followed fixed clinical guidelines. outcome mortality (3 death per 1000 patient standard care; 95% CI 10 fewer 33 more), hospital length stay (27 fewer day standard care; 95% CI 43 fewer 1 1 more) intensive care unit ( ICU) length stay (2 day standard care; 95% CI: 1.5 fewer 5.5 more) uncertain due low certai nty evidence. Certainty evidence Evidence CRT standard care -guided resuscitation low certainty due extremely serious imprecision indirectness (it based single RCT involving 30 participant sepsis ). hospital ICU length stay , certainty also low, additional concern serious risk measurement bias. contrast, high certainty evidence informed comparison CRT lact ate-guided resuscitation (two RCTs involving 400 participant ). panel noted concern",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "65d07b38-50a2-415f-8214-f488862824ac",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ided resuscitation (two RCTs involving 400 participant ). panel noted concern indirect ness sepsis patient felt monitoring aspect circulatory compromise similar dengue . certainty evidence renal replacement therapy rated moderate due indirectness imprecision, 95% CI includes significant benefits. certainty evidence hospital length stay rated low due indirectness, potential performance detection biases, resulting serious risk bias serious imprecision, 95% CI includes significant benefit harms. ICU le ngth stay certainty low due potential measurement bias , indirectness, imprecision. Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 53 Values preference Applying agreed -upon value preference (see 3.2.3) patient severe disease, GDG",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ead83eeb-8ff8-47bb-a720-7cc9157d1aee",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ying agreed -upon value preference (see 3.2.3) patient severe disease, GDG inferred patients, given possible benefit lack harm, would choose capillary refill time measured guide intravenous fluid management. Resource consideration Equity, acceptability, feasibility: panel expected use CRT would require training ensure correct method measurement interpretation. However, use simple, widely available, low -cost intervention would feasible increase equity. GDG concluded recommendation would apply arboviral diseases. GDG judged recommendation would apply similarly pregnancy children. 5.2.2.2 Justification GDG considered evidence comparing CRT standard care, nd CRT lactate levels. Based strong evidence superiority lactate monitoring standard care , see 5.2.2 lactat",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "26d63343-9e26-4ed2-93da-07e25d01c240",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Based strong evidence superiority lactate monitoring standard care , see 5.2.2 lactate, high certainty evidence non -inferiority CRT versus lactate term mortality , GDG panel recommends measuring CRT measuring CRT guide intravenous fluid resuscitation . panel emphasized importance contextualizing CRT result patient ensuring health care personnel adequately trained performing test interpreting results. 5.2.2.3 Practical info capillary refill time (CRT)? CRT accessible marker end organ perfusion. measur e time blood return skin capillary emptied applying pressure. quick , visual, non -invasive test (41), although e ducation health care worker paramount ensure correct measurement interpretation. used recognition hypoperfusion monitoring fluid administr",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2b8701fd-204d-4896-b2d3-40b2af5334eb",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "nterpretation. used recognition hypoperfusion monitoring fluid administration . Detailed guideline available (68,69). factor affect CRT? CRT affected multiple factors, including room temperature, skin temperature , age , sex, room lighting, procedural technique, presence underlying vascular disease , site testing . Variability minimized training, education, standardized protocol mitigate impact ambient factor (67,70). guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 54 CRT standardization protocol Standardized procedure enhance reliability reduce interobserver variability (Figure 5.1) . r eflect procedure research study , infants, child adult : • Check environment: Ensure warm room. Choose site free skin abnormalities. Place patie",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1646d44f-229a-480e-9c2e-5fd579784c8c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ronment: Ensure warm room. Choose site free skin abnormalities. Place patient’s hand level thorax / heart. • Apply firm pressure ventral surface distal phalanx index finger 10 seconds. • Remove pressure. • Measure time return pre -existing skin colour. • Use chronometer (71). • CRT longer 3 second considered abnormal. (70,72) microscope slide used apply pressure RCTs enables visualisation skin blanching ensures even pressure. GDG panel recognized usual clinical practice require glass slide. Figure 5-1. Suggested way measure standardized capillary refill time (67) Notes: 1 – Place patient’s hand level heart (mid chest). 2 – Apply firm pressure ventral surface distal phalanx one finger 10 seconds. done using thumb, available glass microscop",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ffc45db7-8ef6-427e-a42e-f0fde8519474",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "one finger 10 seconds. done using thumb, available glass microscope slide bla nching skin underneath confirmed. 3 – Release pressure measure time taken skin colour return before. Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 55 Table 5-3. Summary finding capillary refill ti me-guided resuscitation compared standard care patient suspected confirmed arbovirus infection receive intravenous fluid infusion Clinical question/ PICO • Population: patient suspected confirmed arbovirus infection • Intervention: capillary refill time guided resuscitation • Comparator: standard careb a. Fluid repletion guided using intravenous fluid challenge subsequent -evaluation peripheral perfusion assess need fluid challenges. Capillary refill time,",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "15f2db2a-77a7-428e-aa88-a9d464be4da7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ion peripheral perfusion assess need fluid challenges. Capillary refill time, peripheral perfusion index, forearm -to- fingertip body temperatu gradient, tissue oxygenation saturation measured . patient “poor peripheral perfusion” (i.e., three four parameter altered) considered suitable fluid repletion. intervention also included fluid targeted minim um cardiac index 2.5 L/min/m2, irrespective peripheral perfusion minimum mean arterial pressure ( MAP ) 65 mmHg. b. Fluid repletion guided using fluid challenge challenge, stroke volume -evaluated assess need fl uid challenges. Hemodynamic goal based 2012 Surviving Sepsis guidelines: Give volume CI ≥ 2.5 L/min/m2; mean arterial pressure ≥ 65 mmHg; CVP ≥ 8 – 12 mmHg; SaO2 ≥ 92%; heart rate ≤ 100/min; UO ≥ 0.5 ml/kg/hr Outcome timeframe Study result measurement Absolute",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "77d02f0b-d204-45a4-92bc-a5f583ce24b0",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "rate ≤ 100/min; UO ≥ 0.5 ml/kg/hr Outcome timeframe Study result measurement Absolute effect estimate Certainty evidence Summary SOC CRT Mortality Relative risk: 1.17 (CI 95% 0.51 – 2.66) Based data 30 participant 1 study Follow -up 10 day 20 per 1000 23 per 1000 low Due concern indirectness, due extremely serious imprecision1 uncertain whether capillary refill time -guided resuscitation increase decrease mortality Difference: 3 per 1000 (CI 95% 10 fewer – 33 more) Hospital length stay Measured by: Days (mean) Scale: - Lower better Based data 30 participant 1 study 43 day 16 day low due serious risk bias, Due concern indirectness, due serious imprecision2 uncertain whether capillary refill time -guided resuscitation increase decrease hospital length stay Difference: ean Difference 27",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4655f7d8-96ed-466e-bc16-144dbf45ad54",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "resuscitation increase decrease hospital length stay Difference: ean Difference 27 fewer (CI 95% 43.3 fewer - 10.7 more) ICU length stay Measured by: Days (mean) Scale: - Lower better Based data 30 participant 1 study 8 day 10 day low Due serious risk bias, due concern indirectness, due serious imprecision3 uncertain whether capillary refill time -guided resuscitation increase decrease ICU length stay Difference: MD 2 (CI 95% 1.5 fewer –5.5 more) 1. Indirectness: Estimates effect calculated body evidence included patient sepsis. mortality baseline risk patient dengue requiring IV infusion used calculate absolute effects; imprecision: extremely serious : 95% CI including important benefit harms. 16 event 30 patient overall 2. Risk bias: serious. Inadequate/lack blinding participant personnel,",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5fc52a13-3411-42c4-a36e-2d9bf4e127bf",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "t overall 2. Risk bias: serious. Inadequate/lack blinding participant personnel, resulting potential performance bias, inadequate/lack blinding outcome assessors, resulting potential detection bias; indirectness: estimate effect calculated body f evidence included patient sepsis.; imprecision: serious ; 30 patient overall 3. Risk bias: serious. Inadequate/lack blinding participant personnel, resulting potential performance bias, Inadequate/lack blinding come assessors, resulting potential detection bias; indirectness: Estimates effect calculated body evidence included patient sepsis.; imprecision: serious. 30 patient overall . guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 56 Table 5-4. Summary finding capillary refill time -guided resuscitation compared lactate -gui",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "da0cb7e4-fef5-4df8-a633-fca011591d32",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": ". Summary finding capillary refill time -guided resuscitation compared lactate -guided resuscitation patient suspected confirmed arbovirus infection Clinical question/ PICO • Population: patient suspected confirmed arbovirus infection • Intervention: capillary refill time guided resuscitationa • Comparator: lactate-guided resuscitationb a. Fluids repeated perfusion target achieved (CRT ≤ 3 seconds) (Castro 2020; Hernández 2019). Intervention also included assessing fluid responsiveness (pulse pressure variation, inferior vena cava variation passive leg raising velocity – time integral Castro 2020 Hernández 2019 stroke volume end -expiratory occlusion est Hernández 2019) safety limit increase central venous pressure ≥ 5 mmHg fluid bolus reached (Castro 2020; Hernández 2019). b. Fluids repeated perfusion target achieved (arterial lactate ≤",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "949235a1-5094-41f7-87ea-b5e13799e9c8",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "nández 2019). b. Fluids repeated perfusion target achieved (arterial lactate ≤ 2 mmol/l decrease> 20% every 2 h) (Castro 2020; Hernández 2019). assessing fluid responsiveness (pulse pressure variation, inferior vena cava variation passive leg raising velocity – time integral Castro 2020 Hernández 2019 stroke volume end -expiratory occlusion test Hernández 2019) safety limit increase CVP ≥ 5 mmHg fluid bolus reached (Castro 2020; Hernández 2019). Outcome timeframe Study result + measurement Absolute effect estimate Certainty evidence Summary Lact ate CRT Mortality Relative risk: 0.89 (CI 95% 0.72 - 1.1) Based data 466 participant 2 study Follow 59 day 20 per 1000 18 per 1000 High spite concern indirectness1 Capillary refill time -guided resuscitation increase mortality comparison lact ate- guided resuscitation",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f9497460-2708-4571-84bc-fc787fe586ec",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "resuscitation increase mortality comparison lact ate- guided resuscitation Difference: 2 fewer per 1000 (CI 95% 6 fewer - 2 more) Renal replacement therapy Relative risk: 0.71 (CI 95% 0.47 – 1.1) Based data 424 participant 1 study Follow -up 90 day 60 per 1000 43 per 1000 Moderate Due concern imprecision indirectness2 Capillary refill time -guided resuscitation probably increase renal replacement therapy comparison lact ate- guided resuscitation Difference: 17 fewer per 1000 (CI 95% 32 fewer - 6 more) Hospital length stay Measured by: Days (mean) , lower better Based data 466 participant 2 study 22.2 day 24.2 day low Due concern indirectness, Due serious risk bias, Due serious imprecision3 uncertain whether capillary refill time guided resuscitation increase decrease hospital length stay comp",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ee993cb8-d239-4034-a67c-074e1a3d077f",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "pillary refill time guided resuscitation increase decrease hospital length stay comparison lact ate- guided resuscitation Difference: MD 2 (CI 95% 8.4 fewer – 12.5 more) ICU length stay Measured by: Days (mean) , lower better Based data 466 participant 2 study 10 day 9.8 day Low Due serious risk bias, Due concern indirectness imprecision4 Capillary refill time -guided resuscitation may increase ICU length stay comparison lact ate- guided resuscitation Difference: 0.2 fewer mean day (CI 95% 1.8 fewer – 1.4 more) 1. Indirectness: Estimates effect calculated body evidence included patient sepsis. mortality baseline risk patient dengue requiring IV infusion used calculate absolute effects. 2. Indirectness: Estimates effect calculated body evidence included patient sepsis. baseline risk acute",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7e407bd4-44a0-4881-9739-d497e956ddf7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "calculated body evidence included patient sepsis. baseline risk acute kidney injury patient acute arboviral disease patient used calculate absolute effects. Imprecision: 95% CI including important benefits. 72 event overall 3. Risk bias: serious : inadequate/lack blinding participant personnel, resulting potential performance bias, inadequate/lack blinding outcome assessors, resulting potential detection bias; indirectness: estimate effect calculated body evidence included patient sepsis.; imprecision: serious. 95% CI including important ben efits harm Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 57 4. Risk bias: serious : inadequate/lack blinding participant personnel, resulting potential performance bias, inadequate/lack blinding outcome assessors, resulting",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6544a38b-37a5-4b7e-8ce3-96b5560ffa94",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ng potential performance bias, inadequate/lack blinding outcome assessors, resulting potential detection bias; indirectness: estimate effect calculated body evidence included patient sepsis.; imprecision: 95% CI including important benefit harm s. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 58 5.2.3 Lactate Strong recommendation recommends use lactate measurement addition standard care guide intravenous fluid management patient suspected confirmed severe arboviral disease . [Strong recommendation, moderate certainty evidence ] • Measurement interpretation must occur conjunction routine patient monitoring . • recommendation intended support clinical decision intravenous fluid resuscitation commenced. intended routine monitoring patients. • Lactate",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ee97420a-7c5c-498d-acad-cce0963e4951",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "commenced. intended routine monitoring patients. • Lactate useful fluid monitoring c ontext liver failure , including yellow fever. 5.2.3.1 Evidence decision Benefits harm Lact ate-guided resuscitation , compared standard care two trial reporting data 430 participants, probably decrease mortality (4 fewer death per 1000, CI 95% 8 fewer - 0 more). Lact ate-guided resuscitation , compared standard care one trial reporting data 82 participants, may decrease ICU length stay (1.5 fewer mean days, CI 95% 3 fewer - 0.1 fewer). Lactate -guided resuscitation , compared central venous oxygen saturation (ScvO2) - guided resuscitation , probably decrease mortality based 4 randomized control trial reporting data 772 participant (7 fewer death per 1000, CI 95% 10 fewer - 3 fewer 29 day post -intervention ) may decrease mechanical ventilation based",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c72ac0af-47b3-4743-995c-058adcd83693",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "fewer - 3 fewer 29 day post -intervention ) may decrease mechanical ventilation based one study reporting data 360 participant (14 fewer patient needing mechanical ventilation per 1000, CI 95% 27 fewer - 7 more). GDG inferred serum lactate ben eficial compared standard care compared central venous oxygen saturation monitoring. Certainty evidence Research evidence available patient sepsis. Two trial compared serum lact ate “standard care” variably implemented facilit include monitoring hydration h aemodynamic status. Certainty evidence mortality moderate due imprecision ( 95% CI included benefit, 180 event overall) indir ectness (data derived patient sepsis). Certainty evidence ICU length stay, Recommendati ons specific patient severe, suspected confirmed, arboviral disease (hospitalized) 5",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b9882658-cbdf-4a96-8a9d-8a67c8fcc3f2",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ons specific patient severe, suspected confirmed, arboviral disease (hospitalized) 59 compared standard care, rated low due serious risk bias (inadequate/lack blinding possible performance detection biases), conce rn indirectness (data derived patient sepsis) serious imprecision (82 patient overall). ScvO2, certainty evidence mortality moderate due imprecision (180 event overall) indirectness (data derived patient w ith sepsis). Certainty evidence mechanical ventilation low due indirectness (data derived patient sepsis) serious imprecision ( 95% CI including benefit harms, 60 event overall). Values preference Applying agreed -upon value preference (see 3.2.3) patient severe disease, GDG inferred patients, given likely mortality benefit would choose lactate measurement additio",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9978c1a8-7507-405d-a23d-ebdcbae65ef9",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "patients, given likely mortality benefit would choose lactate measurement addition standard care guide intravenous fluid management . Resources consideration Resources availability: Lactate readily measurable many low -resource setting . cost measuring lactate include th ose equipment consumables (when used either point -of-care, laboratory measurement) . context recommendation, GDG urge advance availability lactate measurement essential device mechanism channels. GDG agreed recommendation applies arboviral disease absence liver failure (which occur yellow fever) lactate measurement unreliable circumstances. Similarly, panel judged recommendation would apply pregnant breastfeeding wo men children. 5.2.3.2 Justification GDG considered lactic -acid",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1be487d4-3a83-4c6e-b62f-2d9c69a49d90",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "breastfeeding wo men children. 5.2.3.2 Justification GDG considered lactic -acid guided resuscitation standard care (as defined two respective studies) . Evidence presented GDG ScvO2 -guided resuscitation , although treated secondary comparison lactate standard care . study enrolled patient sepsis , outcome arboviral disease specifically available. Lactate measured interval two three hours. GDG agreed strong recom mendation lact ate-guided resuscitation emphasised non -inferiority capillary refill time greater accessib ility lower cost . panel judged multiple comparison favourable lactate allow ed strong recommendation favour use , although noted indirectness evidence derive study patient arbovirus . GDG noted limitation use inter",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "865eefb8-3b3e-4995-bdbc-4c9ca1bb2e8e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ot derive study patient arbovirus . GDG noted limitation use interpretation lactate , especially liver failure . guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 60 5.2.3.3 Practical info blood lactate concentration indicate? Lactate produced anaerobic metabolism. Patients shock typically hypoperfusion, whereby lactate produced release circulation. Higher blood lactate level ssociated poor patient outcomes. However, production lactate may occur many reasons, change blood concentration lag behind physiological improvements. guiding fluid resuscitation , blood lactate typically measured 2 – 4 hourly intervals. Routine patient monitoring Lactate used adjunct r outine patient monitoring severe disease including shock. However, mandatory r egula",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f5d2fae6-58a0-4138-9d36-31c863466323",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "outine patient monitoring severe disease including shock. However, mandatory r egular ly frequent ly measure physiological variable urine output, laboratory value appropriate (such haematocrit). Clinical measure fluid response include blood pressure (including pulse pressure mean arterial pressure), heart rate urine output. Clinical indicator imminen worsening respiratory compromise, pulmonary oedema, include respiratory rate oxygen saturations. use lactate guide fluid therapy Different protocol used. Examples successful h aemodynamic resuscitation using lact ate target include: • lactate decrease 10 30% measured every 2 hour (73), • lactate decrease 10% measured every 3 hour (74), • lactate kinetics 2 hour 10%, 4 hour 20% 6 hour least 30% (75), • targeted lactate clearance least 10% (76). Specific protocol lact",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "be852577-2aa6-4a5c-b04f-d5b703c127b5",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "least 30% (75), • targeted lactate clearance least 10% (76). Specific protocol lactate -guided fluid administration based relevant local international guidance (38). Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 61 Cautions use lactate general, clinical management patient dengue minimally invasive possible due bleeding associated intervention . Care taken w invasive sampling technique (such arterial lines) used lactate measurement . Capillary measurement provides alternative. Lactate monitoring unreliable patient liver failure, feature advanced yellow fever disease occur severe dengue. Table 5-5. Summary finding lact ate-guid ed resuscitation compared Central Venous Oxygen saturation -guided resuscitation patient suspected",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ff959142-b8e3-4743-809c-8c39de784f3b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "red Central Venous Oxygen saturation -guided resuscitation patient suspected confirmed arbovirus infection receive intravenous fluid infusion Clinical question/ PICO • Population: patient suspected confirmed arbovirus infection • Intervention: lactate-guided resuscitationa • Comparator: central Oxygen saturation guided resuscitationb a. Lactate decrease 10 30% measured every 2 hour (Tian 2012), Lactate decrease 10% measured every 3 hour (Yu 2013), lactate kinetics 2 hour 10%, 4 hour 20% 6 hour least 30% (Zhou 2017), targeted lactate clearance least 10% ( Jones 2010). Intervention arm also included EGDT (Tian 2012); CVP ≥8 mm Hg, MAP ≥65 mm Hg (Yu 2013; Zhou 2017; Jones 2010) b. CVP ≥8 mm Hg, MAP ≥65 mm Hg ScvO2≥0.70 (Tian 2012; Yu 20 13; Zhou 2017; Jones 2010) Outcome Timeframe Study result measurement Absolute effect estimate Certainty Evidence Su",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ff43f600-6bf6-47ed-b43b-79fbe1439ad1",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "meframe Study result measurement Absolute effect estimate Certainty Evidence Summary Scv02 Lact ate Mortality Relative risk: 0.65 (CI 95% 0.5 - 0.84) Based data 772 participant 4 study Follow -up 29 day 20 per 1000 13 per 1000 Moderate Due concern imprecision indirectness1 Lact ate-guided resuscitation probably decrease mortality comparison ScvO2 guided resuscitation Difference: 7 fewer per 1000 (CI 95% 10 fewer - 3 fewer) Mechanical ventilation Relative risk: 0.71 (CI 95% 0.45 - 1.14) Based data 360 participant 1 study Follow -up 60 day 50 per 1000 36 per 1000 Low Due concern indirectness, Due serious imprecision2 Lact ate-guided resuscitation may decrease mechanical ventilation comparison Scv02 Difference: 14 fewer per 1000 (CI 95% 27 fewer - 7 more) 1. Indirectness: estimate effect calculated body evidence",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f22621d5-7cb7-4594-ba27-5cb5970d0a30",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "27 fewer - 7 more) 1. Indirectness: estimate effect calculated body evidence included patient sepsis. mortality baseline risk patient dengue requiring IV infusion used calculate absolute effects.; Imprecision: serious. 180 event overall 2. Indirect ness: estimate effect calculated body evidence included patient sepsis. baseline risk organ failure patient dengue requiring IV infusion used calculate absolute effects. imprecision: serious. 95% CI including benefit harms. 60 event overall guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 62 Table 5-6. Summary finding lact ate-guided resuscitation compared standard care patient suspected confirmed arbovirus infection receive intravenous fluid infusion. Clinical question/ PICO • Population: patient suspected",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "42223d2e-7c99-4e5a-abc0-b99ae89ad27c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e intravenous fluid infusion. Clinical question/ PICO • Population: patient suspected confirmed arbovirus infection • Intervention: lactate-guided resuscitation • Comparator: standard careb a. Decrease lactate level least 20% per 2 hour (Jansen 2010) 30% every 2 hour (Chen 2021). Intervention also included heart rate less 100 beats/min (Jansen 2010; Chen 2021), MAP 60 mm Hg (Jansen 2010; Chen 2021), CVP 8 – 12 mm Hg (12 – 15 mechanically ventilated) (Jansen 2010; Chen 2021), use CVP dynamic safety limit fluid challenge (Jansen 2010) , urinary output 0.5 ml/kg/h (Jansen 2010; Chen 2021), rterial oxygen saturation (SaO2) 92% (Jansen 2010; Chen 2021) haemoglobin level 7.0 g/dl (>10.0 g/dl case cardiac ischemia) (Jansen 2010; Chen 2021). ScvO2 measured continuously (Jansen 2010). ScvO2 abov e 70% (Jansen 2010) /or (Chen 2021) lactate",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5e088c92-f654-41b1-b676-383751e4da57",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ontinuously (Jansen 2010). ScvO2 abov e 70% (Jansen 2010) /or (Chen 2021) lactate level decrease least 20% 2 -hour time interval, vasodilator therapy started b. Heart rate less 100 beats/min (Jansen 2010; Chen 2021), MAP 60 mm Hg (Jansen 2010; Chen 2021), CVP 8 – 12 mm Hg (12 – 15 mechanically ventilated) (Jansen 2010; Chen 2021), use CVP dynamic safety limit fluid challenge (Jansen 2010) , urinary output 0.5 ml/kg/h (Jansen 2010; Chen 2021), arterial oxygen satu ration (SaO2) 92% (Jansen 2010; Chen 2021) haemoglobin level 7.0 g/dl (>10.0 g/dl case cardiac ischemia) (Jansen 2010; Chen 2021). use ScvO2 clinical assessment peripheral perfusion allowed discretion attending clinician (Jansen 2010). Outcome Timeframe Study result measurement Absolute effect estimate Certainty evidence Summary",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "927dda54-f24c-4952-8e89-f0336c05332f",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e Study result measurement Absolute effect estimate Certainty evidence Summary SOC Lact ate Mortality Relative risk: 0.79 (CI 95% 0.62 – 1.01) Based data 430 participant 2 study 20 per 1000 16 per 1000 Moderate Due concern imprecision indirectness1 Lact ate-guided resuscitation probably decrease mortality Difference: 4 fewer per 1000 (CI 95% 8 fewer – 0 more) ICU length stay Measured by: Days (mean) , lower better Based data 82 participant 1 study 6 day 4.5 day Low Due serious risk bias, due concern indirectness, due serious imprecision2 Lact ate-guided resuscitation may decrease ICU length stay Difference: MD 1.5 fewer (CI 95% 3 fewer - 0.1 fewer) 1. Indirectness: estimate effect calculated body evidence included patient sepsis. mortality baseline risk patient dengue requiring IV infusion used",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6e4fd306-6a68-484e-b661-cc206cd1b38a",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "sepsis. mortality baseline risk patient dengue requiring IV infusion used calculate absolute effects; imprecision: 95% CI including benefits, 180 eve nt overall 2. Risk bias: serious. inadequate/lack blinding participant personnel, resulting potential performance bias, Inadequate/lack blinding outcome assessors, resulting potential detection bias; indirectness: estimate effect calculated body evidence included patient sepsis.; imprecision: serious : 82 patient overall . Recommendations specific patient severe, suspec ted confirmed, arboviral disease (hospitalized) 63 5.2.4 Passive leg raise test Conditional recommendation suggests use passive leg raise test patient shock, suspected confirmed arboviral disease, clinician uncertain intravenous fluid administration warranted. [Conditional recommendation, low",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2115fd4f-62a4-47cb-8660-bf8e17a0dac0",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ncertain intravenous fluid administration warranted. [Conditional recommendation, low certainty evidence ] • recom mendation intended support clinical decision intravenous fluid resuscitation commenced. intended routine monitoring patients. • Real -time monitoring cardiac output required accurately interpret result passive leg raise test. 5.2.4.1 Evidence decision Benefits harm Benefits: patient suspected confirmed arbovirus infection receive intravenous fluid infusion inpatient setting , cardiac output monitoring passive leg raise may reduce mortality (2 fewer death per 1,000 patient standard care , 95% CI 5 fewer - 5 ), need mechanical ventilation ( 24/1000 fewer events, 95% CI 36 fewer 1 fewer). Harms: Prevention pulmonary oedema GDGs primary concern term - treat ment int",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d62a173e-c874-495e-81a9-5f1b1e3f0075",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Prevention pulmonary oedema GDGs primary concern term - treat ment intravenous fluid , although specific data endpoint available. Overall, panel judged unlikely harm use passive leg raise. Certainty evidence certainty evidence mortality rated moderate, based data 462 participant sepsis across five study ( 95% CI 7 fewer death 6 deaths). mechanical ventilation, certainty low, derived single study involving 120 participant , downgraded due serious risk bias inadequate blinding, imprecision due low number event (28) , indirectness. outcome renal replacement therapy, hospital length stay ICU length stay low certainty . guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 64 Values preference Applying ag",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c4965438-6907-4d02-82da-ad49ca238cf5",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "diseases: dengue, chikungunya, Zika yellow fever 64 Values preference Applying agreed -upon value preference (see 3.2.3), patient severe disease, GDG inferred most, given possible benefit lack harm , would choose passive leg raise test performed guide intravenous fluid management . Resources consideration Equity, acceptability, feasibility: Ultrasound equipment expensive, frequently unavailable requires considerable training maintenance skills. Competence user important determinant accuracy utility. 5.2.4.2 Justification Six RCTs identified tested passive leg raise bolus infusion -guided resuscitation v standar care, n=664 patient sepsis. Known limitation test severe hypovolaemia (where volume venous blood leg small), intra -abdominal pressure raised. sensitivity analys",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2a8ec88b-4848-4c13-afef-ae0b15b47af9",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "blood leg small), intra -abdominal pressure raised. sensitivity analysis look ed passive leg raise test highly similar (n=462 septic patients, 5 RCTs) lower qua lity evidence. GDG decided recommend separately passive leg raise monitored fluid bolus approaches. panel noted measure responsiveness passive leg raise te t heterogeneous across studies, specific recommendation technique use could made. GDG noted difference arboviral disease pathophysiology , also difficulty clinical differentiation absence rapid ly available laboratory diagnostics. noted specifica lly chikungunya patient may prone myocarditis , especially extreme age , plasma leakage dengue profound. 5.2.4.3 Practical info evaluated passive leg raise test (PLR)? PLR used predict wh",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a3fffb55-f893-4a53-81a6-acfd1542aba7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Practical info evaluated passive leg raise test (PLR)? PLR used predict whether volume expansion increase cardiac output (and therefore potentially end -organ perfusion) . PLR, approximately 150 -300 l venous blood leg transferred quickly central circulation . immediate increase cardiac output demonstrates preload responsiveness. mimic fluid challenge without actual fluid infusion ; hemodynamic effect quickly reversible risk fluid overload minimized (77,78). Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 65 measure cardiac output response passive leg raise bolus intravenous fluid Possible measure cardiac output includ e visualisation ultrasound / echocardiography thermodilution technique . Blood pressure indirect measure, less reliable indicator preload responsivene",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c66e0a92-333f-4d7a-be7d-9e7add8e0c57",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ques . Blood pressure indirect measure, less reliable indicator preload responsiveness. choice measure depend specific clinical context available resources. measure venous filling, static measure inferior vena ca va diameter may helpful circumstance considered here. PLR test protocol • Positioning patient semi -recumbent 45° • Record cardiac output baseline. may average multiple measurements. • Quickly lower patient flat, l ift leg least 45° horizontal . • Record cardiac output again, soon possible manoeuvre (maximal effe ct take place 30 90 seconds). • Reposition patient according clinical need. Figure 5-2. Suggested way perform standardized passive leg raise test Notes: Ensure using bed patient rapidly repositioned without discomfort. 1 - Positi",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3561f02c-b4fb-4a26-989a-eceff56a7477",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "using bed patient rapidly repositioned without discomfort. 1 - Position patient semi -recumbent 45 degrees. 2 – Record patient’s cardiac output. chosen modality measurement depend equipment, tra ining resources. direct reproducible measurement employ echocardiography thermodilution techniques. 3 – Lower patient’s torso horizontal position lift leg 45 degrees. 4 – Repeat measurement cardiac output within 30 90 seconds. complete, return patient clinically appropriate position. interpret result context shock, preload responsiveness indicated PLR -related increase cardiac output baseline 10% (79,80). less reliable measure, threshold improvement indirect measure cardiac output known. guideline clinical management arboviral diseases: dengue, chikungunya, Zika",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc1443aa-32ca-46e9-845d-f7f98f166118",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ot known. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 66 act result decision administer fluid individualized , using cycle assessment, intervention, reassessment . patient haemodynamic instability and/or sign circulatory shock : • positive PL R test indicates preload responsiveness low er risk fluid overload . positive PL R give clinician confidence proceed fluid bolus, appropriate monitoring reassessment. • negative PLR test indicates fluid administration may result physiological improvement may increase risk fluid overload. negative PL R prompt evaluation non -hypovolaemic cause shock, act caution intravenous fluid alternative approaches, vasoactive medication may immediately appropriate (81). flui",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6f4c66b9-2797-4047-929b-7c97df7117a9",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "approaches, vasoactive medication may immediately appropriate (81). fluid administration, PLR repeated. Cautions contraindication • Known limitation test severe hypovolaemia (where volume venous blood leg small), discomfort adrenergic stimulation provoked test (82). • Moving patient before, PLR requires care minimise discomfort , ensure appropriate positioning maintained rest care (for example supine semi -recumbent clinically indicated) . • PLR contraindicated patient with: traumatic brain injury due risk increas ing intracranial pressure. deep vein thrombosis lower limb due risk dislodging clot. fracture lower extremity leg amputation due e ffect volume blood recruited test . venous compression stocking Training comp",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5727fbb2-68af-40f2-8b4c-1445b36cb41d",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "volume blood recruited test . venous compression stocking Training competenc Proper training competence essential accurate assessment patient safety. Health care professional receive comprehensive training procedure, including correct positioning patient, accurate recording hemodynamic p arameters interpretation results. Regular competency assessment refresher course recommended maintain high standard practice. Recommendations specific patient severe, suspected confirmed, arboviral disease (hospita lized) 67 Table 5-7. Summary finding cardiac output response leg raise test (LRT) bolus infusion -guided resuscitation compared standard care patient suspected confirmed arbovirus infection receive intravenous fluid infusion Clinical question/ PICO • Populatio n: patient suspected confirmed arbovirus infe",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9cdf4f56-3bfb-49d0-82d3-8f2dff7d69dd",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "usion Clinical question/ PICO • Populatio n: patient suspected confirmed arbovirus infection • Intervention: cardiac output response leg raise test (LRT) bolus infusion guided resuscitation. • Comparator: standard careb a. Fluid challenge performed PLR (Chen 2015; Douglas 2020; Li 2019; Richard 2015) IV fluid (Chen 2015; Kuan 2016; Musikatavorn 2021). Fluid responsiveness assessed pulse pressure variability (Chen 2015; Richard 2015), IVC distension (Chen 2015; Musikatavorn 2021), stroke volume (Chen 2015; Douglas 2020; Kuan 2016; Li 2019; Richard 2015) b. SOC rapid fluid replacement (Li 2019), 30 mL/kg loading NSS (Musikatavorn 2021), intravascular volume expansion administered aliquot 500 ml achieve CVP least 8 cm H2O control group (Richard 2015) described clinician discretion/per clinician criterion (Chen 2015; Douglas 2020; Kuan 2016), Outcome Timeframe Study result measurement",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cbfb9ccf-98a5-4b56-a2d9-f01f53254060",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "teria (Chen 2015; Douglas 2020; Kuan 2016), Outcome Timeframe Study result measurement Absolute effect estimate Certainty evidence Summary SOC LRT Bolus Mortality Relative risk: 0.96 (CI 95% 0.74 – 1.25) Based data 664 participant 6 study Follow -up 10 day 20 per 1000 19 per 1000 Moderate Due concern imprecision indirectness1 Cardiac output response LRT bolus -guided resuscitation may little impact mortality Difference: 1 fewer per 1000 (CI 95% 5 fewer - 5 more) Renal replacement therapy Relative risk: 0.8 (CI 95% 0.35 – 1.83) Based data 403 participant 3 study 60 per 1000 48 per 1000 low Due serious risk bias, due concern indirectness, due serious imprecision2 uncertain whether cardiac output response LRT bolus -guided resuscitation increase decrease renal replacement therapy Difference:",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d693cdb1-52c4-4c84-ac4f-92e7ca2d96af",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "RT bolus -guided resuscitation increase decrease renal replacement therapy Difference: 12 fewer per 1000 (CI 95% 39 fewer –-50 more) Mechanical ventilation Relative risk: 0.66 (CI 95% 0.46 – 0.97) Based data 322 participant 2 study 50 per 1000 33 per 1000 Low Due serious risk bias, due concern imprecision indirectness3 Cardiac output response LRT bolus -guided resuscitation may decrease mechanical ventilation Difference: 17 fewer per 1000 (CI 95% 27 fewer – 1 fewer) Hospital length stay Measured days, lower better Based data 522 participant 4 study 13 Days 11 Days low Due serious risk bias, due concern indirectness, due serious inconsistency, due serious imprecision4 uncertain whether cardiac output response LRT bolus -guided resuscitation increase decrease hospital length stay Difference: MD 2 fewer (CI",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f24a2411-212c-44af-92ce-ddbf841396e6",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ded resuscitation increase decrease hospital length stay Difference: MD 2 fewer (CI 95% 5.4 fewer – 1.3 more) ICU length stay Measured days, lower better Based data 169 participant 2 study 8 Days 8 Days low Due serious risk bias, due concern indirectness, due serious imprecision5 uncertain whether cardiac output response LRT bolus -guided resuscitation increase decrease ICU length stay Difference: MD 0 fewer (CI 95% 6.7 fewer – 6.6 more) guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 68 1. Indirectness: Estimates effect calculated body evidence included patient sepsis. baseline risk patient dengue requiring IV infusion used calculate absolute effects. Imprecision: 95% CI including benefit harm 2. Risk bias: seriou s: inadequate/lack blinding p",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9000fc46-0c8d-43d1-9140-bca1256509ae",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "95% CI including benefit harm 2. Risk bias: seriou s: inadequate/lack blinding participant personnel, resulting potential performance bias, inadequate/lack blinding outcome assessors, resulting potential detection bias ; indirectness: estimate effect calculated body evidence included patient sepsis. baseline risk acute kidney injury patient acute arboviral disease patient used calculate absolute effects. Imprecision: serious : 95% CI including important benefit harm 3. Risk bias: serious : inadequate/lack blinding participant personnel, resulting potential performance bias, Inadequate/lack blinding outcome assessors, resulting potential detection bi as; indirectness: estimate effect calculated body evidence included patient sepsis. baseline risk organ failure patient dengue requiring IV inf",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "31575ed8-a2de-4004-833e-84ee1af9cc24",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "patient sepsis. baseline risk organ failure patient dengue requiring IV infusion used calculate absolute effect . Imprecision: 67 event overall. 4. Risk bias: serious. Inadequate/lack blinding participant personnel, resulting potential performance bias, Inadequate/lack blinding outcome assessors, resulting potential detection bias; inconsistency: erious. confidence interval study overlap included studies/ point estimate included studies. Indirectness: estimate effect calculated body evidence included patient sepsis.; imprecision: serious. 95% CI including benefit harm 5. Risk bias: serious : inadequate/lack blinding participant personnel, resulting potential performance bias, inadequate/lack blinding outcome assessors, resulting potential detection bias; indirectness: estimat",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "60e144ef-ebad-41af-b4bd-5619c53d5f03",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "k blinding outcome assessors, resulting potential detection bias; indirectness: estimate effect calculated body evidence included patient sepsis.; imprecision: serious. 95% CI including benefit harms. Table 5-8. Summary finding cardiac output response leg raise test (LRT) guided resuscitation compared standard care patient suspected confirmed arbovirus infection receive intravenous fluid infusion . Clinical question/ PICO • Population : patient suspected confirmed arbovirus infection • Intervention: cardiac output response leg raise test (LRT) . • Comparator: standard care Outcome timeframe Study result measurement Absolute effect estimate Certainty evidence Summary SOC LRT Mortality Relative risk: 0.91 (CI 95% 0.64 –1.3) Based data 462 participant 5 study Follow -up 10 day 20 per 1000 18 per 1000 Moderate Due",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b78fa2ed-5d7e-4143-b4ac-2894086bb81b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "rom 462 participant 5 study Follow -up 10 day 20 per 1000 18 per 1000 Moderate Due concern indirectness imprecision1 Cardiac output response LRT guided resuscitation probably little impact mortality . Difference: 2 fewer per 1000 (CI 95% 7 fewer – 6 more) Renal replacement therapy Relative risk: 0.59 (CI 95% 0.19 – 1.82) Based data 201 participant 2 study 60 per 1000 35 per 1000 low Due serious risk bias, due serious imprecision2 uncertain whether cardiac output response LRT -guided resuscitation increase decrease renal replacement therapy . Difference: 25 fewer per 1000 (CI 95% 49 fewer – 49 more) Mechanical ventilation Relative risk: 0.52 (CI 95% 0.27 – 0.98) Based data 120 participant 1 study 50 per 1000 26 per 1000 Low Due serious risk bias, due concern imprecision indirectness3 Cardiac output",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b522b8fc-e3d2-41b0-b104-c403ada0c130",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Due serious risk bias, due concern imprecision indirectness3 Cardiac output response LRT guided resuscitation may decrease mechanical ventilation . Difference: 24 fewer per 1000 (CI 95% 36 fewer – 1 fewer) Hospital length stay 13 day 10.2 day low uncertain whether cardiac output response Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 69 Measured day (mean) , lower better Based data 320 participant 3 study Difference: MD 2.78 fewer (CI 95% 7.04 fewer – 1.47 more) Due serious risk bias, due serious inconsistency, due serious imprecision, due concern indirectness4 LRT guided resuscitation increase decrease hospital length stay . ICU length stay Measured day (mean) , lower better Based data 169 participant 2 study 8 day 8 day low Due serious risk bi",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "621b9ca2-49b9-4e05-91eb-c0ccbdfceea8",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "data 169 participant 2 study 8 day 8 day low Due serious risk bias, due serious imprecision, due concern indirectness5 uncertain whether cardiac output response LRT bolus -guided resuscitation increase decrease ICU length stay . Difference : MD 0 fewer (CI 95% 6.7 fewer – 6.6 more) 1. Indirectness: estimate effect calculated body evidence included patient sepsis. baseline risk patient dengue requiring IV infusion used calculate absolute effects. Imprecision: 95% CI including benefit harm 2. Risk bias: serious. Inadequate/lack blinding participant personnel, resulting potential performance bias ; inadequate/lack blinding outcome assessors, resulting potential detection bias; indirectness: serious. Estimates eff ect calculated body evidence included patient sepsis. basel",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a7cecc54-123b-4536-9938-4c1bdd48c4ba",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "imates eff ect calculated body evidence included patient sepsis. baseline risk acute kidney injury patient acute arboviral disease used calculate absolute effects.; imprecision: serious : 95% CI including important ben efits harm 3. Risk bias: serious : inadequate/lack blinding participant personnel, resulting potential performance bias ; inadequate/lack blinding outcome assessors, resulting potential detection bias; indirectness: estimate effect calculated body evidence included patient sepsis. baseline risk organ failure patient dengu e requiring IV infusion used calculate absolute effects. imprecision: 28 event overall 4. Risk bias: serious : inadequate/lack blinding participant personnel, resulting potential performance bias ; inadequate/lack blinding outcome assessors, resulting potential dete",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a7d62655-1355-4491-9e73-b91299d93fdf",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "performance bias ; inadequate/lack blinding outcome assessors, resulting potential detection bias; inconsistency: serious : confidence interval study e overlap included studies/ point estimate inclu ded studies; indirectness: estimate effect calculated body evidence included patient sepsis.; imprecision: serious : 95% CI including benefit harm 5. Risk bias: serious : inadequate/lack blinding participant personnel, resulting potential performance bias, inadequate/lack blinding outcome assessors, resulting potential detection bias; indirectness: estimate effect calculated body evidence included patient sepsis.; imprecision: serious. 95% CI including benefit harm . guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 70 5.3 Corticosteroids",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "45a93fe5-0374-4ce5-b068-7da70ce21172",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "agement arboviral diseases: dengue, chikungunya, Zika yellow fever 70 5.3 Corticosteroids (for severe disease) Conditional recommendation suggests use systemic corticosteroid treatment patient suspected confirmed severe arboviral disease. [ Conditional recommendation, low certainty evidence ] • patient established corticosteroid therapy, decision co ntinue made according anticipated risk /benefit balance. 5.3.1 Evidence decision Benefits harm Benefits : patient severe arboviral disease, uncertain whether steroid increase decrease mortality (6 fewer death per 1000, 95% CI 12 fewer – 3 , 5 -day follow ) based data 258 participant 3 studies. Corticosteroids littl e impact length hospital stay (0.55 mean day longer, 95% CI 0.53 fewer – 1.63 more) based data 124 participant 2 studies. Harms : Co",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "63a9bd75-9498-4993-b24b-d576bfadb138",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ger, 95% CI 0.53 fewer – 1.63 more) based data 124 participant 2 studies. Harms : Corticosteroids probably increase gastrointestinal bleeding (11 per 1000, 95% CI 6 -17 more) based data 33 253 participant without arboviral disease 159 RCTs . Corticosteroids may increase severe adverse event (28 per 1000, 95% CI 40 fewer – 145 more) based data 468 participant 3 studies. uncertain whether steroid use increase decrease organ failure severe bleeding. Certainty evidence Certainty evidence rated low effect length hospital stay, based data 124 participant 2 study due serious inconsistency erious imprecision. Certainty rated low mortality, organ failure severe bleeding. Certainty evidence rated moderate gastrointestinal bleeding, based data 33 253 participant 159 RCTs ; however, patient without arbo",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "07f77ac1-36df-4bc0-8b51-f98b341f9ddc",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "g, based data 33 253 participant 159 RCTs ; however, patient without arboviral disease thus concern indirectness imprecision. median duration corticosteroid treatment 8.5 day (IQR 3.3 –28.0), appreciation short longer course steroid might different adve rse event contributed low certainty rating. Certainty evidence rated low severe adverse events, based data 468 participant three studies, due serious imprecision. Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 71 Values preference Applying agreed -upon value preference (see 3.2.3) patient severe disease, GDG inferred patient would choose avoid corticosteroid overall evidence suggest ing potential harm without strong evidence benefit . Resources considera",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b6ff8d62-da67-4e90-b891-2975fcc18df7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ence suggest ing potential harm without strong evidence benefit . Resources consideration panel intended recommendation apply chikungunya, dengue, yellow fever Zika. 5.3.2 Justification GDG noted corticosteroid variably inconsistently used management several non -arboviral acute infection sepsis , little evidence benefit published data use arboviral infections, particularly dengue. Members concerned adverse event profile corticosteroid potential negative effect immunosuppression . panel member noted corticosteroid used management patient certain disease manifestation sequela caused arboviral infections. Examples cited included acute viral myocardit chikungunya encephalitis . absence robust specific evidence, individual judgement made manife",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fc074553-126d-421f-810d-503a0fd761e8",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "nce robust specific evidence, individual judgement made manifestation severe arboviral disease . panel identified evaluation corticosteroid dengue research prio rity. 5.3.3 Practical info rmation Mechanism action, adverse event profile availability Please, refer Section 4.3 information. recommendation refers systemic (not local topic) corticosteroids. Additionally, patient develop condition complicating arboviral infection may, clinician’s assessment, benefit corticosteroid , example, uveitis, myocarditis, severe pruritus. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 72 Table 5-9. Summary finding corticosteroid compared standard care patient acute severe arboviral disease Clinical question/ PICO • Population: patient acute arboviral disea",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "cb10bade-3830-4634-97db-50d58ce5b87c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "vere arboviral disease Clinical question/ PICO • Population: patient acute arboviral disease (severe patients) • Intervention: corticosteroid • Comparator: standard care Outcome timeframe Study result measurement Absolute effect estimate Certainty evidence Summary SOC Steroids Mortality Relative risk: 0.68 (CI 95% 0.41 – 1.14) Based data 258 participant 3 study Follow -up 5 day 20 per 1000 14 per 1000 low Due serious risk bias, due serious imprecision, due serious inconsistency1 uncertain whether corticosteroid increase decrease mortality . Difference: 6 fewer per 1000 (CI 95% 12 fewer – 3 more) Organ failure Relative risk: 1.3 (CI 95% 0.66 – 2.58) Based data 288 participant 2 study Follow 17.5 day 50 per 1000 65 per 1000 low Due serious risk bias, due serious imprecision2 uncertain whether corticosteroid",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0f8f2a01-0b44-4b1b-878c-23b890ba418c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "serious risk bias, due serious imprecision2 uncertain whether corticosteroid increase decrease organ failure . Difference: 15 per 1000 (CI 95% 17 fewer – 79 more) Severe bleeding Relative risk: 1.13 (CI 95% 0.07 – 17.61) Based data 245 participant 2 study Follow -up 47 25 per 1000 28 per 1000 low Due serious risk bias, due serious imprecision3 uncertain whether corticosteroid increase decrease severe bleeding . Difference: 3 per 1000 (CI 95% 26 fewer – 28 more) Gastro - intestinal bleeding Relative risk: 1.43 (CI 95% 1.22 – 1.66) Based data 33 253 participant without arbovirus 159 RCTs 25 per 1000 36 per 1000 Moderate Due concern indirectness imprecision4 Corticosteroids probably increase gastrointestinal bleeding. Difference: 11 per 1000 (CI 95% 6 – 17 more) Severe adverse event Relative risk: 1.21 (CI",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bc139f14-7560-48fa-b21d-71a0e60caee5",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": ": 11 per 1000 (CI 95% 6 – 17 more) Severe adverse event Relative risk: 1.21 (CI 95% 0. 7 – 2.09) Based data 468 participant 3 study Follow -up 13 day 133 per 1000 161 per 1000 Low Due serious imprecision6 Corticosteroids may increase severe adverse event . Difference: 28 per 1000 (CI 95% 40 fewer – 145 more) Length hospital stay (days) Measured by: Days , lower better Based data 124 participant 2 study 4.1 day 4.65 day Low Due serious inconsistency, due serious imprecision7 Corticosteroids may little impact length hospital stay (days) . Difference: MD 0.55 (CI 95% 0.53 fewer – 1.63 more) 1. Risk bias: serious. Inadequate/lack blinding participant personnel, resulting potential performance bias , inadequate/lack blinding outcome assessors, resulting potential detection bias Inadequate concealment allocation",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5b8ea577-466a-4b62-afb9-f00f76680e7e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "f outcome assessors, resulting potential detection bias Inadequate concealment allocation randomization process, resulting potential selection bias, inadequate sequence generation/ generation comparabl e groups, resulting potential selection bias; inconsistency: serious : best point estimate one study showing mortality reduction two study showed effect; imprecision: serious. 95% CI including absence benefit 2. Risk bias: serio us. Inadequate/lack blinding participant personnel, resulting potential performance bias, inadequate/lack blinding outcome assessors, resulting potential detection bias ; incomplete data and/or large loss follow up; impreci sion: serious : 95% CI including important benefit harm Recommendations specific patient w ith severe, suspected confirmed, arboviral disease (hospitalized) 73 3. Risk bias: serious. Inadequate/lack blinding par",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6ca789f6-6ca9-4ffe-aa7c-e0127c9181e7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "rboviral disease (hospitalized) 73 3. Risk bias: serious. Inadequate/lack blinding participant personnel, resulting potential performance bias ; inadequate/lack blinding outcome assessors, resulting potential detection bias imprecision: serious : 95% CI including important benefit harm 4. Imprecision: 95% CI includes unimportant increase gastrointestinal bleeding. MID used 10 per 1000 ; indirectness : different population (patients without arbovi rus ). median duration corticosteroid treatment 8.5 day (IQR 3.3 –28.0), appreciation short longer course steroid might different adverse event contributed low certainty rating. 5. Imprecision: serious : 95% CI including important benefit harm ; 23 event overall 6. Imprecision: serious : 95% CI including benefit harm 7. Inconsistency: serious. confidence interval study",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b99fd827-71b5-4ada-a032-5c8c8ccd3784",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ing benefit harm 7. Inconsistency: serious. confidence interval study e overlap th included studies/ point estimate included studies.; imprecision: serious : 95% CI include important harm . guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 74 5.4 Immunoglobulin Conditional recommendation suggests use immunoglobulin treatment patient suspected confirmed severe arboviral disease. [Conditional recommendation, low certainty evidence ] 5.4.1 Evidence decision Benefits harm unclear whether use immunoglobulin increase decrease mortality, based data 7 7 participant 2 study (13 fewer death per 1000, CI 95% 19 fewer – 52 more), bleeding based data 31 participant 1 study (22 fewer event per 1000, CI 95% 39 fewer – 3 more), adver",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "361bca8a-c213-4b4e-8b9b-b993f3b0083e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ata 31 participant 1 study (22 fewer event per 1000, CI 95% 39 fewer – 3 more), advers e event based data 31 participant one study (64 event per 1000, CI 95% 59 fewer – 152 more). Certainty evidence Three RCT identified evaluated effect administration either anti -D Rho hyperimmune globulin (two studies) intravenous immunoglobulin (IVIG) (one study). wo study assessed mortality based data 79 participants; one study assessed severe bleeding based data 31 participants; one assessed adverse event based data 31 participants. Certainty across outcome rated low serious risk bias serious imprecision. Values preference Applying agreed -upon value preference (see 3.2.3) patien t severe disease, GDG inferred patient would choose avoid immunoglobulin overall",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0fe3f236-8718-48cf-b758-b069ff2893a6",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ase, GDG inferred patient would choose avoid immunoglobulin overall evidence suggesting absence evidence benefit . Resources consideration Immunoglobulin preparation expensive readily available resource -limited settings. Given paucity supplies, GDG emphasized importance using available immunoglobulin indication evidence beneficial effect, e.g., IVIG patient Guillain -Barré syndrome. Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 75 5.4.2 Justification GDG noted lack evidence demonstrating benefit routine use immunoglobulin patient arboviral disease need reserve use indication evidence clinical benefit. GDG used indicative voting debate, initial position 'research -only' popular. However, significa",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1df47f6d-105f-4281-8881-a9a1c7d72572",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "debate, initial position 'research -only' popular. However, significant minority felt restrictive clinicians, would closer ‘strong against’ recommendation ‘conditional against’ one . discussion led consensus 'conditional against' stance among members, allowing c linicians latitude consider use minority patients. 5.4.3 Practical Information Mechanism action Immunoglobulins used therapeutically bind epitope infectious agent absence host immunity, bind antibody respons ible adverse immune autoimmune conditions. IVIG blood product derived pooled human sera, intravenously administered , contain broad array antibodies. Anti -D Rho hyperimmune globulin IgG fraction plasma pooled -positive red-cell- immunized donor used primarily Rh isoimmunization suppression obst",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "500bc613-28d7-4bbd-99f2-44fb9ab1b8e4",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ositive red-cell- immunized donor used primarily Rh isoimmunization suppression obstetric setting immune thrombocytopenic purpura. Immun oglobulins used management pati ents clinical sequela arboviral infections, Guillain -Barré syndrome, IVIG shown benefit (83). guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 76 Table 5-10. Summary finding Intravenous immunoglobulin compared standard care patient acute arboviral disease Clinical question/ PICO • Population: patient acute arboviral disease, • Intervention: intravenous immunoglobulin • Comparator: standard care Outcome timeframe Study result measurement Absolute effect estimate Certainty evidence Summary SOC Lact ate Mortality Relative risk: 0.34 (CI 95% 0.03 – 3.58) Based data 7 7 parti",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "43610020-69bb-40e2-b1d6-9271bcadd020",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "OC Lact ate Mortality Relative risk: 0.34 (CI 95% 0.03 – 3.58) Based data 7 7 participant 2 studies1 20 per 1000 7 per 1000 low Due serious risk bias, due serious imprecision1 uncertain whether immunoglobulin increase decrease mortality . Difference: 13 fewer per 1000 (CI 95% 19 fewer - 52 more) Severe bleeding Relative risk: 0.11 (CI 95% 0.01 – 1.89) Based data 31 participant 1 study 25 per 1000 3 per 1000 low Due serious risk bias, due serious imprecision2 uncertain whether immunoglobulin increase decrease severe bleeding . Difference: 22 fewer per 1000 (CI 95% 39 fewer - 3 more) Adverse event (any) Relative risk: 3.0 (CI 95% 0.13 – 68.0) Based data 31 participant 1 study 32 per 1000 96 per 1000 low Due serious risk bias , due serious imprecision3 uncertain whether immunoglobulin increase",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "dcde5271-4fce-42fe-90d5-e43abd9c739b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "bias , due serious imprecision3 uncertain whether immunoglobulin increase decrease adverse event . Difference: 64 per 1000 (CI 95% 59 fewer - 152 more) 1. Risk bias: serious : inadequate concealment allocation randomization process, resulting potential selection bias. inadequate/lack blinding participant personnel, resulting potential performance bias ; inadequate/lack blinding ou tcome assessors, resulting potential detection bias; imprecision: serious : 95% CI including important benefit harm 2. Risk bias: serious : inadequate concealment allocation randomization process, resulting potential selection bias ; inadequate/lack blinding participant personnel, resulting potential performance bias ; inadequate/lack blinding outcome assessors, resulting potential detection bias; imprecision: serious : 95% CI including absen",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "54d2ae1a-ca5a-49da-93a6-2ec9b3e03f16",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "sors, resulting potential detection bias; imprecision: serious : 95% CI including absence benefits, 4 event overall 3. Risk Bias: serious : inadequate concealment allocation randomization process, resulting potential selection bias ; inadequate/lack blinding participant personnel, resulting potential performance bias ; inadequate/lack blinding outcome assessors, resulting potential detection bias; impre cision: serious : 95% CI including important benefit harm Recommendations specific patient severe, suspected confirmed, arbovira l disease (hospitalized) 77 5.5 Platelet transfusion Conditional recommendation suggests use prophylactic platelet transfusion patient suspected confirmed severe arboviral disease platelet count <50,000 platelet s/microlit active bleeding. [Conditional recommendation, low certainty evi",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "71168774-fa14-4c14-a525-1768fbf010f0",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "platelet s/microlit active bleeding. [Conditional recommendation, low certainty evidence ] • panel noted specific circumstance platelet transfusion may indicated, including prevention haemorrhage surgery invasive procedure pre-existing anticoagulation treatment. 5.5.1 Evidence decision Benefits harm Benefits: Based data 372 participant one observational study comparing outcome patient received platelet transfusion not, platelet transfusion may decrease length hospital stay (1 fewer mean day ’ duration, CI 95% 1.32 fewer – 0.7 fewer). Harms : uncertain whether platelet transfusion increase decrease mortality (11 event per 1000 based data 460 participant 2 studies, CI 95% 13 fewer – 34 more), severe bleeding (7 fewer event per 1000 based data 460 participa nt 2 studies, CI 95% 22 fewer – 75 more) , clinical blee",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ec894b7f-f194-442d-a5c7-a829548fca06",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "1000 based data 460 participa nt 2 studies, CI 95% 22 fewer – 75 more) , clinical bleeding (23 fewer event per 1000, CI 95% 13 fewer – 34 based data 450 patient two randomized control trials; 2 per 1000, CI 95% 11 fewer – 13 based data 788 partici pant non -randomized study) organ failure (1 fewer per 1000 based data 372 participant one study, CI 95% 21 fewer – 21 more) severe adverse event (15 event per 1000 based data 460 participant 2 studies, CI 95% 2 fewe r – 32 more). addition data summarized systematic review, GDG noted platelet transfusion associated transmission additional blood -borne pathogen , result additional intravenous volume fluid . Certainty evidence Research evidence limited dengue. evidence indirectly applied arboviral infections. evidence summary administrat",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "59ce66a2-b580-4364-b5e7-7c3d47c47952",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "idence indirectly applied arboviral infections. evidence summary administration platelet patient dengue thrombocytopenia informed two ran domized controlled trial one retrospective guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 78 non -randomized observational study , number patient informing estimate varied across outcome 372 788 patients. low certainty effect mortality, severe bleeding, clinic al bleeding, organ failure severe adverse event serious imprecision serious risk bias . Values preference Applying agreed -upon value preference (see 3.2.3), patient severe disease, GDG inferred patient suffering severe arboviral disease, given lack benefit considering possible harm , would choose receive platelet transfusion . Resources ot",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f70b94b2-367b-443b-a9f8-d07c0f9e3583",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "considering possible harm , would choose receive platelet transfusion . Resources consideration Platelet availability may low many setting due cost, availability donor inadequate laboratory storage facilities. Ensuring safety blood product , prevention viral transmission donor also concern resource -limited settings. Blood product may acceptable patients, example, patient religious objection receiving . recommendation applies pregnant breastfeeding woman children. 5.5.2 Justification conditional recommendation administration platelet patient thrombocytopenia active bleeding rest lack demonstrated benefit consequent irrational use scarce resource . addition, use platelet introduces risk transfusion -transmitted infection risk fluid overload. use",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c4b23729-f20a-408e-ad50-0959c22e4052",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "roduces risk transfusion -transmitted infection risk fluid overload. use platelet absence bleeding may appropriate specific circumstances, example preceding surgical pro cedure anticipated blood loss. threshold 10 000 platelet per microli tre discussed prophylactic platelet transfusion based earlier recommendation (33) GDG intended recommendation apply dengue, chikungunya, Zika yellow fever. 5.5.3 Practical info Dengue infection frequently accompanied thrombocytopenia day 3 day 8 following onset illness. mechanism multifactorial remains incompletely understood. condition dengue, platelet transfusion usually administered treat prevent bleeding patient thrombocytopenia platelet dysfunction, depending patient's clinical condition accompanying platelet c oncentration thresholds. However, consi",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "32a308a2-1257-4a6b-8725-09672e4f9bb8",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "patient's clinical condition accompanying platelet c oncentration thresholds. However, consideration different dengue accounting pathophysiology Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 79 disease , expected spontaneous resolution thrombocytopenia low likelihood thrombocytopenia -induced haemorrhage patient dengue. patient bleeding, additional work -up required, including marker coagulation dy sfunction (for example, prothrombin time , activated partial thromboplastin time fibrinogen level ). Table 5-11. Summary finding platelet transfusion compared platelet transfusion patient confirmed suspected dengue fever thrombocytopenia . Clinical question/ PICO • Population: patient suspected confirmed dengue fever thrombocytopenia • Intervention: platelet transfusion •",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "18a17bdc-af10-47c1-97d2-40203e917072",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "suspected confirmed dengue fever thrombocytopenia • Intervention: platelet transfusion • Comparator: platelet transfusion Outcome Timeframe Study result measurement Absolute effect estimate Certainty evidence Summary platelet transfusion platelet transfusion Length hospital stay Measured by: Days (mean) Scale: - Lower better Based data 372 participant 1 study Follow 21 day 5 day 4 day Low Due serious risk bias, Due serious imprecision1 Platelet transfusion may decrease length hospital stay. Difference: MD 1 fewer (CI 95% 1.32 fewer – 0.7 fewer) Mortality Relative risk: 2.89 (CI 95% 0.27 – 31.4) Based data 460 participant 2 study Follow 10.5 20 per 1000 31 per 1000 low Due extremely serious imprecision2 uncertain whether platelet transfusion increase decrease mortality . Difference: 11 per 1000 (CI 95% 13 fewer –",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "83be9cfe-94af-482d-9e3e-1c4754bb7c07",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "transfusion increase decrease mortality . Difference: 11 per 1000 (CI 95% 13 fewer – 34 more) Severe bleeding (RCT) (Mostly melaena haemoptysis) Relative risk: 0.7 (CI 95% 0.23 – 4.02) Based data 460 participant 2 study Follow 21 day 25 per 1000 18 per 1000 Low Due serious risk bias, due serious imprecision3 uncertain whether platelet transfusion increase decrease severe bleeding . Difference: 7 fewer per 1000 (CI 95% 22 fewer - 75 more) Clinical bleeding (RCT) (Excluding petechiae, mostly gingival) Relative risk: 0.83 (CI 95% 0.57 – 1.19) Based data 460 participant 2 study Follow -up 21 day 137 per 1000 114 per 1000 Low Due serious risk bias, due serious imprecision4 uncertain whether platelet transfusion increase decrease clinical bleeding . Difference: 23 fewer per 1000 (CI 95% 59 fewer – 26 more)",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "46df5048-6f11-48e0-b4f6-f85bf0303c62",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e decrease clinical bleeding . Difference: 23 fewer per 1000 (CI 95% 59 fewer – 26 more) Clinical bleeding (non -RCT ) (Any bleeding excluding presence petechiae) Relative risk: 1.01 (CI 95% 0.94 – 1.07) Based data 788 participant 1 study 182 per 1000 184 per 1000 Low Non -RCT without additional limitation Platelet transfusion may little impact clinical bleeding (non -RCT ). Difference: 2 per 1000 (CI 95% 11 fewer – 13 more) Organ failure Relative risk: 0.97 (CI 95% 0.146.84) 50 per 1000 49 per 1000 low uncertain whether platelet guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 80 Based data 372 participant 1 study Follow 21 day Difference: 1 fewer per 1000 (CI 95% 21 fewer – 21 more) Due serious risk bias, Due serious imprecision5 transfusion increase decrease organ failure",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ca8b5ea8-7a85-4be5-a9bf-e16e6e9198c7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "risk bias, Due serious imprecision5 transfusion increase decrease organ failure . Severe adverse event Relative risk: 4.63 (CI 95% 0.78 – 27.4) Based data 460 participant 2 study Follow 10.5 day 8 per 1000 23 per 1000 low Due serious risk bias, Due serious imprecision6 uncertain whether platelet transfusion increase severe adverse event . Difference : 15 per 1000 (CI 95% 2 fewer – 32 more) 1. Risk bias: serious: inadequate/lack blinding participant personnel, resulting potential performance bias; inadequate/lack blinding outcome assessors, resulting potential detection bias; imprecision: serious: 95% CI including unimportant effect. 2. Imprecision: extremely serious : 2 event overall 3. Risk bias: serious . Inadequate/lack blinding participant personnel, resulting potential performance bias, inadequate/lack blinding",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f0241538-0889-42f2-a489-8eabefdaa79b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "articipants personnel, resulting potential performance bias, inadequate/lack blinding outcome assessors, resulting potential detection bias; imprecision: serious : 95% CI including harm ; 11 event 4.. Risk bia s: serious : inadequate/lack blinding participant personnel, resulting potential performance bias; inadequate/lack blinding outcome assessors, resulting potential detection bias; imprecision: ser iou : 95% CI including harms, 89 event 5. Risk bias: serious : Inadequate/lack blinding participant personnel, resulting potential performance bias, inadequate/lack blinding outcome assessors, resulting potential detection bias; imp recision: serious : 95% CI including important benef harm 6. Risk bias: serious. inadequate/lack blinding participant personnel, resulting potential performance bias; inadequate/lack blinding ou",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "32375dc3-ff58-4e9e-9d79-cd995fa5baa4",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "pant personnel, resulting potential performance bias; inadequate/lack blinding outcome assessors, resulting potential detection bias; imprecision : serious : 95% CI including absence imp ortant harm ; 8 event Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 81 5.6 Specific management yellow fever individual yellow fever asymptomatic mild disease mistaken nonspecific febrile illness . minority patients, period remission, illness reappears severe form, high fever, vomiting, prostration, dehydration. Hepatic -induced coagulopathy produce severe haemorrhagic manifestation , including petechiae, ecchy moses, epistaxis hematemesis. Yellow fever distinguished viral haemorrhagic fever characteristic severity liver damage appearance jaundice",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3e2ee065-31b3-4bfd-b39d-3ea2c6739f2a",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "aemorrhagic fever characteristic severity liver damage appearance jaundice. Acute k idney injury frequently lead extreme albuminuria. Late central nervous system manifestation confusion, seizure coma often associated death. 5.6.1 N-acetylcysteine Conditional recommendation suggests use intravenous N -acetylcysteine treatment patient liver failure due probable confirmed yellow fever. [Conditional recommendation, low certainty evidence ] • recommendation applies use N-acetylcysteine adequate supply within health system compromise availability patient therapeutic need greater certainty efficacy (e.g. paracetamol overdose). 5.6.1.1 Evidence decision Benefits harm Benefits : unclear whether N -acetylcysteine treatment might improve prognosis patient live",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f6327c0c-04a8-4c4a-8a5d-f33825669ae3",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "unclear whether N -acetylcysteine treatment might improve prognosis patient liver failure secondary yellow fever virus infection . uncertain whether N- acetylcysteine treatment decrease mortality , reduces use mechanical v entilation, decrease chance liver transplant, reduces severe bleeding length hospital stay. Harms: uncertain N -acetylcysteine effect occurrence severe adverse event based one study 184 patient 11 advers e event ( 95% CI 28 fewer 151 more) 365 day following treatment. Retrospective study (in patient liver failure) reported anaphylactoid reaction led treatment interruption small percentage patient (2%). Harms anaphyl actoid reaction noted felt relatively unimportant considering stated expected value preference patient severe disease. guideline clinical management arboviral",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d8dad80b-478d-4589-8c8a-4a94d15001d7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "preference patient severe disease. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 82 Certainty evidence evidence summary use N -acetylcysteine patient liver failure secondary yellow fever informed five randomized non -randomized study patient liver failure secondary infectious disease yellow fever patient liver failure secondary non -infectious diseas es. Certainty evidence rated low severe adverse event low outcome based primarily serious imprecision. Indirect evidence available study outcome severe bleeding, length hospital stay mecha nical ventilation. Values preference Applying agreed upon value preference (see 3.2.3), patient severe disease, GDG inferred most, given possible benefit minimal harms, wou",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "392641d3-616b-4dd4-b251-0901f1d2446b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "severe disease, GDG inferred most, given possible benefit minimal harms, would choose use intravenous N -acetylcysteine liver failure due yellow fever . Resources consideration N-acetylcysteine highly effective antidote treat paracetamol (acetaminophen) overdose. GDG cognizant risk shortage ex tremely valuable countermeasure case widespread use. Given uncertainty benefit patient liver failure secondary yellow fever, noted use N -acetylcysteine requires adequate supply within health system , use context compromise availability patient . N-acetylcysteine WHO’s List Essential Medicines (47) available inexpensive generic drug. 5.6.1.2 Justification GDG specified target population recommendation adult patient severe yellow fever. w",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0340abaa-1094-47fc-8e5a-a34e7ecb3aa3",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "target population recommendation adult patient severe yellow fever. RCTs use N -acetylcysteine treatment liver failur e population. Indirect e vidence patient infectious disease -induced liver failure provide low certainty evidence mortality, severe bleeding length hospital stay. general, make strong recommendation w hen evidence critical outcome low certainty. situation, GDG felt potential benefit disease particularly poor prognosis outweigh ed minimal harm costs. panel encouraged evaluation N -acetylcysteine yellow fever research priorit y. 5.6.1.3 Practical info Mechanism action N-acetylcysteine frequently used prevent free – radical -related hepatotoxicity resulting paracetamol overdose . Molecular mechanism may include direct oxidant scavenging, Recommendations spec",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "50f60d28-e504-45fa-a444-504ce1723932",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "cetamol overdose . Molecular mechanism may include direct oxidant scavenging, Recommendations spec ific patient severe, suspected confirmed, arboviral disease (hospitalized) 83 glutathione replenishment, reduction disulfides increased H 2S sulfane sulfur specie inside cell (84). Adverse event profile ost commonly reported adverse effect intravenous acetylcysteine anaphylactoid reactions, including rash, pruritus, angioedema, bronchospasm, tachycardia, hypotension. Within trial loading dos treatment paracetamol overdose, seen occur approximately 15% (of total n=180), although discontinuation due adverse reaction occurred 2% (85). Retrospective study found adverse event rate 5% (4/76 participant ). Route, dosage, duration recommendation concern N-acetylcysteine intravenous medication (200 mg/mL, 10 mL ampoule) (47). Different dosage administra",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "91c5a23a-8100-44ee-b59d-bdaefeadfc15",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "intravenous medication (200 mg/mL, 10 mL ampoule) (47). Different dosage administration schedule adopted various condition . However , panel endorsed use according established protocol acute acetaminophen ingestion , follows : Table 5-12. N-acetylcysteine dosing Body weight Loading dose Second dose Third dose 5 kg 20 kg 150 mg/kg 3 ml/kg diluent infused 1 hour 50 mg/kg 7 ml/kg diluent infused 4 hour 100 mg/kg 14 ml/kg diluent infused 16 hour 21 40 kg 150 mg/kg 100 ml diluent infused 1 hour 50 mg/kg 250 ml diluent infused 4 hour 100 mg/kg 500 ml diluent infused 16 hour 41 kg greater 150 mg/kg 200 ml diluent1 infused 1 hour 50 mg/kg 500 ml diluent infused 4 hour 100 mg/kg 1000 ml diluent infused 16 hour Dilute N-acetylcysteine one following three solutions: sterile w",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "d695a33a-75b0-4841-86b3-e9008b10d593",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "nfused 16 hour Dilute N-acetylcysteine one following three solutions: sterile water injection, 0.45% w/v sodium chloride 5% w/v dextrose. detailed weight -based dosage dilution instructions, please refer summary product information (86) indication N -acetylcysteine case non - acetaminophen -induced liver failure (87). guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 84 Dose adjustment Renal impairment: data available determine dose adjustment moderate severe renal impairment required. Hepatic impairment: Although threefold increase acetylcysteine plasma concentration patient hepatic cirrhosis, data vailable determine dose adjustment patient required. consideration Children: mean elimination (t1/2) acetylcysteine longer newborn (11 hours)",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "5733417b-ff05-44dd-a228-e235002aeb09",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Children: mean elimination (t1/2) acetylcysteine longer newborn (11 hours) adult (5.6 hours). Pharmacokinetic information availabl e age groups. Pregnancy: four pregnant woman paracetamol ( acetaminophen ) toxicity, oral IV acetylcysteine administered time delivery. Acetylcysteine detected cord blood three viable infant cardiac blo od fourth infant, sampled autopsy. Breastfeeding: known whether drug excreted human milk. many drug excreted human milk, caution exercised acetylcysteine administered nursing woman. Table 5-13. Summary finding N-acetylcysteine compared standard care patient acute liver failure caused infectious disease Clinical question/ PICO • Population: patient acute live r failure caused infectious disease • Intervention: n -acetylcysteine • Comparator:",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "72236a01-0456-423a-8e92-d021d21005aa",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e live r failure caused infectious disease • Intervention: n -acetylcysteine • Comparator: standard care Outcome timeframe Study result measurement Absolute effect estimate Certainty evidence Summary SOC N- acetyl - cysteine Mortality Relative risk: 0.62 (CI 95% 0.35 – 1.09) Based data 81 participant 2 study Follow -up 15 day 488 per 1000 303 per 1000 low Due extremely serious imprecision3 uncertain whether N - acetylcysteine improves worsen mortality . Difference: 185 fewer per 1000 (CI 95% 317 fewer –44 more) Mechanical ventilation Relative risk: 0.8 (CI 95% 0.23 – 2.76) Based data 80 participant 1 study Follow -up 9 day 125 per 1000 100 per 1000 low Due serious risk bias, due serious indirectness, due serious imprecision4 uncertain whether N - acetylcysteine improves worsen mechanical ventilation . Difference: 25 fewer",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e9918a9f-2960-4649-ae42-69d0d61b2721",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "tain whether N - acetylcysteine improves worsen mechanical ventilation . Difference: 25 fewer per 1000 (CI 95% 160 fewer –110 more) Liver transplant Relative risk: 0.48 (CI 95% 0.26 – 0.89) Based data 37 participant 1 study Follow -up 21 day 750 per 1000 360 per 1000 Low Due extremely serious imprecision7 uncertain whether N - acetylcysteine improves worsen liver transplant . Difference: 390 fewer per 1000 (CI 95% 555 fewer – 82 fewer) Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 85 Severe adverse event Relative risk: 1.25 (CI 95% 0.35 – 4.51) Based data 184 participant 1 study Follow -up 365 day 43 per 1000 54 per 1000 Low Due serious imprecision11 N- acetylcysteine may little impact severe adverse event . Difference: 11 per 1000 (CI 95% 28 fewer – 151 more) Severe bleeding Relative",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7976e6b3-a739-41bd-b529-d64d126a6b39",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e event . Difference: 11 per 1000 (CI 95% 28 fewer – 151 more) Severe bleeding Relative risk: 0.67 (CI 95% 0.2 – 2.18) Based data 80 participant 1 study Follow -up 9 day 150 per 1000 101 per 1000 low Due serious risk bias, due serious indirectness, due serious imprecision12 uncertain whether n - acetylcysteine increase decrease severe bleeding Difference: 49 fewer per 1000 (CI 95% 120 fewer – 177 more) Length hospital stay Measured by: Days (mean) . Scale: 0 – 30, lower better Based data 121 participant 2 study Follow -up 94.5 day 15 day 12.6 day Low Due serious risk bias, due serious indirectness, due serious imprecision13 N- acetylcysteine may reduce length hospital stay Difference: MD 2.37 fewer (CI 95% 3.48 fewer – 1.25 fewer) 3. Imprecision: extremely serious. 95% CI include benefit 4. Risk bias: serious inadequ",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b90a88fa-e97d-4ab0-bff1-082504c9ce2c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "3. Imprecision: extremely serious. 95% CI include benefit 4. Risk bias: serious inadequate/lack blinding participant personnel, resulting potential performance bias ; inadequate/lack blinding outcome assessors, resulting potential detection bias Indirectness: serious : Studies included patient infectious non -infectious hepatitis ; imprecision: serious : 95% CI includes important benefit ha rms 7. Imprecision: serious : 18 event overall 11. Imprecision: serious : 95% CI including important benefit harm 12. Risk bias: serious : inadequate/lack blinding participant personnel, resulting potential performance bias; inadequate /lack blinding outcome assessors, resulting potential detection bias; indirectness: serious : study included patient infectious non -infectious hepatitis; imprecision: serious : 95% CI including important benefit harm",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3c0939f9-8cda-4b59-a900-d9b2e1ccc416",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "-infectious hepatitis; imprecision: serious : 95% CI including important benefit harm 13. Risk bias: serious : Inadequate/lack blinding participant personnel, resulting potential fo r performance bias ; inadequate/lack blinding outcome assessors, resulting potential detection bias; indirectness: serious : Studies included patient infectious non -infectious hepatitis; imprecision: serious. 121 patient overall. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 86 5.6.2 Intravenous monoclonal immunoglobulin TY014 yellow fever research setting recommends use monoclonal immunoglobulin TY014 treatment patient suspected confirmed yellow fever research settings. [ Use research , low certainty evidence ] • Given challenge randomized controlled trial rare iseases, clinical trial coul",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c2613568-d002-4de6-bda1-89dabec21488",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e ] • Given challenge randomized controlled trial rare iseases, clinical trial could conducted outbreak pre-positioned trial protocol monitored emergency use unregistered investigational intervention ( MEURI ) framework (88). 5.6.2.1 Evidence decision Benefits harm patient yellow fever disease, unknown whether monoclonal immunoglobulin TY014 may improve prognosis. use monoclonal immunoglobulin TY014 assessed human infected yellow fever virus. Benefit: Experimental human challenge (phase ) healthy subject demonstrated viraemia 8 individual given TY014 yellow fever vaccine , detectable virus 2 individual receiving placebo . Harm: 37 participants, RR 1.02 ( 95% CI 0.71 -1.46), 16 event per 1000 would expected treated TY014 (95% CI 232 fewer 368 more) . Certainty evidence n",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "26c22a5e-48a2-40eb-b6c3-a2fcf03f48ed",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "treated TY014 (95% CI 232 fewer 368 more) . Certainty evidence published data study use monoclonal immunoglobulin TY014 human infected yellow fever virus. Evidence critical outcome patient yellow fever disease absent. Evidence viral clearance experimental human challenge data low certainty due serious indirectness imprecision. Evidence adverse event low certainty due serious risk bias serious imprecision. Values preference GDG inferred lmost informed patient would choose TY014 treatment except context clinical trial. Recommendations specific patient severe, suspected c onfirmed, arboviral disease (hospitalized) 87 Resources consideration lack availability monoclonal immunoglobulin TY014 settings, particular ly low re ource settings. Mono",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "56701d08-1401-4944-baeb-e194842faacc",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ity monoclonal immunoglobulin TY014 settings, particular ly low re ource settings. Monoclonal immunoglobulin TY014 unlicensed, unregistered medication. 5.6.2.2 Justification Given absence specific treatment option yellow fever, high mortality patient progressing toxic phase developing severe isease, need improved understanding potential therapeutic monoclonal immunoglobulin TY014 improve patient outcomes. Given monoclonal immunoglobulin TY014 unregistered drug without regulatory approval treating ye llow fever, panel recommended research setting . Clinical trial help inform impact critical outcome well timing administration disease progression. yellow fever rare disease, optimal period trial would outbreaks, especially occurrin g urban areas. Pre-established protocols, appropriate e",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9c2923a6-bc6f-4932-9895-77c3a25d9294",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "outbreaks, especially occurrin g urban areas. Pre-established protocols, appropriate ethical regulatory clearance required. Currently, licensed antiviral therapy yellow fever virus. Therefore, managing severe cases, particularly -risk groups, reli e supportive care. highlight unmet need therapeutic prophylactic measure effectively manage yellow fever (89). 5.6.2.3 Practical Information Mechanism action TY014 fully engineered human IgG1 monoclonal antibody designed combat yellow fever virus. produced using Chinese hamster ovary cells. TY014 target envelope (E) protein virus’s surface, preventing virus entering replicating within host cells. Non -clinical vitro vivo study demonstrated safety profile efficacy inhibiting yellow fever virus infection. TY014 currently explored post -infection therapy yello",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3d9eaa0f-56ec-4073-a652-65c7cbb7a5b5",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "low fever virus infection. TY014 currently explored post -infection therapy yellow fever (89). guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 88 Tab le 5-14. Summary finding yellow fever -specific monoclonal antibody TY014 compared placebo patient yellow fever Clinical question/ PICO • Population: patient yellow fever • Intervention: yellow fever -specific monoclonal antibody (TY014) • Comparator: placebo Outcome timeframe Study result measurement Absolute effect estimate Certainty evidence Summary Placebo Yellow fever - specific monoclonal antibody (TY014) Adverse event (any) Relative risk: 1.02 (CI 95% 0.71 – 1.46) Based data 37 participant 1 study Follow -up 84 day 800 per 1000 816 per 1000 low Due serious risk bias , due serious imprecision1 uncertain whether yellow feve",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "31eb22b9-1895-41d5-9ce1-7e76784bd31c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "serious risk bias , due serious imprecision1 uncertain whether yellow fever - specific monoclonal antibody ( TY014) increase decrease adverse event (any) . Difference: 16 per 1000 (CI 95% 232 fewer – 368 more) Viral clearance Based data 10 participant 1 study Follow -up 15 day Viraemia observed none participant received TY014 2 participant received placebo 48 hour infusion (72 hour live- attenuated yellow fever vaccine [YF17D] challenge) low Due serious indirectness , due serious risk bias, due serious imprecision2 uncertain whether yellow fever - specific monoclonal antibody ( TY014) increase decrease viral clearance . 1. Risk bias: serious: inadequate/lack blinding participant personnel, resulting potential performance bias, inadequate/lack blinding outcome assessors, resulting",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6029880e-bfcc-4a94-b941-10783b208785",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ing potential performance bias, inadequate/lack blinding outcome assessors, resulting potential detection bias Imprecision: serious : 95% CI including important benefit harm 2. Risk bias: serious: inadequate/lack blinding participant personnel, resulting potential performance bias ; inadequate/lack blinding outcome assessors, resulting potential detectio n bias indirectness: serious: experimental inoculation yellow fever vaccine virus onoclonal antibody administration 24 hour later; imprecision: serious. 10 patient . Recommendations specific patient severe, suspected confirmed, arboviral disease (hospitalized) 89 5.6.3 Sofosbuvir research setting recommends use sofosbuvir treatment patient suspected confirmed yellow fever research settings. [ Use researc h, low certainty evidence ] • Given challenge",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a00ae463-e03f-4c18-b339-f3d7aa57db10",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "n research settings. [ Use researc h, low certainty evidence ] • Given challenge randomized controlled trial rare diseases, clinical tria l could conducted outbreak pre -positioned trial protocol monitored emergency use unregistered investigational intervention (MEURI) framework. 5.6.3.1 Evidence decision Benefits harm patient yellow fever disease, unknown whether sofosbuvir may improve prognosis. data adverse effect sofosbuvir patient yellow fever. Certainty evidence evidence summary informed one single -arm intervention study patient yellow fever. information important clinical outcomes. Certainty evidence rated low viral clearance due serious risk bias imprecision. Values preference GDG inferred lmost informed patient would choose sofos",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "8a471f9d-8cf4-48bc-b3e6-b91f3d2f9df8",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "preference GDG inferred lmost informed patient would choose sofosbuvir treatment except context clinical trial. Resources consideration Sofosbuvir available area developed tested viral hepatitis C. licensed use yellow fever. 5.6.3.2 Justification published data randomized control trial use sofosbuvir patient yellow fever (90). Given absence specific treatment option yellow fever, high mortality patient progressing toxic phase developing severe disease, need improved understanding potential antiviral improve patient outcomes. Given sofosbuvir antiviral use treat hepa titi C (also Flavivirus family ) may improve outcome guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 90 p",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "63f18e67-bd22-49f1-9782-640d9d1e27b7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 90 patient yellow fever . Given lack evidence, panel recommended research setting . Clinical trial help inform impact critical outcome well timing administration disease progression. yellow fever rare disease, optimal period trial would outbreaks, especially occurring urban areas. Pre -established protocols, appropriate ethical regulatory clearance required. 5.6.3.3 Practical Information Mechanism action Sofosbuvir pan -genotypic inhibitor hepatitis C virus (HCV) NS5B RNA -dependent RNA polymerase, essential viral replication. nucleotide prodrug undergoes intracellular metabolism form pharmacologically active urid ine analog triphosphate (GS -461203), incorporated HCV RNA NS5B polymerase",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a77a925f-34e7-4d57-80bc-ac9f632c7f72",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ne analog triphosphate (GS -461203), incorporated HCV RNA NS5B polymerase act chain terminator. GS -461203 (the active metabolite sofosbuvir) inhibitor human DNA RNA polymerase inhibitor mitoc hondrial RNA polymerase (91). Rationale specific treatment option yellow fever exist , patient receive solely intensive palliative care. Therefore, antiviral anti -flavivirus activity may represent imp ortant alternative drug repurposing attempt improve patient outcome (92). Table 5-15. Summary finding Sofosbuvir compared standard care patient yellow fever Clinical question/ PICO • Population: Patients yellow fever • Intervention: Sofosbuvir • Comparator: Standard care Outcome timeframe Study result measurement Absolute effect estimate Certainty evidence Summary SOC Sofosbuvir Viral clearance Based data 67",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a7e0d669-d871-4769-a923-c1d49c2d50f7",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e Certainty evidence Summary SOC Sofosbuvir Viral clearance Based data 67 participant 1 stud Follow -up 10 day Statistically significant difference viremia treated untreated patient survived observed day 5 6 day 4, 7, 8, 9 10. Statistically significant difference viremia treated untreated patient survive observed day 4, 7, 8 9 day 5, 6 10. low Due serious risk bias, due serious imprecision1 uncertain whether sofosbuvir increase decrease viral clearance . 1. Risk bias: serious : non-RCT adjustment potential confounders; imprecision: serious. 67 patient . access use guideline 91 6 access use guideline website PDF format : full PDF version MAGICapp content. also downloaded directly MAGICapp (see cogwheel",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "78e95cca-5dc9-470b-866f-6f2d972413c2",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "F version MAGICapp content. also downloaded directly MAGICapp (see cogwheel top right). navigate guideline guideline disseminated updated MAGICapp online. End -users also need understand meant strong conditional recommendation (see below) certainty evidence (the extent estimate effect research represent true effect treatment) (38,42). Additional educational mod ules implementation tool health worker • Global vector control response 2017 – 2030 • Eliminate yellow fever epidemic (EYE) strategy 2017 -2026 • Global Arbovirus Initiative • Laboratory testing Zika virus dengue virus fections: interim guidance • Guidelines Clinical Management Sepsis • Guidelines Clinical Diagnosis Treatment Dengue, Chikungunya, Zika - PAHO/WHO | Pan American Health Organization • Integrated Manageme nt Strategy Arbov",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "858e4d73-4f32-45c3-9f14-54ed97d6ee59",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "nd Zika - PAHO/WHO | Pan American Health Organization • Integrated Manageme nt Strategy Arboviral Disease Prevention Control Americas • Establishing syndromic surveillance event -based surveillance system zika, dengue arboviral disease • Comprehensive Guide line Prevention Control Dengue Dengue Haemorrhagic Fever. Revised expanded edition • Zika virus emerging mosquito -borne diseases: European emergency risk communication challenge: response guide • Yellow Fever: Vaccine Preventable Diseases Surveillance Standards • Dengue clinical management : facilitator's training manual • Tool diagnosis care patient susp ected arboviral disease • guideline prevention sexual transmission Zika virus • Case definitions, clinical classification, disease phase Dengue, Chikungunya, Zika - PAHO/WHO | Pan American Health Organization guideline clinical mana",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "113ab744-568e-438b-85e5-24fa285defd1",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ungunya, Zika - PAHO/WHO | Pan American Health Organization guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 92 7 Guideline -relevant research need limitation GDG identified following question priority research improve care patient arbovirus infection : 1. Disease progression classification: • clinical feature , laboratory test biomarkers accurately identify patient high risk progressing non -severe severe disease (e.g. dengue arboviruses) lead clinically actionable intervention ? • clinical feature allow accurate identif ication patient high risk poor outcomes, especially severe disease (e.g., dengue arboviruses) ? • Develop tool predict progression non -severe severe disease (beyond commonly observed warning signs, whic",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6d053a23-ea24-4492-b4ab-926723424ebb",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ct progression non -severe severe disease (beyond commonly observed warning signs, may occu r high prevalence overwhelm health systems). • Investigating discriminant clinical biological marker diseases, potentially incorporating kinetics duration associated features, could enhance development predictive scor e improve diagnostic accuracy 2. Disease management: • Compare efficacy crystalloid versus colloid solution managing severe arboviral diseases. • Investigate subgroup patient colloid may clinically advantageous. • Compare effic acy different fluid resuscitation protocol determine effective approach patient outcomes. • multiple measure fluid resuscitation capillary refill lactate levels, incorporated patient management ? • Evaluate efficacy corticosteroid treatment severe disease, especially",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c5dcaf2a-4193-49ee-935c-a11c706b41ef",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "gement ? • Evaluate efficacy corticosteroid treatment severe disease, especially dengue, determine impact patient outcomes. • Evaluat e cortico steroid treatment fluid management neonate shock. 3. Arbovirus -specific research: • Dengue: Identify disease phenotype utility guiding patient management Understand phase volume resuscitation dengue dengue shock syndrome Guideline -relevant research need limitation 93 Explore role haematocrit modifying patient management strategies. • Chikun gunya: Evaluate use NSAIDs control pain post -acute phase disease Assess optimal strategy using disease -modifying antirheumatic drug (DMARDs) chronic stage . Assess potential benefit immunoglobulin neonate , including evaluation specific IgG versus non -specific IgG. Investigate effectiveness",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e0c9529b-4223-48bd-9a96-caa9647ab8d1",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "luding evaluation specific IgG versus non -specific IgG. Investigate effectiveness immunoglobulin preventing vertical transmission. Investigate shock mechanism chikungunya management. • Zika: Eval uate role antipruritic medication . Evaluate role corticosteroid immunoglobulin Zika - associated neurological disease (encephalitis, Guillain -Barré syndrome). Investigate potential use medical countermeasure pregnancy mitigate risk congenital diseases, specific focus efficacy safety monoclonal antibodies. • Yellow fever: Accelerate evidence generation pre -established research protocol evaluating potential therapeutic s. Research monoclonal antibody treatment. Assess efficacy N -acetylcysteine yellow fever. Evaluate effect plasmapheresis severe yellow fever. Evaluate effect sofosbuvir severe yellow fev",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0858bfce-d84f-488f-9819-2cd796478c98",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "plasmapheresis severe yellow fever. Evaluate effect sofosbuvir severe yellow fever. 4. Inclusive evidence generation: • Ensure evidence generation includes patient populations, including frequently excluded trial (children, immunocompromised, pregnant women). guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 94 8 Publication, dissemination, monitoring evaluation Guidelines disseminated 3 -level structures, partner organization electronic document online resources. impact guideline high level monitored international data clinical outcome arbovir al disease . Member state guideline user encouraged report guideline systematically deployed. subsequent country regional implementation projects, arbovirus team ascertain specifically guid",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4c114575-a2a3-4262-aee6-51b855a7bfed",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "regional implementation projects, arbovirus team ascertain specifically guidelin e use. Facilities end -users encouraged perform clinical audit use guideline recommendation amongst patients. Within guideline, specific target set independence localisation national st rategies c ompromised; local target set audit. Several implementation tool developed help end -users, specifically clinicians, make decision support quality -improvement arbovirus care. planned obsolescence date guideline, arbovirus team monitor evolving rese arch landscape large -impact clinical study would precipitate guideline review. use internal steering group, GDG broader network consult changes. References 95 References 1. Reveiz L. Eviden ce synthesis: guideline fo",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "993c0d1b-40bc-45d8-9564-e63a5d953e2d",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "changes. References 95 References 1. Reveiz L. Eviden ce synthesis: guideline diagnosis treatment dengue, chikungunya, zika Region Americas. Revista Panamericana de Salud Publica/Pan American Journal Public Health. 2022;46 (https://iris.paho.org/handle/10665.2/56147 ). 2. Pan American Health Organization. Guidelines Clinical Diagnosis Treatment Dengue, Chikungunya, Zika [Internet]. License: CC -NC-SA 3.0 IGO. Washington, D.C.; 2022 [cited 2024 Dec 11]. p. 1 –158 (https://iris.paho.org/handle/10665.2/55867 ). 3. Rosenberger KD, Phung Khanh L, Tobian F, Chanpheaktra N, Kumar V, Lum LCS, et l. Early diagnostic indicator dengue versus febrile illness Asia Latin America (IDAMS study): multicentre, prospective, observational study. Lancet Glob Health. 2023 Mar;11(3):e361 –72 (https://doi.org/10.1016/S2214 -109X(22)00514 -9). 4. Wong JM, Adams LE, Durbin AP, Muñoz -Jordán JL, Poehling K",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "74ac1cdb-4f99-479b-9b71-7807b023abe5",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "org/10.1016/S2214 -109X(22)00514 -9). 4. Wong JM, Adams LE, Durbin AP, Muñoz -Jordán JL, Poehling KA, Sánchez -González LM, et al. Dengue: Growing Problem New Interventions. Pediatrics. 2022 Jun 1;149(6) (https://doi.org/10.1542/peds.2021 -055522 ). 5. World Health Organization. Handbook clinical management dengue [Internet]. Geneva: WHO; 2012. 1–118 p (https://www.who.int/publications/i/item/9789241504713 ). 6. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B. Dengue. New England Journal Medicine. 2012 Apr 12;366(15):1423 –32 (https://doi.org/10.1056/nejmra1110265 ). 7. World Health Organization. position paper dengue vaccine – May 2024. Weekly epidemiological record [Internet]. 2024 May 3 [cited 2024 Dec 10];99(18):203 –24 (https://www.who.int/publications/i/item/who -wer -9918 -203-224). 8. World Health Organization. Global Dengue Surveillance Dashboard [Internet]. 2025 [cited 202 5 Jan 12] (https://worldhealthorg.shinyapps.io/dengue_global/ ).",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "050cd2b6-3139-4741-8e96-d471957e7f89",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "board [Internet]. 2025 [cited 202 5 Jan 12] (https://worldhealthorg.shinyapps.io/dengue_global/ ). 9. Pan American Health Organization. PLISA: Health Information Platform Americas. [Internet]. 2024 (https://opendata.paho.org/en ). 10. de Souza WM, Fumagalli MJ, de Lima STS, Parise PL, Carvalho DCM, Hernandez C, et al. Pathophysiology chikungunya virus infection associated fatal outcomes. Cell Host Microbe. 2024 Apr 10;32(4):606 - 622.e8. 10.1016/j.chom.2024.02.011 (https://doi.org/10.1016/j.chom.2023.05.011 ). 11. Cerqueira -Silva T, Pescarini JM, Cardim LL, Leyrat C, Whitaker H, Antunes de B rito CA, et al. Risk death following chikungunya virus disease 100 Million Brazilian Cohort, 2015 -18: matched cohort study self -controlled case series. Lancet Infect Dis. 2024 May;24(5):504 –13 (https://doi.org/10.1016/s1473 - 3099(23)00739 -9). 12. Pan American Health Organization. Case definitions, clinical classification, disease phase Dengue,",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "57527313-f1f4-41f3-9a56-1dee98b34dbf",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "merican Health Organization. Case definitions, clinical classification, disease phase Dengue, Chikungunya, Zika [Internet]. Washington, D.C; 2023 Sep [cited 2024 Dec 10] (https://www.paho.org/en/documents/case -definitions -clinical -classification -and -disease -phases - dengue -chikungunya -and-zika ). 13. Zeller H, Van Bortel W, Sudre B. Chikungunya: History Africa Asia Spread New Regions 2013 –2014. Journal Infectious Diseases. 2016 Dec 15;214(suppl 5):S436 –40 (https://doi.org/10.1093/infdis/jiw391 ). 14. Ministry Health & Family Welfare G I. Chikungunya situation India [Internet]. 2024 [cited 2024 Oct 16] (https://ncvbdc.mohfw.gov.in/index4.php?lang=1&level=0&linkid=486&lid=3765 ). guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 96 15. Wimalasiri -Yapa BMCR, Stassen L, Huang X, Hafner LM, Hu W, Devine GJ, et al. Chikungu nya virus Asia – Pacific: systematic revie",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "443f03ab-77ef-4a04-8c01-ec418617842e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Huang X, Hafner LM, Hu W, Devine GJ, et al. Chikungu nya virus Asia – Pacific: systematic review. Emerg Microbes Infect. 2019;8(1) (https://doi.org/10.1080/22221751.2018.1559708 ). 16. Musso D, Ko AI, Baud D. Zika Virus Infection — Pandemic. New England Journal Medicine. 2019 Oct 10;381(15):1444 –57 (https://doi.org/10.1056/nejmra1808246 ). 17. World Health Organization. Zika Epidemiology Update 2022. Geneva; 2022 Feb (https://www.who.int/publications/m/item/zika -epidemiology -update ---february -2022 ). 18. Rabe IB, Hills SL, Haussig JM, Walker AT, do Santos T, San Martin JL, et al . Review Recent Epidemiology Zika Virus Infection. J Trop Med Hyg. 2025 Feb 11; (https://doi.org/10.4269/ajtmh.24 - 0420 ). 19. Adam A, Jassoy C. Epidemiology Laboratory Diagnostics Dengue, Yellow Fever, Zika, Chikungunya Virus Infections Africa. Pathogens. 2021 Oct 14;10(10):1324 (https://doi.org/10.3390/pathogens10101324 ). 20. Organization WH",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c6935381-793e-46ba-9b33-fab6c089cfb8",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "hogens. 2021 Oct 14;10(10):1324 (https://doi.org/10.3390/pathogens10101324 ). 20. Organization WH. Disease Outbreak News; Yellow fever East, West, Central Africa [Internet]. 2023 (https://www.who.int/emergencies/disease -outbreak -news/item/2022 -DON431 ). 21. Lindsey NP, Horton J, Barrett ADT, Demanou M, Monath TP, Tomori O, et al. Yellow fever resurgence: avoidable crisis? NPJ Vaccines. 2022 Jan;7(1):137 (https://doi.org/10.1038/s41541 -022-00552 -3). 22. World Health Organization. Global yellow fever update, 2023. Weekly Epidemiological Record [Internet]. 2024 [cited 2025 Apr 14];35:457 –78 (https://iris.who.int/bitstr eam/handle/10665/378642/WER9935 -eng - fre.pdf ). 23. WHO. Eliminate yellow fever epidemic (EYE) strategy 2017 -2026. World Health Organisation. 2017;92(16) (https://iris.who.int/bitstream/handle/10665/272408/9789241513661 -eng.pdf?sequence=1 ). 24. World Health Organization. Health topics: Chikungunya [Internet]. 2025 [cited 2025 Jan 15]",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6e41c1fc-5bbb-41ba-8308-6e2c7fbc98f6",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "24. World Health Organization. Health topics: Chikungunya [Internet]. 2025 [cited 2025 Jan 15] (https://www.who.int/health -topics/chikungunya#tab=tab_1 ). 25. World Health Organization. World Health Organization. 2024 [cited 2024 Jul 30]. Countries territory current previous Zika virus transmission (as 27/05/2024) (https://www.who.int/images/default - source/wpr o/health -topic/zika/zika_2024.png?sfvrsn=d4d18799_2 ). 26. World Health Organization. Health topic: Yellow fever [Internet]. 2025 [cited 2025 Jan 15] (https://www.who.int/heal th-topics/yellow -fever#tab=tab_1 ). 27. Muller DA, Depelsenaire ACI, Young PR. Clinical Laboratory Diagnosis Dengue Virus Infection. J Infect Dis. 2017 Mar 1;215(suppl_2):S89 –95 (https://doi.or g/10.1093/infdis/jiw649 ). 28. Tanner L, Schreiber M, Low JGH, Ong A, Tolfvenstam T, Lai YL, et al. Decision Tree Algorithms Predict Diagnosis Outcome Dengue Fever Early Phase Illness. PLoS Negl Trop",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "176cdef0-d50d-49a6-a79d-cb1d483e9550",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "m Predict Diagnosis Outcome Dengue Fever Early Phase Illness. PLoS Negl Trop Dis. 2008 Mar 12;2(3):e196 (https://doi.org/10.1371/journal.pntd.0000196 ). 29. Fischer C, Jo WK, Haage V, Moreira -Soto A, de Oliveira Filho EF, Drexler JF. Challenges towards serologic diagnostics emerging arboviruses. Clinical Microbiology Infection. 2021 Sep;27(9):1221 –9. 10.1016/j.cmi.2021.05.047 (https://doi.org/10.1016/j.cmi.2021.05.047 ). 30. World Health Organization. Laboratory manual fo r yellow fever [Internet]. Geneva; 2023 [cited 2025 Jan 12] (https://www.who.int/publications/i/item/9789240084476 ). 31. Recommendations Laboratory Detection Diagnosis Arbo virus Infections Region Americas. Recommendations Laboratory Detection Diagnosis Arbovirus Infections Region Americas. 2023 (https://doi.org/10.37774/978927512 5878 ). 32. WHO. Laboratory testing Zika virus dengue virus infections: interim guidan",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a0cb0914-d6e2-471e-9acc-192a46311cd8",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "7512 5878 ). 32. WHO. Laboratory testing Zika virus dengue virus infections: interim guidance, 14 July 2022. [Internet]. Geneva; 2022 (https://apps.who.int/iris/handle/10665/359857 ). References 97 33. World Health Organization. Dengue guidelines, diagnosis, treatment, prevention control [Internet]. Geneva: WHO; 2009 [cited 2025 Apr 15]. 1 –157 p (https://iris.who.int/handle/10665/44188 ). 34. Pilar Ramon -Pardo, Laurence Cibrelus, Sergio Yactayo, et al. Chikungunya: case definition acute, atypical chronic cases. Conclusions expert consultation, Managua, Nicaragua, 20 -21 May 2015. Wkly Epidemiol Rec. 2015 Aug 14;90(33):410 –3 (https://pubmed.ncbi.nlm.nih.gov/26281046/ ). 35. World Health Organization. Zika Outbreak Toolbox [Internet]. 2025 [cited 2025 Jan 15] (https://www.who.int/emergencies/outbreak -toolkit/disease -outbreak -toolboxes/zi ka-outbreak - toolbox ). 36. World Health Organization. Yellow Fever: Vaccine Preventable Diseases",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c1ce786c-1a2c-411b-92c4-b4bf00d93ef9",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ka-outbreak - toolbox ). 36. World Health Organization. Yellow Fever: Vaccine Preventable Diseases Surveillance Standards [Internet]. 2020 Apr [cited 2024 Dec 11] (https://www.who.int/publications/m/item/vaccine -preventable -diseases - surveillance -standards -yellow -fever ). 37. Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E. Clinical Practice Guidelines Trust. Washington, D. C.: National Academies Press; 2011 (https://doi.org/10.17226/13058 ). 38. World Health Organization. handbook guideline development [Internet]. 2nd ed. Organization WH, editor. 2014. 1 –180 p (https://iris.who.int/bitstream/handle/10665/145714/9789241548960_eng.pdf ). 39. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck -Ytter Y, Alonso -Coello P, et al. GRADE: emerging consensus rating quality evidence strength recommendations. BMJ. 2008 Apr 26;336(7650):924 –6 (https://doi.org/10.1136/bmj.39489.470347.ad ). 40. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Bro",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "12bd1163-9cc2-4015-b0c0-28cd8b8c3d51",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "(https://doi.org/10.1136/bmj.39489.470347.ad ). 40. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction —GRADE evidence profile summary finding tables. J Clin Epidemiol. 2011 Apr;64(4):383 –94 (https://doi.org/10.1016/j.jclinepi.2010.04.026 ). 41. Schünemann HJ, Guyatt GH. Commentary --goodbye M(C)ID! Hello MID, come from? Health Serv Res. 2005 Apr;40(2):593 –7 (https://pmc.ncbi.nlm.nih.gov/articles/PMC1361157/ ). 42. Schünemann H, Brozek J, Guyatt G, Oxman A. GRADE handbook grading quality evidence strength recommendation [Internet]. 2013 (https://gdt.gradepro.org/app/handbook/handbook.html ). 43. Mejía MFÁ, Shu PY, Ji DD. Accuracy Dengue, Chikungunya, Zika diagnosis primary healthcare physician Teguci galpa, Honduras. BMC Infect Dis. 2023 Jun 1;23(1):371 (https://doi.org/10.1186/s12879 -023-08346 -1). 44. Bagno FF, Figueiredo MM, Villarreal J, Pereira G de C, Godoi LC, da Fonse",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "779073e1-b156-4312-a221-58b19741212e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "12879 -023-08346 -1). 44. Bagno FF, Figueiredo MM, Villarreal J, Pereira G de C, Godoi LC, da Fonseca FG. Undetected Chikungunya virus co -infections Brazilian region presenting hyper -endemic circulation Dengue Zika. Journal Clinical Virology. 2019 Apr;113:27 –30 (https://doi.org/10.1016 /j.jcv.2019.02.006 ). 45. World Health Organization. treatment diarrhoea [Internet]. World Health Organization, editor. 1995 [cited 2024 Nov 18]. p. 1 –46 (https://www.who.int/publi cations/i/item/9241593180 ). 46. World Health Organization. selection fluid food home therapy prevent dehydration diarrhoea : guideline developing national policy [Internet]. 1993 [cited 2024 Dec 11] (https://iris.who.int/handle/10665/62619 ). 47. World Health Organization. Electronic Essential Medicines List (eEML) [Internet]. 2023 [cited 2024 Nov 18] (https://l ist.essentialmeds.org/ ). 48. Abdel Shaheed C, Ferreira GE, Dmitritchenko A, McLachlan",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "72b3bdbe-5fc5-4b71-8892-2c61cd874be2",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "(https://l ist.essentialmeds.org/ ). 48. Abdel Shaheed C, Ferreira GE, Dmitritchenko A, McLachlan AJ, Day RO, Saragiotto B, et al. efficacy safety paracetamol pain relief: overview systematic reviews. Medical Journal Australia. 2021 Apr 30;214( 7):324 –31 (https://doi.org/10.5694/mja2.50992 ). 49. Electronic Medicines Compendium (EMC). Paracetamol 500mg Tablets - Summary Product Characteristics (SmPC) [Internet]. 2024 (https://www.medicines.org.uk/emc/product/15241/smpc ). guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 98 50. Hamerschlak N, Maluf E, Pasquini R, Eluf -Neto J, Moreira FR, Cavalcanti AB, et al. Incidence aplastic anemia agranulocytosis Latin America: LATIN study. Sao Paulo Medical Journal. 2005 Jan;123(3):101 –4 (https://doi.org/10.1590/s1516 -31802005000300002 ). 51. Maluf E, Hamerschlak N, Cavalcanti AB, Junior AA, Eluf -Neto J, Falcao RP, et al. Incidence",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "68059117-8718-443a-9aa4-50a97c3898b1",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "51. Maluf E, Hamerschlak N, Cavalcanti AB, Junior AA, Eluf -Neto J, Falcao RP, et al. Incidence risk factor aplastic anemia Latin American countries: LATIN case -con trol study. Haematologica. 2009 Jan;94(9):1220 –6 (https://doi.org/10.3324/haematol.2008.002642 ). 52. Kötter T, da Costa BR, Fässler M, Blozik E, Linde K, Jüni P, et al. Metamizole -Associated Adverse Events: Systematic Review Meta -Analysis. PLoS One. 2015 Apr 13;10(4):e0122918 (https://d oi.org/10.1371/journal.pone.0122918 ). 53. Tomidis Chatzimanouil MK, Goppelt I, Zeissig Y, Sachs UJ, Laass MW. Metamizole -induced agranulocytosis (MIA): mini review. Mol Cell Pediatr. 2023 Aug 17;10(1):6 (https://doi.org/10.1186/s40348 -023-00160 -8). 54. Sznejder H, Amand C, Stewart A, Salazar R, Scala WAR. Real world evidence use metamizole (dipyrone) Brazilian population. retrospective cohort 380,000 patients. Einst ein (São Paulo). 2022 Apr 25;20 (https://doi.org/10",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "34bc5fb9-58af-4af9-a48e-44ce90155fd4",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ctive cohort 380,000 patients. Einst ein (São Paulo). 2022 Apr 25;20 (https://doi.org/10.31744/einstein_journal/2022ao6353 ). 55. European Medicines Agency (EMA). Assessment report. Referral Article 31 Directive 2 001/83/EC. Metamizole -containing medicinal product [Internet]. 2019 [cited 2024 Nov 27] (https://www.ema.europa.eu/en/documents/referral/metamizole -article -31-referral -chmp -assessment - report_en.pdf ). 56. European Medicine Agency (EMA). Metamizole containing medicinal product - referral [Internet]. 2019 [cited 2024 Nov 18] (https://www.ema.europa.eu/en/medici nes/human/referrals/metamizole - containing -medicinal -products ). 57. Nußbaumer B, Gartlehner G, Kien C, Kaminski -Hartenthaler A, Langer G, Meerpohl JJ, et al. Grade Leitlinien: 15. Von der Evidenz zur Empfehlung – Determinanten, die Richtung und Stärke einer Empfehlung bestimmen. Z Evid Fortbild Qual Gesundhwes. 2014;108(7):421 –31 (https://doi.org/10.1016/j.zefq.2014.08.0",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "1ad15e9a-774e-493e-99a7-bc23a9a711c3",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "men. Z Evid Fortbild Qual Gesundhwes. 2014;108(7):421 –31 (https://doi.org/10.1016/j.zefq.2014.08.004 ). 58. Yasir M, Goyal A, Sonthalia S. Corticosteroid Adverse Effects. In: St atPearls. Treasure Island (FL): StatPearls Publishing; 2024 (https://www.ncbi.nlm.nih.gov/books/NBK531462/ ). 59. Aljebab F, Choonara I, Conroy S. Systematic review toxicity short -course oral corticosteroid children. Arch Dis Child. 2016 Apr;101(4):365 –70 (https://doi.org/10.1136/archdischild -2015 -309522 ). 60. Waljee AK, Rogers MAM, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use oral corticosteroid related harm among adult United States: population based cohort study. BMJ. 2017 Apr 12;j1415 (https://doi.org/10.1136/bmj.j1415 ). 61. Pfizer Labeling. SODIUM CHLORIDE - sodium chloride injection, solution Hospira, Inc. [Internet]. 2014 [cited 2024 Nov 18] (https://l abeling.pfizer.com/ShowLabeling.aspx?id=4612 ). 62. Baxter Corporation. PRESCRIBING INF",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2b55aadc-50ff-414d-a695-4c3e15501af0",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "(https://l abeling.pfizer.com/ShowLabeling.aspx?id=4612 ). 62. Baxter Corporation. PRESCRIBING INFORMATION Lactated Ringer’s Injection, USP [Internet]. 2018 [cited 2024 Nov 18] (https://www.baxter.ca/sites/g/files/ebysai1431/files/2019 - 01/Lactated_Ringer_Injection_EN.pdf ). 63. Standl T, Annecke T, Cascorbi I, Heller AR, Sabashnikov A, Teske W. Nomenclature, Definition Distinction Types Shock. Dtsch Arztebl Int. 2018 Nov 9;115(45):757 –68 (https://doi.org/10.3238/arztebl.2018.0757 ). 64. Koya HH, Paul M. Shock. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 (https://www.ncbi.nlm.nih.gov/books/NBK531492/ ). 65. Wilder -Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet. 2019 Jan;393(10169):350 –63 (https://doi.org/10.1016/s0140 -6736(18)32560 -1). Refe rences 99 66. Paz-Bailey G, Adams LE, Deen J, Anderson KB, Katzelnick LC. Dengue. Lancet. 2024 Feb;403(10427):667 –82 (https://doi.or g/10.1016/s0140 -6736(23)02576 -x). 67. L",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2204a88f-1e8a-4921-8bd9-fecd119188be",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Lancet. 2024 Feb;403(10427):667 –82 (https://doi.or g/10.1016/s0140 -6736(23)02576 -x). 67. Lamprea S, Fernández -Sarmiento J, Barrera S, Mora A, Fernández -Sarta JP, Acevedo L. Capillary refill time sepsis: useful easily accessible tool evaluating perfusion children. Front Pediatr. 2022 Nov 17;10 (https://doi.org/10.3389/fped.2022.1035567 ). 68. World Health Organization. Pocket book hospital care children: Second edition [Internet]. World Health Organization, editor. 2013 [cited 2024 Nov 18]. p. 1 –473 (https://iris.who.int/bitstream/handle/10665/81170/9789241548373_eng.pdf ). 69. World Health Organization. Guidelines Clinical Manag ement Sepsis [Internet]. [cited 2024 Dec 11 (https://www.who.int/news/item/30 -01-2024 -guidelines -on-the-clinical -management -of-sepsis ). 70. Hern ández G, Ospina -Tascón GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, et al. Effect Resuscitation Strategy Targeting Peripheral Perfusion Status v",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4d06c912-f7b1-4e42-a334-a4014accd831",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "bin A, Hurtado J, et al. Effect Resuscitation Strategy Targeting Peripheral Perfusion Status v Serum Lactate Levels 28 -Day Mortality Among Patients Septic Shock. JAMA. 2019 Feb 19;321(7): 654 (https://doi.org/10.1001/jama.2019.0071 ). 71. Jacquet -Lagrèze M, Pernollet A, Kattan E, Ait -Oufella H, Chesnel D, Ruste M, et al. Prognostic value capillary refill time adult patients: systematic review meta -analysis. Crit Care. 2023 Dec 2;27(1):473 (https://doi.org/10.1186/s13054 -023-04751 -9). 72. Castro R, Kattan E, Ferri G, Pairumani R, Valenzuela ED, Alegría L, et al. Effects capillary refill time -vs. lactate -targeted fluid resuscitation regional, microcirculatory hypoxia -related perfusion parameter septic shock: randomized controlled trial. Ann Intensive Care. 2020 Dec 2;10(1):150 (https://doi.org/10.1186/s13613 -020-00767 -4). 73. Tian H huan, Han sha, Lv C jun, Wang T, Li Z, Hao D, et al. [The effect early goal lactate",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9ac2e02a-8c64-47cd-98b6-cab3486c0b41",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "3. Tian H huan, Han sha, Lv C jun, Wang T, Li Z, Hao D, et al. [The effect early goal lactate clearance rate outcome septic shock patient severe pneumonia]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012 Jan;24(1):42 –5 (https://pubmed.ncbi.nlm.nih.gov/22248751/ ). 74. Yu B, Tian H yan, Hu Z jie, Zhao C, Liu L xia, Zhang Y, et al. [Comparison effect fluid resuscitation guided either lactate clearance rate central venous oxygen saturation patient sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2013 Jan;25(10):578 –83 (https://doi.org/10.3760/cma.j.issn.2095 - 4352.2 013.10.002 ). 75. Zhou X, Liu D, Su L, Yao B, Long Y, Wang X, et al. Use stepwise lactate kinetics -oriented hemodynamic therapy could improve clinical outcome patient sepsis -associated hyperlactatemia. Crit Care. 2017 Jan;21(1):33 (https://doi.org/10.1186/s13054 -017-1617 -1). 76. Jones AE. Lactate Clearance v Central Venous Oxygen Saturation",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "f1ceb1f2-9994-4dea-8f5f-734db7930fb3",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "0.1186/s13054 -017-1617 -1). 76. Jones AE. Lactate Clearance v Central Venous Oxygen Saturation Goals Early Sepsis Therapy&lt;subtitle&gt;A Randomized Clinical Trial&lt;/subtitle&gt ; JAMA. 2010 Jan;303(8):739 (https://doi.org/10.1001/jama.2010.158 ). 77. Cavallaro F, Sandroni C, Marano C, La Torre G, Mannocci A, De Waure C, et al. Diagnostic accuracy passive leg raising prediction fluid responsiveness adults: systematic review meta -analysis clinical studies. Intensive Care Med. 2010 Sep 26;36(9):1475 –83 (https://doi.org/10.1007/s00134 -010- 1929 -y). 78. Monnet X, Teboul JL. Passive leg raising. Intensive Care Med. 2008 Apr 23;34(4):659 –63 (https://doi.org/10.1007/s00134 -008-0994 -y). 79. Kuan W Sen, Ibrahim I, Leong BSH, Jain S, Lu Q, Cheung YB, et al. Emergency Department Management Sepsis Patients: Randomized, Goal -Oriented, ninvasive Sepsis Trial. Ann Emerg Med. 2016 Jan;67(3):367 -378.e3 (https://doi.org/10.1016/j.annemergmed.",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ed3f339f-ad55-4316-87b6-801e984ce7a9",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Sepsis Trial. Ann Emerg Med. 2016 Jan;67(3):367 -378.e3 (https://doi.org/10.1016/j.annemergmed.2015.09.010 ). 80. Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL, e al. Fluid Response Evaluation Sepsis Hypotension Shock. Chest. 2020 Jan;158(4):1431 –45 (https://doi.org/10.1016/j.chest.2020.04.025 ). guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 100 81. Monnet X, Teboul JL. Passive leg raising: five rules, drop fluid! Crit Care. 2015 Dec 1;19(1):18 (https://doi.org/10.1186/s13054 -014-0708 -5). 82. Beurton A, Teboul JL, Gavelli F, Gonzalez FA, Girotto V, Galarza L, et al. effect passive leg raising may detected plethysmographic oxygen saturation signal critically ill patients. Crit Care. 2019 Dec 18;23(1):19 (https://doi.org/10.1186/s13054 -019-2306 -z). 83. Kalita J, Misra UK, Chaudhary SK, Das M, Mishra A, Ranjan A, et al. Outcome Guillain –Barré synd",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bdf41438-0870-459d-b588-09482e7e326d",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Kalita J, Misra UK, Chaudhary SK, Das M, Mishra A, Ranjan A, et al. Outcome Guillain –Barré syndrome following intravenous immunoglobulin compared natural course. Eur J Neurol. 2022 Oct 2;29(10):3071 –80 (https://doi.org/10.1111/ene.15500 ). 84. Pedre B, Barayeu U, Ezeriņa D, Dick TP. mechanism action N -acetylcysteine (NAC): emerging role H2S sulfane sulfur species. Pharmacol Ther. 2021 Dec;228:107916 (https://doi.org/10.1016/j.pharmthera.2021.107916 ). 85. Kerr F, Dawson A, Whyte IM, Buckley N, Murray L, Graudins A, et al. Australasian Clinical Toxicology Investigators Collaboration ra ndomized trial different loading infusion rate N -acetylcysteine. Ann Emerg Med. 2005 Apr;45(4):402 –8 (https://doi.org/10.1016/j.annemergmed.2004.08.040 ). 86. Cumberland Pharmaceuticals Inc. Acetylcysteine. Prescribing information [Internet]. 2019 [cited 2024 Nov 18] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0215 39s017lbl.pdf ). 87",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "196e6db0-7297-486d-8125-3723d02676d5",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "2024 Nov 18] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0215 39s017lbl.pdf ). 87. World Health Organization. I.13 N -acetylcysteine – non -acetaminophen -induced acute liver failure – EML EMLc [Internet]. [cited 2024 Nov 29] (https://www.who.int/groups/expert -committee -on-selection - -use-of-essential -medicines/23rd -expert -committee/i13 -n-acetylcysteine ). 88. World Health Organization. Emergency use unproven clinical nterventions outside clinical trials: ethical considerations. Geneva; 2022 (https://www.who.int/publications/i/item/9789240041745 ). 89. Low JG, Ng JHJ, Ong EZ, Kalimuddin S, Wijaya L, Chan YFZ, et al. Phase 1 Trial Therapeutic Anti – Yellow Fever Virus Human Antibody. New England Journal Medicine. 2020 Jul 30;383(5):452 –9 (https://doi.org/10.1056/nejmoa2000226 ). 90. Figueiredo -Mello C, Casadio LVB, Avelino -Silva VI, Yeh -Li H, Sztajnbok J, Joelsons D, et al. Efficacy sofosbuvir treatment yellow fever:",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "da34f4d2-22e3-40ae-90dd-118dd11ce81d",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "I, Yeh -Li H, Sztajnbok J, Joelsons D, et al. Efficacy sofosbuvir treatment yellow fever: protocol randomised controlled trial Brazil (SOFFA study). BMJ Open. 2019 Nov 25;9(11):e027207 (https://doi.org/10.1136/bmjopen -2018 -027207 ). 91. European Medicines Agency (EMA). Sovaldi. SUMMARY PRODUCT CHARACTERISTICS [Internet]. 2022 [cited 2024 Nov 18] (https://www.ema.europa.eu/en/medicines/human/EPAR/sovaldi ). 92. de Freitas CS, Higa LM, Sacramento CQ, Ferreira AC, Reis PA, Delvecchio R, et al. Yellow fever virus susceptible sofosbuvir vitro vivo. PLoS Negl Trop Dis. 2019 Jan 30;13(1):e0007072 (https://doi.org/10.1371/journal.pntd.0007072 ). Annex 1. Declarations Interest 101 Annex 1 . Declarations Interest technical unit collected managed written statement declaration interest (DOI). DOI form reviewed Secretariat. Consultation Quality Norms Standards team Ethic",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "3a40bb36-331d-40dc-ac06-ec8fe9500a8c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "e reviewed Secretariat. Consultation Quality Norms Standards team Ethics team obtained, necessary. Conflicts interest wer e declared three panel member related institutional research funding deemed ground panel ineligibility. start meeting, Secretariat described DOI process GDG member asked verbally update ther DOI; verbal conflict declared. Web search identify additional interest would likely affect members' independence. declaration interest noted GDG member methodologist shown table below. Member ( First name) Role DOI Description Ashutosh Biswas GDG Orlando Cuellar GDG Ismael Diallo GDG Christina Domingo Carrasco GDG Gordon Guyatt Methodologist Pillaveetil Indu GDG Ariel Izcovich Sys rev Emilie Javelle GDG Mikaela Kabore GDG Marta Lado",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "2d0efea1-69e7-4d29-bc79-90c3bd176819",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "Ariel Izcovich Sys rev Emilie Javelle GDG Mikaela Kabore GDG Marta Lado GDG Lucy Lum GDG Yes Sysmex Asia Pacific; $35,000; 2021 Pisake Lumbiganon GDG Kleber Luz GDG Tajeldin Mohameddein Abdallah GDG Carlos Pardo GDG Yes Research funding U nited States National Institutes Health Mostafa Salehi -Vaziri GDG J Erin Staples GDG Yes Employed United States CDC Maria Esterlita Uy GDG Michal Van Herp GDG Liya Wassie GDG Yes Institutional AFI research funding ITM Belgium; 40,000 Euros; work institution paid travel insurance Leo Yee Sin GDG guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 102 Annex 2 . Arbovirus baseline risk estimate survey short survey determine baseline absolute rate clinical outcome used considering evidence Clinical management arbovirus guide",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "7a6e535c-3a99-49c8-8e57-09a724840505",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "utcomes used considering evidence Clinical management arbovirus guidelines. Many thanks advance taking time complete short survey. critical importance GDG respond, determine information effect intervention presented them. information used deliberation create guideline recommendations. aim • produce guideline cohesive, clinician patient use understand benefit harm might receive. sue 1. Research study participant often different wider patient population. always selected, difference might expected in, example, severity disease outcome (amongst things). 2. Research study looking one aspect disease treatment may include patient exactly risk/severity study look another asp",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "c433efa3-52bd-4381-82da-0f26f9c8a97f",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "may include patient exactly risk/severity study look another aspect. solution • use treatment effect found research study starting place. • select \"baseline absolute risk\" outcome throughout guideline. risk associated standard care, placebo. frequently expect see outcome \"normal\" (or non -study) patients. usually give number per 1000 patients. • apply treatment effect study baseline absolute risk, show frequently expect see outcome treated patients. give u estimate actual difference trea tment make (per 1000 patients, example). One small problem! • baseline estimate absolute rate outcome \"normal\" patients. course, variability. looked data observational ran",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "9663bc26-15c2-477b-9917-d2e3ad472a4b",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ts. course, variability. looked data observational ran domised studies, describe range seen. survey asks make decision baseline rate use. Annex 2. Arbovirus baseline risk estimate survey 103 survey work? • present every outcome turn. • outcome, give 5 different value potential baseline rates. span lowest highest rate existing studies. • ask think \"what rate would expect real patient populations\". give information patient seen. example, presenting primary care clinics, admitted hospital different. true disease. example, dengue patient different outcome zika patients. • select one value r epresents rate think relev",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "a58f1e8e-e2ff-4f9d-b549-34f733d58952",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "zika patients. • select one value r epresents rate think relevant population. need information, please email glai@who.int . 6 question survey. Dengue patient dengue, presenting primary care facility (or -patient departments), reasonable estimate mortality? Please choose one following: • 0.25 per 1000 (0.025%) • 1 per 1000 (0.1%) • 5 per 1000 (0.5%) • 10 per 1000 (1 %) • 25 per 1000 (2.5%) • experience, unable estimate Range informed reporting case mortality, observational study low risk patients. patient dengue already admitted hospital , reasonable estimate mortality? Please choose one following: • 5 per 1000 (0.6%) • 20 per 1000 (2%) • 50 per 1000 (5%) • 100 per 1000 (10%) • 180 per 1000 (18%) • experience, unable",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "4ad59315-a18c-45e6-a0ca-1d76f4230c3e",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "50 per 1000 (5%) • 100 per 1000 (10%) • 180 per 1000 (18%) • experience, unable estimate Range informed observational study high risk p atients. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 104 patient dengue, already admitted hospital, reasonable estimate organ failure? Please choose one following: • 10 per 1000 (1%) • 30 per 1000 (3%) • 60 per 1000 (6%) • 100 per 1000 (10%) • 150 per 1000 (15%) • experience, unable estimate Range informed observational study high risk patients. Organ failure life -threatening reduction function [brain, cardiovascular system, coagulation, heart, liver, lung, kidney] requires sp ecific medical support replace function mitigate risk associated dysfunction patient dengue, already admitted hospital, reaso",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0a91afba-005b-48d7-81dc-7ca7c9cf2e40",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ssociated dysfunction patient dengue, already admitted hospital, reasonable estimate severe (major) bleeding? Please choose one following: • 10 per 1000 (1%) • 25 per 1000 (2.5%) • 50 per 1000 (5%) • 100 per 1000 (10%) • 200 per 1000 (20%) • experience, unable estimate Range informed observational study high risk patients. “major bleeding” one of: • fall hemoglobin l evel 2 g/dL • need transfusion least 2 unit packed red blood cell • involvement critical anatomical site (intracranial, spinal, ocular, pericardial, articular, intramuscular compartment syndrome, retroperitoneal).” patient dengue presenting primary healthcare facility (or outpatient departments), reasonable estimate severe (major) bleeding? Please choose one following: • 1 per 1000 (0.1%) • 5 per 1000 (0.5%) • 15 per 100",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ec8bae76-d0f8-4df6-a5cd-4ec7f7baca49",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "lease choose one following: • 1 per 1000 (0.1%) • 5 per 1000 (0.5%) • 15 per 1000 (1.5%) • 30 per 1000 (3%) • 60 per 1000 (6%) Annex 2. Arbovirus baseline risk estimate survey 105 • experience, unable estimate Range informed observational study low risk patients. “major bleeding” one of: • fall hemoglobin level 2 g/dL • need transfusion least 2 unit packed red blood cell • involvement critical anatomical site (intracranial, spinal, ocular, pericardial, articular, intramuscular compartment syndrome, retroperitoneal).” patient dengue, presenting primary care facility (or -patient departments) , reasonable estimate hosptial admission? Please choose one following: • 5 per 1000 (0.5%) • 20 per 1000 (2%) • 50 per 1000 (5%) • 100 per 1000 (10%) • 200 per 1000 (20%) • experience, unable estimate Range",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bf294fae-a94f-4ac1-bcb7-939789bee612",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "• 100 per 1000 (10%) • 200 per 1000 (20%) • experience, unable estimate Range informed observat ional study low risk patients. completed survey. Many thanks taking time help us. guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 106 Annex 3 . Protocol systematic review inform clinical practice guideline management arboviral disease Title: Systematic Review Meta -analysis Interventions Management Arboviral Diseases: Informing Clinical Practice Guidelines Dengue, Zika, Chikungunya, Yellow Fever 1. Introduction 1.1 Background Rationale: Arboviral diseases, includin g Dengue, Zika, Chikungunya, Yellow Fever, continue present significant challenge term morbidity, mortality, economic burden. objective systematic review comprehensively evaluate synthesize existin",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "234e25f4-b6a8-436e-8838-97fc8025df49",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": ". objective systematic review comprehensively evaluate synthesize existing evidence intervention management arboviral diseases, providing foundation development evidence -based clinical practice guidelines. 1.2 Objectives: • identify evaluate effectiveness medical intervention management Den gue, Zika, Chikungunya, Yellow Fever. • assess safety adverse effect associated interventions. • determine impact intervention clinical outcomes, including symptom resolution, disease progression, mortality. • prov ide robust evidence base development clinical practice guidelines. 2. Methods 2.1 Eligibility Criteria: populations, interventions, comparators, outcome interest selected de guideline development group (GDG). questio n development process include: • Identification populations, intervention",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "346f7dbd-5466-461e-ae59-a3b5cc3026dd",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "). questio n development process include: • Identification populations, interventions, comparators, outcome interest • Identification subgroup interest (effect modification different baseline risks) • Outcome prioritization definition outcome relevance ( i.e. utilities) question health effect intervention search randomized controlled study (RCT) (primary search described below). case don’t find RCT overall certainty evidence result low consider conducting additional search Annex 3. Protocol systematic review inform clinical practice guideline management arboviral dise as 107 identify high quality non -RCT.1 question aspect evidence decision process, related health effect intervention ( e.g. resource utilization ) search systematic reviews. 2.2 Search Strategy: comprehens",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e4c7dc8b-df04-45d4-8c7e-913bc3ec8b86",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "resource utilization ) search systematic reviews. 2.2 Search Strategy: comprehensive systematic search conducted electronic database ( Medline , Embase, Cochrane Library LILACS ) inception [insert end date]. Table 1. Search strategy MEDLI NE though Pubmed 1 \"dengue\"[MeSH Terms] \"dengue\"[All Fields] \"dengue s\"[All Fields] (\"zika virus\"[MeSH Terms] (\"zika\"[All Fields] \"virus\"[All Fields]) \"zika virus\"[All Fields] \"zika\"[All Fields] \"zika virus infection\"[MeSH Terms] (\"zika\"[All Fields] \"virus\"[All Fields] \"infection\"[All Fields]) \"zika virus infection\"[All Fields]) (\"chikungunya fever\"[MeSH Terms] (\"chikungunya\"[All Fields] \"fever\"[All Fields]) \"chikungunya fever\"[All Fields] \"chikungunya\"[All Fields]) \"Yellow fever\"[All Fields] \"Yellow fever\"[All Fields] 2 \"randomized controlled trial\"[Publication Type] \"controlled clinical trial\"[Publication Type] \"randomized",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "eca07be4-e862-4f20-97ba-46813cd4f099",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "controlled trial\"[Publication Type] \"controlled clinical trial\"[Publication Type] \"randomized\"[Title/Abstract] \"placebo\"[Title/Abstrac t] \"randomly\"[Title/Abstract] \"trial\"[Title/Abstract] \"groups\"[Title/Abstract] 3 \"animals\"[MeSH Terms] \"humans\"[MeSH Terms] 4 #2 #3 5 \"metaanalys*\"[Title] (\"meta\"[Title] \"analys*\"[Title]) (\"systematic\"[Title] \"review*\"[Tit le]) 6 #1 (#4 #5) Table 2. Search strategy Embase 1 'dengue'/exp dengue 'yellow fever'/exp 'yellow fever' zika 'chikungunya'/exp chikungunya 2 'randomized controlled trial'/de 3 'controlled clinical trial'/de 4 random*:ti,ab,tt 5 'randomization'/de 6 'intermethod comparison'/de 7 placebo:ti,ab,tt 8 compare:ti,tt compared:ti,tt comparison:ti,tt 9 (evaluated:ab evaluate:ab evaluating:ab assessed:ab assess:ab) (compare:ab compared:ab comparing:ab comparison:ab) 10 (open NEXT/1 label):ti,ab,tt 11 ((d",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "ad42a65a-e586-4268-b36e-cf2600fec894",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "pare:ab compared:ab comparing:ab comparison:ab) 10 (open NEXT/1 label):ti,ab,tt 11 ((double single doubly singly) NEXT/1 (blind blinded blindly)):ti,ab,tt 12 'double blind procedure'/de 13 (parallel NEXT/1 group*):ti,ab,tt 14 crossover:ti,ab,tt 'cross over':ti,ab,tt 15 ((assign* match matched allocation) NEAR/6 (alternate group group intervention intervention patient patient subject subject participant participants)):ti,ab,tt 16 assigned:ti,ab,tt allocated:ti,ab,tt 17 (controlled NEAR/8 (study design trial)):ti,ab,tt guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 108 18 volunteer:ti,ab,tt volunteers:ti,ab,tt 19 'human experiment'/de 20 trial:ti,tt 21 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 22 ((random* NEXT/1 sampl* NEAR/8 ('cross",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "0090dbb1-6fd0-43ef-8476-49626612c816",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "#13 #14 #15 #16 #17 #18 #19 #20 22 ((random* NEXT/1 sampl* NEAR/8 ('cross section*' questionnaire* survey survey database databases)):ti,ab,tt) ('comparative study'/de 'controlled study'/de 'randomised controlled':ti,ab,tt 'randomized controlled':ti,ab,tt 'randomly assigned':ti,ab,tt) 23 'cross ‐sectional study' ('randomized controlled trial'/de 'controlled clinical study'/de 'controlled study'/de 'randomised controlled':ti,ab,tt 'randomized controlled':ti,ab,tt 'control group':ti,ab,tt 'control groups':ti,ab,tt) 24 'case control*':ti ,ab,tt random*:ti,ab,tt ('randomised controlled':ti,ab,tt 'randomized controlled':ti,ab,tt) 25 'systematic review':ti,tt (trial:ti,tt OR:ti,tt) 26 nonrandom*:ti,ab,tt random*:ti,ab,tt 27 'random field*':ti,ab,tt 28 ('random cluster' NEAR/4 sampl*):ti,ab,tt 29 'we searched':ab (review:ti,tt review:it) 30 'update review':ab 31",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "b7bfb714-f953-4e68-b099-86aa716d61cd",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "sampl*):ti,ab,tt 29 'we searched':ab (review:ti,tt review:it) 30 'update review':ab 31 (databases NEAR/5 searched):ab 32 (rat:ti,tt rats:ti,tt mouse:ti,tt mice:ti,tt swine:ti,tt porcine:ti,tt murine:ti,tt ep:ti,tt lambs:ti,tt pigs:ti,tt piglets:ti,tt rabbit:ti,tt rabbits:ti,tt cat:ti,tt cats:ti,tt dog:ti,tt dogs:ti,tt cattle:ti,tt bovine:ti,tt monkey:ti,tt monkeys:ti,tt trout:ti,tt marmoset*:ti,tt) 'animal ex periment'/de 33 'animal experiment'/de ('human experiment'/de 'human'/de) 34 #22 #23 #24 #25 #26 #27 #28 #29 #30 #31 #32 #33 35 review:ab review:it trial:ti,tt 36 #34 #35 37 #21 #36 38 systematic review*:ti 39 meta analys*:ti 40 metaanalys*:ti 41 #38 #39 #40 42 #1 (#41 #37) Table 3. Search strategy Cochrane CENTRAL LILACS 1 dengue 'yellow fever' zika chikungunya Ann",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "fb94b299-6f49-4ca3-b420-c679141eef57",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "rategy Cochrane CENTRAL LILACS 1 dengue 'yellow fever' zika chikungunya Annex 3. Protocol systematic review inform clinical practice guideline management arboviral disease 109 2.3 Study Selection: Two independent reviewer screen title abstract eligibility. Full -text article potentially relevant study assessed inclusion. Discrepancies resolved discussion and, necessary, third review er. 2.4 Data Extraction: standardized data extraction form developed, including study characteristics, interventions, comparators, outcomes, key findings. Two reviewer independently extract data included studies. 2.5 Data Synthesis : conduct meta -analysis , feasible , using frequentist random -effects models. perform ubgroup analysis considering potential effect modifier identified question development process. add",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "6c5cc823-559a-483a-b5f7-6c6220de2e1d",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "considering potential effect modifier identified question development process. addition, perform sensitivity nalysis excluding high risk bias study feasible. conduct frequentist random -effects network meta -analysis (NMA) multiple intervention available specific scenario. approach allows comparison multiple treat ments simultaneously accounting direct indirect evidence. estimate -study variance, use restricted maximum likelihood (REML) method, provides robust variance estimate improves precision effect estimate presence heterogeneity. 2.6 Certainty evidence Assessment: assess certainty evidence using grading recommendation assessment, development evaluation (GRADE) approach.2 Two methodologists experience using GRADE rate domain comparison separately",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "e8f605ef-40bc-4a37-8945-804820e892d9",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "dologists experience using GRADE rate domain comparison separately resolve discrepancy consensus. rate certainty comparison outcome high, moderate, low, low, based co nsiderations risk bias, inconsistency, indirectness, publication bias imprecision. assess risk bias use Cochrane 2.0 tool.3 assess risk bias resulting missing data perform sensitivity analysis including mi ssing participant assuming less plausible event rates.4 make judgement imprecision using minimally contextualised approach null effect threshold. minimally contextualised approach considers whether CI incl udes null effect, or, point estimate close null effect, whether CI lie within boundary small important benefit harm.5 define severe severe imprecision",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "63e3624b-eede-41cf-895d-ac9812e7a02f",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "y small important benefit harm.5 define severe severe imprecision considered CI included null effect, important benefit harms.6 Additionally analyse total number patient included meta -analysis less required number patient generated conventional sample size calculation singl e adequately powered trial define optimal information guideline clinical management arboviral diseases: dengue, chikungunya, Zika yellow fever 110 size (OIS) met.7 created GRADE evidence summary (Summary Findings tables) using MAGIC Authoring Publication Platform (www.magicapp.org) provide user friendly format clinician patient allow -use context clinical practice guideline COVID -19. calculate absolute risk RD RRs (and CIs) mean risk control gro",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "bbf35e9a-41fa-4a6d-b0a3-a7095d0ed67c",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "ulate absolute risk RD RRs (and CIs) mean risk control group across included trial . communicate finding conclusion using statement followed published guidance.8 3. References 1. Cuello -Garcia CA, Santesso N, Morgan RL, Verbeek J, Thayer K, Ansari MT, et al. GRADE guidance 24 optimizing integration randomized non -randomized study intervention evidence synthesis health guidelines. Journal Clinical Epidemiology. 2022 Feb;142:200 –8 (https://doi.org/10.1016/j.jclinepi.2021.11.026 ). 2. Atkins D, Best D, Briss PA, et al. Grading quality evidence strength recommendations. BMJ 2004;328:1490 (https://doi.org/10.1136/bmj.328.7454.1490 ). 3. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: revised tool assessing risk bias randomised trials. BMJ. 2019 Aug 28;l4898 (https://doi.org/10.1136/bmj.l4898 ). 4. Guyatt GH, Ebrahi",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "06d501e0-7f4e-4afc-afcd-d16108e23d96",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "domised trials. BMJ. 2019 Aug 28;l4898 (https://doi.org/10.1136/bmj.l4898 ). 4. Guyatt GH, Ebrahim S, Alonso -Coello P, Johnston BC, Mathioudakis AG, Briel M, et al. GRADE guideline 17: assessing risk bias associated missing participant outcome data body evidence. Journal Clinical Epidemiology. 2017 Jul;87:14 – 22 (https://doi.org/10.1016/j.jclinepi.2017.05.005 ). 5. Hultcrantz M, Rind D, Akl EA, et al. grade Working group clarifies construct certainty evidence. J Clin Epidemiol 2017;87:4 –13 (https://doi.org/10.1016/j.jclinepi.2017.05.006 ). 6. Zeng L, Brignardello -Petersen R, Hultcrantz M, Mustafa RA, Murad MH, Iorio A, et al. GRADE Guidance 34: update rating imprecision using minimally contextualized approach. Journal Clinical Epidemiology. 2022 Oct;150:216 –24 (https://doi.org/10.1016/j.jclinepi.2 022.07.014 ). 7. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso -Coello P, Rind D, et al. GRADE guideline 6. Rating q",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    },
    {
        "id": "781bc23c-9c6b-48fe-93fa-1c436086c074",
        "title": "Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever",
        "body": "GH, Oxman AD, Kunz R, Brozek J, Alonso -Coello P, Rind D, et al. GRADE guideline 6. Rating quality evidence —imprecision. Journal Clinical Epidemiology. 2011 Dec;64(12):1283 –93 (https://doi.org/10.1016/j.jclinepi.2011.01.012 ). 8. Santesso N, Glenton C, Dahm P, et al. Grade guideline 26: informative statement communicate finding systematic review interventio ns. J Clin Epidemiol 2020;119:126 –35 (https://doi.org/10.1016/j.jclinepi.2019.10.014 ). World Health Organization Avenue Appia 20 1211 Geneva 27 Switzerland E-mail: cmtm@who.int https://www.who.int",
        "source": "WHO Guidelines: Clinical management of arboviral diseases:dengue, chikungunya, Zika and yellow fever.pdf",
        "language": "en",
        "source_type": "Global"
    }
]